{"original_filename": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a.pdf", "predictions": {"document_type": "prospectus"}, "blobs": [{"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-0", "text": "Curetis N.V.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.40810157194679564, "top_left_y": 0.09362975630611373, "lower_right_x": 0.5888754534461911, "lower_right_y": 0.155622060709705, "height": 0.06199230440359127, "width": 0.18077388149939544}, "blob_type": "image", "predictions": {}, "annotations": {"issuer_name": ["Curetis N.V."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-1", "text": "(a public company with limited liability incorporated under the laws of the Netherlands\n               with its statutory seat in Amsterdam, the Netherlands)\n", "page_number": 0, "bounding_box": {"top_left_x": 0.2067714631197098, "top_left_y": 0.16374519025224454, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.1911073108165883, "height": 0.027362120564343756, "width": 0.5864570737605803}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-2", "text": "Offering of up to 4,791,667 ordinary shares\n", "page_number": 0, "bounding_box": {"top_left_x": 0.3143893591293833, "top_left_y": 0.19794784095767423, "lower_right_x": 0.686819830713422, "lower_right_y": 0.21504916631038906, "height": 0.01710132535271483, "width": 0.3724304715840387}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-3", "text": "The Company (as defined below) is offering up to 4,791,667 newly issued ordinary shares with a nominal value\nof \u20ac0.01 each in its capital (the \"Offer Shares\", which includes, unless the context indicates otherwise, the Addi-\ntional Shares (as defined below)). The Company is targeting to raise approximately \u20ac29.3 million of gross pro-\nceeds from the Offering (as defined below) but based on the maximum number of Offer Shares (excluding Addi-\ntional Shares) it has the possibility to raise up to approximately \u20ac50 million in gross proceeds from the Offering\n(assuming an Offer Price (as defined below) at the upper end of the Offer Price Range (as defined below)).\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3039760581445062, "height": 0.08208636169303118, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-4", "text": "The offering of the Offer Shares (the \"Offering\") consists of (i) a public offering to retail and institutional inves-\ntors in the Federal Republic of Germany (Bundesrepublik Deutschland) (\"Germany\") and (ii) a private place-\nment to certain institutional and other eligible investors in various other jurisdictions. The Offer Shares are being\noffered (i) within the United States to qualified institutional buyers (\"QIBs\") as defined in Rule 144A (\"Rule\n144A\") under the US Securities Act of 1933, as amended (the \"US Securities Act\") in reliance on Rule 144A or\npursuant to another exemption from, or in a transaction not subject to, the registration requirements of the US\nSecurities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the\nUS Securities Act (\"Regulation S\").\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4202650705429671, "height": 0.10944848225737497, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {"rule_144a_applies": ["Rule 144A"]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-5", "text": "Prior to the Offering, there has been no public market for the ordinary shares in the capital of the Company (the\n\"Shares\"). Application has been made to list and admit all of the Shares to trading under the symbol \"CURE\" on\nEuronext in Amsterdam, a regulated market of Euronext Amsterdam N.V. (\"Euronext Amsterdam \") as well as\non the regulated market of Euronext in Brussels, a regulated market of Euronext Brussels nv/sa (\"Euronext\nBrussels\", and together with Euronext Amsterdam, \"Euronext\"). Subject to acceleration or extension of the\ntimetable for the Offering, trading on an \"as-if-and-when-issued\" basis in the Shares on Euronext in Amsterdam\nand Euronext in Brussels is expected to commence on or about 11 November 2015 (the \"First Trading Date\").\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5228730226592561, "height": 0.09576742197520305, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"ticker": ["CURE"], "listing_venue": ["Euronext Amsterdam", "EuronextBrussels"]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-6", "text": "Investing in the Offer Shares involves substantial risks and uncertainties. See \"Risk Factors\" for a descrip-\ntion of the factors prospective investors should carefully consider before investing in the Offer Shares.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5575032064985036, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-7", "text": "Curetis N.V. (at the date of this prospectus (the \"Prospectus\") still a private limited liability company (besloten\nvennootschap met beperkte aansprakelijkheid) named Curetis B.V.) (the \"Company\" and when the term \"Cu-\nretis\" is used in this Prospectus it refers to Curetis AG and for time periods after incorporation of the Company\non 8 October 2015, to Curetis AG and the Company) will be converted into a public company with limited liabil-\nity (naamloze vennootschap) named Curetis N.V. immediately after determination of the Offer Price (as defined\nbelow).\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.646002565198803, "height": 0.0820863616930313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-8", "text": "The price per Offer Share (the \"Offer Price\") is expected to be between \u20ac9.50 and \u20ac12 (inclusive) (the \"Offer\nPrice Range\"). The Offer Price Range is an indicative price range. The Offer Price and the exact number of\nOffer Shares will be determined after the end of the offer period for the Offering (the \"Offer Period\") and after\ntaking into account the conditions described in \"The Offering\". The Offer Period will commence on 28 October\n2015 at 09:00 Central European Time (\"CET\") and end on 10 November 2015 at 16:00 CET, subject to accel-\neration or extension of the timetable for the Offering. Prior to allocation of the Offer Shares (\"Allocation\"), the\nnumber of Offer Shares can be increased or decreased and the Offer Price Range can be changed. Any increase\nin the top end of the Offer Price Range on the last day of the Offer Period or the determination of an Offer Price\nabove the Offer Price Range will result in the Offer Period being extended by at least two business days; any\nincrease in the top end of the Offer Price Range on the day prior to the last day of the Offer Period will result in\nthe Offer Period being extended by at least one business day. Any such change in the number of Offer Shares\nand/or the Offer Price Range will be announced in a press release on the Company's website at\nwww.curetis.com. The Offer Price and the exact number of Offer Shares will be set out in a pricing statement\n(the \"Pricing Statement\") that will be deposited with the Dutch Authority for the Financial Markets (Stichting\nAutoriteit Financi\u00eble Markten) (the \"AFM\") and published through a press release on the Company's website.\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8584865327062847, "height": 0.2056434373663959, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-0-9", "text": "On 26 October 2015, the Company entered into commitment letters (the \"Commitment Letters\") with certain of\nCuretis AG's current shareholders, being aeris CAPITAL Equity Investments, L.P., LSP Curetis Pooling B.V.,\nBioMed Invest II LP, CD-Venture GmbH, Forbion Capital Fund II Co\u00f6peratief U.A. and/or Forbion CF II Co-\nInvest I Co\u00f6peratief U.A., Roche Finance Ltd. and HBM BioCapital II Invest S.a r.l. (the \"Committing Share-\n", "page_number": 0, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8648995297135528, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9200513039760582, "height": 0.05515177426250539, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-0", "text": "holders\"). Pursuant to the Commitment Letters, each of the Committing Shareholders, severally and not jointly,\nhas irrevocably committed to subscribe for, and the Company has agreed to issue and allot to the Committing\nShareholders, Offer Shares at the Offer Price in the Offering. The aggregate commitments of all Committing\nShareholders pursuant to the Commitment Letters amount to approximately \u20ac15,150,777. The Commitment\nLetters will terminate automatically upon the earlier of (i) the termination of the Underwriting Agreement (as\ndefined herein), (ii) the Settlement Date (as defined below) not having occurred before 31 December 2015, and\n(iii) the Sole Global Coordinator on the one hand, or the Company, on the other hand, informing the other, prior\nto the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering. See\n\"The Offering \u2013 Investing Shareholders\". In addition to the Committing Shareholders and under the same terms\nand conditions listed above, STRATEC Biomedical AG (\"STRATEC\") has committed to subscribe for, and the\nCompany has agreed to issue and allot to STRATEC, Offer Shares at the Offer Price in the Offering for a total\namount of approximately \u20ac1 million.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2466866182129115, "height": 0.1616075245831552, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-1", "text": "amount of approximately \u20ac1 million.\nRBC Europe Limited (\"RBC\") is acting as sole global coordinator for the Offering (in such and any other ca-\npacity, the \"Sole Global Coordinator\"). RBC and Bank Degroof Petercam nv/sa (\"Degroof Petercam\") are\ntogether acting as joint bookrunners for the Offering (the \"Joint Bookrunners\"). ICF BANK AG (\"ICF\" and\ntogether with the Joint Bookrunners, the \"Underwriters\") is acting as joint lead manager for the Offering (the\n\"Joint Lead Manager\").\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24711415134672937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32407011543394615, "height": 0.07695596408721678, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-2", "text": "The Company expects to grant the Sole Global Coordinator, on behalf of the Underwriters, an option (the\n\"Over-allotment Option\"), exercisable within 30 calendar days after the First Trading Date, pursuant to which\nthe Sole Global Coordinator, on behalf of the Underwriters, may require the Company to issue to the Underwrit-\ners at the Offer Price up to 15% of the total number of Offer Shares issued in the Offering (the \"Additional\nShares\"), to cover over-allotments or short positions, if any, in connection with the Offering.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40017101325352716, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-3", "text": "Subject to acceleration or extension of the timetable for the Offering, payment (in euro) for, and delivery of, the\nOffer Shares (\"Settlement\") is expected to take place on or about 13 November 2015 (the \"Settlement Date\")\nthrough the book entry systems of Nederlands Centraal Instituut voor Giraal Effectenverkeer B.V. (\"Euroclear\nNederland\"). If Settlement does not take place on the Settlement Date, or at all, the Offering may be withdrawn,\nin which case all applications to purchase the Offer Shares will be disregarded, any allocations made will be\ndeemed not to have been made and any payments made will be returned without interest or other compensation\nand transactions in the Offer Shares on Euronext in Amsterdam and Euronext in Brussels may be annulled. All\ndealings prior to Settlement are at the sole risk of the parties concerned. The Underwriters, the Company, ABN\nAMRO Bank N.V. (\"ABN AMRO\"), in its capacity as listing and paying agent (the \"Listing and Paying\nAgent\") and Euronext do not accept any responsibility or liability with respect to any person as a result of the\nwithdrawal of the Offering or the related annulment of any transaction in Shares on Euronext in Amsterdam and\nEuronext in Brussels.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5677640017101325, "height": 0.1611799914493373, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-4", "text": "This Prospectus does not constitute an offer to sell or the solicitation of an offer to buy Offer Shares to any per-\nson in any jurisdiction to whom or in which such offer or solicitation is unlawful. The Offer Shares have not\nbeen and will not be registered under the US Securities Act. Each investor of the Offer Shares, in making a pur-\nchase, will be deemed to have made certain acknowledgements, representations and agreements as set out in\n\"Selling and Transfer Restrictions\".\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.646002565198803, "height": 0.06840530141085943, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-5", "text": "This Prospectus constitutes a prospectus for the purposes of Article 3 of Directive 2003/71/EC of the European\nParliament and of the Council, and amendments thereto (including those resulting from Directive 2010/73/EU)\n(the \"Prospectus Directive\"), and has been prepared in accordance with Chapter 5.1 of the Dutch Financial\nSupervision Act (Wet op het financieel toezicht) and the rules promulgated thereunder (the \"Dutch Financial\nSupervision Act\"). The Company has requested the AFM to notify its approval in accordance with Article 18 of\nthe Prospectus Directive to the competent authorities in Germany, the German Federal Financial Supervisory\nAuthority (Bundesanstalt f\u00fcr Finanzdienstleistungsaufsicht) (\"BaFin\"), and in Belgium, the Belgian Financial\nServices and Markets Authority (the \"FSMA\"), with a certificate of approval attesting that this Prospectus has\nbeen prepared in accordance with the Prospectus Directive. This Prospectus has been approved by and filed with\nthe AFM.\n", "page_number": 1, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7866609662248825, "height": 0.13381787088499364, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-6", "text": "Sole Global Coordinator and Joint Bookrunner\n            RBC Capital Markets\n", "page_number": 1, "bounding_box": {"top_left_x": 0.3234582829504232, "top_left_y": 0.7999144933732364, "lower_right_x": 0.7013301088270859, "lower_right_y": 0.8345446772124839, "height": 0.03463018383924754, "width": 0.3778718258766627}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-7", "text": "Joint Bookrunner\n", "page_number": 1, "bounding_box": {"top_left_x": 0.439540507859734, "top_left_y": 0.837964942283027, "lower_right_x": 0.5846432889963724, "lower_right_y": 0.8516460025651988, "height": 0.013681060282171864, "width": 0.14510278113663844}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-8", "text": "Bank Degroof Petercam\n", "page_number": 1, "bounding_box": {"top_left_x": 0.4105199516324063, "top_left_y": 0.8580589995724669, "lower_right_x": 0.5894800483675937, "lower_right_y": 0.8721675929884566, "height": 0.01410859341598969, "width": 0.17896009673518742}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-9", "text": "Joint Lead Manager\n", "page_number": 1, "bounding_box": {"top_left_x": 0.4153567110036276, "top_left_y": 0.8755878580589995, "lower_right_x": 0.5798065296251511, "lower_right_y": 0.8892689183411714, "height": 0.013681060282171864, "width": 0.16444981862152352}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-1-10", "text": "ICF\n", "page_number": 1, "bounding_box": {"top_left_x": 0.48428053204353083, "top_left_y": 0.8956819153484396, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.9063702436938863, "height": 0.010688328345446751, "width": 0.03325272067714635}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-2-0", "text": "NOTICE TO NEW HAMPSHIRE RESIDENTS\n", "page_number": 2, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.08507909362975631, "lower_right_x": 0.720677146311971, "lower_right_y": 0.09790508764429243, "height": 0.012825994014536116, "width": 0.4214026602176542}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-2-1", "text": "NEITHER THE FACT THAT A REGISTRATION STATEMENT OR AN APPLICATION FOR A\nLICENCE HAS BEEN FILED UNDER CHAPTER 421-B OF THE NEW HAMPSHIRE REVISED\nSTATUTES (RSA 421-B) WITH THE STATE OF NEW HAMPSHIRE NOR THE FACT THAT A\nSECURITY IS EFFECTIVELY REGISTERED OR A PERSON IS LICENSED IN THE STATE OF\nNEW HAMPSHIRE CONSTITUTES A FINDING BY THE SECRETARY OF STATE OF NEW\nHAMPSHIRE THAT ANY DOCUMENT FILED UNDER RSA 421-B IS TRUE, COMPLETE AND NOT\nMISLEADING. NEITHER ANY SUCH FACT NOR THE FACT THAT AN EXEMPTION OR\nEXCEPTION IS AVAILABLE FOR A SECURITY OR A TRANSACTION MEANS THAT THE\nSECRETARY OF STATE HAS PASSED IN ANY WAY UPON THE MERITS OR QUALIFICATIONS\nOF, OR RECOMMENDED OR GIVEN APPROVAL TO, ANY PERSONS, SECURITY, OR\nTRANSACTION. IT IS UNLAWFUL TO MAKE, OR CAUSE TO BE MADE, TO ANY PROSPECTIVE\nSUBSCRIBER, PURCHASER, CUSTOMER OR CLIENT, ANY REPRESENTATION INCONSISTENT\nWITH THE PROVISIONS OF THIS PARAGRAPH.\n", "page_number": 2, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1085934159897392, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.28388200085506626, "height": 0.17528858486532706, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-3-0", "text": "Contents\n", "page_number": 3, "bounding_box": {"top_left_x": 0.4486094316807739, "top_left_y": 0.10218041898247114, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.11628901239846089, "height": 0.014108593415989745, "width": 0.10278113663845229}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-3-1", "text": "SUMMARY.............................................................................................................................................1\nZUSAMMENFASSUNG......................................................................................................................22\nRISK FACTORS ..................................................................................................................................46\nIMPORTANT INFORMATION ........................................................................................................72\nREASONS FOR THE OFFERING AND USE OF PROCEEDS.....................................................80\nDIVIDENDS AND DIVIDEND POLICY ..........................................................................................82\nCAPITALISATION, INDEBTEDNESS AND WORKING CAPITAL ..........................................84\nSELECTED FINANCIAL INFORMATION ....................................................................................87\nOPERATING AND FINANCIAL REVIEW AND PROSPECTS ...................................................90\nINDUSTRY .........................................................................................................................................117\nBUSINESS...........................................................................................................................................123\nREGULATION ...................................................................................................................................161\nMANAGEMENT, EMPLOYEES AND CORPORATE GOVERNANCE ...................................166\nMAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS ................................182\nDESCRIPTION OF SHARE CAPITAL ..........................................................................................185\nTHE OFFERING ...............................................................................................................................195\nPLAN OF DISTRIBUTION ..............................................................................................................199\nSELLING AND TRANSFER RESTRICTIONS .............................................................................204\nTAXATION ........................................................................................................................................208\nGENERAL INFORMATION ...........................................................................................................226\nGLOSSARY ........................................................................................................................................227\nANNEX I \u2013 FOOTNOTES ................................................................................................................234\nANNEX II \u2013 LIST OF REFERENCES ............................................................................................236\nFINANCIAL SECTION .................................................................................................................... F-1\n", "page_number": 3, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12954253954681488, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6498503634031637, "height": 0.5203078238563488, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-0", "text": "SUMMARY\n", "page_number": 4, "bounding_box": {"top_left_x": 0.4347037484885127, "top_left_y": 0.09876015391192818, "lower_right_x": 0.560459492140266, "lower_right_y": 0.115861479264643, "height": 0.01710132535271483, "width": 0.12575574365175335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-1", "text": "Summaries are made up of disclosure requirements known as \"Elements\". These Elements are numbered in Sec-\ntions A-E (A.1 \u2013 E.7). This summary contains all the Elements required to be included in a summary for this\ntype of security and issuer. Because some Elements are not required to be addressed, there may be gaps in the\nnumbering sequence of the Elements.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18725951261222745, "height": 0.0542967079948696, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-2", "text": "Even though an Element may be required to be inserted in the summary because of the type of securities and\nissuer, it is possible that no relevant information can be given regarding the Element. In this case a short descrip-\ntion of the Element is included in the summary with the mention of \"not applicable\".\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.23514322359982898, "height": 0.04061564771269771, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-3", "text": "Section A \u2013 Introduction and warnings\n", "page_number": 4, "bounding_box": {"top_left_x": 0.3282950423216445, "top_left_y": 0.25651988029072254, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.2731936725096195, "height": 0.016673792218896977, "width": 0.3391777509068924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-4", "text": "Introductions   This summary should be read as an introduction to the prospectus (the \"Prospectus\")\nand             relating to the offering (the \"Offering\") by Curetis N.V. (at the date of the Prospectus\nwarnings        still a private limited liability company (besloten vennootschap met beperkte aanspra-\n                kelijkheid) named Curetis B.V.) (the \"Company\" and when the term \"Curetis\" is used\n                in this summary it refers to Curetis AG and for time after incorporation of the Company\n                on 8 October 2015, to Curetis AG and the Company) of up to 4,791,667 newly issued\n                ordinary shares with a nominal value of \u20ac0.01 each in its capital (the \"Offer Shares\",\n                which includes, unless the context indicates otherwise, the Additional Shares (as de-\n                fined below)), and to the admission to listing and trading of all the ordinary shares in\n                the capital of the Company (\"Shares\") under the symbol \"CURE\" on Euronext in Am-\n                sterdam, a regulated market operated by Euronext Amsterdam N.V. (\"Euronext Am-\n                sterdam\"), and on Euronext in Brussels, a regulated market operated by Euronext Brus-\n                sels NV/SA (\"Euronext Brussels\", and together with Euronext Amsterdam, \"Euron-\n                ext\"). Any decision to invest in the Offer Shares or the Company should be based on\n                consideration of the Prospectus as a whole by the investor.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.294570329200513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.500213766566909, "height": 0.20564343736639595, "width": 0.7194679564691657}, "blob_type": "paragraph", "predictions": {}, "annotations": {"ticker": ["CURE"]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-5", "text": "A.1\n", "page_number": 4, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.2954253954681488, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.30739632321504917, "height": 0.011970927746900395, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-6", "text": "Where a claim relating to the information contained in the Prospectus is brought before\na court, the plaintiff investor might, under the national legislation of the member states\nof the Economic European Area, have to bear the costs of translating the Prospectus\nbefore the legal proceedings are initiated. Civil liability attaches only to those persons\nwho have tabled this summary, including any translation thereof, but only if this sum-\nmary is misleading, inaccurate or inconsistent when read together with the other parts of\nthe Prospectus or if it does not provide, when read together with the other parts of the\nProspectus, key information in order to aid investors when considering whether to in-\nvest in the Offer Shares.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6280461735784524, "height": 0.12227447627191113, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-7", "text": "A.2\n", "page_number": 4, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.6378794356562634, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.6498503634031637, "height": 0.01197092774690034, "width": 0.0350665054413543}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-8", "text": "Consent,\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.6378794356562634, "lower_right_x": 0.2309552599758162, "lower_right_y": 0.6519880290722531, "height": 0.01410859341598969, "width": 0.0701330108827086}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-9", "text": "The Company consents to the use of the Prospectus for a subsequent resale or final\nplacement of Offer Shares by those financial intermediaries that are specifically en-\ngaged by ICF BANK AG (\"ICF\") for purposes of the offer to retail investors in the\nFederal Republic of Germany (Bundesrepublik Deutschland) (\"Germany\"). Germany is\nthe only jurisdiction in which the relevant financial intermediaries may use the Prospec-\ntus for a subsequent resale or a final placement of the Offer Shares and such use is lim-\nited to the Offer Period (as defined below) for the Offering, which is expected to com-\nmence on 28 October 2015 at 09:00 Central European Time (\"CET\") and to end on 10\nNovember 2015 at 16:00 CET. When using the Prospectus, each such financial inter-\nmediary must comply with all applicable laws and regulations and the selling re-\nstrictions set out in the Prospectus.\n", "page_number": 4, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7892261650277896, "height": 0.15006412997007268, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-10", "text": "Consent,\nindication,\n", "page_number": 4, "bounding_box": {"top_left_x": 0.16928657799274485, "top_left_y": 0.6515604959384352, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.6648140230867893, "height": 0.013253527148354038, "width": 0.07738814993954052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-11", "text": "conditions\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.6652415562206071, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.6772124839675074, "height": 0.01197092774690034, "width": 0.07799274486094318}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-12", "text": "and notice\n", "page_number": 4, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.6802052159042326, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.6908935442496793, "height": 0.010688328345446751, "width": 0.07799274486094318}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-13", "text": "The Company accepts responsibility for the consent of the Prospectus with respect to a\nsubsequent resale or final placement of the Offer Shares by the financial intermediaries\nreferred to above. The Prospectus may only be delivered by such financial intermediar-\nies to potential eligible retail investors in Germany together with all supplements pub-\nlished before such delivery. Any supplement to the Prospectus and the names and ad-\ndress of the financial intermediaries engaged by ICF will be available for viewing in\nelectronic form on the website of the Company (www.curetis.com).\n", "page_number": 4, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8909790508764429, "height": 0.09448482257374946, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-14", "text": "In the event of an offer being made by financial intermediaries as referred to\nabove, such financial intermediaries will provide information to the investors on\n", "page_number": 4, "bounding_box": {"top_left_x": 0.27327690447400244, "top_left_y": 0.8943993159469859, "lower_right_x": 0.8917775090689238, "lower_right_y": 0.9256092347156905, "height": 0.031209918768704603, "width": 0.6185006045949214}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-4-15", "text": "", "page_number": 4, "bounding_box": {"top_left_x": 0.8409915356711004, "top_left_y": 0.9474134245404019, "lower_right_x": 0.848851269649335, "lower_right_y": 0.9529713552800342, "height": 0.0055579307396322886, "width": 0.007859733978234584}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-0", "text": "the terms and conditions of the offer at the time the offer is made.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.27871825876662637, "top_left_y": 0.08165882855921335, "lower_right_x": 0.7636033857315598, "lower_right_y": 0.09576742197520308, "height": 0.014108593415989731, "width": 0.48488512696493347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-1", "text": "The Company does not intend to give consent to anyone other than the financial inter-\nmediaries that are specifically engaged by ICF to use the Prospectus in the future.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.2762998790810157, "top_left_y": 0.10346301838392476, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.1333903377511757, "height": 0.029927319367250946, "width": 0.6064087061668681}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-2", "text": "Section B \u2013 Issuer\n", "page_number": 5, "bounding_box": {"top_left_x": 0.42140266021765416, "top_left_y": 0.15049166310389056, "lower_right_x": 0.5798065296251511, "lower_right_y": 0.16246259085079093, "height": 0.011970927746900367, "width": 0.15840386940749696}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-3", "text": "Legal and\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.18640444634459172, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.19923044035912782, "height": 0.012825994014536102, "width": 0.08101571946795649}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-4", "text": "B.1\n", "page_number": 5, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.14207980652962515, "lower_right_y": 0.19837537409149208, "height": 0.01068832834544678, "width": 0.02660217654171705}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-5", "text": "At the date of the Prospectus, the Company is\n", "page_number": 5, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.1876870457460453, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.19923044035912782, "height": 0.011543394613082514, "width": 0.3391777509068924}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-6", "text": "a private limited liability company\n", "page_number": 5, "bounding_box": {"top_left_x": 0.6402660217654171, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19923044035912782, "height": 0.011543394613082514, "width": 0.2400241837968562}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-7", "text": "a\n", "page_number": 5, "bounding_box": {"top_left_x": 0.6311970979443773, "top_left_y": 0.19067977768277042, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.19794784095767423, "height": 0.007268063274903813, "width": 0.00725513905683195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-8", "text": "      commercial      (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of\n      name of the     the Netherlands named Curetis B.V. The Company will be converted into a public com-\n      Company         pany with limited liability (naamloze vennootschap) immediately after determination of\n                      the offer price per Offer Share (the \"Offer Price\") (the \"Conversion\"). The legal and\n                      commercial name of the Company will then be Curetis N.V.\nB.2   Domicile,       The Company is currently a company with private limited liability (besloten ven-\n      legal form,     nootschap met beperkte aansprakelijkheid) incorporated under the laws of the Nether-\n      legislation     lands. The Company is domiciled in Holzgerlingen, Germany. The Company will be\n      and country     converted into a public company with limited liability (naamloze vennootschap) imme-\n      of incorpora-   diately after determination of the Offer Price. The Company has its statutory seat in\n      tion            Amsterdam, the Netherlands, and its principal place of business at Holzgerlingen, Ger-\n                      many. The Company is registered with the Trade Register of the Chamber of Com-\n                      merce, under number 64302679.\nB.3   Current op-     Curetis is a commercial-stage molecular diagnostics company focusing on simple, accu-\n      erations and    rate and rapid solutions for diagnosing infectious diseases and antibiotic resistance in\n      principal       severely ill, hospitalised patients.\n      activities\n                      Today, the diagnosis of infectious diseases in a hospital setting is still largely carried\n                      out through traditional microbiology culture based tests. This process is labour-\n                      intensive and time-consuming, typically delivering results only after 24 hours or even\n                      weeks. As a result, adequate antibiotic therapy decisions are delayed, leading to poor\n                      patient outcomes, longer hospital stays, increased hospital costs and overall spread of\n                      antibiotic resistance, a significant and increasing problem throughout the world.\n                      Curetis' Unyvero platform which consists of the system (L4 Lysator, C8 Cockpit and\n                      A50 Analyzer, together the \"Unyvero System\"), proprietary software and the applica-\n                      tion-specific cartridges (the \"Application Cartridges\", together with the Unyvero Sys-\n                      tem, the \"Unyvero Platform\") enables the early detection of a broad range of different\n", "page_number": 5, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.1996579734929457, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.5852928601966653, "height": 0.3856348867037196, "width": 0.7847642079806529}, "blob_type": "paragraph", "predictions": {}, "annotations": {"country_of_registration/incorporation": ["Netherlands"]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-9", "text": "microorganisms and their related antibiotic resistance genes in a single test from a wide\nvariety of native sample materials. The Unyvero Platform is fully automated and inte-\ngrates all diagnostic steps into a single Application Cartridge. It is easy to use with\nminimum hands-on time of no more than five minutes. It is a walkaway solution that\ndetects within four to five hours most microorganisms that take traditional microbiology\nculture based tests 24 hours or even weeks. This allows clinicians to make early adjust-\nments to a more specific treatment of the patient, saving significant time and cost, in\nparticular by reducing the time of the patient's hospital stay. The Unyvero Platform\nintends to complement rather than replace traditional microbiology.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.5852928601966653, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.12270200940572895, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-10", "text": "The Unyvero Platform has been CE-IVD-marked since 2012 and is commercialised in\nEurope and certain other markets that accept CE-IVD-marking (i.e. Kuwait, Qatar,\nRussia and the United Arab Emirates), through a combination of direct sales in key EU\ncountries and distributors in selected EU markets and rest of the world (i.e. Kuwait,\nQatar, Russia and the United Arab Emirates). Curetis also intends to continue to expand\ninternationally as seen by the recent signing of distribution agreements with Acumen\nResearch Laboratories Pte Ltd. for certain ASEAN markets (Indonesia, Malaysia, Sin-\ngapore and Thailand) and Beijing Clear Biotech Co., Ltd for Greater China (China,\nTaiwan and Hong Kong).\n", "page_number": 5, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.837964942283027, "height": 0.12355707567336471, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-11", "text": "As of 30 June 2015, Curetis' total installed base comprised 70 Unyvero Analyzers.\nThere are currently two commercially available Application Cartridges: the P55 Appli-\ncation Cartridge, which addresses severe forms of pneumonia, and the i60 ITI Applica-\ntion Cartridge, which addresses severe cases of implant and tissue infections.\n", "page_number": 5, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8961094484822574, "height": 0.051731509191962344, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-12", "text": "tion Cartridge, which addresses severe cases of implant and tissue infections.\nThe P55 Application Cartridge was commercially launched in April 2015 and\n", "page_number": 5, "bounding_box": {"top_left_x": 0.27388149939540507, "top_left_y": 0.8965369816160752, "lower_right_x": 0.837968561064087, "lower_right_y": 0.920478837109876, "height": 0.02394185549380079, "width": 0.5640870616686819}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-13", "text": "s the\n", "page_number": 5, "bounding_box": {"top_left_x": 0.8530834340991535, "top_left_y": 0.9063702436938863, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9166310389055152, "height": 0.010260795211628926, "width": 0.026602176541717037}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-14", "text": "is\n", "page_number": 5, "bounding_box": {"top_left_x": 0.8422007255139057, "top_left_y": 0.9067977768277041, "lower_right_x": 0.8518742442563483, "lower_right_y": 0.9166310389055152, "height": 0.0098332620778111, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-5-15", "text": "", "page_number": 5, "bounding_box": {"top_left_x": 0.8409915356711004, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9533988884138521, "height": 0.005985463873450225, "width": 0.010278113663845123}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-0", "text": "second generation version of the P50 Application Cartridge, the pneumonia cartridge\ninitially launched in 2012. It is a CE-IVD-marked Application Cartridge for the fully\nautomated detection of currently 20 microorganisms and 19 antibiotic resistance mark-\ners in native respiratory samples. With the test, Curetis aims to detect the vast majority\nof pneumonia causing pathogens in hospitalised patients and clinically relevant re-\nsistance markers against antimicrobials. Based on its applicability to multiple forms of\npneumonia, Curetis estimates that the P55 Application Cartridge has an addressable\nmarket of 2.3 million incidences per year in the EU and the US.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28174123337363965, "top_left_y": 0.0837964942283027, "lower_right_x": 0.8863361547762999, "lower_right_y": 0.19452757588713127, "height": 0.11073108165882857, "width": 0.6045949214026602}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-1", "text": "The i60 ITI Application Cartridge was launched in May 2014. It is a CE-IVD-marked\nApplication Cartridge for the fully automated detection of currently 61 microorganisms\nand 19 antibiotic resistance markers for eight different clinical indications within the\narea of prosthetic joint infections, diabetic foot ulcers, surgical site infections, catheter-\nassociated infections, deep skin and tissue infections, cardiology-related infections,\nburn wounds and other implant infections. Curetis estimates that the addressable market\nfor the i60 ITI Application Cartridge is 2.1 million cases eligible for testing per year in\nthe EU and the US.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.30782385634886705, "height": 0.10645575032064986, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-2", "text": "To date, more than 30 clinical studies with over 4,000 patient samples have been com-\npleted to validate both Application Cartridges. Additional trials with more than 5,000\nsamples are on-going or scheduled in the coming years. This includes the required clin-\nical studies to obtain US Food and Drug Administration (\"FDA\") clearance for the\nUnyvero System and the LRT55 Application Cartridge (technically equivalent to the\nP55 Application Cartridge). Following FDA clearance, Curetis intends to commercial-\nise the Unyvero System and the LRT55 Application Cartridge in the US through a di-\nrect sales effort beginning in 2017.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4275331338178709, "height": 0.10987601539119285, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-3", "text": "The pipeline products of Curetis include Application Cartridges targeting positive blood\nculture testing and intra-abdominal/gastrointestinal tract infections, both of which Cu-\nretis intends to launch commercially as CE-IVD-marked products in 2016. This is ex-\npected to be followed by a CE-IVD-marked sepsis host response Application Cartridge\ntargeting commercial launch not before late 2017. Curetis also believes its Unyvero\nPlatform has the potential for menu expansion into other areas such as oncology, com-\npanion diagnostics, transplant medicine and veterinary applications.\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5301410859341599, "height": 0.09619495510902093, "width": 0.5955259975816204}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-4", "text": "Curetis believes that it has the following strengths:\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28536880290205563, "top_left_y": 0.5365540829414279, "lower_right_x": 0.6287787182587666, "lower_right_y": 0.5506626763574177, "height": 0.0141085934159898, "width": 0.343409915356711}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-5", "text": "Curetis is\n", "page_number": 6, "bounding_box": {"top_left_x": 0.33373639661426846, "top_left_y": 0.5583582727661394, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.5703292005130398, "height": 0.01197092774690045, "width": 0.06771463119709792}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-6", "text": "a commercial stage molecular diagnostics company selling into Eu-\n", "page_number": 6, "bounding_box": {"top_left_x": 0.41233373639661425, "top_left_y": 0.5583582727661394, "lower_right_x": 0.879081015719468, "lower_right_y": 0.5703292005130398, "height": 0.01197092774690045, "width": 0.4667472793228537}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-7", "text": "", "page_number": 6, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.5609234715690466, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.5677640017101325, "height": 0.0068405301410858765, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-8", "text": "a\n", "page_number": 6, "bounding_box": {"top_left_x": 0.4062877871825877, "top_left_y": 0.5609234715690466, "lower_right_x": 0.4117291414752116, "lower_right_y": 0.5703292005130398, "height": 0.009405728943993164, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-9", "text": "\uf0b7     Curetis is a commercial stage molecular diagnostics company selling into Eu-\n      rope, Russia and Middle East\n\uf0b7     Curetis' focus is on diagnosing pathogens and preventing and combating antibi-\n      otic resistance for severe infections in hospitalised patients\n\uf0b7     Curetis' flexible Unyvero Platform deals with any sample type and covers more\n      microorganisms and resistance markers than competing platforms\n\uf0b7     Curetis has a strong pipeline of high-value products addressing significant unmet\n      medical need\n\uf0b7     Curetis and the Unyvero Platform are validated by extensive clinical studies and\n      endorsed by key opinion leaders and a top-tier investor base\n\uf0b7     Curetis conducts US clinical trials to support US FDA clearance in 2017 and\n      subsequent US commercialisation\n\uf0b7     Curetis and the Unyvero Platform aim to reduce hospital costs by allowing effec-\n      tive treatment to be administered more quickly\n\uf0b7     Curetis' management team combines decades of operational and commercial\n      experience\n\uf0b7     Curetis controls all of the key aspects of its value chain\n\nThe following key trends are expected to drive the infectious disease MDx market\n", "page_number": 6, "bounding_box": {"top_left_x": 0.27750906892382105, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.8832834544677213, "height": 0.31252672082086363, "width": 0.6130592503022974}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-10", "text": "B.4a\n", "page_number": 6, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.8696023941855494, "lower_right_x": 0.15114873035066506, "lower_right_y": 0.8815733219324497, "height": 0.01197092774690034, "width": 0.041112454655380895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-11", "text": "Most signifi-\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.8696023941855494, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.884138520735357, "height": 0.014536126549807626, "width": 0.10036275695284164}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-12", "text": "growth through molecular assay menu expansion, molecular diagnostic technology\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.8832834544677213, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8961094484822574, "height": 0.012825994014536102, "width": 0.5955259975816204}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-13", "text": "cant recent\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.8854211201368106, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.8952543822146216, "height": 0.00983326207781099, "width": 0.08282950423216445}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-14", "text": "growth through molecular assay menu expansion, molecular diagnostic\ndevelopment, and greater adoption of these technologies in medical practice:\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28476420798065294, "top_left_y": 0.8965369816160752, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.9097905087644292, "height": 0.013253527148354038, "width": 0.5181378476420798}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-15", "text": "trends affect-\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.8969645147498931, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.9089354424967935, "height": 0.01197092774690034, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-16", "text": "trends affect-\ning the Com-\n", "page_number": 6, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.910645575032065, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.9251817015818726, "height": 0.014536126549807626, "width": 0.10036275695284164}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-17", "text": "Increase in ageing population to accelerate growth of the MDx market:\n", "page_number": 6, "bounding_box": {"top_left_x": 0.3258766626360339, "top_left_y": 0.9196237708422402, "lower_right_x": 0.8875453446191052, "lower_right_y": 0.9328772979905943, "height": 0.013253527148354038, "width": 0.5616686819830713}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-18", "text": "\uf0b7\n", "page_number": 6, "bounding_box": {"top_left_x": 0.28536880290205563, "top_left_y": 0.9217614365113296, "lower_right_x": 0.2932285368802902, "lower_right_y": 0.9281744335185977, "height": 0.006412997007268162, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-6-19", "text": "3\n", "page_number": 6, "bounding_box": {"top_left_x": 0.841596130592503, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.009673518742442488}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-0", "text": "pany and            According to the US Department of Health & Human Services, around 12.4% of\nindustries in       the US population was older than 65 in 2000. The percentage is expected to\nwhich it op-        grow to 19% by 2030. As the population is ageing, incidence rates of infections\nerates              become more frequent, also supported by overuse of antibiotics in nursing\n                    homes. Moreover, it is predicted that elderly require more often medical services\n                    \u2013 complicated by hospital-acquired infections \u2013 than young adults. In summary,\n                    as the population ages, people become more prone to infectious diseases, thereby\n                    driving the need for faster molecular-based diagnostics.\n                \uf0b7   Antibiotic resistance \u2013 a global medical and economic burden: By 2050,\n                    experts predict that the number of deaths related to drug resistant infections\n                    could possibly increase from the current total of 700,000 to 10 million deaths\n                    and may cause expenditures of US$100 trillion per year worldwide. Anti-\n                    microbial resistance by then would cause more deaths than cancer. Therefore\n                    management believes that the demand for fast and accurate tests for microorgan-\n                    ism identification and antibiotic resistance detection will increase rapidly.\n                \uf0b7   Personalised medicine and companion diagnostics: The trend towards person-\n                    alised medicine \u2013 which according to Curetis' management also includes the mo-\n                    lecular identification of relevant microorganisms and their antibiotic resistance\n                    markers for an early informed choice of antibiotics for any given patient \u2013 is ex-\n                    pected to increase the demand for molecular diagnostic tests. Fully automated\n                    and integrated molecular diagnostics solutions minimising operator intervention\n                    and laboratory settings are likely to play an important role in the further adoption\n                    of personalised medicine.\n                \uf0b7   Progress in biomarker discovery allows addressing unmet clinical need,\n                    such as sepsis: New modern molecular biology techniques, particularly next\n                    generation sequencing, in combination with intelligent bioinformatics and big\n                    data analytics, will contribute to progress in biomarker discovery and increasing-\n                    ly allow for the systematic identification and validation of biomarkers for diag-\n                    nosing specific diseases. However, the results of such research will lead to large\n                    biomarker panels to be tested in order to sufficiently capture complex disease bi-\n                    ology. Moving those complex biomarker panels into standard of care will require\n                    highly multiplexed molecular diagnostics platforms for routine testing.\n                \uf0b7   Decentralisation of molecular testing - testing at point-of need: The need to\n                    have diagnostic test results as quickly as possible fosters the development of\n                    near-patient testing and automated sample-to-answer diagnostic test solutions,\n                    which can be operated by non-specialist medical staff in a non-laboratory set-\n                    ting. The availability of infrastructure-independent, near-patient solutions also\n                    makes molecular diagnostics accessible to less developed and remote areas. Both\n                    trends may drive adoption of multiplex testing.\n                \uf0b7   Reforms in reimbursement systems: New regulations in the US and Europe\n                    introduce new test-specific reimbursement codes for molecular testing. Those\n                    improved coding systems help to ease the billing and payment process. In addi-\n                    tion, more countries will adopt diagnosis related group (\"DRG\") reimbursement\n                    systems that also cover diagnostic tests in its lump-sum payment. In the US, a\n                    new bill was introduced into Congress (HR 6446), called the Improving Diag-\n                    nostic Innovations Act, which seeks to improve the reimbursement process. The\n                    ultimate goal of the bill is to establish fair compensation for innovative, new in\n                    vitro diagnostics (\"IVD\") tests, and is likely to support market penetration for\n                    molecular assays.\n                \uf0b7   Need for cost efficient diagnostics: Constrained healthcare budgets, a growing\n                    world population and higher life expectancy drive the need for more cost-\n", "page_number": 7, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.8302693458743052, "height": 0.7486105173150919, "width": 0.788391777509069}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-1", "text": "effective approaches in healthcare. The goal is to achieve best medical outcomes\n", "page_number": 7, "bounding_box": {"top_left_x": 0.33373639661426846, "top_left_y": 0.8302693458743052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8426678067550235, "height": 0.012398460880718276, "width": 0.5465538089480049}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-2", "text": "effective approaches in healthcare. The goal is to achieve best medical outcomes\nfor patients, while saving money through optimised care cycles and avoidance of\n", "page_number": 7, "bounding_box": {"top_left_x": 0.3349455864570738, "top_left_y": 0.8430953398888413, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.857631466438649, "height": 0.014536126549807626, "width": 0.5538089480048367}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-3", "text": "ineffective therapies. Therefore, management believes that the need for timely\n", "page_number": 7, "bounding_box": {"top_left_x": 0.33313180169286577, "top_left_y": 0.857631466438649, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8700299273193672, "height": 0.012398460880718276, "width": 0.5471584038694075}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-4", "text": "ineffective therapies. Therefore, management believes that the need for timely\nand accurate test information enabling adequate treatment for infections is grow-\n", "page_number": 7, "bounding_box": {"top_left_x": 0.33373639661426846, "top_left_y": 0.8704574604531852, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8849935870029927, "height": 0.014536126549807515, "width": 0.5465538089480049}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-5", "text": "ing and is paving the way for rapid multiplex infectious disease testing.\n", "page_number": 7, "bounding_box": {"top_left_x": 0.3264812575574365, "top_left_y": 0.8854211201368106, "lower_right_x": 0.8192261185006046, "lower_right_y": 0.8986746472851646, "height": 0.013253527148353927, "width": 0.49274486094316805}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-6", "text": "The Company is a holding company without material direct business operations. The\n", "page_number": 7, "bounding_box": {"top_left_x": 0.27388149939540507, "top_left_y": 0.8995297135528003, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.9196237708422402, "height": 0.020094057289439915, "width": 0.6130592503022975}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-7", "text": "B.5\n", "page_number": 7, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.9055151774262505, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.9174861051731509, "height": 0.01197092774690034, "width": 0.0350665054413543}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-8", "text": "Description\n", "page_number": 7, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.9055151774262505, "lower_right_x": 0.2593712212817412, "lower_right_y": 0.9196237708422402, "height": 0.01410859341598969, "width": 0.09854897218863362}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-7-9", "text": "", "page_number": 7, "bounding_box": {"top_left_x": 0.841596130592503, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9533988884138521, "height": 0.006412997007268162, "width": 0.009673518742442488}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-0", "text": "of the Group   Company was incorporated on 8 October 2015 as a private company with limited liabil-\nand the        ity (besloten vennootschap met beperkte aansprakelijkheid). Immediately upon deter-\nCompany's      mination of the Offer Price, a corporate reorganisation (the \"Reorganisation\") will be\nposition       effected whereby the only Share (held by LSP Curetis Pooling B.V. as founding share-\ntherein        holder of the Company) will be cancelled and new Shares will be issued to the current\n               shareholders of Curetis AG. These shareholders will in turn contribute all shares they\n               hold in the share capital of Curetis AG as a contribution in kind against issuance of\n               Shares and the Company will be converted into a public company with limited liability\n               (naamloze vennootschap) named Curetis N.V. As a result of the Reorganisation, Curetis\n               AG will become a wholly owned subsidiary of the Company and the shareholders of\n               Curetis AG will become shareholders of the Company, in aggregate holding 11,107,378\n               Shares. Curetis AG conducted and conducts all business operations presented in the\n               Prospectus.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.2667806755023514, "height": 0.1817015818725951, "width": 0.7182587666263603}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-1", "text": "As part of the Reorganisation, Curetis will restructure its phantom stock option plan.\nUnder this plan, Curetis AG has awarded phantom stock options to officers, employees,\nfreelancers and advisors which entitle them to a payment 365 days after the Settlement\nDate (as defined below). Upon restructuring, the amount of this payment claim is de-\ntermined based on the Offer Price for phantom stock options settled in Shares and on\nthe first stock exchange trading price of the Shares for phantom stock options settled in\ncash. Each beneficiary entitled to 1,000 or less phantom stock options will receive a\npayment in cash 365 days after the Settlement Date. Assuming an Offer Price at the\nupper end of the Offer Price Range (as defined below) and a first stock exchange trad-\ning price equal to such Offer Price, the aggregate cash payment would amount to \u20ac469\nthousand. Each beneficiary entitled to more than 1,000 phantom stock options will\nreceive newly issued Shares for the amount that becomes payable to it 365 days after\nthe Settlement Date. Assuming an Offer Price at the upper end of the Offer Price Range,\nthe aggregate number of new Shares to be issued would be 665,020.\n", "page_number": 8, "bounding_box": {"top_left_x": 0.28174123337363965, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8875453446191052, "lower_right_y": 0.46130825138948267, "height": 0.19153484395040615, "width": 0.6058041112454655}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-2", "text": "At the date of the Prospectus only one Share is outstanding, which is held by LSP Cu-\nretis Pooling B.V. The following table sets forth the shareholders of the Company upon\ncompletion of the Reorganisation which, to the Company's knowledge, directly or indi-\nrectly, will have a notifiable interest in the Company's capital and voting rights within\nthe meaning of the Dutch Financial Supervision Act, following the Reorganisation and\nprior to the issuance of the Offer Shares and Settlement (as defined below), immediate-\nly following the issuance of the Offer Shares and Settlement and assuming (i) an Offer\nPrice at the mid-point of the Offer Price Range, (ii) that either a number of Offer Shares\nleading to gross proceeds corresponding to the Target Proceeds (as defined below) at\nthe mid-point of the Offer price Range or the maximum number of Offer Shares are\nsubscribed for and (iii) either no exercise of the Over-allotment Option or full exercise\nof the Over-allotment Option (as defined below):\n", "page_number": 8, "bounding_box": {"top_left_x": 0.27690447400241835, "top_left_y": 0.4685763146643865, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6327490380504489, "height": 0.16417272338606242, "width": 0.6058041112454655}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-3", "text": "B.6\n", "page_number": 8, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.46900384779820437, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.48097477554510476, "height": 0.011970927746900395, "width": 0.0350665054413543}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-4", "text": "Major\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1596130592503023, "top_left_y": 0.46900384779820437, "lower_right_x": 0.21704957678355502, "lower_right_y": 0.483539974348012, "height": 0.014536126549807626, "width": 0.05743651753325271}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-5", "text": "Shareholders\n", "page_number": 8, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.48268490808037623, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.4950833689610945, "height": 0.012398460880718276, "width": 0.10519951632406288}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-6", "text": "                                                     Shareholdings\n              Following the Reor-    Following the         Following the         Following the         Following the\n              ganisation and prior   Settlement (assum-    Settlement (assum-    Settlement (assum-    Settlement (assum-\n              to issuance of the     ing the issuance of   ing the issuance of   ing issuance of the   ing issuance of the\n              Offer Shares           a number of Offer     a number of Offer     maximum number        maximum number\n                                     Shares at the mid-    Shares at the mid-    of Offer Shares       of Offer Shares\n                                     point of the Offer    point of the Offer    without exercise of   with full exercise of\n                                     Price Range lead-     Price Range lead-     the Over-allotment    the Over-allotment\n                                     ing to the Target     ing to the Target     Option)               Option)\n                                     Proceeds without      Proceeds with full\n                                     exercise of the       exercise of the\n                                     Over-allotment        Over-allotment\n                                     Option)               Option)\nName of       Shares         in %    Shares        in %    Shares        in %    Shares        in %    Shares         in %\nShareholder\naeris\nCAPITAL\nEquity In-\nvestments,\nL.P.1          2,439,165      22%      2,890,666    21%      2,890,666    20%      2,890,666    19%      2,890,666     18%\nLSP Curetis    2,208,528      20%      2,590,639    19%      2,590,639    18%      2,590,639    17%      2,590,639     16%\n", "page_number": 8, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6613937580162462, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.9247541684480547, "height": 0.26336041043180847, "width": 0.7587666263603386}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-8-7", "text": "5\n", "page_number": 8, "bounding_box": {"top_left_x": 0.8409915356711004, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9542539546814878, "height": 0.007268063274903813, "width": 0.010278113663845123}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-0", "text": "Pooling B.V.\n2\n\n\nForbion\nCapital Fund\nII    Co\u00f6per-\natief U.A.3       1,111,269   10%    1,297,212   9%     1,297,212   9%     1,297,212   8%     1,297,212   8%\nKfW                935,162    8%      935,162    7%       935,162   7%      935,162    6%      935,162    6%\nHBM       Bio-\nCapital     II\nInvest\nS.a.r.l.4         1,047,268   9%     1,204,527   9%    1,204,527    8%     1,204,527   8%     1,204,527   8%\nBioMed\nInvest II LP5      780,202    7%      863,922    6%       863,922   6%      863,922    6%      863,922    5%\nRoche    Fi-\nnanz AG6           777,887    7%      908,119    7%       908,119   6%      908,119    6%      908,119    6%\nCD-Venture\nGmbH               435,182    4%      453,786    3%       453,786   3%      453,786    3%      453,786    3%\nQiagen N.V.        307,259    3%      307,259    2%       307,259   2%      307,259    2%      307,259    2%\n         7\nOthers            1,065,456   10%    2,381,667   17%    2,790,504   20%    3,822,753   25%    4,447,753   28%\nTotal            11,107,378   100   13,832,959   100   14,241,796   100   15,274,045   100   15,899,045   100\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.374091492090637, "height": 0.2920051303976058, "width": 0.7617896009673518}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-1", "text": "1\n  With aeris CAPITAL Equity Investments Ltd. as its general partner.\n2\n  The voting rights are attributed to LSP HEF Holding C.V. (with LSP Health Economics Fund Management B.V. acting as general partner) and to Co\u00f6peratif\nLSP IV U.A. (with LSP IV Management B.V. acting as the director) .\n3\n  The voting rights are attributed to Forbion II Management B.V.\n4\n  The voting rights are attributed to HBM BioCapital II LP.\n5\n  The voting rights are attributed to BioMedInvest AG I.\n6\n  The voting rights are attributed to Roche Holding Ltd. Includes the shares that Roche Finance Ltd. has committed to subscribe in the Offering.\n7\n  Others refer to shareholdings with less than three percent in the Company.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1124546553808948, "top_left_y": 0.3749465583582728, "lower_right_x": 0.8681983071342201, "lower_right_y": 0.4548952543822146, "height": 0.07994869602394183, "width": 0.7557436517533253}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-2", "text": "The Company was incorporated on 8 October 2015 for the purpose of the Offering.\nSince its date of incorporation, it has conducted no operations. There is no historical\n", "page_number": 9, "bounding_box": {"top_left_x": 0.27690447400241835, "top_left_y": 0.45874305258657544, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4886703719538264, "height": 0.02992731936725096, "width": 0.603385731559855}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-3", "text": "B.7\n", "page_number": 9, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.46216331765711843, "lower_right_x": 0.14328899637243048, "lower_right_y": 0.47413424540401883, "height": 0.011970927746900395, "width": 0.03325272067714631}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-4", "text": "Selected key\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.46216331765711843, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.4754168448054724, "height": 0.013253527148353983, "width": 0.09250302297460705}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-5", "text": "historical\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.4758443779392903, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.4878153056861907, "height": 0.011970927746900395, "width": 0.06831922611850061}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-6", "text": "historical    Since its date of incorporation, it has conducted no operations. There is no historical\nfinancial     financial information relating to the Company for the six months ended 30 June 2015\ninformation   and 2014 and the years ended 31 December 2014, 2013 and 2012.\n              If the Company had prepared consolidated condensed financial statements under Inter-\n              national Financial Reporting Standards (\"IFRS\"), as adopted in the European Union as\n              of and for the six months ended 30 June 2015 and 2014 and consolidated financial\n              statements for the years ended 31 December 2014, 2013 and 2012 and on the basis of\n              the assumption that the Company had already existed and owned all shares in Curetis\n              AG as from 1 January 2012, there would be no differences between such consolidated\n              financial statements and the financial statements of Curetis AG prepared in accordance\n              with IFRS in relation to the statement of comprehensive income or the cash flow state-\n              ment for the six months ended 30 June 2015 and 2014 and for the years ended\n              31 December 2014, 2013 and 2012. There would only be certain immaterial differences\n              in relation to the statement of financial position arising from the different nominal value\n              of the shares of the Company and Curetis AG, which would result in a different alloca-\n              tion across the items comprising equity. The Prospectus therefore contains Curetis AG's\n              financial statements under IFRS as of and for the financial years ended 31 December\n              2014, 2013 and 2012 and as of 30 June 2015 and the six months ended 30 June 2015\n              and 2014, and the below financial information is taken therefrom.\n", "page_number": 9, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.4890979050876443, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.7426250534416418, "height": 0.2535271483539975, "width": 0.7273276904474002}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-9-7", "text": "6\n", "page_number": 9, "bounding_box": {"top_left_x": 0.841596130592503, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9542539546814878, "height": 0.007268063274903813, "width": 0.009673518742442488}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-0", "text": "Statement of Profit or Loss and Other Comprehensive Income\n", "page_number": 10, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09876015391192818, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.11286874732791792, "height": 0.014108593415989745, "width": 0.4292623941958888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-1", "text": "The table below sets forth Curetis AG's statement of profit or loss and other comprehensive income for the years\nended 31 December 2014, 2013 and 2012 and for the six months ended 30 June 2015 and 2014:\n", "page_number": 10, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.875453446191052, "lower_right_y": 0.1466438648995297, "height": 0.027362120564343742, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-2", "text": "                                                      For the six months             For the year ended\n                                                        ended 30 June                  31 December\n                                                       2015         2014          2014        2013        2012\n                                                                           (in \u20acthousands)\n\n                                                          (unaudited)                        (audited)\n\nRevenue                                                    742           254          275         671        146\nCost of sales                                              665           359          643         219        429\nGross profit                                                  77        (105)       (368)         452      (283)\nDistribution costs                                       1,397          1,107       1,939       1,576      1,864\nAdministrative expenses                                  1,366           867        1,637       1,256      1,437\nResearch and development expenses                        2,943          3,305       6,298       5,895      5,358\nOther income                                                  41           23         111          49         22\nOperating profit                                        (5,588)     (5,362)      (10,132)     (8,226)     (8,919)\nFinance income                                                5            5             6         30         71\nFinance costs                                                 9            12          22          28         43\nFinance costs fair value measurement                     6,783          1,340       2,286       2,497     32,098\nFinance income/costs \u2013 net                              (6,786)     (1,347)       (2,302)     (2,495)    (32,069)\nProfit before income tax                               (12,374)     (6,709)      (12,434) (10,721)       (40,989)\nIncome tax income/expense                                     \u2013            \u2013             \u2013           \u2013       (77)\nProfit for the year                                    (12,374)     (6,709)      (12,434) (10,721)       (40,912)\nOther comprehensive income for the year, net of tax           \u2013            \u2013             \u2013           \u2013           \u2013\nTotal comprehensive income for the year                (12,374)     (6,709)      (12,434) (10,721)       (40,912)\n", "page_number": 10, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.15177426250534418, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6096622488242839, "height": 0.4578879863189397, "width": 0.7756952841596131}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-3", "text": "Statement of Financial Position\n", "page_number": 10, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.6378794356562634, "height": 0.012398460880718276, "width": 0.2230955259975816}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-4", "text": "The table below sets forth Curetis AG's statement of financial position as of 30 June 2015 and as of 31 Decem-\nber 2014, 2013 and 2012:\n", "page_number": 10, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.6703719538264216, "height": 0.024369388627618616, "width": 0.7484885126964933}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-5", "text": "                              30 June                    31 December\n                            (unaudited)                    (audited)\n                               2015          2014          2013          2012\n                             \u20acthousand      \u20acthousand     \u20acthousand     \u20acthousand\n\nAssets\nCurrent assets                    9,835         6,486          8,798        11,129\nCash and cash equivalents         5,940         2,994          5,382         9,777\nTrade receivables                     486           42            140            56\nInventories                       3,199         3,153          2,786         1,005\nOther current assets                  210         297             491           291\nNon-current assets                6,719         7,307          7,308         6,989\nIntangible assets                     225         286             331           336\n", "page_number": 10, "bounding_box": {"top_left_x": 0.10822249093107618, "top_left_y": 0.6746472851646003, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.93373236425823, "height": 0.25908507909362977, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-10-6", "text": "7\n", "page_number": 10, "bounding_box": {"top_left_x": 0.841596130592503, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.95382642154767, "height": 0.005985463873450225, "width": 0.009673518742442488}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-11-0", "text": "Property, plant and equipment                            6,070       6,592       6,457      5,986\nOther non-current assets                                    11           0           7         16\nOther non-current financial assets                         412         429         514        650\nTotal assets                                            16,554      13,793      16,107     18,118\n\n\nEquity and liabilities\nCurrent liabilities                                      1,505       1,305       1,090      1,259\nTrade and other payables                                   831         580         616        634\nProvisions current                                          50          35           6          1\nOther current liabilities                                  371         317         301        446\nOther current financial liabilities                        254         373         167        179\nNon-current liabilities                                145,958     131,024     121,119    112,240\nProvisions non-current                                     819         816         777        770\nProvision PSOP                                           5,342       3,914       2,957      3,090\nOther non-current financial liabilities                    189         258         392        519\nFinancial liability for preferred and common shares    139,608     126,036     116,993    107,860\nTotal liabilities                                      147,463     132,329     122,209    113,499\nEquity                                                (130,909)   (118,536)   (106,102)   (95,380)\nSubscribed equity                                           50          50          50         50\nRetained earnings                                     (130,959)   (118,586)   (106,152)   (95,430)\nTotal equity and liabilities                            16,554      13,793      16,107     18,118\n", "page_number": 11, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.08593415989739205, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5352714835399743, "height": 0.4493373236425823, "width": 0.7654171704957679}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-11-1", "text": "Statement of Cash Flows\n", "page_number": 11, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.5369816160752459, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.5643437366395896, "height": 0.027362120564343728, "width": 0.18137847642079807}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-11-2", "text": "The table below sets forth Curetis AG's statement of cash flows for the six months ended 30 June 2015 and 2014\nand for the years ended 31 December 2014, 2013 and 2012:\n", "page_number": 11, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.875453446191052, "lower_right_y": 0.5981188542112014, "height": 0.027362120564343728, "width": 0.7599758162031439}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-11-3", "text": "                                                           For the six months        For the year ended\n                                                             ended 30 June             31 December\n                                                              2015       2014        2014          2013      2012\n                                                                             (in \u20acthousands)\n\n                                                               (unaudited)                     (audited)\n\nNet cash flows provided by operating activities             (3,525)    (3,992)     (7,481)      (9,173)    (7,025)\nNet cash flow used in investing activities                   (252)       (470)     (1,537)      (1,737)    (1,904)\nNet cash flow provided by / used in financing activities     6,723       5,801      6,630         6,514     6,850\nNet change in cash and cash equivalents                      2,946       1,339     (2,388)      (4,395)    (2,079)\nCash and cash equivalents at the beginning of the year       2,994       5,382      5,382         9,777    11,857\nCash and cash equivalent at the end of the year              5,940       6,721      2,994         5,382     9,777\n", "page_number": 11, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.6053869174861052, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.837537409149209, "height": 0.23215049166310386, "width": 0.7732769044740024}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-11-4", "text": "Description of       As at the date of the Prospectus, there have been no significant changes in the\nsignificant          Company's financial or trading position since 30 June 2015.\nchange to the\nissuer's financial\ncondition and\noperating results\n", "page_number": 11, "bounding_box": {"top_left_x": 0.12817412333736397, "top_left_y": 0.8336896109448483, "lower_right_x": 0.8869407496977025, "lower_right_y": 0.9234715690466011, "height": 0.08978195810175282, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-11-5", "text": "8\n", "page_number": 11, "bounding_box": {"top_left_x": 0.8409915356711004, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9546814878153057, "height": 0.007268063274903813, "width": 0.010278113663845123}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-12-0", "text": "       during or subse-\n       quent to the\n       period covered\n       by the historical\n       financial infor-\n       mation\nB.8    Selected key pro    Not applicable. No pro forma financial information has been included in the Pro-\n       forma financial     spectus.\n       information\nB.9    Profit forecast     Not applicable. The Company has not issued a profit forecast.\nB.10   A description of    Not applicable. There are no qualifications in the auditor's report on the audited\n       the nature of any   financial statements of Curetis AG for the financial years ended 31 December\n       qualifications in   2014, 2013 and 2012. The auditor's report contains an emphasis of matter para-\n       the audit report    graph, in which the auditors draw attention to note 2.1, 31 and 34 of the notes to\n       on the historical   the financial statements, which describe that the Company's ability to continue as a\n       financial infor-    going concern is threatened by risks.\n       mation\n\nB.11   Working capital     Curetis' current cash resources do not provide it with sufficient working capital for\n                           the next twelve months following the date of this Prospectus. Curetis believes that\n                           it has sufficient working capital to continue its current operations until June of\n                           2016. Based on its present requirements under its current business plan which was\n                           prepared with a view to obtaining the net proceeds from the Offering and which\n                           includes costs for building a commercial marketing and sales presence in the US,\n                           Curetis believes its operations will require additional cash resources of approxi-\n                           mately \u20ac4.5 million to provide it with sufficient working capital for the next\n                           twelve months following the date of the Prospectus. If the Offering is completed\n                           and net proceeds of approximately \u20ac25 million are generated (which would be the\n                           case if the Company raises the targeted gross proceeds of approximate \u20ac29.3 mil-\n                           lion from the Offering), these proceeds together with Curetis' current cash re-\n                           sources will provide it with sufficient working capital for the next twelve months\n                           following the date of the Prospectus.\n                           If the Offering should be withdrawn or otherwise not be completed, Curetis will\n                           implement a detailed action plan to address the resulting imminent working capital\n                           shortfall by reducing the cash-outflows. This will include significant cost reduc-\n                           tions and reduced or at least delayed operating and capital expenditures. Primarily,\n                           Curetis will in this scenario suspend the build-up of its US organisation and its\n                           cost-intensive FDA trials in the US resulting in Curetis' inability to obtain the\n                           anticipated FDA clearance in the first half of 2017 and thus not being able to sell\n                           into the US market in 2017 and also in the following years. As a consequence,\n                           revenues from the US would not be generated or would be generated only with a\n                           significant delay. In addition, Curetis will reduce its staff expenditure due to ab-\n                           staining from hiring additional personnel. Regarding capital expenditures, Curetis\n                           will in that case postpone the investment into further multi-cavity injection molds,\n                           which would in turn lead to a postponed reduction in cost of goods sold of its\n                           Application Cartridges. Alternatively, or in conjunction with the above measures,\n                           Curetis may seek additional financing from current or future shareholders private-\n                           ly, whether in form of bridge loans and/or equity. Curetis believes that the actions\n                           mentioned above are likely to be successful and that the implementation of these\n                           cost reduction or financing measures would provide it with sufficient cash to main-\n                           tain its operations until early 2017 and as such continue as a going concern for at\n                           least 12 months from the date of the Prospectus.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.10761789600967352, "top_left_y": 0.0837964942283027, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.8272766139375801, "height": 0.7434801197092774, "width": 0.7829504232164449}, "blob_type": "table", "predictions": {}, "annotations": {"profit_forecast": ["not issued a profit forecast."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-12-1", "text": "In the scenario that Curetis fails to implement the above measures to remedy a\nworking capital shortfall caused by a withdrawal of the Offering, such as the gen-\neration of sufficient funds from additional financing and the described cost reduc-\ntion measures, it may be unable to continue as a going concern and may ultimately\nhave to file for insolvency.\n", "page_number": 12, "bounding_box": {"top_left_x": 0.31559854897218864, "top_left_y": 0.8319794784095768, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.9025224454895254, "height": 0.07054296707994867, "width": 0.5749697702539298}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-12-2", "text": "", "page_number": 12, "bounding_box": {"top_left_x": 0.8409915356711004, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.95382642154767, "height": 0.0068405301410859876, "width": 0.010278113663845123}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-0", "text": "Section C \u2013 Securities\n", "page_number": 13, "bounding_box": {"top_left_x": 0.4062877871825877, "top_left_y": 0.09918768704574604, "lower_right_x": 0.594316807738815, "lower_right_y": 0.11286874732791792, "height": 0.013681060282171878, "width": 0.18802902055622733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-1", "text": "Type and class       The Shares are ordinary shares in the issued and outstanding capital of the Com-\nSecurity identifi-   pany with a nominal value of \u20ac0.01 each.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.1368106028217187, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.16631038905515177, "height": 0.02949978623343308, "width": 0.7013301088270858}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-2", "text": "C.1\n", "page_number": 13, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.13809320222317228, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.15049166310389056, "height": 0.012398460880718276, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-3", "text": "cation number\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17896009673518742, "top_left_y": 0.16631038905515177, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.17699871740059855, "height": 0.01068832834544678, "width": 0.1064087061668682}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-4", "text": "Application has been made to list all Shares under the symbol \"CURE\" on Euron-\next in Amsterdam and Euronext in Brussels under ISIN Code NL0011509294.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.1718683197947841, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19837537409149208, "height": 0.026507054296707994, "width": 0.5616686819830714}, "blob_type": "undefined", "predictions": {}, "annotations": {"ticker": ["CURE"], "isin": ["NL0011509294"]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-5", "text": "C.2\n", "page_number": 13, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.21462163317657118, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.22702009405728943, "height": 0.012398460880718248, "width": 0.03567110036275696}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-6", "text": "Currency of the\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.21504916631038906, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.2278751603249252, "height": 0.01282599401453613, "width": 0.11668681983071341}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-7", "text": "The Shares are denominated in and will trade in euro.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.21504916631038906, "lower_right_x": 0.6813784764207981, "lower_right_y": 0.22573749465583584, "height": 0.01068832834544678, "width": 0.36275695284159615}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-8", "text": "Offer Shares\n", "page_number": 13, "bounding_box": {"top_left_x": 0.1717049576783555, "top_left_y": 0.22830269345874304, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.24070115433946132, "height": 0.012398460880718276, "width": 0.1033857315598549}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-9", "text": "Prior to the execution of the notarial deed of conversion and amendment of the\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2599401453612655, "height": 0.010688328345446751, "width": 0.5616686819830714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-10", "text": "C.3\n", "page_number": 13, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.2496793501496366, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.2620778110303549, "height": 0.012398460880718276, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-11", "text": "Number of\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.2496793501496366, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.261650277896537, "height": 0.011970927746900395, "width": 0.08282950423216448}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-12", "text": "articles of association of the Company, which deed will be executed immediately\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.27618640444634457, "height": 0.013253527148353983, "width": 0.5610640870616687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-13", "text": "Shares issued,\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.26336041043180847, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.27661393758016245, "height": 0.013253527148353983, "width": 0.10217654171704957}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-14", "text": "articles of association of the Company, which deed will be executed immediately\nafter determination of the Offer Price (the \"Deed of Amendment\"), the issued\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.28986746472851643, "height": 0.013253527148353983, "width": 0.5610640870616687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-15", "text": "nominal value\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.27704147071398033, "lower_right_x": 0.28355501813784767, "lower_right_y": 0.2890123984608807, "height": 0.011970927746900395, "width": 0.10519951632406291}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-16", "text": "share capital of the Company consists of 11,107,378 Shares. Immediately after the\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.30354852501068835, "height": 0.013253527148354038, "width": 0.5616686819830714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-17", "text": "per Share\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.2907225309961522, "lower_right_x": 0.250906892382104, "lower_right_y": 0.30440359127832406, "height": 0.013681060282171864, "width": 0.07255139056831925}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-18", "text": "share capital of the Company consists of 11,107,378 Shares. Immediately after the\nexecution of the Deed of Amendment, the authorised capital of the Company will\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3172295852928602, "height": 0.013253527148354038, "width": 0.5616686819830714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-19", "text": "amount to \u20ac550,000 and will consist of 55,000,000 Shares with\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.31765711842667804, "lower_right_x": 0.7484885126964933, "lower_right_y": 0.3309106455750321, "height": 0.013253527148354038, "width": 0.4298669891172914}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-20", "text": "h a nominal value of\n", "page_number": 13, "bounding_box": {"top_left_x": 0.75453446191052, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.32962804617357844, "height": 0.011970927746900395, "width": 0.13422007255139057}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-21", "text": "amount to \u20ac550,000 and will consist of 55,000,000 Shares with a nominal\n\u20ac0.01 each and the issued share capital will consist of 11,107,378 Shares.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.313180169286578, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8210399032648126, "lower_right_y": 0.3450192389910218, "height": 0.013681060282171864, "width": 0.5078597339782346}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-22", "text": "C.4\n", "page_number": 13, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.35271483539974346, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.36511329628046174, "height": 0.012398460880718276, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-23", "text": "Rights attached\n", "page_number": 13, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.35271483539974346, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.3659683625480975, "height": 0.013253527148354038, "width": 0.11668681983071341}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-24", "text": "References to the \"Articles of Association\" hereafter will be to the Company's\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3216444981862152, "top_left_y": 0.35271483539974346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3659683625480975, "height": 0.013253527148354038, "width": 0.5586457073760581}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-25", "text": "to the Shares\n", "page_number": 13, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.36639589568191533, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.3787943565626336, "height": 0.012398460880718276, "width": 0.09552599758162034}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-26", "text": "articles of association as they will read after the execution of the Deed of Amend-\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.36639589568191533, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.38093202223172296, "height": 0.014536126549807626, "width": 0.5701330108827086}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-27", "text": "ment.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3192261185006046, "top_left_y": 0.3826421547669944, "lower_right_x": 0.36094316807738813, "lower_right_y": 0.3920478837109876, "height": 0.009405728943993164, "width": 0.041717049576783516}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-28", "text": "The Shares carry dividend rights. Each Share confers the right to cast one vote in\nthe general meeting of the Company (the \"General Meeting\"). There are no re-\nstrictions on voting rights.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.44121419410004276, "height": 0.04147071398033347, "width": 0.5616686819830714}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-29", "text": "Holders of Shares (\"Shareholders\") have a pre-emptive right in the event of an\nissue of Shares or the granting of rights to subscribe for Shares. Shareholders do\nnot have pre-emptive rights in respect of Shares issued against contribution in kind\nor Shares issued to employees of the Company and any of its group companies or\nShares issued to persons exercising a previously granted right to subscribe for\nShares.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5288584865327063, "height": 0.08123129542539548, "width": 0.5665054413542926}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-30", "text": "Prior to the Conversion, the General Meeting shall resolve to issue the Offer\nShares following the Conversion and to exclude the pre-emptive rights of Share-\nholders with respect to the issuance of the Offer Shares.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5780247969217615, "height": 0.04147071398033353, "width": 0.5616686819830714}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-31", "text": "The Articles of Association provide that the General Meeting may, upon a pro-\nposal of the management board of the Company (the \"Management Board\" and\neach member a \"Managing Director\") which is approved by the supervisory\nboard of the Company (the \"Supervisory Board\" and each member a \"Superviso-\nry Director\"), designate the Management Board as the body authorised, subject to\napproval of the Supervisory Board, to resolve to issue Shares and to grant rights to\nsubscribe for Shares. The resolution designating such authority to the Management\nBoard must specify the number of Shares which may be issued and, if applicable,\nany conditions to the issuance. The designation will only be valid for a specific\nperiod and may from time to time be extended by the General Meeting, in each\ncase not exceeding five years. Unless provided otherwise in the designation, the\ndesignation cannot be cancelled.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.5844377939290295, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7490380504489098, "height": 0.1646002565198803, "width": 0.5640870616686819}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-32", "text": "The Management Board may also be designated to, subject to the approval of the\nSupervisory Board, limit or exclude the pre-emptive rights to which Shareholders\nare entitled if and to the extent that the General Meeting has authorised the Man-\nagement Board for this purpose, and only if the Management Board at that time is\nalso authorised to issue Shares or to grant rights to subscribe for Shares.\n", "page_number": 13, "bounding_box": {"top_left_x": 0.3186215235792019, "top_left_y": 0.7558785805899957, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8242838820008551, "height": 0.06840530141085943, "width": 0.5616686819830714}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-33", "text": "The General Meeting shall designate the Management Board, for a period that\nends 18 months following the Conversion, as the corporate body authorised to,\nsubject to approval of the Supervisory Board, issue Shares or grant rights to sub-\nscribe for Shares and to restrict or exclude pre-emptive rights in respect thereof.\nPursuant to this designation, the Management Board may, subject to approval of\nthe Supervisory Board, resolve to issue Shares or grant rights to subscribe for\nShares (i) up to a maximum of 10% of the total number of Shares issued and out-\n", "page_number": 13, "bounding_box": {"top_left_x": 0.31559854897218864, "top_left_y": 0.8319794784095768, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.9281744335185977, "height": 0.09619495510902099, "width": 0.5743651753325272}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-13-34", "text": "10\n", "page_number": 13, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-14-0", "text": "standing on the Settlement Date (as defined below) plus (ii) an additional 10% of\nthe total number of Shares issued and outstanding on the Settlement Date in con-\nnection with or on the occasion of mergers and acquisitions and strategic alliances.\nSuch authorisation may from time to time be extended by a resolution of the Gen-\n", "page_number": 14, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.08294142796066695, "lower_right_x": 0.8929866989117291, "lower_right_y": 0.14023086789226166, "height": 0.057289439931594716, "width": 0.5840386940749698}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-14-1", "text": "                           Such authorisation may from time to time be extended by a resolution of the Gen-\n                           eral Meeting.\nC.5   Restrictions on      There are no restrictions on the transferability of the Offer Shares in the Articles of\n      transferability of   Association.\n      the Offer Shares\n                           However, the Offering to persons located or resident in, or who are citizens of, or\n                           who have a registered address in countries other than the Netherlands and Germa-\n                           ny, and the transfer of Offer Shares into jurisdictions other than the Netherlands\n                           and Germany may be subject to specific regulations or restrictions.\nC.6   Listing and ad-      Prior to the Offering, there has been no public market for the Shares. Application\n      mission to trad-     has been made to list all Shares under the symbol \"CURE\" on Euronext in Am-\n      ing of the Offer     sterdam and Euronext in Brussels. Subject to acceleration or extension of the time-\n      Shares               table for the Offering, trading in the Shares on Euronext in Amsterdam and Euron-\n                           ext in Brussels is expected to commence, on an \"as-if-and-when-issued\" basis, on\n                           or about 11 November 2015 (the \"First Trading Date\").\nC.7   Dividend policy      The Company expects to retain all earnings, if any, generated by Curetis' opera-\n                           tions for the development and growth of its business and does not anticipate pay-\n                           ing any dividends to the Shareholders in the near future.\n\n                                           Section D \u2013 Risks\n\nD.1   Key risks relat-     Risks Related to Business and Strategy\n", "page_number": 14, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.1368106028217187, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.4566053869174861, "height": 0.3197947840957674, "width": 0.7841596130592503}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-14-2", "text": "ing to the Com-\n                  \uf0b7   Curetis is a company with only a limited amount of products and has in-\npany and its\n                      curred significant losses since inception and expects to incur losses in the\nindustry\n                      foreseeable future. It is not certain that Curetis will achieve or sustain prof-\n                      itability.\n                  \uf0b7   Curetis is currently in the process of obtaining FDA clearance for the Un-\n                      yvero System and the LRT55 Application Cartridge. It is uncertain whether\n                      and when such regulatory clearance will be obtained.\n                  \uf0b7   Curetis may be unable to successfully commercialise its products and may\n                      fail to achieve and sustain sufficient market acceptance.\n                  \uf0b7   Curetis is particularly dependent on the success of, and the ability to mar-\n                      ket, its lead products, the P55 and the i60 ITI Application Cartridges in the\n                      EU and the LRT55 Application Cartridge in the US, on which it has fo-\n                      cused almost all of its business and financial resources in the past.\n                  \uf0b7   The market potential and opportunities for Curetis' lead products may be\n                      smaller than currently anticipated, lowering potential revenue for Curetis.\n                  \uf0b7   Curetis may expand its limited financial and managerial resources to pursue\n                      a particular future product or indication and fail to capitalise on products or\n                      indications that may be more profitable or for which there is a greater like-\n                      lihood of success.\n                  \uf0b7   Curetis may be unable to successfully manage its growth.\n                  \uf0b7   Curetis depends on a few key suppliers for critical product components. In\n                      case of a loss of any of these suppliers or an interruption of supply, Curetis\n                      may not be able to manufacture or outsource manufacturing of its products\n                      in sufficient quantities, in a timely manner or at a cost that is economically\n                      attractive.\n                  \uf0b7   Curetis relies on certain distribution partners to distribute its products in\n                      some of its markets and intends to enter into additional distribution agree-\n                      ments with distribution partners to distribute its products in other markets.\n                      If Curetis is unable to find suitable distribution partners, loses these distri-\n", "page_number": 14, "bounding_box": {"top_left_x": 0.17533252720677148, "top_left_y": 0.45703292005130397, "lower_right_x": 0.8929866989117291, "lower_right_y": 0.9230440359127833, "height": 0.4660111158614793, "width": 0.7176541717049576}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-14-3", "text": "11\n", "page_number": 14, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.013301088270858519}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-15-0", "text": "    bution partners or if Curetis' distribution partners fail to sell its products in\n    sufficient quantities, on commercially viable terms or in a timely manner,\n    Curetis' commercialisation of P55/LRT55 and i60 ITI Application Car-\n    tridges and other future products could be materially delayed or harmed.\n\uf0b7   Curetis' sales cycles are lengthy and sales may fluctuate, which makes it\n    difficult to forecast revenue and product sales.\n\uf0b7   Curetis may not be able to gain the support of leading hospitals and key\n    opinion leaders (\"KOLs\"), or to achieve favourable publication of the re-\n    sults of Curetis' clinical trials in peer-reviewed journals.\n\uf0b7   Curetis may be unable to recruit, train and retain key personnel.\n\uf0b7   Curetis' cash position and operating cash flow may be insufficient to cover\n    expected investment expenses, and Curetis may need to raise additional\n    funds in the future.\n\uf0b7   The molecular diagnostics market is highly competitive and Curetis may\n    not be able to compete effectively.\n\uf0b7   The selling price level in the molecular diagnostics market could decrease\n    in the future which would adversely affect Curetis' business, financial posi-\n    tion and results of operations.\n\uf0b7   Curetis' current and future customers are highly dependent on payments\n    from third-party payers. Inadequate coverage and reimbursement for Cu-\n    retis' diagnostic tests as well as a faster increase of Curetis' costs of produc-\n    tion compared to increases in reimbursement levels could compromise the\n    commercial success of Curetis' products.\n\uf0b7   The manufacture of many of Curetis' products is a highly precise and com-\n    plex process, and if Curetis encounters problems with the manufacturing\n    and the quality of its products, its reputation and business could suffer.\n\uf0b7   Curetis' diagnostics results may not perform as expected and deliver in-\n    complete or incorrect results which could subject Curetis to product liabil-\n    ity claims.\n\uf0b7   A recall of Curetis' products, either voluntarily or at the direction of the\n    relevant regulatory bodies, or the discovery of serious safety issues with\n    Curetis' products that leads to corrective actions, could have a significant\n    adverse impact on Curetis.\n\uf0b7   Curetis' future success is dependent upon Curetis' ability to create, maintain\n    and expand a customer base for its products in large and leading hospitals.\n\uf0b7   Curetis may not be able to develop new products or enhance the capabilities\n    of its products and systems to keep pace with the rapidly changing technol-\n    ogy and customer requirements in Curetis' industry.\n\uf0b7   If the manufacturing, development or testing equipment used by or for\n    Curetis were damaged or destroyed, or if Curetis experiences a significant\n    disruption in its operations or if Curetis experiences any problems with its\n    manufacturing processes for any reason, Curetis' ability to continue to op-\n    erate its business could be materially harmed.\n\uf0b7   A significant amount of Curetis' inventory consists of equipment held by\n    prospective customers who are evaluating their products and may not be\n    converted to revenue in the timeframe that Curetis anticipates or at all.\n\uf0b7   Curetis' intention to enter into agreements with strategic partners in posses-\n    sion of proprietary biomarkers for diagnosis of indications with a view to\n    developing and commercialising new diagnostic products could prove un-\n    successful.\n\uf0b7   Acquisitions or joint ventures could disrupt Curetis' business, cause dilution\n    to Curetis' shareholders and otherwise harm Curetis' business.\n\n\n                                                                             12\n", "page_number": 15, "bounding_box": {"top_left_x": 0.29081015719467956, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8917775090689238, "lower_right_y": 0.9563916203505771, "height": 0.8747327917913638, "width": 0.6009673518742442}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-16-0", "text": "\uf0b7     Curetis will likely lose its current tax losses carried forward.\n\uf0b7     Curetis' operating results could be materially adversely affected by unantic-\n      ipated changes in tax laws and regulations, adjustments to its tax provisions\n      or exposure to additional tax liabilities.\n\uf0b7     Curetis currently generates a portion of its revenue internationally and ex-\n      pects to increase this portion in the future. It is therefore subject to various\n      risks relating to its international activities which could adversely affect Cu-\n      retis' operating results.\n\uf0b7     Curetis is exposed to changes in foreign currency exchange rates.\n\uf0b7     Curetis' employees, independent contractors, principal investigators, dis-\n      tributors, consultants, commercial partners and vendors may engage in mis-\n      conduct or other improper activities, including non-compliance with regula-\n      tory standards and requirements.\n\uf0b7     Curetis relies on third parties to conduct clinical and evaluation studies of\n      its products that are required by the FDA or other regulatory authorities,\n      and those third parties may not perform satisfactorily.\n\uf0b7     Curetis' business could be significantly and negatively affected by current\n      or new governmental regulations and clearance, approval and post-approval\n      requirements, particularly in the EU and the US.\n\uf0b7     Healthcare policy changes, including legislation to reform the US\n      healthcare system, may have a material adverse effect on Curetis' financial\n      position and results of operations.\n\uf0b7     Modifications to Curetis' products, if cleared or approved, may require new\n      clearances or pre-market approvals, or may require Curetis to cease market-\n      ing or recall the modified products until clearances or approvals are ob-\n      tained.\n\uf0b7     Upon the planned launch of operations in the US, Curetis will be subject to\n      federal and state healthcare fraud and abuse laws and other federal and state\n      laws applicable to Curetis' business activities. If Curetis is unable to com-\n      ply with such laws, it could face substantial penalties.\n\uf0b7     Curetis faces risks related to handling hazardous materials and other regula-\n      tions governing environmental safety.\n\uf0b7     Curetis depends on its information technology systems, and any failure of\n      these systems could harm Curetis' business.\n\uf0b7     Curetis has entered into a lease agreement for a manufacturing plant in\n      which its laboratory facilities are located. The unexpected termination or\n      non-renewal of this lease agreement could have a significant adverse effect\n      on Curetis' business, financial position and results of operations.\n\nRisks Related to Intellectual Property\n\uf0b7     If Curetis is unable to protect its intellectual property effectively, its busi-\n      ness would be harmed.\n", "page_number": 16, "bounding_box": {"top_left_x": 0.27871825876662637, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.7678495083368961, "height": 0.685763146643865, "width": 0.6154776299879081}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-16-1", "text": "Curetis depends on certain technologies that are licensed to it. Curetis does\nnot control the intellectual property rights covering these technologies and\nany loss of its rights to these technologies or the rights licensed to it could\nprevent Curetis from selling its products.\nCuretis may be involved in lawsuits to protect or enforce its patents and\nproprietary rights, to determine the scope, enforceability and validity of\nothers' proprietary rights, or to defend against third-party claims of intellec-\ntual property infringement, any of which could be time-intensive and costly\nand may adversely impact Curetis' business or share price.\nCuretis relies on trade secret protection,confidentiality agreements and\n", "page_number": 16, "bounding_box": {"top_left_x": 0.3639661426844015, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8875453446191052, "lower_right_y": 0.9238991021804189, "height": 0.15134672937152627, "width": 0.5235792019347036}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-16-2", "text": "13\n", "page_number": 16, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-17-0", "text": "                              patent assignment agreements.\n                          \uf0b7   Curetis may be subject to damages resulting from claims that Curetis or its\n                              employees, consultants or independent contractors have wrongfully used or\n                              disclosed confidential information of third parties or that Curetis' employ-\n                              ees have wrongfully used or disclosed alleged trade secrets of their former\n                              employers.\n                          \uf0b7   If Curetis' trademarks and trade names are not adequately protected, Curetis\n                              may not be able to build name recognition in its markets of interest, and\n                              Curetis' business may be adversely affected.\nD.3   Key risks relat-    \uf0b7   There has been no public market for the Shares prior to the Offering and the\n      ing to the Shares       Company cannot assure that an active and liquid market in the Offer Shares\n      and the Offering        will develop.\n                          \uf0b7   The market price of the Shares may fluctuate significantly and investors\n                              could lose all or part of their investment.\n                          \uf0b7   Upon completion of the Offering, certain existing Shareholders will retain\n                              substantial influence over the Company, and their interests may be incon-\n                              sistent with those of other Shareholders.\n                          \uf0b7   Retail investors may have to pay a higher price for the Offer Shares than\n                              was envisaged at the time of subscribing.\n                          \uf0b7   The Company has broad discretion in the use of the net proceeds from this\n                              Offering and may not use them effectively.\n                          \uf0b7   The Company will incur increased costs as a result of being a public com-\n                              pany.\n                          \uf0b7   Future issuances or sales of substantial numbers of Shares or securities\n                              convertible into Shares, as part of a stock option programme used as a suc-\n                              cess based management and senior employee remuneration component or\n                              otherwise, or the perception that these issuances or sales may occur, may\n                              adversely affect the market price of the Shares and any future issuance of\n                              Shares may dilute investors' shareholdings. Although the Company, all ex-\n                              isting Shareholders, all former and current employees of Curetis holding\n                              Shares and the Managing Directors are expected to agree in the Underwrit-\n                              ing Agreement and separate lock-up agreements, respectively, to certain re-\n                              strictions on issuing, selling or transferring Shares for a period of 365 days\n                              after the Settlement Date, the Joint Bookrunners (as defined below) may, in\n                              their sole discretion and at any time, waive such restrictions.\n                          \uf0b7   Holders of Shares who are resident or located in certain jurisdictions out-\n                              side the Netherlands, including the US, may be unable to exercise pre-\n                              emptive rights in future offerings and, as a result, may experience dilution.\n                          \uf0b7   If Settlement does not occur, subscriptions for the Offer Shares may be\n                              disregarded and transactions effected in the Shares will be annulled.\n                          \uf0b7   The Company does not intend to pay dividends for the foreseeable future.\n                          \uf0b7   Investors with a reference currency other than euro will become subject to\n                              foreign exchange rate risk when investing in the Shares.\n                          \uf0b7   If securities or industry analysts do not publish research or publish inaccu-\n                              rate or unfavourable research about Curetis' business, or publish projections\n                              that exceed Curetis' actual results, the price of Shares and trading volume\n                              could decline.\n                          \uf0b7   The ability of Shareholders to bring actions or enforce judgments against\n                              the Company, Managing Directors and Supervisory Directors may be lim-\n                              ited.\n                          \uf0b7   Any sale, purchase or exchange of Shares may become subject to the Fi-\n                              nancial Transaction Tax.\n", "page_number": 17, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.9298845660538692, "height": 0.8482257374946558, "width": 0.7841596130592503}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-17-1", "text": "14\n", "page_number": 17, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-0", "text": "\uf0b7   The Company may be classified as a passive foreign investment company\n    for US federal income tax purposes, which could subject US investors in\n    the Shares to significant adverse tax consequences.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.129115006412997, "height": 0.04745617785378366, "width": 0.7889963724304716}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-1", "text": "Section E \u2013 Offer\n", "page_number": 18, "bounding_box": {"top_left_x": 0.4207980652962515, "top_left_y": 0.14322359982898675, "lower_right_x": 0.5701330108827086, "lower_right_y": 0.15647712697734073, "height": 0.013253527148353983, "width": 0.1493349455864571}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-2", "text": "Net proceeds    The Company is targeting to raise approximately \u20ac29.3 million of gross proceeds\nand estimated   from the Offering (the \u201cTarget Proceeds\u201d). On the basis of the maximum number\nexpenses        of Offer Shares (assuming no exercise of the over-allotment option (the \"Over-\n                allotment Option\") that is to be granted by the Company in connection with the\n                Offering) the Company has the possibility to raise up to approximately \u20ac50 million\n                in gross proceeds from the Offering (based on an Offer Price at the upper end of\n                the Offer Price Range (as defined below)).\n                After deducting the estimated expenses, commissions and taxes related to the Of-\n                fering of \u20ac4.3 million, which include approximately \u20ac1.46 million of fees and\n                commissions payable to the Underwriters (as defined below), the Company expects\n                to receive approximately \u20ac25 million in net proceeds from the Offering (based on\n                an Offering that achieves the Target Proceeds).\n\nReasons for     The principal purpose of the Offering is to obtain additional capital to support the\nthe Offering    execution of Curetis' strategy. In addition, the Offering will also create a public\nand use of      market for the Shares, allowing future access to the public equity markets.\nproceeds\n                Assuming the Company raises the Target Proceeds, the Company expects to gener-\n                ate approximately \u20ac25 million in net proceeds.\n                Curetis currently anticipates that over the coming several years it will use the net\n                proceeds of the Offering along with expected cash inflows from gross margin on\n                product sales, in order of importance, as follows:\n                \uf0b7      Approximately 20% to 30% of the net proceeds of the Offering for building\n                       a commercial marketing, sales and support presence in the US in order to\n                       directly commercialise the Unyvero System and Application Cartridges fol-\n                       lowing the anticipated FDA clearance.\n                \uf0b7      Approximately 20% to 25% of the net proceeds of the Offering for acceler-\n                       ating the R&D pipeline of the Unyvero Application Cartridges for Europe-\n                       an, US and global markets, including clinical trials and regulatory approval.\n                \uf0b7      Approximately 15% to 20% of the net proceeds of the Offering for expand-\n                       ing and strengthening the European commercial presence for markets where\n                       Curetis sells the Unyvero Platform directly to end customers.\n                \uf0b7      With the remainder to be used on:\n                             o    a manufacturing capacity expansion,\n                             o    additional working capital requirements, and\n                             o    general corporate purposes.\nTerms and       Offer Shares\n", "page_number": 18, "bounding_box": {"top_left_x": 0.17230955259975816, "top_left_y": 0.168875587858059, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.7545959811885421, "height": 0.5857203933304831, "width": 0.7091898428053205}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-3", "text": "E.1\n", "page_number": 18, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.1414752116082225, "lower_right_y": 0.19153484395040615, "height": 0.01068832834544678, "width": 0.02599758162031439}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-4", "text": "E.2a\n", "page_number": 18, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.3668234288157332, "lower_right_x": 0.1523579201934704, "lower_right_y": 0.3787943565626336, "height": 0.011970927746900395, "width": 0.04232164449818622}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-5", "text": "E.3\n", "page_number": 18, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.7426250534416418, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.7545959811885421, "height": 0.01197092774690034, "width": 0.03567110036275696}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-6", "text": "Offer Shares\nThe Company is offering up to 4,791,667 Offer Shares. The Offering consists of:\n(i) a public offering to retail and institutional investors in Germany and (ii) a pri-\nvate placement to certain institutional investors in various other jurisdictions. The\nOffer Shares are being offered (i) within the United States to qualified institutional\nbuyers (\"QIBs\") as defined in Rule 144A (\"Rule 144A\") under the US Securities\nAct of 1933, as amended (the \"US Securities Act\") in reliance on Rule 144A or\npursuant to another exemption from, or in a transaction not subject to, the registra-\ntion requirements of the US Securities Act, and (ii) outside the United States in\noffshore transactions in reliance on Regulation S under the US Securities Act\n(\"Regulation S\"). The Offering is made only in those jurisdictions in which, and\nonly to those persons to whom, the Offering may be lawfully made.\n", "page_number": 18, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.7563061137238136, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.9132107738349722, "height": 0.15690466011115856, "width": 0.5816203143893591}, "blob_type": "paragraph", "predictions": {}, "annotations": {"transaction": ["public offering", "pri-vate placement"]}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-7", "text": "Terms and\nconditions of\n", "page_number": 18, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.7563061137238136, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.768277041470714, "height": 0.01197092774690034, "width": 0.09733978234582832}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-8", "text": "conditions of\nthe Offering\n", "page_number": 18, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.7695596408721675, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.7832407011543394, "height": 0.013681060282171864, "width": 0.09250302297460702}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-18-9", "text": "15\n", "page_number": 18, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-0", "text": "Over-allotment Option\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.09191962377084224, "lower_right_x": 0.47339782345828296, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.16444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-1", "text": "The Company expects to grant the Sole Global Coordinator (as defined below), on\nbehalf of the Underwriters, the Over-allotment Option, exercisable within 30 cal-\nendar days after the First Trading Date, pursuant to which the Sole Global Coordi-\nnator, on behalf of the Underwriters, may require the Company to issue to the Un-\nderwriters at the Offer Price up to 625,000 Additional Shares, comprising up to\n15% of the total number of Offer Shares issued in the Offering (the \"Additional\nShares\"), to cover over-allotments or short positions, if any, in connection with the\nOffering.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.10773834972210346, "lower_right_x": 0.875453446191052, "lower_right_y": 0.2231722958529286, "height": 0.11543394613082515, "width": 0.5755743651753326}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-2", "text": "Offer Period\n", "page_number": 19, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.22873022659256093, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.24155622060709706, "height": 0.01282599401453613, "width": 0.09189842805320436}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-3", "text": "Prospective investors may subscribe for Offer Shares during the period commenc-\ning on 28 October 2015 at 09:00 CET and ending on 10 November 2015 at 16:00\nCET (the \"Offer Period\"), subject to acceleration or extension of the timetable for\nthe Offering.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.24625908507909364, "lower_right_x": 0.873639661426844, "lower_right_y": 0.3052586575459598, "height": 0.058999572466866185, "width": 0.5737605804111245}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-4", "text": "Subject to acceleration or extension of the timetable for, or withdrawal of, the\nOffering, the timetable below lists certain expected key dates for the Offering:\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8700120918984281, "lower_right_y": 0.3386062419837537, "height": 0.02778965369816161, "width": 0.5610640870616688}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-5", "text": "Event                               Time (CET) and date\nStart of Offer Period               09:00 on 28 October 2015\nEnd of Offer Period                 16:00 on 10 November 2015\nPricing                             10 November 2015\nFirst Trading Date (trading on an   11 November 2015\n\"as-if-and-when-issued\" basis)\nSettlement Date                     13 November 2015\n", "page_number": 19, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.34587430525865753, "lower_right_x": 0.8174123337363967, "lower_right_y": 0.45746045318512185, "height": 0.11158614792646432, "width": 0.5078597339782347}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-6", "text": "Please note that the Company, after consultation with the Joint Bookrunners (as\ndefined below), reserves the right to accelerate or extend the Offer Period.\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8724304715840387, "lower_right_y": 0.49294570329200516, "height": 0.024796921761436552, "width": 0.5634824667472793}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-7", "text": "defined below), reserves the right to acceler\nOffer Price and Number of Offer Shares\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.493373236425823, "lower_right_x": 0.5991535671100363, "lower_right_y": 0.5130397605814451, "height": 0.01966652415562209, "width": 0.29020556227327693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-8", "text": "The Offer Price is expected to be in the range of \u20ac9.50 to \u20ac12 (inclusive) per Offer\nShare (the \"Offer Price Range\"). The Offer Price Range is an indicative price\nrange. The Offer Price may be set within, above or below the Offer Price Range.\nThe Offer Price and the exact number of Offer Shares offered will be determined\nby the Company, after consultation with the Joint Bookrunners, after the end of the\nOffer Period, including any acceleration or extension, on the basis of the book\nbuilding process and taking into account economic and market conditions, a quali-\ntative and quantitative assessment of demand for the Offer Shares, and other fac-\ntors deemed appropriate. The Offer Price, the exact numbers of Offer Shares to be\nissued and the maximum number of Additional Shares will be stated in a pricing\nstatement which will be published through a press release that will also be posted\non the Company's website and deposited with the Dutch Authority for the Financial\nMarkets (Stichting Autoriteit Financi\u00eble Markten, the \"AFM\").\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5228730226592561, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7007268063274904, "height": 0.17785378366823434, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-9", "text": "The Offer Price Range is an indicative price range. The Company, after consulta-\ntion with the Joint Bookrunners, reserves the right to change the Offer Price Range\nand/or to increase the maximum number of Offer Shares prior to the allocation of\nthe Offer Shares (\"Allocation\"). Any such change will be announced in a press\nrelease (that will also be posted on the Company's website).\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.7075673364685763, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7759726378794357, "height": 0.06840530141085943, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-10", "text": "Subscription and Allocation\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.7828131680205216, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.7969217614365113, "height": 0.01410859341598969, "width": 0.20314389359129387}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-11", "text": "Eligible retail investors in Germany who wish to subscribe for Offer Shares should\nsubmit their subscriptions through their own financial intermediary. The financial\nintermediary will be responsible for collecting subscriptions from eligible retail\ninvestors and for submitting their subscriptions to ICF as the retail coordinator (the\n\"Retail Coordinator\"). The Retail Coordinator will consolidate all subscriptions\nsubmitted by eligible retail investors in Germany to financial intermediaries and\ninform the Sole Global Coordinator and the Company. Eligible retail investors in\nGermany are not required to subscribe on a market order (billigst) basis and may\n", "page_number": 19, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.8033347584437794, "lower_right_x": 0.875453446191052, "lower_right_y": 0.9132107738349722, "height": 0.10987601539119274, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-19-12", "text": "16\n", "page_number": 19, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-0", "text": "therefore submit orders providing for a price limit.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.3022974607013301, "top_left_y": 0.08165882855921335, "lower_right_x": 0.6571946795646917, "lower_right_y": 0.09833262077811031, "height": 0.016673792218896963, "width": 0.35489721886336156}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-1", "text": "Allocation is expected to take place after the end of the Offer Period, on or about\n10 November 2015, subject to acceleration or extension of the timetable for the\nOffering. Allocation to investors who applied to subscribe for Offer Shares will be\ndetermined by the Company, after consultation with the Joint Bookrunners, and\nfull discretion will be exercised as to whether or not and how to allot the Offer\nShares. There is no maximum or minimum number of Offer Shares for which pro-\nspective investors may subscribe and multiple (applications for) subscriptions are\npermitted. In the event that the Offering is over-subscribed, investors may receive\nfewer Offer Shares than they applied to subscribe for.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.09876015391192818, "lower_right_x": 0.875453446191052, "lower_right_y": 0.2291577597263788, "height": 0.13039760581445065, "width": 0.5755743651753326}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-2", "text": "Payment\n", "page_number": 20, "bounding_box": {"top_left_x": 0.3010882708585248, "top_left_y": 0.2334330910645575, "lower_right_x": 0.37726723095526, "lower_right_y": 0.25053441641727237, "height": 0.017101325352714858, "width": 0.0761789600967352}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-3", "text": "Payment (in euro) for, and delivery of, the Offer Shares (\"Settlement\") is expected\nto take place on the settlement date, which is expected to be on or about\n13 November 2015 (the \"Settlement Date\"). Taxes and expenses, if any, must be\nborne by the investor. Eligible retail investors in Germany may be charged expens-\nes by their financial intermediary. Investors must pay the Offer Price in immediate-\nly available funds in full in euro on or before the Settlement Date (or earlier in the\ncase of an early closing of the Offer Period and consequent acceleration of pricing,\nAllocation, commencement of trading and payment and delivery).\n", "page_number": 20, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.25609234715690465, "lower_right_x": 0.875453446191052, "lower_right_y": 0.3659683625480975, "height": 0.10987601539119285, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-4", "text": "Delivery of Shares\n", "page_number": 20, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.37238135955536555, "lower_right_x": 0.4443772672309553, "lower_right_y": 0.3864899529713553, "height": 0.014108593415989745, "width": 0.1354292623941959}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-5", "text": "The Offer Shares will be delivered in book-entry form though the facilities of Ne-\nderlands Centraal Instituut voor Giraal Effectenverkeer B.V. (\"Euroclear Neder-\nland\"). If Settlement does not take place on the Settlement Date as planned or at\nall, the Offering may be withdrawn, in which case all subscriptions for the Offer\nShares will be disregarded, any allotments made will be deemed not to have been\nmade, any subscription payments made will be returned without interest or other\ncompensation. All dealings in Shares prior to Settlement and delivery are at the\nsole risk of the parties concerned.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.39290294997862335, "lower_right_x": 0.875453446191052, "lower_right_y": 0.5027789653698161, "height": 0.1098760153911928, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-6", "text": "Commitment of Committing Shareholders\n", "page_number": 20, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5091919623770842, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.523300555793074, "height": 0.0141085934159898, "width": 0.30532043530834335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-7", "text": "On 26 October 2015, the Company entered into commitment letters (the \"Com-\nmitment Letters\") with certain of Curetis AG's current shareholders, being aeris\nCAPITAL Equity Investments, L.P., LSP Curetis Pooling B.V., BioMed Invest II\nLP, CD-Venture GmbH, Forbion Capital Fund II Co\u00f6peratief U.A. and/or Forbion\nCF II Co-Invest I Co\u00f6peratief U.A., Roche Finance Ltd. and HBM BioCapital II\nInvest S.a r.l. (the \"Committing Shareholders\"). Forbion Capital Fund II Co\u00f6per-\natief U.A. and Forbion CF II Co-Invest I Co\u00f6peratief U.A. have committed to\nsubscribe for Offer Shares in a certain total amount with the decision which entity\nwill subscribe for which number of Offer Shares yet to be taken. Pursuant to the\nCommitment Letters, each of the Committing Shareholders, severally and not\njointly, has irrevocably committed to subscribe for, and the Company has agreed to\nissue and allot to the Committing Shareholders, Offer Shares at the Offer Price in\nthe Offering.\nThe aggregate commitments of all Committing Shareholders pursuant to the Com-\nmitment Letters amount to approximately \u20ac15,150,777.\nThe Commitment Letters will terminate automatically upon the earlier of (i) the\ntermination of the Underwriting Agreement (as defined below), (ii) the Settlement\nDate not having occurred before 31 December 2015, and (iii) RBC Europe Limited\nin its capacity as sole global coordinator (the \"Sole Global Coordinator\") on the\none hand, or the Company, on the other hand, informing the other, prior to the\nexecution of the Underwriting Agreement (as defined below), that it has deter-\nmined not to proceed with the Offering.\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.5267208208636169, "lower_right_x": 0.875453446191052, "lower_right_y": 0.8460880718255664, "height": 0.3193672509619495, "width": 0.5755743651753326}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-8", "text": "In addition to the Committing Shareholders and under the same terms and condi-\ntions listed above, STRATEC Biomedical AG (\"STRATEC\") has committed to\nsubscribe for, and the Company has agreed to issue and allot to STRATEC, Offer\nShares at the Offer Price in the Offering for a total amount of approximately \u20ac1\nmillion. STRATEC has not agreed to a lock-up and does not fall under any lock-up\n", "page_number": 20, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.847798204360838, "lower_right_x": 0.8724304715840387, "lower_right_y": 0.9217614365113296, "height": 0.07396323215049161, "width": 0.5725513905683193}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-20-9", "text": "17\n", "page_number": 20, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-0", "text": "arrangement described in this Prospectus.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.08550662676357418, "lower_right_x": 0.5894800483675937, "lower_right_y": 0.09918768704574604, "height": 0.013681060282171864, "width": 0.2799274486094317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-1", "text": "Underwriting Agreement\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.10560068405301411, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.11970927746900385, "height": 0.014108593415989745, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-2", "text": "The Company and the Underwriters are expected to enter into an underwriting\nagreement (the \"Underwriting Agreement\") on or about 10 November 2015 with\nrespect to the Offering. Under the terms and subject to the conditions set out in the\nUnderwriting Agreement, the Company will agree to issue the number the Offer\nShares specified in the Underwriting Agreement at the Offer Price to subscribers\nprocured for by the Underwriters and the Underwriters will severally but not joint-\nly agree to procure subscribers for, or failing which, to subscribe for at the Offer\nPrice from the Company, such number of Offer Shares.\nThe Underwriting Agreement will provide that the obligations of the Underwriters\nto procure subscribers for, or failing which, to subscribe for themselves, the Offer\nShares are subject to, among other things, the following conditions: (i) the approval\nof the Prospectus by the AFM being in full force and effect, (ii) receipt of opinions\non certain legal matters from counsel, (iii) receipt of customary officers' certifi-\ncates, (iv) the absence of a material adverse effect on the business, financial posi-\ntion, results of operations or prospects of Curetis or in financial markets since the\ndate of the Underwriting Agreement, (v) the admission of the Shares to listing on\nEuronext in Amsterdam and Euronext in Brussels occurring no later than 09:00\na.m. CET on the First Trading Date and (vi) certain other customary conditions.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.12312954253954682, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.3830696879008123, "height": 0.2599401453612655, "width": 0.5749697702539298}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-3", "text": "Upon the occurrence of certain specific events, such as the occurrence of (i) a ma-\nterial adverse change in the business, financial position, results of operations or\nprospects of Curetis or in financial markets since the date of the Underwriting\nAgreement, (ii) a material breach of the Underwriting Agreement or (iii) a state-\nment in the Prospectus, the pricing statement or any amendment or supplement to\nthe Prospectus being untrue, inaccurate or misleading, the Underwriters may elect\nto terminate the Underwriting Agreement at any time prior to the Settlement Date.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.3860624198375374, "lower_right_x": 0.875453446191052, "lower_right_y": 0.48225737494655835, "height": 0.09619495510902093, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-4", "text": "Sole Global Coordinator\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.4886703719538264, "lower_right_x": 0.48548972188633616, "lower_right_y": 0.5027789653698161, "height": 0.014108593415989745, "width": 0.17654171704957677}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-5", "text": "RBC Europe Limited is acting as sole global coordinator.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.51004702864472, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.523300555793074, "height": 0.013253527148354038, "width": 0.3875453446191052}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-6", "text": "Joint Bookrunners\n", "page_number": 21, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.533133817870885, "lower_right_x": 0.4449818621523579, "lower_right_y": 0.5438221462163317, "height": 0.010688328345446751, "width": 0.1354292623941959}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-7", "text": "RBC and Bank Degroof Petercam nv/sa are acting as joint bookrunners.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5515177426250535, "lower_right_x": 0.7914147521160823, "lower_right_y": 0.5643437366395896, "height": 0.012825994014536102, "width": 0.48246674727932287}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-8", "text": "Joint Lead Manager\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5741769987174006, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.5857203933304831, "height": 0.011543394613082514, "width": 0.15054413542926237}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-9", "text": "ICF is acting as joint lead manager for the Offering.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5946985891406584, "lower_right_x": 0.6571946795646917, "lower_right_y": 0.6079521162890124, "height": 0.013253527148353927, "width": 0.3482466747279323}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-10", "text": "Underwriters\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3010882708585248, "top_left_y": 0.6143651132962804, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.6267635741769987, "height": 0.012398460880718276, "width": 0.10519951632406288}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-11", "text": "The Joint Bookrunners and ICF are acting as underwriters.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3010882708585248, "top_left_y": 0.6344591705857204, "lower_right_x": 0.7061668681983071, "lower_right_y": 0.648995297135528, "height": 0.014536126549807515, "width": 0.4050785973397823}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-12", "text": "Listing and Paying Agent\n", "page_number": 21, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.6562633604104318, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.6695168875587858, "height": 0.013253527148354038, "width": 0.18379685610640872}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-13", "text": "ABN AMRO Bank N.V. is the listing and paying agent with respect to the Shares\non Euronext in Amsterdam and Euronext in Brussels.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.7011543394613082, "height": 0.024369388627618616, "width": 0.5616686819830714}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-14", "text": "Retail Coordinator for Germany\n", "page_number": 21, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.7178281316802052, "lower_right_x": 0.5447400241837969, "lower_right_y": 0.7293715262932877, "height": 0.011543394613082514, "width": 0.23518742442563484}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-15", "text": "ICF is the retail coordinator for Germany with respect to the Offering.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.7362120564343737, "lower_right_x": 0.782950423216445, "lower_right_y": 0.7490380504489098, "height": 0.012825994014536102, "width": 0.47400241837968565}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-16", "text": "Stabilisation Manager\n", "page_number": 21, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.7567336468576314, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.7695596408721675, "height": 0.012825994014536102, "width": 0.16021765417170497}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-17", "text": "RBC is the stabilisation manager with respect to the Shares on Euronext in Am-\nsterdam and Euronext in Brussels.\n", "page_number": 21, "bounding_box": {"top_left_x": 0.2968561064087062, "top_left_y": 0.7729799059427106, "lower_right_x": 0.8724304715840387, "lower_right_y": 0.8050448909790509, "height": 0.032064985036340254, "width": 0.5755743651753326}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-18", "text": "Interests mate-   Certain of the Underwriters and/or their respective affiliates have in the past been\nrial to the Of-   engaged, and may in the future, from time to time, engage in commercial banking,\nfering (includ-   investment banking and financial advisory and ancillary activities in the ordinary\ning conflicting   course of their business with the Company or any parties related to it, in respect of\ninterests)        which they have received, and may in the future receive, customary fees and com-\n                  missions.\n                  Additionally, the Underwriters may, in the ordinary course of their business, in the\n                  future hold the Company's securities for investment. In respect of the aforemen-\n", "page_number": 21, "bounding_box": {"top_left_x": 0.1735187424425635, "top_left_y": 0.8071825566481402, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.9290294997862334, "height": 0.12184694313809319, "width": 0.7043530834340992}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-19", "text": "E.4\n", "page_number": 21, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.8127404873877726, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.8247114151346729, "height": 0.01197092774690034, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-21-20", "text": "18\n", "page_number": 21, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.014510278113663788}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-0", "text": "tioned, the sharing of information is generally restricted for reasons of confidential-\nity by internal procedures or by rules and regulations. As a result of these transac-\ntions, the Underwriters may have interests that may not be aligned, or could poten-\ntially conflict, with the interests of purchasers or with the interests of the Company.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2968561064087062, "top_left_y": 0.08465156049593843, "lower_right_x": 0.8730350665054414, "lower_right_y": 0.14023086789226166, "height": 0.05557930739632323, "width": 0.5761789600967352}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-1", "text": "The Company is offering to sell the Offer Shares.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.1466438648995297, "lower_right_x": 0.6426844014510278, "lower_right_y": 0.1586147926464301, "height": 0.011970927746900395, "width": 0.3337363966142684}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-2", "text": "E.5\n", "page_number": 22, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.14749893116716545, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.15946985891406584, "height": 0.011970927746900395, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-3", "text": "Person or enti-\n", "page_number": 22, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.14749893116716545, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.15946985891406584, "height": 0.011970927746900395, "width": 0.11185006045949217}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-4", "text": "The Company is offering to sell the Offer Shares.\nThe restrictions of the lock-up arrangements described below, including those on\nsales, issues or transfers of Shares, may be waived by the Joint Bookrunners (act-\ning on behalf of the Underwriters), in their sole discretion and at any time, provid-\ned that during the first 180 days the lock-up of the existing Shareholders may not\nbe waived and that the lock-up for management and employees may not be waived\nat all. If the consent of the Joint Bookrunners (acting on behalf of the Underwrit-\ners) in respect of a waiver of the lock-up arrangements is requested as described\nbelow, the Joint Bookrunners (acting on behalf of the Underwriters) shall not un-\nreasonably withhold their consent and may give their consent conditionally.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.15904232578024796, "lower_right_x": 0.875453446191052, "lower_right_y": 0.29157759726378796, "height": 0.13253527148354, "width": 0.5755743651753326}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-5", "text": "Person or ent\nty offering to\n", "page_number": 22, "bounding_box": {"top_left_x": 0.18016928657799275, "top_left_y": 0.1611799914493373, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.17443351859769132, "height": 0.01325352714835401, "width": 0.09552599758162034}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-6", "text": "sell the Offer\n", "page_number": 22, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.1748610517315092, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.18725951261222745, "height": 0.012398460880718248, "width": 0.09733978234582832}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-7", "text": "sell the Offe\nShares and\n", "page_number": 22, "bounding_box": {"top_left_x": 0.17291414752116083, "top_left_y": 0.18854211201368107, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.20094057289439932, "height": 0.012398460880718248, "width": 0.08827085852478841}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-8", "text": "lockup ar-\n", "page_number": 22, "bounding_box": {"top_left_x": 0.17291414752116083, "top_left_y": 0.20222317229585293, "lower_right_x": 0.2545344619105199, "lower_right_y": 0.21633176571184268, "height": 0.014108593415989745, "width": 0.0816203143893591}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-9", "text": "rangements\n", "page_number": 22, "bounding_box": {"top_left_x": 0.17291414752116083, "top_left_y": 0.21675929884566053, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.2304403591278324, "height": 0.013681060282171864, "width": 0.09310761789600966}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-10", "text": "Company lock-up\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.29713552800342025, "lower_right_x": 0.44014510278113667, "lower_right_y": 0.31124412141941, "height": 0.014108593415989745, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-11", "text": "Pursuant to the Underwriting Agreement, the Company is expected to agree with\nthe Underwriters that, for a period from the date of the Underwriting Agreement\nuntil 365 days from the Settlement Date (the company lock-up period), it will not,\nexcept as set forth below, without the prior consent of the Joint Bookrunners (act-\ning on behalf of the Underwriters), (i) directly or indirectly, issue, offer, pledge,\nsell, contract to sell, sell or grant any option, right, warrant or contract to purchase,\nexercise any option to sell, purchase any option or contract to sell, or lend or oth-\nerwise transfer or dispose of any Shares or other shares of the Company or any\nsecurities convertible into or exercisable or exchangeable for Shares or other shares\nof the Company or file any registration statement under the US Securities Act or\nany similar document with any other securities regulator, stock exchange or listing\nauthority with respect to any of the foregoing; (ii) enter into any swap or any other\nagreement or any transaction that transfers, in whole or in part, directly or indirect-\nly, the economic consequence of ownership of any Shares or other shares of the\nCompany, whether any such transaction is to be settled by delivery of Shares or\nsuch other securities, in cash or otherwise; (iii) publicly announce such an intention\nto effect any transaction referred to in (i) or (ii) above; or (iv) submit to its Share-\nholders or any other body of the Company a proposal to effect any of the forego-\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.3180846515604959, "lower_right_x": 0.875453446191052, "lower_right_y": 0.5669089354424968, "height": 0.24882428388200084, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-12", "text": "ing.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5673364685763147, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.5780247969217615, "height": 0.010688328345446751, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-13", "text": "The foregoing shall not apply to: (a) the issue and offer by or on behalf of the\nCompany of the Offer Shares, (b) the issue of Shares upon exercise of the Over-\nallotment Option and (c) the granting of awards in options or Shares by the Com-\npany or the issuance of Shares upon exercise of options granted by the Company\npursuant to employee incentive schemes disclosed in, and as such grant or issue is\ndisclosed in, the Prospectus.\n", "page_number": 22, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.5857203933304831, "lower_right_x": 0.8742442563482467, "lower_right_y": 0.6669516887558786, "height": 0.08123129542539553, "width": 0.5652962515114872}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-14", "text": "Existing Shareholders lock-up\n", "page_number": 22, "bounding_box": {"top_left_x": 0.309552599758162, "top_left_y": 0.6767849508336896, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.6883283454467721, "height": 0.011543394613082514, "width": 0.21765417170495766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-15", "text": "On 26 October 2015, all existing Shareholders (except for the Managing Directors\nand all former and current employees of Curetis holding Shares who have entered\ninto a separate lock-up agreement) have entered into a lock-up agreement with the\nSole Global Coordinator (acting on behalf of the Underwriters). Pursuant to such\nlock-up agreement and except as set forth below, all such existing Shareholders\nhave agreed, that for a period from the date of the lock-up agreement until 180\ndays from the Settlement Date, they will not and will not thereafter for an addition-\nal period of 185 days without the prior consent of the Joint Bookrunners (acting on\nbehalf of the Underwriters), (i) directly or indirectly, offer, pledge, sell, contract to\nsell, sell or grant any option, right, warrant or contract to purchase, exercise any\noption to sell, purchase any option or contract to sell, or lend or otherwise transfer\nor dispose of, directly or indirectly, any Shares or other shares of the Company or\nany securities convertible into or exercisable or exchangeable for, or substantially\nsimilar to, Shares or other shares of the Company; (ii) enter into any swap or any\nother agreement or any transaction that transfers, in whole or in part, directly or\nindirectly, any of the economic consequence of ownership of any Shares or other\nshares in the capital of the Company, whether any such transaction is to be settled\n", "page_number": 22, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.6926036767849508, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.9281744335185977, "height": 0.2355707567336469, "width": 0.5749697702539298}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-22-16", "text": "19\n", "page_number": 22, "bounding_box": {"top_left_x": 0.8367593712212817, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.013905683192261153}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-0", "text": "by delivery of Shares or such other securities, in cash or otherwise; (iii) make any\nrequest or demand that the Company files any registration statement under the US\nSecurities Act, as amended, or any similar document with any other securities\nregulator, stock exchange or listing authority with respect to any of the foregoing;\nor (iv) any announcement or other publication of the intention to do any of the\nforegoing.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.2968561064087062, "top_left_y": 0.0837964942283027, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.16802052159042324, "height": 0.08422402736212055, "width": 0.5810157194679565}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-1", "text": "The foregoing restrictions shall not apply to (a) any Offer Shares subscribed for in\nthe Offering or any Shares acquired on Euronext in Amsterdam, Euronext in Brus-\nsels or any other stock exchange after the First Trading Date, (b) the lending of\nShares to the Sole Global Coordinator (acting on behalf of the Underwriters) pur-\nsuant to the stock lending agreement, it being understood that the Shares that are\ndelivered to the lenders pursuant to the stock lending agreement shall be subject to\nthe lock-up undertakings set out in this lock-up agreement, (c) an acceptance of a\ngeneral offer for the Shares in the capital of the Company made in accordance with\nthe Dutch Financial Supervision Act or the provision of an irrevocable undertaking\nto accept such an offer, (d) any disposal as a result of a legal merger or demerger of\nthe Company, or (e) any disposal to personal representatives of an individual who\ndies during the lock-up period, provided that such personal representative shall\nhave entered into a lock-up agreement similar to this lock-up agreement or adheres\nto the provisions of this lock-up agreement and assumes all rights and obligations.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.17400598546387344, "lower_right_x": 0.875453446191052, "lower_right_y": 0.3655408294142796, "height": 0.19153484395040618, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-2", "text": "Management and employees lock-up\n", "page_number": 23, "bounding_box": {"top_left_x": 0.3101571946795647, "top_left_y": 0.37238135955536555, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.3864899529713553, "height": 0.014108593415989745, "width": 0.26058041112454655}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-3", "text": "On 26 October 2015, the Managing Directors and all former and current employees\nof Curetis holding Shares have entered into a lock-up agreement with the Sole\nGlobal Coordinator (acting on behalf of the Underwriters). Pursuant to such lock-\nup agreement, each of the Managing Directors and all former and current employ-\nees of Curetis holding Shares, for a period from the date of the lock-up agreement\nuntil 365 days from the Settlement Date shall not, except as set forth below (i)\ndirectly or indirectly, offer, pledge, sell, contract to sell, sell or grant any option,\nright, warrant or contract to purchase, exercise any option to sell, purchase any\noption or contract to sell, or lend or otherwise transfer or dispose of, directly or\nindirectly, any Shares or other shares of the Company or any securities convertible\ninto or exercisable or exchangeable for, or substantially similar to, Shares or other\nshares of the Company; (ii) enter into any swap or any other agreement or any\ntransaction that transfers, in whole or in part, directly or indirectly, the economic\nconsequence of ownership of any Shares or other shares of the Company, whether\nany such transaction is to be settled by delivery of Shares or such other securities,\nin cash or otherwise; (iii) vote in favour of or any submission to the General Meet-\ning or any other body of the Company of a proposal to effect any of the foregoing\nor to (directly or indirectly) effect an increase in the Company\u2019s share capital or\nany request or demand that the Company files any registration statement under the\nUS Securities Act, as amended, or any similar document with any other securities\nregulator, stock exchange or listing authority with respect to any of the foregoing;\nor (iv) any announcement or other publication of the intention to do any of the\nforegoing.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.3089480048367594, "top_left_y": 0.39290294997862335, "lower_right_x": 0.875453446191052, "lower_right_y": 0.7079948696023942, "height": 0.31509191962377087, "width": 0.5665054413542927}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-4", "text": "The foregoing restrictions shall not apply to (a) an acceptance of a general offer for\nthe Shares made in accordance with the Dutch Financial Supervision Act or the\nprovision of an irrevocable undertaking to accept such an offer, (b) any disposal as\na result of a legal merger or demerger of the Company and (c) any disposal to per-\nsonal representatives of an individual who dies during the lock-up period, provided\nthat such personal representative shall have entered into a lock-up agreement simi-\nlar to this lock-up agreement or adheres to the provisions of this lock-up agreement\nand assumes all rights and obligations.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.3004836759371221, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.8242838820008551, "height": 0.10987601539119285, "width": 0.5773881499395406}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-5", "text": "The voting interest of the existing Shareholders will be diluted as a result of the\nissuance of the Offer Shares. The maximum dilution for the existing Shareholders\nnot participating in the Offering pursuant to the issuance of the Offer Shares would\nbe 43.14%, assuming the issuance of the maximum number of Offer Shares and\n", "page_number": 23, "bounding_box": {"top_left_x": 0.2998790810157195, "top_left_y": 0.8255664814023087, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.8888413852073536, "height": 0.06327490380504486, "width": 0.5749697702539298}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-6", "text": "E.6\n", "page_number": 23, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.8315519452757588, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.8435228730226593, "height": 0.01197092774690045, "width": 0.0350665054413543}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-7", "text": "Dilution\n", "page_number": 23, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.8315519452757588, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.8435228730226593, "height": 0.01197092774690045, "width": 0.06348246674727934}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-8", "text": "full exercise of the Over-allotment Option.\n", "page_number": 23, "bounding_box": {"top_left_x": 0.30290205562273276, "top_left_y": 0.8888413852073536, "lower_right_x": 0.6033857315598549, "lower_right_y": 0.9003847798204361, "height": 0.011543394613082514, "width": 0.3004836759371221}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-9", "text": "Not applicable. No expenses have been or will be charged to the investors by the\n", "page_number": 23, "bounding_box": {"top_left_x": 0.3010882708585248, "top_left_y": 0.9072253099615221, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.9217614365113296, "height": 0.014536126549807515, "width": 0.5767835550181379}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-10", "text": "E.7\n", "page_number": 23, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.9076528430953399, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.9196237708422402, "height": 0.01197092774690034, "width": 0.0350665054413543}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-11", "text": "Estimated\n", "page_number": 23, "bounding_box": {"top_left_x": 0.17291414752116083, "top_left_y": 0.9076528430953399, "lower_right_x": 0.2551390568319226, "lower_right_y": 0.9200513039760582, "height": 0.012398460880718276, "width": 0.08222490931076179}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-23-12", "text": "20\n", "page_number": 23, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-24-0", "text": "expenses         Company in relation to the Offering.\ncharged to the\ninvestors by\nthe Company\n", "page_number": 24, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.14023086789226166, "height": 0.05857203933304832, "width": 0.5326481257557437}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-24-1", "text": "21\n", "page_number": 24, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-0", "text": "A translation of the summary in the German language follows this summary. The German translation of this\nsummary has not been approved by the AFM. In the event of inconsistency between the German language\nversion and the English language version of this summary, the English version will prevail.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12612227447627192, "height": 0.041043180846515606, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-1", "text": "ZUSAMMENFASSUNG\n", "page_number": 25, "bounding_box": {"top_left_x": 0.37182587666263606, "top_left_y": 0.13980333475844378, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.15647712697734073, "height": 0.01667379221889695, "width": 0.2521160822249093}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-2", "text": "Zusammenfassungen bestehen aus geforderten offenlegungspflichtigen Angaben, die als \"Elemente\" bezeichnet\nwerden. Diese Elemente sind in den Abschnitten A \u2013 E (A.1 \u2013 E.7) fortlaufend nummeriert. Diese Zusammen-\nfassung enth\u00e4lt alle Elemente, die in eine Zusammenfassung f\u00fcr diese Art von Wertpapier und Emittent aufzu-\nnehmen sind. Da einige Elemente nicht aufgenommen werden m\u00fcssen, k\u00f6nnen in der Nummerierung L\u00fccken\nauftreten.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23899102180418982, "height": 0.06498503634031638, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-3", "text": "Selbst wenn ein Element wegen der Art des Wertpapiers und des Emittenten in die Zusammenfassung aufge-\nnommen werden muss, ist es m\u00f6glich, dass bez\u00fcglich dieses Elements keine relevante Information gegeben\nwerden kann. In einem solchen Fall enth\u00e4lt die Zusammenfassung eine kurze Beschreibung des Elements mit\ndem Hinweis \"entf\u00e4llt\".\n", "page_number": 25, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.0517315091919624, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-4", "text": "Abschnitt A \u2013 Einleitung und Warnhinweise\n", "page_number": 25, "bounding_box": {"top_left_x": 0.31680773881499397, "top_left_y": 0.32492518170158186, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.34117144078666095, "height": 0.016246259085079096, "width": 0.3839177750906892}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-5", "text": "Diese Zusammenfassung sollte als Einleitung des Prospekts (der \"Prospekt\") ver-\nstanden werden. Der Prospekt bezieht sich auf das Angebot (das \"Angebot\") der\nCuretis N.V. (zum Zeitpunkt des Prospekts noch firmierend als Curetis B.V. in der\nRechtsform einer Gesellschaft mit beschr\u00e4nkter Haftung (besloten vennootschap met\nbeperkte aansprakelijkheid)) (die \"Gesellschaft\"; der Begriff \"Curetis\" bezeichnet in\ndieser Zusammenfassung die Curetis AG oder, wenn bezogen auf die Zeit nach Gr\u00fcn-\ndung der Gesellschaft am 8. Oktober 2015, die Curetis AG und die Gesellschaft) von\nbis zu 4.791.667 neu ausgegebenen auf den Inhaber lautenden Stammaktien mit ei-\nnem Nennwert von \u20ac0,01 je Aktie (die \"Angebotsaktien\", wobei, soweit nicht anders\nangegeben, die Zus\u00e4tzlichen Aktien (wie nachstehend definiert) mitumfasst sind) und\nauf die Zulassung zur Notierung und zum Handel aller Stammaktien der Gesellschaft\n(die \"Aktien\") unter dem Symbol \"CURE\" an der Euronext in Amsterdam, einem\nregulierten Markt, der von der der Euronext Amsterdam N.V. (\"Euronext Amster-\ndam\") betrieben wird, und an der Euronext in Br\u00fcssel, einem regulierten Markt, der\nvon der Euronext Brussels NV/SA (\"Euronext Br\u00fcssel\", und zusammen mit Eu-\nronext Amsterdam, \"Euronext\"). Jegliche Entscheidungen, in die Angebotsaktien\noder die Gesellschaft zu investieren, sollten auf die Pr\u00fcfung des gesamten Prospekts\ngest\u00fctzt werden.\n", "page_number": 25, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.36340316374519027, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6088071825566481, "height": 0.24540401881145785, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-6", "text": "A.1\n", "page_number": 25, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.3638306968790081, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.3758016246259085, "height": 0.011970927746900395, "width": 0.0350665054413543}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-7", "text": "Warnhinweise\n", "page_number": 25, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.3638306968790081, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.3758016246259085, "height": 0.011970927746900395, "width": 0.11547762998790809}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-8", "text": "F\u00fcr den Fall, dass ein Anspruch aufgrund der in dem Prospekt enthaltenen Angaben\nvor einem Gericht geltend gemacht wird, k\u00f6nnte es sein, dass der klagende Investor\ngem\u00e4\u00df nationalen Rechtsvorschriften des jeweiligen Mitgliedstaats des Europ\u00e4ischen\nWirtschaftsraums f\u00fcr die \u00dcbersetzung des Prospekts aufkommen muss, bevor das\nVerfahren eingeleitet wird. Nur diejenigen Personen, die die Verantwortung f\u00fcr die\nErstellung dieser Zusammenfassung einschlie\u00dflich ihrer \u00dcbersetzung \u00fcbernommen\nhaben, k\u00f6nnen zivilrechtlich haftbar gemacht werden, jedoch nur f\u00fcr den Fall, dass\ndie Zusammenfassung irref\u00fchrend, unrichtig oder widerspr\u00fcchlich ist, wenn sie zu-\nsammen mit den anderen Teilen des Prospekts gelesen wird, oder sie, wenn sie zu-\nsammen mit den anderen Teilen des Prospekts gelesen wird, nicht alle erforderlichen\nSchl\u00fcsselinformationen, die Anlegern bei der Entscheidung, ob sie in die Angebotsak-\n", "page_number": 25, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6156477126977341, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.7759726378794357, "height": 0.1603249251817016, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-9", "text": "tien investieren, vermittelt.\nDie Gesellschaft stimmt der Nutzung des Prospektes f\u00fcr einen nachtr\u00e4glichen Wie-\nderverkauf oder einer endg\u00fcltigen Platzierung von Angebotsaktien von den Finanzin-\ntermedi\u00e4ren zu, die speziell von der ICF BANK AG (\"ICF\") zum Zweck des Ange-\nbots an Privatanleger in der Bundesrepublik Deutschland (\"Deutschland\") beauftragt\nwurden. Deutschland ist die einzige Jurisdiktion, in der die betreffenden Finanzinter-\nmedi\u00e4re den Prospekt f\u00fcr einen nachtr\u00e4glichen Wiederverkauf oder eine endg\u00fcltige\nPlatzierung der Angebotsaktien nutzen k\u00f6nnen. Diese Nutzung ist auf den Angebots-\nzeitraum (wie nachfolgend definiert) des Angebots begrenzt. Der Angebotszeitraum\nbeginnt voraussichtlich am 28. Oktober 2015 um 09:00 Mitteleurop\u00e4ischer Zeit\n(\"MEZ\") und endet voraussichtlich am 10. November 2015 um 16:00 MEZ. Jeder\n", "page_number": 25, "bounding_box": {"top_left_x": 0.29564691656590086, "top_left_y": 0.7764001710132535, "lower_right_x": 0.9032648125755743, "lower_right_y": 0.9238991021804189, "height": 0.1474989311671654, "width": 0.6076178960096734}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-10", "text": "Zustimmung,\n", "page_number": 25, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.7883710987601539, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.8016246259085079, "height": 0.013253527148354038, "width": 0.10519951632406285}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-11", "text": "A.2\n", "page_number": 25, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7900812312954254, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.8003420265070543, "height": 0.010260795211628926, "width": 0.0290205562273277}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-12", "text": "Angabe, Bedin-\n", "page_number": 25, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.8020521590423257, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.814878153056862, "height": 0.012825994014536213, "width": 0.1197097944377267}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-13", "text": "Angabe, Bed\ngungen und\n", "page_number": 25, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.8153056861906798, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.8285592133390338, "height": 0.013253527148354038, "width": 0.096130592503023}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-14", "text": "Hinweis\n", "page_number": 25, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.8289867464728516, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.840957674219752, "height": 0.01197092774690034, "width": 0.06711003627569528}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-25-15", "text": "22\n", "page_number": 25, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-0", "text": "Finanzintermedi\u00e4r, der den Prospekt verwendet, muss sicherstellen, dass alle anwend-\nbare Gesetze und Regularien der jeweiligen Jurisdiktion und die im Prospekt aufge-\nf\u00fchrten Verkaufsbeschr\u00e4nkungen eingehalten werden.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.30290205562273276, "top_left_y": 0.08294142796066695, "lower_right_x": 0.9008464328899637, "lower_right_y": 0.129115006412997, "height": 0.046173578452330055, "width": 0.5979443772672309}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-1", "text": "Die Gesellschaft \u00fcbernimmt die Verantwortung f\u00fcr die Genehmigung des Prospekts\nim Hinblick auf einen nachtr\u00e4glichen Wiederverkauf oder eine endg\u00fcltige Platzierung\nder Angebotsaktien durch die oben genannten Finanzintermedi\u00e4re. Der Prospekt darf\nnur durch diese Finanzintermedi\u00e4re an geeignete potentielle Privatanleger in Deutsch-\nland mit allen Nachtr\u00e4gen, die vor der \u00dcbergabe ver\u00f6ffentlicht wurden, \u00fcbergeben\nwerden. Jeder Nachtrag zum Prospekt und die Namen und Adressen der Finanzinter-\nmedi\u00e4re, die von ICF beauftragt wurden, werden in elektronischer Form auf der\nWebsite der Gesellschaft (www.curetis.com) abrufbar sein.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.2424112868747328, "height": 0.10944848225737494, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-2", "text": "Falls ein Angebot durch einen Finanzintermedi\u00e4r erfolgt, wird dieser Finanzin-\ntermedi\u00e4r den Anlegern Informationen \u00fcber die Bedingungen des Angebots zum\nZeitpunkt der Vorlage des Angebots zur Verf\u00fcgung stellen.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.2907225309961522, "height": 0.04147071398033347, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-3", "text": "Mit Ausnahme der Finanzintermedi\u00e4re die ausdr\u00fccklich von der ICF beauftragt wurde\nbeabsichtigt die Gesellschaft nicht weitere Zustimmungen zur Nutzung des Prospek-\ntes zu erteilen.\n", "page_number": 26, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8954050785973398, "lower_right_y": 0.3351859769132108, "height": 0.038050448909790535, "width": 0.5816203143893591}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-4", "text": "Section B \u2013- Emittentin\n", "page_number": 26, "bounding_box": {"top_left_x": 0.4068923821039903, "top_left_y": 0.36212056434373663, "lower_right_x": 0.6088270858524788, "lower_right_y": 0.3758016246259085, "height": 0.013681060282171864, "width": 0.2019347037484885}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-5", "text": "B.1   Juristische und     Zum Zeitpunkt dieses Prospekts firmiert die Gesellschaft noch als Curetis B.V. in der\n      kommerzielle        Rechtsform einer Gesellschaft mit beschr\u00e4nkter Haftung nach niederl\u00e4ndischen Recht\n      Bezeichnung der     (besloten vennootschap met beperkte aansprakelijkheid). Unmittelbar nach Festle-\n      Gesellschaft        gung des Angebotspreises pro Angebotsaktie (der \"Angebotspreis\") wird die Gesell-\n                          schaft in eine Aktiengesellschaft (naamloze vennootschap) umgewandelt werden (die\n                          \"Umwandlung\"). Der juristische und kommerzielle Name der Gesellschaft wird dann\n                          Curetis N.V. lauten.\nB.2   Sitz, Rechtsform,   Die Gesellschaft ist eine Gesellschaft mit beschr\u00e4nkter Haftung (besloten vennoot-\n      anwendbares         schap met beperkte aansprakelijkheid) nach niederl\u00e4ndischen Recht. Die Gesellschaft\n      Recht und Land      ist ans\u00e4ssig in Holzgerlingen, Deutschland. Unmittelbar nach Festlegung des Ange-\n      der Gr\u00fcndung        botspreises wird die Gesellschaft in eine Aktiengesellschaft (naamloze vennootschap)\n                          umgewandelt. Die Gesellschaft hat ihren satzungsm\u00e4\u00dfigen Sitz in Amsterdam, den\n                          Niederlanden und ihren Gesch\u00e4ftssitz in Holzgerlingen, Deutschland. Die Gesell-\n                          schaft ist im Handelsregister der Handelskammer unter der Nummer 64302679 einge-\n                          tragen.\nB.3   Derzeitige Ge-      Curetis ist ein kommerziell arbeitendes Molekulardiagnostikunternehmen, welches\n      sch\u00e4fts-t\u00e4tigkeit   sich auf einfache, pr\u00e4zise und schnelle L\u00f6sungen f\u00fcr die Diagnose von Infektionser-\n      und Haupt-          krankungen und Antibiotikaresistenzen bei schwerkranken, hospitalisierten Patienten\n      t\u00e4tigkeiten         spezialisiert.\n                          Auch heutzutage wird die Diagnose von Infektionskrankheiten in einer Kranken-\n                          hausumgebung gr\u00f6\u00dftenteils noch immer durch traditionelle Tests durchgef\u00fchrt, die\n                          auf mikrobiologischen Kulturen basieren. Dieses Vorgehen ist arbeitsintensiv, zeit-\n                          aufw\u00e4ndig und liefert typischerweise erst nach 24 Stunden oder sogar Wochen Test-\n                          ergebnisse. Dadurch werden angemessene Entscheidungen \u00fcber eine Antibiotikathe-\n                          rapie verz\u00f6gert, was zu schlechten Behandlungserfolgen, l\u00e4ngeren Krankenhausauf-\n                          enthalten, h\u00f6heren Krankenhauskosten und der weiteren Ausbreitung von Antibio-\n                          tikaresistenzen f\u00fchrt. Solche Resistenzen stellen ein erhebliches und wachsendes\n                          Problem weltweit dar.\n                          Die von Curetis entwickelte Unyvero Plattform, welche aus dem System (L4 Lysator,\n                          C8 Cockpit und A50 Analyzer, gemeinsam das \"Unyvero System\"), eigenentwickel-\n                          ter Software und den anwendungsspezifischen Kartuschen (die \"Anwendungs-\n                          Kartuschen\", zusammen mit dem Unyvero System, die \"Unyvero Plattform\") be-\n                          steht, erm\u00f6glicht die fr\u00fchzeitige Erkennung eines gro\u00dfen Spektrums verschiedener\n                          Mikroorganismen und deren Antibiotikaresistenzgene in einem einzigen Test aus\n                          einer Vielzahl nativer Probematerialien. Die Unyvero Plattform funktioniert vollau-\n                          tomatisch und integriert s\u00e4mtliche diagnostische Schritte in eine einzige Anwen-\n", "page_number": 26, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.3988884138520735, "lower_right_x": 0.909310761789601, "lower_right_y": 0.920478837109876, "height": 0.5215904232578025, "width": 0.7986698911729142}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-26-6", "text": "23\n", "page_number": 26, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-0", "text": "dungs-Kartusche. Das System ist einfach anzuwenden und hat eine Anwendungsdauer\nvon nicht mehr als f\u00fcnf Minuten. Es ist eine vollautomatische Anwendung, die inner-\nhalb von vier bis f\u00fcnf Stunden die meisten Mikroorganismen identifiziert, wof\u00fcr\ntraditionelle Tests, die auf mikrobiologischen Kulturen basieren, 24 Stunden oder\nsogar Wochen ben\u00f6tigen. Dies erlaubt es Klinik\u00e4rzten fr\u00fchere und gezielte Therapie-\nentscheidungen vorzunehmen, den Zeit- und Kostenaufwand erheblich zu reduzieren,\ninsbesondere durch eine Verk\u00fcrzung der Aufenthaltsdauer des Patienten im Kranken-\nhaus. Die Unyvero Plattform zielt darauf ab, traditionelle Mikrobiologie zu erg\u00e4nzen\nund nicht zu ersetzen.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.08550662676357418, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.20521590423257802, "height": 0.11970927746900384, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-1", "text": "Die Unyvero Plattform ist seit 2012 CE-IVD zertifiziert und wird in Europa und in\nbestimmten anderen M\u00e4rkten, die die CE-IVD Zertifizierung akzeptieren (d.h. Ku-\nwait, Katar, Russland und die Vereinigten Arabischen Emirate), durch eine Kombina-\ntion von Direktvertrieb in zentralen L\u00e4ndern der EU und den Einsatz von Vertriebs-\npartnern in ausgew\u00e4hlten europ\u00e4ischen L\u00e4ndern und dem Rest der Welt (Kuwait,\nKatar, Russland und die Vereinigten Arabischen Emirate) vermarktet. Curetis beab-\nsichtigt, weiterhin international zu expandieren, wie mit dem k\u00fcrzlich erfolgten Ab-\nschluss von Vertriebsvertr\u00e4gen mit Acumen Research Laboratories Pte Ltd. f\u00fcr be-\nstimmte ASEAN Absatzm\u00e4rkte (aktuell Indonesien, Malaysia, Singapur und Thai-\nland) und Beijing Clear Biotech Co., Ltd f\u00fcr die Region Greater China (China, Tai-\nwan und Hongkong) unter Beweis gestellt wurde.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.30713422007255137, "top_left_y": 0.2129115006412997, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.3655408294142796, "height": 0.1526293287729799, "width": 0.5925030229746071}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-2", "text": "Zum 30. Juni 2015 umfasste die von Curetis installierte Instrumentenbasis 70 Unyve-\nro Analyzer. Derzeit vertreibt Curetis zwei Anwendungs-Kartuschen: Die P55 An-\nwendungs-Kartusche, f\u00fcr schwere Formen der Pneumonie (Lungenentz\u00fcndung) und\ndie i60 ITI Anwendungs-Kartusche, f\u00fcr schwere Implantat- und Gewebeinfektionen.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8990326481257558, "lower_right_y": 0.4275331338178709, "height": 0.05515177426250534, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-3", "text": "Die P55 Anwendungs-Kartusche wurde im April 2015 zum ersten Mal kommerziell\nvertrieben und ist die zweite Generation der P50 Anwendungs-Kartusche. Die ur-\nspr\u00fcngliche Pneumonie-Kartusche wurde 2012 auf den Markt gebracht. Sie ist eine\nCE-IVD zertifizierte Anwendungs-Kartusche f\u00fcr die vollautomatische Erkennung von\nderzeit 20 Mikroorganismen und 19 Antibiotikaresistenz-Marker in nativen respirato-\nrischen Proben. Curetis hat das Ziel, mit dem Test die Erkennung der gro\u00dfen Mehr-\nheit der Pneumonie-verursachenden Pathogene bei hospitalisierten Patienten und\nklinisch relevante Resistenzmarker gegen\u00fcber antimikrobiellen Mitteln zu erm\u00f6gli-\nchen. Basierend auf ihrer Anwendbarkeit bei multiplen Formen der Pneumonie,\nsch\u00e4tzt Curetis, dass die P55 Anwendungs-Kartusche einen adressierbaren Markt von\n2,3 Millionen F\u00e4llen pro Jahr in der EU und den USA hat.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5848653270628473, "height": 0.1509191962377084, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-4", "text": "Die i60 ITI Anwendungs-Kartusche wurde im Mai 2014 eingef\u00fchrt. Sie ist eine CE-\nIVD zertifizierte Anwendungs-Kartusche f\u00fcr die vollautomatische Detektion von\nderzeit 61 Mikroorganismen und 19 Antibiotikaresistenz-Marker f\u00fcr acht verschiede-\nne klinische Anwendungsgebiete in den Bereichen der Prothesengelenksinfektion,\ndiabetischen Fu\u00dfulzera, postoperative Wundinfektion, Katheter-assoziierte Infektio-\nnen, Unterhaut- und Weichteil-Gewebeinfektionen, kardiologiebezogene Infektionen,\nBrandwunden und andere Implantatinfektionen. Curetis sch\u00e4tzt, dass es einen adres-\nsierbaren Markt von 2,1 Millionen F\u00e4llen pro Jahr in der EU und den USA gibt, bei\ndenen der Test zur Anwendung kommen k\u00f6nnte.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.7148353997434801, "height": 0.12355707567336471, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-5", "text": "Bis zum heutigen Zeitpunkt wurden mehr als 30 klinische Studien mit \u00fcber 4.000\nPatientenproben abgeschlossen, um beide Anwendungs-Kartuschen zu validieren.\nZus\u00e4tzliche Studien mit mehr als 5.000 Proben laufen noch oder sind f\u00fcr die kom-\nmenden Jahre geplant. Dies umfasst die notwendige klinische Studie, um eine Freiga-\nbe der US-amerikanischen Arzneimittelzulassungsbeh\u00f6rde (Food and Drug Administ-\nration - \"FDA\") f\u00fcr das Unyvero System und die LRT55 Anwendungs-Kartusche\n(technisch gleichwertig mit der P55 Anwendungs-Kartusche) zu erhalten. Nach der\nFreigabe der FDA beabsichtigt Curetis, das Unyvero System und die LRT55 Anwen-\ndungs-Kartusche ab 2017 in den USA durch Direktverk\u00e4ufe zu vertreiben.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.8448054724241129, "height": 0.12355707567336471, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-6", "text": "Die Produktpipeline von Curetis beinhaltet Anwendungs-Kartuschen f\u00fcr Tests der\npositiven Blutkultur und zur Erkennung von Infektionen des intra-\nabdominalen/gastrointestinalen Trakts. Curetis plant eine Einf\u00fchrung beider Kartu-\nschen als CE-IVD zertifizierte Produkte im Jahr 2016. Im Anschluss ist die Einf\u00fch-\nrung einer CE-IVD zertifizierte Sepsis Anwendungs-Kartusche (\"host response\", d.h.\n", "page_number": 27, "bounding_box": {"top_left_x": 0.30773881499395406, "top_left_y": 0.8512184694313809, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.920478837109876, "height": 0.06926036767849508, "width": 0.594316807738815}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-27-7", "text": "24\n", "page_number": 27, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-0", "text": "basierend auf dem Nachweis der Immunantwort des Patienten) nicht vor Ende 2017\ngeplant. Curetis glaubt, dass ihre Unyvero Plattform auch das Potential f\u00fcr eine Aus-\nweitung ihres Anwendungsfeldes in andere Bereiche wie Onkologie, therapiebeglei-\ntende Diagnostika f\u00fcr personalisierte Medizin (Companion Diagnostics), Transplanta-\ntionsmedizin und Veterin\u00e4ranwendungen hat.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.31076178960096734, "top_left_y": 0.0837964942283027, "lower_right_x": 0.9014510278113664, "lower_right_y": 0.15391192817443353, "height": 0.07011543394613083, "width": 0.5906892382103991}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-1", "text": "Curetis ist der Auffassung, folgenden St\u00e4rken zu besitzen:\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.16032492518170158, "lower_right_x": 0.7049576783555018, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.3911729141475212}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-2", "text": "Curetis ist ein kommerzielles molekulardiagnostisches Unternehmen, das in\nEuropa, Russland und im Mittleren Osten Gesch\u00e4fte macht.\nCuretis spezialisiert sich auf die Diagnose von Pathogenen und der Verhinde-\nrung und Bek\u00e4mpfung von Antibiotikaresistenzen f\u00fcr schwere Infektionen bei\nhospitalisierten Patienten.\nDie flexible Unyvero Plattform von Curetis ist mit jedem Probentyp kompati-\nbel und deckt mehr Mikroorganismen und Resistenzmarker ab als konkurrie-\nrende Plattformen.\nCuretis besitzt eine starke Pipeline an hochwertigen Produkten, die signifikan-\nte ungedeckte medizinische Bed\u00fcrfnisse abdecken.\nCuretis und die Unyvero Plattform wurden durch ausf\u00fchrliche klinische Stu-\ndien validiert und werden von f\u00fchrenden Experten und einem renommierten\nInvestorenkreis unterst\u00fctzt\nCuretis f\u00fchrt in den USA klinische Studien durch, um 2017 eine FDA Freigabe\nund den anschlie\u00dfenden Vertrieb in den USA voranzutreiben.\nCuretis und die Unyvero Plattform sind darauf ausgerichtet, Krankenhauskos-\nten durch den schnelleren gezielten Einsatz wirksamer Antibiotika zu reduzie-\nren.\nDas Managementteam von Curetis verf\u00fcgt \u00fcber Jahrzehnte an operativer und\nkommerzieller Erfahrung.\nCuretis kontrolliert alle zentralen Aspekte der Wertsch\u00f6pfungskette.\n", "page_number": 28, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5335613510047028, "height": 0.35271483539974346, "width": 0.5374848851269649}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-3", "text": "", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.18469431380932022, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.1911073108165883, "height": 0.006412997007268079, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-4", "text": "\uf0b7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.2214621633176571, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.2278751603249252, "height": 0.006412997007268079, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-5", "text": "\uf0b7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.2697734074390765, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.27704147071398033, "height": 0.007268063274903813, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-6", "text": "", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.31765711842667804, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.324497648567764, "height": 0.006840530141085932, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-7", "text": "\uf0b7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.3548525010688328, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.3612654980761009, "height": 0.006412997007268106, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-8", "text": "\uf0b7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4031637451902522, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.41000427533133815, "height": 0.006840530141085932, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-9", "text": "\uf0b7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.43736639589568194, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.44420692603676787, "height": 0.006840530141085932, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-10", "text": "", "page_number": 28, "bounding_box": {"top_left_x": 0.31680773881499397, "top_left_y": 0.4861051731509192, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.4925181701581873, "height": 0.006412997007268051, "width": 0.007255139056831894}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-11", "text": "\uf0b7\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5228730226592561, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.529713552800342, "height": 0.0068405301410859876, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-12", "text": "Es wird erwartet, dass die folgenden Trends das Wachstum des MDx Markts f\u00fcr In-\nfektionserkrankungen, durch eine Ausweitung des Anwendungsfeldes f\u00fcr molekulare\nAnalysen, Entwicklung in der Molekulardiagnostiktechnologie und durch eine breite-\n", "page_number": 28, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.586147926464301, "height": 0.03933304831124418, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-13", "text": "B.4a\n", "page_number": 28, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.5476699444206926, "lower_right_x": 0.154776299879081, "lower_right_y": 0.559640872167593, "height": 0.01197092774690034, "width": 0.04474002418379684}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-14", "text": "Wichtigste\n", "page_number": 28, "bounding_box": {"top_left_x": 0.17230955259975816, "top_left_y": 0.5476699444206926, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.5609234715690466, "height": 0.013253527148354038, "width": 0.07920193470374848}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-15", "text": "Wichtig\nj\u00fcngste\n", "page_number": 28, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.5613510047028645, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.5758871312526721, "height": 0.014536126549807626, "width": 0.06227327690447401}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-16", "text": "ste\n  Trends,\n", "page_number": 28, "bounding_box": {"top_left_x": 0.24123337363966144, "top_left_y": 0.5613510047028645, "lower_right_x": 0.3059250302297461, "lower_right_y": 0.5754595981188542, "height": 0.01410859341598969, "width": 0.06469165659008466}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-17", "text": "e sich auf die\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1977025392986699, "top_left_y": 0.5754595981188542, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.586147926464301, "height": 0.010688328345446862, "width": 0.10217654171704957}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-18", "text": "die\n", "page_number": 28, "bounding_box": {"top_left_x": 0.1735187424425635, "top_left_y": 0.5758871312526721, "lower_right_x": 0.19709794437726724, "lower_right_y": 0.586147926464301, "height": 0.010260795211628926, "width": 0.023579201934703753}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-19", "text": "die sich auf die   Analysen, Entwicklung in der Molekulardiagnostiktechnologie und durch eine breite-\nGesellschaft und   re \u00dcbernahme dieser Technologien in die medizinische Praxis, f\u00f6rdern werden:\ndie Branchen, in\ndenen sie t\u00e4tig    \uf0b7     Anstieg der alternden Bev\u00f6lkerung wird das Wachstum des MDx Markts\n                         beschleunigen: Laut dem US-Gesundheitsministeriums (US Department of\nist, auswirken\n                         Health & Human Services) waren im Jahr 2000 ca. 12,4% der amerikanischen\n                         Bev\u00f6lkerung \u00e4lter als 65. Es wird erwartet, dass dieser Prozentsatz bis 2030\n                         auf 19% steigt. Mit Alterung der Bev\u00f6lkerung steigt die Anzahl von Infektio-\n                         nen, was durch eine zu h\u00e4ufige Anwendung von Antibiotika in Pflegeheimen\n                         weiter verst\u00e4rkt wird. Dar\u00fcber hinaus, wird erwartet, dass \u00e4ltere Menschen,\n                         verglichen mit jungen Erwachsenen, h\u00e4ufiger medizinische Dienstleistungen\n                         ben\u00f6tigen \u2013 was durch im Krankenhaus \u00fcbertragene Infektionen verkompli-\n                         ziert wird. Zusammengefasst wird eine Alterung der Bev\u00f6lkerung zu einer ge-\n                         steigerten Anf\u00e4lligkeit f\u00fcr Infektionskrankheiten f\u00fchren, was den Bedarf an\n                         schnellerer molekularbasierten Diagnostik erh\u00f6hen wird.\n                   \uf0b7     Antibiotikaresistenz \u2013 eine globale medizinische und wirtschaftliche Be-\n                         lastung: Experten sch\u00e4tzen, dass bis 2050 die Zahl der Todesf\u00e4lle durch medi-\n                         kamentenresistente Infektionen von derzeit insgesamt 700.000 auf 10 Millio-\n                         nen Toten steigen k\u00f6nnte und Ausgaben von j\u00e4hrlich US$10 Billionen welt-\n                         weit verursachen k\u00f6nnte. Antimikrobielle Resistenzen w\u00fcrden dann mehr To-\n                         desf\u00e4lle verursachen als Krebs. Daher ist die Unternehmensf\u00fchrung von Cure-\n                         tis \u00fcberzeugt, dass der Bedarf an schnellen und pr\u00e4zisen Tests f\u00fcr die Identifi-\n                         zierung von Mikroorganismen und die Erkennung von Antibiotikaresistenzen\n                         schnell ansteigen wird.\n                   \uf0b7     Personalisierte Medizin und begleitende Diagnostika: Es wird erwartet,\n", "page_number": 28, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.5865754595981189, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.926891834117144, "height": 0.3403163745190252, "width": 0.7370012091898428}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-28-20", "text": "25\n", "page_number": 28, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-29-0", "text": "    dass der Trend zu personalisierter Medizin \u2013 welche nach Ansicht der Unter-\n    nehmensf\u00fchrung von Curetis auch die molekulare Identifikation der relevanten\n    Mikroorganismen und deren Antibiotikaresistenz-Markern f\u00fcr eine fr\u00fche fun-\n    dierte Wahl der Antibiotika f\u00fcr den Patienten umfasst \u2013 die Nachfrage nach\n    molekulardiagnostischen Tests steigern wird. Vollautomatische und integrierte\n    molekulardiagnostische L\u00f6sungen, die Personaleinsatz und Laborausstattungen\n    minimieren, werden voraussichtlich eine wichtige Rolle bei der weiteren Um-\n    setzung von personalisierter Medizin spielen.\n\uf0b7   Fortschritt bei der Entdeckung von Biomarkern erlauben es, ungedeckte\n    medizinische Bed\u00fcrfnisse, etwa bei der Behandlung einer Sepsis, zu erf\u00fcl-\n    len: Neue moderne molekularbiologische Techniken, insbesondere die n\u00e4chste\n    Generation der Sequenzierung, in Verbindung mit intelligenter Bioinformatik\n    und der Analyse gro\u00dfer Datenmengen, wird den Fortschritt bei der Entdeckung\n    von Biomarkern vorantreiben und es zunehmend erm\u00f6glichen, Biomarker zur\n    Diagnose von bestimmten Erkrankungen systematisch zu identifizieren und zu\n    validieren. Die Ergebnisse einer solchen Forschung werden jedoch zu gro\u00dfen\n    Biomarkerpanels f\u00fchren, die getestet werden m\u00fcssen, um die komplexe Biolo-\n    gie von Erkrankungen umfassend zu erfassen. Um diese komplexen Bio-\n    markerpanels in Routinebehandlungen verwenden zu k\u00f6nnen ist eine vielf\u00e4lti-\n    ge molekulardiagnostische Plattformen f\u00fcr Routinetests erforderlich.\n\uf0b7   Dezentralisierung der molekularen Diagnostik \u2013 Durchf\u00fchrung von Tests\n    am Bedarfsort: Die Notwendigkeit, diagnostische Testergebnisse schnellst-\n    m\u00f6glich zu erhalten, f\u00f6rdert die Entwicklung von patientennahen Diagnosen\n    und automatisierten diagnostischen Testl\u00f6sungen von der Probe bis zur Ant-\n    wort, die auch ohne Fachpersonal und au\u00dferhalb eines Labors durchgef\u00fchrt\n    werden k\u00f6nnen. Die Verf\u00fcgbarkeit von Infrastruktur-unabh\u00e4ngigen, patienten-\n    nahen L\u00f6sungen macht Molekulardiagnostik auch in weniger entwickelten und\n    abgelegenen Gebieten zug\u00e4nglich. Beide Trends k\u00f6nnten die Verwendung von\n    Multiplex-Testl\u00f6sungen f\u00f6rdern.\n\uf0b7   Reformen im Verg\u00fctungssystem: Neue Regularien in den USA und Europa\n    haben neue test-spezifische Verg\u00fctungsrichtlinien f\u00fcr molekulare Tests einge-\n    f\u00fchrt. Dieses verbesserte Kodierungssystem vereinfacht den Rechnungsstel-\n    lungs- und Bezahlvorgang. Au\u00dferdem werden mehr L\u00e4nder ein Verg\u00fctungs-\n    system f\u00fcr diagnosebezogenen Fallgruppen (diagnosis related group\n    (\"DRG\")) einf\u00fchren, das auch diagnostische Tests mit einer Fallpauschale um-\n    fasst. In den USA wurde dem Kongress eine neue Gesetzesvorlage (HR 6446),\n    das sog. Gesetz zur Verbesserung von diagnostischen Innovationen, vorgelegt,\n    welches den Verg\u00fctungsprozess verbessern soll. Das letztendliche Ziel dieses\n    Gesetzentwurfs ist es, eine faire Entsch\u00e4digung f\u00fcr innovative, neue in vitro\n    Diagnostik Tests (\"IVD\") zu schaffen, was wahrscheinlich zu einer h\u00f6heren\n    Marktdurchdringung von Molekularanalysen beitragen wird.\n\uf0b7   Bedarf f\u00fcr kosteneffiziente Diagnostik: Begrenzte Budgets f\u00fcr Gesundheits-\n    versorgung, eine wachsende Weltbev\u00f6lkerung und h\u00f6here Lebenserwartung\n    steigern den Bedarf an kosteneffizienteren Ans\u00e4tzen im Gesundheitswesen.\n    Das Ziel ist es, die bestm\u00f6gliche Behandlung f\u00fcr Patienten zu erreichen, w\u00e4h-\n    rend Geld durch optimierte Versorgungszyklen und die Vermeidung von inef-\n    fektiven Therapien gespart wird. Daher geht die Unternehmensf\u00fchrung von\n    Curetis davon aus, dass der Bedarf an schnellen und pr\u00e4zisen Testergebnissen,\n    die eine ad\u00e4quate Behandlung von Infektionen erm\u00f6glicht, w\u00e4chst und dies\n    den Weg f\u00fcr schnelle Multiplex-Infektionserkrankungen-Testl\u00f6sungen ebnen\n    wird.\n", "page_number": 29, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.08208636169303121, "lower_right_x": 0.903869407496977, "lower_right_y": 0.8114578879863189, "height": 0.7293715262932877, "width": 0.7255139056831922}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-29-1", "text": "B.5   Beschreibung       Die Gesellschaft ist eine Holding Gesellschaft ohne wesentlichen direkten Gesch\u00e4fts-\n      der Gruppe und     betrieb. Die Gesellschaft wurde am 8. Oktober 2015 als eine Gesellschaft mit be-\n      der Stellung der   schr\u00e4nkter Haftung (besloten vennootschap met beperkte aansprakelijkheid) gegr\u00fcn-\n      Gesellschaft       det. Unmittelbar nach Festlegung des Angebotspreises wird eine Umstrukturierung\n      innerhalb dieser   der Gesellschaft (die \"Umstrukturierung\") durchgef\u00fchrt werden, wobei die derzeit\n      Gruppe             einzige Aktie (gehalten von LSP Curetis Pooling B.V. als Gr\u00fcndungsaktion\u00e4rin der\n                         Gesellschaft) annulliert wird und neue Aktien an die derzeitigen Aktion\u00e4re der Cure-\n", "page_number": 29, "bounding_box": {"top_left_x": 0.1124546553808948, "top_left_y": 0.8234288157332194, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.9243266353142369, "height": 0.10089781958101751, "width": 0.7896009673518742}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-29-2", "text": "26\n", "page_number": 29, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-30-0", "text": "tis AG ausgegeben werden. Als Gegenleistung f\u00fcr die Ausgabe der neuen Aktien\nwerden diese Aktion\u00e4re der Curetis AG alle Aktien, die sie am Grundkapital der\nCuretis AG halten als Sacheinlage in die Gesellschaft einbringen. Zeitgleich wird die\nGesellschaft in eine Aktiengesellschaft (naamloze vennootschap) umgewandelt, die\nnach der Umwandlung als Curetis N.V. firmieren wird.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.31076178960096734, "top_left_y": 0.08465156049593843, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.15391192817443353, "height": 0.0692603676784951, "width": 0.5912938331318017}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-30-1", "text": "Als Folge der Umstrukturierung wird die Curetis AG eine 100%ige Tochtergesell-\nschaft der Gesellschaft werden und die Aktion\u00e4re der Curetis AG werden zu Aktion\u00e4-\nren der Gesellschaft mit einer Gesamtbeteiligung von 11.107.378 Aktien. Die Curetis\nAG f\u00fchrte und f\u00fchrt alle Gesch\u00e4ftst\u00e4tigkeiten, die in dem Prospekt dargestellt werden,\naus.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8990326481257558, "lower_right_y": 0.22530996152201796, "height": 0.06498503634031638, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-30-2", "text": "Als Teil der Umstrukturierung wird Curetis weiterhin ihren Phantom-Stock-Option-\nPlan restrukturieren. Gem\u00e4\u00df diesem Plan, hat die Curetis AG Phantom-Stock-Options\nan Direktoren, Angestellte, freiberufliche Mitarbeiter und Berater ausgegeben, was\ndiese zu einer Zahlung nach Ablauf von 365 Tagen nach dem Abwicklungstag (wie\nnachfolgend definiert) berechtigt. Nach der Umstrukturierung, wird die H\u00f6he dieser\nZahlung, f\u00fcr Phantom-Stock Options die in Aktien zahlbar sind auf Basis des Ange-\nbotspreises ermittelt und f\u00fcr in Bar abzuwickelnde Phantom-Stock Options auf Basis\ndes ersten B\u00f6rsenhandelspreises. Jeder Beg\u00fcnstigte, der ein Anspruch auf 1.000 oder\nweniger Phantom-Stock-Options hat, wird 365 Tage nach dem Abwicklungstag eine\nBarzahlung erhalten. Unter der Annahme, dass der Angebotspreis dem oberen Ende\nder Angebotspreisspanne entspricht und dass der erste B\u00f6rsenhandelspreis dem An-\ngebotspreis entspricht, w\u00fcrde sich die Gesamtzahlung auf \u20ac469 Tausend belaufen.\nJeder Beg\u00fcnstigte, der einen Anspruch auf mehr als 1.000 Phantom-Stock-Options\nhat, wird 365 Tage nach dem Abwicklungstag, neu ausgegebene Aktien in Gegenwert\ndes entsprechenden Betrages erhalten. Unter der Annahme, dass der Angebotspreis\ndem oberen Ende der Angebotspreisspanne entspricht, w\u00fcrde die Gesamtzahl der\nhierf\u00fcr neu ausgegebenen Aktien bei 665.020 liegen.\n", "page_number": 30, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.4685763146643865, "height": 0.23300555793073963, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-30-3", "text": "27\n", "page_number": 30, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-0", "text": "Zum Zeitpunkt des Prospekts wird die einzige ausstehende Aktie von LSP Curetis\nPooling B.V. gehalten. Die folgende Tabelle stellt dar, welche Aktion\u00e4re nach Kennt-\nnis der Gesellschaft welche meldepflichtigen, direkten oder indirekten, Anteile am\nGesellschaftskapital und Stimmrechte gem\u00e4\u00df Definition des niederl\u00e4ndischen Finanz-\naufsichtsgesetzes halten werden. Dargestellt werden die Beteiligungsverh\u00e4ltnisse nach\nAbschluss der Umstrukturierung, Ausgabe der Angebotsaktien und Abwicklung (wie\nnachfolgend definiert) und unmittelbar nach Ausgabe der neuen Aktien und dabei\nunter den Annahmen, dass (i) der Angebotspreis dem Mittelwert der Angebotspreis-\nspanne entspricht, (ii) das entweder durch Ausgabe einer Anzahl von Angebotsaktien\nzum Mittelwert der Angebotspreisspanne Bruttoerl\u00f6se in H\u00f6he des Zielerl\u00f6s (wie\nnachfolgend definiert) erzielt werden oder die Maximalanzahl von Angebotsaktien\nausgegeben werden und (iii) das entweder die Mehrzuteilungsoption (wie nachfol-\ngend definiert) ganz oder \u00fcberhaupt nicht ausge\u00fcbt wird:\n", "page_number": 31, "bounding_box": {"top_left_x": 0.3059250302297461, "top_left_y": 0.0910645575032065, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.2702009405728944, "height": 0.1791363830696879, "width": 0.5937122128174124}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-1", "text": "B.6\n", "page_number": 31, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.09234715690466011, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.10431808465156049, "height": 0.011970927746900381, "width": 0.034461910519951636}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-2", "text": "Hauptaktion\u00e4re\n", "page_number": 31, "bounding_box": {"top_left_x": 0.16505441354292624, "top_left_y": 0.09234715690466011, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.10688328345446772, "height": 0.014536126549807613, "width": 0.1251511487303507}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-3", "text": "                                                                 Beteiligungen\n\n                 Nach Umstrukturie-     Nach      Abwicklung       Nach         Abwicklung    Nach      Abwicklung     Nach      Abwicklung\n                 rung und vor Ausgabe   (basierend auf den         (basierend    auf    den   (basierend auf den       (basierend auf den\n                 der Angebotsaktien     Annahmen, das der          Annahmen, das der          Annahmen, dass die       Annahmen, dass die\n                                        Angebotspreis     dem      Angebotspreis       dem    Maximalanzahl      der   Maximalanzahl     der\n                                        Mittelwert der Preis-      Mittelwert der Preis-      Angebotsaktien           Angebotsaktien\n                                        spanne entspricht, das     spanne entspricht, das     ausgegeben     werden    ausgegeben     werden\n                                        durch Ausgabe einer        durch Ausgabe einer        und die Mehrzutei-       und die Mehrzutei-\n                                        Anzahl von Ange-           Anzahl von Angebotsak-     lungsoption      nicht   lungsoption       voll\n                                        botsaktien der Zieler-     tien der Zielerl\u00f6s er-     ausge\u00fcbt wird)           ausge\u00fcbt wird)\n                                        l\u00f6s erreicht werden        reicht werden und das\n                                        und das die Mehrzu-        die Mehrzuteilungsopti-\n                                        teilungsoption nicht       on voll ausge\u00fcbt wird)\n                                        ausge\u00fcbt wird\n\nName des         Aktien         in %    Aktien          in %       Aktien          in %       Aktien          in %     Aktien          in %\nAktion\u00e4rs\n\naeris\nCAPITAL\nEquity\nInvestments,\nL.P.1              2.439.165    22%       2.890.666      21%         2.890.666        20%       2.890.666      19%       2.890.666      18%\nLSP Curetis\nPooling B.V.\n2                  2.208.528    20%       2.590.639      19%         2.590.639        18%       2.590.639      17%       2.590.639      16%\nForbion\nCapital\nFund      II\nCo\u00f6peratief\nU.A.3              1.111.269    10%       1.297.212       9%         1.297.212         9%       1.297.212       8%       1.297.212       8%\nKfW                 935.162      8%         935.162       7%           935.162         7%         935.162       6%         935.162       6%\nHBM\nBioCapital\nII      Invest\nS.a.r.l.4          1.047.268     9%       1.204.527       9%         1.204.527         8%       1.204.527       8%       1.204.527       8%\nBioMed\nInvest II LP5       780.202      7%         863.922       6%           863.922         6%         863.922       6%         863.922       5%\nRoche\nFinanz AG6          777.887      7%         908.119       7%           908.119         6%         908.119       6%         908.119       6%\nCD-Venture\nGmbH                435.182      4%         453.786       3%           453.786         3%         453.786       3%         453.786       3%\nQiagen N.V.         307.259      3%         307.259       2%           307.259         2%         307.259       2%         307.259       2%\nAndere7            1.065.456    10%       2.381.667      17%         2.790.504        20%       3.822.753      25%       4.447.753      28%\nInsgesamt        11.107.378      100    13.832.959        100       14.241.796         100    15.274.045        100    15.899.045        100\n", "page_number": 31, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.28430953398888414, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.8101752885848653, "height": 0.5258657545959812, "width": 0.7617896009673519}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-4", "text": "  Insgesamt        11.107.378        100      13.832.959        100     14.241.796           100     15.274.045      100       15.899.045       100\n1\n  Mit aeris CAPITAL Equity Investments Ltd. als unbeschr\u00e4nkt haftender Gesellschafter.\n2\n  Die Stimmrechte werden LSP HEF Holding C.V. (mit LSP Health Economics Fund Management B.V. als unbeschr\u00e4nkt haftender Gesellschafter) und Co\u00f6peratif\nLSP IV U.A. (mit LSP IV Management B.V. als Director) zugerechnet.\n3\n  Die Stimmrechte werden Forbion II Management B.V. zugerechnet.\n4\n  Die Stimmrechte werden HBM BioCapital II LP zugerechnet.\n5\n  Die Stimmrechte werden BioMedInvest AG I zugerechnet.\n6\n  Die Stimmrechte werden Roche Holding Ltd. zugerechnet. Inklusive der Aktien, zu deren Erwerb im Rahmen des Angebots sich die Roche Finance Ltd. verpflich-\ntet hat.\n7\n", "page_number": 31, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8106028217186833, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.8935442496793502, "height": 0.08294142796066695, "width": 0.779322853688029}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-5", "text": "7\n    \"Andere\" bezieht sich auf Beteiligungen an der Gesellschaft mit weniger als drei Prozent der Gesellschaft.\n\nB.7           Ausgew\u00e4hlte                   Die Gesellschaft wurde am 8. Oktober 2015 zum Zweck der Durchf\u00fchrung des Ange-\n", "page_number": 31, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.893971782813168, "lower_right_x": 0.9050785973397824, "lower_right_y": 0.9200513039760582, "height": 0.02607952116289014, "width": 0.7944377267230955}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-31-6", "text": "28\n", "page_number": 31, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019951632406287723}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-32-0", "text": "wesentliche his-   bots gegr\u00fcndet. Seit ihrer Gr\u00fcndung verzeichnet sie keinerlei Gesch\u00e4ftst\u00e4tigkeit. Es\ntorische Finanz-   gibt keinerlei historische Finanzinformationen der Gesellschaft f\u00fcr die am 30. Juni\ninformationen      2015 und 2014 endenden Sechsmonatszeitr\u00e4ume und die am 31. Dezember 2014,\n                   2013 und 2012 endenden Gesch\u00e4ftsjahre.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1608222490931076, "top_left_y": 0.08336896109448483, "lower_right_x": 0.9014510278113664, "lower_right_y": 0.14065840102607952, "height": 0.05728943993159469, "width": 0.7406287787182588}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-32-1", "text": "Falls die Gesellschaft konsolidierte verk\u00fcrzte Abschl\u00fcsse in \u00dcbereinstimmung mit\nden in der EU anwendbaren International Financial Reporting Standards (\"IFRS\") f\u00fcr\ndie zum und am 30. Juni 2015 und 2014 endenden sechs Monate und konsolidierte\nAbschl\u00fcsse f\u00fcr die am 31. Dezember 2014, 2013 und 2012 endenden Gesch\u00e4ftsjahre\nerstellt h\u00e4tte und angenommen, die Gesellschaft h\u00e4tte bereits seit dem 1. Januar 2012\nbestanden und alle Anteile der Curetis AG gehalten, best\u00fcnde kein Unterschied zwi-\nschen solchen konsolidierten Abschl\u00fcssen und den gem\u00e4\u00df IFRS erstellten Abschl\u00fcs-\nsen der Curetis AG im Hinblick auf die Gewinn- und Verlustrechnung oder die Kapi-\ntalflussrechnung f\u00fcr die am 30. Juni 2015 und 2014 endenden sechs Monate und f\u00fcr\ndie am 31. Dezember 2014, 2013 und 2012 endenden Gesch\u00e4ftsjahre. Der einzige,\nunwesentliche, Unterschied zwischen den Abschl\u00fcssen w\u00fcrde die Bilanz betreffen, da\naufgrund des unterschiedlichen Nominalwertes der Aktien der Gesellschaft und der\nCuretis AG bestimmte Bestandteile des Eigenkapitals anders ausgewiesen werden\nw\u00fcrden. Die im Prospekt enthaltenen Angaben und die nachfolgenden Daten sind den\ngem\u00e4\u00df IFRS erstellten Abschl\u00fcssen der Curetis AG f\u00fcr die am und zum 31. Dezember\n2014, 2013 und 2012 endenden Gesch\u00e4ftsjahre und die zum 30. Juni 2015 und 30.\nJuni 2014 endenden Sechsmonatszeitr\u00e4ume entnommen.\n", "page_number": 32, "bounding_box": {"top_left_x": 0.3059250302297461, "top_left_y": 0.14194100042753313, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.37751175716118, "height": 0.23557075673364689, "width": 0.5937122128174124}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-32-2", "text": "Gewinn- und Verlustrechnung und Sonstige Ertr\u00e4ge\n", "page_number": 32, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3997434801197093, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.413852073535699, "height": 0.014108593415989745, "width": 0.36759371221281745}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-32-3", "text": "Die nachfolgende Tabelle stellt die Gewinn- und Verlustrechnung und sonstigen Ertr\u00e4ge der Curetis AG f\u00fcr die am\n31. Dezember 2014, 2013 und 2012 endenden Gesch\u00e4ftsjahre und die am 30. Juni 2015 und 2014 endenden\nSechsmonatszeitr\u00e4ume dar:\n", "page_number": 32, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.46045318512184696, "height": 0.040188114578879885, "width": 0.779322853688029}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-32-4", "text": "                                                     F\u00fcr den Sechsmonats-       F\u00fcr das Gesch\u00e4ftsjahr en-\n                                                     zeitraum endend zum                dend zum\n                                                            30. Juni                 31. Dezember\n                                                        2015         2014       2014         2013        2012\n                                                                        (in Tausend \u20ac)\n                                                         (ungepr\u00fcft)                       (gepr\u00fcft)\nUmsatzerl\u00f6se                                                   742      254        275          671         146\nHerstellungskosten der zur Erzielung der Umsatzer-\nl\u00f6se erbrachten Leistungen                                     665      359        643          219         429\nBruttoergebnis vom Umsatz                                       77     (105)     (368)          452       (283)\nVertriebskosten                                            1.397       1.107     1.939         1.576      1.864\nAllgemeine Verwaltungskosten                               1.366        867      1.637         1.256      1.437\nKosten f\u00fcr Forschung und Entwicklung                       2.943       3.305     6.298         5.895      5.358\nSonstige Ertr\u00e4ge                                                41       23        111              49       22\nErgebnis der betrieblichen T\u00e4tigkeit                      (5.588)    (5.362) (10.132)        (8.226)     (8.919)\nFinanzertr\u00e4ge                                                   5           5          6            30       71\nFinanzaufwendungen                                              9        12         22              28       43\nFinanzierungsaufwendungen aus Zeitwertbewer-\ntung                                                       6.783       1.340     2.286         2.497     32.098\nFinanzergebnis                                            (6.786)    (1.347)    (2.302)      (2.495) (32.069)\nErgebnis vor Steuern                                     (12.374)    (6.709) (12.434)       (10.721) (40.989)\nSteuer vom Einkommen und Ertrag                                 \u2013           \u2013          \u2013            \u2013      (77)\nJahres\u00fcberschuss/ -fehlbetrag                            (12.374)    (6.709) (12.434)       (10.721) (40.912)\n", "page_number": 32, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.46900384779820437, "lower_right_x": 0.8978234582829504, "lower_right_y": 0.9234715690466011, "height": 0.45446772124839674, "width": 0.7920193470374849}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-32-5", "text": "29\n", "page_number": 32, "bounding_box": {"top_left_x": 0.8313180169286578, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-33-0", "text": "Sonstiges Ergebnis, vor Steuern         \u2013         \u2013        \u2013          \u2013        \u2013\nJahresgesamtergebnis              (12.374)   (6.709) (12.434)   (10.721) (40.912)\n\nBilanz\n", "page_number": 33, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.909310761789601, "lower_right_y": 0.15476699444206926, "height": 0.07310816588285592, "width": 0.8035066505441355}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-33-1", "text": "Die folgende Tabelle stellt ausgew\u00e4hlte Finanzinformationen aus der Bilanz der Curetis AG am 30. Juni 2015 und\n", "page_number": 33, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.1761436511329628, "height": 0.012398460880718248, "width": 0.7744860943168077}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-33-2", "text": "am 31. Dezember 2014, 2013 und 2012 dar:\n                                                            30. Juni                31. Dezember\n                                                          (ungepr\u00fcft)                 (gepr\u00fcft)\n                                                             2015           2014         2013        2012\n                                                                          in Tausend in Tausend in Tausend\n                                                          in Tausend \u20ac\n                                                                               \u20ac          \u20ac          \u20ac\n\nAktiva\nUmlaufverm\u00f6gen                                                   9.835        6.486        8.798      11.129\nZahlungsmittel und Zahlungsmittel\u00e4quivalente                     5.940        2.994        5.382       9.777\nForderungen aus Lieferungen und Leistungen                          486            42        140            56\nVorr\u00e4te                                                          3.199        3.153        2.786       1.005\nSonstige kurzfristige Verm\u00f6genswerte                                210         297          491         291\nLangfristige Verm\u00f6genswerte                                      6.719        7.307        7.308       6.989\nImmaterielle Verm\u00f6genswerte                                         225         286          331         336\nSachanlageverm\u00f6gen                                               6.070        6.592        6.457       5.986\nSonstige langfristige Verm\u00f6gensgegenst\u00e4nde                           11            0            7           16\nSonstige finanzielle Verm\u00f6genswerte                                 412         429          514         650\nBilanzsumme                                                     16.554       13.793       16.107      18.118\n\n\nPassiva\nKurzfristige Verbindlichkeiten                                   1.505        1.305        1.090       1.259\nVerbindlichkeiten aus Lieferungen und Leistungen und\nsonstige Verbindlichkeiten                                          831         580          616         634\nSonstige R\u00fcckstellungen                                              50            35           6           1\nSonstige kurzfristige Verbindlichkeiten                             371         317          301         446\nSonstige kurzfristige finanzielle Verbindlichkeiten                 254         373          167         179\nLangfristige Verbindlichkeiten                                 145.958      131.024      121.119     112.240\nLanfristige R\u00fcckstellungen                                          819         816          777         770\nR\u00fcckstellungen PSOP                                              5.342        3.914        2.957       3.090\nSonstige langfristige finanzielle Verbindlichkeiten                 189         258          392         519\nFinanzielle Verbindlichkeiten f\u00fcr Vorzugs- und Stammak-\ntien                                                           139.608      126.036      116.993     107.860\nGesamtverbindlichkeiten                                        147.463      132.329      122.209     113.499\nEigenkapital                                                 (130.909)    (118.536)     (106.102)    (95.380)\nGezeichnetes Kapital                                                 50            50           50          50\nGewinn-/Verlustvortrag                                       (130.959)    (118.586)     (106.152)    (95.430)\n", "page_number": 33, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.17657118426678067, "lower_right_x": 0.8990326481257558, "lower_right_y": 0.9132107738349722, "height": 0.7366395895681915, "width": 0.7932285368802903}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-33-3", "text": "30\n", "page_number": 33, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-34-0", "text": "Bilanzsumme   16.554   13.793   16.107   18.118\n", "page_number": 34, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08251389482684908, "lower_right_x": 0.9014510278113664, "lower_right_y": 0.10902094912355707, "height": 0.026507054296707994, "width": 0.7853688029020557}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-34-1", "text": "Kapitalflussrechnung\n", "page_number": 34, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12270200940572894, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.13424540401881147, "height": 0.011543394613082528, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-34-2", "text": "Kapitalflussrechnung\nDie nachfolgende Tabelle stellt Finanzinformationen aus der Kapitalflussrechnung der Curetis AG des am 30. Juni\n2015 und 2014 endenden Sechsmonatszeitraums und f\u00fcr die am 31. Dezember 2014, 2013 und 2012 endenden\nGesch\u00e4ftsjahre dar:\n", "page_number": 34, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.13467293715262932, "lower_right_x": 0.8923821039903265, "lower_right_y": 0.1838392475416845, "height": 0.04916631038905517, "width": 0.7859733978234583}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-34-3", "text": "                                            F\u00fcr den Sechsmonats-\n                                                  zeitraum                 F\u00fcr das Gesch\u00e4ftsjahr endend zum\n                                             endend zum 30. Juni                     31. Dezember\n                                                2015             2014              2014        2013     2012\n                                                                         (in Tausend \u20ac)\n\n                                                 (ungepr\u00fcft)                              (gepr\u00fcft)\n\nNetto Cashflow       aus    betrieblicher\nT\u00e4tigkeit                                     (3.525)          (3.992)          (7.481)     (9.173)   (7.025)\nNetto     Cashflow     aus       Investi-\ntionst\u00e4tigkeit                                  (252)           (470)           (1.537)     (1.737)   (1.904)\nNetto Cashflow        aus     Finanzier-\nungst\u00e4tigkeit                                   6.723           5.801             6.630       6.514    6.850\nNetto Ver\u00e4nderung der Zahlungs-\nmittel und Zahlungsmittel\u00e4quiva-\nlente                                           2.946           1.339           (2.388)     (4.395)   (2.079)\nZahlungsmittel und Zahlungsmittel-\n\u00e4quivalente zum Jahresbeginn                    2.994           5.382             5.382       9.777   11.857\nZahlungsmittel und Zahlungsmittel-\n\u00e4quivalente zum Jahresende                      5.940           6.721             2.994       5.382    9.777\n", "page_number": 34, "bounding_box": {"top_left_x": 0.10761789600967352, "top_left_y": 0.18640444634459172, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.5224454895254382, "height": 0.3360410431808465, "width": 0.781136638452237}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-34-4", "text": "       Beschreibung       Zum Zeitpunkt des Prospektes, gab es seit dem 30. Juni 2015 keine wesentlichen\n       der wesentlichen   Ver\u00e4nderungen in der Finanzlage und den Handelspositionen der Gesellschaft.\n       Ver\u00e4nderungen\n       der Finanzlage\n       und des Be-\n       triebs-\n       ergebnisses der\n       Gesellschaft in\n       oder nach dem\n       von den wesent-\n       lichen histori-\n       schen Finanz-\n       informationen\n       abgedeckten\n       Zeitraum\nB.8    Ausgew\u00e4hlte        Entf\u00e4llt. Dieser Prospekt enth\u00e4lt keine Pro-forma-Finanzinformationen.\n       wesentliche\n       Pro-Forma-Fina\n       nz-\n       informationen\nB.9    Gewinn-            Entf\u00e4llt. Die Gesellschaft hat keine Gewinnprognose abgegeben\n       prognosen\n       oder -sch\u00e4tzung\n       en\nB.10   Eine Beschrei-     Entf\u00e4llt. Es gibt keine Einschr\u00e4nkungen der Best\u00e4tigungsvermerke zu den gepr\u00fcften\n       bung der Be-       konsolidierten Abschl\u00fcssen der Curetis AG f\u00fcr die am 31. Dezember 2014, 2013 und\n       schaffenheit der   2012 endenden Gesch\u00e4ftsjahre. Die Wirtschaftspr\u00fcfer weisen in ihrem Bericht ledig-\n", "page_number": 34, "bounding_box": {"top_left_x": 0.10761789600967352, "top_left_y": 0.5228730226592561, "lower_right_x": 0.909310761789601, "lower_right_y": 0.9196237708422402, "height": 0.39675074818298417, "width": 0.8016928657799275}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-34-5", "text": "31\n", "page_number": 34, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.01813784764207982}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-0", "text": "Qualifikationen\n", "page_number": 35, "bounding_box": {"top_left_x": 0.17412333736396615, "top_left_y": 0.08550662676357418, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.09662248824283882, "height": 0.011115861479264647, "width": 0.11608222490931078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-1", "text": "lich auf die Sachverhalte in den Abschnitten 2.1., 31\n", "page_number": 35, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.08550662676357418, "lower_right_x": 0.6910519951632407, "lower_right_y": 0.09662248824283882, "height": 0.011115861479264647, "width": 0.37726723095526005}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-2", "text": "1 und 34 im Anhang der Ab-\n", "page_number": 35, "bounding_box": {"top_left_x": 0.6916565900846433, "top_left_y": 0.08550662676357418, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.09662248824283882, "height": 0.011115861479264647, "width": 0.2031438935912938}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-3", "text": "       Qualifikationen    lich auf die Sachverhalte in den Abschnitten 2.1., 31 und 34 im Anhang der Ab-\n       zur historischen   schl\u00fcsse hin, in welchen beschrieben wird, dass die F\u00e4higkeit der Gesellschaft, ihre\n       Finanzinforma-     T\u00e4tigkeiten aufrechtzuerhalten durch Risiken gef\u00e4hrdet ist.\n       tion im Pr\u00fc-\n       fungsbericht\nB.11   Working Capi-      Die derzeitigen Barmittel von Curetis sind nicht ausreichend, um sie mit ausreichen-\n       tal                dem Working Capital f\u00fcr die dem Datum des Prospektes folgenden zw\u00f6lf Monate zu\n                          versorgen. Curetis glaubt, dass sie \u00fcber ausreichendes Working Capital verf\u00fcgt, um\n                          die aktuellen Betriebsabl\u00e4ufe bis Juni 2016 weiterzuf\u00fchren. Basierend auf den laufen-\n                          den Erfordernissen ihres derzeitigen Business Plans, der bei Erstellung bereits die\n                          Absicht der Gesellschaft ber\u00fccksichtigte, die Nettoerl\u00f6se aus dem Angebot zu erhal-\n                          ten, und der die Kosten f\u00fcr den Aufbau einer Vermarktungs- und Vertriebspr\u00e4senz in\n                          den USA umfasst, glaubt Curetis, dass etwa \u20ac4.5 Millionen zus\u00e4tzliche Barmittel\n                          n\u00f6tig sein werden, um sie mit ausreichendem Working Capital f\u00fcr die dem Datum des\n                          Prospektes folgenden zw\u00f6lf Monate zu versorgen. Wenn das Angebot abgeschlossen\n                          ist und Nettoerl\u00f6se in H\u00f6he von ungef\u00e4hr \u20ac25 Millionen erreicht wurden (was der Fall\n                          w\u00e4re, wenn die Gesellschaft den angestrebten Zielbruttoerl\u00f6s in H\u00f6he von ungef\u00e4hr\n                          \u20ac29,3 Millionen durch das Angebot erzielt) wird dieser Erl\u00f6s zusammen mit den\n                          derzeitigen Barmitteln von Curetis diese mit ausreichendem Working Capital f\u00fcr die\n                          dem Datum des Prospekts folgenden zw\u00f6lf Monate versorgen.\n                          Sollte das Angebot zur\u00fcckgezogen werden oder nicht abgeschlossen werden, w\u00fcrde\n", "page_number": 35, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.09705002137665669, "lower_right_x": 0.905683192261185, "lower_right_y": 0.3916203505771697, "height": 0.294570329200513, "width": 0.7956469165659008}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-4", "text": "Curetis einen detaillierten Ma\u00dfnahmenplan umsetzen, um die unmittelbar bevorste-\nhende Knappheit an Barmitteln durch Reduktion von Mittelabfl\u00fcssen abzuwenden.\nDies w\u00fcrde eine deutliche Kostenreduzierung und reduzierte oder zumindest verz\u00f6-\ngerte betriebliche Aufwendungen beinhalten. Vor allem w\u00fcrde Curetis in diesem\nFalle, den Aufbau ihrer Pr\u00e4senz in den Vereinigten Staaten und ihre kostenintensiven\nFDA Studien beenden, was dazu f\u00fchren w\u00fcrde, dass Curetis die erwartete FDA Frei-\ngabe im ersten Halbjahr 2017 nicht erhalten w\u00fcrde. Als Folge k\u00f6nnte Curetis ihre\nProdukte weder 2017 noch in den Folgejahren auf dem US-amerikanischen Markt\nvertreiben. Die Erzielung von Ums\u00e4tzen in den Vereinigten Staaten w\u00e4re Curetis dann\ngar nicht oder nur mit erheblicher Verz\u00f6gerung m\u00f6glich. Dar\u00fcber hinaus w\u00fcrde Cure-\ntis ihre Personalkosten durch den Verzicht auf weitere Einstellungen reduzieren. Im\nHinblick auf Kapitalaufwendungen w\u00fcrde Curetis in diesem Fall Investitionen in\nzuk\u00fcnftige Mehrkavit\u00e4ten-Spritzgusswerkzeuge zur\u00fcckstellen, was wiederum zu einer\nverz\u00f6gerten Reduzierung der Herstellkosten der Anwendungskartuschen f\u00fchren w\u00fcr-\nde. Alternativ, oder in Verbindung mit den oben beschriebenen Ma\u00dfnahmen, k\u00f6nnte\nCuretis ebenso derzeitigen oder zuk\u00fcnftigen Aktion\u00e4ren um zus\u00e4tzliche Kapitalma\u00df-\nnahmen ersuchen, etwa in Form von \u00dcberbr\u00fcckungsdarlehen und/oder als Eigenkapi-\ntal. Curetis glaubt, dass die aufgef\u00fchrten Ma\u00dfnahmen voraussichtlich erfolgreich sein\nw\u00fcrden und dass die Durchf\u00fchrung dieser Kostenreduktion oder Finanzierungsma\u00df-\nnahmen sie mit ausreichendem Working Capital versorgen w\u00fcrden, um ihren Ge-\nsch\u00e4ftsbetrieb bis zum Fr\u00fchjahr 2017 aufrecht zu erhalten und so zumindest bis zw\u00f6lf\nMonate nach dem Datum des Prospekts fortzubestehen.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.3916203505771697, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6870457460453185, "height": 0.29542539546814883, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-5", "text": "F\u00fcr den Fall, dass Curetis nach R\u00fccknahme des Angebots nicht dazu in der Lage sein\nsollte die oben genannten Ma\u00dfnahmen, wie die Generierung ausreichender Geldmittel\naus zus\u00e4tzlichen Finanzierungsquellen und die beschriebenen Kostenreduzierungs-\nma\u00dfnahmen, zum Ausgleich einer m\u00f6glichen Barmittelknappheit umzusetzen, k\u00f6nnte\nsie nicht mehr in der Lage sein, ihr Gesch\u00e4ft weiterzuf\u00fchren und k\u00f6nnte schlie\u00dflich\nverpflichtet sein einen Insolvenzantrag zu stellen.\n", "page_number": 35, "bounding_box": {"top_left_x": 0.31076178960096734, "top_left_y": 0.6943138093202224, "lower_right_x": 0.9014510278113664, "lower_right_y": 0.7764001710132535, "height": 0.08208636169303118, "width": 0.5906892382103991}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-6", "text": "Abschnitt C \u2013- Wertpapiere\n", "page_number": 35, "bounding_box": {"top_left_x": 0.38694074969770254, "top_left_y": 0.7930739632321505, "lower_right_x": 0.628174123337364, "lower_right_y": 0.8071825566481402, "height": 0.01410859341598969, "width": 0.24123337363966146}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-7", "text": "Art und Gat-      Die Aktien sind auf den Inhaber lautenden Stammaktien im ausgegebenen und aus-\ntung der ange-    stehenden Kapital der Gesellschaft mit einem jeweiligen Nennwert von \u20ac0.01.\nbotenen\n                  Antrag zur Notierung aller Aktien unter dem Symbol \"CURE\" an der Euronext in\nund/oder zum\n                  Amsterdam und Euronext in Br\u00fcssel unter ISIN Code NL0011509294 wurde einge-\nHandel zuzulas-\n                  reicht.\nsenden Wertpa-\npiere\n", "page_number": 35, "bounding_box": {"top_left_x": 0.16444981862152358, "top_left_y": 0.8221462163317658, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.9256092347156905, "height": 0.10346301838392469, "width": 0.7376058041112454}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-8", "text": "C.1\n", "page_number": 35, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.8298418127404874, "lower_right_x": 0.14268440145102781, "lower_right_y": 0.8422402736212057, "height": 0.012398460880718276, "width": 0.03385731559854897}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-35-9", "text": "32\n", "page_number": 35, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-0", "text": "W\u00e4hrung     der     Die Aktien lauten auf und werden gehandelt in Euro.\nAngebotsaktien\nZahl der ausge-     Vor Unterzeichnung der notariellen Urkunde zur Umwandlung der Gesellschaft und\ngebenen und         \u00c4nderung der Satzung, welche unmittelbar nach Festlegung des Angebotspreises\nvoll eingezahlten   erfolgt (die \"\u00c4nderungsvereinbarung\"), besteht das ausgegebene Aktienkapital der\nAktien              Gesellschaft aus 11.107.378 Aktien. Unmittelbar, nach Vollzug der \u00c4nderungsver-\n                    einbarung, wird das genehmigte Kapital der Gesellschaft \u20ac550.000 betragen, beste-\n                    hend aus 55.000.000 Aktien mit einem Nennwert von jeweils \u20ac0,01, das ausgegebene\n                    Aktienkapital wird aus 11.107.378 Aktien bestehen.\nMit den Wert-       Bezugnahmen auf die Satzung (die \"Satzung\") hiernach beziehen sich auf die Sat-\npapieren ver-       zung der Gesellschaft, in ihrer Form nach Abschluss der \u00c4nderungsvereinbarung.\nbundene Rechte\n                    Die Aktien sind dividendenberechtigt. Jede Aktie berechtigt zur Abgabe einer Stimme\n                    in der Hauptversammlung der Gesellschaft (die \"Hauptversammlung\"). Es gibt\n                    keine Einschr\u00e4nkung der Stimmrechte.\n                    Aktion\u00e4re haben ein Vorkaufsrecht im Falle einer Emission von Aktien oder der Ge-\n                    w\u00e4hrung von Rechten zur Zeichnung von Aktien. Aktion\u00e4re haben kein Vorkaufs-\n                    recht bei Aktienemissionen gegen Sacheinlagen oder bei Aktienemissionen an Ange-\n                    stellten der Gesellschaft oder eines, der Gruppe der Gesellschaft angeh\u00f6rigen, Unter-\n                    nehmens oder bei Aktienemissionen an Personen, die ein bereits fr\u00fcher gew\u00e4hrtes\n                    Recht zur Zeichnung von Aktien aus\u00fcben.\n                    Vor der Umwandlung wird die Hauptversammlung dar\u00fcber beschlie\u00dfen, die Ange-\n", "page_number": 36, "bounding_box": {"top_left_x": 0.16807738814993953, "top_left_y": 0.09234715690466011, "lower_right_x": 0.909310761789601, "lower_right_y": 0.41641727233860626, "height": 0.32407011543394615, "width": 0.7412333736396615}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-1", "text": "C.2\n", "page_number": 36, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.09234715690466011, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.10474561778537837, "height": 0.012398460880718262, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-2", "text": "C.3\n", "page_number": 36, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.12740487387772553, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.13980333475844378, "height": 0.012398460880718248, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-3", "text": "C.4\n", "page_number": 36, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.23086789226165028, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.24326635314236852, "height": 0.012398460880718248, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-4", "text": "botsaktien nach Umwandlung auszugeben und die Vorkaufsrechte der Aktion\u00e4re in\nBezug auf die Ausgabe der Angebotsaktien auszuschlie\u00dfen.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.41641727233860626, "lower_right_x": 0.8990326481257558, "lower_right_y": 0.4433518597691321, "height": 0.026934587430525847, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-5", "text": "Satzungsgem\u00e4\u00df kann die Hauptversammlung auf Vorschlag des Vorstands der Ge-\nsellschaft (der \"Vorstand\" und jedes Mitglied ein \"Mitglied des Vorstands\"), nach\nder Zustimmung durch den Aufsichtsrat der Gesellschaft (der \"Aufsichtsrat\" und\njedes Mitglied ein \"Mitglied des Aufsichtsrats\"), den Vorstand erm\u00e4chtigen, nach\nvorheriger Zustimmung des Aufsichtsrats, die Emission von Aktien der Gesellschaft\nund der Gew\u00e4hrung von Bezugsrechten zu beschlie\u00dfen. In dem durch den erm\u00e4chtig-\nten Vorstand gefassten Beschluss muss die Anzahl der auszugebenen Aktien und,\nfalls zutreffend, auch die Bedingungen der Emission benannt werden. Diese Erm\u00e4ch-\ntigung des Vorstands wird nur f\u00fcr einen bestimmten Zeitraum gelten und kann von\nMal zu Mal durch die Hauptversammlung verl\u00e4ngert werden, jeweils um nicht mehr\nals f\u00fcnf Jahre. Soweit nicht anders angegeben, kann die Erm\u00e4chtigung des Vorstands\nnicht aufgehoben werden.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6143651132962804, "height": 0.1633176571184266, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-6", "text": "Der Vorstand kann auch dazu erm\u00e4chtigt werden \u2013 nach Zustimmung des Aufsichts-\nrats \u2013 die Vorkaufsrechte der Aktion\u00e4re zu beschr\u00e4nken oder auszuschlie\u00dfen. Der\nUmfang dieser Erm\u00e4chtigung des Vorstands wird durch die Hauptversammlung fest-\ngelegt und hat nur G\u00fcltigkeit, wenn der Vorstand zu diesem Zeitpunkt auch dazu\nautorisiert ist, Aktien auszugeben.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6220607097050022, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6900384779820437, "height": 0.0679777682770415, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-7", "text": "Es wird erwartet, dass die Hauptversammlung den Vorstand f\u00fcr einen Zeitraum, der\n18 Monaten nach Umwandlung der Gesellschaft endet, erm\u00e4chtigen wird, nach Zu-\nstimmung des Aufsichtsrats, \u00fcber die Emission von Aktien der Gesellschaft und der\nGew\u00e4hrung von Bezugsrechten zu beschlie\u00dfen und Vorkaufsrechte hinsichtlich dieser\nAktien zu beschr\u00e4nken oder ausschlie\u00dfen. Gem\u00e4\u00df dieser Erm\u00e4chtigung, kann der\nVorstand, nach Zustimmung des Aufsichtsrats, dar\u00fcber beschlie\u00dfen, Aktien auszuge-\nben oder Bezugsrechte zu gew\u00e4hren (i) bis zu einer H\u00f6chstgrenze von 10% der Ge-\nsamtzahl der Aktien, die ausgegeben wurden und am Abwicklungstag (wie nachfol-\ngend definiert) noch ausstehend sind plus (ii) zus\u00e4tzliche 10% der Gesamtzahl der am\nAbwicklungstag ausstehenden Aktien, die in Verbindung mit oder anl\u00e4sslich von\nFusionen und \u00dcbernahmen und strategischen Allianzen ausgegeben wurden. Solch\neine Erm\u00e4chtigung des Vorstands kann von Mal zu Mal durch einen Beschluss der\nHauptversammlung verl\u00e4ngert werden.\n", "page_number": 36, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6973065412569475, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.8747327917913639, "height": 0.1774262505344164, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-8", "text": "C.5   Beschreibung     In der Satzung gibt es keine Beschr\u00e4nkungen der \u00dcbertragbarkeit der Angebotsaktien.\n      aller etwaigen\n                       Jedoch kann das Angebot an Personen, die ihren Aufenthaltsort, ihren Wohnort oder\n      Beschr\u00e4nkungen\n", "page_number": 36, "bounding_box": {"top_left_x": 0.10822249093107618, "top_left_y": 0.8802907225309962, "lower_right_x": 0.900241837968561, "lower_right_y": 0.9303120991876871, "height": 0.05002137665669093, "width": 0.7920193470374849}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-36-9", "text": "33\n", "page_number": 36, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-37-0", "text": "      f\u00fcr die freie     ihre Meldeanschrift nicht in Deutschland oder den Niederlanden haben oder die\n      \u00dcbertragbarkeit   Staatsangeh\u00f6rige eines anderen Landes als Deutschland und den Niederlanden sind,\n      der Angebotsak-   bestimmten Regulierungen oder Beschr\u00e4nkungen unterliegen. Ebenso kann die \u00dcber-\n      tien              tragung der Angebotsaktien au\u00dferhalb Deutschlands und der Niederlande Regulierun-\n                        gen oder Beschr\u00e4nkungen unterliegen.\n\nC.6   Antrag auf Zu-    Vor dem Angebot gab es keinen \u00f6ffentlichen Markt f\u00fcr die Aktien. Ein Antrag zur\n      lassung der       Notierung aller Aktien unter dem Symbol \"CURE\" an der Euronext in Amsterdam\n      Angebotsaktien    und Euronext in Br\u00fcssel wurde eingereicht.\n      zum Handel\n                        Vorbehaltlich einer Verk\u00fcrzung oder Verl\u00e4ngerung des Angebotszeitplans, wird der\n                        Handel der Aktien an der Euronext in Amsterdam und Euronext in Br\u00fcssel voraus-\n                        sichtlich am oder um den 11. November 2015 (der \"Erste Handelstag\") auf \"per\n                        Erscheinen\" Basis beginnen.\nC.7   Dividenden-       Die Gesellschaft beabsichtigt, alle Gewinne die durch die Gesch\u00e4ftst\u00e4tigkeit von\n      politik           Curetis m\u00f6glicherweise erzielt werden f\u00fcr die Entwicklung und Expansion des Ge-\n                        sch\u00e4fts der Gesellschaft zu verwenden und erwartet nicht, in absehbarer Zeit Dividen-\n                        den an die Aktion\u00e4re auszusch\u00fctten.\n", "page_number": 37, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08336896109448483, "lower_right_x": 0.909310761789601, "lower_right_y": 0.33219324497648567, "height": 0.24882428388200084, "width": 0.8035066505441355}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-37-1", "text": "Abschnitt D \u2013 Risiken\n", "page_number": 37, "bounding_box": {"top_left_x": 0.4111245465538089, "top_left_y": 0.34886703719538265, "lower_right_x": 0.6021765417170496, "lower_right_y": 0.3599828986746473, "height": 0.011115861479264633, "width": 0.19105199516324067}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-37-2", "text": "                                      Abschnitt D \u2013 Risiken\n\nD.1   Zentrale Risi-     Risiken im Zusammenhang mit der Gesch\u00e4ftst\u00e4tigkeit und Strategie\n      ken, die der\n                         \uf0b7     Curetis ist ein Unternehmen mit einer eingeschr\u00e4nkten Anzahl an Produkten\n      Gesellschaft und\n                               und hat erhebliche Verluste seit Gr\u00fcndung erfahren und erwartet in absehbarer\n      ihrer Branche\n                               Zeit weitere Verluste zu erleiden. Es ist nicht sichergestellt, dass Curetis Profi-\n      eigen sind\n                               tabilit\u00e4t erreichen oder aufrechterhalten kann.\n                         \uf0b7     Curetis befindet sich aktuell in einem FDA-Freigabe-Verfahren f\u00fcr das Unyve-\n                               ro System und die LRT55 Anwendungs-Kartusche. Es ist offen, ob und wann\n                               eine solche regulatorische Freigabe erteilt wird.\n                         \uf0b7     Curetis k\u00f6nnte nicht in der Lage sein, seine Produkte erfolgreich zu vermark-\n                               ten und eine ausreichende Marktakzeptanz zu erreichen und aufrechtzuerhal-\n                               ten.\n                         \uf0b7     Curetis ist insbesondere vom Erfolg und der F\u00e4higkeit zur Vermarktung seiner\n                               Hauptprodukte, den P55 und i60 ITI Anwendungs-Kartuschen in der EU und\n                               der LRT55 Anwendungs-Kartusche in den USA, abh\u00e4ngig. Hierauf hat Curetis\n                               in der Vergangenheit fast das gesamte Gesch\u00e4ft und die finanziellen Ressour-\n                               cen ausgerichtet.\n                         \uf0b7     Das Marktpotential und die M\u00f6glichkeiten f\u00fcr die Hauptprodukte von Curetis\n                               k\u00f6nnten kleiner sein als derzeit erwartet, was die m\u00f6glichen Ums\u00e4tze von\n                               Curetis reduzieren w\u00fcrde.\n                         \uf0b7     Curetis k\u00f6nnte seine beschr\u00e4nkten finanziellen und organisatorischen Kapazi-\n                               t\u00e4ten auf ein bestimmtes zuk\u00fcnftiges Produkt oder eine bestimmte Indikation\n                               verwenden und es dabei vers\u00e4umen sich auf Produkte oder Indikationen zu\n                               konzentrieren, die weit bessere Erfolgsaussichten haben.\n                         \uf0b7     Curetis k\u00f6nnte nicht in der Lage sein, sein Wachstum erfolgreich zu managen.\n                         \uf0b7     Curetis ist von einigen Hauptlieferanten f\u00fcr kritische Produktkomponenten\n                               abh\u00e4ngig. Im Falle eines Verlustes von einem dieser Zulieferer oder einer Un-\n                               terbrechung der Lieferkette, k\u00f6nnte Curetis nicht in der Lage sein, seine Pro-\n                               dukte in ausreichender St\u00fcckzahl, zeitnah oder zu wirtschaftlichen Kosten zu\n                               produzieren oder die Produktion auszulagern.\n                         \uf0b7     Curetis ist von einigen Vertriebspartnern f\u00fcr den Vertrieb seiner Produkte in\n                               bestimmten M\u00e4rkten abh\u00e4ngig und plant den Abschluss weiterer Vertriebsver-\n                               einbarungen mit Vertriebspartnern, um seine Produkte in anderen M\u00e4rkten zu\n                               vertreiben. Sollte es Curetis nicht gelingen, passende Vertriebspartner zu fin-\n                               den, falls diese Vertriebspartner die Vereinbarungen beenden oder falls die\n", "page_number": 37, "bounding_box": {"top_left_x": 0.10701330108827085, "top_left_y": 0.36041043180846516, "lower_right_x": 0.9044740024183797, "lower_right_y": 0.9221889696451475, "height": 0.5617785378366824, "width": 0.7974607013301088}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-37-3", "text": "34\n", "page_number": 37, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-38-0", "text": "    Vertriebspartner von Curetis nicht in der Lage sind, Curetis Produkte in aus-\n    reichender St\u00fcckzahl, zu wirtschaftlich rentablen Bedingungen oder zeitnah zu\n    verkaufen, k\u00f6nnte die Vermarktung der P55/LRT55 und i60 ITI Anwendungs-\n    Kartuschen oder anderer zuk\u00fcnftiger Produkte erheblich beeintr\u00e4chtigt oder\n    verz\u00f6gert werden.\n\uf0b7   Die Verkaufszyklen von Curetis sind langwierig und die Verkaufszahlen k\u00f6nn-\n    ten schwanken, was es erschwert, Umsatz und Produktverk\u00e4ufe zu prognosti-\n    zieren.\n\uf0b7   Curetis k\u00f6nnte nicht in der Lage sein, die Unterst\u00fctzung von f\u00fchrenden Klini-\n    ken und Experten zu gewinnen oder vorteilhafte Ver\u00f6ffentlichungen der Er-\n    gebnisse der klinischen Studien von Curetis in Zeitschriften, die ihre Artikel\n    vor Ver\u00f6ffentlichung einem sog. Peer-Review unterziehen, zu erreichen.\n\uf0b7   Curetis k\u00f6nnte es nicht gelingen, Schl\u00fcsselpersonal einzustellen, auszubilden\n    oder zu halten.\n\uf0b7   Die Liquidit\u00e4tslage und der operative Cashflow von Curetis k\u00f6nnten nicht\n    ausreichen, um erwartete Investments zu t\u00e4tigen und Curetis k\u00f6nnte gezwun-\n    gen sein, zuk\u00fcnftig zus\u00e4tzliche Finanzmittel aufzunehmen.\n\uf0b7   Der Markt f\u00fcr Molekulardiagnostik ist sehr wettbewerbsintensiv und Curetis\n    k\u00f6nnte nicht in der Lage sein, erfolgreich am Markt zu bestehen.\n\uf0b7   Das Niveau der Verkaufspreise im Markt f\u00fcr Molekulardiagnostik k\u00f6nnte\n    zuk\u00fcnftig sinken, was sich erheblich negativ auf das Gesch\u00e4ft, die Finanz- und\n    Ertragslage von Curetis auswirken k\u00f6nnte.\n\uf0b7   Die aktuellen und zuk\u00fcnftigen Kunden von Curetis sind stark von Zahlungen\n    durch Dritte abh\u00e4ngig. Unzureichende Deckung und R\u00fcckerstattung f\u00fcr diag-\n    nostische Tests von Curetis und ein zu schneller Anstieg von Curetis Produkti-\n    onskosten im Verh\u00e4ltnis zum Anstieg des Levels der R\u00fcckerstattungen, k\u00f6nnte\n    den wirtschaftlichen Erfolg von Curetis Produkten gef\u00e4hrden.\n\uf0b7   Die Produktion vieler Produkte von Curetis ist ein sehr pr\u00e4ziser und komplexer\n    Prozess und falls Probleme bei der Produktion oder Qualit\u00e4t von Curetis Pro-\n    dukten auftreten, k\u00f6nnte der Ruf und das Gesch\u00e4ft von Curetis in Mitleiden-\n    schaft gezogen werden.\n\uf0b7   Die diagnostischen Ergebnisse von Curetis k\u00f6nnten nicht wie erwartet ausfal-\n    len und unvollst\u00e4ndige oder falsche Ergebnisse liefern, was zu Produkthaf-\n    tungsanspr\u00fcchen gegen Curetis f\u00fchren k\u00f6nnte.\n\uf0b7   Ein R\u00fcckruf von Curetis Produkten, freiwillig oder aufgrund einer Anordnung\n    zust\u00e4ndigen Beh\u00f6rden oder die Entdeckung von ernsthaften Sicherheitsrisiken\n    bei Curetis Produkten, die Ma\u00dfnahmen zur Korrektur erfordern, k\u00f6nnten einen\n    erheblichen negativen Einfluss auf Curetis haben.\n\uf0b7   Der zuk\u00fcnftige Erfolg von Curetis h\u00e4ngt von ihrer F\u00e4higkeit ab, einen Kun-\n    denstamm f\u00fcr ihre Produkte in gro\u00dfen und f\u00fchrenden Krankenh\u00e4usern aufzu-\n    bauen, aufrecht zu halten und auszubauen.\n\uf0b7   Curetis k\u00f6nnte nicht in der Lage sein, neue Produkte zu entwickeln oder die\n    M\u00f6glichkeiten ihre Produkte auszusch\u00f6pfen, um mit der sich in diesem Markt-\n    umfeld schnell ver\u00e4ndernden Technologie und Kundenanspr\u00fcchen mitzuhal-\n    ten.\n\uf0b7   Falls die von oder f\u00fcr Curetis verwendeten Anlagen zur Produktion, Entwick-\n    lung oder Pr\u00fcfung besch\u00e4digt oder zerst\u00f6rt werden oder falls Curetis eine er-\n    hebliche St\u00f6rung seiner Betriebst\u00e4tigkeit erf\u00e4hrt oder falls der Produktionspro-\n    zess aus jeglichen Gr\u00fcnden gest\u00f6rt wird, k\u00f6nnte die Fortf\u00fchrung der Ge-\n    sch\u00e4ftst\u00e4tigkeit von Curetis wesentlich beeintr\u00e4chtigt werden.\n\uf0b7   Ein erheblicher Anteil des Inventarbestands von Curetis besteht aus Ger\u00e4ten,\n    die m\u00f6glichen zuk\u00fcnftigen Kunden zu Testzwecken zur Verf\u00fcgung gestellt\n    wurden und welche m\u00f6glicherweise nicht im von Curetis vorgesehenen Zeit-\n", "page_number": 38, "bounding_box": {"top_left_x": 0.30290205562273276, "top_left_y": 0.08336896109448483, "lower_right_x": 0.9068923821039904, "lower_right_y": 0.9209063702436939, "height": 0.8375374091492092, "width": 0.6039903264812576}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-38-1", "text": "35\n", "page_number": 38, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-39-0", "text": "    raum oder gar nicht in Umsatz umgewandelt werden k\u00f6nnen.\n\uf0b7   Curetis Absichten, mit strategischen Partnern, die \u00fcber patentgesch\u00fctzte Bio-\n    marker f\u00fcr die Diagnose von Indikationen verf\u00fcgen, Vereinbarungen abzu-\n    schlie\u00dfen um neue diagnostische Produkte zu entwickeln und zu kommerziali-\n    sieren k\u00f6nnte sich als nicht erfolgreich herausstellen.\n\uf0b7   Akquisitionen oder Joint Ventures k\u00f6nnten das Gesch\u00e4ft von Curetis beein-\n    tr\u00e4chtigen, Verw\u00e4sserung der Beteiligungsverh\u00e4ltnisse der Aktion\u00e4re verursa-\n    chen oder auf andere Art und Weise das Gesch\u00e4ft von Curetis negativ beein-\n    flussen.\n\uf0b7   Curetis wird wahrscheinlich seine derzeitigen steuerlichen Verlustvortr\u00e4ge\n    einb\u00fc\u00dfen.\n\uf0b7   Die Betriebsergebnisse von Curetis k\u00f6nnten von unvorhergesehenen \u00c4nderun-\n    gen der Steuergesetze und -verordnungen, Anpassungen der steuerlichen Best-\n    immungen oder zus\u00e4tzlichen Steuerbelastungen, erheblich nachteilig beein-\n    flusst werden.\n\uf0b7   Derzeit erwirtschaftet Curetis einen Teil ihres Umsatzes im internationalen\n    Umfeld und erwartet einen Anstieg dieses Anteils in der Zukunft. Daher ist\n    Curetis verschiedenen Risiken im Zusammenhang mit seinen internationalen\n    Aktivit\u00e4ten ausgesetzt, die ihr Betriebsergebnis erheblich beeinflussen k\u00f6nn-\n    ten.\n\uf0b7   Curetis ist Wechselkursschwankungen ausgesetzt.\n\uf0b7   Curetis Mitarbeiter, unabh\u00e4ngige Vertragspartner, Studienleiter, Vertriebs-\n    partner, Berater, Gesch\u00e4ftspartner und Verk\u00e4ufer k\u00f6nnten unlauteres oder\n    missbr\u00e4uchliches Verhalten zeigen, einschlie\u00dflich der Nichtbefolgung von re-\n    gulatorischen Standards und Vorgaben.\n\uf0b7   Curetis ist f\u00fcr die Durchf\u00fchrung von klinischen oder Evaluationsstudien seiner\n    Produkte, die von der FDA oder anderen Aufsichtsbeh\u00f6rden gefordert werden,\n    auf Dritte angewiesen und diese Dritten k\u00f6nnten nicht zufriedenstellend arbei-\n    ten.\n\uf0b7   Das Gesch\u00e4ft von Curetis k\u00f6nnte durch aktuelle oder neue Regierungsvor-\n    schriften, Freigabe- und Zulassungsvorgaben, insbesondere in der EU und den\n    USA, erheblich und negativ beeinflusst werden.\n\uf0b7   Ver\u00e4nderungen im Gesundheitswesen, einschlie\u00dflich der Gesetzgebung zur\n    Reform des US-amerikanischen Gesundheitssystems, k\u00f6nnten einen erhebli-\n    chen negativen Einfluss auf die Finanz- und Ertragslage von Curetis haben.\n\uf0b7   Ver\u00e4nderungen von Curetis Produkten, die bereits freigegeben und zugelassen\n    wurden, k\u00f6nnten neue Freigaben- oder Zulassungsverfahren vor der Vermark-\n    tung erforderlich machen oder Curetis k\u00f6nnte gezwungen sein, die Vermark-\n    tung einzustellen oder das ver\u00e4nderte Produkt zur\u00fcckzurufen, bis die Freigaben\n    oder Zulassungen erteilt sind.\n\uf0b7   Ab dem geplanten Start der Gesch\u00e4ftst\u00e4tigkeit von Curetis in den USA, unter-\n    liegt Curetis den dortigen Gesetzen zur Verhinderung von Betrug und Miss-\n    brauch im Gesundheitswesens und anderen anwendbaren Gesetzen auf Bun-\n    des- Einzelstaatenebene in den Vereinigten Staaten. Falls Curetis nicht in der\n    Lage seien sollte, die Einhaltung dieser Gesetze zu gew\u00e4hrleisten, k\u00f6nnten\n    Curetis erhebliche Geldbu\u00dfen auferlegt werden.\n\uf0b7   Curetis unterliegt Risiken beim Umgang mit Gefahrstoffen und bestimmten\n    Vorschriften bez\u00fcglich deren Umweltvertr\u00e4glichkeit.\n\uf0b7   Curetis ist von seinen IT-Systemen abh\u00e4ngig und jeglicher Ausfall dieser Sys-\n    teme k\u00f6nnte dem Gesch\u00e4ft von Curetis schaden.\n\uf0b7   Curetis hat Mietvereinbarungen f\u00fcr einen Produktionsstandort, in dem Labo-\n    reinrichtungen untergebracht sind, abgeschlossen. Eine unerwartete Beendi-\n    gung oder Nicht-Verl\u00e4ngerung dieser Mietvereinbarung k\u00f6nnte einen erhebli-\n\n                                                                         36\n", "page_number": 39, "bounding_box": {"top_left_x": 0.16203143893591293, "top_left_y": 0.08165882855921335, "lower_right_x": 0.909310761789601, "lower_right_y": 0.9576742197520308, "height": 0.8760153911928175, "width": 0.747279322853688}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-40-0", "text": "chen negativen Einfluss auf die Gesch\u00e4ftst\u00e4tigkeit, Finanz- und Ertragslage\n", "page_number": 40, "bounding_box": {"top_left_x": 0.3542926239419589, "top_left_y": 0.0837964942283027, "lower_right_x": 0.9026602176541717, "lower_right_y": 0.09833262077811031, "height": 0.014536126549807613, "width": 0.5483675937122128}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-40-1", "text": "                              von Curetis haben.\n\n                         Risiken im Zusammenhang mit geistigem Eigentum\n                         \uf0b7    Sollte Curetis nicht in der Lage sein, ihr geistiges Eigentum effektiv zu sch\u00fct-\n                              zen, k\u00f6nnte das Gesch\u00e4ft von Curetis gesch\u00e4digt werden.\n                         \uf0b7    Curetis ist von bestimmten Technologien abh\u00e4ngig, f\u00fcr die Curetis die Lizen-\n                              zen erworben hat. Curetis hat keine Kontrolle \u00fcber die geistigen Eigentums-\n                              rechte, die diese Technologien abdecken und jeglicher Verlust der Rechte an\n                              diesen Technologien oder der lizenzierten Rechte, k\u00f6nnte verhindern, dass\n                              Curetis ihre Produkte vertreiben kann.\n                         \uf0b7    Curetis k\u00f6nnte in Gerichtsverfahren zum Schutz oder zur Geltendmachung\n                              ihrer Patente und Eigentumsrechte, zur Festlegung des Umfangs, der Durch-\n                              setzbarkeit und der G\u00fcltigkeit von Eigentumsrechten Dritter oder zur Verteidi-\n                              gung gegen Anspr\u00fcche von Dritten aufgrund einer Verletzung von geistigen\n                              Eigentumsrechten involviert werden, die zeitaufw\u00e4ndig und kostenintensiv\n                              sein k\u00f6nnten und welche einen erheblichen Einfluss auf das Gesch\u00e4ft von\n                              Curetis oder den Aktienpreis haben k\u00f6nnten.\n                         \uf0b7    Curetis ist auf die Wahrung von Betriebsgeheimnissen, die Einhaltung von\n                              Geheimhaltungsverpflichtungen und Patentabtretungsvereinbarungen ange-\n                              wiesen.\n                         \uf0b7    Curetis k\u00f6nnte aufgrund von Behauptungen, dass Curetis oder seine Mitarbei-\n                              ter, Berater oder unabh\u00e4ngige Vertragspartner unrechtm\u00e4\u00dfig vertrauliche In-\n                              formationen von Dritten genutzt oder offengelegt haben oder dass die Mitar-\n                              beiter von Curetis unrechtm\u00e4\u00dfig vermeintliche Gesch\u00e4ftsgeheimnisse ihrer\n                              vorherigen Arbeitgeber genutzt oder offengelegt haben, schadensersatzpflich-\n                              tig sein.\n                         \uf0b7    Falls die Handelsmarken und Markennamen von Curetis nicht ausreichend\n                              gesch\u00fctzt werden, k\u00f6nnte Curetis nicht in der Lage sein, einen Wiedererken-\n                              nungswert in seinen Zielm\u00e4rkten aufzubauen und das Gesch\u00e4ft von Curetis\n                              k\u00f6nnte nachhaltig beeintr\u00e4chtigt werden.\n\nD.3   Zentrale Risiken   \uf0b7    Vor dem Angebot gab es keinen \u00f6ffentlichen Markt f\u00fcr die Aktien und die\n      im Zusammen-            Gesellschaft kann nicht versichern, dass sich ein aktiver und liquider Handel\n      hang mit dem            f\u00fcr die Angebotsaktien entwickelt.\n      Angebot und\n      den Wertpapie-     \uf0b7    Der Marktpreis der Aktien k\u00f6nnte signifikant schwanken und Investoren k\u00f6nn-\n      ren                     ten ihre Investitionen teilweise oder vollst\u00e4ndig verlieren.\n                         \uf0b7    Nach Beendigung des Angebots werden bestimmte bestehende Aktion\u00e4re\n                              weiterhin erheblichen Einfluss auf die Gesellschaft haben und ihre Interessen\n                              k\u00f6nnten nicht mit denen der anderen Aktion\u00e4re \u00fcbereinstimmen.\n                         \uf0b7    Privatanleger k\u00f6nnten einen h\u00f6heren Preis f\u00fcr die Angebotsaktien zu zahlen\n                              haben, als zum Zeitpunkt der Zeichnung absehbar war.\n                         \uf0b7    Die Gesellschaft hat einen weitreichenden Ermessensspielraum bei der Ver-\n                              wendung der Emissionserl\u00f6se und k\u00f6nnte diese nicht effizient verwenden.\n                         \uf0b7    Als b\u00f6rsennotiertes Unternehmen wird die Gesellschaft steigende Kosten ha-\n                              ben.\n                         \uf0b7    Die zuk\u00fcnftigen Emissionen oder Ver\u00e4u\u00dferungen einer erheblichen Anzahl an\n                              Aktien oder in Aktien wandelbare Wertpapiere, entweder als Teil eines Stock\n                              Option Programms als erfolgsbasierte Verg\u00fctungskomponente f\u00fcr das Ma-\n                              nagement oder leitende Mitarbeiter, oder anderweitig, oder die Markterwar-\n                              tung, dass eine solche Emission oder Ver\u00e4u\u00dferung stattfinden k\u00f6nnte, k\u00f6nnte\n                              den Marktpreis der Aktien erheblich beeinflussen und jede zuk\u00fcnftige Ausga-\n                              be von Aktien k\u00f6nnte den Anteilsbesitz der Investoren verw\u00e4ssern. Obwohl\n                              erwartet wird, dass die Gesellschaft, alle bestehenden Aktion\u00e4re, alle fr\u00fcheren\n", "page_number": 40, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.09876015391192818, "lower_right_x": 0.9087061668681983, "lower_right_y": 0.9196237708422402, "height": 0.8208636169303121, "width": 0.7986698911729141}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-40-2", "text": "37\n", "page_number": 40, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-0", "text": "und derzeitigen Mitarbeiter von Curetis, die Aktien halten und die Gesch\u00e4fts-\n", "page_number": 41, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.08550662676357418, "lower_right_x": 0.898428053204353, "lower_right_y": 0.09961522017956391, "height": 0.014108593415989731, "width": 0.5356711003627569}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-1", "text": "f\u00fchrer dem \u00dcbernahmevertrag und den entsprechenden separaten Lock-Up\nVereinbarungen hinsichtlich bestimmter Beschr\u00e4nkungen bei der Ausgabe,\nVer\u00e4u\u00dferung oder \u00dcbertragung von Aktien f\u00fcr einen Zeitraum von 365 Tagen\nnach dem Abwicklungstag zustimmen werden, k\u00f6nnten die Joint Bookrunners\n(wie nachstehend definiert) nach eigenem Ermessen und zu jeder Zeit solche\nBeschr\u00e4nkungen aufheben.\nAktion\u00e4re, die in bestimmten Jurisdiktionen au\u00dferhalb der Niederlande, ein-\nschlie\u00dflich den USA, ans\u00e4ssig sind oder ihren Sitz haben, k\u00f6nnten ihre Vor-\nkaufsrechte bei zuk\u00fcnftigen Angeboten nicht aus\u00fcben und im Ergebnis Ver-\nw\u00e4sserungseffekten unterliegen.\nFalls es nicht zu einer Abwicklung des Angebots kommt, k\u00f6nnten Zeichnun-\ngen der Angebotsaktien hinf\u00e4llig und Transaktionen mit den Aktien annulliert\nwerden.\nDie Gesellschaft beabsichtigt nicht, in absehbarer Zeit Dividenden zu zahlen.\nInvestoren mit einer anderen Referenzw\u00e4hrung als dem Euro k\u00f6nnten bei einer\nInvestition in die Aktien gewissen Fremdw\u00e4hrungsrisiken unterworfen sein.\nFalls Wertpapieranalysten und Branchenexperten keine Analysen ver\u00f6ffentli-\nchen oder unvorteilhafte Berichte in Bezug auf das Gesch\u00e4ft von Curetis ver-\n\u00f6ffentlichen oder Prognosen ver\u00f6ffentlichen, die das tats\u00e4chliche Ergebnis von\nCuretis \u00fcbersteigen, k\u00f6nnte der Aktienpreis und das Handelsvolumen sinken.\nDie M\u00f6glichkeit der Aktion\u00e4re, gegen die Gesellschaft, Gesch\u00e4ftsf\u00fchrer und\nAufsichtsr\u00e4te Klage einzureichen oder Urteile zu vollstrecken, k\u00f6nnte einge-\nschr\u00e4nkt sein.\nJede Ver\u00e4u\u00dferung, jeder Kauf oder Tausch der Aktien k\u00f6nnte der Finanztrans-\naktionssteuer unterliegen.\nDie Gesellschaft k\u00f6nnte gem\u00e4\u00df US-Bundeseinkommenssteuergesetz als passi-\nve ausl\u00e4ndische Investmentgesellschaft klassifiziert werden, was f\u00fcr US ame-\nrikanische Investoren erbliche steuerliche Konsequenzen nach sich ziehen\nw\u00fcrde.\n", "page_number": 41, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.10004275331338179, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5575032064985036, "height": 0.4574604531851218, "width": 0.5374848851269649}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-2", "text": "", "page_number": 41, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.1911073108165883, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.19794784095767423, "height": 0.006840530141085932, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-3", "text": "\uf0b7\n", "page_number": 41, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.2556648140230868, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.2620778110303549, "height": 0.006412997007268106, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-4", "text": "\uf0b7\n", "page_number": 41, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.3039760581445062, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.3108165882855921, "height": 0.006840530141085932, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-5", "text": "\uf0b7\n", "page_number": 41, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.324497648567764, "lower_right_x": 0.3234582829504232, "lower_right_y": 0.33133817870884996, "height": 0.0068405301410859876, "width": 0.0096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-6", "text": "", "page_number": 41, "bounding_box": {"top_left_x": 0.31680773881499397, "top_left_y": 0.3595553655408294, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.3659683625480975, "height": 0.006412997007268106, "width": 0.007255139056831894}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-7", "text": "\uf0b7\n", "page_number": 41, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4236853356135101, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.430525865754596, "height": 0.006840530141085932, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-8", "text": "\uf0b7\n", "page_number": 41, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4715690466011116, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.4788371098760154, "height": 0.007268063274903813, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-9", "text": "", "page_number": 41, "bounding_box": {"top_left_x": 0.31680773881499397, "top_left_y": 0.506626763574177, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.5130397605814451, "height": 0.006412997007268051, "width": 0.007255139056831894}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-10", "text": "Abschnitt E \u2013 Angebot\n", "page_number": 41, "bounding_box": {"top_left_x": 0.4062877871825877, "top_left_y": 0.5810175288584866, "lower_right_x": 0.6088270858524788, "lower_right_y": 0.5968362548097478, "height": 0.015818725951261214, "width": 0.20253929866989112}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-11", "text": "E.1    Gesamtnetto-     Die Gesellschaft beabsichtigt, einen Bruttoerl\u00f6s aus dem Angebot in H\u00f6he von unge-\n       erl\u00f6se und ge-   f\u00e4hr \u20ac29,3 Millionen (der \"Zielerl\u00f6s\") zu erreichen. Basierend auf der H\u00f6chstzahl der\n       sch\u00e4tzte Ge-     Angebotsaktien (unter der Annahme, dass die Mehrzuteilungsoption (die \"Mehrzu-\n       samtkosten       teilungsoption\"), welche von der Gesellschaft im Zusammenhang mit dem Angebot\n                        gew\u00e4hrt werden wird, nicht ausge\u00fcbt wird), hat die Gesellschaft die M\u00f6glichkeit,\n                        einen Bruttoerl\u00f6s in H\u00f6he von bis zu ungef\u00e4hr \u20ac50 Millionen aus dem Angebot zu\n                        erzielen (basierend auf einem Angebotspreis am oberen Ende der Angebotspreisspan-\n                        ne (wie nachfolgend definiert).\n                        Nach Abzug der gesch\u00e4tzten Aufwendungen, Provisionen und Steuern in Bezug auf\n                        das Angebot von \u20ac4,3 Millionen, einschlie\u00dflich ungef\u00e4hr \u20ac1,46 Millionen an Hono-\n                        rar- und Kommissionskosten f\u00fcr die Konsortialbanken (wie nachstehend definiert),\n                        erwartet die Gesellschaft einen Nettoerl\u00f6s von ungef\u00e4hr \u20ac25 Millionen aus dem An-\n                        gebot (basierend auf einem Angebot, bei welchem der Zielerl\u00f6s erreicht wird).\n\nE.2a   Gr\u00fcnde f\u00fcr das   Der Hauptzweck dieses Angebots ist der Zufluss von zus\u00e4tzlichem Kapital, um die\n       Angebot,         Umsetzung der Strategie von Curetis zu unterst\u00fctzen. Zus\u00e4tzlich wird das Angebot\n       Zweckbestim-     auch einen \u00f6ffentlichen Markt f\u00fcr die Aktien der Gesellschaft schaffen, was einen\n       mung der Erl\u00f6-   k\u00fcnftigen Zugang zu den \u00f6ffentlichen Eigenkapitalm\u00e4rkten erm\u00f6glicht.\n       se, gesch\u00e4tzte\n                        Basierend auf der Annahme, dass die Gesellschaft den Zielerl\u00f6s erreicht, erwartet die\n       Nettoerl\u00f6se\n                        Gesellschaft Nettoerl\u00f6se in H\u00f6he von ungef\u00e4hr \u20ac25 Millionen.\n                        Curetis erwartet derzeit, dass sie in den kommenden Jahren die Nettoerl\u00f6se des\n", "page_number": 41, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.619067977768277, "lower_right_x": 0.909310761789601, "lower_right_y": 0.9277469003847798, "height": 0.30867892261650276, "width": 0.7992744860943168}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-41-12", "text": "38\n", "page_number": 41, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.019347037484885088}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-0", "text": "Angebots und die erwarteten Mitteleinfl\u00fcsse der Bruttomarge aus Produktverk\u00e4ufen\n", "page_number": 42, "bounding_box": {"top_left_x": 0.30773881499395406, "top_left_y": 0.08294142796066695, "lower_right_x": 0.9026602176541717, "lower_right_y": 0.10303548525010689, "height": 0.020094057289439943, "width": 0.5949214026602176}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-1", "text": "f\u00fcr folgende Zwecke in absteigender Reihenfolge verwenden wird:\n\uf0b7     Ungef\u00e4hr 20% bis 30% der Nettoerl\u00f6se aus dem Angebot sollen f\u00fcr den Auf-\n      bau einer Pr\u00e4senz, die Vermarktung, den Verkauf und die Kundenbetreuung in\n      den Vereinigten Staaten verwendet werden um nach der erwarteten FDA Frei-\n      gabe dort das Unyvero System und die Anwendungskartuschen direkt vertrei-\n      ben zu k\u00f6nnen.\n\uf0b7     Ungef\u00e4hr 20% bis 25% der Nettoerl\u00f6se aus dem Angebot sollen f\u00fcr die Be-\n      schleunigung der Forschungs- und Entwicklungst\u00e4tigkeiten bezogen auf\n      Unyvero Anwendungskartuschen f\u00fcr den europ\u00e4ischen, amerikanischen und\n      weltweiten Markt, einschlie\u00dflich klinischer Studien und beh\u00f6rdlicher Zulas-\n      sungsverfahren, verwendet werden.\n\uf0b7     Ungef\u00e4hr 20% bis 25% der Nettoerl\u00f6se aus dem Angebot sollen f\u00fcr die Aus-\n      weitung und St\u00e4rkung der kommerziellen Pr\u00e4senz in Europa in M\u00e4rkten in de-\n      nen Curetis die Unyvero Plattform direkt an den Endverbraucher verkauft,\n      verwendet werden.\n\uf0b7     Die noch verbleibenden Mittel sollen verwendet werden f\u00fcr:\n            o   eine Ausweitung der Produktionskapazit\u00e4ten,\n            o   als zus\u00e4tzliches Working Capital und\n            o   f\u00fcr allgemeine Unternehmenszwecke.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.10346301838392476, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.41043180846515603, "height": 0.3069687900812313, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-2", "text": "E.3\n", "page_number": 42, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.42667806755023513, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.4386489952971355, "height": 0.011970927746900395, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-3", "text": "Angebots-\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.42667806755023513, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.43993159469858917, "height": 0.013253527148354038, "width": 0.08282950423216445}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-4", "text": "Angebotsaktien\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3143893591293833, "top_left_y": 0.427105600684053, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.4407866609662249, "height": 0.013681060282171864, "width": 0.11608222490931075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-5", "text": "konditionen\n", "page_number": 42, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.440359127832407, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.4523300555793074, "height": 0.011970927746900395, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-6", "text": "Die Gesellschaft bietet bis zu 4.791.667 Angebotsaktien an. Das Angebot besteht aus:\n(i) einem \u00f6ffentlichen Angebot an private und institutionelle Anleger in Deutschland\nund (ii) einer Privatplatzierung an bestimmte institutionelle Anleger in verschiedenen\nanderen Jurisdiktionen. Die Angebotsaktien werden (i) innerhalb der Vereinigten\nStaaten an qualifizierte institutionelle Anleger (\"QIAs\") gem\u00e4\u00df Definition in Rule\n144A (\"Rule 144A\") des US Securities Act von 1933 in der derzeit g\u00fcltigen Fassung\n(der \"US Securities Act\") in Berufung auf Rule 144A oder gem\u00e4\u00df einer anderen\nAusnahme, oder in einer Transaktion, die den Registrierungspflichten des US Securi-\nties Act nicht unterliegt, und (ii) au\u00dferhalb der Vereinigten Staaten in Offshore-\nTransaktionen gem\u00e4\u00df der Regulation S unter dem US Securities Act (\"Regulation S\")\nangeboten. Das Angebot wird nur in den Jurisdiktionen und nur an jene Personen\nunterbreitet, in denen und an die das Angebot rechtm\u00e4\u00dfig gemacht werden darf.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6113723813595554, "height": 0.1637451902522446, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-7", "text": "Mehrzuteilungsoption\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6186404446344592, "lower_right_x": 0.4782345828295042, "lower_right_y": 0.6323215049166311, "height": 0.013681060282171864, "width": 0.16444981862152358}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-8", "text": "Die Gesellschaft erwartet, dem Sole Global Coordinator (wie nachstehend definiert),\nim Namen der Konsortialbanken die Mehrzuteilungsoption zu gew\u00e4hren, aus\u00fcbbar\ninnerhalb von 30 Kalendertagen nach dem ersten Handelstag, woraufhin der Sole\nGlobal Coordinator im Namen der Konsortialbanken die Gesellschaft auffordern\nkann, bis zu 625.000 zus\u00e4tzliche Aktien (die \"Zusatzaktien\") an die Konsortialban-\nken zum Angebotspreis auszugeben. Bis zu 15% der Angebotsaktien, die im Angebot\nausgegeben werden, k\u00f6nnen Zusatzaktien sein, um Mehrzuteilungen oder m\u00f6gliche\nShort Positionen im Zusammenhang mit dem Angebot abzudecken.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.639162035057717, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.7486105173150919, "height": 0.10944848225737491, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-9", "text": "Angebotszeitraum\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7554510474561779, "lower_right_x": 0.4486094316807739, "lower_right_y": 0.7695596408721675, "height": 0.01410859341598969, "width": 0.13482466747279326}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-10", "text": "Zuk\u00fcnftige Anleger k\u00f6nnen Angebotsaktien w\u00e4hrend des Zeitraums, beginnend am\n28. Oktober 2015 um 09:00 MEZ und endend am 10. November 2015 um 16:00 MEZ\n(der \"Angebotszeitraum\") zeichnen, vorbehaltlich einer Verk\u00fcrzung oder Verl\u00e4nge-\nrung des Zeitplans des Angebots.\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7759726378794357, "lower_right_x": 0.898428053204353, "lower_right_y": 0.831124412141941, "height": 0.05515177426250528, "width": 0.5846432889963724}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-11", "text": "Vorbehaltlich einer Verk\u00fcrzung oder Verl\u00e4ngerung des Zeitplans oder einer R\u00fcck-\nnahme des Angebots, zeigt der nachstehende Zeitplan bestimmte erwartete Stichtage\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.837537409149209, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.870884993587003, "height": 0.03334758443779395, "width": 0.5810157194679565}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-12", "text": "f\u00fcr das Angebot:\n\n Ereignis                       Zeit (MEZ) und Datum\n Beginn des Angebotszeitraums   09:00 am 28. Oktober 2015\n", "page_number": 42, "bounding_box": {"top_left_x": 0.3047158403869408, "top_left_y": 0.8713125267208208, "lower_right_x": 0.8216444981862152, "lower_right_y": 0.9290294997862334, "height": 0.05771697306541257, "width": 0.5169286577992744}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-42-13", "text": "39\n", "page_number": 42, "bounding_box": {"top_left_x": 0.8319226118500604, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-0", "text": "Ende des Angebotszeitraums      16:00 am 10. November 2015\nPreisfestsetzung                10. November 2015\nErster Handelstag (Handel auf   11. November 2015\n\"per-Erscheinen\" Basis)\nAbwicklungstag                  13. November 2015\n", "page_number": 43, "bounding_box": {"top_left_x": 0.31257557436517536, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8530834340991535, "lower_right_y": 0.15604959384352288, "height": 0.07396323215049166, "width": 0.5405078597339782}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-1", "text": "Bitte beachten Sie, dass sich die Gesellschaft das Recht vorbeh\u00e4lt, nach Beratung mit\nden Joint Bookrunners (wie nachstehend definiert) den Angebotszeitraum zu verk\u00fcr-\nzen oder zu verl\u00e4ngern.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.2026507054296708, "height": 0.03890551517742627, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-2", "text": "zen oder zu verl\u00e4ngern.\nAngebotspreis und Zahl der Angebotsaktien\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.20307823856348867, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.22573749465583584, "height": 0.022659256092347174, "width": 0.3198307134220073}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-3", "text": "Es wird erwartet, dass sich der Angebotspreis in einer Spanne von \u20ac9,50 bis \u20ac12 (ein-\nschlie\u00dflich) pro Angebotsaktie bewegen wird (die \"Angebotspreisspanne\"). Die\nAngebotspreisspanne ist eine indikative Preisspanne. Der Angebotspreis kann inner-\nhalb, \u00fcber- oder unterhalb der Angebotspreisspanne festgelegt werden. Der Ange-\nbotspreis und die genaue Anzahl der angebotenen Angebotsaktien wird von der Ge-\nsellschaft nach Beratung mit den Joint Bookrunners, nach Ende des Angebotszeit-\nraums, einschlie\u00dflich etwaiger Verk\u00fcrzungen oder Verl\u00e4ngerungen, auf Basis des\nBook-Building-Verfahrens und unter Ber\u00fccksichtigung der Wirtschafts- und Marktla-\nge sowie einer qualitativen und quantitativen Einsch\u00e4tzung der Nachfrage nach den\nAngebotsaktien und anderen Faktoren, die als daf\u00fcr angemessen befunden wurden,\nfestgelegt. Der Angebotspreis, die exakte Anzahl der auszugebenden Angebotsaktien\nund die maximale Anzahl der Zusatzaktien werden in einem Preisbekanntmachung\nmitgeteilt, die durch eine Pressemitteilung und auch auf der Internetseite der Gesell-\nschaft ver\u00f6ffentlicht und bei der Niederl\u00e4ndischen Beh\u00f6rde f\u00fcr Finanzm\u00e4rkte\n(Stichting Autoriteit Financi\u00eble Markten, die \"AFM\") hinterlegt wird.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.2321504916631039, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.43736639589568194, "height": 0.20521590423257804, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-4", "text": "Die Angebotspreisspanne ist eine indikative Preisspanne. Die Gesellschaft beh\u00e4lt sich\ndas Recht vor, nach Beratung mit den Joint Bookrunners die Angebotspreisspanne zu\n\u00e4ndern und/oder die maximale Anzahl der Angebotsaktien vor der Zuteilung der An-\ngebotsaktien (\"Zuteilung\") zu erh\u00f6hen. Jede solche \u00c4nderung wird in einer Presse-\nmitteilung angek\u00fcndigt werden (welche auch auf der Internetseite der Gesellschaft\nver\u00f6ffentlicht wird).\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.44420692603676787, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5258657545959812, "height": 0.0816588285592133, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-5", "text": "Zeichnung und Zuteilung\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.533133817870885, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.5472424112868748, "height": 0.0141085934159898, "width": 0.1844014510278114}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-6", "text": "Teilnahmeberechtigte Privatanleger in Deutschland, die Angebotsaktien zeichnen\nm\u00f6chten, sollten ihr Angebot zur Zeichnung durch ihre eigenen Finanzintermedi\u00e4r\nabgeben. Der Finanzintermedi\u00e4r ist f\u00fcr das Sammeln von Angeboten zur Zeichnung\nvon berechtigten Privatanlegern und f\u00fcr ihre Einreichung bei der ICF als Retail Coor-\ndinator (der \"Retail Coordinator\") verantwortlich. Der Retail Coordinator wird alle\nAngebote zur Zeichnung, die von teilnahmeberechtigten Privatanlegern in Deutsch-\nland \u00fcber Finanzintermedi\u00e4re abgegeben wurden, konsolidieren und an den Sole Glo-\nbal Coordinator und die Gesellschaft weiterleiten. Teilnahmeberechtigte Privatanleger\nin Deutschland sind nicht verpflichtet zum unlimitierten Marktpreis (Bestens-Auftrag)\nzu zeichnen und k\u00f6nnen daher Auftr\u00e4ge mit Preislimit abgeben.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6908935442496793, "height": 0.13723813595553647, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-7", "text": "Es wird erwartet, dass die Zuteilung nach Abschluss des Angebotszeitraums am oder\num den 10. November 2015 erfolgt, vorbehaltlich der Beschleunigung oder Verl\u00e4nge-\nrung des Angebotszeitplans. Eine Zuteilung an Anleger, die ein Angebot zur Zeich-\nnung von Angebotsaktien abgegeben haben, wird von der Gesellschaft, nach Beratung\nmit den Joint Bookrunners, entschieden und es liegt in ihrem alleinigen Ermessen, ob\nund wie die Angebotsaktien zugeteilt werden. Es gibt keine Mindest-oder H\u00f6chstan-\nzahl an Angebotsaktien, die zuk\u00fcnftige Investoren zeichnen d\u00fcrfen und mehrfache\nZeichnungen beziehungsweise Zeichnungsangebote sind zugelassen. F\u00fcr den Fall,\ndass das Angebot \u00fcberzeichnet ist, k\u00f6nnen Investoren weniger Angebotsaktien erhal-\nten, als die Anzahl, f\u00fcr die sie ein Angebot zur Zeichnung abgegeben haben.\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6973065412569475, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.8345446772124839, "height": 0.13723813595553647, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-8", "text": "Zahlung\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.840957674219752, "lower_right_x": 0.3766626360338573, "lower_right_y": 0.8550662676357418, "height": 0.0141085934159898, "width": 0.06287787182587667}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-9", "text": "Es wird erwartet, dass die Bezahlung (in Euro) f\u00fcr und die Lieferung der Angebotsak-\ntien (\"Abwicklung\") am Abwicklungstag erfolgt, der voraussichtlich am oder um den\n13. November 2015 liegt (der \"Abwicklungstag\"). Falls Steuern und Kosten anfallen,\nm\u00fcssen diese vom Anleger getragen werden. Teilnahmeberechtigte Privatanleger in\nDeutschland k\u00f6nnen von ihrem Finanzintermedi\u00e4r Kosten in Rechnung gestellt be-\n", "page_number": 43, "bounding_box": {"top_left_x": 0.3143893591293833, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8966142684401451, "lower_right_y": 0.9303120991876871, "height": 0.06883283454467726, "width": 0.5822249093107619}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-43-10", "text": "40\n", "page_number": 43, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-0", "text": "kommen. Anleger m\u00fcssen den Angebotspreis in sofort verf\u00fcgbaren Geldmitteln voll-\nst\u00e4ndig in Euro am oder vor dem Abwicklungstag bezahlen (oder fr\u00fcher im Falle\neiner fr\u00fcheren Beendigung des Angebotszeitraums und der daraus folgenden Be-\nschleunigung von Preisfestsetzung, Zuteilung, Beginns des Handels, Zahlung und\nLieferung).\n", "page_number": 44, "bounding_box": {"top_left_x": 0.31076178960096734, "top_left_y": 0.0837964942283027, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.15391192817443353, "height": 0.07011543394613083, "width": 0.5912938331318017}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-1", "text": "Lieferung der Aktien\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.16032492518170158, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.15538089480048373}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-2", "text": "Die Angebotsaktien werden durch buchm\u00e4\u00dfige Lieferung durch das System des\nNederlands Centraal Instituut voor Giraal Effectenverkeer B.V. (\"Euroclear Neder-\nland\") geliefert. Findet die Abwicklung nicht wie geplant am Abwicklungstag oder\n\u00fcberhaupt nicht statt, kann das Angebot zur\u00fcckgezogen werden. In diesem Fall wer-\nden alle Zeichnungen f\u00fcr die Angebotsaktien gegenstandlos, jede Zuteilung, die vor-\ngenommen wurde, wird als nicht vorgenommen angesehen und jede Zahlung auf die\nZeichnung wird ohne Zinsen oder andere Kompensation zur\u00fcckgezahlt. Jeder Aktien-\nhandel vor der Zahlung und Lieferung erfolgt auf alleiniges Risiko der betroffenen\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.2907225309961522, "height": 0.10987601539119282, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-3", "text": "Parteien.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.2907225309961522, "lower_right_x": 0.37726723095526, "lower_right_y": 0.30055579307396324, "height": 0.009833262077811045, "width": 0.06348246674727936}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-4", "text": "Verpflichtung der Verpflichteten Aktienbesitzer\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.3108165882855921, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.32492518170158186, "height": 0.014108593415989745, "width": 0.348851269649335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-5", "text": "Am 26. Oktober 2015 ist die Gesellschaft Verpflichtungserkl\u00e4rungen (die \"Verpflich-\ntungserkl\u00e4rung\") mit den aktuellen Aktion\u00e4ren aeris CAPITAL Equity Investments,\nL.P., LSP Curetis Pooling B.V., BioMed Invest II LP, CD-Venture GmbH, Forbion\nCapital Fund II Co\u00f6peratief U.A. und/oder Forbion CF II Co-Invest I Co\u00f6peratief\nU.A., Roche Finance Ltd. und HBM BioCapital II Invest S.a.r.l. der Curetis AG (die\n\"Verpflichteten Aktion\u00e4re\") eingegangen. Forbion Capital Fund II Co\u00f6peratief U.A.\nund Forbion CF II Co-Invest I Co\u00f6peratief U.A. haben sich verpflichtet, Angebotsak-\ntien zu einem gewissen Gesamtbetrag zu erwerben, wobei die Entscheidung, welche\nGesellschaftt welche Anzahl an Angebotsaktien erwerben wird, noch zu treffen ist.\nGem\u00e4\u00df den Verpflichtungserkl\u00e4rungen hat sich jeder der Verpflichteten Aktion\u00e4re\neinzeln und nicht gemeinsam unwiderruflich zur Zeichnung von Angebotsaktien zum\nAngebotspreis im Rahmen des Angebots und die Gesellschaft zur Ausgabe und Zutei-\nlung der Angebotsaktien zum Angebotspreis an die Verpflichteten Aktion\u00e4re ver-\npflichtet.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.523300555793074, "height": 0.19196237708422403, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-6", "text": "Die Summe aller Verpflichtungen der Verpflichteten Aktion\u00e4re bel\u00e4uft sich gem\u00e4\u00df\nden Verpflichtungserkl\u00e4rungen auf ungef\u00e4hr \u20ac15.150.777.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.529713552800342, "lower_right_x": 0.8990326481257558, "lower_right_y": 0.5575032064985036, "height": 0.027789653698161554, "width": 0.5852478839177752}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-7", "text": "Die Verpflichtungserkl\u00e4rungen enden automatisch (i) bei Beendigung des \u00dcbernah-\nmevertrags (wie nachfolgend definiert), (ii) wenn die Abwicklung nicht vor dem 31.\nDezember 2015 stattgefunden hat und (iii) wenn RBC Europe Limited in seiner Funk-\ntion als sole global coordinator (der \"Sole Global Coordinator\") einerseits oder die\nGesellschaft anderseits, den jeweils anderen vor Unterzeichnung des \u00dcbernahmever-\ntrages dar\u00fcber informiert, dass das Angebot nicht weiterverfolgt wird, abh\u00e4ngig da-\nvon, welche Bedingung fr\u00fcher eintritt.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6601111586147926, "height": 0.09619495510902099, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-8", "text": "Zus\u00e4tzlich zu den Verpflichteten Aktion\u00e4ren und unter den gleichen hier beschriebe-\nnen Bedingungen, haben sich die STRATEC Biomedical AG (\"STRATEC\") im\nRahmen dieses Angebots zur Zeichnung von Angebotsaktien zum Angebotspreis in\nH\u00f6he von ungef\u00e4hr \u20ac1 Million und die Gesellschaft zur Ausgabe und Zuteilung der\nAngebotsaktien zum Angebotspreis an die STRATEC verpflichtet. STRATEC hat\nkeine Lock-up Vereinbarung getroffen und f\u00e4llt auch nicht unter eine der in diesem\nProspekt dargestellten Lock-Up Vereinbarungen.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.7627191107310817, "height": 0.09619495510902099, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-9", "text": "\u00dcbernahmevertrag\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7691321077383497, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.7832407011543394, "height": 0.01410859341598969, "width": 0.14087061668681988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-10", "text": "Die Gesellschaft und die Konsortialbanken werden am oder um den 10. November\n2015 einen \u00dcbernahmevertrag (der \"\u00dcbernahmevertrag\") in Bezug auf das Angebot\nabschlie\u00dfen. Gem\u00e4\u00df den Bedingungen des \u00dcbernahmevertrags verpflichtet sich die\nGesellschaft, die im \u00dcbernahmevertrag festgelegte Anzahl von Angebotsaktien zum\nAngebotspreis an Zeichner, die von den Konsortialbanken vermittelt wurden auszu-\ngeben und die Konsortialbanken verpflichten sich einzeln und nicht gemeinsam,\nZeichner f\u00fcr die Angebotsaktien zu vermitteln oder, sollte dies nicht gelingen, eine\nsolche Anzahl an Angebotsaktien der Gesellschaft zum Angebotspreis selbst zu\nzeichnen.\n", "page_number": 44, "bounding_box": {"top_left_x": 0.3059250302297461, "top_left_y": 0.7875160324925182, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.9119281744335186, "height": 0.12441214194100036, "width": 0.5937122128174124}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-44-11", "text": "41\n", "page_number": 44, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.017533252720677184}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-0", "text": "Der \u00dcbernahmevertrag bestimmt, dass die Verpflichtungen der Konsortialbanken,\nZeichner f\u00fcr die Angebotsaktien zu vermitteln, oder, falls dies nicht gelingt, die An-\ngebotsaktien selbst zu zeichnen, von den folgenden Bedingungen abh\u00e4ngen: (i) der\nvollst\u00e4ndigen und wirksamen Billigung des Prospekts durch die AFM, (ii) dem Erhalt\nvon Opinions der Berater zu bestimmten juristischen Fragestellungen, (iii) dem Erhalt\nvon markt\u00fcblichen Officers' Certificates, (iv) dem Ausbleiben eines schwerwiegenden\nnegativen Ereignisses, bezogen auf die Gesch\u00e4fts- oder Verm\u00f6genslage, die Betriebs-\nergebnisse oder die Gesch\u00e4ftsaussichten von Curetis oder bezogen auf die Finanz-\nm\u00e4rkte seit dem Tag des \u00dcbernahmevertrags, (v) der Notierungsaufnahme der Aktien\nan der Euronext in Amsterdam und der Euronext in Br\u00fcssel, nicht sp\u00e4ter als 9 Uhr\nMEZ am ersten Handelstag und (vi) bestimmten anderen markt\u00fcblichen Bedingun-\ngen.\nBei Auftreten von bestimmten Ereignissen wie dem Auftreten (i) eines schwerwie-\ngenden negativen Ereignisses bezogen auf die Gesch\u00e4fts- oder Verm\u00f6genslage, die\nBetriebsergebnisse oder die Gesch\u00e4ftsaufsichten von Curetis oder bezogen auf die\nFinanzm\u00e4rkten seit dem Tag des \u00dcbernahmevertrags, (ii) einer wesentlichen Ver-\ntragsverletzung des \u00dcbernahmevertrags oder (iii) einer unrichtigen, ungenauen oder\nirref\u00fchrenden Aussage im Prospekt, in der Preisbekanntmachung oder in einem Nach-\ntrag zum Prospekt, k\u00f6nnen die Konsortialbanken den \u00dcbernahmevertrag zu jeder Zeit\nvor dem Abwicklungstag k\u00fcndigen.\nSole Global Coordinator\n", "page_number": 45, "bounding_box": {"top_left_x": 0.27267230955259975, "top_left_y": 0.08251389482684908, "lower_right_x": 0.9032648125755743, "lower_right_y": 0.3847798204360838, "height": 0.3022659256092347, "width": 0.6305925030229746}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-1", "text": "RBC Europe Limited handelt als Sole Global Coordinator.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.31499395405078595, "top_left_y": 0.39333048311244123, "lower_right_x": 0.7079806529625151, "lower_right_y": 0.4070115433946131, "height": 0.013681060282171864, "width": 0.39298669891172916}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-2", "text": "Joint Bookrunners\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4142796066695169, "lower_right_x": 0.4540507859733978, "lower_right_y": 0.4275331338178709, "height": 0.013253527148353983, "width": 0.1402660217654172}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-3", "text": "RBC und Bank Degroof Petercam nv/sa handeln als Joint Bookrunners.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.31680773881499397, "top_left_y": 0.4348011970927747, "lower_right_x": 0.7974607013301088, "lower_right_y": 0.4480547242411287, "height": 0.013253527148353983, "width": 0.48065296251511486}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-4", "text": "Joint Lead Manager\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4557503206498504, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.4685763146643865, "height": 0.012825994014536102, "width": 0.15054413542926243}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-5", "text": "ICF handelt als Joint Lead Manager f\u00fcr das Angebot.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3143893591293833, "top_left_y": 0.4762719110731082, "lower_right_x": 0.6717049576783555, "lower_right_y": 0.4890979050876443, "height": 0.012825994014536102, "width": 0.35731559854897216}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-6", "text": "Konsortialbanken\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4989311671654553, "lower_right_x": 0.4492140266021765, "lower_right_y": 0.5091919623770842, "height": 0.01026079521162887, "width": 0.1354292623941959}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-7", "text": "Die Joint Bookrunner und ICF handeln als Konsortialbanken.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.31499395405078595, "top_left_y": 0.5194527575887131, "lower_right_x": 0.7273276904474002, "lower_right_y": 0.529713552800342, "height": 0.010260795211628926, "width": 0.41233373639661425}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-8", "text": "Listing and Paying Agent\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5468148781530568, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.559640872167593, "height": 0.012825994014536102, "width": 0.1844014510278114}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-9", "text": "ABN AMRO Bank N.V ist der Listing and Paying Agent bez\u00fcglich der Aktien an der\nEuronext in Amsterdam und Euronext in Br\u00fcssel.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3059250302297461, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5976913210773835, "height": 0.03377511757161189, "width": 0.5937122128174124}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-10", "text": "Retail Coordinator f\u00fcr Deutschland\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6083796494228303, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.619067977768277, "height": 0.010688328345446751, "width": 0.26178960096735193}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-11", "text": "ICF ist der Retail Coordinator f\u00fcr Deutschland im Hinblick auf das Angebot.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.628901239846088, "lower_right_x": 0.8313180169286578, "lower_right_y": 0.6421547669944421, "height": 0.013253527148354038, "width": 0.5175332527206772}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-12", "text": "Stabilisierungsmanager\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6566908935442497, "lower_right_x": 0.4848851269649335, "lower_right_y": 0.6703719538264216, "height": 0.013681060282171864, "width": 0.1711003627569529}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-13", "text": "RBC ist der Stabilisierungsmanager im Hinblick auf die Aktien an der Euronext in\nAmsterdam und der Euronext in Br\u00fcssel.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3059250302297461, "top_left_y": 0.6737922188969645, "lower_right_x": 0.8990326481257558, "lower_right_y": 0.7079948696023942, "height": 0.034202650705429716, "width": 0.5931076178960097}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-14", "text": "Einige der Konsortialbanken und/oder die entsprechend mit ihnen verbundenen Un-\nternehmen haben in der Vergangenheit und k\u00f6nnen in Zukunft zeitweise im Firmen-\nkundengesch\u00e4ft, im Investmentbanking, in der Finanzberatung und bei weiteren Ge-\nsch\u00e4ftst\u00e4tigkeiten in ihrem normalen Gesch\u00e4ftsgang mit der Gesellschaft oder anderen\nmit der Gesellschaft verbundenen Parteien in Beziehung gestanden haben oder in\nBeziehung stehen und k\u00f6nnten zuk\u00fcnftig in diesem Zusammenhang markt\u00fcbliche\nGeb\u00fchren und Provisionen erhalten.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.8106028217186833, "height": 0.09277469003847805, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-15", "text": "E.4\n", "page_number": 45, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.718255664814023, "lower_right_x": 0.1444981862152358, "lower_right_y": 0.7302265925609235, "height": 0.01197092774690045, "width": 0.03567110036275696}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-16", "text": "Wesentliche\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.718255664814023, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.7302265925609235, "height": 0.01197092774690045, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-17", "text": "Interessen an\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1759371221281741, "top_left_y": 0.731936725096195, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.7434801197092775, "height": 0.011543394613082514, "width": 0.09915356711003628}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-18", "text": "Interessen an\ndem Angebot\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1674727932285369, "top_left_y": 0.7456177853783669, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.7601539119281744, "height": 0.014536126549807515, "width": 0.10822249093107619}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-19", "text": "(einschlie\u00dflich\n", "page_number": 45, "bounding_box": {"top_left_x": 0.17654171704957677, "top_left_y": 0.7592988456605387, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.7725523728088927, "height": 0.013253527148353927, "width": 0.10399032648125756}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-20", "text": "(einschlie\u00dflich\nInteressenkon-\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1759371221281741, "top_left_y": 0.7729799059427106, "lower_right_x": 0.28234582829504234, "lower_right_y": 0.7849508336896109, "height": 0.01197092774690034, "width": 0.10640870616686823}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-21", "text": "flikten)\n", "page_number": 45, "bounding_box": {"top_left_x": 0.1735187424425635, "top_left_y": 0.7866609662248825, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.7986318939717828, "height": 0.01197092774690034, "width": 0.058041112454655375}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-22", "text": "Dar\u00fcber hinaus k\u00f6nnen die Konsortialbanken in ihrem normalen Gesch\u00e4ftsgang zu-\nk\u00fcnftig die Wertpapiere der Gesellschaft zu Investitionszwecken nutzen. Im Hinblick\nauf das Vorgenannte ist der Informationsaustausch im Allgemeinen aus Vertraulich-\nkeitsgr\u00fcnden durch interne Vorg\u00e4nge oder durch Vorschriften und Regulierungen\neingeschr\u00e4nkt. Als Folge dieser Transaktionen k\u00f6nnten die Konsortialbanken Interes-\nsen haben, die nicht mit den Interessen der Gesellschaft \u00fcbereinstimmen oder m\u00f6g-\nlicherweise mit den Interessen der Gesellschaft oder den Interessen von K\u00e4ufern in\nWiderspruch stehen.\n", "page_number": 45, "bounding_box": {"top_left_x": 0.31076178960096734, "top_left_y": 0.8204360837964942, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.9303120991876871, "height": 0.10987601539119285, "width": 0.5912938331318017}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-45-23", "text": "42\n", "page_number": 45, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-0", "text": "Name der Per-     Die Angebotsaktien werden von der Gesellschaft zum Verkauf angeboten.\nson/des Unter-\n                  Die Joint Bookrunner (die im Namen der Konsortialbanken handeln) k\u00f6nnen auf die\nnehmens,\n                  nachfolgend beschriebenen Beschr\u00e4nkungen durch die Lock-up Vereinbarungen,\ndie/das die An-\n                  einschlie\u00dflich der Beschr\u00e4nkungen hinsichtlich Verkauf, Ausgabe oder \u00dcbertragung\ngebotsgebotsak-\n                  von Aktien, verzichten, wobei auf die Lock-up Verpflichtung der bestehenden Aktio-\ntien zum Kauf\n                  n\u00e4re w\u00e4hrend der ersten 180 Tage und auf die Lock-up Verpflichtung des Vorstands\nanbieten und\n                  und der Mitarbeiter niemals verzichtet werden kann. Falls die Joint Bookrunner (die\nLock-up-\n                  im Namen der Konsortialbanken handeln) wie unten beschrieben um Zustimmung\nVereinbarungen\n                  zum Verzicht auf eine der Lock-up Vereinbarung gebeten werden, sollen sie diese\n                  Zustimmung nicht aus unbilligen Gr\u00fcnden verweigern, d\u00fcrfen ihre Zustimmung aller-\n                  dings von Bedingungen abh\u00e4ngig machen.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.09234715690466011, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.2501068832834545, "height": 0.15775972637879437, "width": 0.7309552599758162}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-1", "text": "E.5\n", "page_number": 46, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.09234715690466011, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.10431808465156049, "height": 0.011970927746900381, "width": 0.03627569528415962}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-2", "text": "Lock-up der Gesellschaft\n", "page_number": 46, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.25609234715690465, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.2702009405728944, "height": 0.014108593415989745, "width": 0.1844014510278114}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-3", "text": "Gem\u00e4\u00df dem \u00dcbernahmevertrag wird sich die Gesellschaft voraussichtlich gegen\u00fcber\nden Konsortialbanken verpflichten, f\u00fcr einen Zeitraum ab dem Datum des \u00dcbernah-\nmevertrags bis zu 365 Tagen nach dem Abwicklungstag (der Lock-up Zeitraum der\nGesellschaft), vorbehaltlich des unten Dargelegten, ohne die vorherige Zustimmung\nder Joint Bookrunners (der im Namen der Konsortialbanken handelt) weder (i) Aktien\nder Gesellschaft oder Wertpapiere, die in Aktien der Gesellschaft umwandelbar, f\u00fcr\ndiese aus\u00fcbbar oder gegen Aktien der Gesellschaft umtauschbar sind, direkt oder\nindirekt auszugeben, anzubieten, zu verpf\u00e4nden, zu verkaufen, sich vertraglich zu\nderen Verkauf zu verpflichten, Kaufoptionen oder Kaufverpflichtungen f\u00fcr sie zu\nver\u00e4u\u00dfern, Verkaufsoptionen f\u00fcr sie zu erwerben, Kaufoptionen, Kaufrechte oder\nBezugsrechte f\u00fcr sie einzur\u00e4umen oder diese in sonstiger Form zu \u00fcbertragen oder zu\nver\u00e4u\u00dfern oder eine Registrierungserkl\u00e4rung gem\u00e4\u00df US Securities Act oder ein \u00e4hnli-\nches Dokument bei einer anderen Wertpapieraufsichtsbeh\u00f6rde, Wertpapierb\u00f6rse oder\nZulassungsbeh\u00f6rde, bezogen auf das Vorangegangene einzureichen; (ii) einen Swap\noder eine andere Vereinbarung oder Transaktion einzugehen, mit dem bzw. der das\nwirtschaftliche Risiko des Eigentums an den Aktien der Gesellschaft vollst\u00e4ndig oder\nteilweise, direkt oder indirekt auf andere \u00fcbertragen wird \u2013 unabh\u00e4ngig davon, ob\nsolche Transaktionen durch Lieferung der Aktien der Gesellschaft oder dieser Wert-\npapiere erf\u00fcllt oder in bar bzw. in sonstiger Form abgerechnet werden; (iii) eine sol-\nche Absicht \u00f6ffentlich anzuk\u00fcndigen, um eine Transaktion wie oben unter (i) oder (ii)\nbeschrieben, zu bewirken, noch (iv) ihren Aktion\u00e4ren oder anderen Organen der Ge-\nsellschaft einen Vorschlag zur Ausf\u00fchrung des Vorgenannten zu unterbreiten.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.5780247969217615, "height": 0.301410859341599, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-4", "text": "Das Vorgenannte soll nicht anwendbar sein auf: (a) die Ausgabe und das Angebot der\nAngebotsaktien durch oder im Namen der Gesellschaft, (b) die Ausgabe von Aktien\nnach Aus\u00fcbung der Mehrzuteilungsoption und (c) die Gew\u00e4hrung von Pr\u00e4mien als\nOptionen oder Aktien durch die Gesellschaft oder die Ausgabe von Aktien nach Aus-\n\u00fcbung von Optionen, die durch Gesellschaft im Rahmen von Mitarbeiterbeteiligungs-\nprogrammen gew\u00e4hrt wurden, sofern eine solche Gew\u00e4hrung oder Ausgabe im Pros-\npekt genannt wurde.\n", "page_number": 46, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.5844377939290295, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.6806327490380505, "height": 0.09619495510902099, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-5", "text": "Lock-up von bestehenden Aktion\u00e4ren\n", "page_number": 46, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.6870457460453185, "lower_right_x": 0.5894800483675937, "lower_right_y": 0.7011543394613082, "height": 0.01410859341598969, "width": 0.2756952841596131}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-6", "text": "Am 26. Oktober 2015 haben alle bestehenden Aktion\u00e4re (mit Ausnahme der Vor-\nstandsmitglieder und aller ehemaligen und derzeitigen Mitarbeitern von Curetis, die\nAktien halten, welche eine separate Lock-up Vereinbarung abgeschlossen haben) eine\nLock-up Vereinbarung mit dem Sole Global Coordinator (handelnd f\u00fcr die Konsorti-\nalbanken) abgeschlossen. Gem\u00e4\u00df dieser Lock-up Vereinbarungen verpflichten sich\nalle bestehenden Aktion\u00e4re, vorbehaltlich des unten Dargelegten, f\u00fcr einen Zeitraum\nvon 180 Tagen nach Abwicklungstag und f\u00fcr weitere 185 Tage nur nach vorheriger\nZustimmung der Joint Bookrunners (handelnd f\u00fcr die Konsortialbanken) (i) weder\ndirekt noch indirekt Aktien der Gesellschaft oder Wertpapiere, die in Aktien der Ge-\nsellschaft umwandelbar, f\u00fcr diese aus\u00fcbbar oder gegen Aktien der Gesellschaft um-\ntauschbar sind, anzubieten, zu verpf\u00e4nden, zu verkaufen, sich vertraglich zu deren\nVerkauf zu verpflichten, Kaufoptionen oder Kaufverpflichtungen f\u00fcr sie zu ver\u00e4u-\n\u00dfern, Verkaufsoptionen f\u00fcr sie zu erwerben, Kaufoptionen, Kaufrechte oder Bezugs-\nrechte f\u00fcr sie einzur\u00e4umen oder diese in sonstiger Form zu \u00fcbertragen oder zu ver\u00e4u-\n\u00dfern; (ii) keine Swap-Vereinbarung oder eine andere Vereinbarung oder Transaktion\neinzugehen, mit dem bzw. der das wirtschaftliche Risiko des Eigentums an den Ak-\n", "page_number": 46, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7079948696023942, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.926891834117144, "height": 0.21889696451474983, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-46-7", "text": "43\n", "page_number": 46, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-47-0", "text": "tien der Gesellschaft vollst\u00e4ndig oder teilweise, direkt oder indirekt auf andere \u00fcber-\ntragen wird \u2013 unabh\u00e4ngig davon, ob solche Transaktionen durch Lieferung der Aktien\nder Gesellschaft oder dieser Wertpapiere erf\u00fcllt oder in bar bzw. in sonstiger Form\nabgerechnet werden; (iii) weder einen Antrag zu stellen noch zu verlangen, dass die\nGesellschaft eine Registrierungserkl\u00e4rung gem\u00e4\u00df US Securities Act oder ein \u00e4hnli-\nches Dokument bei einer anderen Wertpapieraufsichtsbeh\u00f6rde, Wertpapierb\u00f6rse oder\nZulassungsbeh\u00f6rde, bezogen auf das Vorangegangene einreicht, oder (iv) noch eine\nsolche Absicht \u00f6ffentlich anzuk\u00fcndigen.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.3041112454655381, "top_left_y": 0.0837964942283027, "lower_right_x": 0.9020556227327691, "lower_right_y": 0.19452757588713127, "height": 0.11073108165882857, "width": 0.597944377267231}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-47-1", "text": "Die vorstehenden Einschr\u00e4nkungen sollen nicht anwendbar sein auf (a) Angebotsak-\ntien, die w\u00e4hrend des Angebots gezeichnet wurden oder Aktien, die nach dem Ersten\nHandelstag bei der Euronext in Amsterdam, der Euronext in Br\u00fcssel oder auf einem\nanderen Wertpapierb\u00f6rse erworben wurden, (b) Aktien, die dem Sole Global Coordi-\nnator (der im Namen der Konsortialbanken handelt) im Rahmen des Aktienleihvertra-\nges geliehen wurden, wobei davon ausgegangen wird, dass die Aktien, die den Ge-\nbern gem\u00e4\u00df Aktienleihvertrag \u00fcbergeben werden, unter die Lock-up Verpflichtungen\nder Lock-up Vereinbarung fallen, (c) der Annahme eines allgemeinen Angebots f\u00fcr\ndie Aktien der Gesellschaft, das unter den Voraussetzungen des Dutch Financial Su-\npervision Act abgegeben wurde oder der Abgabe einer unwiderruflichen Verpflich-\ntungserkl\u00e4rung ein solches Angebot anzunehmen, (d) jeder Verf\u00fcgung aus einem\nZusammenschluss oder einer Abspaltung der Gesellschaft, oder (e) jeder Verf\u00fcgung\nan pers\u00f6nliche Vertreter eines Individuums, das w\u00e4hrend der Lock-up Frist verstirbt,\nvorausgesetzt, ein solcher pers\u00f6nlicher Vertreter hat eine Lock-up Vereinbarung, die\ndieser Lock-up Vereinbarung \u00e4hnelt, abgeschlossen oder die Verpflichtungen dieser\nLock-up Vereinbarung anerkennt und die Rechte und Pflichten wahrnimmt.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.4202650705429671, "height": 0.21889696451474988, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-47-2", "text": "Lock-up des Vorstands und der Mitarbeiter\n", "page_number": 47, "bounding_box": {"top_left_x": 0.3143893591293833, "top_left_y": 0.427105600684053, "lower_right_x": 0.6330108827085853, "lower_right_y": 0.44121419410004276, "height": 0.014108593415989745, "width": 0.318621523579202}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-47-3", "text": "Am 26. Oktober 2015 haben die Mitglieder des Vorstands und alle ehemaligen und\nderzeitigen Mitarbeitern von Curetis, die Aktien halten, eine Lock-Up Vereinbarung\nmit dem Sole Global Coordinator (handelnd f\u00fcr die Konsortialbanken) abgeschlossen.\nGem\u00e4\u00df diesen Lock-up Vereinbarungen verpflichtet sich jedes Vorstandsmitglied und\nalle ehemaligen und derzeitigen Mitarbeitern von Curetis, die Aktien halten, f\u00fcr einen\nZeitraum von 365 Tagen nach Abwicklungstag vorbehaltlich des unten Dargelegten,\n(i) weder direkt noch indirekt Aktien der Gesellschaft oder Wertpapiere, die in Aktien\nder Gesellschaft umwandelbar, f\u00fcr diese aus\u00fcbbar oder gegen Aktien der Gesellschaft\numtauschbar sind, anzubieten, zu verpf\u00e4nden, zu verkaufen, sich vertraglich zu deren\nVerkauf zu verpflichten, Kaufoptionen oder Kaufverpflichtungen f\u00fcr sie zu ver\u00e4u-\n\u00dfern, Verkaufsoptionen f\u00fcr sie zu erwerben, Kaufoptionen, Kaufrechte oder Bezugs-\nrechte f\u00fcr sie einzur\u00e4umen oder diese in sonstiger Form zu \u00fcbertragen oder zu ver\u00e4u-\n\u00dfern; (ii) keine Swap-Vereinbarung oder eine andere Vereinbarung oder Transaktion\neinzugehen, mit dem bzw. der das wirtschaftliche Risiko des Eigentums an den Ak-\ntien der Gesellschaft vollst\u00e4ndig oder teilweise, direkt oder indirekt auf andere \u00fcber-\ntragen wird \u2013 unabh\u00e4ngig davon, ob solche Transaktionen durch Lieferung der Aktien\nder Gesellschaft oder dieser Wertpapiere erf\u00fcllt oder in bar bzw. in sonstiger Form\nabgerechnet werden; (iii) keinem Vorschlag in der Hauptversammlung oder in einem\nanderen Gremium der Gesellschaft das Voranstehende umzusetzen oder (direkt oder\nindirekt) eine Erh\u00f6hung des Aktienkapitals der Gesellschaft umzusetzen oder jedem\nanderen Antrag oder jeder anderen Aufforderung, dass die Gesellschaft eine Regist-\nrierungserkl\u00e4rung gem\u00e4\u00df US Securities Act oder ein \u00e4hnliches Dokument bei einer\nanderen Wertpapieraufsichtsbeh\u00f6rde, Wertpapierb\u00f6rse oder Zulassungsbeh\u00f6rde bezo-\ngen auf das Vorangegangene einzureichen, zuzustimmen oder (iv) noch solche Ab-\nsicht \u00f6ffentlich anzuk\u00fcndigen.\n", "page_number": 47, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.7900812312954254, "height": 0.3424540401881146, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-47-4", "text": "Die vorstehenden Einschr\u00e4nkungen sollen nicht anwendbar sein auf (a) der Annahme\neines allgemeinen Angebots f\u00fcr die Aktien der Gesellschaft, das unter den Vorausset-\nzungen des Dutch Financial Supervision Act abgegeben wurde oder der Abgabe einer\nunwiderruflichen Verpflichtungserkl\u00e4rung ein solches Angebot anzunehmen, (b) jeder\nVerf\u00fcgung aus einer rechtlichen Zusammenschluss oder einer Abspaltung der Gesell-\nschaft, (c) jeder Verf\u00fcgung an pers\u00f6nliche Vertreter eines Individuums, das w\u00e4hrend\nder Lock-up Frist verstirbt, vorausgesetzt, ein solcher pers\u00f6nlicher Vertreter hat eine\nLock-up Vereinbarung, die dieser Lock-up Vereinbarung \u00e4hnelt, abgeschlossen oder\ndie Verpflichtungen dieser Lock-up Vereinbarung anerkennt und die Rechte und\n", "page_number": 47, "bounding_box": {"top_left_x": 0.3137847642079806, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8996372430471584, "lower_right_y": 0.9196237708422402, "height": 0.12312954253954678, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-47-5", "text": "44\n", "page_number": 47, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-48-0", "text": "                        Pflichten wahrnimmt.\n\nE.6   Verw\u00e4sserung      Der Stimmrechtsanteil der bestehenden Aktion\u00e4re wird infolge der Ausgabe der An-\n                        gebotsaktien verw\u00e4ssert. Die maximale Verw\u00e4sserung f\u00fcr bestehende Aktion\u00e4re, die\n                        nicht am Angebot teilnehmen w\u00e4re 43,14%, unter der Annahme, dass die maximale\n                        Anzahl von Angebotsaktien ausgegeben und die Mehrzuteilungsoption voll ausge\u00fcbt\n                        wird.\n\nE.7   Sch\u00e4tzung der     Entf\u00e4llt. Anlegern wurden oder werden von der Gesellschaft keine Kosten bez\u00fcglich\n      Ausgaben, die     des Angebots in Rechnung gestellt.\n      dem Anleger\n      von der Gesell-\n      schaft in Rech-\n      nung gestellt\n      werden.\n", "page_number": 48, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.08165882855921335, "lower_right_x": 0.909310761789601, "lower_right_y": 0.2902949978623343, "height": 0.20863616930312096, "width": 0.7986698911729142}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-48-1", "text": "45\n", "page_number": 48, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-0", "text": "RISK FACTORS\n", "page_number": 49, "bounding_box": {"top_left_x": 0.4105199516324063, "top_left_y": 0.09876015391192818, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.11543394613082514, "height": 0.016673792218896963, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-1", "text": "An investment in the Offer Shares involves substantial risks. Accordingly, before deciding whether to invest in\nthe Offer Shares, prospective investors should carefully consider the risks and uncertainties described below\ntogether with all the other information contained or incorporated in this Prospectus. The occurrence of any of\nthe events or circumstances described in these risk factors, individually or together with other circumstances,\ncould have a material adverse effect on the Company's business, results of operations, financial position and\nprospects. In that event, the value of the Offer Shares could decline and investors may lose all, or part of their\ninvestment.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22573749465583584, "height": 0.09277469003847799, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-2", "text": "All of these risk factors and events described below are contingencies that may or may not occur. Curetis may\nface a number of these risks described below simultaneously and one or more risks described below may be\ninterdependent. The order in which risks are presented is not necessarily an indication of the likelihood of the\nrisks actually materialising, of the potential significance of the risks or of the scope of any potential harm to\nCuretis' business, results of operations, financial position and prospects.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.30354852501068835, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-3", "text": "The risk factors are based on assumptions that could turn out to be incorrect. Furthermore, although the\nCompany believes that the risks and uncertainties described below are the material risks and uncertainties\nrelating to Curetis and the Offer Shares, other risks, facts or circumstances not presently known to Curetis, or\nthat it currently deems to be immaterial could, individually or cumulatively, prove to be important and could\nhave a material adverse effect on Curetis' business, results of operations, financial position and prospects. The\nvalue of the Shares could decline as a result of the occurrence of any such risks, facts or circumstances or as a\nresult of the events or circumstances described in these risk factors, and prospective investors could lose part or\nall of their investment.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4198375374091492, "height": 0.10902094912355709, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-4", "text": "Prospective investors should read and carefully review the entire Prospectus and should reach their own views\nbefore making an investment decision with respect to any Offer Shares. Furthermore, before making an invest-\nment decision with respect to any Offer Shares, prospective investors should consult their own stockbrokers,\nbank managers, lawyers, auditors or other financial, legal and tax advisers and carefully review the risks asso-\nciated with an investment in the Offer Shares and consider such an investment decision in light of their personal\ncircumstances.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5061992304403591, "height": 0.07909362975630607, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-5", "text": "Risks Related to Business and Strategy\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5228730226592561, "lower_right_x": 0.4540507859733978, "lower_right_y": 0.539546814878153, "height": 0.016673792218896977, "width": 0.3385731559854897}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-6", "text": "Curetis is a company with only a limited amount of products and has incurred significant losses since incep-\ntion and expects to incur losses in the foreseeable future. It is not certain that Curetis will achieve or sustain\nprofitability.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5925609234715691, "height": 0.03890551517742624, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis is a company with only a limited amount of products and has incurred significant losses since incep-tion and expects to incur losses in the foreseeable future. It is not certain that Curetis will achieve or sustainprofitability."]}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-7", "text": "Curetis has incurred significant losses in each period since its inception in 2007 and expects to incur losses in the\nforeseeable future. The cumulative net losses of Curetis as of 30 June 2015 amounted to \u20ac131 million and Cu-\nretis incurred net losses of \u20ac12.4 million for the year ended 31 December 2014 and \u20ac12.4 million for the six\nmonths ended 30 June 2015. Currently, Curetis estimates its current annual cash burn rate to amount to approxi-\nmately \u20ac8 million to \u20ac10 million. Curetis expects that its cash burn rate will, at a minimum, remain at its current\nlevel for the next several years as Curetis plans to to invest significant additional funds towards building up its\ncommercial organisation in the United States of America (\"US\") and the development and commercialisation of\nits technology, which also includes obtaining certification or regulatory clearance of its products for markets\nwhere this is required. Curetis also expects that its distribution costs and administrative expenses will continue to\nincrease due to the establishment of, or further investments in, a dedicated sales force, a distribution network and\nother marketing efforts for its products. Costs associated with the Offering and, if successful, being a public\ncompany will also be incurred.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7661393758016246, "height": 0.1646002565198803, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-8", "text": "Curetis' ability to achieve profitability depends on numerous factors, many of which are beyond the control of\nCuretis. Examples include Curetis' ability to achieve clearance from the US Food and Drug Administration\n(\"FDA\") for Curetis' products, market acceptance of Curetis' products, future product development and Curetis'\nmarket penetration and margins. Curetis may not be able to generate sufficient revenues to achieve or sustain\nprofitability.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8413852073535699, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-9", "text": "Curetis is currently in the process of obtaining FDA clearance for its Unyvero System and the LRT55 Appli-\ncation Cartridge. It is uncertain whether and when such regulatory clearance will be obtained.\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.8790081231295426, "height": 0.024369388627618727, "width": 0.7605804111245466}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis is currently in the process of obtaining FDA clearance for its Unyvero System and the LRT55 Appli-cation Cartridge. It is uncertain whether and when such regulatory clearance will be obtained."]}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-10", "text": "when", "page_number": 49, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.870884993587003, "lower_right_x": 0.7750906892382105, "lower_right_y": 0.8824283882000855, "height": 0.011543394613082514, "width": 0.6590084643288997}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-11", "text": "Curetis intends to use a substantial part of the net proceeds of the Offering to build its commercial organisation\nin the US and launch its products in the US. Curetis' success in the US will in part depend on its ability to obtain\nregulatory clearance from the FDA for its Unyvero automated sample-to-answer molecular diagnostics (\"MDx\")\n", "page_number": 49, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8888413852073536, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9303120991876871, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-49-12", "text": "46\n", "page_number": 49, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-0", "text": "system and its LRT55 Application Cartridge addressing pneumonia (labelled P55 in the EU). In addition, Cu-\nretis' ability to obtain regulatory clearance for other Application Cartridges (as defined below) in Curetis' pipe-\nline, in the future will also be decisive.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12312954253954682, "height": 0.03805044890979051, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-1", "text": "The process of obtaining regulatory clearance is expensive and time-consuming and can vary substantially based\nupon, among other things, the type, complexity and novelty of Curetis' products as well as upon access to a suf-\nficient number of relevant clinical samples (see \"\u2013 Curetis' business could be significantly and negatively affect-\ned by current or new governmental regulations and clearance, approval and post-approval requirements, par-\nticularly in the EU and the US\"). Curetis held a preparatory (so-called \"pre-IDE\") meeting with the FDA in May\n2012 and received written comments from the FDA on its trial design for its Unyvero System and the LRT50\nApplication Cartridge. Although Curetis had originally begun the process of obtaining FDA clearance for the\nUnyvero System and the LRT50 Application Cartridge (labelled P50 in the EU) in 2013, it had to put on hold its\nUS clinical trials and the process of obtaining FDA clearance, which included the halt of the prospective sample\nenrolment and measurement of samples with the LRT50 Application Cartridge during most of 2014 due to a\nseries of quality issues and product improvements in connection with the Unyvero System and the LRT50 Ap-\nplication Cartridge (see \"\u2013 The manufacture of many of Curetis' products is a highly precise and complex pro-\ncess, and if Curetis encounters problems with the manufacturing and the quality of its products, its reputation\nand business could suffer.\"). In July 2015, Curetis renewed its process of obtaining FDA clearance with submis-\nsion of a revised trial protocol to the FDA featuring its new LRT55 Application Cartridge.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12526720820863618, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.337751175716118, "height": 0.21248396750748183, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-2", "text": "Despite prior pre-IDE meeting and Curetis' submission of several supplements to the FDA, the FDA has substan-\ntial discretion in the review and clearance processes and may refuse to accept any application or may decide that\nCuretis' trial design is nevertheless insufficient for clearance and require additional pre-clinical, clinical or other\nstudies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay,\nlimit or prevent regulatory clearance from the FDA.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.41342454040188115, "height": 0.06840530141085932, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-3", "text": "In addition, if during the clinical trials only an insufficient number of pathogens, clinical cases and samples can\nbe found for the pathogens and resistance markers on the LRT55 Application Cartridge, the FDA might not clear\nall 40 analytes that it currently requires in a first pass and as a result costly and time-consuming additional filings\nwould be required. Clinical studies could also show that Curetis' Unyvero System or Application Cartridges may\nnot be sufficiently sensitive or specific to obtain, or may prove to have other characteristics that preclude Curetis\nfrom obtaining, clearance from the FDA.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5023514322359983, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-4", "text": "If the attempts to obtain regulatory clearance from the FDA for the Unyvero System and the LRT55 Application\nCartridges are unsuccessful, Curetis may be unable to build its commercial organisation in the US and generate\nsufficient revenues to sustain and grow its business. Even if regulatory clearance is obtained, it may only have a\nrestrictive scope or contain limitations, which make it commercially unattractive to Curetis.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5639162035057717, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-5", "text": "Curetis may be unable to successfully commercialise its products and may fail to achieve and sustain suff\ncient market acceptance.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1293833131801693, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.6023941855493801, "height": 0.024796921761436552, "width": 0.7357920193470375}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis may be unable to successfully commercialise its products and may fail to achieve and sustain suffi-cient market acceptance."]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-6", "text": "Curetis began to commercialise the P55 pneumonia (\"P55\") and i60 implant and tissue infection (\"ITI\") Appli-\ncation Cartridges for its Unyvero System in the EU in 2012 and 2014, respectively. Thus, it has only limited\nexperience in marketing and selling its products. Curetis intends to continue to expand its commercial presence\nand increase its market share in the European Union (the \"EU\") and enter into the US and other markets. In line\nwith its strategic objectives, the Group recently signed distribution agreements for certain ASEAN markets (In-\ndonesia, Malaysia, Singapore and Thailand) and for China, Taiwan and Hong Kong (together \"Greater China\").\nCuretis therefore has only limited experience in marketing and selling its products in other jurisdictions. Curetis'\nfuture sales of diagnostic products will depend in large part on Curetis' ability to successfully commercialise its\nproducts and sustain sufficient market acceptance. In particular, its future sales will depend on Curetis' ability to\nestablish a product sales force in the US. However, it cannot start marketing until it receives FDA regulatory\nclearance. Curetis' ability to forecast demand in the US and to build the infrastructure required to support such\ndemand and the sales cycle of Curetis' potential customers is largely unproven. If Curetis does not build an effi-\ncient and effective sales force and distribution network in the US or cannot successfully expand its distribution\nnetwork in Europe or elsewhere, Curetis' business and results of operations may be adversely affected.\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8037622915775973, "height": 0.19196237708422403, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-7", "text": "Curetis may not be able to sufficiently demonstrate to physicians, hospitals and other healthcare providers that its\nP55/LRT55 and i60 ITI Application Cartridges are appropriate and preferable options for aiding in the diagnosis\nof pneumonia and implant and tissue infections. In particular, the price of Curetis' Application Cartridges is\nmuch higher than, and will be incurred in addition to, the costs for conventional microbiology culture tests.\nThere can be no assurance that hospitals will be willing to incur the direct costs to purchase Curetis' products or\nthat the government or commercial payers will be willing or able to reimburse hospitals for them. If tightened\nbudgets prevent hospitals from being able to pay for Curetis' products or if government or commercial payers\n", "page_number": 50, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9063702436938863, "height": 0.09619495510902099, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-50-8", "text": "47\n", "page_number": 50, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-0", "text": "refuse to reimburse such hospitals for these payments, this could have a material adverse effect on Curetis' busi-\nness, financial position, cash flows and results of operations.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.879081015719468, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-1", "text": "Furthermore, Curetis may encounter significant difficulty in gaining inclusion in pneumonia and implant and\ntissue infection treatment guidelines of hospitals, which is a prerequisite for hospitals purchasing Curetis' prod-\nucts in any significant quantity, or in gaining broad market acceptance by healthcare providers, third-party pay-\ners and patients using the Unyvero System and Application Cartridges.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17400598546387344, "height": 0.05472424112868747, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-2", "text": "If Curetis fails to successfully commercialise its products, it may not be able to receive a return on the significant\ninvestments it has made and will continue to make in product development, sales and marketing, regulatory,\nmanufacturing and quality assurance, and it may fail to generate sufficient revenues and gain economies of scale\nfrom such investments.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23257802479692177, "height": 0.0517315091919624, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-3", "text": "Curetis is particularly dependent on the success of, and the ability to market, its lead products, the P55 and\nthe i60 ITI Application Cartridges in the EU and the LRT55 Application Cartridge in the US, on which it has\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.2868747327917914, "height": 0.037622915775972654, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis is particularly dependent on the success of, and the ability to market, its lead products, the P55 andthe i60 ITI Application Cartridges in the EU and the LRT55 Application Cartridge in the US, on which it hasfocused almost all of its business and financial resources in the past."]}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-4", "text": "Curetis is currently not a broadly diversified company. Therefore, Curetis' ability to generate revenues depends\nparticularly on the success of its two lead products, the P55 and i60 ITI Application Cartridges in the EU and the\nLRT55 Application Cartridge in the US which is technically identical to the P55 Application Cartridge. Curetis\nhas spent significant time, money and efforts on P55's/LRT55's and i60 ITI's development and commercialisa-\ntion, including costs of clinical studies in the EU and the US. Curetis expects to continue to focus a significant\nportion of its personnel and financial resources on the commercialisation of the LRT55 Application Cartridge\nand its roll-out in the US provided it obtains FDA clearance. If P55 and i60 ITI Application Cartridges do not\nachieve long-term commercial success in European markets, or if the LRT55 and, at a later stage, potentially\nadditional Application Cartridges do not receive regulatory clearance in the US or if such regulatory clearance is\ndelayed or withdrawn after being granted, Curetis' business, financial position, cash flows and results of opera-\ntions will be adversely affected, and Curetis may find it difficult or impossible to obtain new funding.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4480547242411287, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-5", "text": "Curetis may be unable to successfully manage its growth.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.4754168448054724, "height": 0.014108593415989745, "width": 0.40205562273276907}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis may be unable to successfully manage its growth."]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-6", "text": "During the past few years, Curetis has significantly expanded its operations with regard to sales and the manu-\nfacturing of a greater variety of product offerings, especially in the DACH region (Germany, Austria and Swit-\nzerland) as well as in Eastern and Western Europe and the Middle East. It also recently expanded into the Asian\nmarket by entering into distribution agreements for certain ASEAN markets and Greater China. Curetis expects\nthis expansion to continue to an even greater degree as it seeks regulatory clearance from the FDA and, follow-\ning such clearance, the commercial launch of the Unyvero System and the LRT55 Application Cartridge and, at\na later stage, potentially additional Application Cartridges in the US.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5780247969217615, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-7", "text": "Curetis' growth has placed and will continue to place a significant strain on Curetis' management, operating and\nfinancial systems and Curetis' sales, marketing and administrative resources. As a result of Curetis' growth, oper-\nating costs may escalate even faster than planned, and some of Curetis' internal systems and processes, including\nthose related to manufacturing Curetis' products, may need to be enhanced, updated or replaced. If Curetis can-\nnot effectively manage its expanding operations, manufacturing capacity and costs, including scaling to meet\nincreased demand, Curetis may not be able to continue to grow or may grow at a slower pace than expected.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5848653270628473, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6669516887558786, "height": 0.0820863616930313, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-8", "text": "Curetis depends on a few key suppliers for critical product components. In case of a loss of any of these sup-\npliers or an interruption of supply, Curetis may not be able to manufacture or outsource manufacturing of its\nproducts in sufficient quantities, in a timely manner or at a cost that is economically attractive.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.7229585292860197, "height": 0.03933304831124418, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis depends on a few key suppliers for critical product components. In case of a loss of any of these sup-pliers or an interruption of supply, Curetis may not be able to manufacture or outsource manufacturing of itsproducts in sufficient quantities, in a timely manner or at a cost that is economically attractive."]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-9", "text": "The Unyvero platform comprises three components: the system (L4 Lysator, C8 Cockpit and A50 Analyzer,\ntogether the \"Unyvero System\"), proprietary software and the application-specific cartridges (the \"Application\nCartridges\", together with the Unyvero System, the \"Unyvero Platform\").\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7315091919623771, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7712697734074391, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-10", "text": "Curetis currently depends on a number of key suppliers for critical product components, such as Zollner El-\nektronik AG for the manufacture of its Unyvero Systems, Contexo GmbH for the Application Cartridge manu-\nfacturing equipment, Scholz HTIK GmbH for the Application Cartridge and consumables plastic parts as well as\ncertain single source suppliers for specific Unyvero amplification primers, detection probes and the mastermix\nwhich is the enzyme required to start any polymerase chain reaction (\"PCR\") and thus is one of the critical com-\nponents of any PCR based MDx test.\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8597691321077383, "height": 0.08037622915775966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-11", "text": "If any one of these suppliers were to terminate the business relationship with Curetis, go out of business, discon-\ntinue manufacturing the products Curetis uses or otherwise become unable to meet its supply commitments, the\nprocess of securing alternate sources could be lengthy, leading to the delay in Curetis' ability to develop and\nmarket its existing or future products and increase its development and marketing costs. There can be no assur-\n", "page_number": 51, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8683197947840958, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9221889696451475, "height": 0.053869174861051694, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-51-12", "text": "48\n", "page_number": 51, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-0", "text": "ance that replacement products/components would become available or would meet Curetis' quality and perfor-\nmance requirements within an acceptable time or at all.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-1", "text": "During the first half of 2013, for example, Curetis encountered unexpected issues with its Original Equipment\nManufacturer (\"OEM\") supplier of the Unyvero System, Zollner Elektronik AG, which had significant problems\nsupplying Curetis with the ordered quantities at the required quality (see \"\u2013 The manufacture of many of Curetis'\nproducts is a highly precise and complex process, and if Curetis encounters problems with the manufacturing\nand the quality of its products, its reputation and business could suffer.\"). While Curetis may technically be able\nto modify its product candidates to utilise a new source of such critical parts or components, Curetis would need\nto secure CE-IVD-marking and regulatory clearance from the FDA and any other relevant regulatory body in\nother markets for the modified product, and it could take considerable time and necessitate significant expenses\nto perform the requisite tasks prior to and in connection with petition for renewed market clearance.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.2424112868747328, "height": 0.12312954253954682, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-2", "text": "The market potential and opportunities for Curetis' lead products may be smaller than currently anticipated,\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.2787516032492518, "height": 0.022659256092347146, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The market potential and opportunities for Curetis' lead products may be smaller than currently anticipated,lowering potential revenue for Curetis."]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-3", "text": "Curetis makes projections on the number of people who have severe disease incidences such as pneumonia,\nimplant and tissue infections and other indications that Curetis is targeting. These projections are derived from a\nvariety of sources, including scientific literature, surveys of clinics, patient foundations, governmental statistics\nand market research but are highly contingent on a number of variables that are difficult to predict and may\nprove to be too high, resulting in a smaller population of patients who could benefit from Curetis lead products,\nthe P55/LRT55 and the i60 ITI Application Cartridges, than Curetis currently anticipates which would result in\nlower potential revenue for Curetis\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.38520735356990166, "height": 0.09491235570756734, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-4", "text": "Curetis may expand its limited financial and managerial resources to pursue a particular future product or\nindication and fail to capitalise on products or indications that may be more profitable or for which there is a\ngreater likelihood of success.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4407866609662249, "height": 0.04104318084651559, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis may expand its limited financial and managerial resources to pursue a particular future product orindication and fail to capitalise on products or indications that may be more profitable or for which there is agreater likelihood of success."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-5", "text": "To grow its business in the future with its limited financial and managerial resources, Curetis will have to care-\nfully choose which products in the future it believes will achieve the most commercial success. Accordingly, it\nwill need to carefully focus its limited financial and managerial resources on the selection of such products.\nPipeline products in development include Application Cartridges targeting positive blood culture testing and\nintra-abdominal/gastrointestinal tract infections, both of which Curetis intends to launch commercially in 2016\nas well as a sepsis host response Application Cartridge which Curetis does not intend to launch before late 2017.\nIf Curetis uses its limited financial and managerial resources to promote a particular product or indication such\nas the aforementioned or other future products or indications, which are not ultimately sufficiently commercially\nsuccessful, it could have a material adverse effect on the business, financial position and results of operations of\nCuretis.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5814450619923044, "height": 0.13381787088499358, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-6", "text": "Curetis relies on certain distribution partners to distribute its products in some of its markets and intends t\nenter into additional distribution agreements to distribute its products in other markets. If Curetis is unable t\nfind suitable distribution partners, loses these distribution partners or if Curetis' distribution partners fail to\nsell its products in sufficient quantities, on commercially viable terms or in a timely manner, Curetis' com\nmercialisation of P55/LRT55 and i60 ITI Application Cartridges and other future products could be material\nly delayed or harmed.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8700120918984281, "lower_right_y": 0.6806327490380505, "height": 0.08251389482684912, "width": 0.7533252720677147}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis relies on certain distribution partners to distribute its products in some of its markets and intends toenter into additional distribution agreements to distribute its products in other markets. If Curetis is unable tofind suitable distribution partners, loses these distribution partners or if Curetis' distribution partners fail tosell its products in sufficient quantities, on commercially viable terms or in a timely manner, Curetis' com-mercialisation of P55/LRT55 and i60 ITI Application Cartridges and other future products could be material-ly delayed or harmed."]}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-7", "text": "Curetis' products are currently being and are planned to be distributed by distribution partners in some of its\ncurrent and future markets. At the date of this Prospectus, Curetis has agreements with nine distribution partners\nto distribute its products in some of its markets, such as Acumen Research Laboratories Pte Ltd. (\"Acumen\") for\ncertain ASEAN markets and Beijing Clear Biotech Co., Ltd (\"Beijing Clear Biotech\") for Greater China. Fail-\nure to find suitable additional distribution partners or to conclude or renew distribution agreements with current\nor future distribution partners at commercially attractive terms could delay or prevent Curetis from selling its\nproducts or make it unreasonably expensive to do so. At the same time, certain distribution partners may not\ndistribute Curetis' products because they are less incentivised to distribute Curetis' products than products of\nother companies or because such distribution agreements would otherwise conflict with their existing or future\ndistribution obligations towards third parties. As a result, such distribution partners may fail to effectively sell\nCuretis' products, in sufficient quantities, on commercially viable terms or in a timely manner and there is no\ncertainty that Curetis distribution partners will be willing or able to market or distribute the products to the extent\nCuretis expects.\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8653270628473707, "height": 0.17828131680205217, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-8", "text": "Furthermore, Curetis has only a limited influence over its distribution partners' marketing activities. For exam-\nple, Curetis' products could be used outside of its cleared or approved indication (so-called \"off-label\" use). Alt-\nhough Curetis trains its distribution partners not to promote its products for \"off-label\" uses, and Curetis' instruc-\ntions for use in all markets specify that its products are not intended for use outside of those indications cleared\n", "page_number": 52, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8717400598546388, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-52-9", "text": "49\n", "page_number": 52, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.01813784764207982}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-0", "text": "for use, it cannot provide any assurance that no competent regulatory agency will hold Curetis responsible for\nengaging in \"off-label\" promotion. The development of any of these factors could materially delay or harm the\nfurther commercialisation of its products, both of which could have a material adverse effect on Curetis' busi-\nness, financial position, cash flows and results of operations.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-1", "text": "Curetis' sales cycles are lengthy and sales may fluctuate, which makes it difficult to forecast revenue and\nproduct sales.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.879081015719468, "lower_right_y": 0.17999144933732364, "height": 0.026507054296707994, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' sales cycles are lengthy and sales may fluctuate, which makes it difficult to forecast revenue andproduct sales."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-2", "text": "Curetis' sales process involves numerous interactions with multiple individuals and different stakeholder groups\n(such as microbiologists, intensive care unit (\"ICU\") clinicians and hospital administration) at potential custom-\ners sites or organisations testing Curetis' products and will often include in-depth analysis by potential customers\nof Curetis' products, performance of proof-of-principle studies, preparation of extensive documentation and a\nlengthy review process. As a result of these factors and the budgetary cycles of Curetis' potential customers, the\ntime from initial contact with a customer to the receipt of a purchase order will vary significantly and could be\n12 months or longer.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28388200085506626, "height": 0.09619495510902096, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-3", "text": "Given the length and uncertainty of the anticipated sales cycle, Curetis will likely experience fluctuations in\nproduct sales on a period-to-period basis. For example, sales of Curetis' products often involve purchasing deci-\nsions by large public and private institutions and any purchases can require multiple levels of pre-approval. In\naddition, those large institutions, such as public universities, frequently depend on government grants or public\nfunding themselves, indirectly making Curetis' sales dependent on those funding sources. Furthermore, expected\nrevenue streams are highly dependent on hospitals' adoption and use of Curetis' products, and it cannot be as-\nsured that Curetis' hospital clients will use and purchase Application Cartridges regularly.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3864899529713553, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-4", "text": "Curetis may not be able to gain the support of leading hospitals and key opinion leaders (\"KOLs\") or to\nachieve favourable publication of the results of Curetis' clinical trials in peer-reviewed journals\n", "page_number": 53, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.3997434801197093, "lower_right_x": 0.879081015719468, "lower_right_y": 0.42625053441641725, "height": 0.026507054296707966, "width": 0.7593712212817412}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis may not be able to gain the support of leading hospitals and key opinion leaders (\"KOLs\") or toachieve favourable publication of the results of Curetis' clinical trials in peer-reviewed journals"]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-5", "text": "Curetis' strategy includes developing relationships with leading hospitals and KOLs in the industry. This in-\ncludes, for example, leading hospitals such as Charit\u00e9 in Berlin and the University Medical Centre (\"CHU\") in\nNantes. Individuals considered as KOLs include, inter alia, reputable clinicians or microbiologists as well as\nmembers of clinical societies and editors of scientific journals. If these hospitals and KOLs determine that the\nUnyvero System and related Application Cartridges are not clinically effective or that alternative technologies\nare equally or more effective, or if Curetis otherwise encounters difficulty promoting the adoption of the Un-\nyvero Platform, Curetis' revenue growth and ability to achieve profitability could be significantly limited.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5301410859341599, "height": 0.09619495510902093, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-6", "text": "Curetis believes that publication of scientific and medical results in peer-reviewed journals and presentation of\ndata at leading conferences are critical to the broad adoption of the Unyvero Platform. Publications in leading\nmedical journals are subject to a peer-review process, and reviewers may not consider the results of studies in-\nvolving the Unyvero Platform sufficiently novel or worthy of publication. In addition, the publication of less\nfavourable results or questions surrounding the effectiveness of the Unyvero System and related Application\nCartridges in scientific or medical journals or presentations may make it more difficult for Curetis to gain the\nsupport of hospitals and KOLs in the further commercialisation of its products.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6327490380504489, "height": 0.09619495510902099, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-7", "text": "Curetis may be unable to recruit, train and retain key personne\n", "page_number": 53, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.6494228302693459, "lower_right_x": 0.5538089480048367, "lower_right_y": 0.662248824283882, "height": 0.012825994014536102, "width": 0.43288996372430466}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis may be unable to recruit, train and retain key personnel."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-8", "text": "Curetis' future success depends on its ability to recruit, train, retain and motivate key personnel, including Cu-\nretis' research and development, science and engineering, manufacturing and sales and marketing personnel. In\nparticular, Curetis is highly dependent on the technology expertise of its Chief Technology Officer (\"CTO\") and\nChief Operating Officer (\"COO\") as well as certain key R&D employees. As competition for qualified sales\npersonnel is intense in Europe as well as in the US, Curetis' growth depends, in particular, on attracting, retaining\nand motivating highly trained sales personnel with the necessary scientific background and ability to understand\nCuretis' Unyvero Platform at a technical level. In addition, Curetis may need additional employees at its manu-\nfacturing facilities to meet the demand for its products as Curetis scales up its sales and marketing operations.\nBecause of the complex and technical nature of Curetis' products and the dynamic market in which it competes,\nany failure to attract, train, retain and motivate qualified personnel could materially harm Curetis' growth pro-\nspects and could have a material adverse effect on Curetis' business, financial position, cash flows and results of\noperations.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6699444206926036, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.831124412141941, "height": 0.16117999144933737, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-9", "text": "Curetis' cash position and operating cash flow may be insufficient to cover expected investment expenses, an\nCuretis may need to raise additional funds in the future.\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8712212817412334, "lower_right_y": 0.8713125267208208, "height": 0.023514322359982853, "width": 0.7557436517533253}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' cash position and operating cash flow may be insufficient to cover expected investment expenses, andCuretis may need to raise additional funds in the future."]}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-10", "text": "As of 30 June 2015, Curetis had access to slightly more than \u20ac12.7 million of cash. Curetis estimates its current\ncash burn rate to be approximately \u20ac8.0 million to \u20ac10.0 million per year. The Company believes that Curetis'\nexisting cash and cash equivalents, including the funds raised in the Offering, will be sufficient to meet Curetis'\n", "page_number": 53, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8820008550662677, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9221889696451475, "height": 0.04018811457887983, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-53-11", "text": "50\n", "page_number": 53, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-0", "text": "anticipated cash requirements for at least the next 12 months. However, if the Offering will not take place for\nwhatever reason and Curetis is not able to generate sufficient funds from other sources, Curetis' cash and cash\nequivalents will not be sufficient for the next 12 months and will presumably run out of cash in June 2016 which\nmay lead to Curetis not being able to continue as a going concern. In case the Offering will not take place, the\nCompany will implement a detailed action plan to address the imminent working capital shortfall by reducing\nthe cash-outflows. This will include significant cost reductions and reduced or at least delayed operating and\ncapital expenditures, primarily the suspension of the cost-intensive FDA trials in the US and the build-up of its\nUS organisation, as well as reduced staff expenditure due to abstaining from hiring additional personnel and\npostponement in regards to capital expenditures (see \"Capitalisation, Indebtedness and Working Capital \u2013 Work-\ning Capital Statement\").\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.2214621633176571, "height": 0.13638306968790082, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-1", "text": "The Company may need to raise substantial additional capital to:\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.24283882000855067, "height": 0.014108593415989745, "width": 0.44074969770253924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-2", "text": "\uf0b7   expand Curetis' product offerings;\n\uf0b7   expand Curetis' sales and marketing infrastructure;\n\uf0b7   increase Curetis' manufacturing capacity;\n\uf0b7   continue Curetis' research and development activities; and\n\uf0b7   in case the Offering does not take place, fund Curetis' operations.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.6027811366384522, "lower_right_y": 0.3505771697306541, "height": 0.10132535271483539, "width": 0.4873035066505441}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-3", "text": "Curetis' future funding requirements will depend on many factors, some of which are beyond Curetis' control,\nincluding:\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3847798204360838, "height": 0.026079521162890085, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-4", "text": "\uf0b7   the cost and timing of marketing or regulatory clearances, including the FDA clearance;\n\uf0b7   market acceptance of Curetis' products;\n\uf0b7   the cost and timing of establishing further sales, marketing and distribution capabilities;\n\uf0b7   the cost of Curetis' research and development activities;\n\uf0b7   the ability of healthcare providers to obtain coverage and adequate reimbursement by third-party payers\n    for procedures using Curetis' products;\n\uf0b7   the cost of goods associated with Curetis' products;\n\uf0b7   the effect of competing technological and market developments; and\n\uf0b7   the extent to which Curetis is to decide to invest in third-party businesses, products and technologies,\n    including entering into licensing or collaboration arrangements for products.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5848653270628473, "height": 0.19196237708422398, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-5", "text": "Curetis may not be able to obtain additional funds on acceptable terms, or at all. Due to its current cash burn rate,\nCuretis' present cash position and operating cash flow will become insufficient to cover the expected investment\nexpenses and working capital that will be required in the foreseeable future. If Curetis were not able to raise\nadditional funds, it may need to reduce its spending on research and development, production or marketing\nwhich would have a negative impact on Curetis' competitiveness. In addition, Curetis would also have to sus-\npend its FDA trials in the US leading Curetis not to obtain the anticipated FDA clearance in the first half of 2017\nand thus not being able to sell into the US market in 2017 and also in the following years. As a consequence,\nrevenues from the US would not be generated or would be generated only with a significant delay.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-6", "text": "If Curetis raises additional funds by issuing equity or equity-linked securities, Curetis' shareholders may experi-\nence dilution. Debt financing, if available, may involve covenants restricting Curetis' operations or its ability to\nincur additional debt. Any debt or additional equity financing Curetis raises may be at terms that are not favour-\nable to Curetis or its shareholders. If Curetis raises additional funds through collaboration and licensing ar-\nrangements with third parties, it may be necessary to relinquish some rights to its Unyvero Platform, or grant\nlicenses on terms that are not favourable to it, which could reduce its ability to generate future revenues and\nachieve profitability. If Curetis does not have, or is not able to obtain, sufficient funds, it may be required to\ndelay development, clearance or commercialisation of the Unyvero System or the Application Cartridges. Cu-\nretis also may have to reduce marketing or customer support or may even be forced to file for insolvency.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.831124412141941, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-7", "text": "The molecular diagnostics market is highly competitive and Curetis may not be able to compete effectively.\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8567110036275696, "lower_right_y": 0.8589140658401027, "height": 0.014536126549807626, "width": 0.7412333736396615}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["The molecular diagnostics market is highly competitive and Curetis may not be able to compete effectively."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-8", "text": "Curetis competes with other commercial diagnostics companies and anticipates that it will face strong competi-\ntion in the future as expected competitors develop new or improved products and as new companies enter the\nmarket with new technologies. Curetis believes its principal competition comes and will continue to come from\ntraditional diagnostic companies, including, but not limited to, Abbott, Beckman Coulter, Becton Dickin-\n", "page_number": 54, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8653270628473707, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-54-9", "text": "51\n", "page_number": 54, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.017533252720677184}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-0", "text": "son & Co., Roche Diagnostics and QIAGEN, as well as companies offering novel molecular and non-molecular\nmethods, including, but not limited to, bioM\u00e9rieux, Inc., GenMark, Cepheid, Biocartis and T2 Biosystems.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-1", "text": "Most of Curetis' competitors are either publicly traded or are divisions of publicly traded companies, and have a\nnumber of competitive advantages over it, including:\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1466438648995297, "height": 0.027362120564343742, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-2", "text": "greater name and brand recognition, financial and human resources;\nestablished and broader product lines;\nlarger sales forces and more established distribution networks;\nsubstantial intellectual property portfolios;\nlarger and more established customer bases and relationships; and\nbetter established, larger scale and lower-cost manufacturing capabilities.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.15433946130825138, "lower_right_x": 0.6614268440145102, "lower_right_y": 0.27661393758016245, "height": 0.12227447627191107, "width": 0.49758162031438935}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-3", "text": "\uf0b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.1569046601111586, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.16417272338606242, "height": 0.007268063274903813, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-4", "text": "\uf0b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.17870884993587002, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.18469431380932022, "height": 0.0059854638734501975, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-5", "text": "\uf0b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2013681060282172, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.20820863616930313, "height": 0.006840530141085932, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-6", "text": "", "page_number": 55, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.221889696451475, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.22873022659256093, "height": 0.006840530141085932, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-7", "text": "\uf0b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2436938862761864, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.2496793501496366, "height": 0.0059854638734501975, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-8", "text": "\uf0b7\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2663531423685336, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.2731936725096195, "height": 0.006840530141085932, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-9", "text": "Curetis may not effectively compete or be successful in the face of increasing competition from new products\nand technologies introduced by Curetis' existing competitors or new companies entering Curetis' markets. In\naddition, it is possible that Curetis' future competitors will have or develop products or technologies that enable\nthem to produce competitive products with greater capabilities or at lower costs than Curetis' products. Genmark,\nfor example, is currently developing a direct competitive product (ePlex platform), which similarly to Curetis,\ntargets rapid pathogen identification. In addition, other companies like STAT Diagnostica and Atlas Genetics\nhave announced similar technologies and respiratory tests. As an example of antibiotic resistance testing one\ncompeting product is offered by Geneweave Biosciences, which promises faster phenotypic testing (about four\nhours) via its Smarticles\u2122 Technology. Competitors may also be able to respond more quickly and effectively\nthan Curetis to new or changing opportunities, technologies, standards or customer requirements.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42069260367678496, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-10", "text": "The selling price level in the molecular diagnostics market could decrease in the future which would adverse-\nly affect Curetis' business, financial position and results of operations.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.4595981188542112, "height": 0.02565198802907226, "width": 0.7617896009673519}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The selling price level in the molecular diagnostics market could decrease in the future which would adverse-ly affect Curetis' business, financial position and results of operations."]}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-11", "text": "The MDx market is relatively young and Curetis competes with a larger number of commercial diagnostics\ncompanies in this market. Curetis expects that, with the MDx market becoming more mature, the use of scale\neffects and continuous technological improvements, the prices for MDx products and also for Curetis' products\nare likely to decline over the course of time. If Curetis is not able to offset a decrease in product prices by a cor-\nresponding reduction of their costs of goods sold, this could have a material adverse effect on Curetis' business,\nfinancial position, cash flows and results of operations.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5506626763574177, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-12", "text": "Curetis' current and future customers are highly dependent on payments from third-party payers. Inadequate\ncoverage and reimbursement for Curetis' diagnostic tests as well as a faster increase of Curetis' costs of pro-\nduction compared to increases in reimbursement levels could compromise the commercial success of Curetis'\nproducts.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6173578452330055, "height": 0.05344164172723387, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' current and future customers are highly dependent on payments from third-party payers. Inadequatecoverage and reimbursement for Curetis' diagnostic tests as well as a faster increase of Curetis' costs of pro-duction compared to increases in reimbursement levels could compromise the commercial success of Curetis'products."]}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-13", "text": "Successful commercialisation of Curetis' diagnostic products depends, in large part, on the extent to which the\ncosts of Curetis' products are reimbursed to its customers, either separately or through bundled payment, by\nthird-party private and governmental payers, private health insurances as well as public health systems. Cover-\nage and reimbursement will also depend on the applicable healthcare policy framework in the relevant jurisdic-\ntion. For example, in the EU and the US, there is significant uncertainty surrounding third-party coverage and\nreimbursement for the use of tests that incorporate new technology, such as the Unyvero Platform, as it is uncer-\ntain whether and to which extent third-party payers will reimburse Curetis' customers for the use of the Unyvero\nPlatform under current legal frameworks (see also \"\u2013 Healthcare policy changes, including legislation to reform\nthe US healthcare system, may have a material adverse effect on Curetis' financial position and results of opera-\ntions.\").\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7627191107310817, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-14", "text": "Hospitals, clinical laboratories and other healthcare providers generally bill various third-party payers to cover\nall or a portion of the costs and fees associated with diagnostic tests, including the cost of the purchase of Cu-\nretis' products. Curetis current products are used in a hospital inpatient setting, where in most geographic areas\ngovernmental payers, health insurances or funds and other national equivalents in the respective countries, gen-\nerally reimburse hospitals a single bundled payment per patient case. However, third-party payers may deny\ncoverage if they determine that Curetis' products are not cost-effective compared to the use of alternative testing\nmethods or deem them to be experimental or medically unnecessary. Even if third-party payers make coverage\nand reimbursement available, such reimbursement may not be adequate, which could have an adverse effect on\nCuretis' business, financial position, cash flows and results of operations.\n", "page_number": 55, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8926891834117144, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-55-15", "text": "52\n", "page_number": 55, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-0", "text": "The manufacture of many of Curetis' products is a highly precise and complex process, and if Curetis en-\ncounters problems with the manufacturing and the quality of its products, its reputation and business could\nsuffer.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.880894800483676, "lower_right_y": 0.12441214194100043, "height": 0.03933304831124412, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The manufacture of many of Curetis' products is a highly precise and complex process, and if Curetis en-counters problems with the manufacturing and the quality of its products, its reputation and business couldsuffer."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-1", "text": "The manufacture of many of Curetis products is a highly precise and complex process, due in part to strict regu-\nlatory requirements. Problems such as quality issues may arise during manufacturing for a variety of reasons,\nincluding equipment malfunction, failure to follow specific protocols and procedures, problems with raw materi-\nals, natural disasters and environmental factors, and if not discovered before the product is released to market\nsuch problems could result in recalls and product liability exposure. Product quality has had a material impact on\nCuretis' results of operations for the periods under review.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21504916631038906, "height": 0.08208636169303121, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-2", "text": "In 2012 and 2013, Curetis experienced significant delays and shortages in the supply of Unyvero Systems. Dur-\ning that time, Curetis' OEM manufacturer Zollner had not yet been able to produce sufficient quantities of Un-\nyvero Systems at the required quality level. Curetis therefore implemented a series of design changes and an\nadditional layer of Unyvero product and hardware release testing at its own facilities using its own resources\nwhich led to significant additional expenses. In addition, Curetis' inability to deliver sufficient quantities of Un-\nyvero Systems at the required quality level, during that period, led several distributors and customers to reduce\nor even pause their purchases of Unyvero Systems.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31765711842667804, "height": 0.09576742197520305, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-3", "text": "Furthermore, in 2014, the commercial roll-out of the Unyvero Platform has also been slowed down due to devel-\nopment issues with P50 and i60 ITI Application Cartridges that became apparent when broader usage occurred\nas part of Curetis' clinical trials as well as a growing customer base. Reasons for these issues were significant\ndelays with the completion and validation of several modules of the automated production line for the Applica-\ntion Cartridges in Bodelshausen. In the same year, a task force of Curetis' R&D team members completed multi-\nple design changes to the P50 Application Cartridge as well as i60 ITI Application Cartridge, which primarily\nimpacted Curetis' R&D expenses.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4202650705429671, "height": 0.0957674219752031, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-4", "text": "In addition, in 2014, due to the above mentioned series of quality issues and product improvements in connection\nwith the Unyvero System and the LRT50 Application Cartridge, Curetis had to put on hold its US clinical trials\nand the process of obtaining FDA clearance, which included the halt of the prospective sample enrolment and\nmeasurement of samples with the LRT50 Application Cartridge during most of 2014.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-5", "text": "Curetis' revenues and other operating results will depend, in large part, on its ability to manufacture and deliver\nits Application Cartridges in sufficient quantities and quality, in a timely manner, and at a cost that is economi-\ncally attractive. Curetis expects to be required to significantly increase Application Cartridge manufacturing as\ncommercialisation progresses. It may not be able to do so for a variety of reasons, such as an inappropriate as-\nsessment of the quantities of Application Cartridges needed which would lead to a delayed capacity expansion.\nSuch expansion is also time-consuming and error-prone due to the level of sophistication of the Application\nCartridges. In addition, because of the time required to approve and license certain regulated manufacturing\nfacilities, an alternative manufacturer may not be available on a timely basis to replace such production capacity.\nAny of these manufacturing problems could result in significant costs and liability, as well as negative publicity\nand damage to Curetis' reputation that could reduce demand for its products.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6254809747755451, "height": 0.1368106028217187, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-6", "text": "Any failure or delay in delivery or the supply of insufficient quantities or deficient quality of products caused by,\namong other things, quality issues, manufacturing disruptions, mechanical breakdown, a fire or other incident or\na delay in supply of components, could also result, for example, in the complete shut-down of an ongoing clini-\ncal trial or in a delivery shortage to customers. This could, in turn, lead to significant adverse consequences for\nCuretis, such as loss of revenues, or damage to Curetis' reputation.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-7", "text": "Curetis' diagnostics results may not perform as expected and deliver incomplete or incorrect results, which\ncould subject Curetis to product liability claims.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7421975203078238, "height": 0.027789653698161554, "width": 0.7672309552599758}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis' diagnostics results may not perform as expected and deliver incomplete or incorrect results, whichcould subject Curetis to product liability claims."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-8", "text": "Curetis' success will depend on the market's confidence that the Unyvero Platform can provide reliable, high-\nquality diagnostic results. The Company believes that Curetis' customers are likely to be particularly sensitive to\nany defects, errors or a lack of sensitivity or specificity in Curetis' products. If the Unyvero Platform failed to\ndetect the presence of critical bacterial pathogens or critical antibiotic resistance markers, patients could continue\nto suffer from respective infections as a result of such misdiagnosis. In reaction, patients, hospitals, surgeons or\nother parties could try to hold Curetis responsible for all or part of the medical decisions underlying the treat-\nment and expose Curetis to product liability claims. These developments could occur even if hospitals correctly\nuse Curetis' products and follow the warning instructions provided by Curetis. Product liability claims could also\nbe based on an allegation that one of Curetis' products contains a design or manufacturing defect. For example,\npatients or volunteers in hospitals or during the course of clinical trials could hold Curetis responsible for side\neffects from an incorrect treatment therapy arising from defects in Curetis' products.\n", "page_number": 56, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8995297135528003, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-56-9", "text": "53\n", "page_number": 56, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-0", "text": "Any product liability claim could result in substantial damages and be costly and time consuming to defend,\neither of which could materially harm Curetis' business, financial position and results of operations and damage\nits reputation and the market acceptance of the Unyvero Platform. Moreover, any product liability claim brought\nagainst Curetis, with or without merit, could increase product liability insurance rates. As of the date of this\nProspectus, Curetis' upper limit for its insurance policy against third-party claims for product liability or body\ninjuries amounts to \u20ac5 million. It is uncertain whether Curetis' existing or future insurance policies are or will be\nsufficient to cover the risks as set forth above or whether Curetis would even be able to renew its insurance poli-\ncies to such an extent that it could cover any such eventualities. As a result, the amount of any costs, including\nfines or damages, that Curetis might occur in such circumstances, could substantially exceed any upper limits of\ninsurance policies Curetis has in place to cover such losses. This means that in case those upper limits are ex-\nceeded, Curetis would have to fully compensate the difference between the insurance upper limits and the actual\ndamage which could have a significant adverse effect on Curetis' business, financial position and results of oper-\nations. In addition, Curetis' insurance providers could refuse or be unable to make payments although the risk is\ninsured.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.2736212056434374, "height": 0.1885421120136811, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-1", "text": "Patient injuries resulting from defects in Curetis' products could potentially lead to the products being re-\ncalled from the market or significant decline in market demand for the products. Defects, errors or a lack of\nsensitivity or specificity of the Unyvero Platform could also hinder its commercial roll-out and the conduct of\nregulatory clearance procedures. A recall of Curetis' products, either voluntarily or at the direction of the\nrelevant regulatory bodies, or the discovery of serious safety issues with Curetis' products that leads to correc-\ntive actions, could have a significant adverse impact on Curetis.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.367678495083369, "height": 0.07738349722103466, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Patient injuries resulting from defects in Curetis' products could potentially lead to the products being re-called from the market or significant decline in market demand for the products. Defects, errors or a lack ofsensitivity or specificity of the Unyvero Platform could also hinder its commercial roll-out and the conduct ofregulatory clearance procedures. A recall of Curetis' products, either voluntarily or at the direction of therelevant regulatory bodies, or the discovery of serious safety issues with Curetis' products that leads to correc-tive actions, could have a significant adverse impact on Curetis."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-2", "text": "The relevant regulatory bodies may require a recall of Curetis' commercialised products in the event of material\ndeficiencies, or defects in design or manufacture, or in the event that a product poses an unacceptable risk to\nhealth. A government mandated or voluntary recall could occur as a result of an unacceptable risk to health,\ncomponent failures, manufacturing errors, design or labelling defects or other deficiencies and issues. Manufac-\nturers, on their own initiative, may recall a product if any material deficiency in a device is found. A government\nmandated or voluntary recall could occur as a result of an unacceptable risk to health, component failures, manu-\nfacturing errors, design or labelling defects or other deficiencies and issues.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47498931167165453, "height": 0.09576742197520305, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-3", "text": "For example, as a manufacturer of CE-IVD-marked medical devices sold on the European market, Curetis must\nmaintain a vigilance system that enables it to notify relevant regulatory authorities of incidents which may lead\nto (or may have led to) death or serious health consequences for individuals, or to a recall of the relevant prod-\nuct. This includes obligations to submit reports to the relevant national competent authority for recording and\nevaluating when incidents (e.g. any malfunction or deterioration in the characteristics or performance of a de-\nvice) occur, to disseminate information that could be used to prevent a recurrence of the incident or to alleviate\nthe consequences of such incidents, and, where appropriate, to implement a \"Field Safety Corrective Action\"\n(such as a product recall) to reduce the risk of death or serious injury associated with the use of the device.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5912783240701154, "height": 0.10944848225737491, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-4", "text": "Recalls of any of Curetis' products would divert managerial and financial resources and have an adverse effect\non Curetis' business, financial position, cash flows and results of operations, and could impair Curetis' ability to\nproduce its products in a cost-effective and timely manner. New approvals or clearances from regulatory bodies\nmay also need to be obtained before the corrected part of the Unyvero Platform can be marketed or distributed\nagain. Seeking such approvals or clearances may delay Curetis' ability to replace the recalled devices in a timely\nmanner. Curetis may further be required to bear other costs or take other actions that may have a negative impact\non Curetis' sales as well as face significant adverse publicity or regulatory consequences, which could harm\nCuretis' business, including Curetis' ability to market Curetis' products in the future.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7075673364685763, "height": 0.10944848225737491, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-5", "text": "Curetis' future success is dependent upon Curetis' ability to create, maintain and expand a customer base fo\nits products in large and leading hospitals.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8730350665054414, "lower_right_y": 0.7486105173150919, "height": 0.027362120564343728, "width": 0.7575574365175333}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' future success is dependent upon Curetis' ability to create, maintain and expand a customer base forits products in large and leading hospitals."]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-6", "text": "In Europe, Curetis currently markets its products mainly to large and leading hospitals in which patients with\nsevere infections are treated. As of 30 June 2015, Curetis' products were sold to fewer than 10 large and leading\nEuropean hospitals. Curetis is currently targeting around 745 large and leading hospitals in its direct sales territo-\nries in Europe as well as up to 1,208 relevant hospitals via its nine distribution partners covering 12 countries. In\nthe US, Curetis initially intends to focus on the approximately 727 large and/or leading hospitals in which pa-\ntients who have the highest risk of suffering from pneumonia are concentrated.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.837964942283027, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-7", "text": "The adoption of Curetis' products by large and leading hospitals may not be successful for a number of reasons.\nThese include a lack of funding of hospitals, burdensome administration procedures, a lack of clinical or com-\nmercial interest in the Unyvero Platform, a lack of adequate reimbursement of the hospital and the introduction\nof new competing technologies. Any non-acceptance of Curetis' products would make it difficult for Curetis to\nexpand its market in Europe and to successfully introduce its products in the US and to continue its distribution\nefforts in the ASEAN markets and China or other markets.\n", "page_number": 57, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9234715690466011, "height": 0.07909362975630607, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-57-8", "text": "54\n", "page_number": 57, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-0", "text": "Curetis may not be able to develop new products or enhance the capabilities of its products and systems to\nkeep pace with the rapidly changing technology and customer requirements in Curetis' industry.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.11286874732791792, "height": 0.02778965369816161, "width": 0.7672309552599758}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis may not be able to develop new products or enhance the capabilities of its products and systems tokeep pace with the rapidly changing technology and customer requirements in Curetis' industry."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-1", "text": "Curetis' industry is characterised by rapid technological changes, frequent new product introductions and en-\nhancements and evolving industry standards. Curetis' success depends on its ability to develop new products and\napplications for its technology in new markets that develop as a result of technological and scientific advances,\nwhile improving the performance and cost-effectiveness of Curetis' existing products. New technologies, tech-\nniques or products could emerge that might offer better combinations of price and performance than the products\nand systems that Curetis currently sells or plans to sell in the future.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2013681060282172, "height": 0.08208636169303123, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-2", "text": "The market in Europe, the US and Asia is characterised by rapid technological change and innovation. It is criti-\ncal to its success that Curetis anticipates changes in technology and customer requirements and physician, hospi-\ntal and healthcare provider practices and successfully introduces new, enhanced and competitive technologies to\nmeet Curetis' prospective customers' needs on a timely and cost-effective basis.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2629328772979906, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-3", "text": "At the same time, however, Curetis must carefully manage its introduction of new products, including regular\nproduct maintenance. If potential customers believe that such products will offer enhanced features or be sold for\na more attractive price, they may delay purchases until such products are available. Curetis may also have excess\nor obsolete inventory of older products as Curetis transitions to new products, and Curetis has limited experience\nin managing product transitions. If Curetis does not successfully innovate and introduce new technology into its\nanticipated product lines or manage the transitions of Curetis' technology to new product offerings, Curetis' rev-\nenue, results of operations and business will be adversely impacted.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.26336041043180847, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3655408294142796, "height": 0.10218041898247116, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-4", "text": "Curetis is developing additional Application Cartridges intended to be used with the Unyvero System, including\nApplication Cartridges to detect microorganisms and antibiotic resistance markers from positive blood cultures,\na panel in intra-abdominal/gastrointestinal tract infections and a sepsis host response panel.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.413852073535699, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-5", "text": "Curetis may have problems applying its technologies to other areas and Curetis' new applications may not be as\neffective in detection as its initial applications. Any failure or delay in creating a customer base or launching new\napplications may compromise Curetis' ability to achieve its growth objectives.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46173578452330055, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-6", "text": "If the manufacturing, development or testing equipment used by or for Curetis were damaged or destroyed, or\nif Curetis experiences a significant disruption in its operations or if Curetis experiences any problems with its\nmanufacturing processes for any reason, Curetis' ability to continue to operate its business could be material-\n", "page_number": 58, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5262932877297991, "height": 0.051303976058144574, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If the manufacturing, development or testing equipment used by or for Curetis were damaged or destroyed, orif Curetis experiences a significant disruption in its operations or if Curetis experiences any problems with itsmanufacturing processes for any reason, Curetis' ability to continue to operate its business could be material-ly harmed."]}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-7", "text": "Curetis currently develops its diagnostic products exclusively in its own facility in Holzgerlingen, Germany,\nwhereas it manufactures and tests some components at facilities in Bodelshausen, Germany (operated by Curetis)\nand outsources manufacturing and testing of its Unyvero System to facilities in Neukirchen beim Heiligen Blut,\nGermany, that are operated by Zollner Elektronik AG. If these or any future facilities were to be damaged, de-\nstroyed or otherwise unable to operate, whether due to natural disasters, employee malfeasance, terrorist acts,\npower outages, or otherwise, or if Curetis' business is disrupted for any other reason, Curetis may not be able to\nmanufacture its products and develop and test its products in a timely manner or at all.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6327490380504489, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-8", "text": "The manufacture of components of Curetis' products at the facility in Bodelshausen and at the facility at Neu-\nkirchen beim Heiligen Blut involves complex processes, sophisticated equipment and strict adherence to specifi-\ncations and quality systems procedures. Any unforeseen manufacturing problems, such as caused by contamina-\ntion, equipment malfunction, quality problems or failure to strictly follow procedures or meet specifications,\ncould result in delays or shortfalls in production of Curetis' products or the loss of its critical ISO 13485 certifi-\ncation. Identifying and resolving the cause of any manufacturing issues could require substantial time and re-\nsources. If Curetis is unable to keep up with future demand for its products by successfully manufacturing and\nshipping Curetis' products in a timely manner, Curetis' revenue growth could be impaired and market acceptance\nof its products could be adversely affected.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7627191107310817, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-9", "text": "Currently, Curetis maintains insurance coverage against damage to Curetis' property and equipment and against\nbusiness interruption in line with what it believes to be standard practice. This coverage is subject to deductibles,\ncertain ceilings and other limitations. For example, Curetis' policy limit for property damage is between \u20ac2.5\nmillion and \u20ac5 million depending on the cause of damage, such as natural hazards, burglary or vandalism by\nthird parties. In case of shipping risks, Curetis' policy limit ranges between \u20ac5 thousand and \u20ac100 thousand for\neach conveyance depending on the type of damage. If Curetis has underestimated its insurance needs with re-\nspect to an interruption, or if an interruption is not subject to coverage under Curetis' insurance policies, Curetis\nmay not be able to cover its losses.\n", "page_number": 58, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8790081231295426, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-58-10", "text": "55\n", "page_number": 58, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-0", "text": "A significant amount of Curetis' inventory consists of equipment held by prospective customers who are eva\nuating their products and may not be converted to revenue in the timeframe that Curetis anticipates or at all.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8681983071342201, "lower_right_y": 0.10902094912355707, "height": 0.023941855493800762, "width": 0.752720677146312}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["A significant amount of Curetis' inventory consists of equipment held by prospective customers who are eval-uating their products and may not be converted to revenue in the timeframe that Curetis anticipates or at all."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-1", "text": "As of 30 June 2015, approximately \u20ac1.0 million of Curetis' inventory consisted of Unyvero Systems in posses-\nsion of customers that were evaluating and testing its products. If a material number of prospective customers do\nnot adopt the Unyvero Platform within the time periods that Curetis estimates or at all, then Curetis will not be\nable to use the inventory held by these customers to generate revenues. If Curetis is unable to sell or otherwise\ncommercially utilise this inventory to or with other customers or distributors or if such inventory becomes obso-\nlete as Curetis develops the next generation of the Unyvero Platform, Curetis may be required to write off a\nsignificant portion of this inventory.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21547669944420692, "height": 0.09619495510902094, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-2", "text": "Curetis' intention to enter into agreements with strategic partners in possession of proprietary biomarkers for\ndiagnosis of indications with a view to developing and commercialising new diagnostic products could prove\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.2654980761008978, "height": 0.03676784950833689, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' intention to enter into agreements with strategic partners in possession of proprietary biomarkers fordiagnosis of indications with a view to developing and commercialising new diagnostic products could proveunsuccessful."]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-3", "text": "Curetis has already entered and intends to enter into agreements with strategic partners for diagnostic products.\nFor example, on 24 September 2015, Curetis entered into an R&D collaboration and licensing agreement with\nAcumen Research Laboratories Pte Ltd. under which Curetis has obtained a worldwide non-exclusive license to\nAcumen's proprietary sepsis biomarker panel for host response. However, there is no assurance that this or other\nsimilar collaboration arrangements will be successful. Establishing these relationships can be difficult and time-\nconsuming. Discussions may not lead to agreements on favourable terms, if at all. To the extent Curetis agrees to\nwork exclusively with a party in a given area, Curetis' opportunities to collaborate with others or to develop\nopportunities independently would be limited. Even if new strategic relationships were established, this may not\nresult in the successful development or commercialisation of future products.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.40017101325352716, "height": 0.12355707567336471, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-4", "text": "Acquisitions or joint ventures could disrupt Curetis' business, cause dilution to Curetis' shareholders and\notherwise harm Curetis' business.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.43822146216331764, "height": 0.024796921761436497, "width": 0.7666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Acquisitions or joint ventures could disrupt Curetis' business, cause dilution to Curetis' shareholders andotherwise harm Curetis' business."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-5", "text": "Curetis may acquire other businesses, products or technologies, as well as pursue strategic alliances, joint ven-\ntures, technology licenses or investments in complementary businesses. Any of these transactions could be mate-\nrial to Curetis' financial position and operating results and expose Curetis to many risks, including:\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.879081015719468, "lower_right_y": 0.4890979050876443, "height": 0.04147071398033347, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-6", "text": "\uf0b7   disruption in Curetis' relationships with current or future customers or with current or future distributors\n    or suppliers as a result of such a transaction;\n\uf0b7   unanticipated liabilities related to acquired companies;\n\uf0b7   difficulties integrating acquired personnel, technologies and operations into Curetis' existing business;\n\uf0b7   diversion of management time and focus from operating Curetis' business to acquisition integration chal-\n    lenges;\n\uf0b7   increases in Curetis' expenses and reductions in Curetis' cash available for operations and other uses;\n\uf0b7   possible write-offs or impairment charges relating to acquired businesses; and\n\uf0b7   inability to develop a sales force for any additional products.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6703719538264216, "height": 0.17144078666096624, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-7", "text": "Curetis has not made any acquisitions to date and therefore its ability to do so successfully is largely unproven.\nForeign acquisitions further involve unique risks in addition to those mentioned above, including those related to\nintegration of operations across different cultures and languages, currency risks and the particular economic,\npolitical and regulatory risks associated with specific countries.\nIn addition, the anticipated benefit of any acquisition may not materialise. Future acquisitions or dispositions\ncould result in potentially dilutive issuances of Curetis' equity securities, the incurrence of debt, contingent lia-\nbilities or amortisation expenses or write-offs of goodwill, any of which could harm Curetis' financial position.\nCuretis cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any\nsuch transactions might have on Curetis' operating results.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8071825566481402, "height": 0.1303976058144506, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-8", "text": "Curetis will likely lose its current tax losses carried forward.\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.5362756952841596, "lower_right_y": 0.8345446772124839, "height": 0.01410859341598969, "width": 0.4207980652962515}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis will likely lose its current tax losses carried forward."]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-9", "text": "As of 30 June 2015, Curetis had trade tax losses carried forward in the amount of \u20ac43.1 million. As Curetis AG\nis a stock corporation in Germany, it is subject to corporate income tax in Germany. As of 31 December 2014,\ncorporate income tax losses carried forward amounted to \u20ac39.5 million. The tax losses carried forward are likely\nto forfeit at the level of Curetis AG as a result of the contribution of all of Curetis AG's shares into the newly\nestablished Curetis N.V. Under German tax law, losses that are carried forward will forfeit completely, if, inter\nalia, an acquirer, a person affiliated with such acquirer or a group of acquirers with similar interest acquires\n", "page_number": 59, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.840957674219752, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9226165027789653, "height": 0.08165882855921336, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-59-10", "text": "56\n", "page_number": 59, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-0", "text": "directly or indirectly more than 50% of a company's shares. The share contribution of Curetis AG's shares on the\nshares of Curetis B.V. will most likely qualify as an acquisition triggering the forfeiture of the existing losses\ncarried forward. As a consequence, Curetis AG may no longer be able to use its tax losses carried forward, or\nmay only be able to use them to a limited extent. This will, if and once Curetis reaches profitability, result in a\nhigher tax burden than would otherwise be the case. In addition, the Company could lose its future tax carry\nforwards if there is another change of control, i.e. an acquisition of more than 50% of the Company, within the\ncoming five years.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18041898247114152, "height": 0.09533988884138521, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-1", "text": "Curetis' operating results could be materially adversely affected by unanticipated changes in tax laws and\nregulations, adjustments to its tax provisions or exposure to additional tax liabilities.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.21846943138093203, "height": 0.023941855493800762, "width": 0.7666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis' operating results could be materially adversely affected by unanticipated changes in tax laws andregulations, adjustments to its tax provisions or exposure to additional tax liabilities."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-2", "text": "The determination of Curetis' provision for income taxes and other tax liabilities requires significant judgment,\nincluding the adoption of certain accounting policies and Curetis' determination of whether its deferred tax assets\nare, and will remain, available. Although management believes its estimates and judgment are reasonable, they\nremain subject to review by the relevant tax authorities. Curetis cannot guarantee that its interpretation will not\nbe questioned by the relevant tax authorities, or that the relevant tax laws and regulations, or the interpretation\nthereof by the relevant tax authorities, will not be subject to change. Any adverse outcome of such a review may\nlead to adjustments in the amounts recorded in Curetis' financial statements, and could have a materially adverse\neffect on Curetis' operating results and financial position.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3386062419837537, "height": 0.1098760153911928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-3", "text": "Curetis effective tax rates could be adversely affected by changes in tax laws, treaties and regulations, both in-\nternationally and domestically, including possible changes to the patent income deduction regime and wage\nwithholding tax incentive for qualified research and development personnel in Germany and other tax incentives,\nor the way they proportionally impact Curetis' effective tax rate. Any increase of the effective tax rates could\nhave an adverse effect on Curetis' business, financial position, results of operations and cash flows.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.413852073535699, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-4", "text": "Curetis currently generates a portion of its revenue internationally and expects to increase this portion in the\nfuture. It is therefore subject to various risks relating to its international activities, which could adversely\naffect Curetis' operating results.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.4681487815305686, "height": 0.04104318084651559, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis currently generates a portion of its revenue internationally and expects to increase this portion in thefuture. It is therefore subject to various risks relating to its international activities, which could adverselyaffect Curetis' operating results."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-5", "text": "A portion of Curetis' revenue is derived from international sources. Curetis expects this portion to increase in the\nfuture as it continues to expand internationally. Engaging in international business involves a number of difficul-\nties and risks, including:\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.516460025651988, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-6", "text": "\uf0b7   required compliance with existing and changing foreign healthcare and other regulatory requirements and\n    laws, such as those relating to patient privacy or handling of bio-hazardous waste;\n\uf0b7   required compliance with anti-bribery laws, such as the US Foreign Corrupt Practices Act and United\n    Kingdom (\"UK\") Bribery Act, labour laws and anti-competition regulations;\n\uf0b7   required compliance with data protection laws, such as the US Health Insurance Portability and Account-\n    ability Act of 1996 or the UK Data Protection Act;\n\uf0b7   export or import restrictions;\n\uf0b7   various reimbursement and insurance regimes;\n\uf0b7   laws and business practices favouring local companies;\n\uf0b7   longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain\n    foreign legal systems;\n\uf0b7   political and economic instability;\n\uf0b7   potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade\n    barriers;\n\uf0b7   foreign exchange controls;\n\uf0b7   difficulties and costs of staffing and managing foreign operations; and\n\uf0b7   difficulties protecting or procuring intellectual property rights.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8448054724241129, "height": 0.31851218469431375, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-7", "text": "If Curetis is unable to manage the risks arising out if its international operations effectively, this could have\nmaterial adverse effect on Curetis' business, financial position, cash flows and results of operations.\n", "page_number": 60, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.8790081231295426, "height": 0.027789653698161665, "width": 0.7503022974607013}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-8", "text": "ea\n", "page_number": 60, "bounding_box": {"top_left_x": 0.8700120918984281, "top_left_y": 0.8550662676357418, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8619067977768277, "height": 0.0068405301410858765, "width": 0.010278113663845234}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-60-9", "text": "57\n", "page_number": 60, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-0", "text": "Curetis is exposed to changes in foreign currency exchange rates.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5695284159613059, "lower_right_y": 0.09790508764429243, "height": 0.012825994014536116, "width": 0.45405078597339776}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis is exposed to changes in foreign currency exchange rates."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-1", "text": "Curetis currently records its transactions, prepares its financial statements and incurs the main portion of its costs\nin euro. Its results of operations and cash flows will however increasingly become subject to fluctuations due to\nchanges in foreign currency exchange rates, in particular the US dollar but potentially also other currencies such\nas the Swiss franc and certain Asian currencies such as the Chinese Yuan as Curetis expands its operations in\nChina as a result of the recent signing of a distribution agreement with Beijing Clear Biotech for Greater China.\nCuretis' expenses are mainly denominated in euro because Curetis' operations are located in Germany and in US\ndollars (e.g. for the costs incurred in clinical trials in the US). Curetis currently does not apply any currency-\nhedging strategies. If the value of the euro increases relative to foreign currencies in the future, and Curetis does\nnot otherwise increase the prices of its products in such local markets, Curetis' future revenues could be adverse-\nly affected as it converts future revenues from local currencies to euro.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.1368106028217187, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-2", "text": "Curetis' employees, independent contractors, principal investigators, distributors, consultants, commercial\npartners and vendors may engage in misconduct or other improper activities, including non-compliance with\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.29286019666524155, "height": 0.03676784950833689, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' employees, independent contractors, principal investigators, distributors, consultants, commercialpartners and vendors may engage in misconduct or other improper activities, including non-compliance withregulatory standards and requirements."]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-3", "text": "Curetis is exposed to the risk of fraud or other misconduct by its employees, independent contractors, principal\ninvestigators conducting clinical studies, distributors, consultants, commercial partners and vendors. Misconduct\nby these parties could include intentional, reckless or negligent failures: to comply with the regulations of the\nnational regulatory bodies in the EU, the US and other countries; to provide true, complete and accurate infor-\nmation; to comply with established manufacturing standards; to comply with healthcare fraud and abuse laws\nand regulations in the EU, the US and similar foreign national fraudulent misconduct laws; to report financial\ninformation or data accurately; or to disclose unauthorised activities to Curetis. These failures may impact,\namong other things, Curetis' clinical studies and research subjects, as well as Curetis' sales, marketing and educa-\ntion programs.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4275331338178709, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-4", "text": "In particular, the promotion, sales, marketing and business arrangements in the healthcare industry are subject to\nextensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive\npractices. These laws restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales\ncommission, customer incentive programs and other business arrangements. Such misconduct could also involve\nthe improper use of information obtained in the course of clinical studies, which could result in regulatory sanc-\ntions and cause serious harm to Curetis' reputation.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5160324925181702, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-5", "text": "In addition, Curetis only has very limited control over its distribution partners. Any non-compliance by them of\ntheir distribution agreements, in particular by granting economic benefits to persons at customers in charge of\nmaking purchase decisions, can also trigger sanctions against Curetis.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5228730226592561, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5643437366395896, "height": 0.04147071398033353, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-6", "text": "In connection with employee misconduct, Curetis currently has different rules in place, such as internal business\nprinciples and an employee handbook that are applicable to all of its employees. However, it is not always possi-\nble to identify and deter employee misconduct, and Curetis' internal rules and the other precautions taken to\ndetect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses, or in\nprotecting Curetis from governmental investigations or other actions or lawsuits.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6395895681915349, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-7", "text": "If any regulatory or other actions are instituted against Curetis, and it is not successful in defending or asserting\nits rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages,\ndisgorgement, individual imprisonment, possible exclusion from participation in government healthcare pro-\ngrams contractual damages, reputational harm, diminished profits and future earnings, and curtailment of Cu-\nretis' operations. Any of these actions or investigations could result in substantial costs, including legal fees, and\ndivert the attention of management from operating Curetis' business and can have a significant impact on Curetis'\nbusiness.\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.09277469003847794, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-8", "text": "Curetis relies on third parties to conduct clinical and evaluation studies of its products that are required by\n", "page_number": 61, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.7789653698161607, "height": 0.023514322359982853, "width": 0.7648125755743651}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis relies on third parties to conduct clinical and evaluation studies of its products that are required bythe FDA or other regulatory authorities, and those third parties may not perform satisfactorily."]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-9", "text": "the FDA or other regulatory authorities, and those third parties may not perform satisfactorily.\nCuretis has conducted and is conducting a large number of clinical and evaluation studies. The vast majority of\nthese are conducted by third-party investigators. Curetis therefore relies and expects to rely in the future on third\nparties, to conduct studies of its existing and future products. Such third parties may not complete activities on\nschedule or conduct studies in accordance with regulatory requirements or with Curetis' study design. Curetis'\nreliance on third parties that are not controlled by it, does not relieve Curetis of any applicable requirements to\nensure compliance with procedures required under good clinical practices. If these third parties do not success-\nfully carry out their contractual duties or regulatory obligations or fail to meet expected deadlines, if the third\nparties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their fail-\nure to adhere to Curetis' clinical protocols or regulatory requirements or for other reasons, Curetis' studies may\n", "page_number": 61, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9132107738349722, "height": 0.13381787088499353, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-61-10", "text": "58\n", "page_number": 61, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-0", "text": "be extended, delayed, suspended or terminated, and Curetis may not be able to obtain regulatory clearance for its\nproducts from the FDA or other regulatory authorities.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-1", "text": "Curetis' business could be significantly and negatively affected by current or new governmental regulations\nand clearance, approval and post-approval requirements, particularly in the EU and the US.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.15391192817443353, "height": 0.02778965369816161, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis' business could be significantly and negatively affected by current or new governmental regulationsand clearance, approval and post-approval requirements, particularly in the EU and the US."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-2", "text": "Curetis markets and sells its products in a number of EU member countries and certain other countries recognis-\ning CE-IVD-marked devices. It further intends to launch its products in other countries/regions over the next few\nyears, in particular in the US, but also in other jurisdictions such as China. In each country in which Curetis is or\nmay become active, Curetis' products are or may become subject to various and different government regula-\ntions and, depending on the jurisdiction may become subject to review by a number of governmental authorities\ngoverning clinical studies, vigilance reporting and self-certification or approval/clearance procedures. Such regu-\nlations govern activities such as product development, testing, labelling, storage, manufacturing and distribution.\nThese regulatory requirements vary greatly from country to country. Failure to comply with these regulatory\nrequirements, or to obtain required clearances, approvals or certifications, could impair Curetis' ability to com-\nmercialise Curetis' diagnostic products. In addition, the level of regulation could even increase in the future and\nmay become more comprehensive. Curetis cannot predict the effect any future legislation or regulation will have\non it.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32107738349722104, "height": 0.16075245831551946, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-3", "text": "In the EU, market clearance for Curetis' Unyvero Platform is achieved through CE-IVD-marking, which means\nthat Curetis is allowed to self-certify its products after having conducted clinical trials. Market clearance by a\nnotified body is currently not required for Curetis' products. The current European Directive 98/79/EC (in vitro\ndiagnostic medical devices) (the \"IVD Directive\") subdivides in vitro diagnostic (\"IVD\") devices into different\nclasses. Whilst high-risk products can only be CE-IVD-marked after certification by a notified body, other prod-\nucts can be CE-IVD-marked following a self-certification process conducted by the manufacturer. Failure to\ncomply with the certification requirements under the IVD Directive, e.g. self-certification of a product instead of\ncertification of a product by a notified body due to a wrong classification of a product risk category, could re-\nquire Curetis to make changes to the Unyvero System or Application Cartridges, could lead to Curetis no longer\nbeing permitted to affix the CE-IVD-marking to its products and could require it to cease marketing and/or recall\nthe relevant products until certification in compliance with the IVD Directive is obtained. Specifically in October\n2015, Curetis was notified by the Regional Administrative Authority in Stuttgart (Regierungspr\u00e4sidium\nStuttgart) that, due to its inclusion of the test for the pathogen for \"Chlamydophila pneumoniae\" on the panel of\nits P55 Application Cartridge, its P55 Application Cartridge now falls under the scope of annex II, list b of the\nIVD Directive, which requires a market clearance by a notified body. To ensure that the P55 Application Car-\ntridge retains their CE-IVD-marking, Curetis developed and released a software update on 22 October 2015 to\neliminate the affected test from the panels of the P55 Application Cartridge. Curetis anticipates that it will have\nimplemented the necessary corrective measures in all of its customers` Unyvero Systems currently using the P55\nApplication Cartridge by the end of October 2015. Curetis is currently working on conformity assessment proce-\ndures to ensure that the test for Chlamydophila pneumoniae can be included again into the P55 Application Car-\ntridge and intends, upon review and approval by a competent notified body, to introduce a next generation soft-\nware that would again allow the display of the results of the test for the full panel of 21 microorganisms and 19\nantibiotic resistance markers, including the pathogen (Chlamydophila pneumoniae) (see also \"Business \u2013 Prod-\nucts - The P55 Pneumonia Application Cartridge - Description and status\").\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.6596836254809748, "height": 0.32834544677212485, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-4", "text": "A planned European Regulation governing the safety and performance of IVD devices (the \"IVD Regulation\")\n(currently expected to come into force in 2016 with a transitional period of compliance of between three and five\nyears) is expected to classify certain assays as high-risk, thereby requiring the services of a notified body for the\nCE-IVD-marking. The regulation has not yet been enacted. It is possible that the involvement of a notified body\nwill thereafter be required to obtain CE-IVD-marking for some of Curetis' products after the IVD Regulation\ncomes into force. Curetis estimates that obtaining CE-IVD-marking clearance from a notified body under this\nanticipated regulation is likely to increase the time it takes to bring a product to market in the EU by, on average,\nan additional three to six months.\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7729799059427106, "height": 0.10645575032064991, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-5", "text": "Violations of the applicable regulations of the IVD Directive or national laws implementing the IVD Directive\ncould also result in administrative fines payable by Curetis. In addition, Curetis has to ensure that it is in ongoing\ncompliance with the IVD Directive also after the self-certification process. Any failure or material delay in ob-\ntaining such certification for a product could have a material adverse impact on Curetis' business, financial con-\ndition and results of operations\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8512184694313809, "height": 0.06840530141085932, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-6", "text": "Before labelling and marketing Curetis' products for use as clinical diagnostics in the US, Curetis is required to\nobtain: (i) clearance from the FDA under Section 510(k) of the Federal Food, Drug and Cosmetic Act (the\n\"FDCA\"), (ii) approval of a de novo 510(k) submission for Curetis' products, or (iii) pre-market approval\n(\"PMA\") from the FDA, unless an exemption from pre-market review applies. In the 510(k) clearance process,\nthe FDA must determine that a proposed device is \"substantially equivalent\" to a device legally on the market,\n", "page_number": 62, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8580589995724669, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-62-7", "text": "59\n", "page_number": 62, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.01813784764207982}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-0", "text": "known as a \"predicate\" device, with respect to its intended use, technology, safety and effectiveness, in order to\nclear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence.\nThe de novo provision section (513(f)(2) is an alternative pathway to classify novel devices of low to moderate\nrisk for which no substantially equivalent device exists. The PMA pathway requires an applicant to demonstrate\nthe safety and effectiveness of the device based, in part, on extensive data, including, but not limited to, tech-\nnical, preclinical, clinical trial, manufacturing and labelling data. The PMA process is typically required for\ndevices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.\nThe PMA pathway is typically much more costly and uncertain than the 510(k) clearance process.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19410004275331338, "height": 0.10902094912355707, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-1", "text": "The process of obtaining regulatory clearances or approvals, or completing the de novo classification process, to\nmarket a medical device can be costly, time consuming, and sometimes unpredictable, and Curetis may not be\nable to successfully obtain marketing authorisations for its current or future products on a timely basis, if at all.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-2", "text": "Obtaining FDA clearance generally takes from several months to several years, and generally requires detailed\nand comprehensive scientific data and/or clinical data. If the FDA requires Curetis to go through a lengthier,\nmore rigorous examination for any of its current or future products than originally expected, Curetis' product\nintroductions or modifications could be delayed or cancelled, which could cause Curetis' sales to decline and\ncould therefore impair Curetis' financial position significantly. In addition, the FDA may determine that Curetis'\nproducts require the even more costly, lengthy and uncertain PMA process, which could lead to another signifi-\ncant delay in Curetis' attempt to enter the US market.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3424540401881146, "height": 0.09320222317229587, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-3", "text": "cant delay in Curetis' attempt to enter the US market.\nThe FDA can delay, limit or deny clearance or approval of a device for many reasons, including:\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3428815733219325, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.3655408294142796, "height": 0.022659256092347146, "width": 0.6535671100362757}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-4", "text": "\uf0b7   Curetis may not be able to demonstrate to the FDA's satisfaction that its products are substantially equiva-\n    lent to a legally marketed predicate device or safe and effective, sensitive and specific diagnostic tests, for\n    their intended uses (as may be required);\n\uf0b7   the data from Curetis' pre-clinical studies and clinical trials may be insufficient to support clearance or\n    approval, where required; and\n\uf0b7   the manufacturing process or facilities Curetis uses may not meet applicable requirements.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4715690466011116, "height": 0.09918768704574604, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-5", "text": "Even if granted, a 510(k) clearance, de novo submission, or PMA approval for any future product would likely\nplace substantial restrictions on how Curetis' device is marketed or sold, and the FDA will continue to place\nconsiderable restrictions on Curetis' products and operations. Medical devices are subject to the FDA's advertis-\ning and promotion regulations under the FDCA, which require Curetis to ensure that its advertising and promo-\ntion of its products are in accordance with the FDCA. If the FDA believes that Curetis is not advertising and\npromoting its products in accordance with the FDCA, the FDA can take stringent enforcement action from issu-\ning warning letters to forcing a recall of the affected products. Such actions by the FDA could serve as a back-\nground for enforcement action by the Department of Justice and other enforcement agencies, possibly leading to\ncivil and criminal fines and penalties.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6015391192817443, "height": 0.12312954253954678, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-6", "text": "Additionally, the manufacture of medical devices must comply with the FDA's Quality System Regulation\n(\"QSR\"). In addition, manufacturers must register their manufacturing facilities, list their products and comply\nwith requirements relating to labelling, marketing, complaint handling, adverse event and medical device report-\ning, reporting of corrections and removals and import and export. The FDA monitors compliance with the QSR\nand these other requirements through periodic inspections. If Curetis' facilities or those of its manufacturers or\nsuppliers are found to be in violation of applicable laws and regulations, or if Curetis or its manufacturers or\nsuppliers fail to take satisfactory corrective action in response to an adverse inspection, the regulatory authority\ncould take various enforcement actions, including, but not limited to, notices of inspectional observations, warn-\ning letters, operating restrictions or total shutdown of production or withdrawing 510(k) regulatory clearances or\nPMA approvals that have already been granted. Any of these sanctions could impair Curetis' ability to produce\nits products in a cost-effective and timely manner, and could have a material adverse effect on Curetis' reputa-\ntion, business, financial position, cash flows and results of operations. In addition, the FDA may change its\nclearance policies, adopt additional regulations or revise existing regulations, or take other actions, which may\nprevent or delay clearance of Curetis' products or impact Curetis' ability to modify any future cleared products\non a timely basis.\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8140230867892262, "height": 0.2056434373663959, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-7", "text": "The regulatory admission and clearance process and supervision in other countries requiring approval procedures\nprior to commercialisation, subjects Curetis to risks comparable to the ones described above for the US. For\nexample, as part of its strategic plan, Curetis aims to conduct clinical trials with the Food and Drug Administra-\ntion in China (\"CFDA\") through its Chinese distribution partner Beijing Clear Biotech. Pursuant to the agree-\nment with Beijing Clear Biotech, Beijing Clear Biotech is expected to conduct any prospective clinical trials\nrequired for the approval of the Unyvero System and the P55 and i60 ITI Application Cartridges in China and\nwill be responsible for the CFDA registration and the approval process (for further details see \"Business - Mate-\nrial Contracts \u2013 Beijing Clear Biotech\" and \"Business \u2013 Partnerships and Collaboration Agreements\").\n", "page_number": 63, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9298845660538692, "height": 0.10944848225737491, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-63-8", "text": "60\n", "page_number": 63, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-0", "text": "If the current regulatory requirements change or become more comprehensive, or additional regulations arise,\nthis may adversely affect Curetis' ability to obtain or maintain approval of its products or to comply with on-\ngoing regulations in the countries in which it operates, which, in turn, may have a material adverse effect on its\nbusiness, financial position, cash flows and results of operations.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-1", "text": "Healthcare policy changes, including legislation to reform the US healthcare system, may have a material\nadverse effect on Curetis' financial position and results of operations.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.18127404873877725, "height": 0.02778965369816161, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Healthcare policy changes, including legislation to reform the US healthcare system, may have a materialadverse effect on Curetis' financial position and results of operations."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-2", "text": "From time to time, legislation is enacted that could significantly change the healthcare policy and statutory pro-\nvisions governing the reimbursement of Curetis' products by third parties, for example from public health admin-\nistrations or private health insurers. In addition, existing regulations and guidance are often revised or reinter-\npreted in ways that may significantly affect Curetis' business and results of operations.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.24283882000855067, "height": 0.055151774262505365, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-3", "text": "For example, changes in healthcare policy in the US, could substantially impact the sales of Curetis' tests and\nincrease costs. The Affordable Care Act (the \"ACA\"), enacted in March 2010, introduced changes that are ex-\npected to significantly impact the pharmaceutical and medical device industries and clinical laboratories. Under\nthe ACA, for example, expansion in the pool of covered lives may expand the market for clinical diagnostic\ntesting while at the same time, various policies aimed at reducing costs or bundling care may reduce the rates\npaid for such services. The net impact of these factors on the market for Curetis' products is not clear. Moreover,\nsince 2013, certain medical device manufacturers have had to pay an excise tax in an amount equal to 2.3% of\nthe price for which such manufacturer sells its medical devices. Curetis expects that this excise tax will also\napply to some or all of its diagnostic products. Clinicians may decide not to order or offer clinical diagnostic\ntests if third-party payments are inadequate, and Curetis cannot predict whether third-party payers will offer\nadequate reimbursement for procedures utilising Curetis' products to make them commercially attractive.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.40017101325352716, "height": 0.15091919623770844, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-4", "text": "In addition, the ACA establishes an Independent Payment Advisory Board (the \"IPAB\") to reduce the per capita\nrate of growth in spending of the US health insurance program for Americans aged 65 and older (\"Medicare\") if\nexpenditures exceed certain targets. At this point, the triggers for IPAB proposals have not been met. It is unclear\nwhen such triggers may be met in the future and when any IPAB-proposed reductions to payments could take\neffect. Nevertheless, the IPAB has broad discretion to propose policies to reduce healthcare expenditures, which\nmay have a negative impact on payment rates for services, including Curetis' tests. The full impact on Curetis'\nbusiness of the ACA is uncertain. To the extent that the reimbursement amounts for pneumonia and/or implant\nand tissue infection testing decrease in the US, it could adversely affect the market acceptance and hospital adop-\ntion of Curetis' technologies.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5301410859341599, "height": 0.12355707567336466, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-5", "text": "Curetis cannot predict what healthcare programmes and regulations will be ultimately implemented at the EU or\nat the US federal or state levels or within the implementing legislation of the individual EU member states, or the\neffect of any future legislation or regulation. However, these types of provisions, as adopted, could materially\nchange the way healthcare is delivered and financed, and may materially impact numerous aspects of Curetis'\nbusiness. In particular, any changes that lower reimbursements for tests performed using Curetis' products could\nmaterially adversely affect Curetis' business, financial position, cash flows and results of operations.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.619067977768277, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-6", "text": "In addition, in the future there may continue to be additional proposals relating to the reform of the healthcare\nsystems in the US, the EU, any individual member state or any other jurisdiction where Curetis may operate in\nthe future. Certain of these proposals could limit the prices Curetis is able to charge for its products, or the\namounts of reimbursement available for tests performed using its products, and could limit the acceptance and\navailability of Curetis' products. The adoption of some or all of these proposals could have a material adverse\neffect on Curetis' business, financial position, cash flows and results of operations.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-7", "text": "Modifications to Curetis' products, if cleared or approved, may require new clearances or pre-market approv-\nals, or may require Curetis to cease marketing or recall the modified products until clearances or approvals\nare obtained.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8766626360338573, "lower_right_y": 0.7627191107310817, "height": 0.04147071398033353, "width": 0.7611850060459492}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Modifications to Curetis' products, if cleared or approved, may require new clearances or pre-market approv-als, or may require Curetis to cease marketing or recall the modified products until clearances or approvalsare obtained."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-8", "text": "In the EU, any substantial changes or modifications that are made to the design, function or safety of Curetis'\nproducts with the intention of altering the original operation, the original goal or type and which would consti-\ntute a major change may be considered a new product for which Curetis has to undertake new CE-IVD con-\nformity assessment. This could lead to additional costs, e.g. for the carrying out of new clinical studies, and a\ndelay in the commercialisation of Curetis' products.\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.837964942283027, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-9", "text": "In the US, any modification to a device authorised for marketing that could significantly affect its safety or effec-\ntiveness, or that would constitute a major change in its intended use, design or manufacture, requires, for exam-\nple, a new 510(k) clearance or, possibly, approval of a new or revised PMA. The FDA requires every manufac-\nturer to make this determination in the first instance, but the FDA may review any manufacturer's decision. The\nFDA may not agree with Curetis' decisions whether new clearances or approvals are necessary. In such case,\n", "page_number": 64, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9132107738349722, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-64-10", "text": "61\n", "page_number": 64, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.017533252720677184}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-0", "text": "Curetis may be required to cease marketing or to recall the modified product until clearance or approval is ob-\ntained, and Curetis may be subject to significant regulatory fines or penalties.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-1", "text": "In addition, if treatment guidelines change or the standard of care evolves, Curetis may need to redesign and seek\nnew regulatory clearance or approval from the FDA for Curetis' products. If treatment guidelines change so that\ndifferent treatments become desirable for the different species currently subject to the same recommended treat-\nment, the clinical utility of Curetis' Application Cartridges could be diminished and Curetis could be required to\nseek regulatory clearance from the FDA for a revised test that would distinguish between the different species.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.06840530141085933, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-2", "text": "Upon the planned launch of operations in the US, Curetis will be subject to federal and state healthcare fraud\nand abuse laws and other federal and state laws applicable to Curetis' business activities. If Curetis is unable\n", "page_number": 65, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.2377084224027362, "height": 0.03634031637451901, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Upon the planned launch of operations in the US, Curetis will be subject to federal and state healthcare fraudand abuse laws and other federal and state laws applicable to Curetis' business activities. If Curetis is unableto comply with such laws, it could face substantial penalties."]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-3", "text": "to comply with such laws, it could face substantial penalties.\nUpon the planned launch of operations in the US, Curetis' operations will be subject to various federal and state\nfraud and abuse laws. Such laws include the federal and state anti-kickback statutes, physician payment transpar-\nency laws and false claims laws. These laws may impact, among other things, Curetis' proposed sales and mar-\nketing and education programs and require it to implement additional internal systems for tracking certain mar-\nketing expenditures and to report to governmental authorities. In addition, Curetis may be subject to patient pri-\nvacy and security regulations by both the federal government and the states in which Curetis' conducts its busi-\nness. The laws that may affect Curetis' ability to operate include, inter alia:\n\uf0b7      the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowing-\n       ly or wilfully soliciting, receiving, offering or paying any remuneration, overtly or covertly, directly or\n       indirectly, in cash or in kind, in return for or to induce either the referral of an individual for, or the pur-\n       chase, lease, order, arrange for, or recommendation of, any good, facility, item or services for which\n       payment may be made, in whole or in part, under a federal healthcare program;\n\uf0b7      federal false claims laws, which prohibit, among other things, individuals or entities from knowingly\n       presenting, or causing to be presented, claims for payment from or approval by a governmental payer\n       program that are false or fraudulent;\n\uf0b7      the federal Health Insurance Portability and Accountability Act of 1996, which established new federal\n       crimes for, among other things, knowingly and wilfully executing, or attempting to execute, a scheme to\n       defraud any healthcare benefit program, wilfully obstructing a criminal investigation of a health care of-\n       fense, concealing a material fact, or making materially false statements in connection with the delivery of\n       or payment for healthcare benefits, items or services;\n\uf0b7      the federal physician sunshine requirements under the Patient Protection and Affordable Care Act, as\n       amended by the Health Care and Education Reconciliation Act, which requires certain manufacturers of\n       drugs, devices, biologicals, and medical supplies to report annually to the Centres for Medicare & Medi-\n       caid Services information related to payments and other transfers of value to physicians and teaching hos-\n       pitals, and ownership and investment interests held by physicians and their immediate family members.\nIf Curetis' operations are found to be in violation of any of the laws described above or any other governmental\nregulations that apply to it, it may be subject to penalties, including administrative, civil and criminal penalties,\ndamages, fines, disgorgement, the curtailment or restructuring of Curetis' operations, the exclusion from partici-\npation in federal and state healthcare programs and individual imprisonment, any of which could have a material\nadverse effect on Curetis' business, financial condition, cash flows and results of operations.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2381359555365541, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7174005985463874, "height": 0.4792646430098333, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-4", "text": "Curetis faces risks related to handling hazardous materials and other regulations governing environmenta\nsafety.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.7174005985463874, "lower_right_x": 0.8681983071342201, "lower_right_y": 0.7409149209063702, "height": 0.023514322359982853, "width": 0.7496977025392987}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis faces risks related to handling hazardous materials and other regulations governing environmentalsafety."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-5", "text": "Curetis' operations are subject to complex and stringent environmental, health, safety and other governmental\nlaws and regulations that both public officials and private individuals may seek to enforce. Curetis' activities that\nare subject to these regulations include, among other things, Curetis' use of hazardous materials, such as patient\nsamples containing pathogens or clinical isolates of pathogens. Curetis may not be in material compliance with\nthese regulations and costs to achieve compliance may be significant. Existing laws and regulations may also be\nrevised or reinterpreted, or new laws and regulations may become applicable to Curetis, whether retroactively or\nprospectively, that may have a negative effect on Curetis' business and results of operations. It is also impossible\nto eliminate completely the risk of accidental environmental contamination or damage to the health of individu-\nals. In such an event, Curetis could be liable for any damages, which could have a material adverse effect on\nCuretis' business, financial position, cash flows and results of operations.\n", "page_number": 65, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.8824283882000855, "height": 0.13381787088499364, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-65-6", "text": "62\n", "page_number": 65, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-0", "text": "Curetis depends on its information technology systems, and any failure of these systems could harm Curetis'\nbusiness.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.11115861479264642, "height": 0.026079521162890112, "width": 0.7678355501813785}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis depends on its information technology systems, and any failure of these systems could harm Curetis'business."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-1", "text": "Curetis depends on information technology systems for critical parts of its operations, including the storage of\ndata and retrieval of critical business information. Curetis has installed, and expects to expand, a number of en-\nterprise software systems that affect a broad range of business processes and functional areas. These information\ntechnology systems may support a variety of functions, including laboratory operations, test validation, quality\ncontrol and research and development activities. Curetis' clinical trial data for the LRT55 Application Cartridge\ntrials is currently stored on a third-party server. Curetis had also done this for the EU trial for the P50 Applica-\ntion Cartridge in the past and expects to do this also for future FDA trials as well as other larger multi-centre\ntrials for future Application Cartridges.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22873022659256093, "height": 0.10944848225737495, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-2", "text": "Information technology systems are vulnerable to damage from a variety of sources, including network failures,\nmalicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of\nCuretis' servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar dis-\nruptive problems. Failures or significant downtime of Curetis' information technology systems or those used by\nCuretis' third-party service providers could prevent Curetis from conducting its general business operations. Any\ndisruption or loss of information technology systems on which critical aspects of Curetis' operations depend\ncould have an adverse effect on Curetis' business. Further, Curetis stores highly confidential information on its\ninformation technology systems, including information related to clinical data, product designs, trade secret\ninformation, software codes, engineering drawings and plans to create new products. If Curetis' servers or the\nservers of the third-party on which Curetis' clinical data is stored are attacked by a physical or electronic break-\nin, computer virus or other malicious human action, Curetis' confidential information could be stolen, altered or\ndestroyed, which, in turn, could result in damage to Curetis' reputation, to customers stop buying Curetis' prod-\nucts, lawsuits and potential liability, and could have a material adverse effect on Curetis' business, financial\nposition, cash flows and results of operations.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.42667806755023513, "height": 0.19110731081658827, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-3", "text": "Curetis has entered into a lease agreement for a manufacturing plant in which its laboratory facilities are\nlocated. The unexpected termination or non-renewal of this lease agreement could have a significant adverse\neffect on Curetis' business, financial position and results of operations.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.47798204360837965, "height": 0.03719538264215477, "width": 0.7623941958887546}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis has entered into a lease agreement for a manufacturing plant in which its laboratory facilities arelocated. The unexpected termination or non-renewal of this lease agreement could have a significant adverseeffect on Curetis' business, financial position and results of operations."]}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-4", "text": "Curetis has entered into a lease agreement with Joma-Polytec GmbH for 1,600 sqm of manufacturing and logis-\ntics space for its manufacturing plant in which its Bodelshausen laboratory facilities are located. The lease term\nhas been extended until 30 June 2020 and, under the current lease agreement, Curetis has an option to further\nextend the lease by an additional five year term. Curetis has invested significantly in the installation of tailored\nclean rooms, automated Application Cartridge manufacturing equipment and laboratory facilities in the buildings\nlocated at this plant. As a consequence, untimely termination or failure to renew its lease agreement with Joma-\nPolytec GmbH would force Curetis to invest significant monetary and managerial resources to move to an alter-\nnative manufacturing facility and Curetis may have difficulty in meeting deadlines for customer orders due to the\nsignificant production downtime such relocation would cause. As a result, the unexpected termination or non-\nrenewal of this lease agreement could have a significant adverse effect on Curetis' business, financial position\nand results of operations.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6395895681915349, "height": 0.1509191962377085, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-5", "text": "Risks Related to Intellectual Property\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.4419588875453446, "lower_right_y": 0.6703719538264216, "height": 0.01752885848653274, "width": 0.3264812575574365}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-6", "text": "If Curetis is unable to protect its intellectual property effectively, its business would be harmed\n", "page_number": 66, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6836254809747755, "lower_right_x": 0.7629987908101572, "lower_right_y": 0.6973065412569475, "height": 0.013681060282171975, "width": 0.6451027811366384}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["If Curetis is unable to protect its intellectual property effectively, its business would be harmed."]}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-7", "text": "Curetis relies on patent protection as well as trademark, copyright, trade secret protection and confidentiality\nagreements to protect the intellectual property rights related to its proprietary technologies. The strength of pa-\ntents in Curetis' field involves complex legal and scientific questions. Uncertainty created by these questions\nmeans that Curetis' patents may provide only limited protection and may not adequately protect Curetis' rights or\nmay reduce Curetis ability to gain or keep any competitive advantage. Curetis owns three issued patents (two in\nAustralia, one in Singapore), one accepted patent in Australia and 22 pending (EU, US and under the Patent\nCooperation Treaty (\"PCT\") patent applications, including provisional and non-provisional filings, as well as\ntwelve filed and published applications for registered designs (seven in the EU; two in the US, two in Switzer-\nland and one in Japan) (see \"Business \u2013 Intellectual Property\"). If Curetis fails to protect its intellectual property,\nthird parties may be able to compete more effectively against Curetis and Curetis may incur substantial litigation\ncosts in its attempts to recover or restrict use of its intellectual property. In addition, some of Curetis' patents and\npatent applications were not filed by it, but were either acquired by it or are licensed from third parties. Thus,\nthese patents and patent applications were not drafted by Curetis or its attorneys, and Curetis did not control or\nhave any input into the prosecution of these patents and patent applications either prior to Curetis' acquisition of,\nor entry into a license with respect to, such patents and patent applications.\n", "page_number": 66, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9097905087644292, "height": 0.2056434373663959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-66-8", "text": "63\n", "page_number": 66, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-0", "text": "There can be no assurance whether any of Curetis' currently pending or future patent applications will result in\nissued patents with claims that cover Curetis' products and technologies in the EU, the US or other jurisdictions,\nand Curetis cannot predict how long it will take for such patents to be issued. Typically, patents in this field are\ngranted in a time frame of two to seven years after filing and patents can be only enforced from the moment they\nare granted. Currently, Curetis does not own granted patents that can be enforced in the regions in which it is\ncurrently commercially active.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16673792218896966, "height": 0.08165882855921335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-1", "text": "Further, the issuance of a patent is not conclusive as to its inventorship or scope, and there is no guarantee that\nCuretis' issued patents will include claims that are sufficiently broad to cover Curetis' technologies or to provide\nmeaningful protection from Curetis' competitors. Further, it is possible that not all relevant prior art relating to\nCuretis' patents and patent applications has been found, which could invalidate Curetis' issued patents or prevent\na patent from being issued.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.06840530141085935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-2", "text": "Even if patents are issued and even if such patents cover Curetis' products and technologies, other parties may\nchallenge the validity, enforceability or scope of such issued patents in the US in the EU or in other jurisdictions.\nMoreover, there is no guarantee that if such patents were challenged that the patent claims will be held valid,\nenforceable, will be sufficiently broad to cover Curetis' technologies or provide meaningful protection from its\ncompetitors. Nor can it be guaranteed that a court or competent authority will uphold Curetis' ownership rights in\nsuch patents, which could adversely affect Curetis' business, financial position, cash flows and results of opera-\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24283882000855067, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.08892689183411712, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-3", "text": "tions.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3317657118426678, "lower_right_x": 0.154776299879081, "lower_right_y": 0.3420265070542967, "height": 0.010260795211628926, "width": 0.038694074969770245}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-4", "text": "In particular, recent changes to the US patent laws may impact Curetis' ability to obtain and enforce its patent\nrights in the US. For example, recent decisions by US federal courts, including the US Supreme Court, have\nlimited the protection available for clinical diagnostic innovations that rely on naturally occurring genetic se-\nquences and metabolic phenomena. In addition, the Leahy-Smith America Invents Act (the \"AIA\") included a\nnumber of significant changes to US patent law. The US Patent and Trademark Office (\"PTO\") has implemented\nand is periodically revising regulations and procedures to govern administration of the AIA, and many of the\nsubstantive changes to patent law associated with the AIA were enacted 16 March 2013. However, it is not clear\nwhat, if any, impact the AIA will have on the operation of Curetis' business. The AIA and its implementation,\nincluding any future revisions to current PTO regulations, could increase the uncertainties and costs surrounding\nthe prosecution of Curetis' patent applications, all of which could have a material adverse effect on Curetis' busi-\nness, financial position, cash flows and results of operations.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5023514322359983, "height": 0.15049166310389056, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-5", "text": "Furthermore, even if they are unchallenged, Curetis' patents and patent applications may not adequately protect\nits intellectual property, provide exclusivity for Curetis' products and technologies or prevent others from design-\ning around Curetis' claims. Others may independently develop similar or alternative products and technologies or\nduplicate any of Curetis' products and technologies. These products and technologies may not be covered by\nclaims of issued patents owned by Curetis. Any of these outcomes could impair Curetis' ability to prevent com-\npetition from third parties. In addition, competitors could purchase Curetis' products and attempt to replicate\nsome or all of the competitive advantages Curetis derives from its development efforts. If Curetis' intellectual\nproperty, including licensed intellectual property, does not adequately protect its market position against compet-\nitors' products and methods, Curetis' competitive position could be adversely affected, as could Curetis' business.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6323215049166311, "height": 0.12312954253954689, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-6", "text": "Further, if Curetis encounters delays in regulatory approvals, the period of time during which Curetis could mar-\nket a product under patent protection could be reduced. Various extensions may be available; however, the life of\na patent, and the protection it affords is limited and usually a patent expires 20 years after the respective filing.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.6802052159042326, "height": 0.04104318084651559, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-7", "text": "The laws of countries outside the EU or the US do not always protect intellectual property rights to the same\nextent and many companies have encountered significant problems in protecting and defending such rights in\nforeign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not\nsupport or provide legal measures for the enforcement of patents and other intellectual property protection, par-\nticularly those relating to technologies relating to biotechnology, which could make it difficult for Curetis to stop\nan infringement of its patents. Proceedings to enforce Curetis' patent rights in foreign jurisdictions could result in\nsubstantial cost. Also, because Curetis has not pursued patents in all countries, there exist jurisdictions where\nCuretis is not protected against third parties using its proprietary technologies.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7969217614365113, "height": 0.10987601539119274, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-8", "text": "Curetis depends on certain technologies that are licensed to it. Curetis does not control the intellectual prop\nerty rights covering these technologies and any loss of its rights to these technologies or the rights licensed to\nit could prevent Curetis from selling its products.\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8724304715840387, "lower_right_y": 0.847798204360838, "height": 0.037622915775972654, "width": 0.7569528415961306}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis depends on certain technologies that are licensed to it. Curetis does not control the intellectual prop-erty rights covering these technologies and any loss of its rights to these technologies or the rights licensed toit could prevent Curetis from selling its products."]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-9", "text": "Curetis is party to a number of strategic supply agreements, including with Acumen as licensor for the sepsis\nhost response Application Cartridges, (for others see also \"Business \u2013 Material Contracts\") under which Curetis\nis, inter alia, granted rights to intellectual property that is important to Curetis' business. Curetis expects that it\nmay need to enter into additional license agreements in the future. Curetis relies on these licenses to be able to\nuse various proprietary technologies that are material to its business. Curetis also relies on non-exclusive licenses\n", "page_number": 67, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8580589995724669, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-67-10", "text": "64\n", "page_number": 67, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-0", "text": "from other third parties related to materials used in Curetis' research and development activities. Curetis' rights to\nuse these technologies and employ the inventions claimed in the licensed patents are subject to the continuation\nof and Curetis' compliance with the terms of those licenses.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-1", "text": "As Curetis has done previously, it may need to obtain licenses from third parties to advance its research or allow\ncommercialisation of its products and technologies. Curetis cannot provide any assurances that third party pa-\ntents do not exist which might be enforced against Curetis' current or future products and technologies in the\nabsence of such a license. Curetis may fail to obtain any of these licenses on commercially reasonable terms, if at\nall. In that event, Curetis may be required to expend significant time and resources to develop or license re-\nplacement technology. If Curetis is unable to do so, it may be unable to develop or commercialise the affected\nproducts and technologies, which could materially harm Curetis' business and the third parties owning such intel-\nlectual property rights could seek either an injunction prohibiting Curetis' sales or an obligation on Curetis' part\nto pay royalties or other forms of compensation. Even if Curetis is able to obtain a license, it may be non-\nexclusive, thereby giving Curetis' competitors access to the same technologies licensed to it. In addition, in some\ncases, Curetis does not control the prosecution, maintenance, or filing of the patents that are licensed to it, or the\nenforcement of these patents against infringement by third parties.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2967079948696024, "height": 0.16374519025224457, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-2", "text": "Licensing of intellectual property is of critical importance to Curetis' business and involves complex legal, busi-\nness and scientific issues. Disputes may arise between Curetis and its licensors regarding intellectual property\nsubject to a license agreement.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3450192389910218, "height": 0.04104318084651565, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-3", "text": "If disputes over intellectual property that Curetis has licensed prevent or impair its ability to maintain Curetis'\ncurrent licensing arrangements on acceptable terms, Curetis may be unable to successfully develop and commer-\ncialise the affected products and technologies.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39290294997862335, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-4", "text": "Curetis may be involved in lawsuits to protect or enforce its patents and proprietary rights, to determine the\nscope, enforceability and validity of others' proprietary rights, or to defend against third-party claims of intel-\nlectual property infringement, any of which could be time-intensive and costly and may adversely impact Cu-\nretis' business or price of Shares.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.45788798631893973, "height": 0.05130397605814452, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis may be involved in lawsuits to protect or enforce its patents and proprietary rights, to determine thescope, enforceability and validity of others' proprietary rights, or to defend against third-party claims of intel-lectual property infringement, any of which could be time-intensive and costly and may adversely impact Cu-retis' business or price of Shares."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-5", "text": "Curetis' commercial success depends on its ability to develop, manufacture and commercialise its Unyvero Plat-\nform without infringing the patents and other intellectual property rights of third parties. While Curetis has not\nreceived notices of claims of infringement or misappropriation or misuse of other parties' proprietary rights in\nthe past, it may receive such notices in the future. Some of these claims may lead to litigation. Third parties may\nassert that Curetis is employing their proprietary technology without authorisation. For instance, Curetis may be\nsubject to claims that former employees, collaborators or other third parties have an ownership interest in Cu-\nretis' patents or other intellectual property. Litigation may be necessary to defend against these and other claims\nchallenging inventorship or ownership. Because patent applications can take many years to issue, third parties\nmay have currently pending patent applications which may later result in issued patents that Curetis' products\nmay infringe, or which such third parties claim are infringed by the use of Curetis' technologies. It is not sure if\nCuretis will prevail in such actions, or that other actions alleging misappropriation or misuse by Curetis of third-\nparty trade secrets or infringement by Curetis of third-party patents, trademarks or other rights, or challenging\nthe validity of Curetis' patents, trademarks or other rights, will not be asserted against Curetis.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6464300983326208, "height": 0.17828131680205217, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-6", "text": "Litigation may be necessary for Curetis to enforce its patent and proprietary rights or to determine the scope,\nenforceability or validity of the proprietary rights of others. In the event that third parties accuse Curetis of in-\nfringing their patents, Curetis could incur substantial costs and consume substantial resources in defending\nagainst these claims. If such claims prove to be valid, this could lead to significant damages, royalty payments or\nan injunction preventing the sale of certain of Curetis' products, which could have a materially adverse effect on\nCuretis' business, financial position and results of operations. In addition, Curetis may lose valuable intellectual\nproperty rights.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7490380504489098, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-7", "text": "The outcome of any litigation or other proceeding is inherently uncertain and might not be favourable to Curetis.\nIn the event of a successful claim of infringement against Curetis, it could be required to redesign its infringing\nproducts or obtain a license from such third-party to continue developing and commercialising Curetis' products\nand technology (see \"\u2013 Curetis depends on certain technologies that are licensed to it. Curetis does not control\nthe intellectual property rights covering these technologies and any loss of its rights to these technologies or the\nrights licensed to it could prevent Curetis from selling its products.\"). Further, if the scope of protection provided\nby Curetis' patents or patent applications is threatened or reduced as a result of litigation, it could discourage\nthird parties from entering into collaborations with Curetis that are important to the commercialisation of its\nproducts.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8790081231295426, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-8", "text": "Curetis may not have identified all relevant third-party intellectual property rights that may be infringed by Cu-\nretis' technology, nor can there be any assurance that patents will not issue in the future from currently pending\napplications that may be infringed by Curetis' technology or products.\n", "page_number": 68, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8854211201368106, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-68-9", "text": "65\n", "page_number": 68, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-0", "text": "Curetis relies on trade secret protection, confidentiality agreements and invention and patent assignment\nagreements.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.1115861479264643, "height": 0.026507054296707994, "width": 0.7678355501813785}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Curetis relies on trade secret protection, confidentiality agreements and invention and patent assignmentagreements."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-1", "text": "Curetis relies on trade secret protection and confidentiality agreements with Curetis' employees, consultants,\ncorporate partners, advisors and other third parties to protect proprietary know-how, information or technology\nthat is not patentable or that it elects not to patent, in order to maintain its competitive position. Curetis also\nenters into confidentiality and invention or patent assignment agreements with its employees and consultants that\nobligate them to assign to Curetis any inventions developed in the course of their work.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.06840530141085933, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-2", "text": "Curetis' agreements may not be enforceable or may not provide meaningful protection for Curetis' trade secrets\nor other proprietary information in the event of unauthorised use or disclosure or other breaches of the agree-\nments, and Curetis may not be able to prevent such unauthorised disclosure. Monitoring unauthorised disclosure\nis difficult, and Curetis may not have taken sufficient and adequate measures to prevent such disclosure. In addi-\ntion, Curetis' trade secrets may otherwise become known or be independently discovered by competitors, or\ncompetitors could patent proprietary know-how for which Curetis only relies on trade secret protection. If Cu-\nretis was to enforce a claim that a third party had illegally obtained and was using its trade secrets, it would be\nexpensive and time consuming, and the outcome would be unpredictable. If any of the technology or information\nthat Curetis protects as trade secrets were to be lawfully obtained or independently developed by a competitor,\nCuretis would have no right to prevent them from using that technology or information to compete with it. Mis-\nappropriation or unauthorised disclosure of Curetis' trade secrets could impair Curetis' competitive position and\nmay have a material adverse effect on its business, financial position, cash flows and results of operations.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35613510047028646, "height": 0.1616075245831552, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-3", "text": "operations.", "page_number": 69, "bounding_box": {"top_left_x": 0.7581620314389359, "top_left_y": 0.3471569046601112, "lower_right_x": 0.8319226118500604, "lower_right_y": 0.35741769987174005, "height": 0.01026079521162887, "width": 0.07376058041112454}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-4", "text": "may have a material adverse effect on its business, financial position, cash flows and results of operations.\nIn addition, Curetis may not have entered into, and may not in the future enter into, invention or patent assign-\nment agreements with all relevant employees, consultants or other third parties, and any such agreements which\nare entered into may not be enforceable. Curetis may be subject to claims that former employees, consultants or\nother third parties have an ownership interest in Curetis\u2019 patents or other intellectual property. Litigation may be\nnecessary to defend against these and other claims challenging inventorship or ownership, and Curetis could\nincur substantial costs and consume substantial resources in defending these claims. If Curetis fails in defending\nany such claims, it may, in addition to paying monetary damages, lose valuable intellectual property rights, or\nthe exclusive ownership of, or right to use, such intellectual property. This could impair Curetis' competitive\nposition and may have a material adverse effect on its business, financial position, cash flows and results of\noperations.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35656263360410434, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5023514322359983, "height": 0.14578879863189398, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-5", "text": "Curetis may be subject to damages resulting from claims that Curetis or its employees, consultants or inde-\npendent contractors have wrongfully used or disclosed confidential information of third parties or that Cu-\nretis' employees have wrongfully used or disclosed alleged trade secrets of their former employers.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5540829414279607, "height": 0.03805044890979048, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Curetis may be subject to damages resulting from claims that Curetis or its employees, consultants or inde-pendent contractors have wrongfully used or disclosed confidential information of third parties or that Cu-retis' employees have wrongfully used or disclosed alleged trade secrets of their former employers."]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-6", "text": "Many of Curetis' employees were previously employed at universities or other medical device companies, in-\ncluding Curetis' competitors or potential competitors. The agreements Curetis enters into with its employees,\ncollaborators and other third parties to protect its ownership of intellectual property rights may not be sufficient.\nIn addition, Curetis may be subject to claims that these employees or Curetis has inadvertently or otherwise used\nor disclosed trade secrets or other proprietary information of its employees' former employers, or may be subject\nto ownership disputes in the future arising, which could impair Curetis' competitive position and may have a\nmaterial adverse effect on its business, financial position, cash flows and results of operations.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-7", "text": "If Curetis' trademarks and trade names are not adequately protected, Curetis may not be able to build name\nrecognition in its markets of interest, and Curetis' business may be adversely affected.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7011543394613082, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If Curetis' trademarks and trade names are not adequately protected, Curetis may not be able to build namerecognition in its markets of interest, and Curetis' business may be adversely affected."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-8", "text": "Curetis has not yet registered certain of its trademarks, including Curetis and Unyvero, in all of its current mar-\nkets. If Curetis applies to register these trademarks, Curetis' applications may not be allowed for registration, and\nCuretis' registered trademarks may not be maintained or enforced. In addition, opposition or cancellation pro-\nceedings may be filed against Curetis' trademark applications and registrations, and Curetis' trademarks may not\nsurvive such proceedings. If Curetis does not secure registrations for its trademarks, Curetis may encounter more\ndifficulty in enforcing them against third parties than it otherwise would. The failure to protect its trademarks\ncould also impair Curetis' competitive position and may have a material adverse effect on its business, financial\nposition, cash flows and results of operations.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8174433518597691, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-9", "text": "Furthermore, Curetis' registered or unregistered trademarks or trade names may be challenged, infringed, cir-\ncumvented or declared generic or determined to be infringing on other marks. Curetis may not be able to protect\nits rights to the trademarks and/or trade names it needs to build name recognition by potential partners or cus-\ntomers in its future markets, such as the US and China. Over the long term, if Curetis is unable to establish name\nrecognition based on its trademarks and trade names, Curetis may not be able to compete effectively in the MDx\nmarket and its business, financial position, cash flows and results of operations may be adversely affected.\n", "page_number": 69, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9063702436938863, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-69-10", "text": "66\n", "page_number": 69, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-0", "text": "Risks Related to the Offer Shares and the Offering\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.10004275331338179, "height": 0.01496365968362548, "width": 0.44074969770253924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-1", "text": "There has been no public market for the Shares prior to the Offering and the Company cannot assure that an\nactive and liquid market in the Offer Shares will develop.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8772672309552599, "lower_right_y": 0.14194100042753313, "height": 0.026079521162890126, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["There has been no public market for the Shares prior to the Offering and the Company cannot assure that anactive and liquid market in the Offer Shares will develop."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-2", "text": "active and liquid market in the Offer Shares will develop.\nPrior to the Offering, there has not been a public market for the Shares. The Company intends to apply for\nadmission of the Shares to listing and trading on Euronext in Amsterdam and Euronext in Brussels. Curetis\ncannot predict the extent to which an active market for the Shares will develop or be sustained after the Offering,\nor how the development of such a market might affect the market price for the Offer Shares.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.142368533561351, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20478837109876016, "height": 0.06241983753740915, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-3", "text": "The Offer Price will be agreed between the Company and the Joint Bookrunners based on a number of factors,\nincluding market conditions in effect at the time of the Offering, and may not be indicative of the price at which\nthe Shares will trade following Settlement. The market price of the Shares could be subject to significant\nfluctuation. An illiquid market for the Shares may result in lower trading prices and increased volatility, which\ncould adversely affect the value of an investment in the Offer Shares, may cause the Offer Shares to trade at a\ndiscount to the Offer Price and may make it difficult for holders of Shares (the \"Shareholders\") to sell the\nShares at or above the price paid for them or at all.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3069687900812313, "height": 0.0953398888413852, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-4", "text": "The market price of the Shares may fluctuate significantly and investors could lose all or part of their invest-\nment.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.879081015719468, "lower_right_y": 0.3480119709277469, "height": 0.026934587430525847, "width": 0.7636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["The market price of the Shares may fluctuate significantly and investors could lose all or part of their invest-ment."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-5", "text": "The stock markets in general, and the markets for pharmaceutical and biotechnology shares in particular, have\nexperienced extreme volatility that has often been unrelated to the operating performance of particular\ncompanies. Any one of the following factors, among others, may cause a substantial decline in the markets in\nwhich Curetis operates: general economic conditions; geopolitical conditions, including war, acts of terrorism\nand other man-made or natural disasters; regulatory developments in the EU, the US and other jurisdictions;\nchanges in the structure of healthcare payment systems; publication of significant new scientific research;\nannouncements of technological innovations or new products by Curetis or its competitors; developments in\nregulatory clearance processes of Curetis or its competitors; publication of research reports about the\npharmaceutical or biotechnology industries by securities or industry analysts; changes in estimates by stock\nmarket analysts and other events and factors beyond Curetis' control. These factors, and the factors described\nelsewhere in this section, could significantly reduce the trading price of the Shares.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5061992304403591, "height": 0.1509191962377084, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-6", "text": "Upon completion of the Offering, certain existing Shareholders will retain substantial influence over the\nCompany, and their interests may be inconsistent with those of other Shareholders.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5194527575887131, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5472424112868748, "height": 0.027789653698161665, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Upon completion of the Offering, certain existing Shareholders will retain substantial influence over theCompany, and their interests may be inconsistent with those of other Shareholders."]}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-7", "text": "Immediately after Settlement, the existing Shareholders will hold approximately 79% of the Shares (assuming\nthe issue of the maximum number of the Offer Shares at the mid-point of the Offer Price Range and full exercise\nof the Over-allotment Option). As a result, the existing Shareholders will continue to be able to influence or\ncontrol matters requiring approval by the general meeting of the Company, being the corporate body, or where\nthe context so requires, the physical meeting of Shareholders (the \"General Meeting\") and may vote their\nShares in a way with which other Shareholders do not agree.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6361693031209918, "height": 0.08251389482684901, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-8", "text": "Therefore, as a result of their large shareholdings, the existing Shareholders will be able to exert significant in-\nfluence on the General Meeting, and, consequently, on matters decided by the General Meeting, including but\nnot limited to the appointment and dismissal of members of the Company management board (the \"Manage-\nment Board\", each member a \"Managing Director\") or the Company's supervisory board the \"Supervisory\nBoard\", each member a \"Supervisory Director\"), the distribution of dividends, the amendment of the Compa-\nny's articles of association as they will read immediately after the conversion of the Company into a public com-\npany with limited liability (naamloze vennootschap) (the \"Conversion\") (the \"Articles of Association\"), any\nproposed capital increase or the approval of significant transactions. These Shareholders' interest would enable\nthem to block certain corporate measures that require the approval of the General Meeting. Furthermore, this\nconcentration of ownership could adversely affect the trading volume and market price of the Shares and there is\nno indication as to whether or not, when or to what extent these Shareholders will sell any of their Shares. If\nthese Shareholders were to participate in the Offering, their influence may be further strengthened to the extent\nthat they acquire additional Shares. In addition, all shareholder agreements, except for aeris CAPITAL Equity\nInvestments, L.P. and KfW which will continue to pool their voting rights, will end upon the completion of the\nOffering. As many of the existing Shareholders are private equity or venture capital investors it is possible that\nthose investors might want to reduce their stake in Curetis upon expiry of the lock-up period or in case this peri-\nod might be waived in certain cases.\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8751603249251817, "height": 0.2325780247969218, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-9", "text": "In any of the above instances, the interests of such Shareholders could deviate from the interests of the other\nShareholders and the existing Shareholders may delay, postpone or prevent transactions that might be advanta-\n", "page_number": 70, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8820008550662677, "lower_right_x": 0.879081015719468, "lower_right_y": 0.9097905087644292, "height": 0.027789653698161554, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-70-10", "text": "67\n", "page_number": 70, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-0", "text": "geous for investors. Furthermore the concentration of ownership could adversely affect the trading volume and\nmarket price of the Shares.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-1", "text": "Retail investors may have to pay a higher price for the Offer Shares than was envisaged at the time of sub-\nscribing\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.15305686190679776, "height": 0.026934587430525847, "width": 0.7666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Retail investors may have to pay a higher price for the Offer Shares than was envisaged at the time of sub-scribing"]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-2", "text": "Eligible retail investors in Germany are not required to subscribe on a market order (billigst) basis and may\ntherefore submit orders providing for a price limit. If they subscribe on a market order (billigst) basis, eligible\nretail investors that subscribe for the Offer Shares in the Offering, shall, if they subscribe on such basis, be\nobliged to purchase and pay for the number of Offer Shares in their share application, to the extent allocated to\nthem, at the Offer Price, even if the Offer Price is above the upper end of the Offer Price Range. This means such\nretail investors run the risk of paying a higher price for the Offer Shares than was envisaged at the time of sub-\nscribing. Retail investors are entitled to cancel or amend their application, at the financial intermediary where\ntheir original application was submitted, at any time prior to the end of the Offering Period (if applicable, as\naccelerated or extended), in the event that the Offer Price Range is increased above the upper end of the original\nOffer Price Range.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2975630611372381, "height": 0.13723813595553655, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-3", "text": "The Company has broad discretion in the use of the net proceeds from this offering and may not use them\neffectively.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8681983071342201, "lower_right_y": 0.33646857631466437, "height": 0.02565198802907226, "width": 0.752720677146312}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["The Company has broad discretion in the use of the net proceeds from this offering and may not use themeffectively."]}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-4", "text": "The Company's management will have broad discretion in the application of the net proceeds from the Offering\nand could spend the proceeds in ways that do not improve the Company's results of operations or enhance the\nvalue of the Shares. The Company intends to use the net proceeds from the Offering, inter alia, to start building\nits commercial organisation and launch its products in the US and to strengthen and expand its commercial or-\nganisation in the EU, as well as to accelerate the R&D pipeline of new tests. However, the Company's actual use\nof these proceeds may differ substantially from the Company's current plans and investors will not have the\nopportunity as part of their investment decision to assess whether the net proceeds are being used appropriately.\nThe failure by the Company's management to apply these funds effectively could result in financial losses that\ncould have a material adverse effect on Curetis' business and cause the market price of the Shares to decline.\nPending their use, the Company may invest the net proceeds from the Offering in a manner that does not produce\nincome or that loses value.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49294570329200516, "height": 0.14792646430098333, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-5", "text": "The Company will incur increased costs as a result of being a public company\n", "page_number": 71, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5091919623770842, "lower_right_x": 0.654776299879081, "lower_right_y": 0.5215904232578025, "height": 0.012398460880718276, "width": 0.5380894800483677}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["The Company will incur increased costs as a result of being a public company."]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-6", "text": "As a public company, the Company will incur a higher level of legal, accounting, financial compliance, reporting\nand other expenses than it did as a privately owned company as compliance with rules and regulations applicable\nto listed companies will require additional resources and make some activities more time-consuming than they\nhave been in the past. In addition, these rules and regulations could make it more difficult for the Company to\nattract and retain qualified persons to serve on the Management Board and Supervisory Board and may divert its\nmanagement's attention.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6122274476271911, "height": 0.08251389482684901, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-7", "text": "Future issuances or sales of substantial numbers of Shares or securities convertible into Shares, as part of a\nstock option programme used as a success based management and senior employee remuneration component\nor otherwise, or the perception that these issuances or sales may occur, may adversely affect the market price\nof the Shares and any future issuance of Shares may dilute investors' shareholdings. Although the Company,\nall existing Shareholders, all former and current employees of Curetis holding Shares and the Managing\nDirectors are expected to agree in the Underwriting Agreement and separate lock-up agreements, respectively,\nto certain restrictions on issuing, selling or transferring Shares for a period of 365 days after the Settlement\nDate, the Joint Bookrunners may, in their sole discretion and at any time, waive such restrictions.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.735356990166738, "height": 0.10645575032064991, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Future issuances or sales of substantial numbers of Shares or securities convertible into Shares, as part of astock option programme used as a success based management and senior employee remuneration componentor otherwise, or the perception that these issuances or sales may occur, may adversely affect the market priceof the Shares and any future issuance of Shares may dilute investors' shareholdings. Although the Company,all existing Shareholders, all former and current employees of Curetis holding Shares and the ManagingDirectors are expected to agree in the Underwriting Agreement and separate lock-up agreements, respectively,to certain restrictions on issuing, selling or transferring Shares for a period of 365 days after the SettlementDate, the Joint Bookrunners may, in their sole discretion and at any time, waive such restrictions."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-8", "text": "The General Meeting shall designate the Management Board, for a period that ends 18 months following the\nConversion, as the corporate body designated to, subject to approval of the Supervisory Board, issue Shares or\ngrant rights to subscribe for Shares and to restrict or exclude statutory pre-emptive rights in relation to the issue\nof Shares or the granting of rights to subscribe for Shares. Pursuant to this designation, the Management Board\nmay, subject to approval of the Supervisory Board, resolve to issue Shares or grant rights to subscribe for Shares\n(i) up to a maximum of 10% of the total number of Shares issued and outstanding on the Settlement Date (as\ndefined below) plus (ii) an additional 10% of the total number of Shares issued and outstanding on the Settle-\nment Date in connection with or on the occasion of mergers and acquisitions and strategic alliances. Such au-\nthorisation may from time to time be extended by a resolution of the General Meeting, subject to the limitations\nset out above.\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8781530568619068, "height": 0.13296280461735788, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-9", "text": "As part of the Reorganisation (as defined in \"Major Shareholders and Related Party Transactions \u2013 Corporate\nReorganisation\"), Curetis will restructure its phantom stock option plan. Under this plan, Curetis AG has award-\ned phantom stock options to officers, employees, freelancers and advisors which entitle them to a payment 365\n", "page_number": 71, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8888413852073536, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9286019666524156, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-71-10", "text": "68\n", "page_number": 71, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018742442563482453}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-0", "text": "days after the Settlement Date. Upon restructuring, the amount of this payment claim is determined based on the\nOffer Price for phantom stock options settled in Shares and on the first stock exchange trading price of the\nShares for phantom stock options settled in cash. Each PSOP Beneficiary (as defined herein) entitled to 1,000 or\nless phantom stock options will receive a payment in cash 365 days after the Settlement Date. Assuming an\nOffer Price at the upper end of the Offer Price Range and a first stock exchange trading price equal to such Offer\nPrice, the aggregate cash payment would amount to \u20ac469 thousand. Each PSOP Beneficiary entitled to more\nthan 1,000 phantom stock options will receive newly issued Shares for the amount that becomes payable to it\n365 days after the Settlement Date. Assuming an Offer Price at the upper end of the Offer Price Range, the ag-\ngregate number of new Shares to be issued would be 665,020. Assuming that (i) the Offer Price will be set at the\nupper end of the Offer Price Range, (ii) the maximum number of Offer Shares will be issued and (iii) the Over-\nallotment Option will not be exercised, the then existing Shareholders would experience a dilution of 4.3%.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.23514322359982898, "height": 0.15006412997007268, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-1", "text": "Curetis may in the future seek to raise capital through public or private debt or equity financings by issuing addi-\ntional Shares, debt or equity securities convertible into Shares or rights to acquire these securities and exclude\nthe pre-emptive rights pertaining to the then outstanding Shares. In addition, Curetis may in the future seek to\nissue additional Shares as consideration for or otherwise in connection with the acquisition of new businesses.\nFurthermore, Curetis may issue new Shares in the context of any new employment arrangement for involving\nemployees in the capital of the Company. The issuance of any additional Shares may dilute an investor's share-\nholding interest in the Company. Furthermore, any additional debt or equity financing Curetis may need may not\nbe available on terms favourable to Curetis or at all, which could adversely affect Curetis' future plans and the\nmarket price of the Shares. Any additional offering or issuance of Shares by the Company or the perception that\nan offering or issuance may occur could also have a negative impact on the market price of the Shares and could\nincrease the volatility in the trading price of the Shares.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39247541684480547, "height": 0.1569046601111586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-2", "text": "The market price of the Shares could decline if a substantial number of Shares is issued by the Company or sold\nby existing Shareholders in the public market or if there is a perception that such issues or sales could occur.\nFurthermore, a sale of Shares by any or all of the Managing Directors could be considered as a lack of confi-\ndence in the performance and prospects of Curetis and could cause the market price of the Shares to decline.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.45404018811457886, "height": 0.054296707994869575, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-3", "text": "The Company is expected to agree with the Underwriters, pursuant to an underwriting agreement expected to be\ndated on or about 10 November 2015 among the Company and the Underwriters (the \"Underwriting Agree-\nment\"), to restrictions on, inter alia, its ability to issue, sell or transfer Shares for a period of 365 days after the\nSettlement Date. All existing Shareholders, all former and current employees of Curetis holding Shares and the\nManaging Directors have agreed with the Sole Global Coordinator (on behalf of the Underwriters), pursuant to\nseveral lock-up agreements dated 26 October 2015, to restrictions on their ability to, inter alia, sell and transfer\nShares for a period of 365 days after the Settlement Date. The Joint Bookrunners may in their sole discretion and\nat any time, waive certain of such restrictions on issuances, sales or transfers. See \"Plan of Distribution \u2013 Lock-\nup Arrangements\".\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5840102607952117, "height": 0.122702009405729, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-4", "text": "Holders of Shares who are resident or located in certain jurisdictions outside the Netherlands, including the\nUS, may be unable to exercise pre-emptive rights in future offerings and, as a result, may experience dilution.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6259085079093629, "height": 0.027789653698161554, "width": 0.7654171704957677}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["Holders of Shares who are resident or located in certain jurisdictions outside the Netherlands, including theUS, may be unable to exercise pre-emptive rights in future offerings and, as a result, may experience dilution."]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-5", "text": "In the event of an increase in the Company's share capital, Shareholders are generally entitled to pre-emptive\nrights, unless these rights are restricted or excluded either by a resolution of the General Meeting or of the\nManagement Board, with the approval of the Supervisory Board (if the Management Board has been designated\nby the General Meeting).\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6874732791791364, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-6", "text": "However, the securities laws of certain jurisdictions may restrict the Company's ability to allow Shareholders to\nparticipate in offerings of the Company's securities and to exercise pre-emptive rights. Accordingly, subject to\ncertain exceptions, Shareholders with registered addresses, or who are resident or located in certain jurisdictions\noutside the Netherlands, including the US, will not be eligible to exercise pre-emptive rights. As a result, such\nShareholders may experience dilution of their ownership and voting interests in the Company's share capital.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7627191107310817, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-7", "text": "If Settlement does not occur, subscriptions for the Offer Shares may be disregarded and transactions effected\nin the Shares will be annulled.\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8037622915775973, "height": 0.027789653698161554, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If Settlement does not occur, subscriptions for the Offer Shares may be disregarded and transactions effectedin the Shares will be annulled."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-8", "text": "Application has been made for admission of the Shares to listing and trading on Euronext in Amsterdam and\nEuronext in Brussels under the symbol \"CURE\". Curetis expects that the Shares will first be admitted to listing\nand that trading in the Shares will commence on the First Trading Date on an \"as-if-and-when-issued\" basis. The\nSettlement Date, on which Settlement is scheduled to take place, is expected to be on or about 13 November\n2015, the first business day following the First Trading Date. Settlement may not take place on the Settlement\nDate or at all if certain conditions or events referred to in the Underwriting Agreement are not satisfied or\nwaived or occur on or prior to such date (see \"Plan of Distribution\"). Trading in the Shares before Settlement\nwill take place subject to the condition that, if the Offering does not take place, the Offering will be withdrawn,\n", "page_number": 72, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9200513039760582, "height": 0.10987601539119285, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-72-9", "text": "69\n", "page_number": 72, "bounding_box": {"top_left_x": 0.8325272067714631, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.01813784764207982}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-0", "text": "all subscriptions for the Offer Shares will be disregarded, any allotments made will be deemed not to have been\nmade, any subscription payments made will be returned without interest or other compensation and transactions\non Euronext in Amsterdam and Euronext in Brussels will be annulled. All dealings in the Shares prior to\nSettlement are at the sole risk of the parties concerned. The Company, the Underwriters, the Listing and Paying\nAgent and Euronext do not accept any responsibility or liability for any loss incurred by any person as a result of\na withdrawal of the Offering or the related annulment of any transactions on Euronext in Amsterdam and\nEuronext in Brussels.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1778537836682343, "height": 0.09277469003847798, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-1", "text": "The Company does not intend to pay dividends for the foreseeable future\n", "page_number": 73, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.19452757588713127, "lower_right_x": 0.6178960096735188, "lower_right_y": 0.20521590423257802, "height": 0.010688328345446751, "width": 0.49879081015719473}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["The Company does not intend to pay dividends for the foreseeable future."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-2", "text": "The Company does not intend to pay any dividends for the foreseeable future. Payment of future dividends to\nShareholders will effectively be at the discretion of the Management Board, subject to the approval of the\nSupervisory Board after taking into account various factors including Curetis' business prospects, cash\nrequirements, financial performance and new product development. In addition, the Company is a holding\ncompany with no material, direct business operations. Its principal asset is its direct ownership of Curetis AG.\nAs a result, the Company is dependent on loans, dividends and other payments from Curetis AG to generate the\nfunds necessary to meet its financial obligations, including the payment of dividends. Accordingly, investors\ncannot rely on dividend income from the Shares and any returns on an investment in the Shares will likely\ndepend entirely upon any future appreciation in the price of the Shares. The Company can provide no assurance\nthat the price of the Shares will appreciate after the Offering or that the market price for the Shares will not fall\nbelow the Offer Price.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3625480974775545, "height": 0.14749893116716545, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-3", "text": "Investors with a reference currency other than euro will become subject to foreign exchange rate risk when\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8766626360338573, "lower_right_y": 0.4023086789226165, "height": 0.023086789226165028, "width": 0.7611850060459492}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Investors with a reference currency other than euro will become subject to foreign exchange rate risk wheninvesting in the Shares."]}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-4", "text": "The Shares are, and any dividends to be announced in respect of the Shares, will be, denominated in euro. An\ninvestment in the Shares by an investor whose principal currency is not the euro exposes the investor to currency\nexchange rate risk that may impact the value of the investment in the Shares or any dividends.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4548952543822146, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-5", "text": "If securities or industry analysts do not publish research or publish inaccurate or unfavourable research\nabout Curetis' business, or publish projections that exceed Curetis' actual results, the price of Shares and\ntrading volume could decline.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5096194955109021, "height": 0.04147071398033353, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["If securities or industry analysts do not publish research or publish inaccurate or unfavourable researchabout Curetis' business, or publish projections that exceed Curetis' actual results, the price of Shares andtrading volume could decline."]}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-6", "text": "The trading market for the Shares may be affected by the research and reports that securities or industry analysts\npublish about the Company or Curetis' business. If no or few securities or industry analysts commence and main-\ntain adequate research coverage of Curetis, or if one or more of the analysts who covers the Company down-\ngrades the Shares or publishes inaccurate or unfavourable research about Curetis' business, the trading price for\nthe Shares could be negatively impacted. In addition, the analysts' projections may have little or no relationship\nto the results Curetis actually achieves and could cause the price of the Shares to decline if Curetis fails to meet\nthe analysts' projections. If one or more analysts ceases coverage of Curetis or fails to publish reports on Curetis\nregularly, the Company could lose visibility in the financial markets, which in turn could cause the Company's\nmarket price or trading volume of the Shares to decline.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6395895681915349, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-7", "text": "The ability of Shareholders to bring action or enforce judgments against the Company, Managing Directors\nand Supervisory Directors may be limited.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6545532278751603, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.6836254809747755, "height": 0.029072253099615142, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["The ability of Shareholders to bring action or enforce judgments against the Company, Managing Directorsand Supervisory Directors may be limited."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-8", "text": "The ability of Shareholders to bring an action against the Company may be limited under law. Following the\nConversion, the Company will be a public company with limited liability (naamloze vennootschap) incorporated\nunder the laws of the Netherlands. The rights of Shareholders are governed by Dutch law and the Articles of\nAssociation. These rights differ from the rights of Shareholders in typical US corporations and other non-Dutch\ncorporations. It may be difficult for a Shareholder to prevail in a claim against the Company or to enforce\nliabilities predicated upon non-Dutch laws.\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7712697734074391, "height": 0.0808037622915776, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-9", "text": "A Shareholder may not be able to enforce a judgment against the Managing Directors or Supervisory Directors.\nThe Managing Directors and some of the Supervisory Directors are residents of Germany. Consequently, it may\nnot be possible for a Shareholder to effect service of process upon the Managing Directors or the Supervisory\nDirectors within such Shareholder's country of residence, or to enforce against the Managing Directors or the\nSupervisory Directors judgments of courts of such Shareholder's country of residence based on civil liabilities\nunder that country's securities laws. There can be no assurance that a Shareholder will be able to enforce any\njudgment in civil and commercial matters or any judgments against the Managing Directors or the Supervisory\nDirectors who are residents of countries other than those in which the judgment is made\n", "page_number": 73, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7716973065412569, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.887131252672082, "height": 0.11543394613082514, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-73-10", "text": "70\n", "page_number": 73, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-0", "text": "Any sale, purchase or exchange of Shares may become subject to the Financial Transaction Tax.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.7932285368802902, "lower_right_y": 0.09790508764429243, "height": 0.012825994014536116, "width": 0.677750906892382}, "blob_type": "headline", "predictions": {}, "annotations": {"risk_factor": ["Any sale, purchase or exchange of Shares may become subject to the Financial Transaction Tax."]}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-1", "text": "On 14 February 2013, the European Commission adopted a proposal for a Council Directive (the \"Draft\nDirective\") on a common financial transaction tax (the \"Financial Transaction Tax\"). The intention is for the\nFinancial Transaction Tax to be implemented via an enhanced cooperation procedure in eleven member states of\nthe EU (Austria, Belgium, Estonia, France, Germany, Greece, Italy, Portugal, Spain, Slovakia and Slovenia,\ntogether, the \"Participating Member States\").\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.17443351859769132, "height": 0.06883283454467722, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-2", "text": "Pursuant to the Draft Directive, the Financial Transaction Tax will be payable on financial transactions provided\nat least one party to the financial transaction is established or deemed established in a Participating Member\nState and there is a financial institution established or deemed established in a Participating Member State which\nis a party to the financial transaction, or is acting in the name of a party to the transaction. The Financial\nTransaction Tax shall, however, not apply to (inter alia) primary market transactions referred to in Article 5(c)\nof Regulation (EC) No 1287/2006, including the activity of underwriting and subsequent allocation of financial\ninstruments in the framework of their issue.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2736212056434374, "height": 0.09277469003847802, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-3", "text": "The rates of the Financial Transaction Tax shall be fixed by each Participating Member State but for transactions\ninvolving financial instruments other than derivatives shall amount to at least 0.1% of the taxable amount. The\ntaxable amount for such transactions shall in general be determined by reference to the consideration paid or\nowed in return for the transfer. The Financial Transaction Tax shall be payable by each financial institution\nestablished or deemed established in a Participating Member State which is either a party to the financial\ntransaction, or acting in the name of a party to the transaction or where the transaction has been carried out on its\naccount. Where the Financial Transaction Tax due has not been paid within the applicable time limits, each party\nto a financial transaction, including persons other than financial institutions, shall become jointly and severally\nliable for the payment of the Financial Transaction Tax due.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4065840102607952, "height": 0.12312954253954683, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-4", "text": "Investors should therefore note, in particular, that any sale, purchase or exchange of Shares will be subject to the\nFinancial Transaction Tax at a minimum rate of 0.1% provided the abovementioned prerequisites are met. The\ninvestor may be liable to pay this charge or reimburse a financial institution for the charge, or the charge may\naffect the value of the Shares. The issuance of new Shares should not be subject to the Financial Transaction\nTax.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47840957674219753, "height": 0.06498503634031638, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-5", "text": "The Draft Directive is still subject to negotiation among the Participating Member States and therefore may be\nchanged at any time. A committee of the EU Parliament published a draft report on 19 March 2013, suggesting\namendments to the Draft Directive. If the amendments were included in the eventual Directive, the Financial\nTransaction Tax would have an even broader reach. Moreover, once the Draft Directive has been adopted (the\nDirective), it will need to be implemented into the respective domestic laws of the Participating Member States\nand the domestic provisions implementing the Directive might deviate from the Directive itself.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5711842667806755, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-6", "text": "Investors should consult their own tax advisors in relation to the consequences of the Financial Transaction Tax\nassociated with subscribing for, purchasing, holding and disposal of the Shares.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6053869174861052, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-7", "text": "The Company may be classified as a passive foreign investment company for US federal income tax purposes\nwhich could subject US investors in the Shares to significant adverse tax consequences.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8694074969770254, "lower_right_y": 0.6464300983326208, "height": 0.027789653698161554, "width": 0.7539298669891172}, "blob_type": "paragraph", "predictions": {}, "annotations": {"risk_factor": ["The Company may be classified as a passive foreign investment company for US federal income tax purposes,which could subject US investors in the Shares to significant adverse tax consequences."]}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-8", "text": "Curetis may be classified as passive foreign investment company (\"PFIC\") for US federal income tax purposes\nfor the current or any future taxable year.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6806327490380505, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-9", "text": "PFIC status is a factual determination made for each taxable year on the basis of the composition of Curetis'\nincome and its assets for such year. Based on certain estimates of Curetis' gross income and gross assets, as well\nas the nature of its business, Curetis does not believe that it was a PFIC for US federal income tax purposes for\nits most recent taxable year and does not expect that it will be a PFIC for its current taxable year or in the\nforeseeable future. However, there can be no assurance that Curetis will not be considered a PFIC for any future\ntaxable year.\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7695596408721675, "height": 0.08251389482684901, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-10", "text": "If Curetis were to become classified as a PFIC for any taxable year during which a US investor held the Shares,\ncertain adverse US federal tax consequences could apply to such US investor. Prospective US investors are\nurged to review the discussion below under the section \"Taxation \u2013 US Federal Income Tax Considerations\".\n", "page_number": 74, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8174433518597691, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-74-11", "text": "71\n", "page_number": 74, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.016928657799274438}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-0", "text": "IMPORTANT INFORMATION\n", "page_number": 75, "bounding_box": {"top_left_x": 0.33313180169286577, "top_left_y": 0.09876015391192818, "lower_right_x": 0.662031438935913, "lower_right_y": 0.11628901239846089, "height": 0.01752885848653271, "width": 0.3288996372430472}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-1", "text": "General\n", "page_number": 75, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13296280461735785, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.1470713980333476, "height": 0.014108593415989745, "width": 0.07194679564691657}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-2", "text": "Prospective investors are expressly advised that an investment in the Offer Shares entails certain risks and that\nthey should therefore read and carefully review the content of this Prospectus. A prospective investor should not\ninvest in the Offer Shares unless it has the expertise (either alone or with a financial adviser) to evaluate how the\nOffer Shares will perform under changing conditions, the resulting effects on the value of the Shares and the\nimpact this investment will have on its overall investment portfolio. Prospective investors should also consult\ntheir own tax advisers as to the tax consequences of the purchase, ownership and disposition of the Offer Shares.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24497648567764002, "height": 0.08123129542539548, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-3", "text": "The content of this Prospectus is not to be considered or interpreted as legal, financial or tax advice. It is not\nintended to provide the basis of any credit or other evaluation and should not be considered as a recommendation\nby any of the Company, the members of the Management Board and the Supervisory Board or any of the\nUnderwriters or any of their respective representatives that any recipient of this Prospectus should subscribe for\nor purchase any Offer Shares. Prior to making any decision whether to purchase the Offer Shares, prospective\ninvestors should read this Prospectus. Investors should ensure that they read the whole of this Prospectus and not\njust rely on key information or information summarised within it. Each prospective investor should consult his or\nher own stockbroker, bank manager, lawyer, auditor or other financial, legal or tax advisers before making any\ninvestment decision with regard to the Offer Shares, to among other things consider such investment decision in\nlight of his or her personal circumstances and in order to determine whether or not such prospective investor is\neligible to subscribe for the Offer Shares. In making an investment decision, prospective investors must rely on\ntheir own examination of the Company, the Offer Shares and the terms of the Offering, including the merits and\nrisks involved.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2526720820863617, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4275331338178709, "height": 0.17486105173150918, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-4", "text": "Prospective investors should rely only on the information contained in this Prospectus, the Pricing Statement and\nany supplement to this Prospectus within the meaning of Section 5:23 of the Dutch Financial Supervision Act.\nThe Company does not undertake to update this Prospectus, unless required pursuant to Section 5:23 of the\nDutch Financial Supervision Act, and therefore potential investors should not assume that the information in this\nProspectus is accurate as of any date other than the date of this Prospectus. No person has been authorised to\ngive any information or to make any representations in connection with the Offering, other than those contained\nin this Prospectus, and, if given or made, such information or representations must not be relied upon as having\nbeen authorised by or on behalf of the Company, the members of the Management Board or the Supervisory\nBoard, the Listing and Paying Agent, any of the Underwriters or any of their respective representatives. The\ndelivery of this Prospectus at any time after the date hereof will not, under any circumstances, create any\nimplication that there has been no change in the Group's affairs since the date hereof or that the information set\nforth in this Prospectus is correct as of any time since its date.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6006840530141085, "height": 0.1633176571184266, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-5", "text": "No representation or warranty, express or implied, is made or given by or on behalf of any of the Underwriters,\nthe Listing and Paying Agent or any of their affiliates or any of their respective directors, officers or employees\nor any other person, as to the accuracy, completeness or fairness of the information or opinions contained in this\nProspectus, or incorporated by reference herein, and nothing contained in this Prospectus, or incorporated by\nreference herein, is, or shall be relied upon as, a promise or representation by the Underwriters, the Listing and\nPaying Agent or any of their respective affiliates as to the past, present or future. None of the Underwriters or the\nListing and Paying Agent accepts any responsibility whatsoever for the contents of this Prospectus or for any\nother statements made or purported to be made by either itself or on its behalf in connection with the Company,\nthe Group, the Offering, or the Offer Shares. Accordingly, the Underwriters and the Listing and Paying Agent\ndisclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract\nor which they might otherwise be found to have in respect of this Prospectus and/or any such statement.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.758016246259085, "height": 0.14963659683625474, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-6", "text": "Although the Underwriters are party to various agreements pertaining to the Offering and each of the\nUnderwriters has or might enter into a financing arrangement with the Company and/or any of its affiliates, this\nshould not be considered as a recommendation by any of them to invest in the Offer Shares.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8063274903805044, "height": 0.040615647712697656, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-7", "text": "The Listing and Paying Agent is acting exclusively for the Company and no one else in connection with the\nOffering. It will not regard any other person (whether or not a recipient of this Prospectus) as its respective\ncustomer in relation to the Offering and will not be responsible to anyone other than the Company for providing\nthe protections afforded to their respective customers or for giving advice in relation to, respectively, the\nOffering and the listing or any transaction or arrangement referred to herein.\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8815733219324497, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-8", "text": "The distribution of this Prospectus and the Offering may, in certain jurisdictions, be restricted by law, and this\nProspectus may not be used for the purpose of, or in connection with, any offer or solicitation by anyone in any\njurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make\n", "page_number": 75, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8888413852073536, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9294570329200513, "height": 0.04061564771269777, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-75-9", "text": "72\n", "page_number": 75, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-0", "text": "such offer or solicitation. This Prospectus does not constitute an offer of, or an invitation to, purchase any of the\nOffer Shares in any jurisdiction in which such offer or invitation would be unlawful. The Company and the\nUnderwriters require persons into whose possession this Prospectus comes to inform themselves of and observe\nall such restrictions. None of the Company or the Underwriters accepts any legal responsibility for any violation\nby any person, whether or not a prospective investor of Offer Shares, of any such restrictions. The Company and\nthe Underwriters reserve the right in their own absolute discretion to reject any offer to purchase Offer Shares\nthat the Company, the Underwriters or their respective agents believe may give rise to a breach or violation of\nany laws, rules or regulations.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19410004275331338, "height": 0.10902094912355707, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-1", "text": "Responsibility Statement\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.22488242838820008, "height": 0.01667379221889695, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-2", "text": "This Prospectus is made available by the Company. The Company accepts responsibility for the information\ncontained in this Prospectus. The Company declares that, having taken all reasonable care to ensure that, to the\nbest of its knowledge, the information contained in this Prospectus is in accordance with the facts and contains\nno omission likely to affect its import.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23899102180418982, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2937152629328773, "height": 0.054724241128687484, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-3", "text": "Presentation of Financial and Other Information\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30739632321504917, "lower_right_x": 0.5411124546553809, "lower_right_y": 0.3215049166310389, "height": 0.014108593415989745, "width": 0.4256348246674728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-4", "text": "Financial information\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.27388149939540507, "lower_right_y": 0.3522873022659256, "height": 0.01410859341598969, "width": 0.15840386940749696}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-5", "text": "The Company was incorporated on 8 October 2015 for the purpose of the Offering. Since its date of incorpora-\ntion, it has conducted no operations. There is no historical financial information relating to the Company for the\nsix months ended 30 June 2015 and 2014 and the years ended 31 December 2014, 2013 and 2012.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40017101325352716, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-6", "text": "If the Company had prepared consolidated condensed financial statements under International Financial Report-\ning Standards, as adopted in the European Union (\"IFRS\") as of and for the six months ended 30 June 2015 and\n2014 and consolidated financial statements under IFRS for the years ended 31 December 2014, 2013 and 2012\nand on the basis of the assumption that the Company had already existed and owned all shares in Curetis AG as\nfrom 1 January 2012, there would be no differences between such consolidated financial statements and the\nfinancial statements of Curetis AG prepared in accordance with IFRS in relation to the statement of comprehen-\nsive income or the cash flow statement for the six months ended 30 June 2015 and 2014 and for the years ended\n31 December 2014, 2013 and 2012. There would only be certain immaterial differences in relation to the state-\nment of financial position arising from the different nominal value of the shares of the Company and Curetis AG,\nwhich would result in a different allocation across the items comprising equity.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5438221462163317, "height": 0.13723813595553652, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-7", "text": "Due to the immaterial nature of the differences between the financial statements of the Company and Curetis\nAG, the Company is of the view that the financial statements of Curetis AG as of and for the periods included\nherein provide the information required to be presented herein in accordance with Item 20.1 of Annex I of\nCommission Regulation (EC) No 809/2004 and pursuant to the Financial Supervision Act, which is designed to\nensure that investors and potential investors in the Offer Shares are aware of all information that, according to\nthe particular nature of the Company and of the Offer Shares, is necessary to enable investors and potential in-\nvestors to make an informed assessment of the assets and liabilities, financial position, profit and losses and\nprospects of the Company and of the rights attaching to the Offer Shares.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5502351432235998, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-8", "text": "Curetis AG's financial statements under IFRS as of and for the financial years ended 31 December 2014, 2013\nand 2012 included in this Prospectus have been audited by PricewaterhouseCoopers Aktiengesellschaft\nWirtschaftspr\u00fcfungsgesellschaft (\"PwC\"), independent auditors, as stated in its independent auditor's report\nthereon which is also included in this Prospectus. Curetis AG's unaudited interim condensed financial statements\nas of 30 June 2015 and for the six months ended 30 June 2015 and 2014 prepared in accordance with IFRS\napplicable to interim financial reporting (\u201cIAS 34\u201d) (the \"Interim Financial Statements\") are unaudited and\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7490380504489098, "height": 0.08251389482684912, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"periods_of_unaudited_interim_fs": ["for the six months ended 30 June 2015 and 2014"], "unaudited_interim_financial_statements": ["Curetis AG's unaudited interim condensed financial statementsas of 30 June 2015 and for the six months ended 30 June 2015 and 2014"]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-9", "text": "applicable to interim fin\nhave not been reviewed.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7490380504489098, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.7610089781958101, "height": 0.01197092774690034, "width": 0.16384522370012095}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-10", "text": "Where financial data is labelled \"audited\", this means that it was taken from the audited financial statements of\nCuretis AG as of and for the years ended 31 December 2014, 2013 and 2012, prepared in accordance with IFRS,\n(the \"Annual Financial Statements\"). The label \"unaudited\" is used to indicate financial data that was taken\nfrom a source other than the Annual Financial Statements or recomputed from the Annual Financial Statements.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8238563488670372, "height": 0.054724241128687456, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-11", "text": "There are no qualifications in the auditor's report on the audited financial statements of Curetis AG for the finan-\ncial years ended 31 December 2014, 2013 and 2012. The auditor's report contains an emphasis of matter para-\ngraph, in which the auditors draw attention to note 2.1, 31 and 34 of the notes to the financial statements, which\ndescribe that the Company's ability to continue as a going concern is threatened by risks.\n", "page_number": 76, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8858486532706284, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-76-12", "text": "73\n", "page_number": 76, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-0", "text": "Rounding\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.18863361547763, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.0731559854897219}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-1", "text": "Certain figures contained in this Prospectus, including financial information, have been subject to rounding ad-\njustments. Accordingly, in certain instances (i) the sum or percentage change of such numbers may not conform\nexactly with the total figure given; (ii) the sum of the numbers in a column or a row in certain tables may not\nconform exactly with the total figure given for that column or row; and (iii) the corresponding percentage change\nof certain numbers that have been subject to rounding adjustments may be based on unrounded numbers.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17400598546387344, "height": 0.06840530141085933, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-2", "text": "Currencies\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.1977025392986699, "lower_right_y": 0.20008550662676358, "height": 0.012398460880718276, "width": 0.0822249093107618}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-3", "text": "In this Prospectus, unless otherwise indicated: all references to the \"EU\" are to the European Union; all refer-\nences to \"euro\" or \"\u20ac\" are to the lawful currency of the European Union; all references to the \"United States\" or\nthe \"US\" are to the United States of America; all references to \"US dollars\", \"dollars\" or \"US$\" are to the lawful\ncurrency of the United States.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.26336041043180847, "height": 0.05515177426250534, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-4", "text": "Exchange rate information\n", "page_number": 77, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.27661393758016245, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.2907225309961522, "height": 0.014108593415989745, "width": 0.1916565900846433}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-5", "text": "The exchange rates below are provided solely for information and convenience. The rates may differ from the\nactual rates used in the preparation of the financial information appearing in this Prospectus. No representation is\nmade that euros could have been, or could be, converted into US dollars at any particular rate indicated or any\nother rate. The table below sets forth high, low, average and period end exchange rates of US dollars per euro for\neach year indicated (Source: Bloomberg). The average rate for a year means the average of the Bloomberg com-\nposite rates on the last day of each month during a year.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37964942283026937, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-6", "text": "Year                          High     Low         Average    Period end\n                                      US dollars per \u20ac1\n2011                          1.488    1.289          1.392        1.294\n2012                          1.345    1.209          1.285        1.319\n2013                          1.381    1.277          1.328        1.379\n2014                          1.395    1.214          1.329        1.214\n2015 (through 30 June 2015)   1.204    1.055          1.116        1.119\n", "page_number": 77, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.3860624198375374, "lower_right_x": 0.8875453446191052, "lower_right_y": 0.5374091492090637, "height": 0.15134672937152627, "width": 0.7817412333736397}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-7", "text": "The table below sets forth high, low, average and period end exchange rates of US dollars per euro for each\nmonth indicated (Source: Bloomberg).\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5711842667806755, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-8", "text": "Month            High     Low         Average    Period end\n                         US dollars per \u20ac1\nApril 2015       1.122    1.055          1.078        1.122\nMay 2015         1.142    1.086          1.115        1.097\nJune 2015        1.140    1.094          1.121        1.119\nJuly 2015        1.119    1.085          1.100        1.097\nAugust 2015      1.151    1.088          1.111        1.127\nSeptember 2015   1.134    1.112          1.123        1.118\n", "page_number": 77, "bounding_box": {"top_left_x": 0.10761789600967352, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.7503206498503634, "height": 0.17272338606241988, "width": 0.7823458282950423}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-9", "text": "On 30 September 2015 the exchange rate of US$ per \u20ac1 was 1.118.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.758443779392903, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.7716973065412569, "height": 0.013253527148353927, "width": 0.45525997581620314}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-10", "text": "Supplements\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.20737605804111245, "lower_right_y": 0.8003420265070543, "height": 0.0141085934159898, "width": 0.09189842805320435}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-11", "text": "If a significant new factor, material mistake or inaccuracy relating to the information included in this Prospectus\nwhich is capable of affecting the assessment of the Offer Shares, arises or is noted between the date of this Pro-\nspectus and the later of the end of the Offer Period and the start of trading of the Offer Shares on Euronext in\nAmsterdam and Euronext in Brussels, a supplement to this Prospectus is required. Such a supplement will be\nsubject to approval by the AFM in accordance with Section 5:23 of the Dutch Financial Supervision Act and will\nbe made public in accordance with the relevant provisions under the Dutch Financial Supervision Act. The\nsummary shall also be supplemented, if necessary to take into account the new information included in the sup-\nplement.\n", "page_number": 77, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9162035057716973, "height": 0.10944848225737491, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-77-12", "text": "74\n", "page_number": 77, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-0", "text": "Investors who have already agreed to purchase or subscribe for the Offer Shares before the supplement is pub-\nlished shall have the right, exercisable within two business days following the publication of a supplement, to\nwithdraw their acceptances. Investors are not allowed to withdraw their acceptances in any other circumstances.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-1", "text": "Statements contained in any such supplement (or contained in any document incorporated by reference therein)\nshall, to the extent applicable (whether expressly, by implication or otherwise), be deemed to modify or super-\nsede statements contained in this Prospectus or in a document which is incorporated by reference in this Prospec-\ntus. Any statement so modified or superseded shall, except as so modified or superseded, no longer constitute a\npart of this Prospectus. For the avoidance of doubt, references in this paragraph to any supplement being pub-\nlished by the Company do not include the Pricing Statement.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21504916631038906, "height": 0.08208636169303121, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-2", "text": "Notice to Investors\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.24283882000855067, "height": 0.014108593415989745, "width": 0.16505441354292621}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-3", "text": "EXCEPT AS OTHERWISE SET OUT IN THIS PROSPECTUS, THE OFFERING DESCRIBED IN\nTHIS PROSPECTUS IS NOT BEING MADE TO INVESTORS IN THE UNITED STATES, CANADA,\nAUSTRALIA OR JAPAN, AND THIS PROSPECTUS SHOULD NOT BE FORWARDED OR\nTRANSMITTED IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY\nOTHER JURISDICTIONS IN WHICH IT IS UNLAWFUL TO DO SO.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25951261222744765, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3270628473706712, "height": 0.06755023514322356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-4", "text": "The Offer Shares may not be a suitable investment for all investors. Each prospective investor in the Offer\nShares must determine the suitability of that investment in light of its own circumstances. In particular, each\nprospective investor (either alone or with a financial adviser) should:\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3762291577597264, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-5", "text": "\uf0b7   have sufficient knowledge and experience to make a meaningful evaluation of the Offer Shares, the mer-\n    its and risks of investing in the Offer Shares and the information contained or incorporated by reference in\n    this Prospectus, including the financial risks and other risks described in the section \"Risk Factors\".\n\uf0b7   have the expertise to evaluate how the Offer Shares will perform under changing conditions, the resulting\n    effects on the value of the Offer Shares and the impact this investment will have on the prospective in-\n    vestor's overall investment portfolio.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4728516460025652, "height": 0.09020949123557076, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-6", "text": "       vestor's overall investment portfolio.\nBecause of the following restrictions, prospective investors are advised to consult legal counsel prior to making\nany offer for, resale, pledge or other transfer of the Offer Shares.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.47327917913638307, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5083368961094484, "height": 0.03505771697306537, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-7", "text": "This Prospectus does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer\nto acquire Offer Shares in any jurisdiction in which such an offer or solicitation is unlawful or would result in the\nCompany becoming subject to public company reporting obligations outside the Netherlands.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5566481402308678, "height": 0.040615647712697656, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-8", "text": "The distribution of this Prospectus, and the offer or sale of Offer Shares is restricted by law in certain\njurisdictions. This Prospectus may only be used where it is legal to offer, solicit offers to purchase or sell Offer\nShares. Persons who obtain this Prospectus must inform themselves about and observe all such restrictions. None\nof the Company or the Underwriters accepts any legal responsibility for any violation by any person, whether or\nnot a prospective purchaser of Offer Shares, of any such restrictions. The Company and the Underwriters reserve\nthe right in their own absolute discretion to reject any offer to purchase Offer Shares that the Company, the\nUnderwriters or their respective agents believe may give rise to a breach or violation of any laws, rules or\nregulations.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6729371526293287, "height": 0.10902094912355709, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-9", "text": "No action has been or will be taken to permit a public offer or sale of Offer Shares, or the possession or\ndistribution of this Prospectus or any other material in relation to the Offering in any jurisdiction outside the\nNetherlands and Germany where action may be required for such purpose. Accordingly, neither this Prospectus\nnor any advertisement or any other related material may be distributed or published in any jurisdiction except\nunder circumstances that will result in compliance with any applicable laws and regulations.\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.748182984181274, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-10", "text": "Shareholders who have a registered address in, or who are resident or located in, jurisdictions other than the\nNetherlands and Germany and any person (including, without limitation, agents, custodians, nominees and\ntrustees) who has a contractual or other legal obligation to forward this Prospectus to a jurisdiction outside the\nGermany should read the section \"Selling and Transfer Restrictions\".\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8101752885848653, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-11", "text": "NOTICE TO PROSPECTIVE INVESTORS IN THE UNITED STATES\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.6384522370012092, "lower_right_y": 0.827704147071398, "height": 0.010688328345446751, "width": 0.5229746070133011}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-12", "text": "The Offer Shares have not been and will not be registered under the US Securities Act or under the securities\nlaws of any state or other jurisdiction in the United States. The Offer Shares may be offered, sold or otherwise\ntransferred only in the following circumstances: (i) within the United States to qualified institutional buyers\n(\"QIBs\") as defined in Rule 144A under the US Securities Act (\"Rule 144A\") in reliance on Rule 144A or\npursuant to another exemption from, or in a transaction not subject to, the registration requirements of the US\nSecurities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the\n", "page_number": 78, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.837537409149209, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-78-13", "text": "75\n", "page_number": 78, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-0", "text": "US Securities Act. Transfers of the Shares will be restricted and each purchaser of the Shares will be deemed to\nhave made acknowledgments, representations and agreements, as described in the section \"Selling and Transfer\nRestrictions\".\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12312954253954682, "height": 0.03805044890979051, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-1", "text": "In addition, until the end of the 40th calendar day after the commencement of the Offering, an offer or sale of the\nOffer Shares within the United States by a dealer (whether or not participating in the Offering) may violate the\nregistration requirements of the US Securities Act if such offer or sale is made otherwise than in accordance with\nRule 144A or another exemption from registration under the US Securities Act. None of the Company and the\nUnderwriters accept any legal responsibility for any violation by any person, whether or not a prospective\ninvestor in the Offer Shares, of any of the foregoing restrictions.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21504916631038906, "height": 0.08208636169303121, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-2", "text": "THE SHARES OFFERED HEREBY HAVE NOT BEEN RECOMMENDED BY ANY US FEDERAL OR\nSTATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE\nFOREGOING AUTHORITIES HAVE NOT PASSED UPON OR ENDORSED THE MERITS OF THE\nOFFERING OF THE RIGHTS OR THE SHARES OR CONFIRMED THE ACCURACY OR\nDETERMINED THE ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE\nCONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21547669944420692, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3009833262077811, "height": 0.0855066267635742, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-3", "text": "In the United States, this Prospectus is being furnished on a confidential basis solely for the purpose of enabling\na prospective purchaser to consider purchasing the particular securities described herein. The information\ncontained in this Prospectus has been provided by the Company and the other sources identified herein.\nDistribution of this Prospectus to any person other than the offeree specified by the Company and those persons,\nif any, retained to advise such offeree with respect thereto, is unauthorised, and any disclosure of its contents,\nwithout the Company's prior written consent, is prohibited.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39290294997862335, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-4", "text": "This Prospectus is personal to each offeree and does not constitute an offer to any other person or to the public\ngenerally to subscribe for or otherwise acquire the securities described herein. Investors agree to the foregoing\nby accepting delivery of this Prospectus.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.44121419410004276, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-5", "text": "NOTICE TO PROSPECTIVE INVESTORS IN THE UNITED KINGDOM\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.6626360338573156, "lower_right_y": 0.4600256519880291, "height": 0.012398460880718276, "width": 0.5471584038694075}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-6", "text": "In the United Kingdom, this Prospectus is for distribution only to, and is only directed at, persons who (i) have\nprofessional experience in matters relating to investments falling within article 19(5) of the Financial Services\nand Markets Act 2000 (Financial Promotion) Order 2005, as amended, (the \"Financial Promotion Order\"), (ii)\nare persons falling within article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of\nthe Financial Promotion Order or (iii) are persons to whom an invitation or inducement to engage in investment\nactivity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with\nthe issue or sale of the Offer Shares may otherwise lawfully be communicated (all such persons together being\nreferred to as \"relevant persons\"). This Prospectus is directed only at relevant persons and must not be acted on\nor relied on by persons who are not relevant persons. Any investment or investment activity to which this\nProspectus relates is available only to relevant persons and will be engaged in only with relevant persons.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6053869174861052, "height": 0.13723813595553658, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-7", "text": "Furthermore, the Underwriters have warranted that they: (i) have only invited or will only invite participation in\ninvestment activities in connection with the Offering or the sale of the Offer Shares within the meaning of\nSection 21 of the Financial Services and Markets Act 2000 as amended (\"FSMA 2000\"), and have only initiated\nor will only initiate such investment activities to the extent that Section 21(1) of the FSMA 2000 does not apply\nto the Company; and (ii) have complied and will comply with all applicable provisions of FSMA 2000 with\nrespect to all activities already undertaken by each of them or will undertake in the future in relation to the shares\nin, from, or otherwise involving the United Kingdom.\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7079948696023942, "height": 0.09619495510902099, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-8", "text": "NOTICE TO PROSPECTIVE INVESTORS IN THE EUROPEAN ECONOMIC AREA\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.728516460025652, "height": 0.01410859341598969, "width": 0.6342200725513906}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-9", "text": "In relation to each state which is a party to the agreement relating to the member states of the European\nEconomic Area (\"EEA\") and which has implemented the Prospectus Directive other than the Netherlands and\nGermany (a \"Relevant Member State\"), with effect from and including the date on which the Prospectus\nDirective is implemented in that Relevant Member State, an offer to the public of any Offer Shares which are the\nsubject of the Offering contemplated by this Prospectus may not be made in that Relevant Member State prior to\nthe publication of a prospectus in relation to the Offer Shares which has been approved by the competent\nauthority in that Relevant Member State or, where appropriate, approved in another Relevant Member State, all\nin accordance with the Prospectus Directive, except that an offer to the public in that Relevant Member State of\nany Offer Shares may be made at any time under the following exemptions under the Prospectus Directive, if\nthey have been implemented in that Relevant Member State:\n", "page_number": 79, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7357845233005558, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8717400598546388, "height": 0.135955536554083, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-10", "text": "\uf0b7   to any legal entity which is a qualified investor as defined in the Prospectus Directive;\n", "page_number": 79, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8820008550662677, "lower_right_x": 0.7448609431680774, "lower_right_y": 0.8943993159469859, "height": 0.012398460880718165, "width": 0.6287787182587666}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-79-11", "text": "76\n", "page_number": 79, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-0", "text": "\uf0b7   to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus\n    Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the Un-\n    derwriters; or\n\uf0b7   in any other circumstances falling within Article 3(2) of the Prospectus Directive,\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1470713980333476, "height": 0.06199230440359128, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-1", "text": "provided that no such offer of Offer Shares shall require the Company or any Underwriter to publish a\nprospectus pursuant to Article 3 of the Prospectus Directive or any measure implementing the Prospectus\nDirective in a Relevant Member State or supplement a prospectus pursuant to Article 16 of the Prospectus\nDirective.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20735356990166737, "height": 0.050448909790508756, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-2", "text": "In the case of any Offer Shares being offered to a financial intermediary as that term is used in Article 3(2) of the\nProspectus Directive, such financial intermediary will also be deemed to have represented, acknowledged and\nagreed that the Offer Shares acquired by it in the Offering have not been acquired on a non-discretionary basis\non behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which\nmay give rise to an offer of any Offer Shares to the public other than their offer or resale in a Relevant Member\nState to qualified investors as so defined or in circumstances in which the prior consent of the Underwriters has\nbeen obtained to each such proposed offer or resale. Curetis, the Underwriters and their affiliates, and others will\nrely upon the truth and accuracy of the foregoing representation, acknowledgement and agreement.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21846943138093203, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32535271483539974, "height": 0.10688328345446771, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-3", "text": "For the purposes of this provision, the expression an \"offer to the public\" in relation to any Offer Shares in any\nRelevant Member State means the communication in any form and by any means of sufficient information on the\nterms of the Offering and any Offer Shares to be offered so as to enable an investor to decide to purchase any\nOffer Shares, as the same may be varied in that Relevant Member State by any measure implementing the\nProspectus Directive in that Relevant Member State and the expression \"Prospectus Directive\" means Directive\n2003/71/EC as amended, including Directive 2010/73/EU, and includes any relevant implementing measure in\neach Relevant Member State.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3257802479692176, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.427105600684053, "height": 0.10132535271483539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-4", "text": "Documents Incorporated by Reference\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.44420692603676787, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.4600256519880291, "height": 0.015818725951261214, "width": 0.33857315598548976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-5", "text": "The Articles of Association (the Dutch version and an English translation thereof) are incorporated by reference\nin this Prospectus. They are available on the Company's website www.curetis.com.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5019238991021804, "height": 0.026934587430525847, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-6", "text": "Where the documents incorporated by reference themselves incorporate information by reference, such\ninformation does not form part of this Prospectus.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5365540829414279, "height": 0.034202650705429605, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-7", "text": "Prospective investors should rely only on the information that the Company incorporates by reference or\nprovides in this Prospectus. No other documents or information, including the content of Curetis' website \u2013\nwww.curetis.com \u2013 or of websites accessible from hyperlinks on that website, form part of, or are incorporated\nby reference into, this Prospectus.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5976913210773835, "height": 0.05429670799486963, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-8", "text": "Available Information\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6117999144933732, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.6259085079093629, "height": 0.01410859341598969, "width": 0.19830713422007257}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-9", "text": "For so long as any of the Offer Shares are \"restricted securities\" within the meaning of Rule 144(a)(3) under the\nUS Securities Act, the Company will, during any period in which it is not subject to Section 13 or 15(d) of the\nUS Securities Exchange Act of 1934, as amended (the \"US Exchange Act\"), nor exempt from reporting under\nthe US Exchange Act pursuant to Rule 12g3-2(b), make available to any holder or beneficial owner of the Offer\nShares, or to any prospective investor of the Offer Shares designated by such holder or beneficial owner, upon\nthe request of such holder, beneficial owner or prospective investor, the information specified in, and meeting\nthe requirements of, Rule 144A(d)(4) under the US Securities Act.\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7383497221034631, "height": 0.09576742197520316, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-10", "text": "Enforceability of Judgments\n", "page_number": 80, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7524583155194527, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.7695596408721675, "height": 0.017101325352714802, "width": 0.24546553808948007}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-11", "text": "The Company has been advised that there is doubt as to the enforceability in the Netherlands of civil liabilities\nbased on the securities laws of the United States, either in an original action or in an action to enforce a judgment\nobtained in US courts. At the date of this Prospectus, the Company is a private limited liability company\n(besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands that will\nbe converted into a public company with limited liability (naamloze vennootschap) under the laws of the\nNetherlands immediately after determination of the Offer Price. Except for the chairman of the Supervisory\nBoard, all Managing and Supervisory Directors and most of the Company's employees are citizens or residents\nof countries other than the United States. All or a substantial portion of the assets of such persons and all or a\nsubstantial portion of the Company's assets are located outside the United States. As a result, it may not be\npossible for investors to effect service of process within the United States upon the Company or such persons or\nto enforce against any of them in the US courts judgments obtained in US courts, including judgments predicated\n", "page_number": 80, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.880894800483676, "lower_right_y": 0.93373236425823, "height": 0.15091919623770844, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-80-12", "text": "77\n", "page_number": 80, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-0", "text": "upon the civil liability provisions of the securities laws of the United States or any State or territory within the\nUnited States. The United States and the Netherlands currently do not have a treaty providing for the reciprocal\nrecognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. In\naddition, the countries of residence of the members of the Management Board and the Supervisory Board and of\nthe Company's employees may also not have a treaty providing for the reciprocal recognition and enforcement of\njudgments. Consequently, a final judgment for payment given by a court in the United States, whether or not\npredicated solely upon US securities laws, would not be enforceable in the Netherlands.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.18041898247114152, "height": 0.09533988884138521, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-1", "text": "In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favour a final and\nconclusive judgment of the US court has been rendered will be required to file its claim with a court of\ncompetent jurisdiction in the Netherlands. Such party may submit to the Dutch court the final judgment rendered\nby the US court. If and to the extent that the Dutch court finds that the jurisdiction of the US court has been\nbased on grounds which are internationally acceptable and that proper legal procedures have been observed, the\nDutch court will, in principle, give binding effect to such final judgment, without substantive re-examination or\nre-litigation on the merits of the subject matter thereof, insofar as it finds that such judgment (i) does not\ncontravene principles of public policy of the Netherlands and (ii) is not irreconcilable with a judgment of a\nDutch court given between the same parties, or with an earlier judgment of a foreign court given between the\nsame parties in a dispute involving the same cause of action and subject matter, provided that such earlier\njudgment fulfils the conditions necessary for it to be given binding effect in the Netherlands. It is uncertain\nwhether this practice extends to default judgments as well. Dutch courts may deny the recognition and\nenforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages\ngranted by a US court and recognise damages only to the extent that they are necessary to compensate actual\nlosses or damages. Enforcement and recognition of judgments of US courts in the Netherlands are solely\ngoverned by the provisions of the Dutch Civil Procedure Code (Wetboek van Burgerlijke Rechtsvordering).\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.40615647712697733, "height": 0.21846943138093203, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-2", "text": "Market Data and Other Information from Third Parties\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.6045949214026602, "lower_right_y": 0.4343736639589568, "height": 0.014108593415989745, "width": 0.48911729141475213}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-3", "text": "Unless the source is otherwise stated, the market, economic and industry data in this document constitute the\nestimates of Curetis' management, using underlying data from independent third parties. Curetis has obtained\nmarket data and certain industry forecasts used in this document from internal surveys, academic and other\nreports and studies, where appropriate, as well as market research, publicly available information and industry\npublications. Where third-party information has been used in this document, the source of this information has\nbeen identified.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5301410859341599, "height": 0.07909362975630607, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-4", "text": "The information in this Prospectus that has been sourced from third parties has been accurately reproduced and,\nas far as Curetis is aware and able to ascertain from the information published by that third party, no facts have\nbeen omitted that would render the reproduced information inaccurate or misleading. Industry publications\ngenerally state that their information is obtained from sources they believe reliable but that the accuracy and\ncompleteness of such information is not guaranteed and that the projections they contain are based on a number\nof significant assumptions. Although Curetis believes these sources to be reliable, as Curetis does not have\naccess to the information, methodology and other bases for such information, Curetis has not independently\nverified the information. Curetis is not aware of any exhaustive industry or market reports that cover or address\nits specific markets.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6618212911500642, "height": 0.12184694313809319, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-5", "text": "In this Prospectus, Curetis makes certain statements regarding the markets and the competitive position in the\nsectors and geographies in which Curetis competes. Curetis believes these statements to be true based on market\ndata and industry statistics which are in the public domain, but has not independently verified the information.\nFor further information, see \"Annex II List of References\".\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6699444206926036, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-6", "text": "Information Regarding Forward-looking Statements\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.7554510474561779, "height": 0.017101325352714802, "width": 0.45525997581620314}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-7", "text": "This Prospectus contains certain statements that are or may be forward-looking statements with respect to, with-\nout limitation, Curetis' plans, objectives, strategies, products and their expected performance, impact of\nhealthcare costs, marketing authorisation from the FDA, regulatory clearance, reimbursement for Curetis' prod-\nucts, research and development costs, intellectual property protection, timing of regulatory filings, anticipated\ndevelopment in molecular diagnostics industry, Curetis' results of operations and financial position. In some\ncases, investors can identify forward-looking statements by terms such as \"believe\", \"anticipate\", \"expect\", \"es-\ntimate\", \"may\", \"could\", \"should\", \"would\", \"will\", \"intend\", \"plan\" and similar expressions. Such forward-\nlooking statements involve known and unknown risks, uncertainties and other factors which may cause Curetis'\nactual results, financial condition, performance or achievements, or industry results, to be materially different\nfrom any future results, performance or achievements expressed or implied by such forward-looking statements.\n", "page_number": 81, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.9063702436938863, "height": 0.13723813595553658, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-81-8", "text": "78\n", "page_number": 81, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-0", "text": "These forward-looking statements speak only as of the date of this Prospectus and are subject to a number of\nrisks, uncertainties and assumptions described in the sections in this Prospectus entitled \"Risk Factors\" and\nelsewhere in this Prospectus. These forward-looking statements are subject to numerous risks, including, without\nlimitation, the following:\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-1", "text": "\uf0b7   Curetis' status as a development-stage company and Curetis' expectation to incur losses in the future;\n\uf0b7   Curetis' ability to obtain marketing authorisation or regulatory clearance, e.g. from the FDA, for Curetis'\n    products;\n\uf0b7   the market acceptance of Curetis' Unyvero technology;\n\uf0b7   Curetis' ability to timely and successfully develop and commercialise Curetis' existing products and future\n    products;\n\uf0b7   the length of Curetis' anticipated sales cycle;\n\uf0b7   Curetis' ability to gain the support of leading hospitals and key opinion leaders and publish the results of\n    Curetis' clinical trials in peer-reviewed journals;\n\uf0b7   Curetis' future capital needs and Curetis' need to raise additional funds;\n\uf0b7   the performance of Curetis' diagnostics;\n\uf0b7   Curetis' ability to successfully manage Curetis' growth;\n\uf0b7   Curetis' ability to successfully procure all necessary supplies and to manufacture all products in sufficient\n    numbers and quality to satisfy market demand;\n\uf0b7   Curetis' ability to compete in the highly competitive diagnostics market;\n\uf0b7   Curetis' ability to protect and enforce Curetis' intellectual property rights, including Curetis' trade secret-\n    protected proprietary rights in Unyvero;\n\uf0b7   regulatory requirements, including FDA regulation of Curetis' products; and\n\uf0b7   other risks described under \"Risk Factors\".\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5096194955109021, "height": 0.3629756306113724, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-2", "text": "Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be\npredicted or quantified and some of which are beyond Curetis' control, investors are cautioned not to place any\nundue reliance on such forward-looking statements. The events and circumstances reflected in Curetis' forward-\nlooking statements may not be achieved or occur and actual results could differ materially from those projected\nin the forward-looking statements. Moreover, Curetis operates in an evolving environment. New risk factors and\nuncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and\nuncertainties. Any forward-looking statements should not be regarded as a representation or warranty by Curetis,\nthe Underwriters or any other person with respect to the achievement of the results set out in such statements or\nthat the underlying assumptions used will in fact be the case.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6395895681915349, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-3", "text": "Curetis and the Underwriters disclaim any obligation to update any such forward-looking statements in this Pro-\nspectus to reflect future events or developments.\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6737922188969645, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-4", "text": "References to Defined Terms and Incorporation of Terms\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.7045746045318512, "height": 0.01410859341598969, "width": 0.4987908101571946}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-5", "text": "Certain terms used in this Prospectus, including capitalised terms and certain technical and other terms are\nexplained or defined in the section \"Glossary\".\n", "page_number": 82, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7469003847798205, "height": 0.025651988029072315, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-82-6", "text": "79\n", "page_number": 82, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.017533252720677073}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-0", "text": "REASONS FOR THE OFFERING AND USE OF PROCEEDS\n", "page_number": 83, "bounding_box": {"top_left_x": 0.18319226118500603, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8174123337363967, "lower_right_y": 0.10816588285592134, "height": 0.016246259085079096, "width": 0.6342200725513907}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-1", "text": "Reasons for the Offering\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.14065840102607952, "height": 0.014536126549807599, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-2", "text": "The principal purpose of the Offering is to obtain additional capital to support the execution of Curetis' strategy\n(as described in \"Business \u2013 Strategy\" below). In addition, the Offering will also create a public market for the\nShares, allowing future access to the public equity markets.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19709277469003847, "height": 0.04018811457887986, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-3", "text": "Proceeds and Expenses of the Offering\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.2278751603249252, "height": 0.016246259085079096, "width": 0.3391777509068924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-4", "text": "The Company is targeting to raise approximately \u20ac29.3 million of gross proceeds from the Offering (the \u201cTarget\nProceeds\u201d). On the basis of the maximum number of Offer Shares (assuming no exercise of the Over-allotment\nOption), the Company however has the possibility to raise up to approximately \u20ac50 million in gross proceeds\nfrom the Offering (assuming an Offer Price at the upper end of the Offer Price Range). The estimated expenses,\ncommissions and taxes related to the Offering of \u20ac4.3 million, which include approximately \u20ac1.46 million of fees\nand commissions payable to the Underwriters. The following table sets forth the gross proceeds, net proceeds\nand aggregate expenses, costs and fees of the Offering (including fees payable to the Underwriters, assuming no\npayment of the incentive fee) in the scenarios set forth below and, where relevant, assuming an Offer Price at the\nmid-point of the Offer Price Range.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.36511329628046174, "height": 0.12270200940572895, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-5", "text": "                                              Gross proceeds      Net proceeds        Aggregate expenses,\n                                                                                      costs and fees\nScenario                                                           (in \u20ac million)\nTarget Proceeds raised                                     29.3                  25                   4.3\nMaximum number of Offer Shares issued, no\nexercise of the Over-allotment Option                      44.8              39.8                     5.0\nMaximum number of Offer Shares issued, full\nexercise of Over-allotment Option                          51.5              46.2                     5.3\n", "page_number": 83, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.3655408294142796, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.519880290722531, "height": 0.15433946130825132, "width": 0.782950423216445}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-6", "text": "Use of Proceeds\n", "page_number": 83, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5365540829414279, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.5472424112868748, "height": 0.010688328345446862, "width": 0.13724304715840388}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-7", "text": "Assuming the Company raises the Target Proceeds, the Company expects to generate approximately \u20ac25 million\nin net proceeds.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5917058572039333, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-8", "text": "Curetis currently anticipates that over the coming several years it will use the net proceeds of the Offering along\nwith expected cash inflows from gross margin on product sales, in order of importance, as follows:\n\uf0b7      Approximately 20% to 30% of the net proceeds of the Offering for building a commercial marketing,\n       sales and support presence in the US in order to directly commercialise the Unyvero System and Applica-\n       tion Cartridges following the anticipated FDA clearance.\n\uf0b7      Approximately 20% to 25% of the net proceeds of the Offering for accelerating the R&D pipeline of the\n       Unyvero Application Cartridges for European, US and global markets, including clinical trials and regula-\n       tory approval.\n\uf0b7      Approximately 15% to 20% of the net proceeds of the Offering for expanding and strengthening the Eu-\n       ropean commercial presence for markets where Curetis sells the Unyvero Platform directly to end cus-\n       tomers.\n\uf0b7      With the remainder to be used on:\n             o    a manufacturing capacity expansion,\n             o    additional working capital requirements, and\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8371098760153912, "height": 0.23899102180418985, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-9", "text": "general corporate purposes.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.23639661426844014, "top_left_y": 0.844377939290295, "lower_right_x": 0.42503022974607013, "lower_right_y": 0.8580589995724669, "height": 0.013681060282171864, "width": 0.18863361547763}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-10", "text": "o\n", "page_number": 83, "bounding_box": {"top_left_x": 0.20737605804111245, "top_left_y": 0.8482257374946558, "lower_right_x": 0.22067714631197097, "lower_right_y": 0.8550662676357418, "height": 0.0068405301410859876, "width": 0.013301088270858519}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-11", "text": "As of the date of this Prospectus, Curetis cannot predict with certainty all of the specific uses for the net proceeds\nfrom the Offering, or the amounts to be actually spent on the uses set forth above. The amounts and timing of its\nactual use of the net proceeds will vary depending on numerous factors. As a result, Curetis assumes broad\ndiscretion in the use of the net proceeds of the Offering.\n", "page_number": 83, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8648995297135528, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9196237708422402, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-83-12", "text": "80\n", "page_number": 83, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-84-0", "text": "Pending the use of the proceeds from the Offering, Curetis intends to invest the net proceeds in interest-bearing,\ncash and cash equivalents instruments or short term certificates of deposit.\n", "page_number": 84, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-84-1", "text": "81\n", "page_number": 84, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.016928657799274438}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-0", "text": "DIVIDENDS AND DIVIDEND POLICY\n", "page_number": 85, "bounding_box": {"top_left_x": 0.2914147521160822, "top_left_y": 0.09191962377084224, "lower_right_x": 0.7043530834340992, "lower_right_y": 0.10816588285592134, "height": 0.016246259085079096, "width": 0.412938331318017}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-1", "text": "General\n", "page_number": 85, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.12612227447627192, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.013253527148353983, "width": 0.07073760580411124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-2", "text": "Pursuant to Dutch law and the Articles of Association, the distribution of profits will take place following the\nadoption of the Company's annual accounts by the General Meeting. The Company may only make distributions\nto the Shareholders, whether from profits or from its freely distributable reserves, insofar as its shareholders'\nequity exceeds the sum of the paid-up and called-up share capital plus the minimum reserves required under\nDutch law or pursuant to its Articles of Association.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22445489525438223, "height": 0.06755023514322361, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-3", "text": "Subject to the approval of the Supervisory Board and subject to Dutch law and the Articles of Association, the\nManagement Board may determine which part of the Company's profits as per its financial statements for the\nrelevant financial year will be added to the reserves. The remaining part of the profits will be at the disposal of\nthe General Meeting. Distributions of dividends will be made pro rata to the nominal value of each Share.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2321504916631039, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2860196665241556, "height": 0.05386917486105172, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-4", "text": "Subject to the approval of the Supervisory Board and subject to Dutch law and the Articles of Association, the\nManagement Board may resolve to distribute an interim dividend if it determines such interim dividend to be\njustified by the Company's profits. For this purpose, the Management Board must prepare an interim statement\nof assets and liabilities. Such interim statement shall show the financial position of the Company not earlier than\non the first day of the third month before the month in which the resolution to make the interim distribution is\nannounced. An interim dividend can only be paid if (a) an interim statement of assets and liabilities is drawn up\nshowing that the funds available for distribution are sufficient, and (b) the Company's shareholders' equity\nexceeds the sum of the paid-up and called-up share capital plus the reserves required to be maintained by Dutch\nlaw or pursuant to its Articles of Association.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2864471996579735, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4159897392047884, "height": 0.12954253954681488, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-5", "text": "On proposal of the Management Board which has been approved by the Supervisory Board, the General Meeting\nmay resolve that the Company makes distributions to Shareholders from one or more of its freely distributable\nreserves. Distributions from the Company's distributable reserves may be made throughout the financial year,\nand need not be based on the Company's annual accounts adopted by the General Meeting. Any such\ndistributions will be made pro rata to the nominal value of each Share.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4916631038905515, "height": 0.06797776827704144, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-6", "text": "Entitlement to Dividends\n", "page_number": 85, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5057716973065413, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.519880290722531, "height": 0.01410859341598969, "width": 0.21644498186215239}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-7", "text": "All Shares, including the Offer Shares, are equally entitled to dividends and other distributions, if and when\ndeclared.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.5609234715690466, "height": 0.024369388627618727, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-8", "text": "Dividend Policy and History\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.5951261222744763, "height": 0.01752885848653274, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-9", "text": "The Company and Curetis AG have never declared or paid any dividends.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.6220607097050022, "height": 0.013681060282171864, "width": 0.498186215235792}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-10", "text": "The Company expects to retain all earnings, if any, generated by Curetis' operations for the development and\ngrowth of its business and does not anticipate paying any dividends to the Shareholders in the near future.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6566908935442497, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-11", "text": "The Company's dividend policy will be reviewed and may be amended from time to time taking into account\nCuretis' earnings, cash flow, financial condition, capital expenditure requirements and other factors considered\nimportant by the Management Board.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7045746045318512, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-12", "text": "Dividend Ranking of Shares\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.718683197947841, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.73492945703292, "height": 0.01624625908507904, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-13", "text": "All of the Shares, including the Offer Shares, will rank equally and will be eligible and equally entitled to\ndividend that may be declared on the Shares.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7759726378794357, "height": 0.02736212056434384, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-14", "text": "Manner and Time of Dividend Payments\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7930739632321505, "lower_right_x": 0.46795646916565903, "lower_right_y": 0.8067550235143224, "height": 0.013681060282171864, "width": 0.3524788391777509}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-15", "text": "Payment of dividend on the Offer Shares in cash will be made in euro, paid to the Shareholders through\nEuroclear Netherlands, the Dutch centralised securities custody and administration system, and credited\nautomatically to the Shareholders' accounts without the need for the Shareholder to present documentation\nproving ownership of the Shares.\n", "page_number": 85, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-85-16", "text": "82\n", "page_number": 85, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-86-0", "text": "Uncollected Dividends\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.1983071342200725}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-86-1", "text": "An entitlement to any dividend distribution will be barred five years after the date on which those dividends\nwere released for payment. Any dividend that is not collected within this period reverts to the Company and is\nallocated to its general reserves.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.15647712697734073, "height": 0.040615647712697725, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-86-2", "text": "Taxation of Dividends\n", "page_number": 86, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.17058572039333048, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.18469431380932022, "height": 0.014108593415989745, "width": 0.19286577992744863}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-86-3", "text": "In relation to dividend distributions, there are no restrictions under Dutch law in respect of holders of Offer\nShares who are non-residents of the Netherlands. Dividends are generally subject to Dutch withholding tax in the\nNetherlands. See the section \"Taxation\" for a discussion of certain aspects of taxation of dividends and refund\nprocedures.\n", "page_number": 86, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25609234715690465, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-86-4", "text": "83\n", "page_number": 86, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-0", "text": "CAPITALISATION, INDEBTEDNESS AND WORKING CAPITAL\n", "page_number": 87, "bounding_box": {"top_left_x": 0.15296251511487305, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8464328899637243, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.6934703748488513}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-1", "text": "This section sets forth Curetis' capitalisation and indebtedness as of 30 June 2015 on an actual basis, and its\ncapitalisation and the Company's consolidated indebtedness as of 30 June 2015 adjusted to reflect the receipt of\nthe estimated net proceeds from the Offering of \u20ac25 million and implementation of the Reorganisation (based on\nthe assumption that the Company has raised the Target Proceeds).\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.880894800483676, "lower_right_y": 0.17999144933732364, "height": 0.05386917486105172, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-2", "text": "Capitalisation\n", "page_number": 87, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.19452757588713127, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.20949123557075675, "height": 0.01496365968362548, "width": 0.1233373639661427}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-3", "text": "The data presented in the following table shows Curetis' capitalisation as of 30 June 2015 on a historical basis,\nwhich has been derived from the Interim Financial Statements, and as adjusted. The data presented in the \"ad-\njusted\" column has been prepared on the basis of the assumption that the Company had already obtained the net\nproceeds from the Offering of \u20ac25 million (based on the assumption that the Company has raised the Target\nProceeds) and the Reorganisation had already been implemented as of 30 June 2015.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22530996152201796, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2932877297990594, "height": 0.06797776827704147, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-4", "text": "                                                                   The Company\n                                 Curetis AG actual               as of 30 June 2015\n                                 as of 30 June 2015                  (adjusted)\n\n                                                 (in \u20ac thousands)\n\n                                                   (unaudited)\nTotal current liabilities              1,505                           1,505\nof which is guaranteed                   -                               -\nof which is secured1                    137                             137\nunguaranteed/unsecured                 1,368                           1,368\nTotal non-current liabilities2        145,958                          7,759\nof which is guaranteed                   -                               -\nof which is secured1                    161                             161\n                           2\nunguaranteed/unsecured                145,797                          7,598\nTotal liabilities3                    147,463                          9,264\nEquity                               (130,909)                        31,502\nof which is share capital4              50                              138\n                            5\nof which is legal reserve                -                            148,566\nof which is retained earnings6       (130,959)                       (117,202)\n                       7\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30782385634886705, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.6883283454467721, "height": 0.3805044890979051, "width": 0.7478839177750907}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-5", "text": "Total capitalisation7                                                                       16,554                                         40,766\n1   Relates to bank deposits pledged to the lessor of the laser welding plants to secure lease payment obligations of Curetis.\n2   The reduction in total non-current liabilities in the adjusted column is mainly attributable to the fair value measurement of the preferred and common shares\n    in Curetis AG classified as financial liabilities. Subject to the completion of the Offering, all shares in Curetis AG will be converted into a single class of\n    common stock held by the Company (see \"Major Shareholders and Related Party Transactions \u2013 Corporate Reorganisation\") and will no longer be ac-\n    counted for as a financial liability. In addition, the as adjusted column reflects a reduction of amounts payable to certain beneficiaries for a profit sharing\n    bonus upon completion of the Offering (see \"Management, Employees and Corporate Governance \u2013 Profit Sharing Bonus\"). The reduction has been slight-\n    ly offset by an increase in the value of Curetis' liability from its PSOP determined by referencing to the mid-point of the Offer Price Range in the adjusted\n    column compared to the fair value as of 30 June 2015. Please refer to \"Management, Employees and Corporate Governance \u2013 Share based Compensation\n    Plan\" describing that as part of the Reorganisation Curetis will restructure the PSOP resulting in certain beneficiaries no longer being entitled to a settlement\n    in cash, but in new shares in the Company to be issued 365 days after Settlement.\n3   Total liabilities represent the sum of current liabilities and non-current liabilities.\n4   The adjusted share capital reflects the increase in shares due to the conversion of the preferred and common shares in Curetis AG into a single class of\n    common shares and the expected share capital of the Company upon implementation of a capital increase yielding the Target Proceeds at the mid-point of\n    the Offer Price Range.\n5   The increase in the adjusted column results from the conversion of the preferred and common shares in Curetis AG into a single class of common shares and\n    the issuance of new shares in the Company resulting from the capital increase yielding the Target Proceeds at the mid-point of the Offer Price Range.\n6   Retained earnings increased due to the difference between the fair value of the financial liability for preferred and common shares as of 30 June 2015\n    compared to the value of the shares converted as calculated using the mid-point of the Offer Price Range, partly offset by an increase in the value of the\n    PSOs calculated using the mid-point of the Offer Price Range compared to the value as of 30 June 2015 as well as expenses related to the Offering.\n7   Total capitalisation represents the sum of current liabilities, non-current liabilities and equity.\n", "page_number": 87, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.68875587858059, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8888413852073536, "height": 0.2000855066267636, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-87-6", "text": "84\n", "page_number": 87, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-0", "text": "Net Financial Indebtedness\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09876015391192818, "lower_right_x": 0.3524788391777509, "lower_right_y": 0.11286874732791792, "height": 0.014108593415989745, "width": 0.2370012091898428}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-1", "text": "The data presented in the following table shows Curetis' net financial indebtedness as of 30 June 2015 on a his-\ntorical basis, which has been derived from the Interim Financial Statements, and as adjusted. The data presented\nin the \"adjusted\" column has been prepared on the basis of the assumption that the Company had already ob-\ntained and made available to Curetis the net proceeds from the Offering of \u20ac25 million (based on the assumption\nthat the Company has raised the Target Proceeds) and the Reorganisation had already been implemented as of 30\nJune 2015.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12954253954681488, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20863616930312098, "height": 0.0790936297563061, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-2", "text": "                                                                       The Company\n                                      Curetis AG actual              as of 30 June 2015\n                                      as of 30 June 2015                 (adjusted)\n                                                     (in \u20ac thousands)\n                                                       (unaudited)\nCash and cash equivalents                   5,940                         30,152\n                  1\nTrading securities                           486                            486\nLiquidity2                                  6,426                         30,638\nCurrent financial receivables                 -                              -\nCurrent bank debt                             -                              -\nCurrent portion of non-current debt           -                              -\nOther current financial debt                  -                              -\nCurrent financial debt                        -                              -\nCurrent net financial debt                    -                              -\nNon-current bank loans                        -                              -\nBonds issued                                  -                              -\nOther non-current loans                       -                              -\nOther non-current financial debt3          139,608                           -\nNon-current financial indebtedness         139,608                           -\nNet financial indebtedness4                133,182                       (30,638)\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2201795639162035, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6297563061137238, "height": 0.40957674219752027, "width": 0.7690447400241838}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-3", "text": "Net financial indebtedness                                                                 133,182                                      (30,638)\n1   Corresponds to trade receivables as reported in the Interim Financial Statements.\n2   Cash and cash equivalents plus trading securities. The as adjusted column reflects the receipt of the Target Proceeds and the payment of a profit sharing\n    bonus to certain beneficiaries at Settlement (see \"Management, Employees and Corporate Governance \u2013 Profit Sharing Bonus\").\n3   Fully attributable to the fair value measurement of the preferred and common shares in Curetis AG classified as financial liabilities. Subject to the comple-\n    tion of the Offering, all shares in Curetis AG will be converted into a single class of common stock held by the Company and will no longer be accounted\n    for as a financial liability in future financial statements of the Company.\n4   Non-current financial indebtedness less liquidity.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6301838392475417, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.6977340743907653, "height": 0.06755023514322356, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-4", "text": "As at the date of this Prospectus, there have been no significant changes in the Company's financial or trading\nposition since 30 June 2015.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7421975203078238, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-5", "text": "As of 30 June 2015, Curetis AG had pledged bank deposits in an amount of \u20ac412 thousand as collateral for its\nobligations under the finance lease of a laser welding plant, rent payment obligations and credit in the form of\nbank guarantees.\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7896536981616076, "height": 0.0410431808465157, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-6", "text": "Working Capital Statement\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.3573155985489722, "lower_right_y": 0.8208636169303121, "height": 0.01410859341598969, "width": 0.2418379685610641}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-7", "text": "Curetis' current cash resources do not provide it with sufficient working capital for the next twelve months fol-\nlowing the date of this Prospectus. Curetis believes that it has sufficient working capital to continue its current\noperations until June of 2016. Based on its present requirements under its current business plan which was pre-\npared with a view to obtaining the net proceeds from the Offering and which includes costs for building a com-\nmercial marketing and sales presence in the US, Curetis believes its operations will require additional cash re-\nsources of approximately \u20ac4.5 million to provide it with sufficient working capital for the next twelve months\nfollowing the date of this Prospectus. If the Offering is completed and net proceeds of approximately \u20ac25 million\n", "page_number": 88, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9303120991876871, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-88-8", "text": "85\n", "page_number": 88, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-89-0", "text": "are generated (which would be the case if the the Company has raised the Target Proceeds) (see \"Reasons for the\nOffering and Use of Proceeds \u2013 Proceeds and Expenses of the Offering\"), these proceeds together with Curetis'\ncurrent cash resources will provide it with sufficient working capital for the next twelve months following the\ndate of this Prospectus.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-89-1", "text": "If the Offering should be withdrawn or otherwise not be completed, Curetis will implement a detailed action plan\nto address the resulting imminent working capital shortfall by reducing the cash-outflows. This will include\nsignificant cost reductions and reduced or at least delayed operating and capital expenditures. Primarily, Curetis\nwill in this scenario suspend the build-up of its US organisation and its cost-intensive FDA trials in the US re-\nsulting in Curetis' inability to obtain the anticipated FDA clearance in the first half of 2017 and thus not being\nable to sell into the US market in 2017 and also in the following years. As a consequence, revenues from the US\nwould not be generated or would be generated only with a significant delay. In addition, Curetis will reduce its\nstaff expenditure due to abstaining from hiring additional personnel. Regarding capital expenditures, Curetis will\nin that case postpone the investment into further multi-cavity injection molds, which would in turn lead to a\npostponed reduction in cost of goods sold of its Application Cartridges. Alternatively, or in conjunction with the\nabove measures, Curetis may seek additional financing from current or future shareholders privately, whether in\nform of bridge loans and/or equity. Curetis believes that the actions mentioned above are likely to be successful\nand that the implementation of these cost reduction or financing measures would provide it with sufficient cash\nto maintain its operations until early 2017 and as such continue as a going concern for at least 12 months from\nthe date of this Prospectus.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3514322359982899, "height": 0.20478837109876016, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-89-2", "text": "In the scenario that Curetis fails to implement the above measures to remedy a working capital shortfall caused\nby a withdrawal of the Offering, such as the generation of sufficient funds from additional financing and the\ndescribed cost reduction measures, it may be unable to continue as a going concern and may ultimately have to\nfile for insolvency.\n", "page_number": 89, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41342454040188115, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-89-3", "text": "86\n", "page_number": 89, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-0", "text": "SELECTED FINANCIAL INFORMATION\n", "page_number": 90, "bounding_box": {"top_left_x": 0.2750906892382104, "top_left_y": 0.09191962377084224, "lower_right_x": 0.7237001209189843, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.4486094316807739}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-1", "text": "Selected Financial Information of Curetis AG\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.39721886336154777}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-2", "text": "The selected financial information of Curetis AG below as of and for the years ended 31 December 2014, 2013\nand 2012 was taken or derived from the audited financial statements of Curetis AG as of and for the years ended\n31 December 2014, 2013 and 2012, prepared in accordance with IFRS, as adopted by the EU. The selected\nfinancial information as of and for the six months ended 30 June 2015 and 2014 was taken or derived from the\nunaudited interim condensed financial statements of Curetis AG as of and for the six months ended 30 June 2015\nprepared on the basis of IFRS applicable to interim financial reporting (IAS34).\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.2381359555365541, "height": 0.08123129542539548, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"accounting_standards": ["IFRS, as adopted by the EU."]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-3", "text": "For more information on the content and interpretation of this information, see \"Important Information-\nPresentation of Financial and Other information-Financial Information\".\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24583155194527576, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.27233860624198375, "height": 0.026507054296707994, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-4", "text": "Where financial data is labelled \"audited\", this means that it was taken from the Annual Financial Statements.\nThe label \"unaudited\" is used to indicate financial data that was taken from a source other than the Annual Fi-\nnancial Statements or recomputed from the Annual Financial Statements.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28003420265070544, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32064985036340315, "height": 0.04061564771269771, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-5", "text": "The figures in the following have been rounded in accordance with established commercial practice. Figures or\nadditions within a table may therefore result in sums different from those shown in the same table and do not\nalways add up to 100%.\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3685335613510047, "height": 0.04061564771269771, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-6", "text": "Statement of Profit or Loss and Other Comprehensive Income\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.6523579201934704, "lower_right_y": 0.3993159469858914, "height": 0.016673792218896977, "width": 0.5368802902055623}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-7", "text": "The table below sets forth Curetis AG's statement of profit or loss and other comprehensive income for the years\nended 31 December 2014, 2013 and 2012 and for the six months ended 30 June 2015 and 2014:\n", "page_number": 90, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.879081015719468, "lower_right_y": 0.4395040615647713, "height": 0.02607952116289014, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-8", "text": "                                                      For the six months               For the year ended\n                                                        ended 30 June                    31 December\n                                                      2015          2014           2014         2013        2012\n                                                                            (in \u20acthousands)\n\n                                                          (unaudited)                          (audited)\n\nRevenue                                                    742             254         275          671        146\nCost of sales                                              665             359         643          219        429\nGross profit                                                 77          (105)        (368)         452      (283)\nDistribution costs                                       1,397           1,107       1,939        1,576      1,864\nAdministrative expenses                                  1,366             867       1,637        1,256      1,437\nResearch and development expenses                        2,943           3,305       6,298        5,895      5,358\nOther income                                                 41             23         111           49         22\nOperating profit                                        (5,588)         (5,362)   (10,132)      (8,226)     (8,919)\nFinance income                                               5               5            6          30         71\nFinance costs                                                9              12            22         28         43\nFinance costs fair value measurement                     6,783           1,340       2,286        2,497     32,098\nFinance income/costs \u2013 net                              (6,786)         (1,347)    (2,302)      (2,495)    (32,069)\nProfit before income tax                               (12,374)         (6,709)   (12,434) (10,721)        (40,989)\nIncome tax income/expense                                    \u2013               \u2013            \u2013            \u2013       (77)\nProfit for the year                                    (12,374)         (6,709)   (12,434) (10,721)        (40,912)\nOther comprehensive income for the year, net of tax          \u2013               \u2013            \u2013            \u2013           \u2013\nTotal comprehensive income for the year                (12,374)         (6,709)   (12,434) (10,721)        (40,912)\n", "page_number": 90, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.4553227875160325, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.9029499786233434, "height": 0.44762719110731086, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-90-9", "text": "87\n", "page_number": 90, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-91-0", "text": "Statement of Financial Position\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.2762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-91-1", "text": "The table below sets forth Curetis AG's statement of financial position as of 30 June 2015 and as of\n31 December 2014, 2013 and 2012:\n", "page_number": 91, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.142368533561351, "height": 0.026507054296708008, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-91-2", "text": "                                                        30 June                      31 December\n                                                      (unaudited)                      (audited)\n                                                         2015            2014          2013            2012\n                                                       \u20acthousand        \u20acthousand     \u20acthousand       \u20acthousand\n\nAssets\nCurrent assets                                              9,835           6,486          8,798          11,129\nCash and cash equivalents                                   5,940           2,994          5,382           9,777\nTrade receivables                                               486             42            140              56\nInventories                                                 3,199           3,153          2,786           1,005\nOther current assets                                            210           297             491             291\nNon-current assets                                          6,719           7,307          7,308           6,989\nIntangible assets                                               225           286             331             336\nProperty, plant and equipment                               6,070           6,592          6,457           5,986\nOther non-current assets                                           11           0                 7            16\nOther non-current financial assets                              412           429             514             650\nTotal assets                                               16,554          13,793         16,107          18,118\n\n\nEquity and liabilities\nCurrent liabilities                                         1,505           1,305          1,090           1,259\nTrade and other payables                                        831           580             616             634\nProvisions current                                                 50           35                6               1\nOther current liabilities                                       371           317             301             446\nOther current financial liabilities                             254           373             167             179\nNon-current liabilities                                   145,958         131,024       121,119          112,240\nProvisions non-current                                          819           816             777             770\nProvision PSOP                                              5,342           3,914          2,957           3,090\nOther non-current financial liabilities                         189           258             392             519\nFinancial liability for preferred and common shares       139,608         126,036       116,993          107,860\nTotal liabilities                                         147,463         132,329       122,209          113,499\nEquity                                                   (130,909)      (118,536)      (106,102)        (95,380)\nSubscribed equity                                                  50           50             50              50\nRetained earnings                                        (130,959)      (118,586)      (106,152)        (95,430)\nTotal equity and liabilities                               16,554          13,793         16,107          18,118\n", "page_number": 91, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.14279606669516887, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.8516460025651988, "height": 0.70884993587003, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-91-3", "text": "88\n", "page_number": 91, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-92-0", "text": "Statement of Cash Flows\n", "page_number": 92, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-92-1", "text": "The table below sets forth Curetis AG's statement of cash flows for the six months ended 30 June 2015 and 2014\nand for the years ended 31 December 2014, 2013 and 2012:\n", "page_number": 92, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.14279606669516887, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-92-2", "text": "                                                           For the six months            For the year ended\n                                                             ended 30 June                 31 December\n                                                              2015       2014            2014          2013      2012\n                                                                                 (in \u20acthousands)\n\n                                                               (unaudited)                         (audited)\n\nNet cash flows provided by operating activities             (3,525)    (3,992)         (7,481)       (9,173)   (7,025)\nNet cash flow used in investing activities                   (252)       (470)         (1,537)       (1,737)   (1,904)\nNet cash flow provided by / used in financing activities     6,723       5,801           6,630         6,514    6,850\nNet change in cash and cash equivalents                      2,946       1,339         (2,388)       (4,395)   (2,079)\nCash and cash equivalents at the beginning of the year       2,994       5,382           5,382         9,777   11,857\nCash and cash equivalent at the end of the year              5,940       6,721           2,994         5,382    9,777\n", "page_number": 92, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.1470713980333476, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.3762291577597264, "height": 0.22915775972637878, "width": 0.788391777509069}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-92-3", "text": "89\n", "page_number": 92, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.017533252720677073}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-0", "text": "OPERATING AND FINANCIAL REVIEW AND PROSPECTS\n", "page_number": 93, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.1085934159897392, "height": 0.016673792218896963, "width": 0.6438935912938331}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-1", "text": "The following is a review of Curetis AG's results of operations, financial position and cash flows as of and for\nthe three years ended 31 December 2014, 2013 and 2012 and as of and for the six months ended 30 June 2015\nand 2014. It is based on the Annual Financial Statements and the Interim Financial Statements.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.16417272338606242, "height": 0.03805044890979051, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-2", "text": "Where financial information in this section is labelled \"audited\", this means that it was taken from the Annual\nFinancial Statements. The label \"unaudited\" is used in this section to indicate financial data that was taken from\na source other than the Annual Financial Statements or recomputed from the Annual Financial Statements.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21462163317657118, "height": 0.04061564771269774, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-3", "text": "For a description of the corporate restructuring process of Curetis in connection with the Offering and an\nexplanation of why financial statements of Curetis AG are presented as historical financial statements in this\nProspectus, see \"Important Information \u2013 Presentation of Financial and other Information\".\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2625053441641727, "height": 0.04061564771269771, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-4", "text": "The figures in the following have been rounded in accordance with established commercial practice. Figures or\nadditions within a table may therefore result in sums different from those shown in the same table and do not\nalways add up to 100 %.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3108165882855921, "height": 0.04104318084651559, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-5", "text": "This section should be read in conjunction with the sections entitled \"Important Information \u2013 Presentation of\nFinancial and Other Information\" and \"Selected Financial Information\" and the Annual Financial Statements as\nwell as the Interim Financial Statements and notes to those financial statements, included elsewhere in this Pro-\nspectus.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.37238135955536555, "height": 0.05472424112868751, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-6", "text": "Overview\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.40017101325352716, "height": 0.014108593415989745, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-7", "text": "Curetis is a commercial-stage molecular diagnostics company focusing on simple, accurate and rapid solutions\nfor diagnosing infectious diseases and antibiotic resistance in severely ill, hospitalised patients. Today, the diag-\nnosis of infectious diseases in a hospital setting is still largely carried out through traditional microbiology cul-\nture based tests. This process is labour-intensive and time-consuming, typically delivering results only after 24\nhours or even weeks. As a result, adequate antibiotic therapy decisions are delayed, leading to poor patient out-\ncomes, longer hospital stays, increased hospital costs and overall spread of antibiotic resistance, a significant and\nincreasing problem throughout the world.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5130397605814451, "height": 0.09619495510902093, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-8", "text": "Curetis' Unyvero Platform enables the early detection of a broad range of different microorganisms and their\nrelated antibiotic resistance genes in a single test from a wide variety of native sample materials. The Unyvero\nPlatform is fully automated and integrates all diagnostic steps into a single Application Cartridge. It is easy to\nuse with minimum hands-on time of no more than five minutes. It is a walkaway solution that detects within four\nto five hours most microorganisms that take traditional microbiology culture based tests 24 hours or even weeks.\nThis allows clinicians to make early adjustments to a more specific treatment of the patient, saving significant\ntime and cost, in particular by reducing the time of the patient's hospital stay. The Unyvero Platform intends to\ncomplement rather than replace traditional microbiology.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5194527575887131, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.629328772979906, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-9", "text": "The Unyvero Platform is comprised of the Unyvero System, the Unyvero Software, and the Application Car-\ntridges. The Unyvero System is composed of (i) the Lysator for sample pre-processing and microorganism lysis,\n(ii) the Analyzer for processing the Application Cartridges and (iii) the Cockpit, a control panel for running the\nLysator(s) and the Analyzer(s) and displaying, exporting, and storing results. The Application Cartridges are\nsingle-use, disposable and disease specific.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7045746045318512, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-10", "text": "The Unyvero Platform has been CE-IVD-marked since 2012 and is commercialised in Europe and certain other\nmarkets that accept CE-IVD-marking (i.e. Kuwait, Qatar, Russia and the United Arab Emirates). The Unyvero\nPlatform is marketed through a combination of direct sales in key EU countries and distributors in selected EU\nmarkets and rest of the world (i.e. Kuwait, Qatar, Russia and the United Arab Emirates). Curetis also intends to\ncontinue to expand internationally as seen by the recent signing of distribution agreements with Acumen for\ncertain ASEAN markets (Indonesia, Malaysia, Singapore and Thailand) and Beijing Clear Biotech for Greater\nChina.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8033347584437794, "height": 0.09234715690466011, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-11", "text": "As of 30 June 2015, Curetis AG's total installed base comprised 70 Unyvero Analyzers. There are currently two\ncommercially available Application Cartridges: the P55 Application Cartridge, which addresses severe forms of\npneumonia, and the i60 ITI Application Cartridge, which addresses severe cases of implant and tissue infections.\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.8550662676357418, "height": 0.04147071398033353, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-12", "text": "The P55 Application Cartridge was commercially launched in April 2015 and is the second generation version of\nP50 Application Cartridge, the pneumonia cartridge initially launched in 2012. It is a CE-IVD-marked Applica-\ntion Cartridge for the fully automated detection of currently 20 microorganisms and 19 antibiotic resistance\nmarkers in native respiratory samples. With the test, Curetis aims to detect the vast majority of pneumonia caus-\ning pathogens in hospitalised patients and clinically relevant resistance markers against antimicrobials. Based on\n", "page_number": 93, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9303120991876871, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-93-13", "text": "90\n", "page_number": 93, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-0", "text": "its applicability to multiple forms of pneumonia, Curetis estimates that the P55 Application Cartridge has an\naddressable market of 2.3 million incidences per year in the EU and the US. 1\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-1", "text": "The i60 ITI Application Cartridge was launched in May 2014. It is a CE-IVD-marked Application Cartridge for\nthe fully automated detection of currently 61 microorganisms and 19 antibiotic resistance markers for eight dif-\nferent clinical indications within the area of prosthetic joint infections, diabetic foot ulcers, surgical site infec-\ntions, catheter-associated infections, deep skin and tissue infections, cardiology-related infections, burn wounds\nand other implant infections. Curetis estimates that the addressable market for the i60 ITI Application Cartridge\nis 2.1 million cases eligible for testing per year in the EU and the US. 2\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2013681060282172, "height": 0.08208636169303123, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-2", "text": "To date, more than 30 clinical studies with over 4,000 patient samples have been completed to validate both\nApplication Cartridges. Additional trials with more than 5,000 samples are on-going or scheduled in the coming\nyears. This includes the required clinical studies to obtain FDA clearance for the Unyvero System and the\nLRT55 Application Cartridge (technically equivalent to the P55 Application Cartridge). Following FDA clear-\nance, Curetis intends to commercialise the Unyvero System and the LRT55 Application Cartridge in the US\nthrough a direct sales effort beginning in 2017.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2902949978623343, "height": 0.08208636169303118, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-3", "text": "Curetis' pipeline products in development include the Application Cartridges targeting positive blood culture\ntesting and intra-abdominal/gastrointestinal tract infections both of which Curetis intends to launch commercial-\nly as CE-IVD-marked products in 2016. This is expected to be followed by a CE-IVD-marked sepsis host re-\nsponse Application Cartridge targeting commercial launch not before late 2017. Curetis also believes its Un-\nyvero Platform has the potential for menu expansion into other areas such as oncology, companion diagnostics,\ntransplant medicine and veterinary applications.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3792218896964515, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-4", "text": "Key Factors Affecting the Results of Operations\n", "page_number": 94, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.39290294997862335, "lower_right_x": 0.532043530834341, "lower_right_y": 0.41000427533133815, "height": 0.017101325352714802, "width": 0.4159613059250302}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-5", "text": "Set forth below are factors that Curetis believes have materially impacted its results of operations in the periods\nunder review and/or that Curetis' expects to materially impact its results of operations in future periods.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4514749893116717, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-6", "text": "Revenues\n", "page_number": 94, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.46472851646002566, "lower_right_x": 0.18561064087061668, "lower_right_y": 0.47840957674219753, "height": 0.013681060282171864, "width": 0.0683192261185006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-7", "text": "To date, Curetis has generated its revenues primarily from the following sales:\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48525010688328346, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.4993587002992732, "height": 0.014108593415989745, "width": 0.5326481257557436}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-8", "text": "\uf0b7   Sale of Unyvero Systems (sales of the components of the Unyvero System (Analyzer, Lysator and Cock-\n    pit) to distributors and collaboration partners);\n\uf0b7   Sale of Unyvero Application Cartridges;\n\uf0b7   Sale of services (revenues from research and development services performed by Curetis under the\n    Heraeus Medical collaboration and the in-house-measurement of patient-samples); and\n\uf0b7   Sale of spare parts (the re-sale of spare parts for the Unyvero Systems to the OEM supplier of the Un-\n    yvero Systems).\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.629328772979906, "height": 0.12013681060282178, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-9", "text": "While Curetis primarily generated revenues from the sale of its first three Unyvero Systems in 2012, the sale of\nUnyvero Application Cartridges and the sale of services under the collaboration arrangement with Heraeus Med-\nical contributed significantly to revenues of Curetis in 2013 and 2014. In the future, Curetis aims to primarily\ngenerate revenues through a combination of direct and indirect (via distributors) sales of Unyvero Systems and\nUnyvero Application Cartridges. Typically, the sale of Application Cartridges is preceded by the sale and/or\nplacement with clients of Unyvero Systems in which the Application Cartridges are used. If Curetis markets its\nproducts directly to customers, its commercial model of generating revenues involves the placement of Unyvero\nSystems free of charge and the temporarily free provision of application cartridges for testing. Curetis estimates\nthat the average lead time from the first contact with a customer to the customer's routine purchase of Applica-\ntion Cartridges to be approximately 12 months. Curetis estimates that its investment per installed Unyvero Sys-\ntem amounts to approximately \u20ac40 thousand that it aims to recoup through sales of Application Cartridges over\ntime. For customers using between 200-600 Application Cartridges per year, Curetis estimates to generate reve-\nnues in a range of approximately \u20ac50-\u20ac100 thousand per year with such customer at the list prices of the Appli-\ncation Cartridges.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8242838820008551, "height": 0.1885421120136811, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-10", "text": "cation Cartridges.\nIn addition to the sale of Unyvero Systems and Application Cartridges, Curetis intends to generate collaboration\nrevenues from current as well as new collaborations.\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8247114151346729, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8580589995724669, "height": 0.03334758443779395, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-11", "text": "Curetis historical revenues have been driven and Curetis expects that its future revenue will be driven by the\ncommercial roll-out of the Unyvero System and Curetis' current and future Application Cartridges. Curetis ex-\npects that its results will be materially affected by the level of success it has in rolling out its Unyvero Platform\nand the extent to which customers routinely use Unyvero Application Cartridges, which are expected to generate\n", "page_number": 94, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8683197947840958, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9221889696451475, "height": 0.053869174861051694, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-94-12", "text": "91\n", "page_number": 94, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.016928657799274438}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-0", "text": "the majority of revenue in the medium to long term. Furthermore, Curetis believes that the access to the US\nmarket which requires obtaining FDA clearance for the Unyvero Platform and Application Cartridges and suc-\ncessfully establishing a direct marketing and sales organisation in the US will be an important element of Cu-\nretis' revenue generation.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-1", "text": "Product and Manufacturing Quality\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.1675929884566054, "height": 0.014108593415989745, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-2", "text": "Product quality has had a material impact on Curetis' results of operations in the years 2012 to 2014. In the years\n2012 to 2014, a number of technical and qualitative challenges in connection with the Unyvero Platform led\nseveral distributors and customers to reduce or even pause the purchase of Unyvero Systems and Application\nCartridges. Consequently, Curetis' revenues and expenses in the years 2012 to 2014 have been influenced by\ntechnical and qualitative challenges and measures to resolve them and improve the product quality of the Un-\nyvero Platform.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25651988029072254, "height": 0.0825138948268491, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-3", "text": "In 2012 and 2013, Curetis experienced significant delays and shortages in the supply of Unyvero Systems. Dur-\ning that time, Curetis' OEM manufacturer Zollner had not yet been able to produce sufficient quantities of Un-\nyvero Systems at the required quality level. Curetis therefore implemented a series of design changes and an\nadditional layer of Unyvero product and hardware release testing at its own facilities using its own resources.\nCuretis continues to double-check every Unyvero System for any hardware or assembly related defects. This\nfailure to produce sufficient quantities of Unyvero Systems at the required quality level increased research and\ndevelopment expenses during the respective periods due to higher material costs, depreciation for the additional\nUnyvero Systems, personnel expenses for staff engaged in resolving the problem and other operating expenses\nfor third-party services. With almost all Unyvero Systems to date having been refurbished with these latest de-\nsign features, Curetis has not observed material hardware deficiencies in recent quarters. Curetis believes that\ndelivery quality and quantity are now at a level where a robust supply of systems has been established.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.413852073535699, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-4", "text": "In 2014, the commercial roll-out of the Unyvero Platform has also been slowed down and the prospective parts\nfor the FDA LRT55 trial were halted due to multiple Application Cartridges-related development issues that\nbecame apparent when broader usage occurred as part of Curetis' clinical trials as well as a growing customer\nbase. In the same year, in response to these quality issues and need for product improvements, a dedicated task\nforce of Curetis' R&D team members completed multiple design changes and improvements to the P50 Applica-\ntion Cartridge as well as i60 ITI Application Cartridges, which primarily impacted Curetis' R&D expenses.\nThese design changes and improvements were subsequently confirmed at Curetis' facilities and in extensive\nexternal customer site testing. Upon successful completion of these quality improvement measures in the fourth\nquarter of 2014 Curetis has been able to ramp up its manufacturing of Application Cartridges, improve first pass\nyield of lots and obtain favourable customer and distributor feedback upon these improvements.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.13723813595553652, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-5", "text": "With the resolution of these quality issues Curetis has significantly accelerated the commercial roll out in Aus-\ntria, Germany and Switzerland (\"DACH\") as well as other key European markets and through distributors and\nre-started the prospective parts of the FDA LRT55 trial in June 2015.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6053869174861052, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-6", "text": "Commercialisation Efforts\n", "page_number": 95, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6186404446344592, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.6327490380504489, "height": 0.01410859341598969, "width": 0.1856106408706167}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-7", "text": "Curetis' commercial model is largely based on revenues generated from the sales of Application Cartridges,\nwhich generally depend upon (i) placing Unyvero Systems, (ii) converting leads into routine customers, (iii)\ndriving utilisation of the Unyvero Systems and (iv) developing, launching and distributing new Application\nCartridges. Going forward, key metrics such as installed base, average number of Application Cartridges per\nsystem per month and average net selling prices of Application Cartridges will be important to monitor and man-\nage.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7216759298845661, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-8", "text": "Additionally, for certain markets that Curetis covers through its distribution partners (see \"Business \u2013 Marketing\nand Sales \u2013 Distribution Channels\"), Unyvero System and Application Cartridge sales will be dependent on the\ndistribution partners' ability to win government tenders, whereas government tenders are not a relevant factor for\nCuretis in the markets in which it distributes its products directly. Curetis expects that the sales of Unyvero Sys-\ntems to distribution partners and collaborators will be a material component of its total revenues, particularly in\nthe next few years.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8106028217186833, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-9", "text": "Distribution Costs\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8272766139375801, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.837964942283027, "height": 0.010688328345446862, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-10", "text": "Where Curetis markets and sells its products directly, its commercial model of generating revenues, largely with\nthe sale of Application Cartridges, makes it necessary to incur significant levels of distribution costs, e.g.\nthrough the placement of Unyvero Systems for free demo phase testing, the provision of test Application Car-\ntridges for free and time of marketing and distribution staff long before the corresponding expenses translate into\nrevenues. Curetis' estimates the average lead time from the first contact with a customer to a routine purchaser of\nApplication Cartridges, to be approximately 12 months.\n", "page_number": 95, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.9286019666524156, "height": 0.0808037622915776, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-95-11", "text": "92\n", "page_number": 95, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-0", "text": "Prior to 2013, Curetis incurred limited marketing and distribution expenses, as operations were in a pre-\ncommercial phase. Distribution costs increased in 2013 and 2014 in connection with the commercial launch and\nroll-out of the Unyvero Platform and include the related personnel costs. Curetis expects to increase sales and\nmarketing expenses to support the expanded commercial roll-out of the Unyvero Platform. In addition, the com-\nmencement of direct marketing, sales and distribution in the US upon the anticipated FDA clearance is expected\nto lead to significant distribution costs which will, at least initially, impact Curetis' results of operations.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1675929884566054, "height": 0.08251389482684908, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-1", "text": "Research and Development Expenses\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.37726723095526, "lower_right_y": 0.19495510902094912, "height": 0.014108593415989745, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-2", "text": "To date, Curetis' research and development expenses have mainly consisted of the development of the Unyvero\nSystem, software and associated Application Cartridges along with other Application Cartridges in the pipeline\n(i.e. targeting positive blood culture testing, intra-abdominal/gastrointestinal tract infections and sepsis host\nresponse). The development of the Unyvero Platform has been the largest expense to date. With the commercial\nlaunch of the Unyvero Platform in the second calendar quarter of 2012 and the subsequent design improvements\nand upgrades to the Unyvero Platform, the emphasis of research and development expenditures has shifted to\nfurther assay development for additional Application Cartridges as Curetis intends to launch at least one new\nApplication Cartridge per year.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31124412141941, "height": 0.1098760153911928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-3", "text": "Medical and clinical studies\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.324497648567764, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.33689610944848225, "height": 0.012398460880718276, "width": 0.19709794437726724}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-4", "text": "In 2012 and 2013, the prospective, multi-centre European clinical study at five trial sites for the P50 Application\nCartridge generated significant costs. This trial was completed in 2013. In 2014, a prospective clinical trial for\nthe i60 ITI Application Cartridge in prosthetic joint infections (EPJIC study) was initiated and the related re-\nsearch and development expenses are expected to continue impacting Curetis' results of operations in 2015 and\npossibly beyond. Furthermore, other studies relating to the P55 and the i60 ITI Application Cartridges in France\nand the UK that have been initiated in 2014 are expected to continue to impact our results of operations in 2015\nand possibly beyond.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.44121419410004276, "height": 0.09619495510902093, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-5", "text": "Curetis' FDA trial for the Unyvero System and the LRT50 Application Cartridge (labelled P55 outside the US)\nwas originally started in 2013 and incurred significant costs in 2013 and 2014. Due to the quality issues and\nproduct improvements of the Unyvero System and the Application Cartridges the prospective part of the FDA\ntrial was put on hold during most of 2014 and has been re-started in the second quarter of 2015. The collection of\nretrospective samples had continued throughout 2015 and is still on-going. As of 30 September 2015 the Com-\npany has enrolled over 400 patients into the prospective arm of its Unyvero Application Cartridge LRT55 FDA\ntrial and has collected more than 600 retrospective patient samples. In July 2015 and during the course of the\nthird quarter of 2015 the number of actively enrolling sites has been expanded from initially two sites to nine.\nResults of operations will be significantly impacted in the form of research and development expenses by the\ncontinuing Unyvero System and LRT55 Application Cartridge (the second generation version of the LRT50)\nFDA trial and all corresponding clinical as well as pre-clinical work packages, which Curetis expects to com-\nplete during 2016.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6122274476271911, "height": 0.16460025651988025, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-6", "text": "Clinical trials are expected to remain a major part of Curetis' R&D operations and to result in significant expens-\nes as more trials are required for multiple clinical indications and Application Cartridges in several geographies.\nWhile Curetis expects to have collaboration partners share in the cost of clinical trials, for example, in China and\nother Asian markets, these studies will nevertheless require commitment and resources on the side of Curetis.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6737922188969645, "height": 0.05515177426250528, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-7", "text": "In jurisdictions such as the US, the satisfactory outcome of medical and clinical studies is required to obtain\nregulatory clearance for commercialisation. In other countries or regions where clinical and medical studies are\nnot a prerequisite, favourable results are nevertheless likely to improve the perception of the Unyvero Platform\nwith potential customers and therefore likely to lead to an increase in revenues.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.735356990166738, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-8", "text": "Curetis believes that it will also be important to generate favourable results in clinical trials and outcome-related\nstudies in the future in order to demonstrate the value of the Unyvero Platform in real-world settings. The results\nfrom such studies and the extent to which they may be published in high-ranking peer-reviewed scientific and\nclinical journals will have a material impact on gaining customer acceptance, increased utilisation and broader\nmarket acceptance of the Unyvero System.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7430525865754596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8106028217186833, "height": 0.06755023514322367, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-9", "text": "Taxation\n", "page_number": 96, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8272766139375801, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.8371098760153912, "height": 0.0098332620778111, "width": 0.06711003627569527}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-10", "text": "Since its inception in 2007, Curetis has not generated any profits and, as a result, has not paid corporate income\ntaxes. Its accumulated losses totalled \u20ac40.2 million as of 31 December 2014, according to German GAAP. \u20ac39.5\nmillion of those losses could have been carried forward in time under German tax law and used to offset future\nprofits. However, these tax losses carried forward are likely to be forfeited as a result of the contribution of all of\nCuretis AG's shares into the newly established Curetis N.V. in connection with the Offering.\n", "page_number": 96, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9149209063702437, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-96-11", "text": "93\n", "page_number": 96, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-0", "text": "Curetis expects to continue to accumulate losses for the next few years. This will likely lead to respective losses\ncarried forward which could then be set-off against future profits for tax purposes, thus reducing the basis for\nincome taxation for future periods.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-1", "text": "Fair Value Measurement of Shares in Curetis AG\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.15391192817443353, "height": 0.014108593415989745, "width": 0.34885126964933494}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-2", "text": "According to IFRS, the various classes of shares that, under the respective shareholder agreements, had certain\nliquidation preferences and other preference rights, are viewed as financial liabilities rather than equity, the fair\nvalue of which is re-evaluated at the end of each reporting period. The re-evaluation has had a material impact\non Curetis' results of operations by reducing finance income \u2013 net in the six months ended 30 June 2015 by\n\u20ac6,783 thousand and in the years ended 31 December 2014, 2013 and 2012 by \u20ac2,286 thousand, \u20ac2,497 thousand\nand \u20ac32,098 thousand, respectively. However, subject to completion of the Offering, the preferred share classes\nwill be converted into a single class of common shares. At that time, Curetis will begin accounting for all shares\nas equity rather than financial liabilities.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.10987601539119282, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-3", "text": "Phantom Stock Options (Share-based Compensation Plan)\n", "page_number": 97, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2834544677212484, "lower_right_x": 0.526602176541717, "lower_right_y": 0.2975630611372381, "height": 0.014108593415989745, "width": 0.40931076178960096}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-4", "text": "Curetis' existing phantom stock options program (the \"PSOP\") is structured as a cash-settled instrument upon a\ndefined \"exit\" event \u2013 the latter being defined as either a trade-sale, an M&A transaction or an IPO of Curetis.\nThe resulting provision for the PSOP had been recorded as a liability in Curetis' statement of financial position.\nThis share-based payment plan issued by Curetis is accounted for in accordance with IFRS 2.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3591278324070115, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-5", "text": "The effect on the statement of profit or loss and other comprehensive income was driven by the fair value valua-\ntion at the end of each reporting period. The valuation resulted in the following effects:\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3655408294142796, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.39333048311244123, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-6", "text": "The increase in the provision for the PSOP from \u20ac1,087 thousand as of 1 January 2012 to \u20ac3,090 thousand as of\n31 December 2012 led to expenses of \u20ac2,003 thousand recognised for the year ended 31 December 2012, which\nwere allocated to the different line items of the statement of profit or loss and other comprehensive income ac-\ncording to the activity in which the beneficiary engaged. In the year ended 31 December 2012, this resulted in\nexpenses of \u20ac812 thousand in research & development expenses, \u20ac480 thousand in administrative expenses,\n\u20ac657 thousand in distribution costs, and \u20ac54 thousand in cost of sales.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.48225737494655835, "height": 0.08251389482684907, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-7", "text": "The decrease in the provision for the PSOP from \u20ac3,090 thousand as of 31 December 2012 to \u20ac2,957 thousand as\nof 31 December 2013 led to an expense reversal of \u20ac133 thousand recognised for the year ended 31 December\n2013 which were allocated to the different line items of the statement of profit or loss and other comprehensive\nincome according to the activity in which the beneficiary engaged. In the year ended 31 December 2013, this\nresulted in expense reversals of \u20ac53 thousand in research & development expenses, \u20ac32 thousand in administra-\ntive expenses, \u20ac44 thousand in distribution costs and \u20ac4 thousand to cost of sales.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5711842667806755, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-8", "text": "The increase in the provision for the PSOP from \u20ac2,957 thousand as of 31 December 2013 to \u20ac3,914 thousand as\nof 31 December 2014 led to expenses of \u20ac957 thousand recognised for the year ended 31 December 2014 which\nwas allocated to the different line items of the statement of profit or loss and other comprehensive income ac-\ncording to the activity in which the beneficiary engaged. In the year ended 31 December 2014, this resulted in\nexpenses of \u20ac373 thousand in research & development expenses, \u20ac218 thousand in administrative expenses,\n\u20ac338 thousand in distribution costs, and \u20ac28 thousand in cost of sales.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6601111586147926, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-9", "text": "The increase in the provision for the PSOP from \u20ac3,914 thousand as of 31 December 2014 to \u20ac5,342 thousand as\nof 30 June 2015 led to expenses of \u20ac1,428 thousand recognised for the six months ended 30 June 2015 which\nwere allocated to the different line items of the statement of profit or loss and other comprehensive income ac-\ncording to the activity in which the beneficiary engaged. In the six months ended 30 June, 2015, this resulted in\nexpenses of \u20ac515 thousand in research & development expenses, \u20ac315 thousand in administrative expenses,\n\u20ac562 thousand in distribution costs, and \u20ac37 thousand in cost of sales.\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6699444206926036, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7490380504489098, "height": 0.07909362975630618, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-10", "text": "With the completion of the Offering, the PSOP will be restructured into an instrument that will be cash-settled\nonly for PSOP Beneficiaries (as defined herein) who are each entitled to 1,000 or less phantom stock options\nunder the PSOP. This concerns a total of 38 persons who would in total be entitled to an amount of \u20ac469 thou-\nsand assuming an Offer Price at the upper end of the Offer Price Range and a first stock exchange trading price\nequal to such Offer Price. This cash settlement will be paid upon expiry of the agreed lock-up period of 365 days\nfrom the Settlement Date. The remainder of the Payment Claims (as defined herein) will be settled in Shares for\nPSOP Beneficiaries who are each entitled to more than 1,000 phantom stock options under the PSOP. This con-\ncerns a total of 20 persons who would in total be entitled to receive 665,020 Shares assuming an Offer Price at\nthe upper end of the Offer Price Range. This settlement in Shares will take place following expiry of the agreed\nlock-up period for the existing shareholders of 365 days from the Settlement Date. To be able to settle such\nPayment Claims in Shares, the Company will, assuming an Offer Price at the upper end of the Offer Price\n", "page_number": 97, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9063702436938863, "height": 0.1474989311671655, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-97-11", "text": "94\n", "page_number": 97, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-0", "text": "Range, issue 665,020 new Shares. The described settlement in cash and in Shares will lead to the elimination of\nthe PSOP provision in its entirety.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.12355707567336469, "height": 0.038477982043608375, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-1", "text": "Upon completion of the Offering, the current PSOP will not be used for any future grants. Curetis intends to\nimplement a customary long-term equity linked incentive plan on the Company level.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12398460880718255, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1470713980333476, "height": 0.02308678922616504, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-2", "text": "Recent Developments and Outlook\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.4189842805320435, "lower_right_y": 0.1774262505344164, "height": 0.01710132535271483, "width": 0.3035066505441354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-3", "text": "On 25 September 2015, Curetis and Beijing Clear Biotech entered into an exclusive international distribution\nagreement under which Curetis appointed Beijing Clear Biotech as the exclusive distributor of the Unyvero\nSystem and P55 and i60 ITI Application Cartridges in China, Taiwan and Hong Kong. Under the terms of this\nagreement, Beijing Clear Biotech is responsible for conducting and fully funding the prospective required clini-\ncal trials with CFDA and approval procedure required for the approval of the Unyvero System and the P55 and\ni60 ITI Application Cartridges for distribution in China. Curetis is obligated to reward Beijing Clear Biotech for\ncertain achievements in starting the clinical trials and registration process through milestone payments. The\nCompany estimates that marketing in Taiwan will start earlier, as no specific trial is required for product regis-\ntration. For the commercialisation of the Unyvero i60 ITI Application Cartridge, Beijing Clear Biotech is intend-\ned partner with LandMover Medical Technologies Co. Ltd. (Beijing, China), the exclusive Chinese distributor of\nHeraeus Medical. For further details to the contract, see \"Business \u2013 Material Contracts \u2013 Beijing Clear Bio-\ntech\".\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1911073108165883, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.3522873022659256, "height": 0.16117999144933728, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-4", "text": "On 5 October 2015, Curetis and Singapore-based Acumen agreed on a co-operation agreement with regard to the\ndevelopment and marketing of a sepsis host response test and the distribution of the Unyvero System and the\nApplication Cartridges in the ASEAN markets, starting with Singapore, Malaysia, Indonesia and Thailand. Ac-\numen granted Curetis a non-exclusive worldwide rights to develop and market a sepsis host response test as an\nApplication Cartridge for the Unyvero System on the basis of Acumen\u2019s proprietary sepsis host response bi-\nomarker panel. During the R&D phase, Curetis will be responsible for adapting its technology to run the Acu-\nmen sepsis host response biomarker panel with the Unyvero Platform, e.g.; transferring the current pre-analytical\nworkflow. It is Acumen's responsibility to further evaluate and optimise the biomarker panel for its intended use\nand to conduct health economic analyses and studies. Both parties will collaborate in the performance evaluation\nstudies for Asia and Europe required for commercialisation of the product. Curetis intends to first launch the\nApplication Cartridge as CE-IVD Application Cartridge in Europe and other regions accepting CE-IVD-\nmarkings. For further details to both contracts, see \"Business \u2013 Material Contracts \u2013 Acumen\".\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5262932877297991, "height": 0.16417272338606248, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-5", "text": "In October 2015, Curetis identified and recruited the Company's future Supervisory Directors, including industry\nexperts Bill Rhodes (future chairman of the board) and Mario Crovetto (future chairman of the audit committee)\n(see \"Management, Employees and Corporate Governance \u2013 Supervisory Board-Supervisory Directors\").\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5746045318512185, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-6", "text": "The third quarter of 2015 was the first full calendar quarter of patient sample enrolment into the LRT55 FDA\ntrial. Curetis has enrolled more than 400 prospective patient samples into the trial and the clinical trial network\nhas been expanded to its present full size of nine trial sites.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.62248824283882, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-7", "text": "In the third quarter of 2015, Curetis received \u20ac5,989 thousand of the second and final tranche of its series B\nfinancing round, while the remaining \u20ac800 thousand will be paid into the newly incorporated Company.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6566908935442497, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-8", "text": "During the third quarter of 2015 and in recent weeks, Curetis continued to commercially roll out the Unyvero\nPlatform in its direct sales territories and has been working closely with all its nine distribution partners in sup-\nporting their respective approaches to the territories. Unyvero System placements have continued and additional\ncommercial accounts have been identified and some converted into buying customers.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7178281316802052, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-9", "text": "Description of Principal Items of the Statement of Profit or Loss and Other Comprehen-\nsive Income\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.73492945703292, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.7627191107310817, "height": 0.027789653698161665, "width": 0.7629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-10", "text": "Revenue\n", "page_number": 98, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7798204360837965, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.7905087644292432, "height": 0.010688328345446751, "width": 0.06348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-11", "text": "Curetis is a single-segment entity. Revenues are generated through the sale of Unyvero Systems, Application\nCartridges and spare parts for Unyvero Systems and the provision of services. With regard to revenues in 2014,\nCuretis repurchased Unyvero Systems from distributors whose distribution agreements it had terminated which\nled to a reversal of revenues in the second half of 2014.\n", "page_number": 98, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8525010688328345, "height": 0.052586575459598106, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-12", "text": "Cost of Sales\n", "page_number": 98, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8683197947840958, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.8824283882000855, "height": 0.01410859341598969, "width": 0.09189842805320435}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-13", "text": "Cost of sales includes the costs for sold products manufactured as well as delivery costs for the sold merchan-\ndise. Manufacturing costs for products manufactured in-house include the directly allocable individual material\n", "page_number": 98, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8888413852073536, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9166310389055152, "height": 0.027789653698161665, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-98-14", "text": "95\n", "page_number": 98, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-0", "text": "and production costs, the allocable parts of the overhead costs for production including depreciation of produc-\ntion equipment and reduction in inventories.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-1", "text": "In 2012, as the development of the first Unyvero Application Cartridge (the P50) was still on-going, Curetis\naccounted for the incurred material expenses for the prototypes of the P50 Application Cartridge under material\nexpenses in cost of sales. From 2013 onwards, when the development of the prototypes of the P50 Application\nCartridge was completed, Curetis separated these material expenses and allocated them to the research and de-\nvelopment expenses.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.06840530141085933, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-2", "text": "Distribution Costs\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.24425634824667472, "lower_right_y": 0.21376656690893545, "height": 0.012398460880718248, "width": 0.12877871825876663}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-3", "text": "Distribution costs include all individual sales and overhead sales costs. They include all expenses for personnel,\nmarketing, materials and depreciation, in addition to other sales expenditures.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2496793501496366, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-4", "text": "Administrative Expenses\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.27704147071398033, "height": 0.014108593415989745, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-5", "text": "Administrative expenses include personnel, depreciation and other costs of the central administrative areas,\nwhich are not related to production, sales or research and development.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.31124412141941, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-6", "text": "Research and Development Expenses\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.37726723095526, "lower_right_y": 0.34031637451902524, "height": 0.012398460880718276, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-7", "text": "Research expenses are defined as costs incurred for research conducted to gain new scientific or technical\nknowledge and understanding. Development expenses are defined as costs incurred for the application of re-\nsearch findings or other knowledge to a plan or design for the production of new or substantially improved mate-\nrials, devices, products, processes, systems or services before the start of commercial production or use.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40188114578879863, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-8", "text": "For the periods under review, Curetis' research and development expenses mainly reflect salaries of research and\ndevelopment personnel and the costs of certain outsourced research and development services, working on (i)\nmanufacturing, engineering and operations not included in the cost of goods sold, (ii) research and development\nprogrammes focused on the expansion of the menu of application-specific cartridges and (iii) system engineer-\ning. It also includes the costs of reagents and Application Cartridges that are used in the research and develop-\nment of assays and other experiments with the Unyvero Platform, costs of consultants, as well as expenses relat-\ned to quality assurance, clinical, regulatory and medical affairs, clinical trial operations, and to filing new patents\nand maintaining Curetis' intellectual property portfolio. Finally, it also includes the annual depreciation expenses\nrelated to production equipment, laboratory and engineering equipment, capitalised Unyvero Systems for inter-\nnal use, amortisation of intangible fixed assets such as software, as well as depreciation related to the share of\nCuretis' offices and facilities used in research and development activities.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5579307396323215, "height": 0.14792646430098338, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-9", "text": "Other Income\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.5848653270628473, "height": 0.010688328345446751, "width": 0.10217654171704958}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-10", "text": "Other income mainly comprises income from grants, income from the re-charging of transportation costs to\ncustomers and claims against employees for the compensation of the partially private use of business cars.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5946985891406584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6220607097050022, "height": 0.027362120564343728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-11", "text": "Operating Profit\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.635741769987174, "lower_right_x": 0.2351874244256348, "lower_right_y": 0.6498503634031637, "height": 0.01410859341598969, "width": 0.11910519951632405}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-12", "text": "Operating profit measures Curetis' earning power from on-going operations and corresponds to earnings before\nfinancial result and taxes.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6562633604104318, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6806327490380505, "height": 0.024369388627618727, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-13", "text": "Finance income/costs \u2013 net\n", "page_number": 99, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6973065412569475, "lower_right_x": 0.309552599758162, "lower_right_y": 0.7114151346729372, "height": 0.01410859341598969, "width": 0.19286577992744858}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-14", "text": "Finance income/costs -net consists of finance costs fair value measurement of Curetis AG' preferred and com-\nmon shares, finance income, comprised mainly of interest on bank deposits, and finance costs, comprised mainly\nof lease obligations with regard to a laser welding module. For further details see \"\u2013 Key Factors Affecting the\nResults of Operations \u2013 Fair Value Measurement of Shares in Curetis AG\".\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7729799059427106, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-15", "text": "Results of Operations\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.30350665054413545, "lower_right_y": 0.8029072253099615, "height": 0.013253527148353927, "width": 0.18802902055622733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-16", "text": "The following table presents the statement of profit or loss and other comprehensive income of Curetis AG for\nthe six months ended 30 June 2015 and 2014, which was taken from the Interim Financial Statements and for the\nyears ended 31 December 2014, 2013, 2012, which was taken from the Annual Financial Statements.\n", "page_number": 99, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8584865327062847, "height": 0.04147071398033342, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-99-17", "text": "96\n", "page_number": 99, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-100-0", "text": "                                                  For the six months\n                                                        ended                         For the year ended\n                                                       30 June                          31 December\n                                                     (unaudited)                           (audited)\n                                                   2015          2014          2014          2013          2012\n                                                 \u20acthousand     \u20acthousand     \u20acthousand     \u20acthousand     \u20acthousand\n\nRevenue                                               742           254           275            671          146\nCost of sales                                         665           359           643            219          429\nGross profit                                              77       (105)         (368)           452        (283)\nDistribution costs                                   1,397         1,107         1,939         1,576        1,864\nAdministrative expenses                              1,366          867          1,637         1,256        1,437\nResearch and development expenses                    2,943         3,305         6,298         5,895        5,358\nOther income                                              41            23        111               49         22\nOperating profit                                   (5,588)       (5,362)      (10,132)        (8,226)      (8,919)\nFinance income                                            5             5              6            30         71\nFinance costs                                             9             12            22            28         43\nFinance costs fair value measurement                 6,783         1,340         2,286         2,497       32,098\nFinance income/costs \u2013 net                         (6,786)       (1,347)       (2,302)        (2,495)    (32,069)\nProfit before income tax                          (12,374)       (6,709)      (12,434)       (10,721)    (40,989)\nTax income                                                \u2013             \u2013              \u2013            \u2013        (77)\nProfit for the period                             (12,374)       (6,709)      (12,434)       (10,721)    (40,912)\nOther comprehensive income for the period, net\nof tax                                                    \u2013             \u2013              \u2013            \u2013             \u2013\nTotal comprehensive income for the period         (12,374)       (6,709)      (12,434)       (10,721)    (40,912)\n", "page_number": 100, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.09020949123557076, "lower_right_x": 0.8857315598548973, "lower_right_y": 0.5797349294570329, "height": 0.4895254382214621, "width": 0.7750906892382105}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-100-1", "text": "97\n", "page_number": 100, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-0", "text": "Comparison of the years ended 31 December 2012 and 2013\nRevenues\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.11628901239846089, "height": 0.031209918768704575, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-1", "text": "Revenue increased significantly from \u20ac146 thousand in 2012 by \u20ac525 thousand to \u20ac671 thousand in 2013. This\nincrease is mainly attributable to the fact that Curetis commenced commercialising the Unyvero System and P50\nApplication Cartridge only in the late 2012 and therefore only generated revenues in the fourth quarter of 2012.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1675929884566054, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-2", "text": "The following table sets forth a breakdown of Curetis' revenues by products and services, consisting of sale of\nUnyvero Systems, sales of cartridges, sales of services and sale of spare parts, for each of the periods presented,\nbased on the Annual Financial Statements:\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.03805044890979051, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-3", "text": "                                 For the year ended 31 December\n                                           (audited)\n                          2013                               2012\n                                           \u20ac thousand\nSale of Unyvero Systems                   250                       136\nSales of cartridges                        33                        10\nSales of services                         388                        \u2013\nSale of spare parts                         \u2013                        \u2013\nTotal revenues                            671                       146\n", "page_number": 101, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.21932449764856776, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.4117144078666097, "height": 0.19238991021804192, "width": 0.7708585247883918}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-4", "text": "Revenues from the sale of Unyvero Systems increased from \u20ac136 thousand in 2012 by \u20ac114 thousand, or 84%,\nto \u20ac250 thousand in 2013.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4446344591705857, "height": 0.024369388627618616, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-5", "text": "Revenues from sales of cartridges increased from \u20ac10 thousand in 2012 by \u20ac23 thousand to \u20ac33 thousand in\n2013.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-6", "text": "The increase in revenues from the sale of Unyvero Systems and from the sale of the Unyvero cartridges was due\nto an increase in quantities sold in 2013 as a result of the fact that Curetis only commenced commercialising the\nUnyvero system and P55 Application Cartridge in late 2012.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5301410859341599, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-7", "text": "Revenues generated with the sales of services were \u20ac388 thousand in 2013 and were attributable to the develop-\nment of specific bio assays on the i60 ITI Application Cartridge as part of Curetis' R&D-collaboration with\nHeraeus Medical.\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5780247969217615, "height": 0.04147071398033353, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-8", "text": "Geographical split\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.6147926464300983, "height": 0.013253527148354038, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-9", "text": "The following table sets forth a breakdown of Curetis' revenues by distribution method and geography for each\nof the periods presented based on the Annual Financial Statements:\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6220607097050022, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6498503634031637, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-10", "text": "                                       For the year ended 31 December\n                                                 (audited)\n                                    2013                            2012\n                                                 \u20ac thousand\n\nDirect Distribution DACH1                        388                        \u2013\nDirect Distribution outside DACH2                  \u2013                        \u2013\n                        3\nIndirect Distribution                            283                       146\nTotal revenues                                   671                       146\n", "page_number": 101, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.6532706284737068, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.8268490808037623, "height": 0.17357845233005553, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-11", "text": "Total revenues                                                                                   671                                                   146\n1 Reported as Germany, Austria and Switzerland in the Annual Financial Statements\n2 Consists of Belgium, France, Ireland, Luxembourg, the Netherlands, as all countries except for DACH in which Curetis markets products directly, reported as\n\"Western Europe\" in the Annual Financial Statements\n3 Consists of Bulgaria, Italy, Kuwait, Romania, Russia, Spain, Portugal, Qatar, United Arab Emirates, reported as \"Rest of World\" in the Annual Financial\nStatements\n", "page_number": 101, "bounding_box": {"top_left_x": 0.1124546553808948, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.8785805899957246, "height": 0.05130397605814452, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-101-12", "text": "98\n", "page_number": 101, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.018137847642079707}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-0", "text": "Cost of sales\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.09189842805320435}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-1", "text": "Cost of sales decreased from \u20ac429 thousand in 2012 by \u20ac210 thousand, or 49%, to \u20ac219 thousand in 2013. This\ndecrease was mainly due to the fact that the costs of sales shown in 2012 included significant expenses for Ap-\nplication Cartridge prototypes which were included in R&D expenses in 2013. In 2012, as the development of\nthe first Unyvero Application Cartridge (the P50) was still on-going, Curetis accounted for the incurred material\nexpenses for the prototypes of the P50 Application Cartridge under material expenses in cost of sales. From 2013\nonwards, when the development of the prototypes of the P50 Application Cartridge was completed, Curetis sepa-\nrated these material expenses and allocated them to the research and development expenses.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.20179563916203505, "height": 0.09619495510902094, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-2", "text": "Gross profit\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.20820863616930313, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.221889696451475, "height": 0.013681060282171864, "width": 0.08585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-3", "text": "As a result of the above, Curetis' gross profit increased from a loss of \u20ac283 thousand in 2012 by \u20ac735 thousand\nto a profit of \u20ac452 thousand in 2013.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.25651988029072254, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-4", "text": "Distribution costs\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.2736212056434374, "height": 0.010688328345446807, "width": 0.12575574365175335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-5", "text": "Distribution costs decreased from \u20ac1,864 thousand in 2012 by \u20ac288 thousand, or 15%, to \u20ac1,576 thousand in\n2013. This decrease was mainly due to the release of the PSOP in 2013 for employees engaged in distribution\nand marketing activities shown as personnel expenses in Curetis' statement of profit or loss and other compre-\nhensive income. This effect was only partly offset by an increase of \u20ac83 thousand in staff expenses, due to a\nhigher average number of employees engaged in distribution activities and higher consulting and other operating\nexpenses resulting from market research studies commissioned and performed in 2013 and higher expenses for\nApplication Cartridges used at customer sites for demonstration purposes.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37964942283026937, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-6", "text": "Administrative expenses\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.40017101325352716, "height": 0.014108593415989745, "width": 0.16928657799274482}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-7", "text": "Administrative expenses decreased from \u20ac1,437 thousand in 2012 by \u20ac181 thousand, or 13%, to \u20ac1,256 thousand\nin 2013. This decrease was mainly due to the release of the provision for the PSOP in 2013 for employees en-\ngaged in administrative activities shown as personnel expenses in Curetis' statement of profit or loss and other\ncomprehensive income. This effect was only partly offset by an increase in staff expenses of \u20ac81 thousand for\nadditionally hired employees and higher amortisation of \u20ac44 thousand for intangible assets, including a newly\nimplemented ERP-System.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4890979050876443, "height": 0.08251389482684907, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-8", "text": "Research and development expenses\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.5096194955109021, "height": 0.0141085934159898, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-9", "text": "Research and development expenses increased from \u20ac5,358 thousand in 2012 by \u20ac537 thousand, or 10%, to\n\u20ac5,895 thousand in 2013. This increase mainly resulted from increases of \u20ac262 thousand in depreciation and\namortisation relating to Unyvero Systems used in clinical trials and for research and development purposes, the\nincrease of \u20ac576 thousand in material costs for Application Cartridges used in clinical trials and research and\ndevelopment and the increase of \u20ac107 thousand in other operating expenses due to higher costs for third-party\nservices and higher travel costs. These increases were only partly offset by a decrease in personnel expenses of\n\u20ac667 thousand, of which \u20ac858 thousand resulted from the release of provisions for the PSOP, which were offset\nby an increase of \u20ac192 thousand in staff expenses.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6259085079093629, "height": 0.10987601539119274, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-10", "text": "Other income\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.635741769987174, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.646002565198803, "height": 0.010260795211628926, "width": 0.09613059250302296}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-11", "text": "Other income increased from \u20ac22 thousand in 2012 by \u20ac27 thousand, or 123%, to \u20ac49 thousand in 2013, mainly\ndue to received compensation of \u20ac18 thousand in 2013 due to damaged deliveries.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6558358272766139, "lower_right_x": 0.879081015719468, "lower_right_y": 0.6831979478409577, "height": 0.027362120564343728, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-12", "text": "Operating profit\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.7037195382642155, "height": 0.013253527148354038, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-13", "text": "As a result of the above, the operating loss decreased from \u20ac8,919 thousand in 2012 by \u20ac693 thousand, or 8%, to\n\u20ac8,226 thousand in 2013.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7340743907652844, "height": 0.023086789226165028, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-14", "text": "\u20ac8,226 thousand in 2013.\nFinance income/costs \u2013 net\n", "page_number": 102, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7345019238991022, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.7558785805899957, "height": 0.021376656690893503, "width": 0.18863361547763002}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-15", "text": "Finance income/costs \u2013 net decreased from \u20ac32,069 thousand in 2012 by \u20ac29,574 thousand, or 92%, to \u20ac2,495\nthousand in 2013. This decrease was mainly due to a decrease in the finance costs of the fair value measurement\nof the preferred and common shares in Curetis AG from \u20ac32,098 thousand in 2012 to \u20ac2,497 thousand in 2013.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8071825566481402, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-16", "text": "Profit before income tax\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.8272766139375801, "height": 0.013681060282171864, "width": 0.16989117291414751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-17", "text": "As a result of the above, loss before income tax decreased from \u20ac40,989 thousand in 2012 by \u20ac30,268 thousand\nto \u20ac10,721 thousand in 2013. Excluding the loss resulting from the valuation of the PSOP and the finance costs\nfrom the fair value measurement of the preferred and common shares, loss before income tax increased from\n\u20ac6,888 thousand in 2012 by \u20ac1,469 thousand, or 21%, to \u20ac8,357 thousand in 2013.\n", "page_number": 102, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8888413852073536, "height": 0.054724241128687456, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-102-18", "text": "99\n", "page_number": 102, "bounding_box": {"top_left_x": 0.8331318016928658, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.017533252720677073}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-0", "text": "Profit for the year\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.24062877871825877, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.12515114873035066}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-1", "text": "Profit for the year decreased from a loss of \u20ac40,912 thousand in 2012 by \u20ac30,191 thousand to a loss of \u20ac10,721\nthousand in 2013. Excluding the loss resulting from the valuation of the PSOP and the finance costs from the fair\nvalue measurement of the preferred and common shares, loss for the year increased from \u20ac6,811 thousand in\n2012 by \u20ac1,546 thousand, or 23%, to \u20ac8,357 thousand in 2013.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16032492518170158, "height": 0.05472424112868747, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-2", "text": "Comparison of the years ended 31 December 2013 and 2014\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.1881145788798632, "height": 0.014108593415989745, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-3", "text": "Revenues\n", "page_number": 103, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.195382642154767, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.20521590423257802, "height": 0.009833262077811017, "width": 0.06711003627569527}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-4", "text": "Revenue decreased from \u20ac671 thousand in 2013 by \u20ac396 thousand, or 59%, to \u20ac275 thousand in 2014. This\ndecrease was mainly due to the numerous technical and qualitative challenges to the Unyvero System and Appli-\ncation Cartridges in 2013 and 2014 (see \"\u2013 Key Factors Affecting Results of Operations \u2013 Product and Manufac-\nturing Quality\"), as well as the decrease in revenues from the provision of services for the development of spe-\ncific bio assays.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2834544677212484, "height": 0.06840530141085932, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-5", "text": "The following table sets forth a breakdown of Curetis' revenues by products and services, consisting of the sale\nof Unyvero Systems, sales of cartridges, sales of services and the sale of spare parts, for each of the periods\npresented, based on the Annual Financial Statements:\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-6", "text": "                                 For the year ended 31 December\n                                           (audited)\n                          2014                                    2013\n                                          \u20ac thousand\nSale of Unyvero Systems                    33                            250\nSales of cartridges                       154                             33\nSales of services                          46                            388\nSale of spare parts                        42                             \u2013\nTotal revenues                            275                            671\n", "page_number": 103, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.5301410859341599, "height": 0.19196237708422398, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-7", "text": "Revenues from the sale of Unyvero Systems decreased from \u20ac250 thousand in 2013 by \u20ac217 thousand to \u20ac33\nthousand in 2014. This decrease was driven by a lower number of Unyvero Systems sold in 2014 due to various\ntechnical and qualitative challenges resulting in reduced order volumes for several months in 2014. In addition,\nCuretis repurchased Unyvero Systems from distributors whose distribution agreements it had terminated which\nled to a reversal of revenues in the second half of 2014. The effect of the repurchase of three Unyvero Systems\nwas a reduction in revenues of \u20ac108 thousand and a corresponding decrease in costs of sales of \u20ac107 thousand\ndue to re-obtaining ownership to the Unyvero Systems. The effect on EBIT was therefore \u20ac1 thousand.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6353142368533561, "height": 0.09533988884138511, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-8", "text": "Curetis' agreements do not contain an obligation for Curetis to repurchase Unyvero Systems upon termination.\nThe repurchase of Unyvero Systems in 2014 was a one-time solution in negotiations with the relevant distribu-\ntors to find a mutual solution in good faith to terminate the agreement. It is not part of Curetis' business model to\nrepurchase Unyvero Systems.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6968790081231295, "height": 0.05429670799486963, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-9", "text": "Revenues from sales of cartridges increased from \u20ac33 thousand in 2013 by \u20ac121 thousand to \u20ac154 thousand in\n2014 due to the larger number of cartridges sold as a result of an increase in the number of customers with whom\nthe Unyvero System had been placed and which were routinely purchasing cartridges in 2014.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.7451902522445489, "height": 0.04104318084651559, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-10", "text": "Revenues from the sale of services decreased from \u20ac388 thousand in 2013 by \u20ac342 thousand to \u20ac46 thousand in\n2014 due to the completion of the collaboration project with Hereaus Medical in early 2014.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7793929029499786, "height": 0.027362120564343728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-11", "text": "Revenues from the sale of spare parts amounted to \u20ac42 thousand in 2014 and resulted from the re-sale of redun-\ndant spare parts for the Unyvero System to the supplier of those spare parts.\n", "page_number": 103, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8140230867892262, "height": 0.027789653698161665, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-12", "text": "The following table sets forth a breakdown of Curetis' revenues by distribution method and geography for each\nof the periods presented based on the Annual Financial Statements:\n", "page_number": 103, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8482257374946558, "height": 0.027789653698161554, "width": 0.7623941958887545}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-103-13", "text": "100\n", "page_number": 103, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-0", "text": "                                              For the year ended 31 December\n                                                         (audited)\n                                       2014                             2013\n                                                         \u20ac thousand\nDirect Distribution DACH1                          157                         388\nDirect Distribution outside DACH   2\n                                                     \u2013                          \u2013\nIndirect Distribution3                             118                         283\nTotal revenues                                     275                         671\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.2535271483539974, "height": 0.17186831979478406, "width": 0.777509068923821}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-1", "text": "Total revenues                                                                             275                                                           671\n1 Reported as Germany, Austria and Switzerland in the Annual Financial Statements\n2 Consists of Belgium, France, Ireland, Luxembourg, the Netherlands, as all countries except for DACH in which Curetis markets products directly, reported as\n\"Western Europe\" in the Annual Financial Statements\n3 Consists of Bulgaria, Italy, Kuwait, Romania, Russia, Spain, Portugal, Qatar, United Arab Emirates, reported as \"Rest of World\" in the Annual Financial\nStatements\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1124546553808948, "top_left_y": 0.2535271483539974, "lower_right_x": 0.8748488512696493, "lower_right_y": 0.30354852501068835, "height": 0.05002137665669093, "width": 0.7623941958887545}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-2", "text": "Cost of sales\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.32107738349722104, "lower_right_x": 0.20616686819830712, "lower_right_y": 0.3347584437793929, "height": 0.013681060282171864, "width": 0.08766626360338572}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-3", "text": "Cost of sales increased significantly from \u20ac219 thousand in 2013 by \u20ac424 thousand to \u20ac643 thousand in 2014.\nThis increase mainly resulted from write-downs on Unyvero Systems for marketability discounts. These write-\ndowns amounting to \u20ac313 thousand have been accounted for because some older, technically outdated Unyvero\nSystems that were used with (potential) customers for demonstration purposes or in-house could no longer be\nsold at fair market value.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.06541256947413426, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-4", "text": "Gross profit\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.41684480547242414, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.43095339888841383, "height": 0.01410859341598969, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-5", "text": "Due to the above factors, Curetis' gross profit decreased from a profit of \u20ac452 thousand in 2013 to a loss of \u20ac368\nthousand in 2014.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46173578452330055, "height": 0.024369388627618616, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-6", "text": "Distribution costs\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4715690466011116, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.483539974348012, "height": 0.011970927746900395, "width": 0.1233373639661427}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-7", "text": "Distribution costs increased from \u20ac1,576 thousand in 2013 by \u20ac363 thousand, or 23%, to \u20ac1,939 thousand in\n2014, mainly due to an increase in expenses for personnel engaged in distribution activities from \u20ac778 thousand\nin 2013 by \u20ac352 thousand to \u20ac1,130 thousand in 2014. This increase in expenses for personnel engaged in distri-\nbution activities mainly result from the valuation of the PSOP that led to expenses of \u20ac338 thousand in 2014,\nwhile compared to income of \u20ac44 thousand in 2013.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4920906370243694, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5600684053014109, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-8", "text": "Administrative expenses\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5673364685763147, "lower_right_x": 0.28174123337363965, "lower_right_y": 0.5814450619923044, "height": 0.01410859341598969, "width": 0.1656590084643289}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-9", "text": "Administrative expenses increased from \u20ac1,256 thousand in 2013 by \u20ac381 thousand, or 30%, to \u20ac1,637 thousand\nin 2014. This increase mainly resulted from the increase in personnel expenses by \u20ac228 thousand (thereof \u20ac158\nthousand from the valuation of the PSOP in 2014, compared to income of \u20ac23 thousand in 2013). Third-party\ncosts increased by \u20ac109 thousand in 2014, due to additional costs for the extension of the series B financing\nround.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6549807610089782, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-10", "text": "Research and development expenses\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6639589568191535, "lower_right_x": 0.36638452237001207, "lower_right_y": 0.6772124839675074, "height": 0.013253527148353927, "width": 0.25090689238210395}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-11", "text": "Research and development expenses increased from \u20ac5,895 thousand in 2013 by \u20ac403 thousand, or 7%, to\n\u20ac6,298 thousand in 2014. This increase mainly resulted from the increase in personnel expenses of employees\nengaged in research and development activities by \u20ac507 thousand (thereof \u20ac370 thousand from the higher valua-\ntion of PSOP in 2014, while that provision was reduced by \u20ac53 thousand in 2013). Material costs included in\nresearch and development expenses increased from \u20ac576 thousand in 2013 to \u20ac740 thousand in 2014 as a result\nof additional Application Cartridges needed to solve technical and qualitative challenges in 2014. This was only\npartly offset by a decrease in other operating expenses, resulting from a decrease in the utilisation of third-party\nservices due to the completed development of the Unyvero Systems.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7935014963659683, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-12", "text": "Other income\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8033347584437794, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.8135955536554083, "height": 0.010260795211628815, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-13", "text": "Other income increased from \u20ac49 thousand in 2013, by \u20ac62 thousand, or 127% to \u20ac111 thousand in 2014, mainly\ndue to compensation received from insurance providers for transport-related damages.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8234288157332194, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8499358700299273, "height": 0.026507054296707966, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-14", "text": "Operating profit\n", "page_number": 104, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.8499358700299273, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.870884993587003, "height": 0.020949123557075677, "width": 0.1124546553808948}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-15", "text": "As a result of the above, operating loss increased from \u20ac8,226 thousand in 2013 by \u20ac1,906 thousand, or 23%, to\n\u20ac10,132 thousand in 2014.\n", "page_number": 104, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8785805899957246, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.904232578024797, "height": 0.025651988029072315, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-104-16", "text": "101\n", "page_number": 104, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-0", "text": "Finance income/costs \u2013 net\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.09576742197520308, "height": 0.010688328345446765, "width": 0.18923821039903266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-1", "text": "Finance income/costs \u2013 net decreased from \u20ac2,495 thousand in 2013 by \u20ac193 thousand, or 8%, to \u20ac2,302 thou-\nsand in 2014 mainly due to a decrease of \u20ac211 thousand in the finance costs of the fair value measurement of the\npreferred and common shares in Curetis AG, which was only partly compensated by lower interest from bank\ndeposits.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16032492518170158, "height": 0.05472424112868747, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-2", "text": "Profit before income tax\n", "page_number": 105, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.1671654553227875, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.18084651560495937, "height": 0.013681060282171864, "width": 0.1686819830713422}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-3", "text": "As a result of the above, loss before income tax increased from \u20ac10,721 thousand in 2013 by \u20ac1,713 thousand, or\n16%, to \u20ac12,434 thousand in 2014.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21205643437366395, "height": 0.024369388627618643, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-4", "text": "16%, to \u20ac12,434 th\nProfit for the year\n", "page_number": 105, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.21205643437366395, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.23599828986746474, "height": 0.02394185549380079, "width": 0.1233373639661427}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-5", "text": "As Curetis did not record income tax expenses in 2013 or 2014, profit for the year equalled the profit before\nincome tax in both years. Adjusted for the loss resulting from the valuation of the PSOP and the finance costs\nfrom the fair value measurement of the preferred and common shares, loss for the year increased from \u20ac8,357\nthousand in 2013 by \u20ac834 thousand, or 10%, to \u20ac9,191 thousand in 2014.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2975630611372381, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-6", "text": "Comparison of the six months ended 30 June 2014 and 2015\n", "page_number": 105, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3108165882855921, "lower_right_x": 0.5374848851269649, "lower_right_y": 0.32492518170158186, "height": 0.014108593415989745, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-7", "text": "Revenues\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.0683192261185006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-8", "text": "Revenues increased significantly from \u20ac254 thousand in the first six months of 2014 by \u20ac488 thousand to \u20ac742\nthousand in the first six months of 2015. This increase was mainly due to the broader market penetration of the\nUnyvero Platform after Curetis successfully resolved its technical and qualitative challenges by the fourth quar-\nter of 2014 (see \"\u2013 Key Factors affecting Results of Operations \u2013 Product and Manufacturing Quality\"). In addi-\ntion, Curetis generated revenues through newly added distributors for Italy and the Middle East and from selling\nUnyvero Systems to a new pharmaceutical collaboration partner in the first six months of 2015.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3548525010688328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4343736639589568, "height": 0.07952116289012401, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-9", "text": "The following table sets forth a breakdown of Curetis' revenues by products and services, consisting of sale of\nUnyvero Systems, sales of cartridges, sales of services and sale of spare parts, for each of the periods presented,\nbased on the Interim Financial Statements:\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.44420692603676787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48225737494655835, "height": 0.03805044890979048, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-10", "text": "                                 For the six months ended 30 June\n                                           (unaudited)\n                          2015                                  2014\n                                           \u20ac thousand\nSale of Unyvero Systems                  474                           108\nSales of cartridges                      268                            58\nSales of services                          \u2013                            46\nSale of spare parts                        \u2013                            42\nTotal revenues                           742                           254\n", "page_number": 105, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.48952543822146216, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6840530141085934, "height": 0.19452757588713127, "width": 0.7744860943168077}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-11", "text": "Revenues from the sale of Unyvero Systems increased from \u20ac108 thousand in the first six months of 2014 by\n\u20ac366 thousand to \u20ac474 thousand in the first six months of 2015. This increase was mainly driven by a larger\nnumber of Unyvero Systems sold due to the fact that Curetis added two new distributors in Italy and the Middle\nEast, the orders of which contributed to revenues in the first six months of 2015. Curetis also sold several Un-\nyvero Systems to a new pharmaceutical collaboration partner in the first six months of 2015. The revenues from\nthe sale of Unyvero Systems for the six months ended 30 June 2014 are higher than the revenues from sale of\nUnyvero Systems for the entire year ended 31 December 2014 due to revenue reversals in the second half of\n2014 resulting from the re-purchase of Unyvero Systems from distributors whose distribution agreements had\nbeen terminated by Curetis.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8135955536554083, "height": 0.12312954253954678, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-12", "text": "Revenues from sales of cartridges increased from \u20ac58 thousand in the first six months of 2014 by \u20ac210 thousand\nto \u20ac268 thousand in the first six months of 2015 due to the larger number of cartridges as a result of an increase\nin the number of customers with whom the Unyvero System had been placed and which were routinely purchas-\ning cartridges in the first six months of 2015.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-13", "text": "No revenues from the sale of services and from the sale of spare parts were generated in the first six months of\n2015.\n", "page_number": 105, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8820008550662677, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9063702436938863, "height": 0.024369388627618616, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-105-14", "text": "102\n", "page_number": 105, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-0", "text": "The following table sets forth a breakdown of Curetis' revenues by distribution method and geography for each\nof the periods presented based on the Interim Financial Statements:\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-1", "text": "                                           For six months ended 30 June\n                                                     (unaudited)\n                                    2015                             2014\n                                                     \u20ac thousand\n                            1\nDirect Distribution DACH                       445                          122\nDirect Distribution outside DACH2               39                           \u2013\n                        3\nIndirect Distribution                          258                          132\nTotal revenues                                 742                          254\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.11842667806755024, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.28815733219324496, "height": 0.1697306541256947, "width": 0.7787182587666264}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-2", "text": "Total revenues                                                                             742                                                           254\n1 Reported as Germany, Austria and Switzerland in the Annual Financial Statements\n2 Consists of Belgium, France, Ireland, Luxembourg, the Netherlands, as all countries except for DACH in which Curetis markets products directly, reported as\n\"Western Europe\" in the Annual Financial Statements\n3 Consists of Bulgaria, Italy, Kuwait, Romania, Russia, Spain, Portugal, Qatar, United Arab Emirates, reported as \"Rest of World\" in the Annual Financial\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1124546553808948, "top_left_y": 0.28815733219324496, "lower_right_x": 0.880894800483676, "lower_right_y": 0.32834544677212485, "height": 0.040188114578879885, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-3", "text": "3 Consists of\nStatements\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.32834544677212485, "lower_right_x": 0.17533252720677148, "lower_right_y": 0.33732364258230013, "height": 0.008978195810175282, "width": 0.059250302297460714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-4", "text": "Statements\n\nCost of sales\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.337751175716118, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.3587002992731937, "height": 0.020949123557075677, "width": 0.09189842805320435}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-5", "text": "Cost of sales increased from \u20ac359 thousand in the first six months of 2014 by \u20ac306 thousand, or 85%, to \u20ac665\nthousand in the first six months of 2015. This increase mainly resulted from an increase in the number of Un-\nyvero Systems and Application Cartridges sold. Cost of sales increased significantly less than revenues due to a\nshift of the product mix towards the Application Cartridges which were sold at significantly higher gross mar-\ngins than the Unyvero Systems in the first six months of 2015.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3655408294142796, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4343736639589568, "height": 0.0688328345446772, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-6", "text": "Gross profit\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4407866609662249, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.4548952543822146, "height": 0.014108593415989745, "width": 0.0852478839177751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-7", "text": "Due to the above factors, Curetis' gross profit increased from a loss of \u20ac105 thousand in the first six months of\n2014 to a gross profit of \u20ac77 thousand in the first six months of 2015.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4890979050876443, "height": 0.02778965369816161, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-8", "text": "Distribution costs\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.24062877871825877, "lower_right_y": 0.5083368961094484, "height": 0.009405728943993108, "width": 0.12515114873035066}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-9", "text": "Distribution costs increased from \u20ac1,107 thousand in the first six months of 2014 by \u20ac290 thousand, or 26%, to\n\u20ac1,397 thousand in the first six months of 2015. This increase was mainly due to an increase in personnel ex-\npenses of \u20ac432 thousand (thereof an increase of \u20ac281 thousand based on the valuation of the PSOP). This was\nonly partly offset by a decrease in other operating expenses.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5194527575887131, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5711842667806755, "height": 0.051731509191962344, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-10", "text": "Administrative expenses\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.5934159897392048, "height": 0.012398460880718276, "width": 0.16989117291414751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-11", "text": "Administrative expenses increased from \u20ac867 thousand in the first six months of 2014 by \u20ac499 thousand, or\n58%, to \u20ac1,366 thousand in the first six months of 2015. This increase mainly resulted from an increase in other\noperating expenses by \u20ac408 thousand due to the costs of preparing IFRS financial statements and other expenses\nrelated to the Offering.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6536981616075246, "height": 0.05215904232578028, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-12", "text": "Research and development expenses\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6631038905515177, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.6759298845660539, "height": 0.012825994014536102, "width": 0.2466747279322854}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-13", "text": "Research and development expenses decreased from \u20ac3,305 thousand in the first six months of 2014 by \u20ac362\nthousand, or 11%, to \u20ac2,943 thousand in the first six months of 2015. This decrease was mainly due to a de-\ncrease in other operating expenses resulting from a decrease in internal demand for Application Cartridges for\nresearch and development purposes of \u20ac158 thousand and a reduction in other operating expenses such as the\npurchase of third-party services of \u20ac85 thousand, due to the now resolved technical and qualitative challenges\nand lower material costs for these Application Cartridges. Furthermore the shipping costs for Unyvero Systems\nto clinical trial sites decreased by \u20ac65 thousand since the US trial sites had mostly been equipped with the latest\nUnyvero Systems by 2014.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7935014963659683, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-14", "text": "Operating profit\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7999144933732364, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.8131680205215904, "height": 0.013253527148354038, "width": 0.1154776299879081}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-15", "text": "As a result of the above, operating losses increased from a loss of \u20ac5,362 thousand in the first six months of 2014\nby \u20ac226 thousand, or 4%, to a loss of \u20ac5,588 thousand in the first six months of 2015.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8473706712270201, "height": 0.026934587430525903, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-16", "text": "Finance income/costs \u2013 net\n", "page_number": 106, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8546387345019238, "lower_right_x": 0.3041112454655381, "lower_right_y": 0.8653270628473707, "height": 0.010688328345446862, "width": 0.18802902055622733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-17", "text": "Finance costs net increased significantly from \u20ac1,347 thousand in the first six months of 2014 by \u20ac5,439 thou-\nsand to \u20ac6,786 thousand in the first six months of 2015 mainly due to an increase in the finance costs of the fair\nvalue measurement of the preferred and common shares in Curetis AG.\n", "page_number": 106, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9162035057716973, "height": 0.04104318084651559, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-106-18", "text": "103\n", "page_number": 106, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-107-0", "text": "Profit before income tax\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.16989117291414751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-107-1", "text": "As a result of the above, loss before income tax increased from \u20ac6,709 thousand in the first six months of 2014\nby \u20ac5,665 thousand to \u20ac12,374 thousand in the first six months of 2015.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.13296280461735785, "height": 0.027362120564343742, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-107-2", "text": "Profit for the period\n", "page_number": 107, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.13980333475844378, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.15391192817443353, "height": 0.014108593415989745, "width": 0.1396614268440145}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-107-3", "text": "As Curetis did not record income tax expenses in the first six months of 2014 or 2015, profit for the period in the\nfirst six months of 2014 equalled the profit before income tax in in the first six months of 2015. Adjusted for the\nloss resulting from the valuation of the PSOP and the finance costs from the fair value measurement of the pre-\nferred and common shares, loss for the period decreased from \u20ac4,573 thousand in the first six months of 2014 by\n\u20ac410 thousand, or 9%, to \u20ac4,163 thousand in the first six months of 2015.\n", "page_number": 107, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.22830269345874304, "height": 0.06797776827704147, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-107-4", "text": "104\n", "page_number": 107, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-108-0", "text": "Financial Position\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.15961305925030228}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-108-1", "text": "The following table presents the statement of financial position of Curetis AG as of 30 June 2014 and 2015,\nwhich was taken from the Interim Financial Statements, and as of 31 December 2012, 2013 and 2014, which was\ntaken from the Annual Financial Statements.\n", "page_number": 108, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15391192817443353, "height": 0.03805044890979052, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-108-2", "text": "                                                        30 June                       31 December\n                                                      (unaudited)                       (audited)\n                                                         2015             2014            2013        2012\n                                                      \u20acthousand         \u20acthousand      \u20acthousand \u20acthousand\nAssets\nCurrent assets                                                  9,835       6,486           8,798      11,129\nCash and cash equivalents                                       5,940       2,994           5,382       9,777\nTrade receivables                                                486             42           140            56\nInventories                                                     3,199       3,153           2,786       1,005\nOther current assets                                             210          297             491         291\nNon-current assets                                              6,719       7,307           7,308       6,989\nIntangible assets                                                225          286             331         336\nProperty, plant and equipment                                   6,070       6,592           6,457       5,986\nOther non-current assets                                          11             0               7           16\nOther non-current financial assets                               412          429             514         650\nDeferred tax assets                                                 \u2013            \u2013               \u2013           \u2013\nTotal assets                                                16,554         13,793          16,107      18,118\n\n\nEquity and liabilities\nCurrent liabilities                                             1,505       1,305           1,090       1,259\nTrade and other payables                                         831          580             616         634\nProvisions current                                                50             35              6           1\nOther current liabilities                                        371          317             301         446\nOther current financial liabilities                              254          373             167         179\nNon-current liabilities                                    145,958        131,024         121,119     112,240\nProvisions non-current                                           819          816             777         770\nProvision PSO                                                   5,342       3,914           2,957       3,090\nOther non-current financial liabilities                          189          258             392         519\nFinancial liability for preferred and common shares        139,608        126,036         116,993     107,860\nTotal liabilities                                          147,463        132,329         122,209     113,499\nEquity                                                    (130,909)      (118,536)       (106,102)    (95,380)\nSubscribed equity                                                 50             50              50          50\nRetained earnings                                         (130,959)      (118,586)       (106,152)    (95,430)\nTotal equity and liabilities                                16,554         13,793          16,107      18,118\n", "page_number": 108, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.16417272338606242, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.8858486532706284, "height": 0.7216759298845661, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-108-3", "text": "105\n", "page_number": 108, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-0", "text": "Comparison of the years ended 31 December 2012 and 2013\nCurrent assets\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.11628901239846089, "height": 0.031209918768704575, "width": 0.4183796856106409}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-1", "text": "Cash and cash equivalents\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-2", "text": "Cash and cash equivalents decreased from \u20ac9,777 thousand as of 31 December 2012 by \u20ac4,395 thousand, or\n45%, to \u20ac5,382 thousand as of 31 December 2013. For the reasons for this decrease, please see \"\u2013 Cash Flow\"\nbelow.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.18469431380932022, "height": 0.03805044890979051, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-3", "text": "Inventories\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19452757588713127, "lower_right_x": 0.19528415961305925, "lower_right_y": 0.20649850363403163, "height": 0.011970927746900367, "width": 0.07920193470374849}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-4", "text": "Inventories increased from \u20ac1,005 thousand as of 31 December 2012 by \u20ac1,781 thousand to \u20ac2,786 thousand as\nof 31 December 2013. This increase mainly resulted from accumulation of Unyvero Systems towards the end of\n2013 in expectation of increased sales activity in the beginning of 2014.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.25651988029072254, "height": 0.04147071398033347, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-5", "text": "Other current assets\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.26336041043180847, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.27533133817870886, "height": 0.011970927746900395, "width": 0.1396614268440145}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-6", "text": "Other current assets increased from \u20ac291 thousand as of 31 December 2012 by \u20ac200 thousand, or 69%, to \u20ac491\nthousand as of 31 December 2013. This increase mainly resulted from higher VAT receivables.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8772672309552599, "lower_right_y": 0.31124412141941, "height": 0.02778965369816161, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-7", "text": "Non-current assets\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.3304831124412142, "height": 0.009405728943993164, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-8", "text": "Non-current assets\nProperty, plant and equipment\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3309106455750321, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.3548525010688328, "height": 0.023941855493800734, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-9", "text": "Property, plant and equipment increased from \u20ac5,986 thousand as of 31 December 2012 by \u20ac471 thousand, or\n8%, to \u20ac6,457 thousand as of 31 December 2013. This increase mainly resulted from an increase of \u20ac575 thou-\nsand in Unyvero Systems used for R&D and clinical trials and additional investments of \u20ac115 thousand in multi-\ncavity molding tools for the production of plastic parts for the Unyvero Application Cartridges which were only\npartly offset by straight-line depreciation of property, plant and equipment.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42924326635314236, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-10", "text": "Other non-current financial assets\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.43736639589568194, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.4476271911073108, "height": 0.01026079521162887, "width": 0.23216444981862155}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-11", "text": "Other non-current financial assets decreased from \u20ac650 thousand as of 31 December 2012 by \u20ac136 thousand, or\n21%, to \u20ac514 thousand as of 31 December 2013. This decrease resulted from a decrease of \u20ac150 thousand in\npledged bank deposits for the laser welding plant, only partly compensated by an increase of \u20ac14 thousand in\nrent deposits due to additional rented facility. The bank deposits are pledged as a security to the bank for the\nfinance lease of a laser welding plant.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45788798631893973, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5254382214621633, "height": 0.06755023514322361, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-12", "text": "Current liabilities\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.533133817870885, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.5438221462163317, "height": 0.010688328345446751, "width": 0.12575574365175335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-13", "text": "Trade and other payables\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.5677640017101325, "height": 0.01410859341598969, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-14", "text": "Trade and other payables decreased from \u20ac634 thousand as of 31 December 2012 by \u20ac18 thousand, or 3%, to\n\u20ac616 thousand as of 31 December 2013. This decrease mainly resulted from a slightly higher level of supplies\nand services in December 2012 than in December 2013.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6122274476271911, "height": 0.03805044890979048, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-15", "text": "Non-current liabilities\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6220607097050022, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.6327490380504489, "height": 0.010688328345446751, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-16", "text": "Provisions PSOP\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.6545532278751603, "height": 0.01197092774690045, "width": 0.1215235792019347}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-17", "text": "Provisions PSOP decreased from \u20ac3,090 thousand as of 31 December 2012 by \u20ac133 thousand, or 4%, to \u20ac2,957\nthousand as of 31 December 2013. This decrease was due to a lower valuation of the PSOP as of 31 December\n2013 due to regular adjustments made to the multi-year business plans mainly in terms of product development\ntimelines, revenue expectations going forward and the relative assessment of likelihood of various alternative\nexit scenarios.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.728516460025652, "height": 0.06541256947413421, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-18", "text": "Other non-current financial liabilities\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.7503206498503634, "height": 0.01197092774690034, "width": 0.2569528415961306}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-19", "text": "Other non-current financial liabilities\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7507481829841812, "lower_right_x": 0.37182587666263606, "lower_right_y": 0.7592988456605387, "height": 0.008550662676357512, "width": 0.2557436517533253}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-20", "text": "Other non-current financial liabilities comprise of liabilities from finance leases.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.7597263787943566, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.7729799059427106, "height": 0.013253527148354038, "width": 0.5386940749697703}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-21", "text": "Other non-current financial liabilities decreased from \u20ac519 thousand as of 31 December 2012 by \u20ac127 thousand,\nor 24%, to \u20ac392 thousand as of 31 December 2013. This decrease resulted from the decrease of long term liabili-\nties from finance lease. This liability is released on a straight line basis. No new finance leases were entered into\nin 2013.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8328345446772125, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-22", "text": "Financial liability for preferred and common shares\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8422402736212057, "lower_right_x": 0.46856106408706166, "lower_right_y": 0.8550662676357418, "height": 0.012825994014536102, "width": 0.35308343409915355}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-23", "text": "Financial liabilities for preferred and common shares increased from \u20ac107,860 thousand in 2012 by \u20ac9,133 thou-\nsand, or 8% to \u20ac116,993 thousand in 2013. This increase reflects the higher valuation of the preferred shares\nfrom 2012 to 2013 as well as the respective annual business plan updates and assessment of relative exit scenario\nlikelihoods.\n", "page_number": 109, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9153484395040615, "height": 0.053869174861051694, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-109-24", "text": "106\n", "page_number": 109, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-0", "text": "Equity\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08550662676357418, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.09833262077811031, "height": 0.01282599401453613, "width": 0.04836759371221282}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-1", "text": "Equity decreased from a negative \u20ac95,380 thousand as of 31 December 2012 by \u20ac10,722 thousand, or 11%, to a\nnegative \u20ac106,102 thousand as of 31 December 2013. This decrease was due to the negative total comprehensive\nincome Curetis generated in 2013.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.1466438648995297, "height": 0.041043180846515606, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-2", "text": "Comparison of the years ended 31 December 2013 and 2014\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-3", "text": "Current Assets\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.18127404873877725, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.19153484395040615, "height": 0.010260795211628898, "width": 0.10157194679564692}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-4", "text": "Cash and cash equivalents\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.21547669944420692, "height": 0.014108593415989718, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-5", "text": "Cash and cash equivalents decreased from \u20ac5,382 thousand as of 31 December 2013 by \u20ac2,388 thousand, or\n44%, to \u20ac2,994 thousand as of 31 December 2014. For the reasons for this decrease, please see \"\u2013 Cash Flow\"\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.258230012825994, "height": 0.03634031637451901, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-6", "text": "below.\nInventories\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2586575459598119, "lower_right_x": 0.1977025392986699, "lower_right_y": 0.2825994014536127, "height": 0.02394185549380079, "width": 0.0822249093107618}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-7", "text": "Inventories increased from \u20ac2,786 thousand as of 31 December 2013 by \u20ac367 thousand, or 13%, to \u20ac3,153 thou-\nsand as of 31 December 2014. This increase mainly resulted from the increase in inventories of Unyvero Sys-\ntems for sales and demonstration purposes.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.879081015719468, "lower_right_y": 0.3317657118426678, "height": 0.04147071398033347, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-8", "text": "Other current assets\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.3514322359982899, "height": 0.009833262077811045, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-9", "text": "Other current assets decreased from \u20ac491 thousand as of 31 December 2013 by \u20ac194 thousand, or 40%, to \u20ac297\nthousand as of 31 December 2014. This decrease resulted from less VAT receivables at the balance date as of\n31 December 2014.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.3993159469858914, "height": 0.03719538264215477, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-10", "text": "Non-current Assets\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.41000427533133815, "lower_right_x": 0.24969770253929868, "lower_right_y": 0.4202650705429671, "height": 0.010260795211628926, "width": 0.13361547762998793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-11", "text": "Property, plant and equipment\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.430525865754596, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.4446344591705857, "height": 0.01410859341598969, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-12", "text": "Property, plant and equipment increased slightly from \u20ac6,457 thousand as of 31 December 2013 by \u20ac135 thou-\nsand, or 2%, to \u20ac6,592 thousand as of 31 December 2014. This increase mainly resulted from additional invest-\nments of \u20ac143 thousand in manufacturing plants, \u20ac183 thousand in Unyvero Systems for clinical trials and R&D\npurposes and multi-cavity molding tools.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5053441641727234, "height": 0.05429670799486963, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-13", "text": "Other non-current financial assets\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.523300555793074, "height": 0.010688328345446751, "width": 0.2327690447400242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-14", "text": "Other non-current financial assets decreased from \u20ac514 thousand as of 31 December 2013 by \u20ac85 thousand, or\n17%, to \u20ac429 thousand as of 31 December 2014. This decrease mainly resulted from the decrease of pledged\nbank deposits for the laser welding plant required to be held as collateral for the finance lease. This liability is\nreleased on a straight line basis. No new finance leases were entered into in 2014.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5878580589995724, "height": 0.054724241128687456, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-15", "text": "Current liabilities\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5946985891406584, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.605814450619923, "height": 0.011115861479264577, "width": 0.12575574365175335}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-16", "text": "Trade and other payables\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6152201795639162, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.629328772979906, "height": 0.0141085934159898, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-17", "text": "Trade and other payables decreased from \u20ac616 thousand as of 31 December 2013 by \u20ac36 thousand, or 6%, to\n\u20ac580 thousand as of 31 December 2014. This decrease resulted from a decrease of outstanding trade payables\nincurred in the ordinary course of business.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6772124839675074, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-18", "text": "Other current financial liabilities\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6836254809747755, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.6973065412569475, "height": 0.013681060282171975, "width": 0.22249093107617895}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-19", "text": "Other current financial liabilities increased from \u20ac167 thousand as of 31 December 2013 by \u20ac206 thousand, or\n123%, to \u20ac373 thousand as of 31 December 2014. This increase resulted primarily from increased outstanding\ninvoices incurred in the ordinary course of business.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7045746045318512, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7456177853783669, "height": 0.0410431808465157, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-20", "text": "Non-current liabilities\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7554510474561779, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.7661393758016246, "height": 0.010688328345446751, "width": 0.15417170495767835}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-21", "text": "D...e 2 tn NOND", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7738349722103464, "lower_right_x": 0.23881499395405079, "lower_right_y": 0.7798204360837965, "height": 0.005985463873450114, "width": 0.12273276904474002}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-22", "text": "Provisions PSOP\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7798204360837965, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.7892261650277896, "height": 0.009405728943993164, "width": 0.1215235792019347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-23", "text": "Provisions PSOP increased from \u20ac2,957 thousand as of 31 December 2013 by \u20ac957 thousand, or 32%, to \u20ac3,914\nthousand as of 31 December 2014. This increase was due to a higher valuation of the PSOs as of 31 December\n2014 in combination with a higher volume of vested PSOs than as of 31 December 2013.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.8371098760153912, "height": 0.04061564771269777, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-24", "text": "Other non-current financial liabilities\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.844377939290295, "lower_right_x": 0.37182587666263606, "lower_right_y": 0.8554938007695596, "height": 0.011115861479264577, "width": 0.25453446191052}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-25", "text": "Other non-current financial liabilities decreased from \u20ac392 thousand as of 31 December 2013 by \u20ac134 thousand,\nor 34%, to \u20ac258 thousand as of 31 December 2014. This decrease resulted from the decrease of long term liabili-\nties from finance leases.\n", "page_number": 110, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8648995297135528, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9029499786233434, "height": 0.03805044890979059, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-110-26", "text": "107\n", "page_number": 110, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-0", "text": "Financial liability for preferred and common shares\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.35368802902055624}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-1", "text": "Financial liabilities for preferred and common shares increased from \u20ac116,993 thousand in 2013 by \u20ac9,043 thou-\nsand, or 8% to \u20ac126,036 thousand in 2014. This increase reflects the higher valuation of the preferred shares\nfrom 2013 to 2014 in the course of regular business plan updates and expectations with regards to the likelihood\nof various exit scenarios.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1573321932449765, "height": 0.051731509191962385, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-2", "text": "Equity\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.18127404873877725, "height": 0.014108593415989745, "width": 0.04897218863361548}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-3", "text": "Equity decreased from a negative \u20ac106,102 thousand as of 31 December 2013 by \u20ac12,434 thousand, or 12%, to a\nnegative \u20ac118,536 thousand as of 31 December 2014 due to the negative total comprehensive income Curetis\ngenerated in 2014.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.879081015719468, "lower_right_y": 0.2291577597263788, "height": 0.0414707139803335, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-4", "text": "Comparison of the six months ended 30 June 2015 and the year ended 31 December 2014\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.2424112868747328, "lower_right_x": 0.7400241837968561, "lower_right_y": 0.25651988029072254, "height": 0.014108593415989745, "width": 0.620918984280532}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-5", "text": "Current Assets\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.26421547669944423, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.27618640444634457, "height": 0.01197092774690034, "width": 0.09975816203143895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-6", "text": "Cash and cash equivalents\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.28430953398888414, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.2975630611372381, "height": 0.013253527148353983, "width": 0.18379685610640872}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-7", "text": "Cash and cash equivalents increased from \u20ac2,994 thousand as of 31 December 2014 by \u20ac2,946 thousand, or\n98%, to \u20ac5,940 thousand as of 30 June 2015. This increase mainly resulted from proceeds from the first tranche\nof the capital increase of the series B extension financing round that was only used partly to cover the operating\nlosses and cash outflows for investments in the first six months of 2015.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.35784523300555793, "height": 0.05386917486105175, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-8", "text": "Trade receivables\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.37964942283026937, "height": 0.010688328345446807, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-9", "text": "Trade receivables increased from \u20ac42 thousand as of 31 December 2014 by \u20ac444 thousand to \u20ac486 thousand as\nof 30 June 2015. This increase was due to the higher revenues that were mainly generated late in the second\nquarter of 2015.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.38948268490808036, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4279606669516888, "height": 0.038477982043608416, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-10", "text": "Inventories\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.1977025392986699, "lower_right_y": 0.4476271911073108, "height": 0.01026079521162887, "width": 0.0822249093107618}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-11", "text": "Inventories increased slightly from \u20ac3,153 thousand as of 31 December 2014 by \u20ac46 thousand, or 1%, to \u20ac3,199\nthousand as of 30 June 2015. This increase mainly resulted from an increase in finished products, i.e. Applica-\ntion Cartridges on stock, due to increased demands for customer demonstrations and the FDA trial, respectively.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45788798631893973, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49807610089781956, "height": 0.04018811457887983, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-12", "text": "Other current assets\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.2539298669891173, "lower_right_y": 0.5173150919196238, "height": 0.011543394613082514, "width": 0.13845223700120918}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-13", "text": "Other current assets decreased from \u20ac297 thousand as of 31 December 2014 by \u20ac87 thousand, or 29%, to \u20ac210\nthousand as of 30 June 2015. This decrease mainly resulted from lower VAT receivables and lower amounts of\ndeferred expenses.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5669089354424968, "height": 0.040615647712697656, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-14", "text": "Non-current Assets\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.24909310761789602, "lower_right_y": 0.5848653270628473, "height": 0.010688328345446751, "width": 0.13361547762998793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-15", "text": "Intangible Assets\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5946985891406584, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.6088071825566481, "height": 0.01410859341598969, "width": 0.1215235792019347}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-16", "text": "Intangible assets decreased from \u20ac286 thousand as of 31 December 2014 by \u20ac61 thousand, or 21% to \u20ac225 thou-\nsand as of 30 June 2015, due to straight-line amortisation of Curetis' ERP-system and other software.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6152201795639162, "lower_right_x": 0.879081015719468, "lower_right_y": 0.6430098332620778, "height": 0.027789653698161665, "width": 0.7617896009673518}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-17", "text": "Property, plant and equipment\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.6635314236853356, "height": 0.01410859341598969, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-18", "text": "Property, plant and equipment decreased from \u20ac6,592 thousand as of 31 December 2014 by \u20ac522 thousand, or\n8%, to \u20ac6,070 thousand as of 30 June 2015. This decrease mainly resulted from straight-line depreciation of\nproperty, plant and equipment only partly compensated by the investment in new property, plant and equipment.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6699444206926036, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7114151346729372, "height": 0.04147071398033353, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-19", "text": "Other non-current financial assets\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7178281316802052, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.731936725096195, "height": 0.0141085934159898, "width": 0.23216444981862155}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-20", "text": "Other non-current financial assets decreased from \u20ac429 thousand as of 31 December 2014 by \u20ac17 thousand, or\n4%, to \u20ac412 thousand as of 30 June 2015. This decrease resulted from the decrease of \u20ac17 thousand for pledged\nbank deposits for the laser welding plant.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7392047883710987, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7798204360837965, "height": 0.04061564771269777, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-21", "text": "Current liabilities\n", "page_number": 111, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.7875160324925182, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.8003420265070543, "height": 0.012825994014536102, "width": 0.12212817412333737}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-22", "text": "Trade and other payables\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.808037622915776, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.8204360837964942, "height": 0.012398460880718276, "width": 0.17472793228536881}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-23", "text": "Trade and other payables increased from \u20ac580 thousand as of 31 December 2014 by \u20ac251 thousand, or 43%, to\n\u20ac831 thousand as of 30 June 2015. This increase mainly resulted from the increased material and other operating\nexpenses resulting in higher invoices that were not paid at the reporting date.\n", "page_number": 111, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8704574604531852, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-111-24", "text": "108\n", "page_number": 111, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-0", "text": "Provisions current\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.09619495510902094, "height": 0.011115861479264633, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-1", "text": "Provisions current increased from \u20ac35 thousand as of 31 December 2014 by \u20ac15 thousand, or 43%, to \u20ac50 thou-\nsand as of 30 June 2015 due to higher provisions for warranties to reflect the increase in warranty risk as a result\nof the increase in revenues.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14365113296280463, "height": 0.03805044890979052, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-2", "text": "Other current liabilities\n", "page_number": 112, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.15348439504061565, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.16502778965369816, "height": 0.011543394613082514, "width": 0.15900846432889965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-3", "text": "Other current liabilities increased from \u20ac317 thousand as of 31 December 2014 by \u20ac54 thousand, or 17% to \u20ac371\nthousand as of 30 June 2015 mainly due to the increase in services received but not yet paid for and higher liabil-\nities for holidays not taken by employees as of the reporting date on 30 June 2015.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21547669944420692, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-4", "text": "Other current financial liabilities\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.33796856106408707, "lower_right_y": 0.23386062419837536, "height": 0.011970927746900367, "width": 0.22249093107617895}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-5", "text": "Other current financial liabilities decreased from \u20ac373 thousand as of 31 December 2014 by \u20ac119 thousand, or\n32%, to \u20ac254 thousand as of 30 June 2015. This decrease was mainly due to the decrease of goods already deliv-\nered but not yet paid for.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2804617357845233, "height": 0.038050448909790535, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-6", "text": "ered but not yet paid fo\nNon-current liabilities\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2804617357845233, "lower_right_x": 0.2720677146311971, "lower_right_y": 0.30440359127832406, "height": 0.023941855493800734, "width": 0.156590084643289}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-7", "text": "Provisions PSOP\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3142368533561351, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.32407011543394615, "height": 0.009833262077811045, "width": 0.1215235792019347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-8", "text": "Provisions PSOP increased from \u20ac3,914 thousand as of 31 December 2014 by \u20ac1,428 thousand, or 36%, to\n\u20ac5,342 thousand as of 30 June 2015. This increase was due to regular adjustments made to the multi-year busi-\nness plans in terms of product development timelines, revenue expectations going forward, relative assessment\nof likelihood of various alternative exit scenarios etc. resulting in corresponding fair value adjustments for the\nPSOP.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3993159469858914, "height": 0.0645575032064985, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-9", "text": "Other non-current financial liabilities\n", "page_number": 112, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.41000427533133815, "lower_right_x": 0.37122128174123337, "lower_right_y": 0.4202650705429671, "height": 0.010260795211628926, "width": 0.2551390568319226}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-10", "text": "Other non-current financial liabilities decreased from \u20ac258 thousand as of 31 December 2014 by \u20ac69 thousand,\nor 27%, to \u20ac189 thousand as of 30 June 2015. This decrease mainly resulted from the decrease of long term\nliabilities from finance lease. This liability is released on a straight line basis. No new finance leases were en-\ntered into in the first six months of 2015.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.430525865754596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48182984181274047, "height": 0.05130397605814446, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-11", "text": "Financial liability for preferred and common shares\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4920906370243694, "lower_right_x": 0.46856106408706166, "lower_right_y": 0.5053441641727234, "height": 0.013253527148354038, "width": 0.35308343409915355}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-12", "text": "Financial liability for preferred and common shares increased from \u20ac126,036 thousand as of 31 December 2014\nby \u20ac13,572 thousand, or 11%, to \u20ac139,608 thousand as of 30 June 2015. This increase reflects the higher valua-\ntion of the preferred shares as of 30 June 2015 as well as the respective annual business plan updates and as-\nsessment of relative exit scenario likelihoods and corresponding fair value adjustments.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5669089354424968, "height": 0.05429670799486952, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-13", "text": "Equity\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.16384522370012092, "lower_right_y": 0.5878580589995724, "height": 0.013681060282171864, "width": 0.04836759371221282}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-14", "text": "Equity decreased from a negative \u20ac118,536 thousand as of 31 December 2014 by \u20ac12,373 thousand, or 10%, to a\nnegative \u20ac130,909 thousand as of 30 June 2015. This decrease was due to the negative total comprehensive in-\ncome Curetis generated in the first six months of 2015.\n", "page_number": 112, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5946985891406584, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.635741769987174, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-112-15", "text": "109\n", "page_number": 112, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-0", "text": "Liquidity and Capital Resources\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.1013253527148354, "height": 0.016246259085079096, "width": 0.28536880290205563}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-1", "text": "Curetis' liquidity requirements relate primarily to the funding of research and development expenses, marketing\nand distribution expenses, general and administrative expenses, capital expenditures, and working capital re-\nquirements. Historically, Curetis was funded almost exclusively through the issuance of shares to venture capital\nand strategic investors in two rounds of equity financing: Prior to 2012, Curetis had already raised \u20ac36.5 million\nin equity capital in its seed stage (2007/2008, including founders, business angels and aeris CAPITAL) and a\nseries A financing round with multiple closings (November 2009: Hybrid Industry Development, aeris\nCAPITAL, LSP, BioMed Invest and KfW; April 2011 CD Venture; November 2011: Forbion Capital Partners\nand Roche Venture Fund).\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22402736212056434, "height": 0.10816588285592134, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-2", "text": "In April 2013, Curetis closed a series B financing round of \u20ac12.5 million in equity capital. HBM of Switzerland\nled that round as a new investor with the current institutional Shareholders and management also participating.\nThe payments into capital reserves were made in tranches and tied to a set of milestones which were subsequent-\nly amended and reached in 2014 with corresponding residual payments of \u20ac5.8 million into capital reserves.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2321504916631039, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2864471996579735, "height": 0.0542967079948696, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-3", "text": "On 21 November 2014, Curetis closed an extension to its series B financing round of \u20ac14.5 million. This round\nwas led by new investors LSP-HEF and QIAGEN with existing institutional investors also participating. Pay-\nment of the \u20ac1.00 per share totalling \u20ac893,293 was duly received in 2014 whereas payment of the first tranche of\n\u20ac6.8 million into the capital reserves was received in the first calendar quarter of 2015 and of the second tranche\nof \u20ac6.8 million was received in the third quarter of 2015.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.36212056434373663, "height": 0.07524583155194525, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-4", "text": "Since its inception, Curetis raised an aggregate of \u20ac63.7 million in two equity financing rounds.\nCuretis has not financed its business activities through bank loans and has no outstanding lines of credit with\nbanks.\nThe Company's cumulative net losses up to 30 June 2015 amounted to \u20ac131 million. The Company expects to\ncontinue incurring losses over the next few years.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.45788798631893973, "height": 0.08892689183411717, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-5", "text": "As of 31 December 2014 and 30 June 2015, the Company held \u20ac2,994 thousand and \u20ac5,940 thousand, respec-\ntively, as cash and cash equivalents.\n", "page_number": 113, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4583155194527576, "lower_right_x": 0.879081015719468, "lower_right_y": 0.48567764001710134, "height": 0.027362120564343728, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-113-6", "text": "110\n", "page_number": 113, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-114-0", "text": "Cash Flow\n", "page_number": 114, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.08507909362975631, "lower_right_x": 0.21100362756952842, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.09310761789600969}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-114-1", "text": "The following table presents the statement of cash flows of Curetis AG for the six months ended 30 June 2015\nand 2014, which was taken from the Interim Financial Statements, and for the years ended 31 December 2014,\n2015 and 2012, which was taken from the Annual Financial Statements.\n", "page_number": 114, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1573321932449765, "height": 0.04147071398033349, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-114-2", "text": "                                                          30 June                        31 December\n                                                        (unaudited)                        (audited)\n\n                                                     2015        2014         2014          2013        2012\n                                                    \u20acthousand   \u20acthousand    \u20acthousand    \u20acthousand    \u20acthousand\n\nProfit before income tax                            (12,374)      (6,709)    (12,434)      (10,721)     (40,989)\nAdjustments for:\n     Net finance cost                                  6,786       1,347        2,302        2,495        32,069\n     Depreciation, amortisation and impairments          837          683       1,448        1,272           956\n     Changes in provisions (excluding deferred\n     taxes)                                            1,445          858       1,023        (121)         2,033\nChanges in working capital relating to:\n     Inventories                                         (46)      (454)        (367)       (1,781)        (919)\n     Trade receivables and other receivables           (351)          400         383        (138)         (702)\n     Trade payables and other payables                   182       (110)          180        (180)           496\nIncome taxes received (+) / paid (\u2013)                        -            -           -             -               -\nInterest received (+) / paid (\u2013)                          (3)          (7)        (17)             2           29\nNet cash flows provided by operating activities       (3,525)     (3,992)      (7,481)      (9,173)      (7,025)\n\n\nInvestments in intangible assets                          (2)         (44)        (67)         (89)        (210)\nInvestments in property, plant and equipment           (252)       (431)       (1,512)      (1,649)      (2,384)\nReceipts from sale of assets                                \u2013           4            4             \u2013         690\nProceeds from disposal of fixed assets                      2           \u2013          38              1           \u2013\nNet cash flow used in investing activities             (252)       (470)       (1,537)      (1,737)      (1,904)\n\n\nPayments of finance lease liabilities                    (66)         (63)      (128)        (122)          (49)\nCash received from issuance of preferred shares        6,789       5,864        6,758        6,636         6,899\nNet cash flow provided by / used in financing\nactivities                                             6,723       5,801        6,630        6,514         6,850\nNet change in cash and cash equivalents                2,946       1,339       (2,388)      (4,395)      (2,079)\n\n\nCash and cash equivalents at the beginning of the\nyear                                                   2,994       5,382        5,382        9,777        11,857\nChange in cash and cash equivalents                    2,946       1,339       (2,388)      (4,395)      (2,079)\nCash and cash equivalent at the end of the\nyear                                                   5,940       6,721        2,994        5,382         9,777\n", "page_number": 114, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.16075245831551946, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.8892689183411714, "height": 0.728516460025652, "width": 0.782950423216445}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-114-3", "text": "111\n", "page_number": 114, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-0", "text": "Comparison of the years ended 31 December 2012 and 2013\nNet cash flows used in operating activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.11928174433518597, "height": 0.03420265070542966, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-1", "text": "Net cash flows used in operating activities increased from a cash outflow of \u20ac7,025 thousand in 2012 by \u20ac2,148\nthousand, or 31%, to a cash outflow of \u20ac9,173 thousand in 2013. This was mainly due to increases in inventory\ndriven by increased purchases of Unyvero Systems in 2013. In 2012 the trade payables increased resulting in a\npositive effect on the operating cash flow in 2012, while Curetis had a slight decrease in trade payables in 2013.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18127404873877725, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-2", "text": "Net cash flows used in investing activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1876870457460453, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.20179563916203505, "height": 0.014108593415989745, "width": 0.28536880290205563}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-3", "text": "Net cash flows used in investing activities decreased from a cash outflow of \u20ac1,904 thousand in 2012 by \u20ac167\nthousand or 9% to a cash outflow of \u20ac1,737 thousand in 2013. This was mainly due to fewer investments in\nmanufacturing plants that were only partly offset by increased investments for multi-cavity-molding-tools and\nUnyvero Systems. Furthermore, in 2012 Curetis sold a laser welding module under a sale-and-lease-back-\nagreement and received an amount of \u20ac690 thousand as purchase price from the leasing company as part of this\ntransaction.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.07909362975630613, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-4", "text": "Net cash flows provided by financing activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.31124412141941, "height": 0.014108593415989745, "width": 0.31983071342200725}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-5", "text": "Net cash flows provided by financing activities decreased from a cash inflow of \u20ac6,850 thousand in 2012 by\n\u20ac336 thousand, or 5%, to \u20ac6,514 thousand in 2013. This was mainly due to higher cash inflows from the capital\nincrease in 2012 (series A financing round) compared to 2013 (part of the series B financing round).\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3591278324070115, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-6", "text": "Comparison of the years ended 31 December 2013 and 2014\n", "page_number": 115, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.37238135955536555, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.3864899529713553, "height": 0.014108593415989745, "width": 0.4207980652962515}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-7", "text": "Comparison of the years ended 31 Decemb\n", "page_number": 115, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.3864899529713553, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.40017101325352716, "height": 0.013681060282171864, "width": 0.2859733978234583}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-8", "text": "Net cash flows used in operating activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.40059854638734504, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.4070115433946131, "height": 0.006412997007268051, "width": 0.28597339782345826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-9", "text": "Net cash flows used in operating activities decreased from a cash outflow of \u20ac9,173 thousand in 2013 by \u20ac1,692\nthousand, or 18%, to a cash outflow of \u20ac7,481 thousand in 2014. This was mainly due to fewer purchases of\nUnyvero Systems in 2014 than in 2013. In addition, there were increased cash-in-flows from trade and other\nreceivables in 2014 than in 2013.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.4677212483967507, "height": 0.05087644292432658, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-10", "text": "Net cash flow used in investing activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.49080803762291575, "height": 0.01239846088071822, "width": 0.2762998790810157}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-11", "text": "Net cash flow used in investing activities decreased from a cash outflow of \u20ac1,737 thousand in 2013 by \u20ac200\nthousand, or 12%, to a cash outflow of \u20ac1,537 thousand in 2014. This was mainly due to fewer investments in\nproperty, plant and equipment.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5391192817443352, "height": 0.040188114578879885, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-12", "text": "Net cash flow provided by financing activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5468148781530568, "lower_right_x": 0.43047158403869407, "lower_right_y": 0.5600684053014109, "height": 0.013253527148354038, "width": 0.3143893591293833}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-13", "text": "Net cash flow provided by financing activities increased from a cash inflow of \u20ac6,514 thousand in 2013 by \u20ac116\nthousand or 2%, to a cash inflow of \u20ac6,630 thousand in 2014. This was mainly due to increased cash inflows\nfrom a capital increase (part of the series B financing round and the extension of the series B financing round).\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6088071825566481, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-14", "text": "Comparison of the six months ended 30 June 2014 and 2015\n", "page_number": 115, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.6220607097050022, "lower_right_x": 0.5386940749697703, "lower_right_y": 0.6327490380504489, "height": 0.010688328345446751, "width": 0.41958887545344625}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-15", "text": "Comparison of the six months ended 30 Ju\nNet cash flows used in operating activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6327490380504489, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.6566908935442497, "height": 0.02394185549380079, "width": 0.29020556227327693}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-16", "text": "Net cash flows used in operating activities decreased from a cash outflow of \u20ac3,992 thousand in the first six\nmonths of 2014 by \u20ac467 thousand, or 12%, to a cash outflow of \u20ac3,525 thousand in the first six months of 2015\nprimarily due to a significantly higher loss before income tax and a decrease in trade and other receivables that\nwas only partly offset by an increase in net finance costs and increased changes in provisions.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718255664814023, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-17", "text": "Net cash flow used in investing activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.39117291414752114, "lower_right_y": 0.7387772552372809, "height": 0.01410859341598969, "width": 0.27569528415961303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-18", "text": "Net cash flow used in investing activities decreased from a cash outflow of \u20ac470 thousand in the first six months\nof 2014 by \u20ac218 thousand or 46%, to a cash outflow of \u20ac252 thousand in the first six months of 2015. This was\nmainly due to fewer investments in property, plant and equipment.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7866609662248825, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-19", "text": "Net cash flow provided by / used in financing activities\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7930739632321505, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.8071825566481402, "height": 0.01410859341598969, "width": 0.3730350665054413}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-20", "text": "Net cash flow provided by financing activities increased from of \u20ac5,801 thousand in the first six months of 2014\nby \u20ac922 thousand or 16%, to \u20ac6,723 thousand in the first six months of 2015. This was mainly due to higher\ncash inflows from the series B expansion capital increase.\n", "page_number": 115, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8550662676357418, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-115-21", "text": "112\n", "page_number": 115, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-0", "text": "Off-Balance Sheet Arrangements\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.1013253527148354, "height": 0.016246259085079096, "width": 0.29081015719467956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-1", "text": "Except for the arrangements mentioned in \"\u2013 Financial Commitments/Contractual Obligations\" below, Curetis\nhad not entered in any off-balance sheet arrangements as of 30 June 2015.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14279606669516887, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-2", "text": "Financial Commitments / Contractual Obligations\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.1569046601111586, "lower_right_x": 0.5507859733978234, "lower_right_y": 0.1735784523300556, "height": 0.016673792218896977, "width": 0.43349455864570735}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-3", "text": "Curetis leases its offices and production facility under non-cancellable operating lease agreements. The lease\nterm is 5 years and the agreements are renewable at the end of the lease term at market rate.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21504916631038906, "height": 0.027362120564343756, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-4", "text": "Curetis also leases machinery and vehicles under non-cancellable operating leases agreements. The lease term is\n3 years and the agreements are not renewable at the end of the lease term. The future aggregate minimum lease\npayments under non-cancellable operating leases and existing purchase commitments were as of 30 June 2015 as\nfollows:\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2736212056434374, "height": 0.0517315091919624, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-5", "text": "in \u20acthousand                                  2014    2013    2012\nNo later than 1 year                          2,528   4,515   1,733\nLater than 1 year and no later than 5 years   1,323    143     290\nLater than 5 years                              34       \u2013       \u2013\nTotal                                         3,885   4,658   2,022\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.2804617357845233, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.3911928174433519, "height": 0.11073108165882856, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-6", "text": "Financial Liabilities\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.4194100042753313, "height": 0.012825994014536102, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-7", "text": "The following table sets forth a breakdown of Curetis' financial liabilities as of 31 December 2014 by remaining\nterm:\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46130825138948267, "height": 0.023941855493800734, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-8", "text": "in \u20acthousand                               Up to 1 year     1-3 years      3-5 years   More than 5 years\nTrade and other payables                            580               \u2013           \u2013                   \u2013\nFinance lease liabilities                           133              258          \u2013                   \u2013\nFinancial liabilities for common shares               \u2013               \u2013           \u2013             126,036\nOther financial liabilities                         240               \u2013           \u2013                   \u2013\nThe amounts disclosed are the contractual undiscounted cash flows.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8899637243047158, "lower_right_y": 0.5951261222744763, "height": 0.12697734074390765, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-9", "text": "Capital Expenditures and Investments\n", "page_number": 116, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6152201795639162, "lower_right_x": 0.4498186215235792, "lower_right_y": 0.6284737067122702, "height": 0.013253527148354038, "width": 0.33313180169286577}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-10", "text": "Curetis' capital expenditures and investments for the six months ended 30 June 2015 and for the years ended 31\nDecember, 2014, 2013 and 2012 related primarily to investments in its manufacturing facility, multi cavity tools\nfor the production of plastic parts for Application Cartridges, Unyvero Systems used for research & development\npurposes and clinical trials and software. Curetis defines capital expenditure as its investments in property, plant\nand equipment and in intangible assets.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7114151346729372, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-11", "text": "The investments in intangible assets relate to Curetis ERP-system and other standard software throughout all\nperiods.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7456177853783669, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-12", "text": "In the year ended 31 December 2012, Curetis invested \u20ac2,384 thousand in property, plant and equipment (mainly\nmanufacturing facility and equipment cleanrooms, Unyvero Systems, Multi-cavity-tools) and \u20ac210 thousand in\nintangible assets.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7935014963659683, "height": 0.04147071398033342, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-13", "text": "In the year ended 31 December 2013, Curetis invested \u20ac1,649 thousand in property, plant and equipment (mainly\na multi cavity molding tool for the production of plastic parts for Application Cartridges and Unyvero Systems)\nand \u20ac89 thousand in intangible assets.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8413852073535699, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-14", "text": "In the year ended 31 December 2014, Curetis invested \u20ac1,512 thousand in property, plant and equipment (mainly\na multi cavity molding tool for the production of plastic parts for Application Cartridges and Unyvero Systems\nused for research & development purposes and clinical trials) and \u20ac67 thousand in intangible assets.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8888413852073536, "height": 0.037622915775972654, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-15", "text": "used for research & development purposes and clinical trials) and \u20ac67 thousand in intangible assets.\nIn the six months ended 30 June 2015, Curetis invested \u20ac252 thousand in property, plant and equipment and \u20ac2\nthousand in intangible assets.\n", "page_number": 116, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8892689183411714, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9247541684480547, "height": 0.035485250106883304, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-116-16", "text": "113\n", "page_number": 116, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-0", "text": "In the third quarter of 2015, Curetis made a one-time up-front payment with regard to licensing certain intellec-\ntual property of its collaboration partner Acumen (see \"Business \u2013 Material Contracts\").\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-1", "text": "Curetis currently intends to start planning an expansion of its production capacity once the utilisation of the\nexisting production capacity reaches 25% to 30% (corresponding to approximately 250 thousand to 300 thou-\nsand Application Cartridges per year). Curetis estimates that doubling the production capacity would require\ncapital expenditures of \u20ac5 million to \u20ac6 million) payable over a period of approximately two years.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17400598546387344, "height": 0.05472424112868747, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-2", "text": "The on-going development of Curetis' product pipeline (see \"Business \u2013 Products \u2013 Application Cartridge Pipe-\nline\") will require significant investments into respective research and development (mainly costs of personnel\nand material). Curetis intends to use parts of the proceeds of the Offering to cover these costs (see \"Reasons for\nthe Offering and Use of Proceeds\"). In addition, the on-going and future CE-IVD evaluation studies and the\nclinical trials of Curetis' existing and potentially future products for clearance with the FDA and other respective\nauthorities will require significant investments which Curetis also aims to fund using proceeds from the Offering\n(see \"Reasons for the Offering and Use of Proceeds\"). This includes milestone payments to be made to its distri-\nbution partner Beijing Clear Biotech Co. Ltd. for the clearing procedure with the China Food and Drug Admin-\nistration and the related clinical studies for marketing Curetis' products in China (see \"Business \u2013 Material Con-\ntracts\").\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17443351859769132, "lower_right_x": 0.880894800483676, "lower_right_y": 0.31765711842667804, "height": 0.14322359982898672, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-3", "text": "At the date of this Prospectus, Curetis has not firmly committed to any principal future investments except for\nthe up-front one-time payment of several hundred thousand euros to be made by Curetis to Acumen. (For further\ninformation see \"Business \u2013 Material Contracts \u2013 Acumen\".\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.3625480974775545, "height": 0.038050448909790535, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-4", "text": "Critical Accounting Policies and Estimates\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.3963232150491663, "height": 0.017101325352714802, "width": 0.3681983071342201}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-5", "text": "The preparation of financial statements in conformity with IFRS requires the management of Curetis to make\nestimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent\nassets and liabilities at the date of the financial statements and the reported amount of revenue and expenses\nduring the period. Actual results could differ from those estimates.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46515604959384355, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-6", "text": "Significant areas requiring the use of management estimates relate to the determination of the useful lives of\nproperty, plant and equipment, inventories, the valuation of stock options, provisions, the valuation of preferred\nshares, discounted cash flows for impairment testing, the recognition of deferred tax assets and the determination\nof the fair value of certain financial instruments.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.523300555793074, "height": 0.0517315091919624, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-7", "text": "Useful Economic Lives of Intangible Assets and Property, Plant and Equipment\n", "page_number": 117, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.539974348011971, "lower_right_x": 0.6723095525997581, "lower_right_y": 0.5540829414279607, "height": 0.01410859341598969, "width": 0.555018137847642}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-8", "text": "The uniform determination of the useful economic life for intangible assets and property, plant and equipment of\nCuretis is subject to the estimations made by the management of Curetis.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5882855921333904, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-9", "text": "Inventories\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.6156477126977341, "height": 0.010688328345446751, "width": 0.08282950423216444}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-10", "text": "Inventories are valued at the lower value of acquisition and manufacturing cost and net realisable value. The net\nrealisable value is determined by subtracting the costs incurred up to completion from the expected sales price of\nthe end product. If assumptions regarding future share prices or end product market potentials are not\nappropriate, this may lead to a further need for depreciating inventories.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.678922616502779, "height": 0.05344164172723387, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-11", "text": "Share-based Compensation Plan\n", "page_number": 117, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6938862761864044, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.7071398033347585, "height": 0.013253527148354038, "width": 0.23155985489721886}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-12", "text": "Curetis has a cash-settled share-based payment plan in place. The estimation of the fair value of the phantom\nstock options is based on an option pricing model. Estimating the fair value for share-based payment transactions\nrequires determination of the most appropriate valuation model, which depends on the terms and conditions of\nthe option plan. The estimate also requires determination of the most appropriate inputs to the valuation model\nincluding the expected life of the phantom stock option, volatility, likely exit scenarios and their respective\nprobabilities and dividend yield and making assumptions about them.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7969217614365113, "height": 0.08251389482684901, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-13", "text": "Provisions\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.18984280532043532, "lower_right_y": 0.8208636169303121, "height": 0.010688328345446751, "width": 0.07436517533252722}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-14", "text": "When accounting for provisions, management must make assumptions regarding the probability of certain\nbusiness transactions resulting in an impending loss of commercial benefit for Curetis. Estimates regarding the\namount and timing of possible economic outflows form the basis for the measurement of provisions. If the actual\namount and the timing differ from estimates made, then this may affect the results of Curetis.\n", "page_number": 117, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8854211201368106, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-117-15", "text": "114\n", "page_number": 117, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-0", "text": "Preferred and Common Shares\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.21765417170495766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-1", "text": "Preferred and common shares in Curetis AG were measured at their fair value. For the determination of the fair\nvalue the management of Curetis needed to make assumptions on several input factors (e.g. business\ndevelopment, weighted average cost of capital, beta factors). Upon successful completion of an IPO and thereby\nconversion of the preferred share classes into a single class of common shares Curetis expects this to revert back\nto accounting for all shares as equity rather than financial liabilities.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.17400598546387344, "height": 0.06840530141085933, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-2", "text": "Impairments\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1876870457460453, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.20094057289439932, "height": 0.01325352714835401, "width": 0.09189842805320435}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-3", "text": "To test for impairment, the value in use is determined by means of the discounted cash flow method.\nAssumptions regarding future business developments and general underlying data are to be made for this\npurpose. If there are any changes in these input factors, the recognition of impairment may be necessary.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2496793501496366, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-4", "text": "Deferred Tax Assets\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.27704147071398033, "height": 0.014108593415989745, "width": 0.14510278113663844}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-5", "text": "The calculation of deferred tax assets requires assumptions to be made with regard to the level of future taxable\nincome and the timing of recovery of deferred tax assets. These assumptions take account of forecast operating\nresults and the impact on earnings of the reversal of taxable temporary differences. Since future business\ndevelopments cannot be predicted with certainty and to some extent cannot be influenced by Curetis, the\nmeasurement of deferred tax assets is subject to uncertainty.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3522873022659256, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-6", "text": "Recent Accounting Pronouncements\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.36896109448482256, "lower_right_x": 0.42986698911729143, "lower_right_y": 0.3830696879008123, "height": 0.014108593415989745, "width": 0.3137847642079807}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-7", "text": "Accounting was originally made under the rules of German GAAP (HGB). Curetis AG converted the financial\nstatements of 2012, 2013 and 2014 as well as the interim financials per 30 June 2014 and 2015 to IFRS and will\nuse IFRS as the leading accounting standards going forward.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3963232150491663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43779392902949976, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-8", "text": "Quantitative and Qualitative Disclosures about Market and Financial Risks\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.4685763146643865, "height": 0.014108593415989745, "width": 0.6535671100362757}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-9", "text": "Curetis' business is exposed to a variety of financial risks such as currency risks, fair value interest risks, cash\nflow risks, interest rate risks and price risks. Curetis' finance department has implemented a number of measures\nto identify and evaluate such risks in close collaboration with the operations department.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48525010688328346, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5250106883283454, "height": 0.03976058144506195, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-10", "text": "Market risk\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.539974348011971, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.5506626763574177, "height": 0.010688328345446751, "width": 0.08645707376058041}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-11", "text": "Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of\nchanges in market prices. Curetis has significant international operations and is therefore influenced by foreign\ncurrency exchange rates and interest rates. However, Curetis currently does not hold any securities available for\nsale and Curetis keeps all its liquidity in immediately available money market funds.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6147926464300983, "height": 0.05429670799486963, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-12", "text": "Foreign exchange risk\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.6430098332620778, "height": 0.0141085934159898, "width": 0.16021765417170497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-13", "text": "Curetis is exposed to foreign currency risks primarily through its business. Curetis identifies its main currency\nrisk in US dollars because certain purchase transactions are made in US dollars. Curetis has not yet entered into\nany currency hedging arrangements in order to cover its exposure. Curetis is managing its foreign currency risks\nby identifying its mid-term-US dollar needs within its rolling forecast and it opportunistically takes advantage of\nrebounds of the currently historical low exchange rates to cover these demands. In sum, Curetis was exposed to\nvery limited foreign exchange risk during the periods from 2012 to 2014 as a result of the limited number of\ntransactions in foreign currencies it undertook. At present, Curetis is not exposed to any material foreign curren-\ncy risk, except for the US dollar expenses for the US FDA trial. Revenues are mainly generated in euro.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7592988456605387, "height": 0.10987601539119285, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-14", "text": "Other market risk\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.7725523728088927, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.7832407011543394, "height": 0.010688328345446751, "width": 0.12212817412333737}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-15", "text": "Curetis is not exposed to equity price risk or commodity price risk as it does not invest in these classes of in-\nvestments.\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7930739632321505, "lower_right_x": 0.879081015719468, "lower_right_y": 0.8174433518597691, "height": 0.024369388627618616, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-16", "text": "Credit risk\n", "page_number": 118, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8341171440786661, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.8473706712270201, "height": 0.013253527148354038, "width": 0.0773881499395405}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-17", "text": "The finance department works in close cooperation with the other operating departments to identify capital risks\nrelated to account receivables balances. Curetis analyses the credit risk of each new client before standard pay-\nment and delivery terms and conditions are offered. Curetis has also implemented a well-organised dunning\nsystem and in 2014, Curetis had write-downs on trade receivables of \u20ac2 thousand in (2013: \u20ac0 thousand, 2012:\n\u20ac0 thousand). The credit risk on the accounts receivables is limited because Curetis primarily sells to large labor-\n", "page_number": 118, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9234715690466011, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-118-18", "text": "115\n", "page_number": 118, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-119-0", "text": "atories, pharmaceutical companies and public hospitals in Central and Western Europe and all of these partners\nhave very good credit ratings. Outside of Europe, Curetis works together with large and experienced distributors.\nIf Curetis expands the business to other countries with a generally higher customer creditworthiness risk, Curetis\nwill consider a commercial credit insurance to cover the risks.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1368106028217187, "height": 0.051731509191962385, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-119-1", "text": "Cash and cash equivalents as well as short-term deposits are invested in euro-denominated money market funds\nwith highly reputable banks. Curetis follows a strong no-risk-policy which means that Curetis just has sight\ndeposits at banks and sometimes time deposits with short fixed-terms.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-119-2", "text": "Liquidity risk\n", "page_number": 119, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2013681060282172, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.21547669944420692, "height": 0.014108593415989718, "width": 0.09673518742442562}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-119-3", "text": "In the past, Curetis has been mostly driven by research and development during the reporting periods and Curetis\nis at a rather early stage of commercialisation. Therefore, the main source of cash inflows have been (and will\ncontinue to be) obtained through capital increases. Curetis monitors its liquidity through monthly and quarterly\nrolling forecasts and financial reports. Curetis has not yet established any credit line with financial institutions.\nThe ability of Curetis to maintain adequate cash reserves to sustain the Company's activities in the medium to\nlong term is highly dependent on its ability to increase cash inflows from product sales, as well as the sale of\nnew shares. As a consequence Curetis is exposed to significant liquidity risks in the medium term.\n", "page_number": 119, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.3180846515604959, "height": 0.09619495510902093, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-119-4", "text": "116\n", "page_number": 119, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-0", "text": "INDUSTRY\n", "page_number": 120, "bounding_box": {"top_left_x": 0.43530834340991537, "top_left_y": 0.08507909362975631, "lower_right_x": 0.560459492140266, "lower_right_y": 0.10260795211628901, "height": 0.017528858486532697, "width": 0.12515114873035066}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-1", "text": "Overview\n", "page_number": 120, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.11928174433518597, "lower_right_x": 0.20193470374848851, "lower_right_y": 0.1333903377511757, "height": 0.014108593415989731, "width": 0.08585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-2", "text": "Since the discovery of deoxyribonucleic acid (\"DNA\") over 60 years ago, followed by the development of the\nsequencing and polymerase chain reaction technology, there have been many advances in the research of human\nhealth and diseases. Insights into the molecular mechanisms underlying normal human physiology and disease\nhave given way to the continuous discovery of variations and dysregulations of genes that can be used as bi-\nomarkers to assess disease predisposition, detect disease at its earliest stages, diagnose and classify diseases in\ntremendous detail, determine the individual patient's prognosis to respond to therapeutic intervention and moni-\ntor disease recurrence post intervention. Diagnostic methods and products for detecting nucleic acid-based bi-\nomarkers are summarised under the term molecular diagnostics and can also be used to identify microorganisms\ncausing an infection.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27105600684053016, "height": 0.12099187687045748, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-3", "text": "The availability of methods to fast and reliably detect and characterise specific nucleic acids in a large variety of\nsample type materials easily obtained from patients has made MDx a driver of innovation in medicine allowing\nfor a shift to an increasingly personalised and more effective healthcare.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28003420265070544, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.31979478409576745, "height": 0.039760581445062004, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-4", "text": "MDx testing of DNA derived from pathogens causing infections are by far the largest segment of the MDx mar-\nket and infectious diseases are still one of the leading causes of death worldwide.3 The fast and precise detection\nof pathogens as well as biomarkers relating to their resistance to anti-infective agents has become paramount in\neffectively managing infections in individual patients, controlling outbreaks and pandemics, and the more in-\nformed use of scarce antibiotics resources thereby may slow down the spread of antibiotic resistant pathogens \u2013\none of the medical challenge in the 21st century. 4\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32791791363830697, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.40914920906370245, "height": 0.08123129542539548, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-5", "text": "Initially, the vast majority of MDx tests targeted single viruses or bacteria and were used to screen larger popula-\ntions effectively for these pathogens. Due to increasingly personalised healthcare syndromic-based multiplexed\nMDx tests are becoming increasingly important. 5 These multiplexed tests allow for the simultaneous detection of\nnumerous specific nucleic acids important in clinical syndromes and hence can provide a detailed picture of\nthose microorganisms underlying an individual patient's infection including their antibiotic resistance pattern,\nthus allowing for a personalised approach to treatment with anti-infectious agents at the earliest stage of care.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.49807610089781956, "height": 0.08123129542539542, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-6", "text": "Size of the Molecular Diagnostics Market\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.47339782345828296, "lower_right_y": 0.5288584865327063, "height": 0.01624625908507904, "width": 0.35792019347037485}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-7", "text": "The global MDx market is estimated at US$5 billion in 2013 and presents a significant share of the total in vitro\ndiagnostics market.6 In 2013 the largest markets, in terms of sales, were North America with US$2.4 billion,\nEurope with US$1.3 billion followed by Asia with US$0.8 billion.7 Other segments in the IVD market include\nimmunoassays, clinical chemistry, point of care, haematology, or coagulation. The MDx market is growing rap-\nidly: in the period from 2006-2014 its compounded annual growth rate (\"CAGR\") was 13.6%8 and in 2013-2018\nit is expected to grow by a CAGR of 9.7% globally, translating in a US$8 billion global MDx market in 2018 in\nterms of sales.9\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6361693031209918, "height": 0.09277469003847794, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-8", "text": "Molecular Diagnostics Market by Application\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.5120918984280532, "lower_right_y": 0.669089354424968, "height": 0.01624625908507915, "width": 0.39661426844014513}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-9", "text": "In 2013, infectious disease testing with a share of 45.3% was the largest segment of the MDx market. Oncology\n(14.5%), blood screening (14.4%), genetics (9.4%), microbiology (9.1%) and others (7.4%) have significantly\nsmaller shares.10 Curetis products target the infectious disease, as well as the microbiology markets. Curetis\nbelieves that there is crucial need for multiplex MDx assay menus comprising respiratory tract, gastrointestinal\ntract, sepsis, CNS/Meningitis and HCV (hepatitis C virus) tests.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7524583155194527, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-10", "text": "However, pathogen identification is still underserved by MDx methods and vastly relies on traditional microbi-\nology culture based tests despite an increasing need for faster and more comprehensive diagnostics.11 Thus, even\nthough modern medicine and medical research are evolving and have achieved remarkable advances, infectious\ndiseases are still one of the leading causes of death worldwide and are expected to have a significant impact on\nhealth in the future. In addition, conditions like climate change, increasing international trade and travelling in a\nglobalised world facilitate the spread of pathogens, disease and antibiotic resistance. 12 Therefore, Curetis sets a\nclear focus on assays in severe infectious diseases in hospitalised patients capturing relevant microorganisms and\nantibiotic resistance markers.\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8653270628473707, "height": 0.10645575032064991, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-11", "text": "Apart from an increasing frequency of infectious disease outbreaks, emerging antimicrobial resistance provides a\nsevere challenge to any further improvement in managing infectious diseases. Abundant and inadequate use of\nantibiotics in agriculture and human medical treatment leads to a sharp rise in antimicrobial resistance, which is\nspreading at global scale.13 According to the World Health Organisation (\"WHO\"), in Europe 25,000 deaths per\n", "page_number": 120, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9298845660538692, "height": 0.054724241128687456, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-120-12", "text": "117\n", "page_number": 120, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-0", "text": "year are associated with multi-drug resistant14 (resistance against one agent in three or more antimicrobial cate-\ngories15) infections, which lead to \u20ac1.5 billion treatment costs for the EU.16 One in ten microorganisms is report-\ned to be multi-resistant.17 Antibiotics are being prescribed to approximately one third of all people with a health\ninsurance every year.18 On a global scale antibiotics consumption has increased by 36% from 2000 to 2011 19 and\n30% of antimicrobial drug use in hospitals is unnecessary. 20\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15305686190679776, "height": 0.06797776827704145, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-1", "text": "At the same time, only very few novel antimicrobials prove their value in clinical trials and reach the market. 21\nThis situation shows the need for a more informed use of available antibiotics. However, rapid diagnostics ena-\nbling guided antibiotic therapy are still missing.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2013681060282172, "height": 0.04104318084651562, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-2", "text": "The Obama administration with its National Strategy on Combating Antibiotic-Resistant Bacteria22, the WHO\nwith its Global action plan on antimicrobial resistance 23 and the G7 summit's discussions and Leaders' Declara-\ntion24 expressed their commitment to take action against antimicrobial resistance. US President Obama an-\nnounced in 2015 the goal to reduce antibiotic use in outpatient care by 50% and in inpatient care by 20% until\n202025 and the WHO has declared the need for 'effective, rapid and low-cost diagnostic tools'.26\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27661393758016245, "height": 0.06840530141085932, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-3", "text": "Compared to traditional methods for the detection of microorganisms (microbiology cultures), modern and effec-\ntive MDx tests aid in the earlier and more accurate detection of microorganisms. 27 Fast diagnostics can provide\ndirections to selecting effective antimicrobial agents with greater likelihood or adjust empiric treatment at an\nearlier stage in the cycle of care.28 Hence, a variety of fast sample-to-answer (sample-to-answer describes the\nprocess from patient sample drawing at beside until test result available for patient treating physician) molecular\ndiagnostics test systems and new advanced pathogen and resistance biomarker assays have become and are be-\ncoming available in recent years.29 These fast multiplexed MDx assays can effectively complement conventional\nmicrobiology by providing timely and accurate information to tailor treatment to individual patients (personal-\nised medicine). However, MDx is not expected to replace microbiology culture based diagnostics as this tradi-\ntional method is still the backbone of epidemiological studies.\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27704147071398033, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4202650705429671, "height": 0.14322359982898675, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-4", "text": "Such MDx tests may also aid in preventing the further spreading of antimicrobial resistances by preventing mis-\nuse of scarce antibiotic resources. They further support the pharmaceutical industry in their clinical validation of\nnew antibiotics by identifying suitable patients for enrolment into clinical trials faster, allowing for shorter and\nsmaller trials and more targeted use of those antibiotics that make it to the market (companion diagnostics). 30\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.48225737494655835, "height": 0.05515177426250534, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {"industry": ["pharmaceutical"]}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-5", "text": "With regard to clinical applications for multiplexed MDx, Curetis believes that assays targeting pathogens causa-\ntive for upper respiratory tract infections (\"URTI\") are primary driver for current MDx instrument placements.\nFurthermore, CNS (central nervous system)/meningitis testing and lower respiratory tract assays are believed to\nhave a great potential for the MDx market for the next years. Lower respiratory tract infections (\"LRTI\"), most-\nly pneumonia, are dominated by bacterial aetiology whereas upper respiratory tract infections \u2013 e.g.; common\ncold, flu \u2013 are primarily attributed to viral agents. 31 While upper respiratory infection diagnostics mostly relies on\nswabs, testing for LRTI requires handling of different, challenging samples types. In addition, LRTI panels shall\ncapture antibiotic resistance genes to enable better treatment decisions. In addition, market growth is expected to\nbe accelerated by multiplex tests addressing other disease areas, like implant and tissue infection, gastrointestinal\ntract infection and sepsis \u2013 all addressing a significant clinical need, see \"Business\".\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6259085079093629, "height": 0.13723813595553652, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-6", "text": "The Molecular Diagnostics Market by Geography\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.6566908935442497, "height": 0.01752885848653274, "width": 0.43107617896009676}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-7", "text": "Segmenting the MDx market geographically, in 2013 North America had by far the largest share with 47%, in\nterms of sales, while Europe contributed 27%, Asia 16% and RoW 10%.32\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6699444206926036, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6977340743907653, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-8", "text": "In the period from 2013 to 2018 North American MDx sales are expected to grow by 9% CAGR from US$2.4\nbillion to US$3.6 billion. Europe is expected to increase its MDx market size by 9% CAGR from US$1.3 billion\nto $US2 billion by 201833, comprising US$159 million in the UK, US$472 million in Germany, US$355 million\nin France, US$324 million in Italy, US$204 million in Spain and Rest of Europe (\"RoE\") with US$516 mil-\nlion.34 The Asian market is expected to grow from 2013 to 2018 by 12% CAGR from US$0.8 billion to US$1.4\nbillion. Until 2018 the share of RoW is growing by 11% CAGR and is expected to increase market volume from\nUS$514 million to US$875 million.35\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7994869602394186, "height": 0.09533988884138522, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-9", "text": "The Molecular Diagnostics Market by Customer\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.5368802902055623, "lower_right_y": 0.831124412141941, "height": 0.01410859341598969, "width": 0.42140266021765416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-10", "text": "Molecular testing \u2013 which has traditionally been performed mostly by large specialised and complex laboratories\nwith highly trained staff \u2013 has now also entered facilities with less skilled and trained staff as widely automated\nand integrated MDx systems simplify the laboratory workflow and require less training and no special laboratory\ninfrastructure. Major end-users of MDx tests are currently hospital laboratories and mainly in the US so-called\nreference laboratories, accounting for a combined 90% share of the global MDx market in 2013. 36 Of these,\nhospital laboratories account for 54.7% of the total market and are the largest end-user customer group.37 Placing\n", "page_number": 121, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.08251389482684901, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-121-11", "text": "118\n", "page_number": 121, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-0", "text": "systems in hospital departments depends on the individual hospital infrastructure and if they consider that mo-\nlecular testing should be exclusively performed within laboratories or not. Despite the opportunity for decentral-\nised MDx systems placements outside traditional laboratory settings (e.g. in intensive care units), the Curetis\nmanagement expects that molecular testing for severe infectious disease will still mostly be performed in micro-\nbiology laboratories. However, point of need placements or patient near MDx system installation are also ex-\npected to be gaining share. For more details see \"Business \u2013 Marketing and Sales \u2013 Sales process\".\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16673792218896966, "height": 0.08165882855921335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-1", "text": "The Molecular Diagnostics Market by Technology\n", "page_number": 122, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.18084651560495937, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.19752030782385635, "height": 0.016673792218896977, "width": 0.4353083434099154}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-2", "text": "Today's prevailing molecular biology technology used for human molecular diagnostics is the polymerase chain\nreaction with a 41.7% share in the global MDx market in 2013. Isothermal nucleic acid amplification technology\n(\"INAAT\") has a 17.5% share, closely followed up by fluorescence in-situ hybridisation (\"FISH\") technologies\nfor anatomical pathology and cytogenetics with a 16.6% share. Next generation sequencing (\"NGS\") and DNA\nsequencing account together for 6.9% and other methods for the remaining 17.1%. 38 PCR is expected to be the\nleading method in the MDx market and is expected to hold a market value of more than US$3 billion in 2018.39\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.2937152629328773, "height": 0.08208636169303121, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-3", "text": "PCR is a well-established method, which allows producing multiple copies of nucleic targets using thermostable\nenzymes for nucleic acid duplication and applying a cyclic temperature profile. With each cycle the amount of\ntarget nucleic acid in the reaction is doubled. Hence, the amplification is exponential; therefore billions of copies\ncan be generated within a short period of time. As a limitation, the targeted nucleic acid sequence has to be\nknown a priori to design the test. The broad adoption and acceptance of PCR is owed to its high specificity and\nsensitivity. Curetis' Unyvero platform relies on a combination of PCR and microarray-based PCR product detec-\ntion, combining the advantages of PCR in terms of sensitivity and specificity with the multiplexing capabilities\nof microarrays.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.41000427533133815, "height": 0.10944848225737491, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-4", "text": "NGS comprises methods that permit to sequence the human (or bacterial) genome(s) rapidly at low costs, cur-\nrently at about US$1,000 per human genome. While detailed information of the DNA sequences can be obtained\nat high resolution, interpreting this information requires significant computational resources and bioinformatics\nskills. NGS workflows are often very complex, require time, many manual steps and skilled staff as well as well-\nequipped laboratories and sophisticated data handling. NGS is connected to major capital investments but further\nadvances in technology are likely to result in lower prices. However, despite several companies working on\nhighly automated and integrated NGS solutions for potential use in the IVD market for considerable time al-\nready, none of these have yet reached the routine diagnostics market in infectious disease at the point of need.\nThus, the management believes, that NGS based technologies at present do not yet constitute a direct competi-\ntion to Unyvero.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5536554082941428, "height": 0.1368106028217187, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-5", "text": "Molecular Diagnostics Market Dynamics\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.47339782345828296, "lower_right_y": 0.5844377939290295, "height": 0.017101325352714802, "width": 0.35792019347037485}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-6", "text": "The following key trends are expected to drive the infectious disease MDx market growth through molecular\nassay menu expansion, molecular diagnostic technology development, and greater adoption of these technologies\nin medical practice:\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.639162035057717, "height": 0.04104318084651559, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-7", "text": "\uf0b7   Increase in ageing population to accelerate growth of the MDx market: According to the US Depart-\n    ment of Health & Human Services, around 12.4% of the US population was older than 65 in 2000. The\n    percentage is expected to grow to 19% by 2030. 40 As the population is ageing, incidence rates of infec-\n    tions become more frequent, also supported by overuse of antibiotics in nursing homes. 41 Moreover, it is\n    predicted that elderly require more often medical services \u2013 complicated by hospital-acquired infections 42\n    \u2013 than young adults. In summary, as the population ages, people become more prone to infectious diseas-\n    es, thereby driving the need for faster molecular-based diagnostics.43\n\uf0b7   Antibiotic resistance \u2013 a global medical and economic burden: By 2050, experts predict that the num-\n    ber of deaths related to drug resistant infections could possibly increase from the current total of 700,000\n    to 10 million deaths and may cause expenditures of US$100 trillion per year worldwide.44 Anti-microbial\n    resistance by then would cause more deaths than cancer. 45 Therefore management believes that the de-\n    mand for fast and accurate tests for microorganism identification and antibiotic resistance detection will\n    increase rapidly.\n\uf0b7   Personalised medicine and companion diagnostics: The trend towards personalised medicine \u2013 which\n    according to Curetis' management also includes the molecular identification of relevant microorganisms\n    and their antibiotic resistance markers for an early informed choice of antibiotics for any given patient \u2013\n    is expected to increase the demand for molecular diagnostic tests. Fully automated and integrated molecu-\n    lar diagnostics solutions minimising operator intervention and laboratory settings are likely to play an im-\n    portant role in the further adoption of personalised medicine.\n", "page_number": 122, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.9230440359127833, "height": 0.27704147071398033, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-122-8", "text": "119\n", "page_number": 122, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-0", "text": "Progress in biomarker discovery allows to address unmet clinical need, such as sepsis: New modern\nmolecular biology techniques, particularly next generation sequencing, in combination with intelligent bi-\noinformatics and big data analytics, will contribute to progress in biomarker discovery and increasingly\nallow for the systematic identification and validation of biomarkers for diagnosing specific diseases.\nHowever, the results of such research will lead to large biomarker panels to be tested in order to suffi-\nciently capture complex disease biology. Moving those complex biomarker panels into standard of care\nwill require highly multiplexed molecular diagnostics platforms for routine testing.\nDecentralisation of molecular testing - testing at point-of need: The need to have diagnostic test re-\nsults as quickly as possible fosters the development of near-patient testing and automated sample-to-\nanswer diagnostic test solutions, which can be operated by non-specialist medical staff in a non-\nlaboratory setting. The availability of infrastructure-independent, near-patient solutions also makes mo-\nlecular diagnostics accessible to less developed and remote areas. Both trends may drive adoption of mul-\ntiplex testing.\nReforms in reimbursement systems: New regulations in the US and Europe introduce new test-specific\nreimbursement codes for molecular testing. Those improved coding systems help to ease the billing and\npayment process. In addition, more countries are expected to adopt diagnosis related group (\"DRG\") re-\nimbursement systems that also cover diagnostic tests in its lump-sum payment. In the US, a new bill was\nintroduced into Congress (HR 6446), called the Improving Diagnostic Innovations Act, which seeks to\nimprove the reimbursement process. The ultimate goal of the bill is to establish fair compensation for in-\nnovative, new IVD tests, and is likely to support market penetration for molecular assays.\nNeed for cost efficient diagnostics: Constrained healthcare budgets, a growing world population and\nhigher life expectancy drive the need for more cost-effective approaches in healthcare. The goal is to\nachieve best medical outcomes for patients, while saving money through optimised care cycles and\navoidance of ineffective therapies. Therefore, management believes that the need for timely and accurate\ntest information enabling adequate treatment for infections is growing and is paving the way for rapid\nmultiplex infectious disease testing.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46472851646002566, "height": 0.37964942283026937, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-1", "text": "\uf0b7\n", "page_number": 123, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.08849935870029928, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.09576742197520308, "height": 0.007268063274903799, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-2", "text": "\uf0b7\n", "page_number": 123, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.19153484395040615, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.19794784095767423, "height": 0.006412997007268079, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-3", "text": "\uf0b7\n", "page_number": 123, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.28131680205215903, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.2894399315946986, "height": 0.008123129542539576, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-4", "text": "\uf0b7\n", "page_number": 123, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3860624198375374, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.39290294997862335, "height": 0.006840530141085932, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-5", "text": "Considerations Regarding MDx Testing Solutions in Microbiology\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.6916565900846433, "lower_right_y": 0.49551090209491233, "height": 0.017101325352714802, "width": 0.5761789600967352}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-6", "text": "In the past, conventional molecular methods of microbiology involved many labour- and costly-intensive han-\ndling steps in the laboratory, which had to be performed by highly skilled and trained laboratory technicians.\nSuch steps comprised sample preparation, isolation of DNA, its amplification, detection and as well as the final\nresult interpretation. Smaller and mid-sized hospitals, therefore outsourced testing to independent laboratories,\nwhich hence required logistics and increased the time to result for the physician ordering the test with potential\ndelays in the initiation of adequate therapies.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5917058572039333, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-7", "text": "Recently automated sample-to-answer platforms to perform a scalable volume of tests in shorter time with less\nhands-on time of moderately trained staff have been introduced to the market. Their high level of integration in\nfully contained systems limit the risk of contamination allowing performing the test outside a typical laboratory\nenvironment and even at the point of need. Based on Curetis' experience the traditional MDx applications for the\nmicrobiology market are still dominated by either manual technologies or high throughput systems with different\nlevels of automation and integration available, the sample-to-answer platform market is significantly growing.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6806327490380505, "height": 0.08251389482684912, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-8", "text": "Unfavourable working conditions in laboratories such as increased workloads connected to long working hours\nas well as exposure to dangerous chemicals and pathogens, make higher paid job opportunities in life science\ncompanies more attractive to lab technicians. The resulting shortage in skilled laboratory technicians required for\nconventional molecular testing in combination with the rapidly increasing demand for molecular information\nsignificantly drives the demand for simple and highly automated sample-to-answer solutions.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7558785805899957, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-9", "text": "Business models within the MDx Market\n", "page_number": 123, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7704147071398033, "lower_right_x": 0.46856106408706166, "lower_right_y": 0.7832407011543394, "height": 0.012825994014536102, "width": 0.3524788391777509}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-10", "text": "MDx is a fast moving and innovation driven market and is a rapidly growing and evolving segment within the\nIVD market.46 There are numerous companies including large IVD players as well as small start-up companies\nactive in the MDx field. Traditionally, the MDx market can be characterised as follows:\n", "page_number": 123, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8413852073535699, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-11", "text": "Large well established IVD companies offering MDx mainly through batch-based high through put\nplatforms with a variety of assay menus.\n", "page_number": 123, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.877297990594271, "height": 0.02607952116289014, "width": 0.7164449818621524}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-12", "text": "", "page_number": 123, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.8520735356990167, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8584865327062847, "height": 0.006412997007268051, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-13", "text": "The MDx market has been traditionally dominated by large companies that have been present in this mar-\nket for years focusing on continuously expanding their installed base of high-throughput platforms: In\n2013 Roche accounted an estimated market share of 31.4%, followed by Novartis (Chiron) with 10%,\n", "page_number": 123, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.8854211201368106, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9251817015818726, "height": 0.039760581445062004, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-123-14", "text": "120\n", "page_number": 123, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-124-0", "text": "Hologic (Gen-Probe) with 9.9%, QIAGEN with 8.8% and Abbott Diagnostics with 6.8%. 47 On the basis\nof its market observations, Curetis believes that companies commercialising sample-to-answer platforms,\nlike Cepheid or BioFire (now bioM\u00e9rieux) have gained significant market share over the past years.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-124-1", "text": "    Most of the large companies offer high-throughput instruments targeting large laboratories that have to\n    process high volumes of samples and have highly skilled staff at their disposal. However, recent acquisi-\n    tions of smaller competitors by large IVD players such as Becton Dickinson with HandyLab, bioM\u00e9rieux\n    with BioFire, Luminex with GenturaDx or Roche with Iquum and Geneweave \u2013 illustrate a shift in their\n    strategies confirming that even the large players are now considering personalised medicine and patient-\n    near-testing as attractive markets.\n\uf0b7   Companies that develop and market integrated, automatic, scalable and random-access sample-to-\n    answer systems.\n    The Curetis' Unyvero Platform is a sample-to-answer device platform with single-use disposable Applica-\n    tion Cartridges. It is integrated and highly automated and can be scaled to customers' needs. There are\n    several companies who have introduced similar systems to the market such as Cepheid (GeneXpert\u2122),\n    Genmark (e-Plex\u2122, not yet launched), bioM\u00e9rieux (BioFire with FilmArray\u2122), T2 Biosystems Inc.\n    (T2DX\u2122), Nanoshphere (Verigene System\u2122), Roche (IQUUM with the Liat\u2122), Stat Diagnostica (DI-\n    AGcore\u2122, not yet launched), and Biocartis (Idylla\u2122, not yet launched for infectious disease testing).\n    The assays developed by these companies focus on syndromic disease testing targeting different distinct\n    clinical indications, like respiratory diseases or sepsis. In order to assess the competitive situation in terms\n    of assays a detailed distinction between panel composition and which kind of samples can be tested has to\n    be made.\n\uf0b7   Companies that develop and commercialise sequencing or mass spectrometry based molecular\n    diagnostics systems.\n    Functional competition includes companies that develop and commercialise sequencing or mass spec-\n    trometry based molecular diagnostics systems, such as Bruker, or automated culture-based technologies,\n    e.g.; Abbott's Iridica system and Accelerate Diagnostics (Accelerate ID / AST).\n\uf0b7   Companies that develop assays for MDx systems that are commercialised by other companies.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5151774262505344, "height": 0.38221462163317654, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-124-2", "text": "    For a customer owning an MDx platform the attractiveness of the actual system is higher as a larger assay\n    menu for different indications or applications are available. Therefore, besides its strong in-house R&D\n    expertise, Curetis collaborates with companies that could provide new biomarker content and/or develop\n    assays for its Unyvero Platform in order to grow its Application Cartridge pipeline. However, Curetis cur-\n    rently does not anticipate that being an original equipment manufacturer test provider for other companies\n    will become a core part of its business strategy.\n\uf0b7   Clinical service laboratories that develop and design assays for MDx systems that are commercially\n    available (laboratory developed tests).\n    Clinical service laboratories, such as Quest or LabCorp, design, validate and perform assays within their\n    facilities. Often, the assays can be performed on a specific \"open\" instrument or manually by skilled per-\n    sonnel. These so called laboratory developed tests (\"LDTs\") are typically cheaper in terms of cost per test\n    for end-users and faster to the market. However, market penetration and commercial attractiveness is of-\n    ten limited due to regulatory constraints, the need for independent validation in each laboratory, and the\n    need for skilled laboratory staff. Therefore, Curetis' is primarily pursuing a strategy to launch regulatory\n    cleared tests into the market.\n\uf0b7   Companies offering manual kits for microbiology or MDx labs.\n    Curetis is an integrated company offering an entire product line consisting of systems, software and con-\n    sumables (Application Cartridges) and, consequently positions itself as one-shop provider and does not\n    anticipate to solely commercialise assays like companies such as MobiDiag or others.\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5156049593843522, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8029072253099615, "height": 0.28730226592560926, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-124-3", "text": "Competition\n", "page_number": 124, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.8170158187259513, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.8336896109448483, "height": 0.016673792218896977, "width": 0.10822249093107619}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-124-4", "text": "The Unyvero Platform is a sample-to-answer MDx solution. There are several other companies who develop and\ncommercialise similar systems. In terms of devices and assays Curetis believes its key competitors include bio-\nM\u00e9rieux (BioFire with its FilmArray\u2122 platform) and GenMark with its upcoming ePlex\u2122 platform. Taking into\nconsideration the broader market, devices of other key competitors can be extended to include Cepheid (GeneX-\npert\u2122), T2 Biosystems Inc. (T2DX\u2122), Nanoshphere (Verigene System\u2122), Roche (IQUUM with the Liat\u2122),\n", "page_number": 124, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9162035057716973, "height": 0.06840530141085932, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-124-5", "text": "121\n", "page_number": 124, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-0", "text": "Stat Diagnostica (DIAGcore\u2122) and Biocartis (Idylla\u2122). Disease-related assays competitors including those\nproviding reagent kits only and LDT developers have to be separately assessed by each application.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-1", "text": "For Curetis' P55 Application Cartridge, Curetis believes that it currently has no direct competitor as there is\ncurrently no other company offering an Application Cartridge covering such a broad range of bacteria and other\natypical pathogens (excluding viral targets), fungi and antibiotic resistance markers. Other companies, such as\nBioFire, Nanosphere, GenMark, Luminex, Seegene, Genomica, Miacom, PathoFinder, Fast-track, Randox,\nArcDia and Icubate are primarily targeting the upper respiratory tract with their panels. Their panels mainly\ncomprise viruses and a few bacteria and at times a limited number of antibiotic resistance markers only.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2013681060282172, "height": 0.08208636169303123, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-2", "text": "For Curetis' i60 ITI Application Cartridge, Mobidiag is currently the only company with a commercially similar\nproduct to Unyvero i60 ITI. However it is a manual test only. In terms of pathogen panel composition assays of\ncompetitors are very different and Curetis' i60 ITI Application Cartridge covers the broadest range of antibiotic\nresistance markers. In addition, Diaxonhit and BioFire are currently developing tests for which the panel compo-\nsition is not yet known.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.27661393758016245, "height": 0.06840530141085932, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-3", "text": "Management believes that Curetis' Unyvero Platform has certain key characteristics that clearly differentiate\nfrom other sample-to-answer systems:\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.3108165882855921, "height": 0.027362120564343728, "width": 0.7484885126964933}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-4", "text": "e it\n", "page_number": 125, "bounding_box": {"top_left_x": 0.8645707376058042, "top_left_y": 0.2860196665241556, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2937152629328773, "height": 0.007695596408721694, "width": 0.015114873035066423}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-5", "text": "\uf0b7   Based on its corporate market analysis, Curetis believes that due to the proprietary lysis technology its\n    Unyvero Platform is able to process a broader variety of sample types than competing platforms. No la-\n    bour intensive manual sample preparation is necessary and even difficult and blood-contaminated native\n    samples can be processed. Biofilm-building pathogens can be identified by the Unyvero Platform. Fur-\n    thermore, the Unyvero Platform is CE-IVD-marked for a variety of samples including sputum, broncho-\n    alveolar lavage, tracheal aspirate, exudate, catheter tip, pus, sonication fluid, synovial fluid, swab and tis-\n    sue. Further samples such as blood, urine, stool and formalin-fixed paraffin embedded tissues present fur-\n    ther options for extending the variety of samples for future applications. Fresh or frozen samples and also\n    samples that have been stored in different media can be processed easily on the Unyvero Platform. As the\n    lysis is integrated into the workflow, hands-on time and potential handling errors are significantly re-\n    duced.\n\uf0b7   What also sets apart Curetis' Unyvero Platform is its high multiplexing capacity based on end-point PCR,\n    which allows for the execution of eight independent multiplex PCR reactions simultaneously. Therefore,\n    Curetis can identify a broad range of microorganisms and antibiotic resistance markers in a single run.\n\uf0b7   Focusing on severe infectious diseases and having developed a P55 Application Cartridge and i60 ITI\n    Application Cartridge and planning to develop further Application Cartridges in the severe infectious dis-\n    ease area, Curetis has a highly differentiated positioning in the market.\n\uf0b7   Considering its panel design, Curetis believes no comparable assays have been identified in the markets\n    to date that would offer disease-directed coverage of such a broad range of bacterial markers combined\n    with antibiotic resistance markers.\n", "page_number": 125, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6130825138948268, "height": 0.2954253954681488, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-125-6", "text": "122\n", "page_number": 125, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-0", "text": "BUSINESS\n", "page_number": 126, "bounding_box": {"top_left_x": 0.44014510278113667, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5556227327690447, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.11547762998790806}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-1", "text": "Overview\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-2", "text": "Curetis is a commercial-stage molecular diagnostics company focusing on simple, accurate and rapid solutions\nfor diagnosing infectious diseases and antibiotic resistance in severely ill, hospitalised patients. Today, the diag-\nnosis of infectious diseases in a hospital setting is still largely carried out through traditional microbiology cul-\nture based tests. This process is labour-intensive and time-consuming, typically delivering results only after 24\nhours or even weeks. As a result, adequate antibiotic therapy decisions are delayed, leading to poor patient out-\ncomes, longer hospital stays, increased hospital costs and overall spread of antibiotic resistance, a significant and\nincreasing problem throughout the world.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25181701581872595, "height": 0.09491235570756734, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-3", "text": "Curetis' Unyvero Platform enables the early detection of a broad range of different microorganisms and their\nrelated antibiotic resistance genes in a single test from a wide variety of native sample materials. The Unyvero\nPlatform is fully automated and integrates all diagnostic steps into a single Application Cartridge. It is easy to\nuse with minimum hands-on time of no more than five minutes. It is a walkaway solution that detects within four\nto five hours most microorganisms that take traditional microbiology culture based tests 24 hours or even weeks.\nThis allows clinicians to make early adjustments to a more specific treatment of the patient, saving significant\ntime and cost, in particular by reducing the time of the patient's hospital stay. The Unyvero Platform intends to\ncomplement rather than replace traditional microbiology.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25224454895254383, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36810602821718685, "height": 0.11586147926464302, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-4", "text": "The Unyvero Platform is comprised of the Unyvero System, the Unyvero Software, and the Application Car-\ntridges. The Unyvero System is composed of (i) the Lysator for sample pre-processing and microorganism lysis,\n(ii) the Analyzer for processing the Application Cartridges and (iii) the Cockpit, a control panel for running the\nLysator(s) and the Analyzer(s) and displaying, exporting, and storing results. The Application Cartridges are\nsingle-use, disposable and disease specific.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4433518597691321, "height": 0.06755023514322361, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-5", "text": "The Unyvero Platform has been CE-IVD-marked since 2012 and is commercialised in Europe and certain other\nmarkets that accept CE-IVD-marking (i.e. Kuwait, Qatar, Russia and the United Arab Emirates). The Unyvero\nPlatform is marketed through a combination of direct sales in key EU countries and distributors in selected EU\nmarkets and rest of the world (i.e. Kuwait, Qatar, Russia and the United Arab Emirates). Curetis also intends to\ncontinue to expand internationally as seen by the recent signing of distribution agreements with Acumen for\ncertain ASEAN markets (Indonesia, Malaysia, Singapore and Thailand) and Beijing Clear Biotech for Greater\nChina.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.5438221462163317, "height": 0.09277469003847794, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-6", "text": "As of 30 June 2015, Curetis' total installed base comprised 70 Unyvero Analyzers. There are currently two\ncommercially available Application Cartridges: the P55 Application Cartridge, which addresses severe forms of\npneumonia, and the i60 ITI Application Cartridge, which addresses severe cases of implant and tissue infections.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5942710560068405, "height": 0.040615647712697656, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-7", "text": "The P55 Application Cartridge was commercially launched in April 2015 and is the second generation version of\nP50 Application Cartridge, the pneumonia cartridge initially launched in 2012. It is a CE-IVD-marked Applica-\ntion Cartridge for the fully automated detection of currently 20 microorganisms and 19 antibiotic resistance\nmarkers in native respiratory samples. With the test, Curetis aims to detect the vast majority of pneumonia caus-\ning pathogens in hospitalised patients and clinically relevant resistance markers against antimicrobials. Based on\nits applicability to multiple forms of pneumonia, Curetis estimates that the P55 Application Cartridge has an\naddressable market of 2.3 million incidences per year in the EU and the US. 48\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6968790081231295, "height": 0.09533988884138522, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-8", "text": "The i60 ITI Application Cartridge was launched in May 2014. It is a CE-IVD-marked Application Cartridge for\nthe fully automated detection of currently 61 microorganisms and 19 antibiotic resistance markers for eight dif-\nferent clinical indications within the area of prosthetic joint infections, diabetic foot ulcers, surgical site infec-\ntions, catheter-associated infections, deep skin and tissue infections, cardiology-related infections, burn wounds\nand other implant infections. Curetis estimates that the addressable market for the i60 ITI Application Cartridge\nis 2.1 million cases eligible for testing per year in the EU and the US. 49\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7858058999572467, "height": 0.08165882855921336, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-9", "text": "To date, more than 30 clinical studies with over 4,000 patient samples have been completed to validate both\nApplication Cartridges. Additional trials with more than 5,000 samples are on-going or scheduled in the coming\nyears. This includes the required clinical studies to obtain FDA clearance for the Unyvero System and the\nLRT55 Application Cartridge (technically equivalent to the P55 Application Cartridge). Following FDA clear-\nance, Curetis intends to commercialise the Unyvero System and the LRT55 Application Cartridge in the US\nthrough a direct sales effort beginning in 2017.\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7930739632321505, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.8751603249251817, "height": 0.08208636169303118, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-10", "text": "Curetis' pipeline products in development include the Application Cartridges targeting positive blood culture\ntesting and intra-abdominal/gastrointestinal tract infections both of which Curetis intends to launch commercial-\nly as CE-IVD-marked products in 2016. This is expected to be followed by a CE-IVD-marked sepsis host re-\n", "page_number": 126, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8820008550662677, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9230440359127833, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-126-11", "text": "123\n", "page_number": 126, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-0", "text": "sponse Application Cartridge targeting commercial launch not before late 2017. Curetis also believes its Un-\nyvero Platform has the potential for menu expansion into other areas such as oncology, companion diagnostics,\ntransplant medicine and veterinary applications.\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-1", "text": "Combined, the two marketed and three pipeline Application Cartridges address more than 8.13 million cases\neligible for testing in the EU and the US per year. 50 Assuming an average Application Cartridge selling price of\n\u20ac200, this would result in a potential total available market of \u20ac1.6 billion per year. The total MDx market cur-\nrently amounts to US$5 billion. It represents a significant segment of the in-vitro diagnostics market and is ex-\npected to grow at a 9.7% compound annual growth rate from 2013 to 2018, reaching a market value of US$8\nbillion in 2018.51\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.21205643437366395, "height": 0.0790936297563061, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-2", "text": "Curetis currently plans to use a significant portion of the net proceeds of the Offering to build a direct commer-\ncial marketing, sales and support presence in the US in order to directly commercialise the Unyvero Platform\nand products in the US market following the anticipated FDA clearance. Curetis intends to use the remainder of\nthe proceeds to expand and strengthen the European commercial presence, to fund working capital requirements\nto finance the placement of the Unyvero System, to accelerate the R&D pipeline of the Application Cartridges\nfor European, US and global markets, including clinical trials and regulatory approvals needed and to expand\nmanufacturing capacity. (for more details, see \"Reasons for the Offering and Use of Proceeds \u2013 Use of Pro-\nceeds\").\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3309106455750321, "height": 0.10902094912355709, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-3", "text": "Strengths\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.36212056434373663, "height": 0.017101325352714802, "width": 0.08766626360338574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-4", "text": "Curetis believes that the following strengths will enable it to execute its strategy to develop the Unyvero Plat-\nform into a premium solution for diagnosing infectious diseases and detecting antibiotic resistance markers in\nhospitalised patients:\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.41727233860624197, "height": 0.04147071398033347, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-5", "text": "\uf0b7   Curetis is a commercial stage molecular diagnostics company selling into Europe, Russia and Mid-\n    dle East\n    Since CE-IVD-marking its first product in 2012, Curetis is a commercial stage molecular diagnostics\n    company. Today, Unyvero Systems are installed with customers in Europe, Russia and the Middle East as\n    well as with clinical trials sites in the US. Curetis currently is selling CE-IVD-marked Unyvero Systems,\n    P55 and i60 ITI Application Cartridges into Europe, Russia and the Middle East and recently entered into\n    distribution agreements to expand its presence in the ASEAN and the markets in Greater China.\n\uf0b7   Curetis focus is on diagnosing pathogens and preventing and combating antibiotic resistance for\n    severe infections in hospitalised patients\n    Unyvero Application Cartridges provide comprehensive answers that allow better and earlier treatment\n    decisions, as they combine high-multiplex testing for the presence of microorganisms such as bacteria and\n    fungi with clinically relevant antibiotic resistance markers which is crucial information for preventing and\n    combating antibiotic resistance. The P55 Application Cartridge currently detects 20 microorganisms and\n    19 antibiotic resistance markers, while the i60 ITI Application Cartridge currently detects 61 microorgan-\n    isms and 19 antibiotic resistance markers.\n\uf0b7   Curetis' flexible Unyvero Platform deals with any sample type and covers more microorganisms\n    and resistance markers than competing platforms\n    With its currently marketed and pipeline products, the Unyvero Platform provides a disruptive platform\n    that is fast, easy and flexible to use and which requires only a few minutes of hands-on time by non-\n    specialised laboratory or clinical personnel. It can be used both in an intensive care unit environment as\n    well as in a microbiology laboratory. Sample-to-answer takes about four to five hours, a fraction of the\n    time required by traditional microbiology culture based tests. The Unyvero Platform can test more native\n    sample types for a broader range of microorganisms and antibiotic resistance markers than competing\n    platforms.\n\uf0b7   Curetis has a strong pipeline of high-value products addressing significant unmet medical need\n    Curetis is developing a range of products expected to enter the market in the coming years. Retaining its\n    focus on severe infectious diseases in a hospital setting, the most advanced product candidate is an Appli-\n    cation Cartridge targeting positive blood cultures, with a potential commercial launch in 2016. Similarly,\n    an Application Cartridge targeting intra-abdominal/gastrointestinal tract infections is planned to be com-\n    mercially launched in 2016 and a sepsis host response Application Cartridge is under development target-\n    ing commercial launch not before late 2017, respectively. All of these pipeline products address signifi-\n    cant unmet medical needs and have a highly attractive market potential. For all of its pipeline products,\n    Curetis can leverage its existing installed base of Unyvero Systems. Curetis believes that its Unyvero\n", "page_number": 127, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.503206498503634, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-127-6", "text": "124\n", "page_number": 127, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-0", "text": "Platform furthermore may have future applications in areas beyond infectious disease such as oncology,\ncompanion diagnostics, transplant medicine and veterinary applications.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-1", "text": "Curetis and the Unyvero Platform are validated by extensive clinical studies and endorsed by key\nopinion leaders and a top-tier investor base\n", "page_number": 128, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1470713980333476, "height": 0.027789653698161623, "width": 0.7158403869407497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-2", "text": "Published clinical trial data demonstrate the Unyvero advantage. More than 30 completed studies with da-\nta from over 4,000 patient samples have been generated and published to date in order to evaluate product\nperformance, clinical validity and clinical utility. These include sponsor initiated studies as well as in-\ncreasingly investigator-initiated studies. Curetis has furthermore developed a broad network of key opin-\nion leaders across Europe and the US. KOLs have provided valuable input during product development,\nstimulated market awareness and helped to create product demand. Lead-user programs with KOLs have\nvalidated key product components, supported product optimisation, and helped to address market entry\nbarriers by generating testimonials and by creating market awareness via publications in peer-reviewed\njournals and presentations at conferences.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.15348439504061565, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27704147071398033, "height": 0.12355707567336469, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-3", "text": "    Curetis has furthermore benefited from the on-going commitment of its Shareholders that have invested\n    more than \u20ac63.5 million in several financing stages. These Shareholders include leading players in the\n    venture capital as well as the diagnostic industry, such as aeris CAPITAL, LSP, Forbion, HBM, Roche,\n    BioMed Invest, QIAGEN and others.\n\uf0b7   Curetis conducts US clinical trials to support US FDA clearance in 2017 and subsequent US com-\n    mercialisation\n    Curetis currently conducts a prospective multi-centre clinical trial in the US with the Unyvero System and\n    the LRT55 lower respiratory tract Application Cartridge with the goal of fully enrolling patient samples\n    and submission to the FDA in the second half of 2016 and obtaining FDA clearance in 2017. Curetis\n    plans to build a US commercial organisation allowing it to sell directly to hospital end-customers and la-\n    boratories once FDA clearance has been received.\n\uf0b7   Curetis and the Unyvero Platform aim to reduce hospital costs by allowing effective treatment to be\n    administered more quickly\n    The Unyvero Platform's fast testing capabilities enable doctors to prescribe targeted treatment earlier than\n    when using traditional microbiology culture based tests. Such antibiotic stewardship improves patient\n    outcomes, reduces antimicrobial resistance and decreases the spread of infections caused by multidrug-\n    resistant organisms. By administering the appropriate antibiotic therapy regimen at an early stage, overall\n    use of antibiotics and associated costs can be reduced, as well as the length of stay in hospitals. As a re-\n    sult, hospitals can optimise their margins under existing DRG reimbursement situations.\n\uf0b7   Curetis' Management Team combines decades of operational and commercial experience\n    Curetis' management team combines decades of operational and commercial experience in the industry.\n    More specifically, four co-founders are still active for Curetis today and previously worked at Philips de-\n", "page_number": 128, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6301838392475417, "height": 0.34672937152629335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-4", "text": "    veloping a similar platform, while others have gained relevant experience in the MDx and broader\n    healthcare sector at other renowned companies such as Epigenomics, Agilent Technologies, Hewlett\n    Packard, Siemens, Qiagen, Abbott, Beckman Coulter and Becton Dickinson. In addition, members of the\n    management team have experience with privately held as well as publicly traded emerging growth com-\n    panies and key aspects of the successful management of an MDx company such as product development,\n    operations, marketing and sales.\n\uf0b7   Curetis controls all of the key aspects of its value chain\n    Curetis has control over the key aspects of its value chain and does not outsource the critical parts of its\n    operations. The Company conducts its own R&D, as it develops a broader range of products, and Appli-\n    cation Cartridge production is conducted at the Company's own facility. This ISO 13485 certified facility\n    is highly automated and scalable, allowing Curetis to retain control over quality and margins and further\n    secure its intellectual property. The Company also controls direct sales and marketing channels in a range\n    of key markets.\n", "page_number": 128, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6306113723813596, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8230012825994014, "height": 0.19238991021804186, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-5", "text": "Strategy\n", "page_number": 128, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.837537409149209, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.8537836682342882, "height": 0.01624625908507915, "width": 0.07799274486094317}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-6", "text": "The strategic goal of Curetis is to become a leading provider of molecular diagnostic solutions for severe infec-\ntions in hospitalised patients. The aim is to achieve this with the current Unyvero Platform and on-going product\ndevelopment, increasing sales in existing territories, growing the commercial footprint to include countries such\n", "page_number": 128, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8683197947840958, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9089354424967935, "height": 0.040615647712697656, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-128-7", "text": "125\n", "page_number": 128, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-0", "text": "as the US and optimising the pricing model and cost structure by territory and Application Cartridge, respective-\nly.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.879081015719468, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-1", "text": "Curetis continues to improve the Unyvero System and evolve the existing Application Cartridges as well as\ndevelop new Application Cartridges. In addition to the P55 and i60 ITI Application Cartridges that are currently\non the market, the Company plans to develop and commercially launch Application Cartridges targeting blood\nculture and intra-abdominal/gastrointestinal tract infections in 2016 and Application Cartridges targeting sepsis\nhost response not before late 2017. Thereafter, it plans to release an additional Application Cartridge every year.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.06840530141085933, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-2", "text": "Curetis' strategy is to use a mix of direct sales and distributors to grow its commercial footprint, targeting key\ndecision makers at potential customers' sites and aiming to sell to larger hospitals and laboratories.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.221889696451475, "height": 0.027362120564343728, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-3", "text": "In terms of marketing and pricing, the company follows a razor/razor blade model that aims to place the Unyvero\nSystem in hospitals and laboratories at a low initial cost to the customer with the sale of Application Cartridges\nbeing the driver of revenue generation.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2702009405728944, "height": 0.04147071398033347, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-4", "text": "The initial direct sales effort is in Germany, Austria and Switzerland and has been expanded to include France,\nthe UK and Benelux countries. In other markets, Curetis has distributor relationships in territories in Europe,\nsuch as Italy and Spain, Russia, as well as in the Middle East, and recently in Asia. There are plans to add further\ncountries to the distributor network.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32834544677212485, "height": 0.0517315091919624, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-5", "text": "A key to commercial growth is marketing and selling products in the US and Curetis is currently conducting\nclinical trials in the US with the goal of fully enrolling patient samples and submission to the FDA in the second\nhalf of 2016 and obtaining FDA clearance in 2017. Such clearance should allow a 2017 commercial launch and\nit is planned that a direct sales strategy will be implemented, thus requiring the creation of a US sales and mar-\nketing as well as support team.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-6", "text": "Another important element of Curetis' strategy is to identify and team up with the right collaboration partners in\ncertain Asian markets such as the ASEAN region or China. In that regard, Curetis recently expanded into China\nand the ASEAN market by entering into distribution agreements with Acumen for certain ASEAN markets (In-\ndonesia, Malaysia, Singapore and Thailand) and Beijing Clear Biotech for Greater China. These collaborations\nare expected to address the required R&D and clinical trial as well as regulatory clearance strategies in these\nmarkets as well as commercial distribution following regulatory clearance in each of these markets via these\npartners.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5096194955109021, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-7", "text": "In addition, the company intends to broaden its customer base by entering into additional arrangements with\nstrategic partners, such as its current partner Heraeus Medical GmbH, a manufacturer of bone cement, and phar-\nmaceutical companies conducting clinical trials in infectious disease.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-8", "text": "Curetis aims to control the key parts of its value chain and outsource where it can benefit from the experience of\nothers. Product development and the Application Cartridge manufacturing takes place in dedicated facilities\ncontrolled by Curetis. The manufacturing of the instruments of the Unyvero System are outsourced to Zollner\nElektronik AG, a German OEM manufacturer with manufacturing experience for other diagnostic companies.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5639162035057717, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.619067977768277, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-9", "text": "History\n", "page_number": 129, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6361693031209918, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.6494228302693459, "height": 0.013253527148354038, "width": 0.06650544135429261}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-10", "text": "2007-2009\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.19105199516324062, "lower_right_y": 0.6772124839675074, "height": 0.01410859341598969, "width": 0.07557436517533252}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-11", "text": "In 2007, a group of engineers, a physician and biologists from Philips Medizin Systeme B\u00f6blingen GmbH co-\nfounded Curetis. This group includes today's CTO Andreas Boos, COO Johannes Bacher, Director of Bio-Assay\nDevelopment Dr. Gerd L\u00fcdke and Medical Director Dr. Anne Thews. In 2008, in addition to a capital increase\nby the founders and the management, aeris CAPITAL AG, a Swiss family office, also contributed to Curetis\nwith a seed funding of \u20ac1.4 million. During this time the decision was made to focus on a lower respiratory tract\nApplication Cartridge as a commercially attractive indication area. In November 2009, the \u20ac18.5 million series A\nfinancing round was successfully closed with a syndicate led by aeris CAPITAL and co-investors LSP, BioMed\nInvest and KfW.\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6840530141085934, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.7935014963659683, "height": 0.10944848225737491, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-12", "text": "2010-2012\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.8208636169303121, "height": 0.010688328345446751, "width": 0.07799274486094317}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-13", "text": "In 2010, a first in-house validation testing of P50 Application Cartridge with clinical samples was initiated. In\nApril 2011, Oliver Schacht became the Chief Executive Officer (\"CEO\") of Curetis and under his leadership the\ncompany successfully extended its series A financing round by \u20ac15.6 million. In the fall of 2011, Curetis opened\nits manufacturing site for production of the Unyvero Application Cartridges in Bodelshausen, Germany. Curetis\nofficially launched its P50 Application Cartridge during ECCMID conference in April 2012 for commercialisa-\ntion in Germany, Austria and Switzerland. The CE (Conformit\u00e9 Europ\u00e9enne) performance evaluation study for\nthe Unyvero System and the P50 Application Cartridge was successfully completed in May 2012 and a multi-\n", "page_number": 129, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9251817015818726, "height": 0.09448482257374946, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-129-14", "text": "126\n", "page_number": 129, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-0", "text": "centre prospective EU clinical trial clinical study was initiated. In the same year, Curetis entered into collabora-\ntions with Heraeus Medical and Cempra Pharmaceuticals.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11073108165882856, "height": 0.025651988029072245, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-1", "text": "2013-2015\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.1368106028217187, "height": 0.01068832834544678, "width": 0.07799274486094317}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-2", "text": "In 2013, Curetis extended its commercial operations into the Benelux, Russia, Eastern Europe and the Middle\nEast. Concurrently, Curetis initiated an FDA clearance study for the LRT50 Application Cartridge at five initial\nclinical sites in the US. In April 2013, Curetis closed a \u20ac12.5 million series B financing round led by HBM and,\nin November 2014, it secured a \u20ac14.5 million extension of its series B financing round. In May 2014, Curetis\nofficially launched in Europe its second Application Cartridge targeting implant and tissue infection (i60 ITI\nApplication Cartridge). This was followed by the next generation P55 Application Cartridge, which was success-\nfully completed and introduced to the market in the second quarter of 2015. In June 2015, Curetis strengthened\nthe executive team by appointing Dr. Achim Plum as its Chief Commercial Officer (\"CCO\") and started expand-\ning its direct sales effort in its key European markets (France, Benelux and UK).\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.12355707567336469, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-3", "text": "Products\n", "page_number": 130, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2868747327917914, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.2975630611372381, "height": 0.010688328345446751, "width": 0.08222490931076178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-4", "text": "Unyvero Platform\n", "page_number": 130, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.3142368533561351, "lower_right_x": 0.24486094316807738, "lower_right_y": 0.32834544677212485, "height": 0.014108593415989745, "width": 0.12696493349455865}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-5", "text": "Curetis launched its CE-IVD-marked Unyvero Platform with a first disposable Application Cartridge for\npneumonia in 2012. The Unyvero Platform is a highly-automated sample-to-answer molecular diagnostics\nplatform, based on multiplexed end-point polymerase chain reaction with an array-based detection process. It\nintegrates fully automated sample preparation, analysis and identification of disease relevant pathogens and\nantibiotic resistance markers to provide timely high-quality information to its end-users. The scalable system is\ndesigned to be either placed in laboratory settings or directly in hospital wards or intensive care units. Time-to-\nresult is four to five hours for the different Application Cartridges, including 30 minutes of automated sample\npreparation (lysis) and total hands-on time of no more than five minutes. The Unyvero Platform's intuitive\nworkflow with only minimal hands-on time enables untrained hospital staff to perform molecular tests at the\npoint of need, such as ICUs.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4719965797349295, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-6", "text": "A trial designed for FDA clearance as prerequisite to commercialise the Unyvero Platform, including the LRT55\nApplication Cartridge in the US is currently on-going. Curetis held a pre IDE meeting in year 2012 with the\nFDA and received written comments from the FDA on the trial design. The clinical trial includes nine\nparticipating trial sites in the US and targets enrolling 1,500 prospective samples and approximately 1,000\nretrospective samples. In addition, a series of preclinical experiments have been designed and will be conducted\nin parallel. The trial is expected to be completed in 2016 for a subsequent US commercial launch anticipated in\nthe first half of 2017.\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5711842667806755, "height": 0.09277469003847794, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-7", "text": "Unyvero Platform components\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.5810175288584866, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.5951261222744763, "height": 0.01410859341598969, "width": 0.20556227327690446}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-8", "text": "The Unyvero Platform is composed of three devices (L4 Lysator, C8 Cockpit and A50 Analyzer together the\n\"Unyvero System\") together with proprietary software and the developed Application Cartridges (the \"Unyvero\nPlatform\"):\n", "page_number": 130, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6430098332620778, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-130-9", "text": "127\n", "page_number": 130, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-0", "text": "", "page_number": 131, "bounding_box": {"top_left_x": 0.21281741233373638, "top_left_y": 0.12954253954681488, "lower_right_x": 0.7696493349455864, "lower_right_y": 0.3022659256092347, "height": 0.17272338606241983, "width": 0.55683192261185}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-1", "text": "", "page_number": 131, "bounding_box": {"top_left_x": 0.3143893591293833, "top_left_y": 0.31979478409576745, "lower_right_x": 0.6039903264812576, "lower_right_y": 0.38435228730226595, "height": 0.0645575032064985, "width": 0.2896009673518743}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-2", "text": "Figure 1: Unyvero Platform\n", "page_number": 131, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.43394613082513894, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.4446344591705857, "height": 0.010688328345446751, "width": 0.16142684401451027}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-3", "text": "The Unyvero L4 Lysator:\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45788798631893973, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.47028644719965795, "height": 0.01239846088071822, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-4", "text": "This instrument is used for sample pre-processing and pathogen lysis. It performs proprietary software-\ncontrolled lysis of up to four samples, simultaneously within 30 minutes, combining mechanical, thermal,\nenzymatic and chemical lysis steps and allows the use of a wide range of native sample types due to a\nproprietary sample processing method (several patents pending). Biofilm-building pathogens can be detected by\nthe Unyvero Platform. In addition, the Unyvero Platform is approved for a broad variety of native patient sample\ntypes including sputum, (mini) broncho-alveolar lavage, tracheal aspirates, aspirates and exudates, catheter tips,\npus, sonication fluid, synovial fluid, swabs and tissue. The lysis of further sample types such as blood, urine,\nstool and formalin-fixed paraffin embedded tissues is also possible with the proprietary Unyvero lysis method.\nUp to two L4 Lysators can be attached to a single C8 Cockpit allowing to process up to eight samples\nsimultaneously within 30 minutes.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6143651132962804, "height": 0.13595553655408288, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-5", "text": "The Unyvero C8 Cockpit:\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6220607097050022, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.6348867037195383, "height": 0.012825994014536102, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-6", "text": "This device is the control panel for the L4 Lysator and A50 Analyzer. It has a touchscreen and built-in bar code\nreader and runs on proprietary in-house developed Unyvero software. Step-by-step instructions guide the user\nfrom preparing a test to executing the fully automated process in the Analyzer in just a few minutes. The results\ndisplay, storage of results and data storage, as well as information about the performed tests including the\ncartridge's shelf-life and lot numbers, are generated automatically. Data can be exported as PDF files via a USB\nkey or to a connected printer. It also features built-in interfaces for possible future connectivity to standard\nhospital and laboratory information systems.\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7374946558358273, "height": 0.0949123557075674, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-7", "text": "The Unyvero A50 Analyzer:\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.758443779392903, "height": 0.013253527148354038, "width": 0.1989117291414752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-8", "text": "Figure 2: Unyvero sample tube, sample tube\ncap, sample pretreatment tool and Unyvero\nmastermix tube\n", "page_number": 131, "bounding_box": {"top_left_x": 0.5894800483675937, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.7798204360837965, "height": 0.031209918768704603, "width": 0.2617896009673518}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-9", "text": "This instrument consists of mechanical, electronic, pneumatic and\noptical elements and enables a fully-automatic random-access\nprocessing of the Unyvero Application Cartridges. Once a run is\nstarted the Analyzer automatically executes and controls all sample\nprocessing and analysis steps (including DNA extraction, DNA\npurification, PCR set-up, highly multiplexed end-point PCR\namplification and a hybridisation array-based fluorescence\ndetection) inside the cartridge. For safety and robustness and to\navoid issues of calibration or waste-removal, the Analyzer contains\nneither reagents nor waste. All fluidics are handled within the\nsealed cartridge. Up to eight A50 Analyzers can be attached to a\nsingle C8 Cockpit allowing to process up to 16 samples\n", "page_number": 131, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.9303120991876871, "height": 0.1646002565198803, "width": 0.46493349455864574}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-10", "text": "", "page_number": 131, "bounding_box": {"top_left_x": 0.6711003627569528, "top_left_y": 0.8760153911928175, "lower_right_x": 0.6928657799274486, "lower_right_y": 0.8815733219324497, "height": 0.0055579307396322886, "width": 0.021765417170495738}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-131-11", "text": "128\n", "page_number": 131, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-0", "text": "simultaneously within four to five hours.\nUnyvero Application Cartridges:\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.39117291414752114, "lower_right_y": 0.11928174433518597, "height": 0.03420265070542966, "width": 0.27569528415961303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-1", "text": "With eight parallel and fully independent multiplex endpoint PCR chambers, the single-use, disposable and\nsealed Application Cartridges facilitate the identification of a broad range of disease relevant microorganisms\nand antibiotic resistance markers within a closed system, thus enabling truly syndromic infectious disease\ntesting. The P55 Application Cartridge currently comprises 20 microorganisms and 19 antibiotic resistance\nmarkers, while the i60 ITI Application Cartridge encompasses currently 61 microorganisms and 19 antibiotic\nresistance markers. All cartridges have the same physical design and format and contain a DNA extraction and\npurification column with silica membrane, all required reagents and buffers, a mixing vessel for PCR set-up, a\nwaste chamber and eight fully independent PCR chambers with integrated multiplex end-point PCR\namplification and array-based detection. Unyvero Application Cartridges differ only in the primer composition\nin the eight PCR chambers, in the detection probes on the specific detection arrays in each PCR chamber and in\nthe indication and sample selection protocols (software), Application Cartridge execution protocols and\nlabelling. Each cartridge has two specific loading slots: one for the sealed Unyvero sample tube, containing the\nlysed patient sample, and the other for the sealed Unyvero mastermix tube. All cartridges are prefilled with all\nrequired reagents except for the PCR mastermix and have a self-contained fluidic system. Curetis believes that\nthis closed fluidic system significantly reduces the contamination risk. After being used, the single-use cartridge\ncan be handled as standard waste in hospitals.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.34459170585720394, "height": 0.21846943138093203, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-2", "text": "Workflow\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.3655408294142796, "height": 0.013681060282171864, "width": 0.0683192261185006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-3", "text": "The Unyvero Platform is a modular, flexible easy-to-use platform which substantially reduces turn-around time\nfrom up to 24 hours or even weeks to around four to five hours. This allows physicians to adjust treatment at a\nmuch earlier stage than with traditionally microbiology culture based test as the current clinical standard of care.\nCuretis believes that the reduced hands-on time of no more than five minutes and the intuitive workflow makes\nthe system operable by non-specially trained laboratory personnel and reduces the risks of errors. The Unyvero\nworkflow consists of five steps:\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4548952543822146, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-4", "text": "\uf0b7   Step 1: The native patient sample is transferred into the Unyvero sample tube and is sealed with the Un-\n    yvero sample tube cap.\n\uf0b7   Step 2: By selecting an application and indication on the cockpit and scanning the sample tube or alterna-\n    tively manual entry of sample information using the on-screen keyboard, the Lysator automatically opens.\n    The sealed Unyvero sample tube is loaded into the Lysator where the lysis is carried out fully automati-\n    cally for 30 minutes.\n\uf0b7   Step 3: After lysis, the Unyvero sample tube and mastermix tube are plugged into the cartridge.\n\uf0b7   Step 4: After scanning the preloaded Unyvero Cartridge, it is inserted into the Analyzer for further fully\n    automatic processing.\n\uf0b7   Step 5: Comprehensive results are available in approximately four to five hours and will be displayed on\n    the Unyvero C8 Cockpit screen without any further operator interaction. Results include a quick overview\n    of positively identified pathogens and resistance markers, a more detailed result screen for all pathogens\n    and all resistance markers tested for, as well as relevant test-log information. After the test has been com-\n    pleted, the cartridge is simply taken out of the Analyzer and can be discharged into hospital waste.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6861906797776828, "height": 0.2248824283882001, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-5", "text": "Application Cartridge Pipeline\n", "page_number": 132, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7007268063274904, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.7139803334758443, "height": 0.013253527148353927, "width": 0.21704957678355502}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-6", "text": "Curetis focuses on Application Cartridges for severe infectious diseases in hospitalised patients with a high\nunmet need and significant prevalence in developed countries that require multi-analyte combinations of\npathogens (bacteria, fungi and in the future potentially also viruses and parasites) and antibiotic resistance\nmarkers. These hospitalised patients are mostly in intensive care and have a high mortality rate as they represent\na high medical need and a significant economic burden. With many years of experience at major medical device\nand MDx companies such as HP, Agilent and Philips, Curetis' Application Cartridge development team is able to\ndevelop Unyvero Application Cartridges entirely in-house for manufacturing at Curetis' manufacturing site.\nCuretis plans to extend its product range with at least one additional Application Cartridge every year and to\ncontinuously update and evolve its existing Application Cartridges' content and performance in order to meet\nfuture market needs and the changing pathogen and antibiotic resistance landscape.\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.857631466438649, "height": 0.13638306968790082, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-7", "text": "Curetis intends to design Application Cartridges for specific indications covering all relevant pathogens and\nantibiotic resistance markers and therefore enabling a comprehensive diagnosis for a given disease for the\nmajority of relevant cases. Currently, Curetis is commercialising the P55 and the i60 ITI Application Cartridges\nin Europe and other markets accepting CE-IVD-marking. A blood culture Application Cartridge is under\ndevelopment. The pipeline further includes an intra-abdominal/gastrointestinal tract infection Application\n", "page_number": 132, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8648995297135528, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9328772979905943, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-132-8", "text": "129\n", "page_number": 132, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-0", "text": "Cartridge and a sepsis host response Application Cartridge. Potential additional development areas on the\nApplication Cartridges are tuberculosis (TB, including MDR (multi-drug-resistant) and XDR (extensively drug\nresistant) markers), pediatrics or CNS infections.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-1", "text": "The following figure 3 shows Curetis' current and potential future Application Cartridge pipeline:\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13296280461735785, "lower_right_x": 0.7738814993954051, "lower_right_y": 0.1470713980333476, "height": 0.014108593415989745, "width": 0.658403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-2", "text": "Ea) ED\nCommercial EE\ntts P55 Pneumonia\n\nProducts in\ndevelopment cE Co\n\nFuture product\nopportunities", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15305686190679776, "lower_right_x": 0.7986698911729141, "lower_right_y": 0.4082941427960667, "height": 0.2552372808892689, "width": 0.683192261185006}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-3", "text": "Figure 3: Curetis' Application Cartridge pipeline\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41684480547242414, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.4275331338178709, "height": 0.010688328345446751, "width": 0.28536880290205563}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-4", "text": "Product development phases\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4433518597691321, "lower_right_x": 0.31680773881499397, "lower_right_y": 0.4566053869174861, "height": 0.013253527148353983, "width": 0.20133010882708585}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-5", "text": "Curetis' product development follows a systematic stage-gated process, as shown in the figure 4 below, of five\nphases under its ISO 13485 certified Quality Management System:\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.45703292005130397, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49123557075673363, "height": 0.03420265070542966, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-6", "text": "Fone \u00ae Design ee Design vena @\nane Input Output Validation Clearance", "page_number": 133, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.4916631038905515, "lower_right_x": 0.879081015719468, "lower_right_y": 0.5917058572039333, "height": 0.1000427533133818, "width": 0.7539298669891172}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-7", "text": "Figure 4: Curetis product development process\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.3893591293833132, "lower_right_y": 0.6122274476271911, "height": 0.010688328345446751, "width": 0.27388149939540507}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-8", "text": "The time to develop and market a molecular diagnostics product varies and depends on many factors such as the\nmultiplexing level, amount of different sample types, the targeted clinical indication and expected performance\nin terms of clinical sensitivity, as well clinical specificity. On average, the development of a new Application\nCartridge through market launch as CE-IVD-marked Application Cartridge in the EU takes around 12 months.\nDevelopment costs are to some degree dependent on the Application Cartridge complexity and regulatory\npathway.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6220607097050022, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7045746045318512, "height": 0.08251389482684901, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-9", "text": "For all its current Application Cartridges, as well as new products, Curetis typically sets up sponsor-initiated and\ninvestigator driven studies depending on the product life cycle of the test. In the initial phase, observational stud-\nies focus on product performance comparing the Unyvero test to the standard of care. These are often followed\nby trials evaluating clinical validity, as well as proving clinical utility.\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7678495083368961, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-10", "text": "Curetis' commitment to clinical evaluation is reflected in several additional clinical projects targeting in total of\napproximately 5,000 patient samples, which are either currently enrolling or in preparation:\n", "page_number": 133, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8037622915775973, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-11", "text": "an on-going FDA clearance study for LRT55 Application Cartridge targeting more than 2,500 samples\ntested (1,500 prospective and 1,000 retrospective);\na more intensive evaluation of the P55 Application Cartridge clinical utility;\na large prosthetic joint infection study (European Prosthetic Joint Infection Cohort, the \"EPJIC\") testing\naround 500 samples;\ngeographic expansion of studies into France, UK and other countries;\n", "page_number": 133, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.8101752885848653, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9166310389055152, "height": 0.10645575032064991, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-12", "text": "\uf0b7\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8135955536554083, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8204360837964942, "height": 0.0068405301410859876, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-13", "text": "", "page_number": 133, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.847798204360838, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8546387345019238, "height": 0.0068405301410858765, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-14", "text": "\uf0b7\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8696023941855494, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8755878580589995, "height": 0.005985463873450114, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-15", "text": "\uf0b7\n", "page_number": 133, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.9063702436938863, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.9123557075673364, "height": 0.005985463873450114, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-133-16", "text": "130\n", "page_number": 133, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-0", "text": "companion diagnostic clinical trial with large pharmaceutical partner initiated for phase III Amikacin trial\nsupport;\nfurther studies for claim extension, e.g. P55 Application Cartridge for paediatrics;\na health technology assessment (\"HTA\") in the UK; and\na reimbursement study in Germany.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1778537836682343, "height": 0.09277469003847798, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-1", "text": "\uf0b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.08849935870029928, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.09576742197520308, "height": 0.007268063274903799, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-2", "text": "", "page_number": 134, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.12312954253954682, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.12954253954681488, "height": 0.006412997007268065, "width": 0.0054413542926239344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-3", "text": "\uf0b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.1470713980333476, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.15305686190679776, "height": 0.00598546387345017, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-4", "text": "\uf0b7\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.1671654553227875, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.17443351859769132, "height": 0.007268063274903813, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-5", "text": "As of 30 June 2015, Curetis has successfully finalised and published around 30 single-centre or multi-centre\nclinical studies with data from over 4,000 prospective and retrospective patient samples available. For the\nP50/P55 and the i60 ITI Application Cartridges, CE-IVD performance evaluations have been successfully com-\npleted.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2394185549380077, "height": 0.055151774262505365, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-6", "text": "The following tables represent Curetis' clinical development programs for the LRT55 and P55 Application Car-\ntridges in table 1 and for the i60 ITI Application Cartridge in table 2 at the date of this Prospectus in order of the\ngoal of the study.\n", "page_number": 134, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24583155194527576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2868747327917914, "height": 0.04104318084651562, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-7", "text": "Table 1: Curetis' current clinical (LRT55/P55 Application Cartridge) development program\n", "page_number": 134, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.294570329200513, "lower_right_x": 0.7158403869407497, "lower_right_y": 0.30782385634886705, "height": 0.013253527148354038, "width": 0.5991535671100363}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-8", "text": "Study                   Area     Principle investigator / Centre          Goal        Type          Size\n\n                                 S. Butler-Wu, University of Washing-\n                                 ton / Seattle, WA / US\n                                 K. Carroll, Johns Hopkins University\n                                 / Baltimore, MD / US\n                                 D. Hardy, University of Rochester /\n                                 Rochester, NY / US\n                                 R. Humphries, UCLA/ Los Angeles,\n                                 CA / US\n                                                                                   Reg,   Obs,\nLRT55 FDA trial          US      G. Kallstrom, Summa Health / Akron,      510(k)                   >2,500\n                                                                                   RS, MC,. SI\n                                 OH / US\n                                 R. Patel, Mayo Clinic / Rochester,\n                                 MN / US\n                                 M. Sims, William Beaumont Hospital\n                                 / Detroit, MI /US\n                                 R. Wunderink, Northwestern Univer-\n                                 sity / Chicago, IL /US\n                                 F. Wu, Columbia University / New\n                                 York, NY / US\n                                 V. Enne, University College London /\nPneumonia MDx                                                                      Obs,      PS,\n                         UK      London, D. Livermore / Norwich /          CV                      1,200\n/HTA                                                                               MC, II\n                                 UK\n\nP55 testing in im-\n                                                                                   Obs, RS, SC;\nmunocompromised          CH      D. Stolz, University / Basel / CH         CU                       600\n                                                                                   II\npatients\n\nP55 testing in ARDS                                                                Obs, RS, SC,\n                         DE      P.-M. Rath / University / Essen           CU                       120\npatients                                                                           II\n\nP55 validation                   K. Templeton, Royal Infirmary of                  Obs, PS, SC,\n                         UK                                                CU                       96\nagainst rPCR                     Edinburgh / UK                                    II\n                                  F. For\u00eat / Namur, J. Chastre / Paris,\n                                 Olivier Mimoz\nP55 and antimicrobi-                                                               Int,   Ran,\n                        Global   / Poitiers Cedex, M. Wolff / Paris, A.   CDx                       500\nal                                                                                 MC, PI\n                                 Torres\n                                 / Barcelona, R. M\u00e1\u00f1ez / Barcelona\n                                 K.P. Hunfeld, Nordwest KH / Frank-                Obs, PS, SC,\nP55 predicting sepsis    DE                                               Cl Ext                    120\n                                 furt / G                                          II\n", "page_number": 134, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.3215049166310389, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9247541684480547, "height": 0.6032492518170158, "width": 0.7738814993954051}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-134-9", "text": "131\n", "page_number": 134, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-0", "text": "Study               Area   Principle investigator / Centre   Goal      Type        Size\n\n\nP55 / i60 and DRG          T. R\u00fcnz Klinikverbund Nordwest,          Obs, PS; SC,\n                    DE                                       HE                    150\nCodes                      Sindelfingen, D                          II\n", "page_number": 135, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.08251389482684908, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1718683197947841, "height": 0.08935442496793501, "width": 0.7762998790810157}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-1", "text": "CV = clinical validity, CU = clinical utility, CDx = companion diagnostics, Cl Ext = claim extension, HE = health economic\nReg = regulatory, Obs = observational, RS = retrospective, MC = multi-centre, SI = sponsor-initiated, II = investigator-initiated, SC = single centre, PS= prospec-\ntive, Int = interventional, Ran = randomised, PI = pharma-initiated\n", "page_number": 135, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.1748610517315092, "lower_right_x": 0.8875453446191052, "lower_right_y": 0.20906370243693886, "height": 0.03420265070542966, "width": 0.777509068923821}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-2", "text": "Table 2: Curetis' current clinical (i60 ITI Application Cartridge) development program\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.22530996152201796, "lower_right_x": 0.6831922611850061, "lower_right_y": 0.23599828986746474, "height": 0.01068832834544678, "width": 0.5646916565900847}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-3", "text": "Study                     Area   Principle investigator / Centre         Goal       Type          Size\n\nEPJIC: i60 in PJI soni-   EU     A. Trampuz, Charit\u00e9 / Berlin / G        CU     Obs, PS, MC,      500\ncation fluids                                                                   II\n\ni60 in bone & joint       FR     S. Corvec, CHU de Nantes, Nantes / F    CU     Obs, PS, MC,      120\ninfections                                                                      II\n\ni60 in tissue             FR     M. Rottmann, Hospital         Raymond   CU     Obs, RS, SC,      250\n                                 Ponicar\u00e9, Garches                              II\n\nP55 / i60 and DRG         DE     T. R\u00fcnz Klinikverbund Nordwest, Sin-    HE     Obs, PS, SC, II   150\nCodes                            delfingen, D\n", "page_number": 135, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.2381359555365541, "lower_right_x": 0.8778718258766627, "lower_right_y": 0.43394613082513894, "height": 0.19581017528858485, "width": 0.7720677146311972}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-4", "text": "CU = clinical utility, HE = health economic\nObs = observational, PS= prospective, MC = multi-centre, II =\n", "page_number": 135, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.4360837964942283, "lower_right_x": 0.40931076178960096, "lower_right_y": 0.4600256519880291, "height": 0.02394185549380079, "width": 0.30290205562273276}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-5", "text": "= investigator-initiated, RS =\n", "page_number": 135, "bounding_box": {"top_left_x": 0.4111245465538089, "top_left_y": 0.4510474561778538, "lower_right_x": 0.5405078597339782, "lower_right_y": 0.4595981188542112, "height": 0.008550662676357401, "width": 0.12938331318016927}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-6", "text": "= retrospective, SC =\n", "page_number": 135, "bounding_box": {"top_left_x": 0.5411124546553809, "top_left_y": 0.4510474561778538, "lower_right_x": 0.6348246674727932, "lower_right_y": 0.4600256519880291, "height": 0.008978195810175282, "width": 0.09371221281741227}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-7", "text": "= single centre,\n", "page_number": 135, "bounding_box": {"top_left_x": 0.6354292623941958, "top_left_y": 0.4510474561778538, "lower_right_x": 0.7055622732769045, "lower_right_y": 0.46045318512184696, "height": 0.009405728943993164, "width": 0.07013301088270862}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-8", "text": "=\n", "page_number": 135, "bounding_box": {"top_left_x": 0.40931076178960096, "top_left_y": 0.4523300555793074, "lower_right_x": 0.4105199516324063, "lower_right_y": 0.45788798631893973, "height": 0.005557930739632344, "width": 0.001209189842805325}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-9", "text": "The P55 Pneumonia Application Cartridge\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.4111245465538089, "lower_right_y": 0.4878153056861907, "height": 0.012825994014536157, "width": 0.2956469165659008}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-10", "text": "Medical need\n", "page_number": 135, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.49551090209491233, "lower_right_x": 0.21100362756952842, "lower_right_y": 0.5079093629756306, "height": 0.012398460880718276, "width": 0.09492140266021766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-11", "text": "Pneumonia is a severe, life-threatening acute infection of the lower respiratory tract. It results from various\ncauses, most commonly bacteria. The current diagnosis process and treatment of pneumonia is imprecise and\nfraught with problems. It is a fast progressing disease associated with high treatment costs, mortality rates up to\n29.3% and an average hospital stay of 8 to 23 days. 52\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5703292005130398, "height": 0.05429670799486963, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-12", "text": "Pneumonia is classified in community-acquired pneumonia (\"CAP\"), healthcare-associated pneumonia\n(\"HCAP\") and hospital-acquired pneumonia (\"HAP\") with its sub-class ventilator-associated pneumonia\n(\"VAP\").53 A CAP is acquired in the community without a history of medical intervention and is mostly caused\nby viruses. Patients with a CAP usually follow a mild course, however 20%-40% of them need to be\nhospitalised.54 Such hospitalisation are cases classified as severe community-acquired pneumonia (\"sCAP\").\nHAP constitutes up to 25% of all ICU infections and in over 50% of all cases antibiotics are prescribed. 55\nBecause hospitalised individuals are exposed to more dangerous, often drug-resistant bacteria, such HAP tends\nto be more deadly than CAP. Antibiotics administered for HAP are often given intravenously, are expensive,\nmay produce greater side effects and may be used in combination. Empirically based initial regimen is\ninadequate in up to 45% of cases,56 however adequate initial treatment can significantly reduce both mortality\nand length of stay,57 with potential cost savings of several thousand euros per patient. For VAP, the length of\nstay (\"LOS\") in intensive care is increased by a mean of 6 days 58 and additional costs are as high as US$40,000\nper patient.59 Those VAPs, a subset of HAP associated with mechanical ventilation, have an incidence of 11%\nand a mortality of 29%.60\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.7678495083368961, "height": 0.1970927746900385, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-13", "text": "The underlying cause in pneumonia cases is usually diagnosed through a microbiology culture from a respiratory\nsample. Results from microbiology cultures typically take two days or longer.61 Therefore, clinicians must\nalmost always begin treatment before lab results are available to validate their treatment selection. In addition,\nantibiotic resistances complicate the difficulty of therapy selection. Antibiotic resistances have risen steadily in\nthe last several decades due to inadequate antibiotic treatment. 62 Clinical studies have demonstrated that\nadequate initial antibiotic treatment for most severe acute infections significantly improves medical outcome. 63\nIn addition, appropriate and early antibiotic selection will limit the risk of increasing antibiotic resistance in the\npopulation as a whole.\n", "page_number": 135, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8849935870029927, "height": 0.10902094912355698, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-135-14", "text": "132\n", "page_number": 135, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-0", "text": "Market potential\n", "page_number": 136, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.11608222490931076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-1", "text": "In Europe, the ECDC (European Centre for Disease Prevention Control) reported in 2008 an incidence of\nhospital acquired infections (\"HAI\") of 837,500 with a rate of 24% pneumonia cases resulting in 201,000 HAPs\nand VAPs.64 The incidence for hospitalised sCAPs for Europe is estimated at approximately 1 million cases\nannually.65 CDC's official 2010 US hospital statistics reported 1,128,000 discharges because of pneumonia.66\nCuretis estimates the total potentially available market for severe pneumonia in EU and US is 2.3 million\nincidences (see table 3 below) per year.67\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.1876870457460453, "height": 0.0820863616930312, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-2", "text": "Table 3: Estimated P55 market potential\nVariables for incidence of                    EU                      US              Total potential\nsevere pneumonia                     (approx. market size)   (approx. market size)   available market\n HAI                                       837,500 1                  n.a.                  n.a.\n HAP (24% of HAI) 1                         201,000                   n.a.                  n.a.\n sCAP                                     1,000,000 2                 n.a.                  n.a.\nHospitalised/ severe pneumonia             1,201,000              1,128,000 3           2,329,000\n", "page_number": 136, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.19452757588713127, "lower_right_x": 0.879081015719468, "lower_right_y": 0.29585292860196666, "height": 0.10132535271483539, "width": 0.7732769044740024}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-3", "text": "Sources: 1 ECDC (2008); 2 Chalmers et al. (2014); 3 CDC (2010)\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29628046173578454, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.30782385634886705, "height": 0.011543394613082514, "width": 0.31015719467956465}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-4", "text": "Description and status\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.33689610944848225, "height": 0.012398460880718276, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-5", "text": "The P55 Application Cartridge, initially released in 2012 as P50 Application Cartridge, is a CE-IVD-marked\nApplication Cartridge for the fully automated detection of currently 20 microorganisms and 19 antibiotic\nresistance markers in native respiratory samples, such as sputum, tracheal aspirates and broncho-alveolar lavage\nfluids with no pre-culturing required. This Application Cartridge combines the necessary detection of bacteria, a\nfungus and resistance markers into a single test to aid diagnosing pneumonia.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4125694741342454, "height": 0.06755023514322356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-6", "text": "The P55 Application Cartridge targets severe cases of pneumonia in hospitalised patients who are mostly in\nintensive care and have a high mortality rate. It has a total sample-to-answer time of around four to five hours,\nwith a hands-on time of about five minutes. According to a CE performance evaluation study, the P55\nApplication Cartridge has achieved an overall clinical sensitivity of 94% and a clinical specificity of 99.4%. 68\nThe test as its previous version is faster than microbiology culture and identifies many pathogens that are\noverlooked in microbiology cultures. 69 The P55 Application Cartridge has been clinically validated in thousands\nof patient samples.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5151774262505344, "height": 0.09491235570756734, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-7", "text": "The Unyvero pneumonia Application Cartridge of microorganisms and resistance gene markers was designed\nbased on feedback of clinical experts and international and national guidelines. It aims to detect at least 90% of\nhealthcare-associated pneumonia causing pathogens and clinical relevant resistances against antimicrobials. The\nApplication Cartridge is primarily designed to capture patients at risks for:\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5228730226592561, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.5771697306541257, "height": 0.05429670799486963, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-8", "text": "\uf0b7   microorganisms causing severe, and complicated to treat, forms of pneumonia, e.g. Pseudomonas aeru-\n    ginosa,\n\uf0b7   microorganisms carrying antibiotic resistance and where patients may need isolation (MRSA, Klebsiella),\n\uf0b7   infections with multidrug-resistant bacteria, that might not be targeted by empiric treatment schemes, and\n\uf0b7   rare, but difficult to detect pathogens like Legionella sp.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.5844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6772124839675074, "height": 0.09277469003847794, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-9", "text": "The Application Cartridge composition takes pathogen incidences into account. It includes those microorganisms\nshowing an incidence of above 1%. The Application Cartridge is completed by adding pathogens with lower\nincidence but a high clinical need, such as Legionella sp.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-10", "text": "The P55 Application Cartridge covers 19 antibiotic resistance markers, including:\n", "page_number": 136, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.731936725096195, "lower_right_x": 0.6662636033857315, "lower_right_y": 0.7456177853783669, "height": 0.013681060282171864, "width": 0.5489721886336154}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-11", "text": "\uf0b7   \u00df-Lactam resistance, including ESBL,\n\uf0b7   kpc resistance,\n\uf0b7   macrolide resistance,\n\uf0b7   quinolone resistance, and\n\uf0b7   multi-drug resistance.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.8533561351004703, "height": 0.0979050876442924, "width": 0.3053204353083434}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-12", "text": "Until recently, the P55 Application Cartridge could detect 21 microorganisms and 19 antibiotic resistance mark-\ners based on the Company\u00b4s assumption that the P55 Application Cartridge fell under the scope of Annex III of\nthe IVD Directive, which specifies the procedures and requirements for a manufacturer to affix the CE-IVD-\nmarking before introducing a product in the market.\n", "page_number": 136, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9157759726378795, "height": 0.05429670799486963, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-136-13", "text": "133\n", "page_number": 136, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-137-0", "text": "The Company was recently notified in October 2015 after a routine interaction with the Regional Administrative\nAuthority in Stuttgart (Regierungspr\u00e4sidium Stuttgart) that, due to its inclusion of the assay for the pathogen for\n\"Chlamydophila pneumoniae\" on the panel of its P55 Application Cartridge, the P55 Application Cartridge falls\nunder the scope of annex II, list b of the IVD Directive, which sets forth additional requirements for the purpose\nof affixing the CE-IVD-marking. In order to be able to continue to commercialise the P55 Application Cartridge\nuntil these additional requirements have been fulfilled, Curetis developed and released on 22 October 2015 a\nsoftware update for the Unyvero System that prevents the reporting of a result of the test for the relevant patho-\ngen (Chlamydophila pneumoniae). Curetis anticipates that it will have implemented the necessary corrective\nmeasures in all of its customers` Unyvero Systems currently using the P55 Application Cartridge by the end of\nOctober 2015. Curetis believes that after the software update has been fully implemented, the P50 Application\nCartridge (which will be discontinued shortly anyway) and the P55 Application Cartridge will be in full compli-\nance with the applicable regulations. As a result of this development, the P55 Application Cartridge that is com-\nmercialised in Europe and certain other markets that accept CE-IVD-marking currently detects 20 microorgan-\nisms and 19 antibiotic resistant markers.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2736212056434374, "height": 0.1885421120136811, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-137-1", "text": "Curetis is currently working on conformity assessment procedures to ensure that the test for Chlamydophila\npneumoniae can be included into the P55 Application Cartridge and intends, upon review and approval by the\nrelevant notified body to introduce a next generation software that will once again allow the display of the results\nof the test for the full panel of 21 microorganisms and 19 antibiotic resistance markers, including the pathogen\n(Chlamydophila pneumoniae).\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3514322359982899, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-137-2", "text": "In addition to the Unyvero System, Curetis intends to launch the LRT55 Application Cartridge (in the US the\nP55 Application Cartridge is labelled LRT55 Application Cartridge), which is currently undergoing a clinical\ntrial towards an FDA clearance expected under the 510(k) de-novo process in the US. For further details see \"\u2013\nProducts -Unyvero Platform\". The following table 4 presents all finalised studies on the P50/P55 Application\nCartridge during the period 2011-2015 which is in order of the goal of the study.\n", "page_number": 137, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.42667806755023513, "height": 0.06797776827704144, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-137-3", "text": "Table 4: Finalised studies and publications on the P50/P55 Application Cartridge (2011-2015)\nStudy                Country   Goal   Type     Size   Main result                       Authors and Date of publication\n                                                      Detection of additional patho-\n                                       Obs.           gens in 127 cases significantly\nP55 Pneumonia                  Reg                                                      Manual of the P55 Pneumonia Application,\n                       DE              RS,     392    improves pathogen identifica-\nApplication                    (CE)                                                     2015\n                                      SC, SI          tion, Sensitivity 94%, Speci-\n                                                      ficity 99.4%\n                                                      Pathogen detection: Sensitivi-\n                                                      ty 80.6%, Specificity 96.0%\n                                                      Unyvero detected 156 addi-\nP50      Perfor-                       Obs,\n                               Reg                    tional pathogens confirmed by     Klein M. et al. \u2013 23rd ECCMID, April, 27 \u2013\nmance    Evalua-       DE              RS,     1048\n                               (CE)                   sequencing, 86.6% PPV for         30, 2013, Berlin, D, poster\ntion                                  SC; SI\n                                                      \u1e9e-lactamase resistance, Time\n                                                      to result ~5 hours vs. 48 h for\n                                                      microbiology\n                                                      Sample to answer Unyvero vs.\n                                                      culture: 4h vs. 96h\nP50 impact on\n                                       Int,           Therapy changes in 6h in 67%      Jamal W. et al. 2014, J Clin Microbiol, 52:\nclinical man-         KW       CU              56\n                                      SC, II          of patients                       2487 \u2013 92\nagement\n                                                      63% of patients improved\n                                                      clinically\n                                       Int,                                             Udristipoiu, R., et al. \u2013 AASCIT Communi-\nP50 Evaluation\n                       RU      CU      PS,      3     Case reports,                     cations, Volume 1, Issue 3, 20.10.2014,\nat ICU\n                                      SC, II                                            online, Publication only\n                                                      overall sensitivity of 80.5%\n                                      Obs,                                              Pranada, AB, et\n                                                      and an overall specificity of\nEvaluation P50         DE      CU      PS,     31                                       66. DGHM, October 5-8, 2014 Dresden,\n                                                      95.3% for pathogen identifica-\n                                      SC, II                                            Germany, Poster\n                                                      tion.\n                                                      Mean turnaround times were\n                                                      6.5 h for multiplex PCR and\nP50       clinical                    Obs,                                              Kunze et al. Ann Clin Microbiol Antimi-\n                                                      71 h for conventional micro-\nutility in VAP         DE      CU      PS,     40                                       crob.    2015    Jun   13;14:33.   doi:\n                                                      biology, 55% (n = 16) of\npatients                              SC, II                                            10.1186/s12941-015-0091-3.\n                                                      results concordant in patients\n                                                      with CPIS) > 5 (n = 29)\n                                      Obs,            90% overall sensitivity, more     Platt, G. et al.\nP50 in CAP and\n                       UK      CU      PS,     65     pathogen identified compared      25th ECCMID, April, 25 \u2013 28, 2015, Co-\nHAP\n                                      MC, II          to microbiology                   penhagen, DK, ePoster\n                                                      Pathogen detection 48 \u2013 72h\n                                                      earlier by Unyvero\n                                                                                        Mokaddas, E. et al.\nP50 in tertiary                        Int,           For 12 patients antimicrobials\n                      KW       CU              36                                       23rd ECCMID, April, 27, 2013, Berlin, D,\ncare hospital                         SC, II          were modified based on\n                                                                                        talk\n                                                      Unyvero results: in VAP\n                                                      patients 6/18, in HAP patients\n", "page_number": 137, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.9226165027789653, "height": 0.4886703719538264, "width": 0.7889963724304716}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-137-4", "text": "134\n", "page_number": 137, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-138-0", "text": "Study                  Country   Goal   Type      Size   Main result                         Authors and Date of publication\n                                                         2/10, in sCAP patients 4/11.\n\n                                         Obs,            Pneumocystis jirovecii detect-\nPneumocystis                                                                                 Weile, J et al.\n                                         PS,             ed in 1.49%, eight cases\njirovecii -              DE      CU               739                                        113th ASM, May 18 \u2013 21, 2013 Denver,\n                                         MC,             (1.08%) were detected with\ndetection rates                                                                              CO, USA, Poster\n                                          SI             P50 application.\n                                                         Native, fresh clinical samples\n                                                         tested with assay prototype\n                                                         Sensitivity depending on\nValidation        of\n                                         Obs,            microorganisms between 91 \u2013         Schulte B. et al.\nmultiplexed\n                         DE      CV      PS,      274    100%, Specificity 100%,             22nd ECCMID, March, 31 \u2013 April, 3 2012,\nPneumonia\n                                        SC, SI           Good phenotype and genotype         London, UK, poster\nAssay\n                                                         correlation     for    antibiotic\n                                                         resistance for, P. aeruginosa\n                                                         and E. coli.\n                                                         Pathogen detection: Sensitivi-\nP50      against                         Obs,            ty 89%, Specificity 98%             Malczynski M. et al.\ncomposite                US      CV      PS,      26     Antibiotic resistance detec-        53th ICAAC, September, 10 \u2013 13, 2013,\ncomparator                              SC, SI           tion: Sensitivity 86%, Speci-       Denver, USA, poster\n                                                         ficity 97%\n                                        Obs,             Unyvero detects additional\nP50 validation in                                                                            K\u00f6nig B. et al.\n                         DE      CV      PS,      120    pathogens in 19% of cases and\nroutine lab                                                                                  ISMD, May, 29 \u2013 31 2014 Graz, A, talk\n                                        SC; II           2-3 days earlier\n                                                         In 88.6% of clinically con-\nP50       clinical                      Obs,                                                 van Dessel H. et al.\n                                                         firmed VAP (>104 microor-\nutility in pneu-         NL      CV      RS,      66                                         NVVM, April, 15 \u2013 16, 2014, Papendal,\n                                                         ganisms). Unyvero P50 was\nmonia                                   SC, II                                               NL, poster\n                                                         able to identify the pathogen.\n                                                         K. pneumonia detected in 12\n                                        Obs,             samples by Unyvero, by              B. Gross et al.\nP50 and kpc              DE      CV      RS,      12     standard culture and MALDI-         24st ECCMID, May 9 -13, 2014, Barcelona,\n                                        SC, II           TOF. KPC markers, 11/of12           Spain, Abstract only\n                                                         correlated.\n                                                         82.5% sensitivity, 95.3%\nP50 in multi-                           Obs,             specificity 54% of the cases        Pranada A. et al.\npathogen infec-          DE      CV      PS,      50     multiple pathogens          were    54th ICAAC, September, 5 \u2013 9, 2014,\ntions                                   SC, II           identified,    additional     17    Washington, USA, Poster\n                                                         pathogens identified\n                                                         The Unyvero prototype found\n                                                         one case with relevant patho-\n                                                         gens while traditional micro-\n                                         Obs,\n                                                         biology identified four cases.      Karrasch, M. et al.\nP50 and fastidi-                         PS,\n                         DE      CV               302    Specificity for fastidious          Case Reports in Clinical Pathology, 2015,\nous pathogens                            MC,\n                                                         pneumonial pathogen identifi-       Vol. 2, No. 2\n                                          SI\n                                                         cation as well as coverage of\n                                                         nosocomial pathogens should\n                                                         be improved.\n                                                         78.7% sensitivity (95% CI\n                                                         lower bound: 72.1%) and\n                                         Obs,\n                                                         96.6% specificity (95% CI           Schulte et al. PLoS ONE 9(11):\nP50 testing vs         DE, BE,           PS,\n                                 CV               739    lower bound: 96.1%). Time to        e110566.doi:10.1371/journal.pone.0110566,\nstandard of care         ES              MC,\n                                                         result was 5.2 hours (median)       2015\n                                          SI\n                                                         for the prototype test and 43.5\n                                                         h for standard-of-care.\n                                                         Traditional        microbiology\n                                                         culture based tests found in\n                                                         104 cases 96 pathogens which\n                                                         are also on the P50 panel,\n                                                         while Unyvero detected 76%\n                                                         of these 96 pathogens and\n                                        OBS,\nP50 against                                              identified 68 additional mi-\n                         CH      CV     RS, II,   119                                        Calligaris-Maibach R.C., et al., 2013\nmicrobiology                                             croorganisms not listed in the\n                                         SC\n                                                         traditional        microbiology\n                                                         culture based tests report.\n                                                         Phenotypic         antimicrobial\n                                                         susceptibility or resistance\n                                                         was predicted in 82% cases by\n                                                         Unyvero.\n                                                         Combination of different lysis\nUniversal lysis                          Obs,            procedures in an automated          Klein M. et al.\nfor    molecular         DE      Feas    RS,      14     sample preparation allows to        64. DGHM, September, 30 \u2013 October, 3\nAssays                                  SC, SP           process different sample types      2012, Hamburg, D, poster\n                                                         regardless of their origin.\nMolecular      \u1e9e-                        Obs,            3rd generation cephalosporin        Barth S. et al.\nlactamase                DE      Feas    RS,      183    resistance genotyping with          64. DGHM, September, 30 \u2013 October, 3\nresistance                              SC, SI           PPV 99% and NPV 67%.                2012, Hamburg, D, poster\n", "page_number": 138, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.9303120991876871, "height": 0.8486532706284737, "width": 0.7889963724304716}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-138-1", "text": "135\n", "page_number": 138, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-0", "text": "Study               Country   Goal     Type     Size   Main result                      Authors and Date of publication\ntesting\n\nRapid Detection                                        Pathogen identification sensi-\n                                        Obs,                                            Barth S. et al.\nof pathogens and                                       tivity of 81% and specificity\n                      DE      Feas.     RS,     228                                     AMP 2012, October, 25 \u2013 27, 2012, Long-\nantibiotic    re-                                      of 99%. PPV for antibiotic\n                                       SC, SI                                           beach, USA, poster\nsistance                                               resistance testing of 83.3%.\n                                                       Unyvero allows processing of\n                                        Obs,                                            Schwarzer; K. et al. 24rd ECCMID, May\nNovel      lysis                                       a wide range of diverse clini-\n                      DE      Feas      RS,     20                                      9.-13, 2014, Barcelona, Spain, Abstract\ntechnology                                             cal samples including tissue,\n                                       SC, SI                                           only\n                                                       cartilage\n                                        Int,\nP50 in      CAP                        Ran,\n                    Global    Cl Ext            450                                     Data not yet published\npatients                                MC,\n                                         PI\n                                       Obs,\nP50 \u2013 neonates\n                      DE      Cl Ext    PS,     100                                     Data not yet published\n& C. fibrosis\n                                       SC, II\n", "page_number": 139, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.2890123984608807, "height": 0.20735356990166737, "width": 0.7823458282950423}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-1", "text": "                                                   SC, II\nReg = regulatory, CU = clinical utility, CV = clinical validity, Cl Ext = claim extension\nObs = observational, RS = retrospective, Int = interventional, SC = single centre, II = investigator-initiated, PS= prospective, MC = multi-centre, SI = sponsor-\ninitiated, Ran = randomised, PI = pharma-initiated\n", "page_number": 139, "bounding_box": {"top_left_x": 0.11185006045949214, "top_left_y": 0.2890123984608807, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3180846515604959, "height": 0.029072253099615197, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-2", "text": "Competition\n", "page_number": 139, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3274903805044891, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.3381787088499359, "height": 0.010688328345446807, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-3", "text": "At the date of this Prospectus, competitive key MDx products for respiratory tract infections are ePlex\u2122 RP test\n(not yet launched by GenMark Diagnostics, Inc.), FilmArray\u2122 RVP (by BioFire Diagnostics, Inc. / bioM\u00e9-\nrieux), RVP V1 and RVP Fast (both by Luminex Corporation) and Verigene\u2122 RV Plus (by Nanosphere, Inc.).\nAll of which are focusing on URTI, and therefore mainly featuring virus panels. Further tests by additional com-\npanies on other platforms are also in development.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.413852073535699, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-4", "text": "The i60 ITI Implant and Tissue Infections Application Cartridge\nMedical need\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.45404018811457886, "height": 0.030354852501068785, "width": 0.43591293833131806}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-5", "text": "Implant and tissue infections represent a significant risk factor during the healing process after surgery or trauma\nand can significantly influence or delay the recovery process, making early and reliable identification of the\ncausative pathogens just as necessary as an adequate antimicrobial treatment. Some of the most common\noccurring infections are: prosthetic joint infections (\"PJI\"), surgical site infections (\"SSI\"), diabetic foot ulcers,\ncatheter-associated infections, deep skin and tissue infections, cardiology-related infections, other implant\ninfections and burn-wound infections.\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5433946130825139, "height": 0.07866609662248825, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-6", "text": "The number of patients requiring joint replacement or internal fixation devices increases due to prosthetic joint\ninfections.70 Even considering the progress in the prevention and treatment of implant-associated infections, the\nabsolute number of patients with such infections is increasing as a lifelong risk for bacterial seeding on the\nimplant has to be taken in account. After initial hip replacement surgery, an infection rate of less than 1% for the\nfollowing two years is to be expected, while for a knee replacement an infection rate of less than 2% is to be\nexpected.71 A much higher incidence of infection occurs in revision surgery patients. It can reach up to 40% after\nprimary replacement.72 The numbers of revisions done for reasons of an infection are rising. Compared to 2005\nthe demand for hip revision procedures is expected to double by 2026 in the US, while the demand for knee\nreplacements is estimated to double by 2015 in the US. 73 Patients receiving a fixation of open fractures are\nestimated to have a 30% risk of infection. 74 Costs concerning ITIs pose a significant burden for the healthcare\nsystem. For example, the average cost difference between an aseptic and a septic hip replacement is US$8,893\nand can be attributed to an incremental length of stay of 24 days. 75\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7169730654125694, "height": 0.1633176571184266, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-7", "text": "Surgical site infections represent 20% of all HAIs,76 affecting up to 17%77 of postoperative patients and leading\nto 220,000 postoperative wound infections per year in Germany. 78 These infections vary in severity; some are\nlimited to skin and subcutaneous tissue while other more aggressive forms involve deep soft tissues, such as\nmuscles and fascia. SSIs have a major impact on patients' life quality. Infected surgical patients are twice as\nlikely to die, spend 60% more time in intensive care units and have a five times higher likelihood to be\nreadmitted to hospital after discharge. 79 In the US about 8,000 deaths can be associated with SSIs per year. 80\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8058999572466866, "height": 0.08465156049593847, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-8", "text": "Diabetic foot infections (\"DFIs\") are high incidence clinical problems and represent the most common cause of\ndiabetes-related admission to hospital. The continued rise in incidence of diabetes in developed and less devel-\noped countries, the increasing body weight of many diabetic patients, and their greater longevity all contribute to\nthe growth of the problem. The rise of DFIs are associated with potentially serious sequelae, and are in fact\namong the leading causes of foot amputations in the developed world, constituting 40%-60% of all non-trauma-\nassociated foot amputations.81 In Germany, diabetic foot accounts for up 70% of all amputations. 82 When proper-\nly managed, most patients can be cured. However, many patients needlessly undergo amputations because of\nimproper diagnostic and therapeutic approaches.83 DFIs usually begin in a diabetic foot wound, most often a\n", "page_number": 139, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9221889696451475, "height": 0.10859341598973926, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-139-9", "text": "136\n", "page_number": 139, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-0", "text": "neuropathic ulceration. While all wounds are colonised with microorganisms to some extent, 40%-80% of pa-\ntients will present with a clinically important infection, involving up to 2-3 different pathogens when there is\nassociated gangrene.84 The average costs for deep diabetic foot infections are very high, costing on average US$\n35,000 per patient.85\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-1", "text": "Catheter related bloodstream infections account for 11% of all HAIs and constitute therefore an important issue\nin hospital settings.86 In Europe and the USA, more than 50% of patients admitted to hospitals will use a catheter\nduring their hospital stay.87 Of these an average 3% of the catheterisations will result in infections with some\nestimates putting the incidence as high as 16%.88\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19752030782385635, "height": 0.05087644292432664, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-2", "text": "estimates putting the incidence as high as 16%.\nCatheter associated infections can pose a huge cost burden on the healthcare system, with estimated additional\n\u20ac34 million per year in Germany alone.89\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19794784095767423, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23557075673364686, "height": 0.037622915775972626, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-3", "text": "Conventional diagnosis of implant and tissue infections \u2013 encompassing orthopaedic implant infections and SSIs\nbut also diabetic foot infections, catheter-associated infections, deep skin and tissue infections and cardiology-\nrelated infections \u2013 has shown low accuracy and is problematic. Physicians usually have to wait up to two weeks\nfor diagnostic results from the different clinically relevant sample types in the case of certain PJIs. Therefore,\ntreatment is initiated before diagnostic results are available.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31124412141941, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-4", "text": "As in other severe infections, physicians generally believe that rapid and accurate detection of the disease-\ncausing pathogens and drug resistance markers, followed by the implementation of appropriate antibiotic\ntherapy, hold the potential to significantly reduce patient mortality rates, length of stay and costs.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3591278324070115, "height": 0.04147071398033347, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-5", "text": "Market potential\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3655408294142796, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.37964942283026937, "height": 0.014108593415989745, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-6", "text": "The market size for the ITI Application Cartridge is estimated by using disease incidences in Europe and the US\nfor each of its eight applications (see table 5), with the exception of the \u2018deep skin and tissue infections' market\nas there was a lack of sufficient data.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4241128687473279, "height": 0.03805044890979048, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-7", "text": "Table 5: Estimated i60 ITI market potential\n", "page_number": 140, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.43394613082513894, "lower_right_x": 0.40024183796856105, "lower_right_y": 0.4463445917058572, "height": 0.012398460880718276, "width": 0.2823458282950423}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-8", "text": "Total Implant and Tissue Infections by indication   Incidence\nDiabetic Foot Ulcer Infections                      355,320\nDecubitus Ulcer Infections                           31,338\nBurn Wound Infections                                38,409\nSurgical Site Infections (SSIs)                     582,012\nOrthopaedics / Prosthetic Joint Infections (PJIs)   607,834\nCatheter-associated Bloodstream Infections          501,400\nCardiology-related Infections                        11,902\nAll indications                                     2,128,215\n", "page_number": 140, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.4514749893116717, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.6425823001282599, "height": 0.19110731081658822, "width": 0.7835550181378477}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-9", "text": "Source: Margolis et al. (2011); American Diabetes Association (2014); Diabetes Deutschland (2012); Richard et al. (2011); Livesley and Chow (2002); Dorner et\nal. (2009); Deutsche Gesellschaft f\u00fcr Verbrennungsmedizin (2014); Mayhall (2003); Klevens et al. (2007) in Jhung (2009); Geffers (2011); Brun-Buisson\n(2001); Michelotti et al. (2012); Sunderlin (2006).\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6772124839675074, "height": 0.031209918768704492, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-10", "text": "However, as Curetis is only focusing on severe diseases, the overall incidence of infections related to each\nspecific indication is multiplied with a specific share of severe cases \u2013 management estimates- so that\nconsequently only severe ITI infections are considered. Therefore, management believes in total 1.2 million ITI\ncases per year in Europe and 0.9 million cases per year in US are eligible for Unyvero testing.90\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7456177853783669, "height": 0.05515177426250539, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-11", "text": "Description and status\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.7661393758016246, "height": 0.01410859341598969, "width": 0.15477629987908098}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-12", "text": "The i60 ITI Application Cartridge currently detects 61 microorganisms and 19 antibiotic resistance markers.\nCuretis' management strives to detect the vast majority of pathogens and resistance markers for eight different\nindications: prosthetic joint infections, diabetic foot infections, surgical site infections, catheter-associated\ninfections, deep skin and tissue infections, cardiology-related infections, other implant infections and burn-\nwound infections. A diverse range of sample types such as aspirates and exudates, pus, sonication fluid, swabs,\nsynovial fluid and tissue can be used. Moreover, biofilm-building pathogens can be identified by the Unyvero\nPlatform.\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8653270628473707, "height": 0.09277469003847805, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-13", "text": "The i60 ITI Application Cartridge has been jointly developed and co-funded by Heraeus Medical GmbH, a\nworldwide market leader in orthopaedic bone cement who offers comprehensive infection management\nsolutions. Curetis pays a customer referral commission to Heraeus Medical, but has retained full control on\n", "page_number": 140, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9166310389055152, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-140-14", "text": "137\n", "page_number": 140, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-0", "text": "product commercialisation. For more details see \"\u2013 Partnerships and Collaboration Agreements \u2013 Heraeus\nMedical\" and \"\u2013 Material Contracts \u2013 Heraeus Medical GmbH\".\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.10944848225737494, "height": 0.02436938862761863, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-1", "text": "The i60 ITI Application Cartridge was launched in Europe in the second quarter of 2014. According to the CE\nperformance evaluation study it has an overall clinical sensitivity of 67% \u2013 key microorganisms between 75%\nand 100% \u2013 and a clinical specificity of 97.8%.91 The Application Cartridge has been clinically validated in\nhundreds of patient samples. The second generation of the i60 ITI Application Cartridge is already in\ndevelopment and is intended to be launched by Curetis in spring 2016.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.06840530141085933, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-2", "text": "The following table 6 presents all finalised studies on Curetis' i60 ITI Application Cartridge during the period\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.20863616930312098, "height": 0.014108593415989718, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-3", "text": "2013-2015 in order of the specified goal of the study.\nTable 6: Finalised studies and publications on Unyvero i60 ITI Application Cartridge (2013-2015)\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20863616930312098, "lower_right_x": 0.7496977025392987, "lower_right_y": 0.2419837537409149, "height": 0.033347584437793926, "width": 0.6342200725513906}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-4", "text": "                                                                                         Authors and date\nStudy                Country   Goal    Type     Size   Main result\n                                                                                         of publication\n                                                                                         Motejadded H. et\n                                                       Performance for pathogen ID       al.      \u2013      24rd\ni60 Performance                 Reg    Obs,\n                       DE                       339    in native samples: 67.0%          ECCMID, May, 10\nEvaluation                     (CE)   RS, SI\n                                                       sensitivity, 97.8% specificity    \u2013 13, 2014, Barce-\n                                                                                         lona, E, poster\n                                                       Sonication, sensibility, speci-   Rodr\u00edguez, S G et\n                                       Obs,            ficity and predictive values      al. \u2013 16th EFFORT\nDiagnosis of PJI       E       CU     PS, SC,   33     were slightly higher for Un-      Congress,        27,\n                                        II             yvero i60 system than for         29.05.         2015,\n                                                       traditional culture.              Praque, Poster\n                                                                                         Borde, J. et al. \u2013\n                                                       96% (52/54) agreement be-\nPJI: 16s broad                        Obs,                                               25th      ECCMID,\n                                                       tween 16S rRNA gene PCR\nrange       PCR        DE      CV      RS,      54                                       April, 25 \u2013 28,\n                                                       and culture. U-ITI and culture\nagainst Unyvero                       SC, II                                             2015, Kopenhagen,\n                                                       results were 82% (23/28).\n                                                                                         DK, Poster\n                                                       22 cartridges yielded a con-\n                                                       cordantly negative result\n                                                                                         Kerschner, H. et al.\n                                                       (43%) and 12 cartridges\n                                                                                         \u2013 9. \u00d6sterreichi-\n                                       OBs,            showed a concordantly posi-\nPerformance                                                                              scher Infektions-\n                       A       CV     PS, SC,   53     tive result (24%). Discordant\nevaluation i60                                                                           kongress,     15-18.\n                                        II             results were observed for 11\n                                                                                         April 2015, Saal-\n                                                       cartridges (22%), in nine of\n                                                                                         felden./ A, Poster\n                                                       which the ITI test was pre-\n                                                       sumed to be false negative.\n                                                       Overall degree of agreement\n                                                       between i60 and culture 82%,      Borde, J. et al. \u2013\n                                       Obs,\n                                                       AST testing in culture-           Infection,   2015\ni60 Pilot Study        DE      CV     PS, SC,   54\n                                                       negative samples: overall         May 29, Open\n                                        II\n                                                       degree of agreement for i60 in    Access\n                                                       20/21 cases.\n                                                       Potential to identify difficult   Barth S. et al. \u2013 65.\n                                       Obs,\ni60     prototype:                                     to grow, biofilm-associated       DGHM, Septem-\n                       DE      Feas    RS,      100\nfirst validation                                       pathogens, e.g.; Propionibac-     ber, 22 \u2013 25, 2013,\n                                      SC, SI\n                                                       terium sp. Finigoldia magna       Rostock, D, poster\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1094316807738815, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.7413424540401881, "height": 0.49893116716545527, "width": 0.7847642079806529}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-5", "text": "Reg = regulatory, CU = clinical utility, CV = clinical validity, Cl Ext = claim extension,\nObs = observational, RS = retrospective, SI = sponsor-initiated, PS= prospective, SC = single centre, II = investigator-initiated,\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7413424540401881, "lower_right_x": 0.7176541717049577, "lower_right_y": 0.7592988456605387, "height": 0.017956391620350676, "width": 0.6021765417170496}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-6", "text": "Competition\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7687045746045319, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.7793929029499786, "height": 0.010688328345446751, "width": 0.08766626360338574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-7", "text": "Traditional microbiology culture based tests are the current standard for most targets that are covered by the ITI\nApplication Cartridge. But some standard methods for PJI, like cultures of synovial fluid, have demonstrated low\nclinical sensitivity, particularly in patients that have already been taking antibiotics. Curetis does not intend to\nsubstitute traditional culturing, but rather to complement effective diagnosis, particularly for critical and severe\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8448054724241129, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-8", "text": "cases.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8452330055579308, "lower_right_x": 0.156590084643289, "lower_right_y": 0.8546387345019238, "height": 0.009405728943993052, "width": 0.041112454655380895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-9", "text": "At the date of this prospectus, Mobidiag with its Prove-it Bone & Joint assay is the only company with a\ncommercially product similar to the i60 ITI Application Cartridge. However, it is a manual test only. Diaxonhit\nis developing its BJI InoPlex assay which is intended to be used in case of suspicion of PJIs and other companies\nsuch as BioM\u00e9rieux are also believed to be developing tests in this indication area.\n", "page_number": 141, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8648995297135528, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9183411714407866, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-141-10", "text": "138\n", "page_number": 141, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-0", "text": "In contrast to its competitors, Curetis offers a test with higher multiplexing capacity covering a broader range of\npathogens (bacteria and fungi) as well as more antibiotic resistance markers. Curetis also targets eight indication\nareas while competitors address only a single/a few indication(s).\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-1", "text": "BC-G1 Blood Culture Application Cartridge\n", "page_number": 142, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13296280461735785, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.1470713980333476, "height": 0.014108593415989745, "width": 0.309552599758162}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-2", "text": "Curetis plans to enter the strategically important sepsis market with two differentially positioned products ad-\ndressing the unmet need in this clinical condition: first in the pipeline \u2013 the bacteraemia blood culture Applica-\ntion Cartridge BC-G1 (Blood Culture Generation 1), described in the next section complemented by a Sepsis\nHost Response Application Cartridge, Curetis 5th application to be launched after the IAI/GTI Application Car-\ntridge.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.221889696451475, "height": 0.06840530141085935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-3", "text": "Medical need\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.24027362120564344, "height": 0.011543394613082514, "width": 0.09673518742442565}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-4", "text": "Sepsis is a complex syndrome defined by: a) the detection of bacteria in the blood stream (bacteraemia) and b)\nthe systemic host response to this infection called Systemic Inflammatory Response Syndrome (\"SIRS\").92 SIRS\nis defined as the presence of two or more of the following symptoms: abnormal body temperature, fast heart rate\nand/or respiratory rate or poor blood gas results, and an elevated white blood cell count. 93 More precisely, sepsis\nis a SIRS in response to an infectious process and consists of a combination of factors related to the particular\ninvading pathogen and to the status of the host's immune system. 94\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-5", "text": "Sepsis is a disease with poor prognosis as approximately 50% of people with severe sepsis and 80% of people\nwith septic shock die.95 Sepsis is the most common cause of death in people who have been hospitalised and\noccurs in 4.2% of all hospitalisations.96 Hospital stays related to sepsis were on average between 8.8 to 15.8\ndays.97 Sepsis is the leading cause of death in ICUs (e.g.; in Germany 60,000 cases per year).98 The worldwide\nincidence of sepsis is estimated to be 30 million cases per year.99 In the US sepsis affects approximately 149 to\n240 in 100,000 people depending on source,100 and severe sepsis contributes to more than 200,000 deaths per\nyear.101 In the US sepsis has a higher incidence than common cancer types and even heart failure and was the\nmost expensive condition treated in US hospital stays in 2009, at an aggregate cost of US$15.4 billion for nearly\n1.6 million hospitalisations.102\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46045318512184696, "height": 0.12227447627191107, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-6", "text": "If an infection is the underlying cause of SIRS, pathogen identification becomes relevant to guide the appropriate\nchoice for the antibiotic regimen. The early diagnosis is necessary to properly manage sepsis, as initiation of\ndirected therapy is of key importance to reducing mortality.103 Within the first three hours of suspected sepsis,\ndiagnostics should obtain appropriate cultures before starting antibiotics. However, with conventional methods\npathogen identification in the blood is successful in only about 30%-40% of cases.104 A retrospective study by\nKumar et al. showed that administration of an effective antimicrobial therapy within the first hour was associated\nwith a survival rate of 79.9%, however each hour of delay in antimicrobial administration over the ensuing six\nhours was associated with an average decrease in survival of 7.6%. 105\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5775972637879435, "height": 0.10944848225737491, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-7", "text": "Market potential\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5844377939290295, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.5985463873450192, "height": 0.01410859341598969, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-8", "text": "Sepsis is the top disease of the total infectious disease diagnostic market in Europe and the US.106 The global\nblood culture (\"BC\") test market is expected to grow at an annual rate of 7% until 2019. 107 Time required to test\npositivity by the traditional microbiological culture method is around 15 hours, but individual bottles may turn\npositive between just a few hours and several days 108 with positive rates in around 30%-40% depending on lit-\nerature.109 Over the last five years classical culture-based microbiology has been more and more replaced with\nmore rapid pathogen identification by MALDI-TOF MS (Matrix Assisted Laser Disorption Ionisation - Time Of\nFlight Mass Spectrometry). However, this technology has certain limitations for antibiotic resistance testing, as\nwell as for the detection of poly-microbial infections.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7148353997434801, "height": 0.10987601539119274, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-9", "text": "Based on official US statistics, in 2010 around 808,000 patients were discharged from hospitals diagnosed with\nsepsis,110 while in the EU, using the incidence prevalence of the disease of one in 1,000 inhabitants, 111 504,700\nsepsis cases per year can be estimated. Based on a BC positivity rate of 30% (conservative assumption) 112 there\nis a relevant segment of approximately 390,000 positive blood cultures in the US and EU per year which is re-\ngarded to constitute the estimated market potential for the BC-G1 Application.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7900812312954254, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-10", "text": "The following table 7 summarises the described market potential for BC-G1 blood culture application.\n", "page_number": 142, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8077388149939541, "lower_right_y": 0.8204360837964942, "height": 0.02394185549380079, "width": 0.6922611850060459}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-11", "text": "Table 7: Estimated market potential for BC-G1 blood culture application\nVariables for incidence of sepsis and                                       EU                US          Total potential\npositive blood cultures                                                 (market size)    (market size)   available market\nIncidence sepsis                                                         504,700 1,2       808,000 3        1,312,700\nBC positivity rate                                                         30 % 4           30 % 4             30% 4\nBC positive cases / estimated market potential\n                                                                             151,410       242,4003          393,810\nfor BC-G1\nSources: 1 Martin (2012); 2 Statista (2015b); 3 ECDC (2008); 4 Dellinger et al. (2013)\n", "page_number": 142, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.8208636169303121, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9333048311244121, "height": 0.11244121419410003, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-142-12", "text": "139\n", "page_number": 142, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-0", "text": "Description and status\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-1", "text": "As a prerequisite to successfully target the BC market, the Application Cartridge's coverage for pathogens and\nantibiotic resistances must enable informed therapy decisions and shall reflect current clinical guidelines in order\nto differentiate favourably to competition. The BC Application Cartridge, currently under development, is aimed\nto be based on a comprehensive analyte Application Cartridge targeting clinically most relevant microorganisms\nand related antibiotic resistance markers using specimen like BCs, punctuates and cerebrospinal fluid. The BC\nApplication Cartridge is intended to address this unmet need by providing diagnostic results with fast turn-\naround-time with minimal hands-on time compared to conventional methods. Its broad coverage of all relevant\npathogens and resistance mechanisms will be a key differentiator toward current and upcoming competition. The\nBC Application Cartridge will mostly consist of analytes already addressed by the P55 or i60 ITI Application\nCartridges. R&D will focus on the adaptation of those analytical reactions to BC samples. In addition, the valida-\ntion of this Application Cartridge has to be performed for various commercially available culturing systems by\nof a couple of commercial providers. Curetis intends to launch the BC-G1 Application Cartridge in the EU in\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2702009405728944, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-2", "text": "spring 2016.\nCompetition\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2702009405728944, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.3039760581445062, "height": 0.03377511757161178, "width": 0.08766626360338574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-3", "text": "At the date of this Prospectus companies active in molecular diagnostics of infectious diseases (e.g. bioM\u00e9rieux,\nGenMark, Nanosphere, Mast Diagnostica, Mobidiag, Biocartis, Cepheid and T2Bio) are considered as potential\ncompetitors for the BC Application Cartridge regarding the most important product features: (1) cost effective-\nness, (2) ease of use and (3) Application Cartridge coverage.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3655408294142796, "height": 0.05472424112868751, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-4", "text": "The IAI/GTI-G1 Intra-Abdominal/Gastrointestinal Tract Infection Application Cartridge\n", "page_number": 143, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.37238135955536555, "lower_right_x": 0.7158403869407497, "lower_right_y": 0.3864899529713553, "height": 0.014108593415989745, "width": 0.599758162031439}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-5", "text": "Curetis anticipates launching a differentiated Application Cartridge targeting the digestive tract and its severe\n(hospitalised) infections. This product will not only focus on a gastrointestinal panel detecting water and food-\nborne diarrhoea pathogens as most competitors do. Rather, the newly developed Curetis product is intended to\nprimarily target severe Intra-Abdominal Infections (\"IAIs\"), including indications such as appendicitis, gastritis /\nduodenitis and diverculitis. Targeting Gastrointestinal Tract Infections (\"GTI\") including infectious enteritis,\ndiarrhoea and other gastrointestinal tract infections.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4754168448054724, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-6", "text": "Medical need\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.49380076955964086, "height": 0.011970927746900395, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-7", "text": "Infections of the digestive tract have a variety of etiologies, involve different part of this system and show varia-\nbility in their cause, some being mild and self-limiting, others being life-threatening with the need for rapid di-\nagnosis and intervention. In line with Curetis' overall strategy, the focus is on severe digestive tract infections,\nwhich represent a high risk to patients, especially for those that are seriously ill, elderly or very young, immuno-\ncompromised or in intensive care. All targeted indications present a significant burden in terms of patient mor-\nbidity and mortality and are associated with significant costs of health services around the world.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5848653270628473, "height": 0.08251389482684901, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-8", "text": "Food-borne diarrhoea outbreaks are most commonly transmitted through ingestion of food or water contaminat-\ned with feces (most cases caused by bacteria including E. coli, Salmonella and Shigella). It is the disease of the\ndeveloping world and of children, and is estimated to account for one billion cases and more than two million\ndeaths annually worldwide. In the US, 3.7 million emergency department visits in 2010 for unknown gastrointes-\ntinal symptoms of which 1.3 million resulted in hospitalisations 113 were reported with costs of over US$6 bil-\nlion.114 Outbreaks of gastrointestinal tract infections are a serious concern in the community, especially in the\nkindergartens, schools, nursing homes and hospital environments. Therefore early and rapid diagnosis is critical\nin stopping the transmission of this highly contagious disease.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-9", "text": "Enteritis is characterised by gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal\ndiscomfort and can be caused by viruses (50%-70%, most frequent are noro or rota viruses), bacteria (15%-\n20%), often Salmonella or Campylobacter) or parasites (10%-15%). A fast, molecular diagnostic test would\nallow for more efficient and timely rule-in and rule-out and has the potential to eliminate a significant number of\nhospital admissions. In addition, particularly in hospital settings, rapid diagnosis provides important information\nfor implementing infection control measures.\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7900812312954254, "height": 0.08251389482684912, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-10", "text": "An additional severe problem represents healthcare- and antibiotic-associated diarrhoea with the major causative\npathogen being toxin-producing Clostridium difficile. In the US, over 300,000 cases of Clostridium difficile\ncases are diagnosed annually \u2013 numbers steadily increasing \u2013 with associated health-care costs of at least US$1\nbillion.115\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8507909362975631, "height": 0.05429670799486963, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-11", "text": "Intra-abdominal infections involve different organs, such as appendices, pancreas or peritoneum and include a\nwide spectrum of pathological conditions, ranging from uncomplicated appendicitis to fecal peritonitis. In the\nevent of complicated IAIs, the infection proceeds beyond a singularly affected organ and causes either localised\nperitonitis (intra-abdominal abscesses) or diffuse peritonitis. Effectively treating patients with complicated intra-\nabdominal infections involves both source control and antimicrobial therapy. 116 However, antimicrobial re-\n", "page_number": 143, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8580589995724669, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-143-12", "text": "140\n", "page_number": 143, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-0", "text": "sistance has become a major challenge complicating the treatment and management of intra-abdominal infec-\ntions.117\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.10944848225737494, "height": 0.02436938862761863, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-1", "text": "Complicated intra-abdominal infections \u2013 community or healthcare acquired \u2013 are a common problem, with\nappendicitis alone affecting approximately 300,000 per year and consuming more than 1 million hospital days\nin the US.118 The source of infection involves appendicitis (37%), cholecystitis (13.4%), colonic (7.3%) and\ngastroduodenal perforations (7.3%) or diverticulitis (7.7%). 119 Intra-abdominal infection is the second most\ncommon cause of infectious mortality in the intensive care unit 120 and the CAIO (Complicated intra-abdominal\ninfections observational) study showed on overall mortality rate of 7.5%. 121 Spontaneous bacterial peritonitis is\nan acute bacterial infection with 1-year mortality rates ranging from 50%-70%.122 In 2010 overall, about 30% of\nthe hospital stays for appendicitis involved a perforated appendix with a significant risk of peritonitis \u2013 a life-\nthreating disease.123 In the United States, in 2009, acute pancreatitis was the most common gastroenterology\ndischarge diagnosis with a cost of 2.6 billion dollars.124\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.25609234715690465, "height": 0.1368106028217187, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-2", "text": "For IAI, diagnostics should always be obtained for patients with hospital-acquired infections as well as for pa-\ntients with community-acquired infections who are known to be at risk for drug-resistant bacteria. In these pa-\ntients, causative pathogens and resistance patterns are unpredictable and always require sampling from the site of\ninfection.125 In many clinical laboratories, species identification and susceptibility testing of anaerobic isolates,\nfrequent in IAI/GTI are not routinely performed. In addition, antimicrobial resistance (e.g.; ESBL-producing\nEnterobacteriaceae) has become a major challenge complicating the treatment and management of intra-\nabdominal infections. Therefore, IAI/GTI Application Cartridge presents a high unmet medical need, where\nfaster, more comprehensive diagnostic results will have an impact on medical and economic outcomes.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37238135955536555, "height": 0.10944848225737497, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-3", "text": "Market potential\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.39333048311244123, "height": 0.020949123557075677, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-4", "text": "The total available market was estimated by the number of hospital discharges per disease in the US focusing on\nthe severe indications: infectious enteritis and diarrhoea126 plus those related to intra-abdominal infections as\nappendicitis, gastritis/duodentitis, as well as diverculitis. 127 As the incidence of pancreatitis and peritonitis is\nrelatively low, those are not taken into account. EU calculations are based on US numbers with the assumption\nof the same incidence rates as in the US population based on a number of 508 million inhabitants in the EU.128\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4681487815305686, "height": 0.06840530141085932, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-5", "text": "The following table 8 shows the potential market for IAI and GTI Application Cartridges.\nTable 8: Estimated market potential for IAI/ GTI-G1 Application Cartridges\n", "page_number": 144, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.47498931167165453, "lower_right_x": 0.722490931076179, "lower_right_y": 0.5091919623770842, "height": 0.03420265070542966, "width": 0.6051995163240629}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-6", "text": "                                                        US              EU3           Total potential\nVariables for incidences of IAI / GTI\n                                                    (market size)   (market size)    available market\n                       1\nInfectious Enteritis                                  218,000         345,132             563,132\n                                                1\nDiarrhoea and other gastrointestinal symptoms         638,000        1,010,067          1,648,067\nSum Gastrointestinal Tract Infections (GTI)           856,000        1,355,199          2,211,1994\n             2\nAppendicitis                                          311,000         492,368            803,368\n                           2\nGastritis/Duodenitis                                  138,000         218,478            356,478\n               2\nDiverticulitis                                        316,000         500,284            816,284\n                                                                4                4\nSum Intra-Abdominal Infections (IAI)                  765,000        1,211,130          1,976,1304\nTotal Sum of GTI and IAI                             1,621,0005      2,566,3295         4,187,3295\n", "page_number": 144, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.5096194955109021, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.6904660111158615, "height": 0.18084651560495935, "width": 0.788391777509069}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-7", "text": "Source: 1 HCUP(2013a); 2 CDC (2007); 3 Statista (2015b);   4\n                                                               Initial estimated target market for IAI/GTI-G1 considers only severe IAI incidences;   5\n                                                                                                                                                          Estimated\ntotal potential available market including GTI\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1124546553808948, "top_left_y": 0.6917486105173151, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.7148353997434801, "height": 0.023086789226165028, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-8", "text": "The initial estimated target market in the EU and US accounts for about 2 million incidences per year, as shown\nin table 8. Given the initial focus on severe cases of IAIs incidences of GTI comprising enteritis, diarrhoea and\nother gastrointestinal symptoms have been excluded from the initial target market estimates. Nevertheless, the\nestimated total potential available for an IAI/GTI-G1Application Cartridge across EU and US is more than 4\nmillion cases per year, resulting in a market potential of several hundred million euros.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7315091919623771, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7986318939717828, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-9", "text": "Description and status\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.8195810175288585, "height": 0.012825994014536102, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-10", "text": "At this stage, the customer requirements have been completed and the panel design is under development. Cu-\nretis intends to start the CE performance evaluation in the second half of 2016 and aims to launch the IAI/GTI\nApplication Cartridges in the EU not before the fourth quarter of 2016.\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8674647285164601, "height": 0.04018811457887994, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-11", "text": "Competition\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.8884138520735357, "height": 0.013253527148354038, "width": 0.08766626360338574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-12", "text": "At the date of this Prospectus, competitors offer specific products covering pathogens of diarrhoea-type tract\ninfections (bacteria, toxins, parasites and viruses; no antibiotic resistance markers) excluding severe IAI. These\n", "page_number": 144, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8956819153484396, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9226165027789653, "height": 0.02693458743052579, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-144-13", "text": "141\n", "page_number": 144, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-0", "text": "competitors include bioM\u00e9rieux (FilmArray\u2122), Becton Dickinson (BD-Max\u2122), Cepheid (GeneXpert\u2122), Ge-\nnomica (CLART), Fast Track Diagnostics, Luminex (xTAG), Pathofinder (Smart 17 Fast), Seegene (Seeplex\u2122)\nand Sacace\u2122. As Curetis is planning to target severe forms of IAIs and GTIs as well as having demonstrated its\nability to develop differentiated highly multiplexed Application Cartridges comprising disease relevant microor-\nganisms and antibiotic resistance markers, management believes at this point of time that Curetis can offer a new\nApplication Cartridge with differentiated features compared to existing competitor products.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16673792218896966, "height": 0.08165882855921335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-1", "text": "Sepsis Host Response Application Cartridge\n", "page_number": 145, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.17400598546387344, "lower_right_x": 0.42019347037484883, "lower_right_y": 0.1876870457460453, "height": 0.013681060282171864, "width": 0.30108827085852474}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-2", "text": "Medical need\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.2056434373663959, "height": 0.011115861479264633, "width": 0.09673518742442565}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-3", "text": "As described above, early identification of sepsis can be challenging due to its non-specific clinical symptoms\nand the differentiation of SIRS versus sepsis is rather difficult (because SIRS can also occur in patients without\nthe presence of infection).129 In addition, both medical conditions are treated differently and correlate with vary-\ning prognosis. In the past, biomarkers were intensively studied trying to identify analytes that may help to aid the\ndiagnosis of SIRS, respectively sepsis. So far, a couple of single biomarker analyte tests such as procalcitonin,\nC-reactive protein, or cytokines are commercially available to judge the presence of an infection, however, all of\nthem have limitations and are not clearly correlating with disease progression in SIRS/sepsis. The assessment of\nthe host response status as either confirming an infection or as indicator for the progression of the sepsis repre-\nsents a significant marker opportunity and will complement microorganism identification as pre-requisite to\nearly adjust antibiotic treatment.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.35185976913210776, "height": 0.1368106028217187, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-4", "text": "Market potential\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.37280889268918344, "height": 0.014108593415989745, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-5", "text": "Curetis' management expects that an Application Cartridge for the early diagnosis of sepsis will make a differ-\nence in a significant proportion of cases and, as it can be performed within the first hours of hospital admission,\nmay also help to save significant costs. Curetis estimates the sepsis host response market to be larger than the\nmicroorganism ID in blood cultures. Based on numbers discussed in the BC-G1 blood culture application car-\ntridge market potential, around 1.3 million130 patients would be eligible for a Sepsis Host Response test repre-\nsenting a total available market in the US und EU of several hundred million depending on price points and with\na potential further market potential by applying the Application Cartridge in emergency rooms (see table 9). As\nSepsis Host Response testing is a complementary application, major cannibalisation of the microorganism identi-\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4963659683625481, "height": 0.11714407866609661, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-6", "text": "fication test BC-G1 Application Cartridge is not anticipated at the outset.\nTable 9: Estimated market potential for the sepsis host response Application Cartridge\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.496793501496366, "lower_right_x": 0.6777509068923822, "lower_right_y": 0.5224454895254382, "height": 0.02565198802907226, "width": 0.562273276904474}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-7", "text": "                                                                  US              EU           Total potential\nIncidence of sepsis by territories\n                                                              (market size)   (market size)   available market\nIncidence sepsis                                               504,700 1,2      808,000 3        1,312,700\nSources: 1 Martin (2012); 2 Statista (2015a); 3 ECDC (2008)\n", "page_number": 145, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.5228730226592561, "lower_right_x": 0.8911729141475212, "lower_right_y": 0.5878580589995724, "height": 0.06498503634031638, "width": 0.7853688029020557}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-8", "text": "Description and status\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6019666524155622, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.6152201795639162, "height": 0.013253527148353927, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-9", "text": "Curetis has entered into a licensing and R&D agreement with Acumen Research Laboratories (Singapore), that\ndeveloped a proprietary panel of mRNA biomarkers and interpretative algorithm for the analysis of peripheral\nblood lymphocytes. The panel allows (a) the detection of an infection and (b) the early detection of sepsis based\non altered gene regulation in the patient's immune cells. The biomarkers constituting the panel were discovered\nby microarray technologies and validated by manual real-time PCR. However, for an effective adoption of the\ntest in the clinical routine, a sample-to-answer solution that can be implemented in a near-patient setting is re-\nquired. Hence, both companies are working on the transfer of the panel to the Unyvero Platform and anticipating\na joint further clinical validation of this Sepsis Host Response Application Cartridge.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6220607097050022, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.731936725096195, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-10", "text": "Competition\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.7524583155194527, "height": 0.01410859341598969, "width": 0.08706166868198308}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-11", "text": "Regarding the Sepsis Host Response tests some companies have recently focused their development efforts on\nthe detection of cell surface markers (CD64, LeukoDX), on the cells' physical properties (CytoVale), on mRNA\nexpression in leukocytes (ImmuneXpress) or on multi-analyte biomarker tests (Anagnostics, now Cube DX).\nHowever, no diagnostic test with high predictive values for differentiating sepsis from SIRS is currently com-\nmercially available.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.827704147071398, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-12", "text": "Future product developments\n", "page_number": 145, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.844377939290295, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.8567764001710133, "height": 0.012398460880718276, "width": 0.2079806529625151}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-13", "text": "Going forward, Curetis plans to continuously improve its existing Unyvero Application Cartridges and advance\nthe development of new Application Cartridges. Curetis plans to introduce at least one new CE-IVD-marked\nApplication Cartridge per year.\n", "page_number": 145, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8572039333048311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9029499786233434, "height": 0.04574604531851223, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-145-14", "text": "142\n", "page_number": 145, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-0", "text": "Severe infectious disease areas such as tuberculosis (TB, including MDR and XDR markers), paediatrics, trans-\nplant infections, CNS infections, etc. could be additional product development areas on the Unyvero Platform.\nOther indication areas such as oncology, companion diagnostics, transplant medicine and veterinary may also be\nfuture indication areas for the Unyvero Platform, e.g. in collaboration with strategic partners.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-1", "text": "With regard to software development, Curetis will strive to implement further features and functionality as re-\nquired by customers, e.g. connectivity to the hospital and laboratory IT infrastructure as well as various levels of\nserver solutions.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.18469431380932022, "height": 0.03805044890979051, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-2", "text": "In the long term, Curetis may also take into consideration the design of a simplified cartridge and possibly in-\nstrument series for less complex applications that address a broader market, if required by customers or corporate\npartners. Such product might be scaled-down to lower multiplexing levels (less than 10 analytes) with a simpli-\nfied Analyzer and a less complex Application Cartridge at lower cost of goods sold (\"COGS\"). In addition, if\nfuture commercially attractive market opportunities should demand qPCR applications, Curetis believes that\nchanging the Unyvero Analyzer to a real-time PCR system with 4/6-color optics is also feasible with minimal\ninstrument and cartridge changes.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2902949978623343, "height": 0.09576742197520305, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-3", "text": "Partnerships and Collaboration Agreements\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3039760581445062, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.32107738349722104, "height": 0.017101325352714858, "width": 0.38754534461910517}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-4", "text": "Heraeus Medical\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.3467293715262933, "height": 0.011970927746900395, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-5", "text": "In September 2012, Curetis has entered into a strategic R&D collaboration with commercial opportunities with\nHeraeus Medical (\"HM\"), one of the leaders in orthopaedic bone cement, in the area of PJI. During the first\nphase of the collaboration Curetis and Heraeus Medical collaborated on the R&D phase of the i60 ITI Applica-\ntion Cartridge. Upon request by Heraeus Medical and its customers and KOLs several microorganisms as well as\nantibiotic resistance markers were designed into the product and subsequently clinically validated. After having\nsuccessfully co-developed the PJI application as part of the i60 ITI Application Cartridge, the collaboration\nagreement has now entered into the commercial phase. Both companies' sales and marketing teams have estab-\nlished steering committee meetings and closely coordinate marketing activities such as trade fairs, exhibitions\nand clinical studies (e.g. EPJIC study with Prof. Trampuz at Charit\u00e9 hospital in Berlin) as well as operational\nsales tactics in various markets. The HM regional sales managers have teamed up with the senior account man-\nagers of Curetis for joint customer visits and discussions on combinations of the i60 ITI Application Cartridge\nand the various HM bone cements may address comprehensive infection management. For more details see \"Ma-\nterial Contracts \u2013 Heraeus Medical GmbH (\"Heraeus Medical\")\".\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.533133817870885, "height": 0.1778537836682343, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-6", "text": "Collaboration Agreements with Pharmaceutical Companies\n", "page_number": 146, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.5468148781530568, "lower_right_x": 0.532043530834341, "lower_right_y": 0.5609234715690466, "height": 0.0141085934159898, "width": 0.41293833131801694}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-7", "text": "Curetis has entered into three collaboration projects (see table 10) where the partner is a pharmaceutical compa-\nny typically using the Unyvero Platform in a clinical trial of a novel antibiotic. The agreements can range from a\nsimple R&D collaboration and service agreement where Curetis acts as central reference lab for a clinical trial\n(e.g. in the Cempra phase III oral solithromycin trial in community-acquired bacterial pneumonia) to situations\nwhere the pharmaceutical company purchases the Unyvero System, software and cartridges outright and com-\nmissions certain installation, training and support services from Curetis to set up the Unyvero Platform at various\nclinical trial sites. This latter model is currently pursued under the phase III Amikacin trial and was also the\nmodel of choice in a former Sanofi Pasteur phase IIb trial.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6763574176998718, "height": 0.10902094912355709, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-8", "text": "A single deal offers the potential for Curetis to place multiple Unyvero Platforms and sell corresponding\nApplication Cartridges to a single partner over a defined period of up to several years for a given trial.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7114151346729372, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-9", "text": "Table 10: Curetis' projects with pharmaceutical partners\n", "page_number": 146, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7178281316802052, "lower_right_x": 0.4879081015719468, "lower_right_y": 0.731936725096195, "height": 0.0141085934159898, "width": 0.37182587666263606}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-10", "text": "Pharmaceutical      Study\n                                Drug Compound                     Status\nPartner             Phase\nSanofi    Pasteur                                                 terminated upon return of drug from\n                    Phase IIb   KB001-A Project\n(SP)                                                              SP to Kalobios\nCempra                          Oral solithromycin in Community\n                    Phase III                                     Completed\nPharmaceuticals                 Acquired Pneumonia\nLarge\nPharmaceutical      Phase III   Amikacin in VAP                   On-going\nCompany\n", "page_number": 146, "bounding_box": {"top_left_x": 0.10761789600967352, "top_left_y": 0.7340743907652844, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.8888413852073536, "height": 0.1547669944420692, "width": 0.7805320435308343}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-11", "text": "Economics in these collaborations range from a simple \"each party bears their own cost and owns their own\ndata\" (Cempra) to outright purchases of the Unyvero System, Unyvero Software and Application Cartridges (e.g.\n", "page_number": 146, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8956819153484396, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9234715690466011, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-146-12", "text": "143\n", "page_number": 146, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-0", "text": "Sanofi) with added full time equivalent (\"FTE\") based services provided by Curetis upon request such as\ninstallation, trainings, on-going service and support. However, it is important to note that none of these deals\ninclude any licenses being granted by Curetis to any of the partners and hence there are also no milestones nor\nroyalties on future product sales to be expected. The upside potential lies in the ability to broaden and expand the\ninstalled base of the Unyvero Platforms at the expense of pharmaceutical partners and their trials.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15305686190679776, "height": 0.06797776827704145, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-1", "text": "Acumen\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.1778537836682343, "height": 0.01068832834544678, "width": 0.06348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-2", "text": "On 5 October 2015, Curetis and Acumen entered into a non-exclusive patent license and research collaboration\nagreement under which Acumen grants Curetis the non-exclusive worldwide rights to develop and market a\nsepsis host response test as an Application Cartridge for the Unyvero System.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2291577597263788, "height": 0.0414707139803335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-3", "text": "During the research and development collaboration, Acumen is expected to further develop its technology under-\nlying the license and Curetis is expected to be responsible for adapting its technology to run the Acumen sepsis\nhost response biomarker panel with the Unyvero Platform, e.g.; transferring the current pre-analytical workflow.\nBoth parties will collaborate in the performance evaluation studies for Asia and Europe required for commercial-\nisation of the product. Curetis intends to first launch the Application Cartridge as CE-IVD Application Cartridge\nin Europe and other regions accepting CE-IVD-markings. Under the terms of the agreement, both parties bear\ntheir respective R&D costs themselves.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.3317657118426678, "height": 0.09619495510902093, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-4", "text": "Further, Acumen and Curetis on 5 October 2015 entered into a distribution agreement under which Acumen\ndistributes the Unyvero System and the P55 and i60 ITI Application Cartridges in the ASEAN markets starting\nwith Singapore, Malaysia, Indonesia and Thailand. Both parties may at a later point mutually agree to amend the\nagreement to include additional territories of the ASEAN region. For further details to both contracts, see \"Mate-\nrial Contracts \u2013 Acumen\".\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4035912783240701, "height": 0.06541256947413421, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-5", "text": "Beijing Clear Biotech\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.4343736639589568, "height": 0.014108593415989745, "width": 0.15477629987908098}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-6", "text": "On 25 September 2015, Curetis and Beijing Clear Biotech entered into an exclusive international distributor\nagreement under which Curetis appointed Beijing Clear Biotech as the exclusive distributor of the Unyvero\nSystems and P55 and i60 ITI Application Cartridges in China, Taiwan and Hong Kong (collectively \"Greater\nChina\").\n", "page_number": 147, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.05515177426250534, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-7", "text": "Under the agreement, Beijing Clear Biotech is responsible for conducting and fully funding any prospective\nclinical trials required for the approval of the Unyvero System and the P55 and i60 ITI Application Cartridges in\naccordance with CFDA guidelines. Furthermore, Beijing Clear Biotech is responsible for the CFDA registration\nand the approval process as Curetis' Chinese representative. Curetis shall compensate Beijing Clear Biotech for\ncertain achievements in starting the clinical trial and pursuing the CFDA clinical trial and registration process\nthrough milestone payments. Both parties will closely collaborate before submission of the proposal of a clinical\nstudy design to CFDA in all relevant areas.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5985463873450192, "height": 0.09619495510902087, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-8", "text": "Beijing Clear Biotech will become the exclusive distributor for Unyvero Systems and P55 and i60 ITI Applica-\ntion Cartridges. Both parties have agreed that Beijing Clear Biotech is obligated to purchase a minimum amount\nof Curetis' products per contractual year. Beijing Clear Biotech will be responsible for the local marketing which\nis based on and shall correspond with Curetis' global marketing strategy. Curetis expects marketing in Taiwan to\nstart earlier as no specific trial is required for product registration. Curetis is obligated to provide support ser-\nvices, including technical and scientific training, for the promotion, marketing and distribution of the Unyvero\nSystem and the P55 and i60 ITI Application Cartridges. For the commercialisation of the Unyvero i60 ITI Ap-\nplication Cartridge, Beijing Clear Biotech is expected to partner with LandMover Medical Technologies Co. Ltd.\n(Beijing, China), the exclusive Chinese distributor of HM (see above).\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.728516460025652, "height": 0.1235570756733646, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-9", "text": "For further details, see \"Material Contracts \u2013 Beijing Clear Biotech\".\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.735356990166738, "lower_right_x": 0.585247883917775, "lower_right_y": 0.7490380504489098, "height": 0.013681060282171864, "width": 0.46977025392986693}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-10", "text": "Production\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.7798204360837965, "height": 0.01410859341598969, "width": 0.10217654171704958}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-11", "text": "For instrument manufacturing, Curetis has decided to co-develop and subsequently outsource all of its instru-\nments' manufacturing to a third-party manufacturer. With regard to cartridges, they are developed and manufac-\ntured entirely in-house. Curetis has established a sophisticated manufacturing site for its cartridges where it has\nfull control over the entire production process ensuring that cartridges meet stringent quality requirements.\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8499358700299273, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-12", "text": "Unyvero System\n", "page_number": 147, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.8648995297135528, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.8781530568619068, "height": 0.013253527148354038, "width": 0.11366384522370013}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-13", "text": "Curetis' EMS (Electronic Manufacturing Services) provider and partner Zollner Elektronik AG is an established\nand experienced medical device manufacturer for large brand name companies and has flexible production pro-\ncesses ensuring to meet demands with different volume requests. Zollner has established a Curetis dedicated\n", "page_number": 147, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8854211201368106, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9260367678495084, "height": 0.04061564771269777, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-147-14", "text": "144\n", "page_number": 147, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-0", "text": "manufacturing island and Unyvero team where in a single eight hour shift for five days week, up to three sys-\ntems (Lysator, Cockpit and Analyzer) can be assembled and tested per week. Zollner has an established 24/7\nmanufacturing operations, providing significant capacities and capabilities for major scale up of Unyvero manu-\nfacturing operations. Curetis' management believes that manufacturing capacity will not become a bottleneck in\nthe foreseeable future. Zollner also has all required certifications under all applicable ISO standards for IVD\ninstrument manufacture and is also setting up the Unyvero System manufacturing in order to be compliant with\nfuture US FDA inspections and manufacturing standards.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.18041898247114152, "height": 0.09533988884138521, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-1", "text": "Application Cartridges\n", "page_number": 148, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.20863616930312098, "height": 0.014108593415989718, "width": 0.16021765417170497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-2", "text": "As part of its operational strategy, Curetis decided to build and operate its own cartridge manufacturing facility\ninside of premises leased to it. The cartridge manufacturing facility based in Bodelshausen, Germany, has been\noperational since October 2011.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2552372808892689, "height": 0.04018811457887983, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-3", "text": "As per current capacity utilisation with a single eight hour shift for five days a week, up to 1,000 cartridges per\nweek can be manufactured. The current output can be significantly increased by extending the manufacturing\nshifts until a 24/7 manufacturing is reached and by undertaking small changes and moderate incremental invest-\nment to the production line, for example, with a higher throughput variant of the laser-welding for cartridge\nbaseplates or duplication of a few critical assembly steps on the existing line. The current cartridge assembly line\nis highly automated and complies with ISO 13485 requirements and is operated in three ISO 8 and ISO 7 clean-\nrooms. Throughout the manufacturing process, each cartridge and its components are meticulously tested by a\nsuite of in-process quality control measurements in order to ensure consistent, stable and reliable product quality\nwith a high first-pass yield. Finally, every batch of Unyvero Application Cartridges produced is subject to final\nQC (Quality Control) release testing with well-defined negative as well as positive control materials.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.40017101325352716, "height": 0.13723813595553658, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-4", "text": "Marketing and Sales\n", "page_number": 148, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.41342454040188115, "lower_right_x": 0.2980652962515115, "lower_right_y": 0.43095339888841383, "height": 0.017528858486532684, "width": 0.18198307134220076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-5", "text": "Customers\n", "page_number": 148, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.44420692603676787, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.45703292005130397, "height": 0.012825994014536102, "width": 0.0743651753325272}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-6", "text": "In 2009, Curetis' marketing team in collaboration with external IVD-industry experts conducted extensive\nmarket research in 2009 on various aspects of customer needs, key market drivers, potential market entry\nbarriers and competitive landscape. Based on the findings of this process, a strong value proposition and product\npositioning has been developed. This has also been instrumental in customer segmentation.\n", "page_number": 148, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.519880290722531, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-7", "text": "The research of Curetis revealed three primary stakeholder groups: 1) the clinician ordering the test; 2) the\nhospital (microbiology) laboratory; and 3) the hospital finance and administration, all of whom will be actively\ninvolved in the purchase decision at varying levels. In terms of product benefits, physicians seek timely\ndiagnostic results that can be used to better inform or confirm a treatment decision and improve patient\noutcomes. While for a microbiology laboratory manager the steadily decreasing availability of trained\nlaboratorians, the need to perform testing during off-shifts and in satellite testing locations is driving the need for\nsimple-to-use, robust technologies. Ultimately, the decision whether a proposed new testing solution is cost\neffective and affordable on a routine basis must be made by the payer, which in case of hospitalised in-patients\nunder the DRG-reimbursement system is typically the hospital purchasing and finance departments. Strong key\naccount management shall ensure that all stakeholders are targeted early in the sales process. Table 11 below\npresents Curetis' key stakeholders and key messages relating to the Unyvero Platform's selling proposition:\n", "page_number": 148, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6772124839675074, "height": 0.15091919623770833, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-8", "text": "Table 11: Curetis' key stakeholders and key messages relating the Unyvero Platform\n", "page_number": 148, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.6836254809747755, "lower_right_x": 0.6964933494558646, "lower_right_y": 0.7024369388627618, "height": 0.018811457887986327, "width": 0.5858524788391778}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-9", "text": "Key Stakeholder\n", "page_number": 148, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.702009405728944, "lower_right_x": 0.24123337363966144, "lower_right_y": 0.7199657973492946, "height": 0.017956391620350565, "width": 0.1324062877871826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-10", "text": "Key Messages\n", "page_number": 148, "bounding_box": {"top_left_x": 0.35368802902055624, "top_left_y": 0.7024369388627618, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.7161179991449337, "height": 0.013681060282171864, "width": 0.11064087061668681}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-11", "text": "Key Stakeholder                   Key Messages\nTreating clinicians               \uf0b7    fast and accurate\n                                  \uf0b7    understandable and useful information\n                                  \uf0b7    can be operated in different hospital wards, particularly relevant in\n                                       ICUs where 24/7 access is key\nMicrobiologist                    \uf0b7    ease of use\n                                  \uf0b7    minimal hands-on time\n                                  \uf0b7    on-demand random-access\n                                  \uf0b7    full automation, walk away\n                                  \uf0b7    fast and accurate\nMolecular biologist /laboratory   \uf0b7    ease of use\nmanager                           \uf0b7    minimal hands-on time\n", "page_number": 148, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.7165455322787516, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.9140658401026079, "height": 0.19752030782385632, "width": 0.7781136638452236}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-148-12", "text": "145\n", "page_number": 148, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-0", "text": "Key Stakeholder           Key Messages\n                          \uf0b7    on-demand random-access\n                          \uf0b7    full automation, walk away\n                          \uf0b7    additional source of revenue for private laboratories in hospital out-\n                               sourcing\n                          \uf0b7    fast and accurate\nHospital administration   \uf0b7    full transparent total cost of ownership\n                          \uf0b7    integration, automation\n                          \uf0b7    health economics arguments such as reduced length of stay, more\n                               prudent use of antibiotics, disaster prevention in MDR outbreaks,\n                               identifying additional DRG codes that can be applied to certain pa-\n                               tients to allow for optimised margins\n", "page_number": 149, "bounding_box": {"top_left_x": 0.10882708585247884, "top_left_y": 0.0867892261650278, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.2851646002565199, "height": 0.1983753740914921, "width": 0.7817412333736397}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-1", "text": "Sales process\n", "page_number": 149, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.30055579307396324, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.3138093202223172, "height": 0.013253527148353983, "width": 0.09552599758162032}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-2", "text": "Curetis' typical sales process starts with an introductory visit to the microbiology laboratory director and senior\nmicrobiology staff. The goal is to introduce Unyvero and assess general interest in evaluating the Unyvero\nPlatform during a demonstration phase. However, the goal is also to initiate contact to any new hospital customer\nvia the gatekeeping microbiology laboratory function. The primary objective apart from getting a demo phase\nagreed upon is to seek joint introductory meetings with the senior microbiology staff and the various ICUs and\nclinicians in any relevant ICU. Since the latter can be multiple ICUs (sometimes over a dozen in major university\nhospitals) with multiple 24/7 rotating shift operations each, it is paramount to identify one or a few key ICUs as\ninternal product champions. The clinicians are ultimately the end-customers of Unyvero Application Cartridge\nresults for use in treatment assessment and optimisation medical care for their patients. They will also be the\nones routinely requesting a Unyvero test to be done. At this stage a discussion about the ideal placement of the\nUnyvero System during a demonstration usually takes place. Where appropriate a central location in the\nmicrobiology laboratory is the preferred option, however, patient near ICU placement is also an option.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4843950406156477, "height": 0.16331765711842666, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-3", "text": "Overall the entire sales process including commercial negotiations with the purchasing and hospital finance\nteams typically takes around 12 months from start to finish, i.e. to the point in time when the hospital begins\npurchasing Unyvero Application Cartridges in routine. Depending on the time of year and budget cycle a\ncontractual arrangement can take significantly longer than that as well.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4920906370243694, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.546387345019239, "height": 0.05429670799486963, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-4", "text": "Curetis' marketing provides sales and sales support tools adapted to the specifics of each stakeholder and\nstimulates demand by setting up awareness campaigns for infectious disease specialists, internists and\nintensivists.\n", "page_number": 149, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.879081015719468, "lower_right_y": 0.5917058572039333, "height": 0.03805044890979048, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-5", "text": "Additional customer segmentation reflects the business opportunity per customer / institution and is linked to\nsize of the hospital reflected in the number of beds available at the institution. In the IVD market, hospitals with\nmore than 500 beds generate approximately 80% of company's revenues but represent only 20% of the\ncompany's customer base. Therefore, the Curetis sales strategy is based on a key account management approach\nand this \u2018Pareto principle', initially only targeting large hospitals with clear focus on departments like\npneumology, large ICUs or orthopaedics wards depending on the promoted Application Cartridge. Accordingly,\nCuretis is focusing direct sales activities on university or teaching hospitals and hospital chains with more than\n500 beds. In its direct sales region in Europe (as defined below) Curetis currently estimates to address more than\n745131 relevant target hospitals. In addition, in the US it is presumed that a target of 727132 relevant hospitals can\nbe approached in the future. Furthermore, Curetis has identified the number of 1.208 target hospitals in sales\nregions where Curetis is currently presented by indirect distribution or is striving for future indirect channels.\nPrimarily, the focus lies on high- volume consumable orders instead of achieving profit by hardware placements\nor simply maximising the number of instrument placements. Consequently Curetis aims to optimise the\nutilisation of each placed hardware unit rather than solely maximising installed base of instruments. Therefore,\nCuretis, with its tests primarily targeting in-patients (hospitalised) with severe infections, is focusing its sales and\ncommercialisation efforts on laboratories in hospitals and independent laboratories serving larger hospitals.\nCustomer segmentation relies on the size of the hospital defined by the number of beds per institution (see table\n12). In addition to the relevant target hospitals there are more than 2,810 self-administered MDx labs in Europe\nand more than 2,000 of these laboratories are present in the US. Furthermore, 1,399 target hospitals in China and\n56 target hospitals in certain ASEAN markets have been identified by Curetis (see table 13).\n", "page_number": 149, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8755878580589995, "height": 0.2740487387772552, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-149-6", "text": "146\n", "page_number": 149, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-0", "text": "Table 12: Hospitals by country and size\nHospitals by country and size             Total number          Small           Medium              Large\n                                           of hospitals       (up to 199       (200 to 499       (>499 beds)\n                                                                beds)             beds)\nAustria                                            280 3             184 3              65 3              31 3\nGermany                                          1,825 1             907 1             671 1            247 1\nSwitzerland                                        306 1             250 1              43 1              14 1\n                                                          1                1                 1\nItaly                                            1,399               932               333              134 1\nFrance                                           1,971 1           1,118 1             598 1            255 1\nUnited Kingdom                                     984 1             630 1             183 1            171 1\nSpain                                              808 1             516 1             196 1              96 1\nSweden                                              81 1              44 1              21 1              16 1\nNetherlands                                         93 1                91              57 1              27 1\nDACH                                            2,411 1;3         1,341 1;3          779 1;3           292 1;3\nEurope (incl. countries listed above)           7,747 1;3         4,590 1;3         2,167 1;3          990 1;3\n                                                          1                2                 2\nUnited States                                    5,686             3,368             1,591              727 2\n", "page_number": 150, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8948004836759371, "lower_right_y": 0.3582727661393758, "height": 0.2731936725096195, "width": 0.7889963724304716}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-1", "text": "United States                                                                    5,686                   3,368                    1,591                      727\nSource: 1 Data information intelligence GmbH (2015); 2 Hospital size numbers extrapolated based on shares in the EU CDC (2011); 3 Bundesministerium f\u00fcr\nGesundheit (2014) Curetis will also face certain market entry barriers mostly related to upfront investments for the implementation of the new technology as\nmost laboratories and microbiology centres are cost centres, which do not directly benefit from the current DRG reimbursement scheme. Additionally, the\nUnyvero Platform will be an add-on test not replacing traditional testing \u2013 in this case cultures, which are perceived as comparatively cheap. Therefore, Curetis\nwill pursue a sales strategy whereby it will offer customers a number of different financial options for its products and services, from a straight cash purchase of\nthe Unyvero Platform, to reagent lease/rental agreements (pursuant to which Curetis would provide the Unyvero Platform on the basis that the customer commits\nto buying a certain number of Application Cartridges from Curetis over a set period of time, with the cost of such Application Cartridges incorporating a reagent-\nrental charge for the use of the Unyvero Platform).\n", "page_number": 150, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.3582727661393758, "lower_right_x": 0.8881499395405078, "lower_right_y": 0.43993159469858917, "height": 0.08165882855921336, "width": 0.7817412333736397}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-2", "text": "Table 13: Hospitals in China, Indonesia, Thailand, Malaysia and Singapore\n", "page_number": 150, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.45446772124839674, "lower_right_x": 0.6045949214026602, "lower_right_y": 0.46515604959384355, "height": 0.010688328345446807, "width": 0.48609431680773885}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-3", "text": "                                              Total number\n                       Total number    of potential target hospitals\nHospitals by country\n                        of hospitals           >500 beds*\n                                              > 800 beds**\n       China             756,9091           1,3991* / 7182**\n     Indonesia            2,2383                  102**\n      Thailand            1,3104                  202**\n     Malaysia              3945                   262*\n     Singapore              266                    NA\n", "page_number": 150, "bounding_box": {"top_left_x": 0.12333736396614269, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6250534416417273, "height": 0.15690466011115867, "width": 0.7617896009673518}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-4", "text": "                            Singapore                                                  26                                       NA\nSources: 1 Novumed (2013a); 2 Novumed (2013b); 3 Exim Bank Malaysia (2014); 4 Asia Pacific Observatory on Health Systems and Policies (2015); 5 REFSA\n(2015); 6 Ministry of Health Singapore (2014)\n", "page_number": 150, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6237708422402736, "lower_right_x": 0.8675937122128174, "lower_right_y": 0.6485677640017101, "height": 0.024796921761436552, "width": 0.7515114873035067}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-5", "text": "Investment in brand awareness\n", "page_number": 150, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.33313180169286577, "lower_right_y": 0.6737922188969645, "height": 0.010688328345446751, "width": 0.21765417170495766}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-6", "text": "As Curetis is marketing its innovative Unyvero Platform to a diverse and demanding customer base\nimplementing a solution that offers the potential to improve upon the current standard of care, Curetis'\nmanagement believes it will need to continue making additional investments in clinical validation, scientific\npublications, brand awareness and market education. Some of Curetis' tests will require market access activities\nto prove their value and to obtain sufficient reimbursement by relevant payers for certain countries.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.751603249251817, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-7", "text": "Curetis has developed a full suite of marketing communications tools using print and online channels. Curetis\nalso supplies supporting evidence for the various individual stakeholders, for instance microbiologists and\nclinicians are best approached by a first-in-class scientific marketing. This not only includes the classical\nmarketing mix, but also compiles information on health economics and clinical outcomes research.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8135955536554083, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-8", "text": "It is not uncommon for clinicians not to be fully trained with respect to the underlying microbiology of infectious\ndiseases and antibiotic treatment schemes, nor on MDx approaches. Especially genotypic antibiotic resistance\nmarkers, their interpretation and correlation to phenotypic resistance profiles are not common knowledge.\n", "page_number": 150, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8614792646430098, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-9", "text": "Therefore, Curetis' marketing in addition focuses on medical education of physicians through its team of clinical\napplication specialists, participation in scientific conferences, organising scientific sessions and symposia, and\nby enforcing publications in peer-reviewed journals. The conference schedule primarily focuses on well selected\n", "page_number": 150, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8683197947840958, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9093629756306114, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-150-10", "text": "147\n", "page_number": 150, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-0", "text": "scientific congresses e.g. ECCMID, AACC, ICAAC, DGHM, \u00d6GHM, SGM, and AMP and others, if\nappropriate.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08465156049593843, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.11201368106028217, "height": 0.027362120564343742, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-1", "text": "Awareness is also created through producing marketing materials for the Curetis sales team and its third-party\npartners that helps the sales team convey the required investment in Curetis products based on medical outcome\nimprovement and streamlining laboratory processes.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.16032492518170158, "height": 0.041043180846515606, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-2", "text": "In order to receive valuable input during R&D, stimulate market awareness and the demand for its products,\nCuretis had made a significant investment in establishing a lead-user program in the past. Lead-user programs\nwith key opinion leaders have shown good success in creating market awareness. The KOL selection by Curetis\nis based on the following criteria:\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.221889696451475, "height": 0.054724241128687484, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-3", "text": "The KOL has a strong reputation in the area of infectious diseases and/or in molecular diagnostics;\nis a key opinion leader in the clinical and/or laboratory space with strong influence on peers; and\nis an 'early innovator', a member of clinical society, an editor of scientific journal or a member of guide-\nline setting agency and could therefore act as a promoter of the product.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.30055579307396324, "height": 0.07182556648140231, "width": 0.7146311970979444}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-4", "text": "\uf0b7\n", "page_number": 151, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2321504916631039, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.2394185549380077, "height": 0.007268063274903813, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-5", "text": "\uf0b7\n", "page_number": 151, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2539546814878153, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.2620778110303549, "height": 0.008123129542539576, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-6", "text": "\uf0b7\n", "page_number": 151, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.27661393758016245, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.2834544677212484, "height": 0.006840530141085932, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-7", "text": "Strong lead-user programs can help to shape the adoption curve as lead users may turn into first clients and can\nbecome high volume end-users. Initial usage by some of these KOL driven sites can range up to several hundred\ncartridges per year as part of clinical evaluation studies (partly or fully sponsored by Curetis) and also result in\ncommercial purchase of several hundred cartridges per year thereafter (e.g. Essen, Basel, Nantes).\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30739632321504917, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3625480974775545, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-8", "text": "Distribution Channels\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3758016246259085, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.38820008550662677, "height": 0.012398460880718276, "width": 0.16021765417170497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-9", "text": "To distribute the Unyvero System and the Unyvero Application Cartridges, Curetis has adopted a dual approach\ncombining direct sales in the home markets of Germany, Austria and Switzerland (the \"DACH region\") and\nother key markets such as UK, France and Benelux with indirect sales through specialised distributors in other\nEuropean countries such as Spain, Italy, Russia, Bulgaria, Romania, the Middle East, including Qatar, Kuwait\nand the United Arab Emirates and Asian countries such as Indonesia, Malaysia, Singapore, Thailand, China,\nTaiwan and Hong Kong and other markets outside the US (together the \"RoW\"). While it is currently beyond the\nmeans of Curetis to adopt a direct sales model in all geographies, the company considers it of utmost importance\nto directly sell the Unyvero Platform in many relevant key markets right from the start to obtain direct customer\nfeedback and further develop its product portfolio along the market needs.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3963232150491663, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.519880290722531, "height": 0.12355707567336466, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-10", "text": "In addition, Curetis expects to address the most important market in the US through its own dedicated sales and\nmarketing organisation once Unyvero obtains US FDA clearance (see below).\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5540829414279607, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-11", "text": "The choice between direct sales and indirect sales distribution is based on the attractiveness of the market in\nterms of size, pricing, and reimbursement, the ease of market access in terms of regulations, structure and com-\nplexity of the healthcare system, and payer situation. As well as markets are selected based on the availability of\nsuitable distributors with appropriate size, portfolio, sales channels, experience, networks, and reputation to\nintroduce an innovative product like Unyvero in their respective market. It is also not uncommon for MDx com-\npanies to start with a distributor model before going direct once economics permit establishing a direct sales\ninfrastructure.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6566908935442497, "height": 0.09619495510902099, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-12", "text": "Curetis going forward will therefore evaluate on a case-by-case basis whether the chosen distribution channel is\nadequate to also cater for the new target disease segments, or a new structure should be put in place.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6908935442496793, "height": 0.027789653698161554, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-13", "text": "Direct Sales Markets\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6981616075245831, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.7114151346729372, "height": 0.013253527148354038, "width": 0.14570737605804113}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-14", "text": "Unyvero was initially launched in 2012 in the home market of German speaking countries, i.e. Germany, Austria\nand Switzerland by Curetis' own sales force. Curetis' sales team for the DACH region and its direct sales markets\nin Europe is currently comprised of five key account managers with backgrounds in instrument placements and\nconsumable sales into the hospital market and considerable experience in the IVD market. The team combines\nexpertise in microbiology with expertise in hospital IVD sales, instrument business, and consumable sales. As of\n11 September 2015 a team of three clinical application specialists are engaged in the scientific and clinical as-\npects of the sales process, take responsibility for customer training and supports the sales team. Furthermore, a\nteam of four strategic marketing and business development specialists (as of 11 September 2015) support the\ndirect sales market.\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8401026079521163, "height": 0.11885421120136819, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-15", "text": "For after sales support and maintenance, Curetis has established a concept of system replacement instead of\nonsite repair. Thus, in case of system failure or required maintenance, systems are rapidly replaced minimising\ndown-time for the customer as well as reducing the need for a costly service organisation. The established re-\nplacement model ensures that from a customer perspective downtime is minimal with replacements in DACH\nregion and most European markets taking place within one to a few days. Only in a few rare instances (e.g. if\n", "page_number": 151, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9166310389055152, "height": 0.06541256947413432, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-151-16", "text": "148\n", "page_number": 151, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-152-0", "text": "export / import restrictions make a simple replacement cumbersome and time consuming e.g. in Russia or Mid-\ndle East or for US FDA trial) Curetis uses its engineering team to provide ad hoc on-site repair and service.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-152-1", "text": "Curetis plans to further evolve this commercial organisation in line with the market adoption of the Unyvero\nSystem and its growing product portfolio. This is expected to result in additional incremental recruiting for the\nDACH region and Western European Markets direct sales teams as well as for corresponding application spe-\ncialist support. As of 30 June 2015, Curetis' installed base via direct sales efforts comprised 36 Unyvero Analyz-\ners.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18469431380932022, "height": 0.06541256947413425, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-152-2", "text": "Curetis decided in early 2015 to address key Western European markets directly and in early 2015 started to\naddress key accounts in these markets through dedicated international key account sales. Going forward, Curetis\nplans to expand its direct sales efforts in Western Europe and eventually establish regional sales teams in key\nmarkets such as France, Benelux, UK and possibly also Scandinavia.\nIndirect Sales Markets\nIn addition to the direct sales initiative of Curetis' commercial team, there are several distribution agreements in\nplace for the following European countries:\n\uf0b7      Spain, Portugal: Diagnostics and Research Products Laboratorios LETI, SLU\n\uf0b7      Italy: Arrow Diagnostics Srl\n\uf0b7      Romania: High Tech Laboratories SRL\n\uf0b7      Bulgaria: SGP Bio Dynamics Ltd.\nIn the RoW markets, Curetis currently plans to commercialise Unyvero through distribution partners.\nAs for the on-going distribution agreements in some European countries mentioned above, Curetis expects its\ncurrent and future distributors at their expense to:\n\uf0b7      cater for local product registrations as required;\n\uf0b7      perform local clinical studies as required;\n\uf0b7      take responsibility for local marketing based on guidelines and materials provided by Curetis' global\n       marketing team;\n\uf0b7      maintain a local inventory; and\n\uf0b7      install the Unyvero System, train customers, and provide first level service.\nDistribution agreements usually feature minimal sales commitments and purchase commitments of the Unyvero\nSystems and Application Cartridges commensurate with the size and structure of the respective market. As of 30\nJune 2015, Curetis' installed base via distributors comprised 15 Unyvero Systems.\nCurrently distribution agreements are in place for the following countries:\n\uf0b7      Russia, Ukraine, Belarus, Kazakhstan: BioLine LLC.\n\uf0b7      Qatar & UAE: Al Zahrawi Medical LLC\n\uf0b7      Kuwait: Advanced Technology Company\n\uf0b7      Singapore, Malaysia, Indonesia and Thailand: Acumen Research Laboratories Pte Ltd.\n\uf0b7      China, Taiwan and Hong Kong: Beijing Clear Biotech CO., LTD\nThe total contractual minimum purchase requirements of all distributors amount to 324 Unyvero Systems and\n581,520 Application Cartridges (P55 and i60 ITI) in the period between 2015 and 2021. Investors should note\nthat shortcomings of distributors to reach minimum purchase quantities do normally not lead to a \"forced\" pur-\nchase of the minimum quantities, but to a termination of the distribution agreements or termination of exclusivity\nin territories for such distributor. The above minimum purchase requirements do not guarantee any certain min-\nimum future levels of revenues.\nOutlook USA\nWith its US clinical trial for the LRT55 Application Cartridge currently on-going, Curetis expects to submit to\nthe US FDA clearance in the second half of 2016 and, provided that the US FDA clears the product, envisages a\nlaunch in the US in the first half of 2017.\n", "page_number": 152, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8995297135528003, "height": 0.705002137665669, "width": 0.7648125755743652}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-152-3", "text": "149\n", "page_number": 152, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-0", "text": "As of 30 September 2015 the Company has enrolled over 400 patients into the prospective arm of its Unyvero\nApplication Cartridge LRT55 FDA trial and has collected more than 600 retrospective patient samples. In July\n2015 and during the course of the third quarter of 2015 the number of actively enrolling sites has been expanded\nfrom initially two sites to nine. During September 2015, Curetis has added Columbia University in New York as\nthe ninth trial site and successfully completed the site initiation visit and trainings.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15305686190679776, "height": 0.06797776827704145, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-1", "text": "Curetis currently plans to market and sell the Unyvero Platform and any future cleared Application Cartridges\ndirectly in the US through establishing its own US-based commercial organisation including sales, marketing\nand after-sales support. This is expected to take the form of a wholly owned Curetis US subsidiary to be built\norganically at a location to be determined in the US in the second half of 2016.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21504916631038906, "height": 0.054724241128687484, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-2", "text": "Using the proceeds from this Offering, Curetis intends to start building this commercial organisation in late 2016\nthrough hiring a US leadership team preparing the product launch and for senior sales and marketing roles. For\nthe first half of 2017 Curetis plans to prepare for marketing which includes pricing, messaging and positioning\nissues. In the same term, Curetis aims to hire and train 10 to 20 people as an initial US sales team and application\nspecialist support for the various sales regions. With this sales force, Curetis expects to target the aforementioned\n727 larger key accounts representing the majority of the revenue potential for Unyvero. Curetis plans to further\nevolve this US subsidiary and commercial organisation in line with the market adoption of the Unyvero Platform\nand its growing product portfolio.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21547669944420692, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.33133817870884996, "height": 0.11586147926464305, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-3", "text": "While a direct commercialisation of Unyvero products in the US is Curetis' designated strategic path forward in\nthis important market, Curetis constantly explores alternative and complementary commercialisation channels\nthrough strategic partnerships or even merger and acquisition partners that could jump-start market introduction\nand accelerate market penetration in the US.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.39290294997862335, "height": 0.054724241128687456, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-4", "text": "Pricing and Reimbursement\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4070115433946131, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.4236853356135101, "height": 0.016673792218896977, "width": 0.24727932285368803}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-5", "text": "Reimbursement\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.4493373236425823, "height": 0.01197092774690034, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-6", "text": "In the IVD-market, sales volumes and prices of innovative products will depend in large part on the availability\nof coverage and reimbursement from third-party payers, which includes depending on public funding through\ngovernmental programs, private insurance plans and workers' compensation plans. In most healthcare settings,\nreimbursement schemes are complex, processes to achieve reimbursement for new technologies is tedious and\ntime consuming and payors may deny coverage or reimbursement. As a result, even though a new product may\nhave been cleared for commercial distribution, it may find limited demand for the product until reimbursement\napproval has been obtained from governmental and private third-party payors. However, specific reimbursement\ncodes for laboratory tests are in most countries only applicable for out-patients healthcare. In addition, some\npublic funding is already available in most countries for certain established tests and is often technology-\nspecific, thus code stacking or cross-walking and using corresponding codes is quite usual to overcome\nchallenging reimbursement situations.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45788798631893973, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6088071825566481, "height": 0.1509191962377084, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-7", "text": "Curetis has analysed existing reimbursement schemes in the DACH-region, other European countries and the\nUS, where hospitalised in-patients with severe infections are typically covered under the DRG system. With\nDRG, hospitals receive a lump-sum payment, e.g.; up to \u20ac22 thousand in Germany for a life-threatening case of\nVAP treated in intensive care.133 Therefore, Curetis has taken the strategic direction to target hospitalised\npatients first as in most countries DRG systems as hospitals' general financing are in place covering diagnostics\nas part of a lump sum payment per patient without specific reimbursement codes for a laboratory test required.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6152201795639162, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6977340743907653, "height": 0.08251389482684912, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-8", "text": "In addition, the current list prices and future anticipated application prices for Curetis' Unyvero Application\nCartridges, amount to a small fraction of this overall DRG payment. It is also favourable in some countries that\npathogen identification by a lab test may even warrant seeking higher DRG rates.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7456177853783669, "height": 0.04147071398033353, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-9", "text": "To conclude, Curetis' management believes that existing DRG reimbursement schemes codes and their national\nequivalents can be used in most major markets and therefore an adoption of the Unyvero technology seems\nfeasible.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7520307823856349, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7935014963659683, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-10", "text": "Outcomes research and health economics\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8101752885848653, "lower_right_x": 0.405683192261185, "lower_right_y": 0.8208636169303121, "height": 0.010688328345446751, "width": 0.2902055622732769}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-11", "text": "Curetis' management believes that outcomes-based research which demonstrates actual medical and economic\nbenefits upon implementing the Unyvero Platform, and health economic modelling proving the medical and\neconomic value of the Unyvero will considerably support the commercial sales and baking-up the Application\nCartridges sales price, particularly in areas where no reimbursement is currently available.\n", "page_number": 153, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8824283882000855, "height": 0.05515177426250539, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-12", "text": "The on-going and planned clinical studies shall demonstrate:\n\uf0b7     diagnostic value for labs/microbiologists/clinicians;\n", "page_number": 153, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8922616502778965, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.9260367678495084, "height": 0.03377511757161189, "width": 0.41172914147521156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-153-13", "text": "150\n", "page_number": 153, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-0", "text": "\uf0b7   clinical utility / medical outcome improvement to clinicians (e.g. actual reduction in length of stay or\n    reduced antibiotics usage or shorter time to adequate antibiotic therapy selection); and\n\uf0b7   economic outcome improvement to hospital administration/payors (for details see below).\n", "page_number": 154, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1333903377511757, "height": 0.04831124412141939, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-1", "text": "In cooperation with external experts, Curetis has created an internal health economic app conducting a health\neconomic modelling utilising VAP patients to demonstrate the potential value of the P55 Application Cartridge\ncompared against today's standard, microbial culture. This economic modelling app \u2018Impact of Faster Pneumo-\nnia Testing with the P55 Application Cartridge' (internally named BaseCase app) provides clinical evidence and\nestimates health outcome costs related to the utilisation of the Unyvero Platform specific to a hospital. The mod-\nel is evidence based, relies on scientific publications about its in- and output variables. Those include: number of\nICU beds in the hospital, number of cases suspicious for VAP, average age of death, overall life expectancy,\ninadequate treatment rate, mortality rate among patients with inadequate initial therapy, LOS, and cost of stand-\nard of care, respectively Unyvero testing. The data and assumptions in the model are based on comprehensive\nUS and EU studies showing that initial inadequate treatment results in higher mortality and an average longer\nLOS in the ICU, compared to patients with initial adequate treatment. 134 Indeed, 10%-73% of VAP treatment is\nreported to be inadequate.135 Regarding LOS, the ICU stay is increased by six days to a total length of 26.3 days\nin ICU for inadequate treatment, while for an adequate treatment a LOS in the ICU of 32.8 days has been identi-\nfied.136 Mortality rate of 15.6% for adequate treatment of VAP is rising to 37%, if VAP is treated inadequate-\nly.137 In a study shorter LOS translates into an overall cost reduction ranging from approximately of US$6 thou-\nsand per VAP patient.138 As Unyvero does not intend to replace microbiology, but rather complement it, its im-\nplementation will of course add costs to the laboratory.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.14322359982898675, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.37280889268918344, "height": 0.2295852928601967, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-2", "text": "Based on the data above, for the group of initially adequate treated patients, the overall cost is associated with\napproximately US$31,500 for a VAP patient while for initially inadequate treated patients it would relate to\napproximately US$29,500 and consequently around US$1,000 savings for the hospital.139\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42069260367678496, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-3", "text": "More precisely, for a hospital with 90 ICU beds and an inadequate treatment rate of 30%, treatment costs when\nthe Unyvero Platform is utilised could decrease by approximately US$397 thousand per year.140 In case of a\nsmaller hospital with 45 ICU beds only, however, a higher rate of inadequate treatment costs-cuts may be in the\nrange of US$342 thousand.141 The net savings per patient can be in the range of US$510 to US$952142 and may\nresult in a significantly lower mortality rate.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.430525865754596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.49764856776400174, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-4", "text": "Pricing\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.17291414752116083, "lower_right_y": 0.5254382214621633, "height": 0.012825994014536102, "width": 0.057436517533252726}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-5", "text": "Curetis has implemented a pricing strategy similar to a classic razor / razor-blade business model with covering\nonly full-costs, or very low margins for hardware, but with substantial margins for the consumables. In its initial\nmarket assessment, Curetis assessed pricing based on total process and process flow cost of standard of care, as\nwell as of using competitive products. Curetis research on infectious disease tests confirmed that target prices\nshould be set at least at a similar level to the total cost of ownership of currently marketed manual or semi-\nautomated tests. The modular concept of the Unyvero Platform does not only meet various throughput needs, but\nalso allows set-up of a minimal configuration at reasonable total cost of ownership which can be easily expanded\nwith growing test demand. This approach has been independently validated in some customer settings where\nother MDx kits have been replaced by P55 Application Cartridges at near full list prices.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6554082941427961, "height": 0.12227447627191113, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-6", "text": "Most of the currently available low-complexity molecular tests on the market are in the price range of \u20ac15 to \u20ac25\nfor centralised testing and \u20ac30 to \u20ac40 for decentralised settings. Higher complexity molecular infectious disease\ntests (more than 10 parameters) are in the price range of \u20ac90 to \u20ac205. Curetis' management believes that the\nsuperior features of the Unyvero Platform, such as faster time-to-answer with the potential to improve patient\nmanagement, justify a pricing premium and thus the company is pursuing a value-added pricing strategy. Such\nvalue based pricing is based on the modelled health economic savings overall and a certain proportion of these\nsavings to be allocated to the Unyvero Application Cartridge prices with the remainder benefiting the hospital\nbudgets and ultimately the healthcare system at large.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7716973065412569, "height": 0.10859341598973915, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-7", "text": "Therefore, Curetis set end-customer list-prices for its CE-IVD-marked Application Cartridges in the EU direct\nsales markets in the range of \u20ac192 (P55 Application Cartridge) to \u20ac262 (i60 ITI Application Cartridge) and the\ncurrently offered discount structure also reflects this pricing premium. This pricing strategy is supported by an\nestimation of the perceived value of Unyvero products through customer feedback and accounts for the\nsimultaneous test of 39 and 80 analytes as well as for the sample preparation fully integrated in the Curetis\nPlatform. Lastly, the initially targeted customers are early innovators and fast adopters, which are typically not\nprice-sensitive.\n", "page_number": 154, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8743052586575459, "height": 0.09491235570756729, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-154-8", "text": "151\n", "page_number": 154, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-0", "text": "Intellectual Property\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.1013253527148354, "height": 0.016246259085079096, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-1", "text": "It is essential for Curetis to achieve and ensure a sustainable and reliable protection of the intellectual property\nrights related to the Unyvero Platform products and the underlying proprietary technology and manufacturing\nprocesses. To this end, we have sought and we will continue to seek obtaining and maintaining patents and other\napplicable forms of protection for inventions, know-how as well as proprietary technology and manufacturing\nprocesses of commercial relevance.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1838392475416845, "height": 0.06797776827704148, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-2", "text": "Curetis utilises diverse methods to achieve the desired protection, including patents (see table 14 below), design\nregistrations (see table 15 below), trademarks (see table 16 below), copyrights and trade secrets. Where\nnecessary, Curetis may also rely on third parties to develop, complement and maintain our proprietary position.\nCuretis' success will furthermore depend on its ability to defend and enforce their intellectual property rights, to\nmaintain our licenses, to use third-party intellectual property rights, to preserve the confidentiality of the trade\nsecrets and to operate without infringing the valid and enforceable patents and other proprietary rights of third\nparties. Customary non-disclosure agreements and non-disclosure agreement sections as part of other legal\nagreements, including but not limited to employment agreements, consulting agreements, clinical trial\nagreements, material transfer agreements, collaboration agreements and others are used by Curetis to protect our\nrights in relationship with other parties.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1911073108165883, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3274903805044891, "height": 0.1363830696879008, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-3", "text": "Patents\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.3522873022659256, "height": 0.010688328345446751, "width": 0.05320435308343409}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-4", "text": "The granted and filed patents focus on protecting critical elements of the instrumentation of the Unyvero\nPlatform and the proprietary Unyvero Application Cartridges, specifically related to sample preparation and\nhomogenisation and to DNA amplification and detection. All patent inventors are Curetis' employees or\nmembers of its Management Board.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41727233860624197, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-5", "text": "\uf0b7   The patent \"Processing and Analysis of Viscous Liquid Biological Samples\" relates to sample preparation\n    and homogenisation (patent belongs to patent family 1). The patent has been filed, abandoned in certain\n    regions for strategic reasons and is currently pending in the US. For details, see table below.\n\uf0b7   The patent \"Universally Applicable Lysis Buffer and Processing Methods for the Lysis of Bodily Sam-\n    ples\" relates to sample preparation and homogenisation (patent belongs to patent family 1). The patent has\n    been filed, has been issued (Singapore, grant date 13 May 2015), has been granted in Australia (term:\n    twenty years from 9 May 2011) and is currently pending in the EU and other foreign jurisdictions. For de-\n    tails, see table below.\n\uf0b7   The patent \"Apparatus and Method for a Lysis of a Sample, in particular for an Automated and/or Con-\n    trolled Lysis of a Sample\", relating to the instrumentation for and sample preparation and homogenisation\n    (patent belongs to patent family 3). The patent has been filed and is pending in the EU and other foreign\n    jurisdictions. For details, see table below.\n\uf0b7   The patent \"Reaction Vessel For PCR Device and Method of Performing PCR\", relating to the Unyvero\n    PCR Chamber, describes a method to perform an integrated PCR and detection in one integrated reaction\n    vessel (patent belongs to patent family 2). The patent has been filed and has been granted in Australia\n    (term: twenty years from 19 May 2011) and is pending in the EU and other foreign jurisdictions. For de-\n    tails, see table below.\n", "page_number": 155, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6806327490380505, "height": 0.2569474134245404, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-6", "text": "Table 14: Curetis' inventor and patent overview\n    Patents and Patent Family            Inventor       Patent Number                          Status\n                                                                                                   Filed: 27. Jan. 2009\n                                                             EP09001095.0\n                                                                                               Published: 28 Jul. 2010\n                                                           EP 2210936 (A1)\n                                                                                            Abandoned: 29 Mar. 2011\n                                                        PCT/EP/2010/000252                  Abandoned: 30 Mar. 2015\nProcessing and Analysis of Viscous\n                                                           WO 2010/086099                      Published: 5 Aug. 2010\nLiquid Biological Samples (Patent      Matthias Klein       JP 2012-515539                     Published: 12 Jul. 2012\nFamily 1)\n                                                                              No Response to Decision of Refusal dated\n                                                                                                          11 Mar. 2015\n                                                                                                 Lapsed: 11 Jul. 2015\n                                                        US-2011-0281272-A1                    Published: 17 Nov. 2011\n                                                                                                   Filed: 17 May 2010\n                                                              EP10005128.3\n                                                                                              Published: 23 Nov. 2011\n                                                                EP 2388312\n                                                                                             Abandoned: 29 Jun. 2012\nUniversally Applicable Lysis Buffer    Matthias Klein\n                                                         PCT/EP/2011/02303                          Filed: 9 May 2011\nand Processing Methods for the Lysis    Gerd L\u00fcdke\n                                                           WO 2011/144304                     Published: 24 Nov. 2011\nof Bodily Samples (Patent Family 1)    Andreas Boos\n                                                            EP 11 718 666.8           Regional Phase EP: 3 Dec. 2012\n                                                             EP 2571976 A1\n                                                        US 2013-0065223-A1                     Published: 14 Mar. 2013\n", "page_number": 155, "bounding_box": {"top_left_x": 0.10640870616686819, "top_left_y": 0.6874732791791364, "lower_right_x": 0.8917775090689238, "lower_right_y": 0.9213339033775118, "height": 0.2338606241983754, "width": 0.7853688029020557}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-155-7", "text": "152\n", "page_number": 155, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-0", "text": "                                                                    SG 185466               Granted: 13 May 2015\n                                                               JP 2013-526284             Published: 24 Jun. 2013\n                                                                                 Decision of Refusal: 30 Jun. 2015\n                                                                                      Response due: 30 Oct. 2015\n                                                               HK 13108207.7                   Filed: 12 Jul. 2013\n                                                               AU 2011254936                Granted: 25 Jun. 2015\n                                                                                             Filed: 19 May 2010\n                                                                 EP10005237.2\n                                                                                        Abandoned: 23 Aug. 2011\n                                                           PCT/EP/2011/002507                 Filed: 19 May 2011\n                                                              WO 2011/144345            Published: 24 Nov. 2011\n                                         Gerd L\u00fcdke            EP 11 720 402.4    Regional Phase EP: 3 Dec. 2012\nReaction Vessel For PCR Device and                                 EP 2571617       Publication EP: 27 Mar. 2013\n                                        Andreas Boos\nMethod of Performing PCR (Patent                          IN:9813/DELNP/2012                   Filed: 8 Nov. 2012\n                                      Hassan Motejadded\nFamily 2)                                                 US-2013-0130267-A1             Published: 23 May 2013\n                                       Johannes Bacher\n                                                            ZL 201180024484.8              Granted: 19 Aug. 2015\n                                                              CN 102933300 B\n                                                              HK Nr 1183460A             Published: 27 Dec. 2013\n                                                               AU 2011254887             Registered: 17 Jul. 2014\n                                                                    SG 185467              Granted: 25 Sep. 2015\n                                                                   EP 2737294              Published: 4 Jun. 2014\n                                                            WO2013/013687A1               Published: 31 Jan. 2013\nApparatus and Method for a Lysis of\n                                        Andreas Boos           AU 2011373961                  Filed: 17 Dec. 2013\na Sample, in particular for an\n                                         Gerd L\u00fcdke        US 2014/0242678 A1            Published: 28 Aug. 2014\nAutomated and/or Controlled Lysis\n                                       Johannes Bacher           CA 2,839,951                  Filed: 27 Jul. 2011\nof a Sample (Patent Family 3)\n                                                               CN 103718012A              Published: 9 Apr. 2014\n                                                               JP 2014-521955                 Filed: 26 May 2014\n", "page_number": 156, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8941958887545345, "lower_right_y": 0.3753740914920906, "height": 0.29371526293287725, "width": 0.788391777509069}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-1", "text": "                                                                                        JP 2014-521955                                 Filed: 26 May 2014\nLegend: \"Filed\": The patent application has been received by the respective patent office; \"granted\": patent has been granted by the respective patent office;\n\"abandoned\": No further efforts were undertaken by Curetis for obtaining patent protection. \"Published\": Publication date; EP = European Patent; PCT = Patent\nCooperation Treaty; WO = World Organisation for Intellectual Property; US = United States of America; SG = Singapore; JP = Japan; HK = Hong Kong; AU =\nAustralia; IN = India; CA = Canada; CN = China.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.11185006045949214, "top_left_y": 0.3753740914920906, "lower_right_x": 0.8887545344619106, "lower_right_y": 0.4185549380076956, "height": 0.043180846515605, "width": 0.7769044740024185}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-2", "text": "Patent Family 1 is protecting the initial sample lysis and liquefaction process; Patent Family 2 is protecting in-\nstrumentation when used in conjunction with the described reaction vessel for PCR device within a dependent\nclaim; Patent Family 3 is completely focused on the instrumentation for the lysis process and is not protecting\nthe Unyvero Application Cartridge, but the instrumentation.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.48140230867892264, "height": 0.05429670799486963, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-3", "text": "Patents of the type mentioned above are typically granted between two and seven years upon filing. The respec-\ntive patents will expire 20 years after filing.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5156049593843522, "height": 0.026934587430525847, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-4", "text": "Only in cases where a patent is granted to Curetis, Curetis may prosecute patent infringements. Curetis currently\ndoes not own granted patents that can be enforced in the regions in which it is currently commercially active.\nHowever, the filing and publication dates are relevant for obtaining priority with regard to an invention (i.e.\nconflicting patents filed by another party at a later point in time are rejected).\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5228730226592561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5775972637879435, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-5", "text": "Registered Design \"Column Adaptor\" has been published in the EU, Japan, US, Switzerland\nRegistered Design \"Sample Handling Tool\" has been published in the EU, US, Switzerland\nRegistered Design for \"Unyvero System\", \"Lysator\", \"Analyzer\" and \"Cockpit\" has been published in the\nEU.\n", "page_number": 156, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.5844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6532706284737068, "height": 0.06883283454467726, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-6", "text": "", "page_number": 156, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5878580589995724, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.5946985891406584, "height": 0.0068405301410859876, "width": 0.007859733978234584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-7", "text": "\uf0b7\n", "page_number": 156, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6096622488242839, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6156477126977341, "height": 0.005985463873450225, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-8", "text": "\uf0b7\n", "page_number": 156, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6327490380504489, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.6387345019238991, "height": 0.005985463873450225, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-9", "text": "Table 15: Curetis' design registration\n", "page_number": 156, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6631038905515177, "lower_right_x": 0.3603385731559855, "lower_right_y": 0.6742197520307824, "height": 0.011115861479264688, "width": 0.24365175332527206}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-10", "text": "                                    Number                             Status\nCommunity     Design     \"Column    EU 001 197 560       Filed: 24. Feb. 2010 Published: 10. May\nAdapter\"                                                                                    2010\nJapanese Design \"Column Adaptor\"        JP 1456898    Filed: 8. Jun. 2012 Published: 3. Dec. 2012\nCommunity     Design     \"Column    EU 001 966 433   Filed: 21. Dec. 2011 Published: 2. Jan. 2012\nAdaptor\"\nUS Design \"Column Adapter\"            US D683,044      Filed: 21. Dec. 2011 Issued 21. May 2013\nSwiss Design \"Part of Analysis         CH 138 957        Filed: 21. May 2012 Published: 13. Jul.\nDevice\"                                                                                   2012\nCommunity      Design     \"Sample   EU 002 070 441    Filed: 9. Jul. 2012 Published: 11. Jul. 2012\nHandling Tool\"\nUS Design \"Sample Handling Tool\"     US 29/433,060     Filed: 25. Sep. 2012 Issued: 24. Feb. 2015\n                                          D723180\n", "page_number": 156, "bounding_box": {"top_left_x": 0.1094316807738815, "top_left_y": 0.6772124839675074, "lower_right_x": 0.871825876662636, "lower_right_y": 0.9157759726378795, "height": 0.23856348867037203, "width": 0.7623941958887545}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-156-11", "text": "153\n", "page_number": 156, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-0", "text": "Swiss Design \"Sample Handling             CH 139 083        Filed: 20. Jul. 2012 Published: 31. Aug.\nTool\"                                                                                           2012\nCommunity     Design    \"Unyvero   EU002210401-0001    Filed: 27. Mar. 2013 Published: 2. Apr. 2013\nSystem\"\nCommunity Design \"Lysator\"         EU002210401 -0002   Filed: 27. Mar. 2013 Published: 2. Apr. 2013\nCommunity Design \"Analyser\"        EU002210401-0003    Filed: 27. Mar. 2013 Published: 2. Apr. 2013\nCommunity Design \"Cockpit\"         EU002210401 -0004   Filed: 27. Mar. 2013 Published: 2. Apr. 2013\n", "page_number": 157, "bounding_box": {"top_left_x": 0.10701330108827085, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8712212817412334, "lower_right_y": 0.21889696451474988, "height": 0.13723813595553652, "width": 0.7642079806529625}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-1", "text": "No oppositions have been received to date.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.21889696451474988, "lower_right_x": 0.4117291414752116, "lower_right_y": 0.2394185549380077, "height": 0.020521590423257824, "width": 0.30169286577992743}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-2", "text": "FTO (Freedom to Operate)\n", "page_number": 157, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.25609234715690465, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.26849080803762293, "height": 0.012398460880718276, "width": 0.19286577992744863}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-3", "text": "Curetis collaborates with several external patent attorneys across the globe to assess, evaluate and implement its\nintellectual property protection strategy. This includes monitoring the patent landscape with respect to new\ndevelopments on relevant technology, biomarkers and Application Cartridges as well as with respect to filed\npatents, registered designs and trademarks.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32962804617357844, "height": 0.05301410859341599, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-4", "text": "Curetis does not own the IP for reagents and markers and their use, including the spin column, the PCR\nmastermix and the fluorophore labels. These are used for pre-lysis, sample preparation, amplification, detection\nand quality control purposes. The detailed reagent composition is not disclosed by the suppliers. A license is\nrequired to become a legitimate user for some of the reagents. Under its existing supplier agreement with the\nsupplier for the reagents and the spin column used for the sample preparation and the PCR mastermix, Curetis\nhas been granted the worldwide distribution rights for the sample preparation reagents. For the PCR mastermix\nreagents, distribution rights cover all countries except Australia, Canada, Israel, Korea, Mexico and the US.\nDepending on the actual timeline when Curetis intends to begin commercialisation in these excluded regions,\nthere is a potential need to obtain a so-called \"Chemically Modified Enzyme License\" from Roche Molecular\nSystems, Inc. and F. Hoffmann-La Roche Ltd. Terms and conditions for obtaining such a license are readily\navailable if and when needed and Curetis has already received a standard template agreement draft for such a\nlicense in the past and Curetis could simply sign this standard agreement if and when needed.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.5010688328345447, "height": 0.16289012398460884, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-5", "text": "Supplier agreements have furthermore been concluded for the supply with labelled primers and probes, including\nthe necessary license governing the use of fluorophore dyes that are incorporated in the Unyvero products.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5356990166737923, "height": 0.026507054296708077, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-6", "text": "The markers selected by Curetis for incorporation into the current Unyvero products are either in public domain,\nare no longer protected by a patent or have been newly developed by Curetis. In the future, Curetis may decide\nto obtain a license for one or more targets to complement Application Cartridge coverage with one or more\nspecific markers that are protected.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5972637879435656, "height": 0.053869174861051694, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-7", "text": "Furthermore, as the functionality of future products has not yet been defined, it is not yet clear whether Curetis\nmight need any other licenses for one or more of the functions, methods, reagents or processing steps of such\nfuture products.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.645575032064985, "height": 0.040615647712697656, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-8", "text": "Standard software licenses are required for the Unyvero instruments, including but not limited to a Microsoft\noperating system, image processing, database driver and other proprietary driver libraries. Certain open source\nsoftware used in the Unyvero product requires publishing a corresponding disclaimer notice.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6943138093202224, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-9", "text": "Proprietary Rights and Processes\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.7216759298845661, "height": 0.0141085934159898, "width": 0.2327690447400242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-10", "text": "In addition to the filed patents and registered designs, Curetis relies on proprietary technology and processes\n(including trade secrets) to protect the Unyvero products and technology. All full-time and temporary\nemployees, scientific advisors, contractors and consultants working for Curetis who have access to confidential\ninformation of Curetis are therefore required to execute confidentiality agreements in order to safeguard Curetis'\nproprietary technologies, methods, processes, know-how, and trade secrets. This is complemented by preserving\nthe integrity and confidentiality of Curetis' proprietary technology and processes by maintaining physical\nsecurity of Curetis' premises and physical and electronic security of its information technology systems. All its\nfull-time and temporary employees and where applicable, Curetis' independent contractors, OEM manufacturing\npartners and consultants, are also bound by invention assignment obligations, pursuant to which rights to all\ninventions and other types of intellectual property conceived by them during the course of their employment are\nassigned and licenced to Curetis.\n", "page_number": 157, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8785805899957246, "height": 0.1504916631038905, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-157-11", "text": "154\n", "page_number": 157, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-0", "text": "Trademarks, domain names and designs\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.08507909362975631, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.28234582829504234}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-1", "text": "Curetis has secured trademark protection for its corporate name \"Curetis\" and its product platform \"Unyvero\" in\nGermany, Switzerland, the EU and the USA. Both trademarks have been filed but not yet published in China.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.13296280461735785, "height": 0.027362120564343742, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-2", "text": "Table 16: Curetis' trademark registrations\n\n Brand                                Number       Filed        Published    No objection\n                       DE302008010146.6/44      15 Jan 2008   22 Aug 2008      7 Jan 2009\n                                    CH603237    27 Jul 2010    27 Jul 2010   15 Mar 2011\n                                 US77/930,558   7 Dec 2010    19 Mar 2013      1 Feb 2011\n                                EU007160955     28 May 2009     8 Jun 2009    15 Jul 2009\n                                 CN 16871246\n Curetis\n                                 CN 16871247\n                                                5 May 2015\n                                 CN 16871248\n                                 CN 16871249\n                       DE302010032715.4/01      31 May 2010   10 Dec 2010    11 Apr. 2011\n                                    CH613203    21 Mar 2011   21 Mar 2011     21 Jul 2011\n                                 US85/068,577   17 May 2011   17 May 2011     17 Jun 2011\n                                EU009532029     18 Nov 2010    27 Jan 2011   11 May 2011\n Unyvero                         CN 16871250\n                                 CN 16871251    5 May 2015\n                                 CN 16871252\n", "page_number": 158, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.493373236425823, "height": 0.3535699016673792, "width": 0.7636033857315598}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-3", "text": "Curetis currently has registered eleven domain names for the \"Curetis\" family of domains and ten domain names\nfor the \"Unyvero\" family of domains.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5301410859341599, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-4", "text": "Employees\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5438221462163317, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.5609234715690466, "height": 0.017101325352714913, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-5", "text": "Since it was founded in 2007, Curetis has grown from six employees to a total full-time equivalent headcount of\n54 as of 30 June 2015 (not including marginal employment (mini-jobs):\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.6019666524155622, "height": 0.027789653698161665, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-6", "text": "Table 17: Curetis' employment overview\n", "page_number": 158, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6083796494228303, "lower_right_x": 0.37968561064087064, "lower_right_y": 0.6233433091064557, "height": 0.014963659683625452, "width": 0.2629987908101572}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-7", "text": "                                      Headcount as of\n                    31 Dec 2012   31 Dec 2013       31 Dec 2014   30 June 2015\nR&D (incl. CRQ)             18            20                22             24\nManufacturing                8            10                10             11\nMarketing & Sales           11            11                10             12\nG&A                          6             7                 7              7\nTotal                       43            48                49             54\nFTE                        42.5          47.1              47.6           52.6\n", "page_number": 158, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.6318939717828131, "lower_right_x": 0.8905683192261185, "lower_right_y": 0.7969217614365113, "height": 0.16502778965369813, "width": 0.7847642079806529}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-8", "text": "Approximately 28% of Curetis' employees have a Ph.D. and around 63% of employees hold a Master's degree or\nequivalent. Curetis' team members have many years of relevant industry experience and have worked in a\nregulated industry.\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.844377939290295, "height": 0.04104318084651559, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-9", "text": "Curetis' key technical staff consists of the CTO, the COO, its Medical Director, its Director Bio-Assay\nDevelopment, Senior Scientists Head of Software Development, Head of Quality and Regulatory Affairs and\nSenior Engineers for firmware and hardware. The key technical staff's relevant collective expertise and\nexperience encompasses product development for MDx including hardware, software and Application\nCartridges, manufacturing, medical affairs and clinical trials, all regulatory aspects of IVD development in EU\n", "page_number": 158, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-158-10", "text": "155\n", "page_number": 158, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-0", "text": "and US, quality management under ISO 13485, as well as a relevant background for working in the medical\ndevice and diagnostics industry.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-1", "text": "None of Curetis' employees are subject to any collective bargaining agreement.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.652962515114873, "lower_right_y": 0.1333903377511757, "height": 0.014108593415989731, "width": 0.5374848851269649}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-2", "text": "Facilities\n", "page_number": 159, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1466438648995297, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.16075245831551946, "height": 0.014108593415989745, "width": 0.08222490931076178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-3", "text": "Curetis headquarters are located at Holzgerlingen, Germany, where it leases approximately 1,500 sqm of office\nspace pursuant to a lease agreement most recently amended on 27 September 2013. The lease has a fixed term\nuntil 31 August 2018 with the one-time option to be extended until 31 August 2021. After that term, the lease\nagreement is automatically extended for an indefinite period of time unless terminated with nine months prior\nnotice by either lessor or lessee.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24625908507909364, "height": 0.06883283454467723, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-4", "text": "Curetis also leases approximately 1,600 sqm of manufacturing and logistics space in Bodelshausen, Germany,\npursuant to a lease agreement (for more details see \"\u2013 Material Contracts\").\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2526720820863617, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2804617357845233, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-5", "text": "In addition Curetis leases three manufacturing line modules for Laserwelding, Leakage Testing and Spin Column\nHolder Sealing and Testing which are installed in Bodelshausen (for more details see \"\u2013 Material Contracts\").\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.314664386489953, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-6", "text": "Material Contracts\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.3420265070542967, "height": 0.010688328345446751, "width": 0.16989117291414751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-7", "text": "Heraeus Medical GmbH (\"Heraeus Medical\")\n", "page_number": 159, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3587002992731937, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.37280889268918344, "height": 0.014108593415989745, "width": 0.3180169286577993}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-8", "text": "On 20 September 2012, Curetis and Heraeus Medical entered into an R&D collaboration and commercial\nagreement establishing a framework for collaborations with respect to the development and commercialisation of\nthe ITI Application Cartridge for use on the Unyvero System.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.42069260367678496, "height": 0.04147071398033347, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-9", "text": "Under the terms of the agreement Heraeus Medical funded all Application Cartridge development work for the\nPJI-specific markers at a fixed rate per Application Cartridge and also paid for cartridges and sample testing in\nthe analytical and clinical validation stages. The commercialisation collaboration in relation to the ITI Applica-\ntion Cartridge has an unlimited term and will only cease once commercialisation of the ITI Application Cartridge\nends within the relevant territory, defined as Europe and the rest of the world that accepts CE-IVD-marking for\nIVD clearance.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5083368961094484, "height": 0.08123129542539542, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-10", "text": "The sales and marketing teams of Curetis and Heraeus Medical have formed a steering committee and working\ngroups that coordinate the activities in the markets. Curetis remains solely responsible for all Unyvero product\nmarketing, sales and after sales support, whereas Heraeus Medical remains solely responsible for its product\ncommercialisation.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5707567336468576, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-11", "text": "If customers start buying the Unyvero Systems and i60 ITI Application Cartridges upon referral or with collabo-\nration from Heraeus Medical, Curetis is required to pay a placement fee for any Unyvero Platform that gets pur-\nchased for cash outright by referral customers and sales commission to Heraeus Medical. This allows Curetis to\nleverage on Heraeus Medical's sales organisation across the DACH and EU markets. Future expansion into other\nmarkets is contemplated by both parties. There are no licenses granted either way under this agreement and there\nare no exclusivity restrictions other than the agreement for Curetis not to enter into any other research or devel-\nopment collaboration with a provider of products directly competing with the Heraeus Medical in orthopaedics\nsettings.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6874732791791364, "height": 0.1064557503206498, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-12", "text": "Acumen\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.7148353997434801, "height": 0.010688328345446751, "width": 0.06348246674727932}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-13", "text": "On 5 October 2015, Curetis and Acumen entered into two separate collaboration agreements. First, a non-\nexclusive patent license and research collaboration agreement, under which Curetis has obtained a limited, royal-\nty-bearing, non-exclusive, non-transferrable, non-sublicensable license to Acumen's proprietary sepsis biomarker\npanel for detection of sepsis host response in blood samples. Under this agreement the parties further agree to a\nresearch and development collaboration, in which Acumen is expected to further develop its technology underly-\ning the license and Curetis is expected to develop products based on such technology and develop a novel sepsis\nhost response Application Cartridge which the parties will jointly validate in a series of clinical studies in Singa-\npore, Germany and the UK. It is envisaged that Curetis becomes the manufacturer of the sepsis host response\nApplication Cartridge, subject to an up-front one-time payment of several hundred thousand euros by Curetis to\nAcumen and a single digit royalty percentage on net sales to be paid to Acumen for all such sepsis host response\nsales except for the territories where Acumen is the exclusive distributor of Unyvero products (see below). The\nagreement is set to expire upon the expiration of the last claim of any of the relevant patents, provided that it is\nnot terminated by one of the parties.\n", "page_number": 159, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9012398460880718, "height": 0.17657118426678065, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-159-14", "text": "156\n", "page_number": 159, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-0", "text": "Secondly, a distribution agreement under which Acumen will become the exclusive distributor of Unyvero Sys-\ntems and P55 and i60 ITI Application Cartridges in Singapore, Malaysia, Thailand and Indonesia. Both parties at\nlater point may mutually agree to amend the agreement to include additional territories of the ASEAN region.\nUnder the terms of the agreement, Acumen is subject to certain minimum purchase commitments for the Un-\nyvero Systems and the Application Cartridges per year. The agreement provides an initial three year term, which\nshall be automatically extended for one year, provided that it is not terminated by one of the parties. During that\nperiod, Acumen has exclusive rights to market, sell and distribute all Unyvero products in the respective territo-\nries. In return, Acumen needs to commit to annual minimum purchases of Unyvero systems as well as Applica-\ntion Cartridges. Transfer prices for the Unyvero Systems and Application Cartridges are defined and reflect\ntypical MDx industry 30% to 40% distributor margins on the consumable sales. In case Acumen fails to meet its\nannual minimum commitments fixed in the contract, Curetis has the right to either terminate the agreement in its\nentirety, or to terminate Acumen's territorial exclusivity.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24882428388200087, "height": 0.16374519025224454, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-1", "text": "Beijing Clear Biotech\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.27704147071398033, "height": 0.014108593415989745, "width": 0.15538089480048367}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-2", "text": "On 25 September 2015, Curetis and Beijing Clear Biotech entered into exclusive international distributor agree-\nment for seven years, which shall be automatically extended for additional five years, provided that it is not\nterminated by one of the parties. They have agreed that Beijing Clear Biotech is appointed as the exclusive dis-\ntributor of Unyvero Systems and P55 and i60 ITI Application Cartridges in Greater China, consisting of China,\nHong Kong and Taiwan.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.35185976913210776, "height": 0.06840530141085938, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-3", "text": "Under the agreement Beijing Clear Biotech shall be responsible for conducting and implementing as well as\nfully funding of comprehensive CFDA clinical trials of the Unyvero System and the P55 and i60 ITI Application\nCartridges according to CFDA guidelines. Beijing Clear Biotech shall act as direct contact for the Beijing CFDA\nand is obligated to file the Unyvero Platform CFDA registration as Curetis' Chinese representative. Curetis is\nobligated to fully support Beijing Clear Biotech for obtaining CFDA clearance by providing its expert\nknowledge. Further, Curetis shall compensate Beijing Clear Biotech for certain milestone achievements, consist-\ning of (1) initiation of up to three clinical trial sites as marked by first patient enrolment and (2) regulatory ap-\nproval by CFDA of the Unyvero System and the P55 and i60 ITI Application Cartridges. Curetis shall be respon-\nsible for the labelling of instruments and consumables according to the requirements of the CFDA during the\nclinical trial and after the approval.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4959384352287302, "height": 0.13723813595553652, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-4", "text": "Beijing Clear Biotech will become the exclusive distributor for Unyvero Systems and P55 and i60 ITI Applica-\ntion Cartridges. Beijing Clear Biotech is responsible for the local marketing which is to correspond with Curetis'\nglobal marketing strategy. The marketing activities of Beijing Clear Biotech shall include marketing with hospi-\ntals as well as with physicians and microbiology laboratories and/or core laboratory marketing. Curetis shall,\nupon Beijing Clear Biotech's request, provide support services, including technical and scientific training for the\npromotion, marketing and distribution of the products as well as the provision of second level of technical sup-\nport.\nBeijing Clear Biotech committed to annual minimum purchases of Unyvero Systems as well as Application\nCartridges. Transfer prices for the Unyvero Systems and Application Cartridges are defined and reflect typical\nMDx industry 30% to 40% distributor margins on the consumable sales. The agreement may be terminated upon\nwritten notice by either party in case of a breach by the other party under the terms of the agreement and its fail-\nure to remedy that breach within 30 days. In case Beijing Clear Biotech fails to meet its annual minimum com-\nmitments fixed in the contract, Curetis has the right to either terminate the agreement in its entirety, or to termi-\nnate Beijing Clear Biotech territorial exclusivity.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.1988029072253099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-5", "text": "Cempra Pharmaceuticals (\"Cempra\")\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.3802902055622733, "lower_right_y": 0.728516460025652, "height": 0.01410859341598969, "width": 0.26481257557436516}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-6", "text": "In July 2012, Curetis and Cempra Pharmaceuticals, Inc. entered into a collaboration agreement for the use of\nUnyvero pneumonia Application Cartridges and reference lab testing services by Curetis for Cempra's global\nphase III trial for solithromycin capsules for treatment of community acquired bacterial pneumonia (CABP). The\nagreement, inter alia, specifies the transfer of the resulting microbiology information and clinical data, pursuant\nto which Curetis shall generate the Application Cartridge data, which it may publish after consultation with\nCempra. Both Cempra and Curetis may use the material and data to support its clinical trials and regulatory\nsubmissions (including but not limited to FDA submissions) for their respective products. In total, data has been\ngenerated from measuring more than 800 clinical sputum samples from over 100 trial sites globally. Upon suc-\ncessful completion of the phase III trial and some top line data having been presented by Cempra at ECCMID\n2015 in Copenhagen, Curetis is closely collaborating with Cempra on final data analysis for the Cempra filing\nwith the FDA for clearance of their drug and joint as well as individual publications.\n", "page_number": 160, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.73492945703292, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8849935870029927, "height": 0.15006412997007268, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-160-7", "text": "157\n", "page_number": 160, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-0", "text": "Pharmaceuticals Company\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.18923821039903266}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-1", "text": "On 28 May 2015, Curetis and a new pharmaceutical collaboration partner entered into an agreement on the pur-\nchase and use of Unyvero Systems and P55 Application Cartridges as well as certain services and support activi-\nties to be delivered by Curetis as part of the on-going global phase III clinical trial for the drug Amikacin. Under\nthis agreement Curetis will deliver, install and service a number of Unyvero Systems across multiple western\nEuropean countries and sites for the pharmaceutical company. The project is expected to last for up to two years\nuntil its completion. The duration of phase III trial is expected to be 19 months and at the end of phase III the\npharmaceutical company has the option (but not the obligation) to sell some or all of the Unyvero Systems back\nto Curetis at a pre-determined residual value of \u20ac10 thousand per system.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.21504916631038906, "height": 0.10944848225737495, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-2", "text": "Zollner Elektronik AG (\"Zollner\")\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.3567110036275695, "lower_right_y": 0.2424112868747328, "height": 0.013681060282171864, "width": 0.2412333736396614}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-3", "text": "On 27 May 2009, Curetis and Zollner entered into a framework agreement, pursuant to which Zollner shall per-\nform certain development and manufacturing services for the Unyvero System. Under the terms of the agree-\nment, each party retains rights to its respective intellectual property (\"IP\"). The agreement specifies that Manu-\nfacturing IP created jointly or solely by Zollner while performing work and services for Curetis shall be solely\nwith Zollner. For any Manufacturing IP owned by Zollner, Curetis will receive non-exclusive, non-transferable,\nworld-wide, royalty free, irrevocable perpetual license (without a right to sublicense) to use, provided that such\nManufacturing IP is embodied in a product provided to Curetis. As of today, there is no such Manufacturing IP.\nThis Agreement is for an indefinite period of term and may be terminated with 12 months prior written notice.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3591278324070115, "height": 0.1098760153911928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-4", "text": "Over the course of the collaboration, the framework agreement has been expanded by a development agreement\nin 2010 and related project agreements for various development projects as well as by a strategic supply agree-\nment signed in June 2013 under which Zollner became the OEM contract manufacturer for all Unyvero instru-\nment systems for Curetis.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3655408294142796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42069260367678496, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-5", "text": "Horst Scholz GmbH & Co. KG | High Tech in Kunststoff (\"Scholz HTIK\")\n", "page_number": 161, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.43394613082513894, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.4480547242411287, "height": 0.014108593415989745, "width": 0.5163240628778718}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-6", "text": "On 1 February 2013, Curetis and Scholz HTIK entered into a framework agreement, pursuant to which Scholz\nHTIK shall perform certain services in the area of tool development and tool making (injection molding tools to\nmake plastics parts) and manufacturing product components (i.e. all plastics parts for the Unyvero Application\nCartridges) for Curetis. The parts for the Unyvero products comprise inter alia the base plates, valve plate, PCR\nchamber parts, spin column holder, waste chamber, reagent container, plungers and housing body parts. All\nrights, title, interest and ownership in the injection molding tools and plastic products specified in this agree-\nment, including the respective intellectual property rights shall be transferred and assigned to and solely belong\nto Curetis. Under this agreement, Scholz guarantees that all such rights solely belong to Curetis. The framework\nagreement constitutes the legal basis for all legal relations between the parties after February 2013, in particular\nfor the supply agreement. On 2 January 2013, Curetis and Scholz HTIK entered into a supply agreement pursu-\nant to which Scholz shall manufacture and supply products, such as base plates, valve plate, PCR chamber parts,\nspin column holder, waste chamber, reagent container, plungers or housing body parts exclusively for and to\nCuretis. Both agreements are for indefinite period of term and may be terminated with 12 months prior written\nnotice. All molds owned by Curetis before collaborating with Scholz HTIK were transferred from a previous\nsupplier to Scholz HTIK to ensure an immediate production start in January 2013.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6601111586147926, "height": 0.2056434373663959, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-7", "text": "In addition to volume production with these pre-existing molds, Curetis subsequently commissioned a series of\nmulti-cavity injection molds (owned by Curetis yet stored and used on site at Scholz HTIK) under a strategic\nlease agreement with Scholz HTIK for all injection molded plastics parts entered into on 28 July 2015. The\nagreement is for an indefinite period of term and may be terminated with 12 months prior written notice or may\nbe terminated earlier by Curetis once the last order for related plastic parts has been fulfilled.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.735356990166738, "height": 0.06883283454467726, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-8", "text": "Contexo GmbH (\"Contexo\")\n", "page_number": 161, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7486105173150919, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.7627191107310817, "height": 0.0141085934159898, "width": 0.19770253929866988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-9", "text": "On 30 April 2010, Curetis and Contexo entered into a collaboration and contract manufacturing agreement for\nthe manufacturing of a pilot line and the automated Unyvero Application Cartridge manufacturing line modules.\nUnder the terms of the agreement, Curetis receives drawings as well as documentation of the automated manu-\nfacturing line modules and components. Curetis has acquired ownership in all of the construction documents of\nthe pilot line whereas the copyright rights and all rights related to the Contexo index machine base technologies\n(\"Rundtakt- und L\u00e4ngstakt-Basistechnologien\") remain with Contexo. For the automated manufacturing line\nmodules Curetis will receive a full set of QA documentation, assembly drawings and wiring diagrams as well as\noperating manuals for all third-party components incorporated. Until 30 June 2015 all but two modules have\nbeen tested and fully accepted. The remaining manufacturing line modules are expected to be completed in due\ncourse and upon receipt of final QA documentation and site acceptance testing Curetis will make the remaining\noutstanding payments of less than \u20ac200 thousand in full.\n", "page_number": 161, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.1474989311671655, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-161-10", "text": "158\n", "page_number": 161, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-0", "text": "Commerz Real Mobilienleasing GmbH (\"Commerz Real\")\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5193470374848851, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.403869407496977}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-1", "text": "On 1 August 2012, Curetis has concluded a leasing agreement for three manufacturing line modules. The leasing\nperiod during which no termination is possible shall be 57 months and the total purchase costs are \u20ac690 thou-\nsand. Curetis has pledged one bank account as collateral. All payments under the leasing contract have been\nmade in due time. Under the terms of this agreement, Curetis is obligated to buy the equipment at the end of the\nleasing period at its residual value if so requested by Commerz Real. If Commerz Real does not make use of this\nright, then Commerz Real is entitled to offer the object to any other third party.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.0820863616930312, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-2", "text": "Joma-Polytec GmbH, Lease Agreement Bodelshausen Facility\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.21547669944420692, "height": 0.014108593415989718, "width": 0.43591293833131806}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-3", "text": "On 18 February 2010 Curetis and Joma-Polytec GmbH entered into a leasing agreement for about 1,600 sqm of\nmanufacturing, office and logistics space. Based on an amendment of the leasing agreement dated 14 June 2010\nthe leasing period did not commence until 1 September 2010. According to the amended leasing agreement the\nleasing term ends on 30 June 2020 and can be extended by an additional five year term at the request of Curetis.\nOtherwise it shall be automatically extended for an additional one year period, provided that it is not terminated\nby one of the parties at least six months prior to expiration. (see \"Risk Factors - Curetis has entered into a lease\nagreement for a manufacturing plant in which its laboratory facilities are located. The unexpected termination\nor non-renewal of this lease agreement could have a significant adverse effect on Curetis' business, financial\nposition and results of operations.\").\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.34544677212483965, "height": 0.12355707567336466, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-4", "text": "PCR Mastermix Supply Agreement\n", "page_number": 162, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.3587002992731937, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.37280889268918344, "height": 0.014108593415989745, "width": 0.24486094316807738}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-5", "text": "Effective as of January 1, 2010, Curetis entered into a supply agreement with a large single source supplier for\npurchase of PCR mastermix reagent and other product components, which are used as integral parts of Curetis\u2019\nApplication Cartridges. Pursuant to the agreement, Curetis has the right to resell such product components sup-\nplied under the agreement, except for the PCR mastermix, in conjunction and jointly repackaged with Curetis\u2019\nproducts worldwide. Further, the agreement provides that Curetis has the right to resell the mastermix repack-\naged and refilled for use only in conjunction with Curetis\u2019 products worldwide except in Australia, Canada,\nIsrael, Korea, Mexico and the US. In these exempted countries Curetis may acquire the right to resell the mas-\ntermix as described above, if (1) Curetis has been granted a license by the owner of the intellectual property\nrights for the use of the requisite intellectual property rights with respect to its relevant product in such country\nor (2) the protection of the respective intellectual property rights has expired in such country. A standard tem-\nplate agreement draft for obtaining such a license is readily available if and when needed. Curetis assumes costs\nfor such licenses of a one-time up-front payment of no more than US$500 thousand and on-going royalty pay-\nments in the amount of a mid-single digit percentage rate on net sales of relevant IP protected products. Pursuant\nto the existing mastermix supply agreement, Curetis, or any of its affiliates, are not permitted to resell any of the\nproduct components, including the mastermix, to third parties as stand-alone items for use other than in conjunc-\ntion with Curetis\u2019 products. Under the agreement, Curetis is subject to certain minimum annual purchase re-\nquirements. The supplier has a right to terminate the agreement on 180 days\u2019 notice if Curetis does not meet its\nminimum annual purchase requirements. The term of the supply agreement ends at the end of 2016 and shall be\nautomatically extended for additional one year periods, provided that it is not terminated by one of the parties at\nleast 180 days prior to expiration.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6532706284737068, "height": 0.2740487387772553, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-6", "text": "Distribution Agreements\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.6806327490380505, "height": 0.0141085934159898, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-7", "text": "Curetis uses its standard distribution agreement template for most of its Unyvero distribution partners, which\nspecifies the particular Unyvero product and the respective distribution territory. The distribution agreements\ntypically contain provisions for exclusive distribution within a particular territory and provide for a three to five\nyear term. During that period the distributor has exclusive rights to market, sell and distribute all Unyvero prod-\nucts under this agreement. In return each distributor needs to commit to annual minimum purchases of Unyvero\nSystems as well as Application Cartridges. Transfer prices for the Unyvero Systems and Application Cartridges\nare defined and reflect typical MDx industry distributor margins on the consumable sales. In case a distributor\nfails to meet its annual minimum commitments fixed in the contract Curetis has the right to either terminate such\nagreement in its entirety, or to terminate said distributor's territory exclusivity in such country. Each of these\nagreements can be extended by mutual agreement between the parties. Furthermore, the agreements also contain\ntypical change of control provisions which comprise a merger of the company, the sale of all assets or the liqui-\ndation of the company.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8516460025651988, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-8", "text": "Insurance\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8687473279179136, "lower_right_x": 0.20616686819830712, "lower_right_y": 0.880718255664814, "height": 0.01197092774690034, "width": 0.09068923821039902}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-9", "text": "Curetis maintains insurance to cover its potential exposure for a number of claims and losses, including public\nliability, product liability, transportation and business interruption insurance.\n", "page_number": 162, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8956819153484396, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9234715690466011, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-162-10", "text": "159\n", "page_number": 162, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-163-0", "text": "In addition, Curetis has obtained directors' and officers' liability insurance, which covers expenses, capped at a\ncertain amount, that Curetis' board members may incur in connection with their conduct as members of Curetis'\nboard of directors. Management believes that the insurance coverage Curetis has is adequate in light of the risks\nCuretis faces.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1368106028217187, "height": 0.051731509191962385, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-163-1", "text": "Legal Proceedings\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.17015818725951262, "height": 0.016673792218896977, "width": 0.16021765417170497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-163-2", "text": "There are no and there have been no governmental, legal or arbitration proceedings (including any such proceed-\nings which are pending or threatened of which Curetis is aware), during the previous twelve months which may\nhave, or have had in the recent past, significant effects on Curetis and/or Curetis' financial position or profitabil-\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.22530996152201796, "height": 0.04104318084651562, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-163-3", "text": "ity.\n", "page_number": 163, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22659256092347158, "lower_right_x": 0.13905683192261184, "lower_right_y": 0.2394185549380077, "height": 0.01282599401453613, "width": 0.02357920193470374}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-163-4", "text": "160\n", "page_number": 163, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-0", "text": "REGULATION\n", "page_number": 164, "bounding_box": {"top_left_x": 0.41717049576783555, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.10902094912355707, "height": 0.01710132535271483, "width": 0.1632406287787183}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-1", "text": "In each of the countries in which Curetis markets its products, it must comply with local regulations affecting,\namong other things, design and product standards, packaging requirements and labelling requirements. A sum-\nmary of the most important regulations is set out below.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.16631038905515177, "height": 0.04018811457887986, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-2", "text": "European Union\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.19709277469003847, "height": 0.016246259085079096, "width": 0.14570737605804113}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-3", "text": "In the EU, Curetis is currently required to comply with the local rules and regulations which implement the IVD\nDirective. The IVD Directive provides the regulatory framework for manufacturers who place IVD devices on\nthe EU market. Each member state of the EU (each, a \"Member State\") is required to implement the IVD Di-\nrective into its national legislation.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2116289012398461, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2659256092347157, "height": 0.0542967079948696, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-4", "text": "Additional European Directives, Regulations and local rules have to be followed to be in compliance with the\nregulations. This includes the Directive Waste Electrical and Electronic Equipment (WEEE 2012/19/EC), the\nDirective on Packaging and Waste (2013/2/EC), Regulation of Registration, Evaluation and Restriction of\nChemicals (REACH 1907/2006) and others.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.3270628473706712, "height": 0.053869174861051694, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-5", "text": "CE Conformity Mark\n", "page_number": 164, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.34159897392047883, "lower_right_x": 0.2672309552599758, "lower_right_y": 0.3557075673364686, "height": 0.014108593415989745, "width": 0.14993954050785974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-6", "text": "In order to demonstrate compliance with the essential requirements of the IVD Directive and to obtain the right\nto bear the CE-conformity mark (without which Curetis' products could not be marketed as IVDs in Europe),\neach of Curetis' products must undergo a conformity assessment procedure, which procedure varies according to\nthe type of device and its classification. For moderate-risk IVD devices (\"general IVDs\"), the conformity proce-\ndure involves the manufacturer issuing an EC Declaration of Conformity (a \"Conformity Declaration\") based\non a self-assessment of the conformity of its products with the relevant essential requirements of the IVD Di-\nrective and registering such Conformity Declaration with the governmental or regulatory body that is responsible\nfor regulating medical devices in the Relevant Member State (the \"Competent Authority\"). The Relevant\nMember State is usually the manufacturer's place of incorporation. For all other classifications of IVD devices, a\nconformity assessment procedure requires notification to a notified body in the Relevant Member State (a noti-\nfied body is an organisation accredited by the Relevant Member State to conduct conformity assessments) who\nwould typically audit and examine the quality system of the manufacturer, as well as design and validation of a\ndevice before issuing a certification demonstrating compliance with the relevant essential requirements of the\nIVD Directive.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5506626763574177, "height": 0.1885421120136811, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-7", "text": "Curetis' Unyvero Platform and the Unyvero Application are classified as \"general\" IVDs. Based on a self-\nassessment of the conformity of these products with the relevant essential requirements of the IVD Directive,\nCuretis issued a Conformity Declaration and registered these products with the German Competent Authority\n(BfArM; Federal Institute for Drugs and Medical Devices) as CE-IVD-marked IVDs for distribution in the EU\non 12 May 2012. Curetis is therefore entitled to bear the CE-conformity mark to the Unyvero Platform and the\nUnyvero Application Cartridges, which allows Curetis to market these products in the EU, as well as in countries\nrecognising CE-IVD-marked IVD devices (for further information, see \"Customers, marketing and sales -\nChannels to market\" above). As part of its strategy, Curetis intends, in general, to seek CE-IVD-mark status for\neach of its assays so that they can be marketed in the EU and the key countries where the CE-IVD-mark is ac-\ncepted.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6973065412569475, "height": 0.13681060282171875, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-8", "text": "The IVD Directive is due to be replaced by a new European Regulation governing the safety and performance of\nIVD Regulation which is currently expected to come into force in 2017, with a transitional period of compliance\nof between three and five years. Changes that are expected to be introduced by the IVD Regulation can be divid-\ned into two areas: technical, IVD-specific areas which cover the essential requirements, the classification system,\nthe conformity assessment procedures and clinical evidence requirements; and features, such as the designation\nand monitoring of notified bodies, as well as vigilance and market surveillance systems. The IVD Regulation is\ncurrently being considered by the European Council and thereafter its text will be subject to debate between the\nCouncil and the European Parliament. However, the changes that are anticipated to be brought into effect are\nexpected to impact all key IVD stakeholders operating in Europe.\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7041470713980333, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.827704147071398, "height": 0.12355707567336471, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-9", "text": "For manufacturers involved in the type of products developed and manufactured by Curetis, this may involve\ncomplying with a more stringent, time-intensive and costly set of requirements impacting the design and manu-\nfacturing of devices. Both new and pre-existing devices will need to comply with the requirements of the IVD\nRegulation. New clinical evidence requirements specific to the IVD sector are also expected with respect to the\nway a device works to provide a diagnosis. Curetis quality management system (for further information, see\n\"Quality management system\") has already taken these requirements into account in its development process,\nand Curetis therefore believes it is unlikely that the additional requirements for clinical evidence would signifi-\n", "page_number": 164, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9303120991876871, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-164-10", "text": "161\n", "page_number": 164, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-0", "text": "cantly impact the Unyvero Platform or Curetis' Application Cartridges which are currently on the market or\nunder development. Manufacturers of CE-IVD-marked assays that are currently on the market and which would\nnot meet the new requirements may have to provide additional information to their relevant Competent Authori-\nty.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-1", "text": "The change that will likely have the most significant impact on Curetis is the new classification system for IVDs.\nThis new classification system will likely be based on the classification system of the IMDRF (former GHTF)\nand is still in use for the classification of IVD different countries. Under the current IVD Directive, Curetis' Un-\nyvero Platform and the Application Cartridges (except for the P55 Application cartridges which are able to de-\ntect the \"Chlamydophila pneumoniae\" pathogen which needs to be certified by a notified body) are moderate-\nrisk IVD devices which do not require the involvement of a notified body in the certification process. However,\nthe new classification system defined in the IVD Regulation may change the risk classification for single target\nanalytes of the Curetis applications to a higher class that would require the services of a notified body to enable\nthem to be CE-IVD-marked. It can therefore be expected that the time to market for such assays, once the new\nIVD Regulation is in force, would be delayed by one to two quarters (on average) when compared to the current\nself-certification process. As the new IVD Regulation is unlikely to become effective earlier than the first quarter\nof 2017, Curetis intends to apply the self-certification process to CE-IVD-mark for its BC-G1 and ITI-G2 assays.\nFor assays that are currently expected to be launched in, or after, the first quarter of 2017, Curetis' current devel-\nopment timelines take into account the additional time needed for obtaining CE- mark status associated with\ncomplying with the requirements of the new IVD Regulation.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.3514322359982899, "height": 0.2116289012398461, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-2", "text": "The IVD Regulation also includes new labelling requirements, such as the development of a unique device iden-\ntification (UDI) system, to make devices more traceable. Management believes that these new labelling require-\nments will have minimal impact on Curetis' products, as Curetis' quality management system is prepared to inte-\ngrate these new requirements into Curetis' products in order to help ensure a smooth transition upon the imple-\nmentation of the IVD Regulation.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42667806755023513, "height": 0.06797776827704144, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-3", "text": "As a manufacturer of CE-IVD-marked medical devices sold on the European market, Curetis must also maintain\na vigilance system that enables it to notify relevant regulatory authorities of incidents which may lead to (or may\nhave led to) death or serious injury/health consequences for individuals, or a recall of the relevant product. This\nincludes obligations to submit reports to the relevant national Competent Authority (or Authorities) for recording\nand evaluation when incidents (comprising any malfunction or deterioration in the characteristics and/or perfor-\nmance of a device, as well as any inadequacy in the labelling or the instructions for use which, directly or indi-\nrectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterio-\nration in their state of health) occur, for the dissemination of information which could be used to prevent a recur-\nrence of the incident or to alleviate the consequences of such incidents, and where appropriate, by the implemen-\ntation of a \"Field Safety Corrective Action\" to reduce the risk of death or serious injury associated with the use\nof the device (such as a product recall).\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5840102607952117, "height": 0.15006412997007273, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-4", "text": "Research Use and Clinical Investigations\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.40507859733978235, "lower_right_y": 0.6122274476271911, "height": 0.01410859341598969, "width": 0.28960096735187424}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-5", "text": "In the EU, subject to certain restrictions set out in the Active Implantable Medical Devices Directive (Directive\n90/385/EC), the Medical Devices Directive (Directive 93/42/EC), the In-Vitro Diagnostic Medical Devices (Di-\nrective 98/79/EC) and the local laws and regulations implementing these Directives in each Member State, de-\nvices without the CE-conformity mark may be used for clinical investigations, for example for the purposes of\ndetermining whether the particular device will meet the requirements of the IVD Directive and the Medical De-\nvices Directive.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6977340743907653, "height": 0.07909362975630607, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-6", "text": "United States\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.2351874244256348, "lower_right_y": 0.728516460025652, "height": 0.01410859341598969, "width": 0.11970979443772671}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-7", "text": "In the US, IVDs are medical devices as defined in section 201(h) of the Federal Food, Drug and Cosmetic Act\n1938, as amended, and may also be biological products subject to section 351 of the Public Health Service Act\n1944. Like other medical devices, IVDs are subject to premarket and post market controls as defined in the US\nCode of Federal Regulations, including 21CFR820, Quality System Regulation. Clinical laboratories running\nIVDs are subject to the Clinical Laboratory Improvement Amendments of 1988 (CLIA).\n", "page_number": 165, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8140230867892262, "height": 0.06883283454467726, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-8", "text": "Requirement for Premarket Notification or Approval\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8272766139375801, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.8413852073535699, "height": 0.0141085934159898, "width": 0.3730350665054413}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-9", "text": "IVDs are classified in one of three classes (Class I, II or III) depending on risk and the extent of controls the\nFDA determines are necessary to reasonably ensure their safety and efficacy. The classification of an IVD de-\ntermines the appropriate premarket process.\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8892689183411714, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-10", "text": "\uf0b7   Class I: general controls, such as registration, listing, labelling and adherence to quality system regula-\n    tions; generally exempt from the premarket notification (510(k)) requirement;\n", "page_number": 165, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8991021804189825, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9256092347156905, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-165-11", "text": "162\n", "page_number": 165, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-0", "text": "Class II: general controls, and special controls such as performance standards, patient registries and/or\npost-market surveillance; generally subject to 510(k) requirements; and\n", "page_number": 166, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12227447627191107, "height": 0.03719538264215476, "width": 0.7164449818621524}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-1", "text": "\uf0b7\n", "page_number": 166, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.08849935870029928, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.09576742197520308, "height": 0.007268063274903799, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-2", "text": "\uf0b7      Class III: general controls; generally subject to PMA requirements.\nPursuant to the 510(k) process, a person who wants to market certain Class I, most Class II (or some Class III)\ndevices intended for human use in the US must submit a 510(k) premarket notification to the FDA at least 90\ndays before marketing the device (unless the device is exempt from the 510(k) requirements). The FDA will then\nreview the 510(k) premarket notification and determine whether the proposed device is \"substantially equiva-\nlent\" to a previously cleared 510(k) device, a device which has been reclassified from Class III to Class II or I, or\na device that was in commercial distribution before 28 May 1976, for which the FDA has not yet called for the\nsubmission of PMA applications, referred to as a \"predicate\" device. The type of studies required to demonstrate\nsubstantial equivalence may include the following:\n\uf0b7      in the majority of cases, analytical studies using clinical samples (sometimes supplemented by carefully\n       selected artificial samples) will suffice;\n\uf0b7      for some IVDs, the link between analytical performance and clinical performance is not well defined. In\n       these circumstances, clinical information may be required. Where clinical information is required, the\n       producer must (unless a relevant exemption applies) apply for an investigational device exemption\n       (\"IDE\"), which would allow the investigational device to be used in a clinical study in order to collect\n       safety and effectiveness data; and\n\uf0b7      for microbiological multiplexed PCR based tests like the LRT application, the FDA issued a guidance\n       document on 27 August 2014 ( Guidance for Industry and Food and Drug Administration Staff: Highly\n       Multiplexed Microbiological / Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devic-\n       es). Following this guidance, the sample set for the Curetis LRT application requires at least 1500 pro-\n       spective clinical patient samples to determine specificity.\nIn making its determination, the FDA compares the proposed device to the predicate device. If the two devices\nhave the same intended use and the same technological characteristics, or the same intended use and different\ntechnological characteristics, but the information submitted to FDA does not raise new questions of safety and\neffectiveness and demonstrates that the device is at least as safe and effective as the predicate, the device may be\ncleared for marketing. 510(k) submissions generally include, among other things, a description of the device, its\nintended use and its manufacturing, device labelling, medical devices to which the device is substantially equiva-\nlent, safety and biocompatibility information and the results of performance testing. Marketing may commence\nonly when the FDA issues a clearance letter finding the proposed device to be substantially equivalent to the\npredicate. If the device is not found to be substantially equivalent, a reclassification process could be requested\nby the applicant. After a device receives 510(k) clearance, any product modification that could significantly\naffect the safety or effectiveness of the product, or any product modification that would constitute a significant\nchange in intended use, requires a new 510(k) clearance or PMA. If the FDA determines that the non-exempt\nproduct does not qualify for 510(k) clearance the FDA must approve a PMA before the product can be marketed\nin the United States.\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6361693031209918, "height": 0.5134672937152629, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-3", "text": "The FDA has implemented more stringent clinical investigation and PMA requirements for devices that are\nclassified as Class III. Pursuant to the PMA process, the relevant person who wants to market the device in the\nUS would be required to provide clinical and laboratory data that establishes that the new device is safe and\neffective using clinical outcome measures rather than proving substantial equivalence to another legally market-\ned product or pre-amendment device. Information about the device and its components, device design, manufac-\nturing and labelling, among other information, must also be included in the PMA. As part of the PMA review,\nthe FDA will inspect the device manufacturer's facilities for compliance with quality system regulation, or QSR,\nrequirements, which govern design, testing, control, documentation and other aspects of quality assurance with\nrespect to manufacturing. The FDA will approve the new device for commercial distribution if it determines that\nthe data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance\nthat the device is safe and effective for its intended use(s). The PMA can include post-approval conditions in-\ncluding, among other things, restrictions on labelling, promotion, sale and distribution, or requirements to do\nadditional clinical studies post approval. Even after approval of a PMA, a new PMA or PMA supplement is\nrequired to authorise certain modifications to the device, its labelling or its manufacturing process. After a device\nis cleared, or approved for marketing by the FDA, numerous and pervasive regulatory requirements continue to\napply. These include compliance with, but are not limited to:\n", "page_number": 166, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8619067977768277, "height": 0.21932449764856776, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-4", "text": "regulation on registration of the manufacturer and listing of the IVD devices in the FDA database when\nstarting commercial distribution;\n", "page_number": 166, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.8717400598546388, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.8982471141513467, "height": 0.026507054296707966, "width": 0.7146311970979444}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-5", "text": "\uf0b7\n", "page_number": 166, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8730226592560923, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.8811457887986319, "height": 0.008123129542539576, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-166-6", "text": "163\n", "page_number": 166, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-0", "text": "\uf0b7   the QSR, which governs, among other things, how manufacturers design, test, manufacture, exercise\n    quality control over and document manufacturing of their products;\n\uf0b7   Part 11 compliance with FDA required e-records of documents in the manufacturer's quality system de-\n    fined as \"in scope\";\n\uf0b7   labelling and claims regulations, which prohibit the promotion of products for unapproved or \"off-label\"\n    uses and impose other restrictions on labelling;\n\uf0b7   advertising and promotion in accordance with the requirements of the FD&C Act and its implementing\n    regulations and FDA guidance, including FDA guidance on off-label dissemination of information and\n    responding to unsolicited requests for information;\n\uf0b7   Medical Device Reporting regulation, which requires reporting to the FDA certain adverse experiences\n    associated with the use of the product;\n\uf0b7   complaint handling regulations designed to track, monitor and resolve complaints related to the Compa-\n    ny's products;\n\uf0b7   in some cases, on-going monitoring of the Company's products' performance and periodic reporting to the\n    FDA of such performance results; and\n\uf0b7   the federal Physician Sunshine Payment Act and various state laws on reporting remunerative relation-\n    ships with healthcare customers.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.37280889268918344, "height": 0.28772979905942714, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-1", "text": "If a relevant person wants to market a device in the US and wants to test it in a clinical study in the US prior to\nobtaining 510(k) or PMA approval, that person will have to obtain an approved IDE unless the device is exempt.\nAn approved IDE allows an investigational device to be used in a clinical study in order to collect safety and\neffectiveness data to support a PMA or 510(k) clearance application.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4343736639589568, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-2", "text": "Research Use Only in the United States (\"RUO\")\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4510474561778538, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.4630183839247542, "height": 0.011970927746900395, "width": 0.3391777509068924}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-3", "text": "In the US, certain IVD products may also be sold (subject to certain restrictions) as research use only (RUO)\nproducts, without 510(k) clearance or PMA approval. Producers selling RUO IVD products must prominently\nlabel them: For Research Use Only. Not for use in diagnostic procedures.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5113296280461735, "height": 0.03976058144506195, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-4", "text": "Investigational Use Only (\"IUO\")\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.35066505441354295, "lower_right_y": 0.539546814878153, "height": 0.013253527148353927, "width": 0.23518742442563484}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-5", "text": "In the US, certain IVD products may also be sold (subject to certain restrictions) as IUO products, without\n510(k) clearance or PMA approval. Certain IUO-labelled products are exempt from the IDE regulation. Any\nIUO product that is being shipped or delivered for product testing prior to full commercial marketing must be\nprominently labelled: \"For Investigational Use Only. The performance characteristics of this product have not\nbeen established.\".\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6122274476271911, "height": 0.06541256947413421, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-6", "text": "Emergency Use Authorisation (EUA)\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.37726723095526, "lower_right_y": 0.6430098332620778, "height": 0.0141085934159898, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-7", "text": "Under section 564 of the FD&C Act, the FDA Commissioner may allow unapproved medical products or unap-\nproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or\nlife-threatening diseases or conditions caused by chemical, biological, radiological and nuclear (CBRN) threat\nagents when there are no adequate, approved, and available alternatives.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7045746045318512, "height": 0.05515177426250528, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-8", "text": "Clinical Laboratory Improvement Amendments of 1988 (\"CLIA\")\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.5701330108827086, "lower_right_y": 0.731936725096195, "height": 0.0141085934159898, "width": 0.4546553808948005}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-9", "text": "CLIA establishes quality standards for laboratory testing and a certification programme for clinical laboratories\nin the US. CLIA requirements vary according to the technical complexity in the testing process and risk of harm\nin reporting erroneous results. These regulations established three categories of testing on the basis of the com-\nplexity of the testing methodology:\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7935014963659683, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-10", "text": "\uf0b7   waived tests (these are tests that can be operated outside of specialised, dedicated laboratory environ-\n    ments and without the need for technically specialised and highly trained staff);\n\uf0b7   tests of moderate complexity, and\n\uf0b7   tests of high complexity.\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8721675929884566, "height": 0.06883283454467715, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-11", "text": "Producers of IVDs apply for CLIA categorisation of their IVDs during the premarket process. Under CLIA,\nlaboratories performing only waived tests are subject to less regulation, whereas laboratories performing moder-\nate or high complexity tests are subject to more stringent laboratory standards governing certification, personnel,\n", "page_number": 167, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8785805899957246, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-167-12", "text": "164\n", "page_number": 167, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-0", "text": "proficiency testing, patient test management, quality assurance, quality control, and inspections, among other\nrequirements.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-1", "text": "Curetis and US Regulation\n", "page_number": 168, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.12612227447627192, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.1874244256348247}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-2", "text": "Management believes that the Unyvero Platform will fall into FDA classifications that require the submission of\na premarket notification 510(k). This assessment was based on FDA feedback. The Curetis LRT application is\nexpected to require a de novo 510(k) submission. Currently, none of Curetis' products have received 510(k)\nclearance or PMA approval. Curetis assumes that it will require clinical data to support a 510(k) clearance appli-\ncation for the Unyvero Platform with the LRT application and will submit a de novo 510(k) by Q4 2016.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.21547669944420692, "height": 0.0688328345446772, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-3", "text": "The product concepts were well received by the FDA during a pre-submission meeting in June 2011. The Agen-\ncy laid down the regulatory pathway and provided detailed feedback regarding the planned clinical trial design\nespecially for the planned molecular comparator methods. In May 2012 a face to face meeting with the FDA\ntook place to discuss additional details directly with an FDA expert group. Based on the FDA feedback Curetis'\nclinical trial has been started and evolved and amended to comply with the most recent FDA guideline on multi-\nplex infectious disease tests (issued in August 2014). The data collected within the European pre-and post-\nmarket trials should also be used to support the US- Submission.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31765711842667804, "height": 0.09576742197520305, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-4", "text": "Other Territories\n", "page_number": 168, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3317657118426678, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.34544677212483965, "height": 0.013681060282171864, "width": 0.15477629987908104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-5", "text": "In accordance with Curetis' commercialisation strategy, Curetis will develop a country specific regulatory strate-\ngy for countries outside of the EU and the US (including but not limited to China, Hong Kong, Taiwan, Singa-\npore, Thailand, Indonesia, Malaysia, Russia, and the Middle East as well as potential further RoW markets going\nforward). Some of these target countries require samples from their local population to be included in clinical\nstudies used to support product registration applications. Curetis with potential future collaboration and distribu-\ntion partners, therefore, intends to conduct either individual national or even multinational clinical studies (which\nlook at samples from each of the target countries, where possible) and multi-country regulatory auditing to gain\nmaximum efficiency in product registrations in countries outside of the EU and the US.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4719965797349295, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-6", "text": "Regulation of End Users\n", "page_number": 168, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.32769044740024184, "lower_right_y": 0.5027789653698161, "height": 0.014108593415989745, "width": 0.21221281741233372}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-7", "text": "In general, users of any diagnostic platform are required to respect local laws and regulations when providing\nhealthcare services, including performing diagnostic activities. For example, in a number of jurisdictions an\nISO15189 accreditation needs to be obtained on a test-by-test basis to qualify for reimbursement. The norm\nrequires laboratories to have a Quality Management System. As most laboratories have a Quality Management\nSystem in place, the amount of work to obtain ISO15189 accreditation for Unyvero is considered limited given\nthe sample-to-result nature of the platform. However, Curetis will provide guidelines to customers to allow then\nto be able to comply with the internal and external laboratory standards based on the feedback by the German\nMedical association.\n", "page_number": 168, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6233433091064557, "height": 0.10731081658828556, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-168-8", "text": "165\n", "page_number": 168, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-0", "text": "MANAGEMENT, EMPLOYEES AND CORPORATE GOVERNANCE\n", "page_number": 169, "bounding_box": {"top_left_x": 0.13603385731559856, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.7297460701330108}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-1", "text": "General\n", "page_number": 169, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.12612227447627192, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.013253527148353983, "width": 0.07073760580411124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-2", "text": "Set out below is a summary of certain information concerning the Management Board, the Supervisory Board,\nCuretis' employees and corporate governance. It is based on relevant provisions of Dutch law as in effect on the\ndate of this Prospectus, the Articles of Association, the Management Board Rules, the Supervisory Board Rules\nand the Committee Rules (all as defined below). This section summarises the Articles of Association as to be\namended pursuant to the Deed of Amendment (as defined below) immediately after determination of the Offer\nPrice and reflects the (envisaged) governance structure and related arrangements as per that moment.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2381359555365541, "height": 0.08123129542539548, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-3", "text": "This summary does not purport to give a complete overview and should be read in conjunction with, and is\nqualified in its entirety by reference to the relevant provisions of Dutch law as in force on the date of this\nProspectus and the Articles of Association, the Management Board Rules and the Supervisory Board Rules as in\neffect upon Conversion. The Articles of Association in the governing Dutch language and in an unofficial\nEnglish translation thereof are available on the Company\u2018s website (www.curetis.com), the Management Board\nRules, the Supervisory Board Rules and the Committee Rules in the English language (only) will be available\nimmediately after Conversion.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24583155194527576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34074390765284307, "height": 0.09491235570756731, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-4", "text": "Management Structure\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.3715262932877298, "height": 0.016246259085079096, "width": 0.2031438935912938}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-5", "text": "The Company has a two-tier board structure consisting of the Management Board (bestuur) and the Supervisory\nBoard (raad van commissarissen).\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3860624198375374, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4125694741342454, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-6", "text": "The Management Board is among other things responsible for the day-to-day management, formulating\nstrategies and policies, and setting and achieving the Company's objectives. The Supervisory Board supervises\nand advises the Management Board.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4608807182556648, "height": 0.04061564771269771, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-7", "text": "Management Board\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.28960096735187424, "lower_right_y": 0.4916631038905515, "height": 0.016673792218896977, "width": 0.17412333736396612}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-8", "text": "Responsibility, powers and functioning\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.519880290722531, "height": 0.01410859341598969, "width": 0.2714631197097944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-9", "text": "The Management Board is responsible for the management of Curetis' operations, subject to the supervision of\nthe Supervisory Board. The Management Board's responsibilities include, among other things, defining and\nattaining the Company's objectives, determining the Company's strategy and risk management policy, and day-\nto-day management of the Company's operations. The Management Board may perform all acts necessary or\nuseful for achieving the Company's objectives, with the exception of those acts that are prohibited by law or by\nthe Articles of Association. Pursuant to the Management Board Rules, the Managing Directors will divide their\ntasks among themselves in mutual consultation, subject to the approval of the Supervisory Board. In performing\ntheir duties, the Managing Directors must carefully consider and act in accordance with the interests of the\nCompany and the business connected with it, taking into consideration the interests of all the stakeholders of\nCuretis (which includes but is not limited to its customers, its employees and the Shareholders).\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6631038905515177, "height": 0.13681060282171864, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-10", "text": "The Management Board shall timely provide the Supervisory Board with all information necessary for the\nexercise of the duties of the Supervisory Board. The Management Board is required to notify the Supervisory\nBoard in writing of the main features of the Company\u2018s strategic policy, general and financial risks and\nmanagement and control systems, at least once per year. The Management Board must submit certain important\ndecisions to the Supervisory Board and/or the General Meeting for approval, as more fully described below.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6699444206926036, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7387772552372809, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-11", "text": "Subject to certain statutory exceptions, the Management Board as a whole is authorised to represent the\nCompany. Each Managing Director, acting jointly with another Managing Director, has the authority to represent\nthe Company. In addition, pursuant to the Articles of Association, the Management Board is authorised to\nappoint proxy holders (procuratiehouders) who are authorised to represent the Company within the limits of the\nspecific delegated powers provided to them in the proxy.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8140230867892262, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-12", "text": "Management board rules\n", "page_number": 169, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8272766139375801, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.8413852073535699, "height": 0.0141085934159898, "width": 0.1777509068923821}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-13", "text": "Pursuant to the Articles of Association, the Management Board may adopt rules of procedure that regulate\ninternal matters concerning its functioning and internal organisation (the \"Management Board Rules\"). The\nManagement Board Rules will be in effect upon Conversion and require the approval of the Supervisory Board.\n", "page_number": 169, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8892689183411714, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-169-14", "text": "166\n", "page_number": 169, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-0", "text": "Composition, appointment and removal\n", "page_number": 170, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3935912938331318, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.2744860943168077}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-1", "text": "The Articles of Association provide that the Management Board shall consist of two or more members and that\nthe Supervisory Board determines the exact number of Managing Directors after consultation with the\nManagement Board. As of the date of the Conversion, the Management Board will consist of four Managing\nDirectors.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1573321932449765, "height": 0.051731509191962385, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-2", "text": "The General Meeting appoints the Managing Directors. The Supervisory Board shall make a non-binding\nnomination in case a Managing Director is to be appointed. The nomination must be included in the notice of the\nGeneral Meeting at which the appointment will be considered. If no nomination has been made, which is also\nconsidered to be the case if the Supervisory Board's vote on the nomination ties, this must be stated in the notice.\nHowever, the General Meeting is not bound by a nomination and may appoint a Managing Director at its\ndiscretion, provided a proposal to appoint another person has been put on the agenda of the relevant General\nMeeting or, failing that, the entire issued capital is represented at the General Meeting and the resolution to\nappoint the alternative Managing Director has been adopted unanimously. The Supervisory Board may appoint\none of the Managing Directors as chief executive officer, or grant any other title to a Managing Director.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2902949978623343, "height": 0.1231295425395468, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-3", "text": "A resolution of the General Meeting to appoint a Managing Director in accordance with the nomination of the\nSupervisory Board shall be adopted by an absolute majority of the votes cast. A resolution of the General\nMeeting to appoint a Managing Director other than in accordance with a nomination of the Supervisory Board,\nbut in accordance with the agenda for such General Meeting, shall require an absolute majority of the votes cast\nrepresenting at least a third of the Company's issued share capital.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3655408294142796, "height": 0.06840530141085938, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-4", "text": "The General Meeting may at any time, at the proposal of the Supervisory Board, suspend or dismiss a Managing\nDirector. Should the General Meeting wish to suspend or dismiss a Managing Director other than in accordance\nwith a proposal of the Supervisory Board, such suspension or dismissal needs to be adopted by an absolute\nmajority of the votes cast, representing at least a third of the Company's issued capital. The Supervisory Board\nmay at all times suspend but not dismiss a Managing Director. A General Meeting must be held within three\nmonths after a suspension of a Managing Director has taken effect, in which meeting a resolution must be\nadopted to either terminate or extend the suspension, for a maximum period of another three months. The\nsuspended Managing Director must be given the opportunity to account for his or her actions at that meeting. If\nneither such resolution is adopted nor the General Meeting has resolved to dismiss the Managing Director, the\nsuspension will cease after the period of suspension has expired.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5096194955109021, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-5", "text": "Term of appointment\n", "page_number": 170, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5228730226592561, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.5369816160752459, "height": 0.0141085934159898, "width": 0.14993954050785974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-6", "text": "The Managing Directors will be appointed for a term of not more than four years. A Managing Director may be\nreappointed for a term of not more than four years at a time. The Supervisory Board has prepared a resignation\nschedule for the Managing Directors which is reflected in the right hand column labelled 'Term' of the table\nunder the heading \"\u2013 Managing Directors\" below.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5433946130825139, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5985463873450192, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-7", "text": "Meetings and decision-making\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6117999144933732, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.6259085079093629, "height": 0.01410859341598969, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-8", "text": "Pursuant to the Management Board Rules, the Managing Directors shall endeavour to achieve that resolutions\nare as much as possible adopted unanimously. Where unanimity cannot be reached and the law and the Articles\nof Association or the Management Board Rules do not prescribe a larger majority, resolutions of the\nManagement Board are adopted by a majority vote. In the event of a tied vote, the resolution will be decided on\nby the Supervisory Board.\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-9", "text": "Pursuant to the Articles of Association, the Management Board shall furthermore require the approval of the\nSupervisory Board for a number of resolutions which include:\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7079948696023942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.735356990166738, "height": 0.027362120564343728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-10", "text": "\uf0b7   the issue and acquisition of any of the Company's shares or debt instruments, or of debt instruments is-\n    sued by a limited partnership or general partnership of which the Company is a fully liable partner;\n\uf0b7   the application or the withdrawal for quotation in the listing on any stock exchange of the Company's\n    shares or debt instruments, or of debt instruments issued by a limited partnership or general partnership of\n    which the Company is a fully liable partner;\n\uf0b7   the entry into or termination of a long-term cooperation of the Company or a dependent company with\n    another legal entity or company or as fully liable partner in a limited partnership or general partnership, if\n    such cooperation or termination is of major significance to the Company;\n\uf0b7   the participation for a value of at least one-fourth of the amount of the issued capital with the reserves\n    according to the most recent adopted balance sheet (whether consolidated or not) with explanatory notes\n    of the Company or by a dependent company in the capital of another company, as well as a significant in-\n    crease or reduction of such a participation;\n", "page_number": 170, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7451902522445489, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9333048311244121, "height": 0.18811457887986316, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-170-11", "text": "167\n", "page_number": 170, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-0", "text": "\uf0b7     investments involving an amount equal to at least the sum of one-fourth of the Company's issued capital\n      plus the reserves as shown in its most recent adopted balance sheet (whether consolidated or not);\n\uf0b7     a proposal to amend the Articles of Association;\n\uf0b7     a proposal to dissolve (ontbinden) the Company;\n\uf0b7     a proposal to conclude a legal merger (juridische fusie) or a demerger (splitsing);\n\uf0b7     application for bankruptcy (faillissement) or for suspension of payments (surs\u00e9ance van betaling);\n\uf0b7     the termination of the employment of a considerable number of employees of the Company or of a de-\n      pendent company at the same time or within a short period of time;\n\uf0b7     far-reaching changes in the employment conditions of a significant number of employees of the Company\n      or of a dependent company; or\n\uf0b7     a proposal to reduce the issued share capital.\nDutch law and the Articles of Association provide that decisions of the Management Board involving a\nsignificant change in the Company's identity or character are subject to the approval of the General Meeting.\nSuch changes include in any event:\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3386062419837537, "height": 0.2535271483539974, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-1", "text": "\uf0b7   the transfer of all or substantially all of the Company's business to a third party;\n\uf0b7   the entry into or termination of a long-term cooperation with other legal entities or companies, or as a\n    fully liable partner in a limited partnership or a general partnership, if such cooperation or termination\n    thereof is of material significance to the Company; or\n\uf0b7   the acquisition or disposal by the Company or Curetis AG of a participation in the capital of a company\n    with a value of at least one-third of the sum of the assets of the Company according to the Company's\n    consolidated balance sheet including the explanatory notes in its last adopted annual accounts.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4583155194527576, "height": 0.10987601539119285, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-2", "text": "In addition, pursuant to the Articles of Association, the Supervisory Board may determine that other resolutions\nof the Management Board are subject to its approval, such resolutions must be clearly defined in a resolution\nadopted by the Supervisory Board and should be notified to the Management Board.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.5061992304403591, "height": 0.04147071398033342, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-3", "text": "Pursuant to the Articles of Association and the Management Board Rules, resolutions can also be adopted with-\nout holding a meeting, provided those resolutions are adopted in writing or in a reproducible manner by electron-\nic means of communication and all Managing Directors entitled to vote have consented to adopting the resolu-\ntions outside a meeting.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5677640017101325, "height": 0.051731509191962344, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-4", "text": "In each of the abovementioned situations, the lack of approval (whether of the General Meeting or of the Super-\nvisory Board) does not affect the authority of the Management Board or the Managing Directors to represent the\nCompany.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6182129115006413, "height": 0.04061564771269777, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-5", "text": "Conflict of interest\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.645575032064985, "height": 0.013253527148353927, "width": 0.13603385731559853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-6", "text": "The laws of the Netherlands provide that a managing director of a Dutch public company with limited liability\n(naamloze vennootschap), such as the Company (after the Conversion), may not participate in the adoption of\nresolutions (including deliberations in respect of these) if he or she has a direct or indirect personal interest con-\nflicting with the interests of the company. Such a conflict of interest only exists if in the situation at hand the\nManaging Director is deemed to be unable to serve the Company's interests and its connected business with the\nrequired level of integrity and objectivity. Pursuant to the Management Board Rules, each Managing Director\nshall immediately report any (potential) personal conflict of interest concerning a Managing Director to the\nchairman of the Supervisory Board and to the other Managing Directors and shall provide all information rele-\nvant to the conflict.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.7729799059427106, "height": 0.12013681060282178, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-7", "text": "If no resolution can be adopted by the Management Board as a consequence of such a personal conflict of inter-\nest, the resolution concerned will be adopted by the Supervisory Board. All transactions in which there are con-\nflicts of interests with Managing Directors will be agreed on terms that are customary in the sector concerned\nand disclosed in the Company's annual report.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8371098760153912, "height": 0.05429670799486963, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-8", "text": "The existence of a (potential) personal conflict of interest does not affect the authority to represent the Company,\nas described under \"\u2013 Responsibilities, powers and functioning\" above. Each time when a resolution is adopted\nwhile one or more of the Managing Directors had a conflict of interest, the Management Board will afterwards\ninform the General Meeting and the Supervisory Board thereof and will indicate how they have dealt with such a\nconflict of interest.\n", "page_number": 171, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9097905087644292, "height": 0.06541256947413421, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-171-9", "text": "168\n", "page_number": 171, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-0", "text": "Managing directors\n", "page_number": 172, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.1402660217654172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-1", "text": "At the date of this Prospectus, the Management Board is composed of the following four members who will be\nre-appointed upon the Conversion:\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.13296280461735785, "height": 0.027362120564343742, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-2", "text": "                                           Date of Appoint-\n    Name          Age       Position            ment1               Term\nOliver Schacht,          Chief Executive                      until 31 December\n     PhD          45         Officer            2015                 2018\n                         Chief Operating\nJohannes Bacher   46         Officer             2015         until 30 June 2019\n                        Chief Technology\n Andreas Boos     55         Officer            2015          until 30 June 2019\n                        Chief Commercial                      until 31 December\nDr. Achim Plum    47         Officer            2015                 2018\n", "page_number": 172, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.13894826849080805, "lower_right_x": 0.8712212817412334, "lower_right_y": 0.31252672082086363, "height": 0.1735784523300556, "width": 0.7503022974607013}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-3", "text": "1\n The appointment of the Management Board has taken place as of the date of incorporation of the Company and the re-appointment of the Management Board\nwill take place as of the date of the Conversion.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3159469858914066, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3420265070542967, "height": 0.02607952116289014, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-4", "text": "The Company's registered address, Max-Eyth-Stra\u00dfe 42, 71088 Holzgerlingen, Germany, serves as the business\naddress for the Managing Directors (see \"Description of Share Capital \u2013 General\" below).\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3762291577597264, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-5", "text": "Oliver Schacht\n", "page_number": 172, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3826421547669944, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.39333048311244123, "height": 0.010688328345446807, "width": 0.10640870616686819}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-6", "text": "Mr. Oliver Schacht, an expert in the diagnostics industry, has been CEO of Curetis AG since April 2011 and\nprior to that was a Supervisory Board member of Curetis AG from mid-2010 to end of the first quarter of 2011.\nHe was a co-founder and CFO of Epigenomics AG in Berlin and CEO of the US subsidiary Epigenomics Inc.\n(Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies\nand financing measures (including an IPO), as well as in finance, M&A transactions and alliance negotiations.\nDuring his time at Epigenomics AG (1999-2011) he headed all central business functions, including corporate\nfinance, investor relations, PR, marketing and business development at the Berlin headquarters. Mr. Schacht\nobtained his Diploma in European Business Administration at the European School of Business in Reutlingen\nand London in 1994 as well as a master's degree and a PhD at the University of Cambridge (UK). During his\ntime at Mercer Management Consulting (1995-1999), he worked on projects in the fields of M&A, growth strat-\negies and reorganisation in the pharmaceutical, biotechnology and other industries.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4031637451902522, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5540829414279607, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-7", "text": "Johannes Bacher\n", "page_number": 172, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5604959384352287, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.5737494655835828, "height": 0.013253527148354038, "width": 0.12031438935912937}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-8", "text": "Mr. Johannes Bacher combines 20 years of R&D and managerial experience with extensive expertise in the\nfields of international project management, finance, human resources, legal affairs and the design of\norganisational structures. Hence, the Curetis co-founder is ideally suited to managing all R&D operations and\nclinical trials of Curetis. Mr. Bacher has a degree in Electrical Engineering (Dipl. Ing.) and has already worked\nfor several international medical technology companies, including Hewlett Packard, Agilent and Philips Medical\nSystems.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6635314236853356, "height": 0.08251389482684901, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-9", "text": "Andreas Boos\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6712270200940573, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.6840530141085934, "height": 0.012825994014536102, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-10", "text": "With over 25 years of professional experience at Hewlett Packard, Agilent and Philips, Curetis co-founder Mr.\nAndreas Boos boasts a wealth of international experience in developing and implementing solutions for patient\nmonitoring and on-site molecular diagnostics. As a graduate Electrical Engineer (Dipl. Ing.), Mr. Boos has\nsuccessfully applied his project management skills to lead the development of several innovative and\ncommercially successful medical devices for the global markets. In addition to his extensive knowledge of\ncustomer requirements, Mr. Boos brings to Curetis a comprehensive understanding of quality systems, standards\nand global regulatory approval procedures. At Curetis he holds overall responsibility for manufacturing as well\nas continuous product improvements.\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6908935442496793, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8003420265070543, "height": 0.10944848225737502, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-11", "text": "Dr. Achim Plum\n", "page_number": 172, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8101752885848653, "lower_right_x": 0.23035066505441354, "lower_right_y": 0.8208636169303121, "height": 0.010688328345446751, "width": 0.11426844014510278}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-12", "text": "Dr. Achim Plum joined Curetis in 2015 as Chief Commercial Officer overseeing all commercial activities\nincluding global marketing and sales, business development and medical affairs. He joined from a senior\nmanagement position with Siemens where he was responsible for the assessment and development of novel\napproaches to the in vitro diagnostics market. Prior to Siemens, Dr. Plum worked for eight years with the\npublicly traded German-American molecular diagnostics company Epigenomics AG, most recently as Senior\nVice President Business and Strategy. At Epigenomics he built sales and marketing teams and distribution\nnetworks in Europe and the U.S., negotiated strategic commercial agreements with leading diagnostics industry\n", "page_number": 172, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9251817015818726, "height": 0.09448482257374946, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-172-13", "text": "169\n", "page_number": 172, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-0", "text": "players and led Curetis' corporate communications and compliance functions. Following undergraduate studies\nat the University of Bonn (Germany) and the University of East Anglia in Norwich (UK), Dr. Plum obtained his\nPhD in Molecular Genetics from the University of Bonn in 1999 for developing and studying novel genetic\nmodels of human diseases.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1368106028217187, "height": 0.051731509191962385, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-1", "text": "Supervisory Board\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.28355501813784767, "lower_right_y": 0.17015818725951262, "height": 0.016673792218896977, "width": 0.16807738814993956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-2", "text": "Responsibility, powers and functioning\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.19837537409149208, "height": 0.014108593415989745, "width": 0.2714631197097944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-3", "text": "The Supervisory Board is responsible for supervising the conduct and policies of the Management Board and of\nthe general course of affairs of the Company and its business enterprise. The Supervisory Board also provides\nadvice to the Management Board.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.24625908507909364, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-4", "text": "In performing their duties, the Supervisory Directors are required to be guided by the interests of the Company\nand its business enterprise, taking into account the interests of Curetis' stakeholders (which include but are not\nlimited to Curetis' employees and the Shareholders). The Supervisory Board will also observe the corporate\nsocial responsibility issues that are relevant to Curetis' business. The Supervisory Board is responsible for the\nquality of its own performance. The Supervisory Board may, at the Company's expense, seek the advice which it\ndeems desirable for the correct performance of its duties.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2526720820863617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3347584437793929, "height": 0.08208636169303118, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-5", "text": "The Supervisory Board will draw up a profile (profielschets) for its size and composition taking into account the\nnature of Curetis' business, the Supervisory Board's activities and the desired expertise and background of the\nSupervisory Directors. The Supervisory Board must discuss the profile at the occasion of its adoption and review\nit annually and each amendment of the profile must be discussed in the General Meeting.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.39675074818298417, "height": 0.05515177426250534, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-6", "text": "Supervisory board rules\n", "page_number": 173, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.41000427533133815, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.4241128687473279, "height": 0.014108593415989745, "width": 0.16807738814993956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-7", "text": "Pursuant to the Articles of Association, the Supervisory Board may adopt rules of procedure concerning the\ndivision of its duties and its working methods (\"Supervisory Board Rules\") (and that of its committees as\ndescribed below. The Supervisory Board Rules will be in effect upon the Conversion.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.430525865754596, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4719965797349295, "height": 0.04147071398033347, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-8", "text": "Composition, appointment and removal\n", "page_number": 173, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4886703719538264, "lower_right_x": 0.3935912938331318, "lower_right_y": 0.5010688328345447, "height": 0.012398460880718332, "width": 0.2756952841596131}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-9", "text": "The Articles of Association provide that the Supervisory Board must consist of a minimum of three members,\nwith the exact number of Supervisory Directors to be determined by the Supervisory Board. As of the date of the\nConversion, the Supervisory Board will consist of six members. Only natural persons may be appointed as\nSupervisory Director.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5626336041043181, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-10", "text": "The General Meeting appoints the Supervisory Directors upon a non-binding nomination of the Supervisory\nBoard. Any nomination by the Supervisory Board must be drawn up with due observance of the profile\n(profielschets) for the size and the composition of the Supervisory Board. The nomination must specify the\nreasons for the nomination. If no nomination has been made, which is also considered the case if the Supervisory\nBoard's vote on the nomination ties; this must be stated in the notice. However, the General Meeting is not\nbound by a nomination and may appoint a Supervisory Director at its discretion, provided a proposal to appoint\nanother person has been put on the agenda of the relevant General Meeting or, failing that, the entire issued\ncapital is represented at the General Meeting and the resolution to appoint the alternative Supervisory Director\nhas been adopted unanimously.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5707567336468576, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6926036767849508, "height": 0.12184694313809319, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-11", "text": "A resolution of the General Meeting to appoint a Supervisory Director in accordance with the nomination of the\nSupervisory Board shall be adopted by an absolute majority of the votes cast. A resolution of the General\nMeeting to appoint a Supervisory Director other than in accordance with a nomination of the Supervisory Board,\nbut in accordance with the agenda for such General Meeting shall require an absolute majority of the votes cast\nrepresenting at least a third of the Company's issued share capital. The Supervisory Board shall appoint one of its\nSupervisory Directors as chairman and shall appoint one of its Supervisory Directors as vice-chairman.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7007268063274904, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.781530568619068, "height": 0.0808037622915776, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-12", "text": "The General Meeting may at any time, at the proposal of the Supervisory Board, suspend or dismiss a\nSupervisory Director. Should the General Meeting wish to suspend or dismiss a Supervisory Director other than\nin accordance with a proposal of the Supervisory Board, such suspension or dismissal needs to be adopted by an\nabsolute majority of the votes cast representing at least a third of the Company's issued share capital. A General\nMeeting must be held within three months after a suspension of a Supervisory Director has taken effect, in which\nmeeting a resolution must be adopted to either terminate or extend the suspension for a maximum period of\nanother three months. The suspended Supervisory Director must be given the opportunity to account for his or\nher actions at that meeting. If neither such resolution is adopted nor the General Meeting has resolved to dismiss\nthe Supervisory Director, the suspension will cease after the period of suspension has expired.\n", "page_number": 173, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9119281744335186, "height": 0.12227447627191101, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-173-13", "text": "170\n", "page_number": 173, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-0", "text": "Term of appointment\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.08507909362975631, "lower_right_x": 0.26481257557436516, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.14631197097944376}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-1", "text": "Supervisory Directors are appointed for a maximum period of four years, provided that, unless a member of the\nSupervisory Board resigns at an earlier date, his or her term of office lapses on the day of the first annual\nGeneral Meeting to be held in the fourth year after the year of his or her appointment. A Supervisory Director\nmay be reappointed for a term of not more than four years at a time, with due observance of the provision in the\nprevious sentence. A Supervisory Director may be reappointed for a total of three consecutive four-year terms,\nwhich period may or may not be interrupted, unless the General Meeting resolves otherwise. The Supervisory\nDirectors must retire periodically in accordance with a rotation plan to be drawn up by the Supervisory Board.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.20179563916203505, "height": 0.09619495510902094, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-2", "text": "Meetings and decision-making\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.2291577597263788, "height": 0.014108593415989745, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-3", "text": "According to the Supervisory Board Rules, resolutions of the Supervisory Board can only be adopted in a\nmeeting at which at least the majority of the Supervisory Directors is present or represented, provided that any\nmember of the Supervisory Board with a direct or indirect personal conflict of interest (as specified in the\nSupervisory Board Rules) with the Company, is not taken into account when establishing this quorum.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2907225309961522, "height": 0.05515177426250534, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-4", "text": "The Supervisory Board holds at least four meetings per year, or more often as deemed necessary or desirable by\none or more Supervisory Directors or Managing Directors. Meetings of the Supervisory Board are attended by\nthe Managing Directors, unless the Supervisory Board decides otherwise and save for certain meetings as\ndescribed in the Supervisory Board Rules.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3522873022659256, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-5", "text": "Pursuant to the Articles of Association, resolutions of the Supervisory Board will be adopted both at and outside\na meeting by an absolute majority of the votes cast. In case of a tied vote, the proposal shall have been rejected.\nThe Articles of Association specify that the Supervisory Board Rules may provide that resolutions can only be\nadopted if one or more Supervisory Directors with a specific function vote in favour of a specific proposal. The\nSupervisory Board Rules contain such a provision (see next paragraph).\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4275331338178709, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-6", "text": "Pursuant to the Supervisory Board Rules, the Supervisory Directors shall endeavour to achieve that resolutions\nare as much as possible adopted unanimously. Where unanimity cannot be reached and if no larger majority is\nrequired by law, the Articles of Association or the Supervisory Board Rules, the Supervisory Board may adopt\nresolutions by an absolute majority of the votes cast at the meeting. In the event of a tie in voting, the proposal\nshall have been rejected.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5027789653698161, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-7", "text": "Conflict of interest\n", "page_number": 174, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5194527575887131, "lower_right_x": 0.250906892382104, "lower_right_y": 0.5318512184694314, "height": 0.012398460880718276, "width": 0.13301088270858527}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-8", "text": "Similar to the rules that apply to the Managing Directors as described above, Dutch law also provides that a\nsupervisory director of a Dutch public company with limited liability, such as the Company (after the\nConversion), may not participate in the adoption of resolutions (including deliberations in respect of these) if he\nor she has a direct or indirect personal interest conflicting with the interests of the company.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5917058572039333, "height": 0.051731509191962344, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-9", "text": "Each Supervisory Director (other than the chairman of the Supervisory Board) shall immediately report any\n(potential) personal conflict of interest concerning a Supervisory Director to the chairman of the Supervisory\nBoard and must provide him with all information relevant to the (potential) conflict. In case the chairman of the\nSupervisory Board has a (potential) personal conflict of interest he shall immediately report such potential\nconflict to the vice-chairman of the Supervisory Board and shall provide all information relevant to the\n(potential) personal conflict of interest. If both the chairman and the vice-chairman of the Supervisory Board\nhave a (potential) personal conflict of interest with respect to the same matter, they will report and provide\ninformation to one of the other Supervisory Directors.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7101325352714836, "height": 0.10859341598973926, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-10", "text": "If as a result of such a personal conflict of interest either or both the chairman or vice-chairman of the\nSupervisory Board are not entitled to vote, the resolution of the Supervisory Board will be adopted by the other\nSupervisory Directors validly present or represented, by unanimous votes.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7575887131252672, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-11", "text": "If, as a result of such a personal conflict of interest all Supervisory Board are unable to participate in the\ndeliberations and the decision-making process and no resolution of the Supervisory Board can be adopted, the\nresolution can be adopted by the General Meeting.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.804617357845233, "height": 0.03890551517742624, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-12", "text": "resolution can be adopted by the General Meeting.\nAll transactions in which there is a conflict of interest with one or more Supervisory Directors shall be agreed on\nterms that are customary in the sector concerned and disclosed in the Company's annual report.\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8050448909790509, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.8401026079521163, "height": 0.03505771697306548, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-13", "text": "Supervisory directors\n", "page_number": 174, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.8683197947840958, "height": 0.013681060282171975, "width": 0.14993954050785974}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-14", "text": "Upon the Conversion, the Supervisory Board will be composed of the following six Supervisory Directors:\n", "page_number": 174, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8355501813784765, "lower_right_y": 0.8888413852073536, "height": 0.013681060282171864, "width": 0.7194679564691657}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-174-15", "text": "171\n", "page_number": 174, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-0", "text": "         Name            Age        Position         Date of Ap-          Term\n                                                     pointment1\nWilliam E. Rhodes, III   61      Chairman of the        2015       End of annual General\n                                 Directors' Board                  Meeting held in 2019\nMario Crovetto           62     Chairman of the         2015       End of annual General\n                                Audit Committee                    Meeting held in 2019\nDr. Werner Schaefer      67      Vice-Chairman          2015       End of annual General\n                                                                   Meeting held in 2018\nDr. Frank Muehlenbeck    44    Member of the board      2015       End of annual General\n                                                                   Meeting held in 2016\nDr. Rudy Dekeyser        53    Member of the board      2015       End of annual General\n                                                                   Meeting held in 2016\nDr. Holger Reithinger    49    Member of the board      2015       End of annual General\n                                                                   Meeting held in 2016\n", "page_number": 175, "bounding_box": {"top_left_x": 0.11003627569528417, "top_left_y": 0.08165882855921335, "lower_right_x": 0.8893591293833132, "lower_right_y": 0.3317657118426678, "height": 0.25010688328345443, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-1", "text": "1\n    The appointment of the Supervisory Board will take place as of the date of the Conversion.\n\nThe Company's registered address, Max-Eyth-Stra\u00dfe 42, 71088 Holzgerlingen, Germany, serves as the business\naddress for all Supervisory Directors.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33646857631466437, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3817870884993587, "height": 0.04531851218469435, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-2", "text": "William E. Rhodes, III\n", "page_number": 175, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.3817870884993587, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.40102607952116287, "height": 0.019238991021804153, "width": 0.1523579201934704}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-3", "text": "William E. Rhodes, III, will be appointed as the chairman of the Supervisory Board. Mr. Rhodes is a healthcare\nexecutive with more than 30 years of experience in the healthcare industry. He is currently serving as Operating\nPartner with Linden Capital Partner's investment team since January of 2013. During his 14-year career at\nBecton, Dickinson and Company (BD, 1998-2012) Mr. Rhodes served several senior leadership positions,\nincluding such roles as Worldwide President of BD Biosciences (2009-2011). He was responsible for BD's\ncorporate M&A activities as well as leading and growing operating companies. Furthermore, he founded BD\nVentures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior\nbusiness development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also served as president at The\nWilliam-James Co. and has a track record of 20 successful acquisitions and divestitures. He was director of\nAndor Technologies plc (2013-2014), and has served on the boards of Novocell Inc., Conticare Medical, Vitagen\nInc., the California Healthcare Institute, BIO, San Jose State University Research Foundation and Silicon Valley\nLeadership Group. He currently serves as director of Third Day Advisors LLC (since 2013), as director of\nOmega Group plc (since 2013), Paramit Corporation LLC (since 2014) and Cellector Corporation (since 2015),\nand as a member of the Advisory Board of Cayuga Venture Fund (since 2013), as advisory council member of\nMcGovern Family Center for Life Sciences, Cornell University (since 2013) and Entrepreneurship at Cornell,\nCornell University (since 2015). Moreover, he is on the Editorial Board of the journal Clinical and Translational\nMedicine. Mr. Rhodes holds a Master's degree in International Business from Seton Hall University and a BSc\ndegree from Cornell University. He originated eleven US patents for novel topical drugs and has been a lecturer\non entrepreneurship in life sciences, innovation technology and M&A at Cornell University, Seton Hall\nUniversity and San Jose State University.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6827704147071398, "height": 0.2727661393758017, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-4", "text": "Mario Crovetto\n", "page_number": 175, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6904660111158615, "lower_right_x": 0.22551390568319227, "lower_right_y": 0.7011543394613082, "height": 0.010688328345446751, "width": 0.1094316807738815}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-5", "text": "Mario Crovetto will be appointed as the chairman of the Audit Committee. Mr. Crovetto currently works as an\nindependent advisor on M&A and corporate projects, notably integrations, divestments and financing since\n2011. From 1999 to 2011 he was the CFO of Eurand NV (Specialty Pharmaceuticals), which he took public to\nNASDAQ in 2007. In the 1990 to 1999 period he held various senior business positions at Recordati (Pharma-\nceuticals) including VP of Corporate Development, Division Manager of Diagnostics and CFO. Prior to that he\nheld various positions at Montedison (Speciality Chemicals), Digital Equipment Corporation, Mobil and SIAR\n(Management Consulting). Mr. Crovetto holds a BSc in Economics from the Universit\u00e0 Cattolica del Sacro\nCuore, Milan and a master's degree in Business Economics of Harvard University, Cambridge, MA.\n", "page_number": 175, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8200085506626763, "height": 0.10902094912355698, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-6", "text": "Dr. Werner Schaefer\n", "page_number": 175, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8272766139375801, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.8405301410859342, "height": 0.013253527148354038, "width": 0.14328899637243048}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-7", "text": "Dr. Werner Schaefer is a specialist in the in-vitro diagnostics industry. He has nearly 30 years of management\nexperience in in-vitro diagnostics, holding various international management positions throughout his career \u2013\nincluding general management, marketing and R&D, at major companies comprising Behringwerke/Hoechst,\nAbbott, Boehringer Mannheim and Roche Diagnostics. At Boehringer and Roche, he led the laboratory systems\nbusiness unit and he served also as a member of the executive board of Roche Diagnostics GmbH until 2001.\nSince then, he has worked as a consultant and serves on various executive boards and supervisory boards in\n", "page_number": 175, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9298845660538692, "height": 0.08208636169303118, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-175-8", "text": "172\n", "page_number": 175, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-0", "text": "highly specialised diagnostics and medical technology companies. He was a member of the supervisory board of\nBRAHMS AG (2002 to 2009, sold to Thermo Fisher) mtm laboratories AG (2003 to 2011, sold to Roche),\nVivacta Limited (2006 to 2012, sold to Novartis), Signature AG (2012-2013), Genomatix Software GmbH (2011\nto 2013) and Cognoptix Inc. (2009 to 2014). He currently serves as a member of the advisory board of Human\nGmbH (since 2005), as the chairman of the board of directors of ProteoMediX AG (since 2012) and as Vice-\nChairman of Curetis AG (since 2014). Dr. Schaefer has a PhD in Chemistry from the Philipps University\nMarburg.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.18041898247114152, "height": 0.09533988884138521, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-1", "text": "Dr. Frank Muehlenbeck\n", "page_number": 176, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.1876870457460453, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.19837537409149208, "height": 0.01068832834544678, "width": 0.16747279322853686}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-2", "text": "Dr. Frank Muehlenbeck is a Partner at EMBL Ventures, a Heidelberg based VC fund since October of 2015.\nPreviously Dr. Muehlenbeck managed the healthcare business of aeris CAPITAL (2006-2015), a private\ninvestment office advising high-net-worth individuals. At aeris CAPITAL, Dr. Muehlenbeck has been\nresponsible for investments in life science companies. He previously worked at firstVentury Equity GmbH, a\nventure capital company in Heidelberg, and Steinbeis, a technology transfer institution in Germany. At Steinbeis\nhe founded the Steinbeis Transfer Center Biotech-Consult in 2001, a profit center within a franchise network.\nInvestments where Frank Muehlenbeck served or serves on the board include US based IonTorrent (investment\nin 2009, sold to Life Technologies in 2010), Heidelberg based Affimed (investment in 2001, IPO on NASDAQ\nin 2014, on the board until 2015; co-investors Orbimed, Life Science Partners, BiomedInvest, NovoNordisk and\nothers), ConformMIS Inc. (investment 2004, board position since 2009, IPO on NASDAQ in 2015) and Sonetik\nAG (Switzerland \u2013 board position (Verwaltungsrat) since 2014). Previous board positions included privately\nheld companies Solstice LLC (drug development company in California), L\u00f6ser Medizintechnik GmbH\n(medtech company in Leipzig), Tuebingen Scientific GmbH (medtech company in T\u00fcbingen) and Amphivena\nTherapeutics Inc (drug development company in California). From 2009 to 2015 Dr. Muehlenbeck served as\nchairman of the supervisory board at Curetis AG. Frank Muehlenbeck holds a lectureship at Karlsruhe university\nfor commercial aspects of biotechnology. He studied Technical Biology at Stuttgart University and holds a\nDoctorate in Cell Biology.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.440359127832407, "height": 0.23215049166310386, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-3", "text": "Dr. Rudy Dekeyser\n", "page_number": 176, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4476271911073108, "lower_right_x": 0.250906892382104, "lower_right_y": 0.46173578452330055, "height": 0.014108593415989745, "width": 0.13361547762998793}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-4", "text": "Dr. Rudy Dekeyser is a non-executive director of the issuer. Dr. Dekeyser, joined LSP in 2012 to become\nmanaging partner of LSP's Health Economics Fund. His prime focus and responsibility within LSP is to invest in\nunlisted securities. Prior to joining LSP, Dr. Dekeyser was Managing Director of VIB (1995 to 2012), the\nFlanders Institute for Biotechnology, which he helped establish in 1995. Under his leadership, the institute has\ngrown to become one of Europe's most successful incubators in the area of life sciences. Over the years, Dr.\nDekeyser has been appointed as Director of many companies and has been a senior Advisor to a number of\ninvestment firms. Dr. Dekeyser served on the supervisory board of many companies, including Ablynx NV\n(2001 to 2007), CropDesign (1998 to 2006), Pronota NV (2004 to 2012), ActoGeniX NV (2006 to 2012) and\nMultiplicom NV (2010 to 2012). He currently serves as a member of the supervisory board of Sequana Medical\nAG (since 2014), Celyad SA (since 2005), reMYND NV (since 2009) and EMBLEM GmbH (since 2001). Since\nNovember 2014, he has been a member of the supervisory board at Curetis AG. Dr. Dekeyser is a Co-Founding\nBoard Member of the European Association of Science and Technology Transfer Professionals (ASTP). Dr.\nDekeyser has a Master's degree in Zoology and a Ph.D. in Molecular Biology from the Ghent University and is\nchairman/member of many international advisory boards on innovation in life sciences.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6596836254809748, "height": 0.1915348439504062, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-5", "text": "Dr. Holger Reithinger\n", "page_number": 176, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6665241556220607, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.6806327490380505, "height": 0.0141085934159898, "width": 0.1535671100362757}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-6", "text": "Dr. Holger Reithinger is a General Partner and Head of the Munich Office of Forbion Capital Partners (since\nApril 2010). He holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra\n(founder of Forbion's portfolio company Pieris AG); all in the department of Prof. Dr. Hartmut Michel (Nobel\nLaureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, Dr. Reithinger studied Molecu-\nlar Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. After his studies,\nDr. Reithinger gained operational experience as a product development manager at Biometra/ Whatman Plc\n(now part of GE Healthcare). He started his career in Venture Capital in 1997 as an Investment Manager at\nTechnologieholding VC GmbH which at that time was one of the leading German Venture Capital firm. Tech-\nnologieholding was acquired by the 3i Group in early 2000, where Dr. Reithinger became a Director at its Ger-\nmany's healthcare practice. Following this assignment he became Principal and later Partner at Global Life Sci-\nence Ventures, a well-established life sciences-focused partnership with offices in Switzerland and Germany.\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.837964942283027, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-7", "text": "Dr. Reithinger has served on the Boards of numerous life sciences companies including Epigenomics (IPO\n2004), MBT (assets sold to Medigene AG), 4SC (IPO 2005), Fibrex Medical (assets licensed to Ikaria Inc.),\nAgendia BV, Santaris A/S (sold to Roche 2014) and Cellnovo Limited (2014-2015). Dr. Reithinger currently\nholds board seats at Curetis AG (since 2011), Cellnovo Group S.A. (since 2015, IPO 2015), Allecra Therapeutics\nGmbH (since 2013) and Rigontec GmbH (since 2015).\n", "page_number": 176, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9132107738349722, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-176-8", "text": "173\n", "page_number": 176, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-0", "text": "Supervisory board committees\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3282950423216445, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-1", "text": "As of the date of the Conversion, the Supervisory Board will have a Remuneration Committee, an Audit\nCommittee and a Nomination and Appointment Committee. Each of the committees has a preparatory and/or\nadvisory role to the Supervisory Board. In accordance with the Supervisory Board Rules, the Supervisory Board\nwill draw up rules on each Supervisory Board committee's role, responsibilities and functioning, which rules will\nbe in effect upon the Conversion (\"Committee Rules\"). The committees consist of Supervisory Directors. They\nreport their findings to the Supervisory Board, which is ultimately responsible for all decision-making.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1876870457460453, "height": 0.0820863616930312, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-2", "text": "Remuneration committee\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20179563916203505, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.21333903377511756, "height": 0.011543394613082514, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-3", "text": "The Remuneration Committee advises the Supervisory Board on the exercise of its duties regarding the remuner-\nation policy of the Managing Directors within Curetis', including analysing developments of the Code, and pre-\nparing proposals for the Supervisory Board on these subjects. The duties of the Remuneration Committee in-\nclude the preparation of proposals of the Supervisory Board on the remuneration policy for the Managing Direc-\ntors to be adopted by the General Meeting, and on the remuneration of the individual Managing Directors to be\ndetermined by the Supervisory Board. The Remuneration Committee also prepares a remuneration report on the\nexecution of the remuneration policy for the Management Board during the respective year to be adopted by the\nSupervisory Board. The Remuneration Committee meets at least three times every year.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.1098760153911928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-4", "text": "The Remuneration Committee will consist of Dr. Frank Muehlenbeck, Dr. Rudy Dekeyser and Mr. William E.\nRhodes (chairman).\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3659683625480975, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-5", "text": "The rules for the Remuneration Committee will be published on the Company's website under www.curetis.com.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8760580411124547, "lower_right_y": 0.3864899529713553, "height": 0.014108593415989745, "width": 0.7587666263603385}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-6", "text": "Audit committee\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.4125694741342454, "height": 0.012825994014536102, "width": 0.11668681983071343}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-7", "text": "The duties of the Audit Committee include the supervision and monitoring as well as advising the Management\nBoard and each Managing Director regarding the operation of the Company's internal risk management and\ncontrol systems. The Audit Committee advises the Supervisory Board on the exercise of certain of its duties and\nprepares nominations and reviews for the Supervisory Board in this regard. The Audit Committee also supervis-\nes the submission of financial information by the Company, the compliance with recommendations of internal\nand external accountants, the Company's policy on tax planning, the Company's financing arrangements, assists\nthe Supervisory Board with the Company's information and communications technology. It furthermore main-\ntains regular contact with and supervises the external accountant and it prepares the nomination of an external\naccountant for appointment by the General Meeting. The Audit Committee also issues preliminary advice to the\nSupervisory Board regarding the approval of the annual accounts and the annual budget and major capital ex-\npenditures. The Audit Committee meets at least four times a year.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5711842667806755, "height": 0.1509191962377084, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-8", "text": "The Audit Committee will consist of Dr. Holger Reithinger, Dr. Rudy Dekeyser and Mr. Mario Crovetto (chair-\nman).\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6053869174861052, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-9", "text": "The rules for the Audit Committee will be published on the Company's website under www.curetis.com.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6152201795639162, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.6280461735784524, "height": 0.012825994014536213, "width": 0.7067714631197097}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-10", "text": "Nomination and appointment committee\n", "page_number": 177, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6425823001282599, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.6566908935442497, "height": 0.0141085934159898, "width": 0.28536880290205563}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-11", "text": "The Nomination and Appointment Committee advises the Supervisory Board on its duties regarding the selec-\ntion and appointment of Managing Directors and Supervisory Directors. The duties of the Nomination and Ap-\npointment Committee include preparing the selection criteria and appointment procedures for Managing Direc-\ntors and Supervisory Directors, and proposing the profile for the Supervisory Board. It also periodically assesses\nthe scope and composition of the Management Board and the Supervisory Board, and the functioning of the\nindividual directors. The Nomination and Appointment Committee also proposes on appointments and reap-\npointments. It supervises the Management Board's policy on selection criteria and appointment procedures for\nthe Management Board. The Nomination and Appointment Committee meets at least once every year.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7716973065412569, "height": 0.10859341598973915, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-12", "text": "The Nomination and Appointment Committee will consist of Dr. Frank Muehlenbeck, Dr. Holger Reithinger and\nDr. Werner Schaefer (chairman).\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8071825566481402, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-13", "text": "The rules for the Nomination and Appointment Committee will be published on the Company's website under\nwww.curetis.com.\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.837964942283027, "height": 0.024369388627618727, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-14", "text": "Medical Advisory Board\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.33192261185006044, "lower_right_y": 0.870884993587003, "height": 0.01624625908507915, "width": 0.21644498186215233}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-15", "text": "Curetis is currently in the process of establishing an international medical advisory board (\"MAB\") consisting of\nseveral KOLs (clinicians and/or microbiologists) in order to ensure constant input and feedback on its current,\nand future product and clinical development strategies for all targeted diseases, syndromic panels and geographic\n", "page_number": 177, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8854211201368106, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.9264643009833262, "height": 0.04104318084651559, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-177-16", "text": "174\n", "page_number": 177, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-0", "text": "areas. Four internationally recognised experts (US, Switzerland, Germany, Belgium) in the field of pneumonia,\nimplant, tissues infection and also sepsis have accepted their nomination. In addition, other experts have been\napproached in order to expand the MAB expertise in areas including antibiotic resistance. Contracts are currently\nunder negotiation and an inaugural meeting of the new MAB is expected to take place in 2016.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-1", "text": "Diversity and Limitation of Supervisory Positions\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.17015818725951262, "height": 0.016673792218896977, "width": 0.43107617896009676}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-2", "text": "As the Company does not qualify as a \"large company\" within the meaning of Dutch legislation that came into\nforce on 1 January 2013 requiring large Dutch companies to pursue a policy of having at least 30% of the seats\non both the management board and the supervisory board to be held by men and at least 30% of those seats to be\nheld by women, these requirements do not apply to the Company. For the same reason, the Dutch legislation\nlimiting the number of supervisory positions to be occupied by managing directors or supervisory directors is not\napplicable to the Company.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18426678067550234, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2663531423685336, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-3", "text": "Remuneration and Equity Holdings\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28003420265070544, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.29713552800342025, "height": 0.017101325352714802, "width": 0.31015719467956465}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-4", "text": "The Supervisory Board establishes the remuneration of the individual members of the Management Board in\naccordance with the principles laid down in the Management Board remuneration policy as adopted by the\nGeneral Meeting. The Supervisory Board presents to the General Meeting for approval any proposal providing\nfor the remuneration of the members of the Management Board in the form of shares or options. This proposal\nmust include the number of shares and/or options that may be granted to the Management Board and which\ncriteria apply to a grant or modification. The Company's current remuneration policy provides for competitive\ncompensation so as to enable the Company to recruit and maintain competent management. Its general principles\nare:\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41727233860624197, "height": 0.10645575032064986, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-5", "text": "annual fixed salary according to industry standards; and\nvariable salary that will be linked to milestones/performance objectives that includes clinical, commer-\ncial, operational and financial goals to be set annually by the Supervisory Board.\nThe variable salary may be comprised of two components: (a) an annual cash bonus payment in accord-\nance with industry standards; and/or (b) granting of share options and/or performance share awards in ac-\ncordance with an employee incentive plan that may be adopted by the Company.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.4279606669516888, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5267208208636169, "height": 0.09876015391192816, "width": 0.7158403869407497}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-6", "text": "\uf0b7\n", "page_number": 178, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.430525865754596, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.43779392902949976, "height": 0.007268063274903758, "width": 0.008464328899637233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-7", "text": "\uf0b7\n", "page_number": 178, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.4523300555793074, "lower_right_x": 0.12575574365175332, "lower_right_y": 0.46045318512184696, "height": 0.008123129542539576, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-8", "text": "Adjustments to variable remuneration\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.539974348011971, "lower_right_x": 0.38210399032648124, "lower_right_y": 0.5540829414279607, "height": 0.01410859341598969, "width": 0.2666263603385731}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-9", "text": "Pursuant to Dutch law and the Dutch Corporate Governance Code the remuneration of Managing Directors may\nbe reduced or Managing Directors may be obliged to repay (part of) their variable remuneration to the Company\nif certain circumstances apply.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6015391192817443, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-10", "text": "Pursuant to the Dutch Corporate Governance Code, any variable remuneration component conditionally awarded\nto a Managing Director in a previous financial year which would, in the opinion of the Supervisory Board,\nproduce an unfair result due to extraordinary circumstances during the period in which the predetermined\nperformance criteria have been or should have been applied, the Supervisory Board will have the power to adjust\nthe value downwards or upwards. In addition, the Supervisory Board will have the authority under the Dutch\nCorporate Governance Code and Dutch law to recover from a Managing Director any variable remuneration\nawarded on the basis of incorrect financial or other data (claw back).\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7032920051303976, "height": 0.09491235570756729, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-11", "text": "Pursuant to Dutch law, the Supervisory Board may furthermore adjust the variable remuneration (to the extent\nthat it is subject to reaching certain targets and the occurrence of certain events) to an appropriate level if\npayment of the variable remuneration were to be unacceptable according to requirements of reasonableness and\nfairness.\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7622915775972637, "height": 0.05130397605814441, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-12", "text": "In addition Dutch law prescribes that, in case the value of the Shares or rights to subscribe for such Shares\ngranted by the Company to the respective Managing Directors as part of their remuneration increases during a\nperiod in which a public takeover bid is made for the Shares, the remuneration of that respective Managing\nDirector will be reduced by the amount by which the value of the Shares or rights to subscribe for such Shares so\ngranted by the Company to such member has increased. To the extent the increase in value exceeds the\nremuneration of the respective Managing Director; the Company shall have a claim against the respective\nManaging Director for such excess. Similar provisions apply in the situation of an intended legal merger or\ndemerger, or if the Company intendeds to enter into certain transactions that are of such significance to the\nCompany that the Management Board requires the approval of the General Meeting pursuant to Dutch law (i.e.,\ntransactions that fall within the scope of Section 2:107a Dutch Civil Code).\n", "page_number": 178, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9097905087644292, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-178-13", "text": "175\n", "page_number": 178, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-0", "text": "Remuneration for the management board\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.40931076178960096, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.29383313180169285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-1", "text": "The total remuneration costs in relation to the three members of the management board of Curetis AG, Andreas\nBoos, Johannes Bacher, and Oliver Schacht, in 2014 amounted to \u20ac992 thousand, as set forth in the following\ntable:\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.14365113296280463, "height": 0.03805044890979052, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-2", "text": " Name      Base salary/    Employer's   Annual   Other benefits     Social security      Total remu-\n           consultancy       pension    bonus      (car lease,      and other pay-        neration\n               fee          contribu-            travel expens-         ments\n                              tions                    es)\nAndreas    \u20ac150 thousand       0          0        0 (only cost       \u20ac105 thousand      \u20ac263 thousand\n Boos                                            reimbursement     (increase valuation\n                                                  no additional     PSOP-provision)\n                                                   flat catering\n                                                                    \u20ac8 thousand (in-\n                                                    expenses)\n                                                                    crease valuation\n                                                                     profit sharing\n                                                                       provision)\nJohannes   \u20ac150 thousand       0          0        0 (only cost       \u20ac105 thousand      \u20ac261 thousand\n Bacher                                          reimbursement     (increase valuation\n                                                  no additional     PSOP-provision)\n                                                   flat catering\n                                                                    \u20ac6 thousand (in-\n                                                    expenses)\n                                                                    crease valuation\n                                                                     profit sharing\n                                                                       provision)\n Oliver    \u20ac190 thousand       0          0        0 (only cost       \u20ac278 thousand      \u20ac468 thousand\nSchacht                                          reimbursement     (increase valuation\n                                                  no additional     PSOP-provision)\n                                                   flat catering\n                                                    expenses)\n", "page_number": 179, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.15006412997007268, "lower_right_x": 0.8935912938331319, "lower_right_y": 0.5130397605814451, "height": 0.3629756306113724, "width": 0.7877871825876663}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-3", "text": "At the date of this Prospectus, there are no amounts reserved or accrued by the Company or its subsidiaries to\nprovide pension, benefit, retirement or similar benefits for current members of the Management Board.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5194527575887131, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5472424112868748, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-4", "text": "Remuneration of the supervisory board\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5639162035057717, "lower_right_x": 0.39117291414752114, "lower_right_y": 0.5763146643864899, "height": 0.012398460880718276, "width": 0.27569528415961303}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-5", "text": "The total remuneration of the members of the supervisory board of Curetis AG in relation to 2014 amounted to\n\u20ac36 thousand.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6088071825566481, "height": 0.024369388627618616, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-6", "text": "The remuneration of the members of the Supervisory Board of the Company is envisaged to be resolved upon\nConversion as follows: The chairman of the Supervisory Board will receive an annual remuneration of \u20ac60\nthousand, the vice-chairman of the Supervisory Board will receive an annual remuneration of \u20ac40 thousand and\neach other member of the Supervisory Board will receive an annual remuneration of \u20ac20 thousand. Each\ncommittee chairperson will receive an additional remuneration of \u20ac10 thousand per year. Additionally, each\nboard member is entitled to a meeting fee of \u20ac2 thousand and a teleconference fee of \u20ac1 thousand.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6998717400598546, "height": 0.08123129542539542, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-7", "text": "At the date of this Prospectus, there are no amounts reserved or accrued by the Company or its subsidiaries to\nprovide pension, benefit, retirement or similar benefits for current members of the Supervisory Board.\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7345019238991022, "height": 0.026934587430525903, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-8", "text": "Equity holdings\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.2267230955259976, "lower_right_y": 0.7618640444634459, "height": 0.013253527148354038, "width": 0.11124546553808949}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-9", "text": "The number of shares in Curetis AG held at the date of this Prospectus and the number of Shares envisaged to be\nheld immediately following the issuance of Shares in the Company upon the Conversion by the Managing and\nSupervisory Directors (on the basis of the assumption that the Offer Price corresponds to the mid-point of the\nOffer Price Range) are as follows:\n", "page_number": 179, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7691321077383497, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8234288157332194, "height": 0.05429670799486963, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-10", "text": "Name              Shares in Curetis AG as of the   Shares in the Company immediately\n                     date of this Prospectus        following the issuance of Shares in\n                                                    the Company upon the Conversion\nOliver Schacht                8,259                              18,450\nJohannes Bacher              95,897                              118,754\n", "page_number": 179, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.8281316802052159, "lower_right_x": 0.9081015719467956, "lower_right_y": 0.9234715690466011, "height": 0.09533988884138522, "width": 0.8022974607013301}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-179-11", "text": "176\n", "page_number": 179, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-0", "text": "Name           Shares in Curetis AG as of the   Shares in the Company immediately\n                  date of this Prospectus        following the issuance of Shares in\n                                                 the Company upon the Conversion\nAndreas Boos              46,334                              44,846\n", "page_number": 180, "bounding_box": {"top_left_x": 0.10822249093107618, "top_left_y": 0.08465156049593843, "lower_right_x": 0.9141475211608222, "lower_right_y": 0.15348439504061565, "height": 0.06883283454467722, "width": 0.805925030229746}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-1", "text": "Under the PSOP (see \"\u2013 Share based Compensation Plan\" below) Oliver Schacht is entitled to receive 173,901\nnew shares in the Company and Johannes Bacher, Andreas Boos and Dr. Achim Plum are each entitled to\nreceive 65,646 new shares in the Company (assuming an Offer Price at the mid-point of the Offer Price Range).\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16374519025224454, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20222317229585293, "height": 0.03847798204360839, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-2", "text": "receive 65,646 new shares in the Company (assuming an Offer Price at the mid-point of the Offer Price Range).\nThe vice-chairman of the Supervisory Board is entitled to receive a certain amount of cash from certain of the\nexisting Shareholders or, at the option of such existing shareholders, a corresponding number of Shares\nfollowing 365 days after the Settlement Date.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2026507054296708, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2496793501496366, "height": 0.04702864471996579, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-3", "text": "following 365 days after the Settlement Date.\nThe Managing Directors who hold Shares are expected to enter into lock-up arrangements with the Underwriters.\nSee also \"Plan of Distribution \u2013 Lock-up Arrangements\".\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2501068832834545, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2860196665241556, "height": 0.03591278324070113, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-4", "text": "Employment, Service and Severance Agreements\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.31680205215904234, "height": 0.016246259085079096, "width": 0.42623941958887546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-5", "text": "As of the date of this Prospectus, the current members of the Management Board are employed by Curetis AG.\nThe four members of the Management Board are expected to enter into a service agreement with the Company\nupon the Conversion. The terms and conditions of each of these service agreements (including in relation to any\nseverance payments) will be aligned with the provisions in the Corporate Governance Code. The agreements will\nbe entered into for a term of a maximum of four years.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4065840102607952, "height": 0.07524583155194525, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-6", "text": "The service agreements that the Managing Directors are expected to enter into with the Company are expected to\nprovide for the following: Oliver Schacht shall receive a fixed annual remuneration of \u20ac240 thousand and a\nbonus of up to \u20ac120 thousand, Johannes Bacher and Andreas Boos shall each receive an annual remuneration of\n\u20ac200 thousand and a bonus of up to \u20ac80 thousand and Achim Plum shall receive an annual remuneration of \u20ac200\nthousand, a bonus of up to \u20ac100 thousand and a company car.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41342454040188115, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.48182984181274047, "height": 0.06840530141085932, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-7", "text": "Upon the Conversion the Supervisory Directors do not have an employment, service or severance contract with\nthe Company.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5160324925181702, "height": 0.027362120564343784, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-8", "text": "Potential Conflicts of Interest and Other Information\n", "page_number": 180, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.529713552800342, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.5438221462163317, "height": 0.01410859341598969, "width": 0.4643288996372431}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-9", "text": "The Supervisory Directors, Dr. Frank Muehlenbeck, Dr. Rudy Dekeyser and Dr. Holger Reithinger are affiliated\nwith aeris CAPITAL Equity Investments, L.P., LSP Curetis Pooling B.V.and Forbion Capital Fund II Co\u00f6per-\natief U.A., who will, upon the Conversion, be (indirect) major shareholders of the Company, respectively. See\nalso \"Major Shareholders and Related Party Transactions \u2013 Major Shareholders\". This subjects these Supervi-\nsory Directors to a conflict of interests as a shareholder representative on the one hand and as a Supervisory\nDirector on the other. The Supervisory Director Dr. Werner Schaefer is entitled to receive a certain number of\nShares from certain existing Shareholders or, at the option of the respective shareholders, a corresponding\namount in cash 365 days after the Settlement Date (see \"-Remuneration and Equity Holdings \u2013 Equity Hold-\nings\"). This subjects him to a conflict of interest as a future Shareholder, on the one hand, and his duties as a\nSupervisory Director on the other. In addition, the Managing Directors will hold a minor indirect stake in the\nCompany following Settlement and are beneficiaries under Curetis phantom stock option program (see \"Man-\nagement Employees and Corporate Governance - Share-based Compensation Plan\". As such a conflict of inter-\nests may arise between the interests typically attributed to Shareholders and the interests of the Managing Direc-\ntors. See also \"\u2013 Equity Holdings\", \"Major Shareholders and Related Party Transactions \u2013 Major Sharehold-\ners\", \"\u2013 Management Board \u2013 Conflict of Interest\" and \"\u2013 Supervisory Board \u2013 Conflict of Interest\".\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7661393758016246, "height": 0.2056434373663959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-10", "text": "Other than these circumstances, Curetis is not aware of any potential conflicts between the personal interests or\nother duties of Supervisory Directors and personal interests or other duties of Managing Directors on the one\nhand and the interests of the Company on the other hand. There is no family relationship between any Managing\nDirector and any Supervisory Director.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.827704147071398, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-11", "text": "During the last five years, none of the Managing Directors or Supervisory Directors: (i) has been convicted of\nfraudulent offenses; (ii) has served as a director or officer of any entity subject to bankruptcy proceedings, re-\nceivership or liquidation; or (iii) has been subject to any official public incrimination and/or sanctions by statuto-\nry or regulatory authorities (including designated professional bodies), or disqualification by a court from acting\nas a member of the administrative, management or supervisory body of an issuer, or from acting in the manage-\nment or conduct of the affairs of any issuer.\n", "page_number": 180, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.9166310389055152, "height": 0.08251389482684912, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-180-12", "text": "177\n", "page_number": 180, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-0", "text": "Other than as disclosed herein, Curetis is not aware of any arrangement or understanding with major Sharehold-\ners, suppliers, customers or others pursuant to which any Managing Director or Supervisory Director was select-\ned as a member of such management or supervisory bodies of the Company.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.12569474134245404, "height": 0.040615647712697725, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-1", "text": "Liability of Managing Directors and Supervisory Directors\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.6239419588875453, "lower_right_y": 0.15647712697734073, "height": 0.01667379221889695, "width": 0.5084643288996372}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-2", "text": "Under the laws of the Netherlands, the Managing Directors and Supervisory Directors may be liable towards the\nCompany for damages in the event of improper or negligent performance of their duties. They may be jointly\nand severally liable for damages towards the Company for infringement of the Articles of Association or of\ncertain provisions of the Dutch Civil Code. In addition, they may be liable towards third parties for infringement\nof certain provisions of the Dutch Civil Code. In certain circumstances, they may also incur additional specific\ncivil and criminal liabilities.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17058572039333048, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.2496793501496366, "height": 0.07909362975630613, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-3", "text": "Insurance\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2672082086361693, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.2804617357845233, "height": 0.013253527148354038, "width": 0.09250302297460701}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-4", "text": "The Managing Directors, the Supervisory Directors and certain other employees and all other directors and/or\nofficers of Curetis are insured under an insurance policy taken out by Curetis against damages resulting from\ntheir conduct when acting in their capacities as members or officers.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3386062419837537, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-5", "text": "Indemnification\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3522873022659256, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.3659683625480975, "height": 0.01368106028217192, "width": 0.14087061668681983}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-6", "text": "Pursuant to the Articles of Association, and unless the laws of the Netherlands provide otherwise, the following\nwill be reimbursed to inter alia current and former Managing Directors and Supervisory Directors: (i) the rea-\nsonable costs of conducting a defence against claims based on acts or failures to act in the exercise of their duties\nor any other duties currently or previously performed by them at the Company's request; (ii) any damages or\nfines payable by them as a result of an act or failure to act as referred to under (i); and (iii) the reasonable costs\nof appearing in other legal proceedings or investigations in which they are involved as current or former Manag-\ning Directors or Supervisory Directors, with the exception of proceedings primarily aimed at pursuing a claim on\ntheir own behalf.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4890979050876443, "height": 0.10645575032064986, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-7", "text": "There shall be, however, no entitlement to reimbursement if and to the extent that: a Dutch court or, in the event\nof arbitration, an arbitrator has established in a final and conclusive decision that the act or failure to act of the\nperson concerned can be characterised as wilful (opzettelijk) or grossly negligent (grove schuld) misconduct,\nunless the laws of the Netherlands provide otherwise or this would, in view of the circumstances of the case, be\nunacceptable according to standards of reasonableness and fairness; or the costs or financial loss of the person\nconcerned are covered by insurance and the insurer has paid out the costs or financial loss.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5810175288584866, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-8", "text": "Share-based Compensation Plan\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5981188542112014, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.6122274476271911, "height": 0.01410859341598969, "width": 0.28597339782345826}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-9", "text": "As part of the Reorganisation (as defined herein), Curetis AG will restructure the phantom stock option plan that\nit implemented on 11 June 2010 and amended on 17 April 2013. The PSOP comprises phantom stock options\nawarded to officers, employees, freelancers and advisors of Curetis AG (the \"PSOP Beneficiaries\") by individu-\nal grant agreements, entitling the PSOP Beneficiaries to a payment by Curetis AG in the event of a trade sale,\nmerger, stock exchange listing or comparable transaction (\"Payment Claims\"). Under the PSOP, in the event of\na stock exchange listing, the Payment Claims become due after expiry of the lock-up period applicable to the\nexisting Shareholders.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.7216759298845661, "height": 0.09619495510902099, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-10", "text": "The Payment Claims of the PSOP Beneficiaries will be settled as follows:\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.7421975203078238, "height": 0.01410859341598969, "width": 0.4987908101571946}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-11", "text": "The Payment Claims of the 38 PSOP Beneficiaries who are each entitled to 1,000 phantom stock options or less\n(\"Cash-settled PSOP Beneficiaries\", each a \"Cash-settled PSOP Beneficiary\") will be cash-settled. The Pay-\nment Claim for each Cash-settled PSOP Beneficiary shall amount to the aggregate number of phantom stock\noptions held by such PSOP Beneficiary multiplied by the Payment Claim for one phantom stock option (defined\nas the first stock exchange trading price per Share multiplied by 2 minus \u20ac1). This means that their rights under\nthe PSOP will remain unaffected and they will receive a payment in cash from Curetis AG after expiry of the\nlock-up period of 365 days from the Settlement Date. Assuming an Offer Price at the upper end of the Offer\nPrice Range and a first stock exchange trading price equal to such Offer Price, the Cash-settled PSOP Benefi-\nciaries would be entitled to an aggregate cash payment of \u20ac469 thousand.\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-12", "text": "The Payment Claims of the 20 PSOP Beneficiaries who are each entitled to more than 1,000 phantom stock\noptions (\"PSOP Roll-Over Beneficiaries\", each a \"PSOP Roll-Over Beneficiary\") will be settled in Shares as\nfollows: Curetis AG and the Company will, prior to the Share Swap (as defined herein) enter into an agreement\n", "page_number": 181, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8785805899957246, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.9200513039760582, "height": 0.04147071398033353, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-181-13", "text": "178\n", "page_number": 181, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-0", "text": "with each individual PSOP Roll-Over Beneficiary, by which the rights and obligations of the respective PSOP\nRoll-Over Beneficiary and Curetis AG under the PSOP shall be amended to the effect that each PSOP Roll-Over\nBeneficiary shall receive Shares after expiry of the lock-up period of 365 days from the Settlement Date (each\nsuch agreement a \"PSOP Roll-Over Agreement\", all PSOP Roll-Over Agreements together the \"PSOP Roll-\nOver Agreements\"). The Payment Claim for each PSOP Roll-Over Beneficiary shall amount to the aggregate\nnumber of phantom stock options held by such PSOP Beneficiary multiplied by the Payment Claim for one\nphantom stock option (defined as the Offer Price per Share multiplied by 2 minus \u20ac1).\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.18127404873877725, "height": 0.09619495510902094, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-1", "text": "Each PSOP Roll-Over Agreement provides for (i) a sale and assignment of the Payment Claim from the respec-\ntive PSOP Roll-Over Beneficiary to the Company against a purchase price equal to the nominal value of the\nPayment Claim, (ii) the granting of rights by the Company to the PSOP Roll-Over Beneficiary to subscribe for\nShares (the \"Roll-Over Options\"), (iii) the exercise of the Roll-Over Options by the PSOP Roll-Over Benefi-\nciary with effect as from and under the condition precedent of the expiry of the lock-up period, resulting in the\nsubscription by the PSOP Roll-Over Beneficiary for a number of Shares equal to the Payment Claim of the re-\nspective PSOP Roll-Over Beneficiary divided by the Offer Price (rounded to the nearest whole number) (the\n\"Roll-Over Shares\"), and (iv) a set-off of the payment obligation for the Roll-Over Shares against the purchase\nprice for the Payment Claim.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3103890551517743, "height": 0.12270200940572898, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-2", "text": "The aggregate number of Roll-Over Shares to be issued will depend on the Offer Price. Assuming an Offer Price\nat the upper end of the Offer Price Range, the aggregate number of new Shares to be issued would be 665,020.\nAssuming (i) an Offer Price at the upper end of the Offer Price Range, (ii) that the maximum number of Offer\nShares will be issued and (iii) that the Over-allotment Option will not be exercised, the then existing Sharehold-\ners would experience a dilution of 4.3%. Assuming (i) an Offer Price at the upper end of the Offer Price Range,\n(ii) that the maximum number of Offer Shares will be issued and (iii) that the Over-allotment Option will be\nexercised in full, the then existing Shareholders would experience a dilution of 4.2%.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41342454040188115, "height": 0.0957674219752031, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-3", "text": "The PSOP Roll-Over Agreements provide that, to the extent possible 52% of the Roll-Over Shares shall be sold\nin one or several (at most six) transactions organised by the Company within a period of six months following\nthe expiry of the lock-up period, each of them comprising a minimum of 60,000 Roll-Over Shares, in order for\nthe PSOP Roll-Over Beneficiaries to be able to generate the funds to pay German taxes and, if applicable, social\nsecurity contributions due as a result of the exercise of the Roll-Over Options and the issue of the Roll-Over\nShares. To the extent that such 52% of the Roll-Over Shares, or part thereof, have not yet been sold in such\ntransactions after expiry of such six-month period, the PSOP Roll-Over Beneficiaries, each of them separately\nand individually for his/her account, may request that all remaining Roll-Over Shares shall be issued and credit-\ned to their respective securities accounts. To the extent that the PSOP Roll-Over Beneficiaries do not make such\nrequest, the Company shall be entitled to continue to try to sell the remaining part of said 52% of the Roll-Over\nShares in such transactions and can after 24 months from expiry of the lock-up period issue and credit any re-\nmaining Roll-Over Shares to the respective PSOP Roll-Over Beneficiaries.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.5840102607952117, "height": 0.1637451902522446, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-4", "text": "The PSOP will not be used for any future grants and be closed and terminated in its entirety to be re-placed by a\nlong-term equity linked incentive plan at the Company level.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6186404446344592, "height": 0.02736212056434384, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-5", "text": "Profit Sharing Bonus\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.3041112454655381, "lower_right_y": 0.6494228302693459, "height": 0.017101325352714802, "width": 0.18863361547762997}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-6", "text": "In the past, a number of employees and directors have waived salary payment claims against Curetis AG in a\ntotal amount of \u20ac577 thousand in consideration for a profit sharing bonus. On the basis of the respective agree-\nments, as amended from time to time, such bonuses will become payable upon completion of the Offering. Cu-\nretis will therefore have to make a payment of approximately \u20ac790 thousand to the respective beneficiaries after\nthe Settlement Date.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.728516460025652, "height": 0.06541256947413421, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-7", "text": "Employees\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.7627191107310817, "height": 0.0141085934159898, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-8", "text": "For an overview of the total numbers of employees of Curetis, subdivided per operating segment, see \"Business\n\u2013 Employees\". Curetis AG is not required to install a works council under German Law. The Company shall not\nbe required to install a works council in the Netherlands since the Company shall have no (or in any case less\nthan 50) employees in the Netherlands.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.831124412141941, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-9", "text": "Dutch Corporate Governance Code\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.42563482466747277, "lower_right_y": 0.8619067977768277, "height": 0.017528858486532628, "width": 0.31015719467956465}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-10", "text": "The Dutch Corporate Governance Code, as amended, became effective on 1 January 2009 and finds its statutory\nbasis in Book 2 of the Dutch Civil Code. The Dutch Corporate Governance Code applies to the Company as it\nhas its statutory seat in the Netherlands and the Shares will be listed on the regulated market Euronext in\nAmsterdam and Euronext in Brussels.\n", "page_number": 182, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9281744335185977, "height": 0.05301410859341604, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-182-11", "text": "179\n", "page_number": 182, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-0", "text": "The Dutch Corporate Governance Code defines a company as a long-term form of collaboration between the\nprincipal corporate bodies of a company. For the Company, these corporate bodies include the Management\nBoard, the Supervisory Board and the General Meeting. The Management Board values and considers the\ninterests of the various stakeholders involved. According to the Dutch Corporate Governance Code, good\ncorporate governance results in effective decision-making in a manner which enhances shareholder value and\nenables a company to maintain a culture of integrity, transparency and trust.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16673792218896966, "height": 0.08165882855921335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-1", "text": "The Dutch Corporate Governance Code is based on a \"comply or explain\" principle. Accordingly, companies are\nrequired to disclose in their annual report filed in the Netherlands whether or not they are complying with the\nvarious principles and provisions of the Dutch Corporate Governance Code that are addressed to the board of\ndirectors or, if any, the supervisory board of the company. If a company deviates from a best practice provision\nin the Dutch Corporate Governance Code, the reason why must be properly explained in its annual report.\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.06840530141085935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-2", "text": "Compliance with the Dutch Corporate Governance Code\n", "page_number": 183, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.25609234715690465, "lower_right_x": 0.5126964933494559, "lower_right_y": 0.2702009405728944, "height": 0.014108593415989745, "width": 0.3954050785973398}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-3", "text": "The Company fully endorses the underlying principles of the Dutch Corporate Governance Code, and is\ncommitted to adhering to the best practices of the Dutch Corporate Governance Code as much as possible. The\nCompany fully complies with the Dutch Corporate Governance Code with the exception of the following\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3180846515604959, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-4", "text": "provisions:\n", "page_number": 183, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3180846515604959, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.3317657118426678, "height": 0.013681060282171864, "width": 0.07799274486094317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-5", "text": "\uf0b7   Best practice provision III.2.1 provides all supervisory directors, with the exception of not more than one\n    person, shall be independent within the meaning of best practice provision III.2.2. As per the date of the\n    Conversion, three out of six of the Supervisory Directors, being Dr. Frank Muehlenbeck, Dr. Rudy\n    Dekeyser and Mr. William E. Rhodes, III, are not deemed independent. They will not meet these re-\n    quirements of independence. Dr. Muehlenbeck and Dr. Dekeyser will not meet these requirements be-\n    cause they are affiliated with two of the largest shareholders, being LSP Curetis Pooling B.V. and aeris\n    CAPITAL Equity Investments, L.P. (each holding more than 10% of the issued and outstanding share\n    capital of the Company). The intention to appoint both of them (and not only one of them) is based on the\n    aim to secure sufficient continuity within the Supervisory Board. Mr. Muehlenbeck and Mr. Dekeyser\n    have been supervisory directors of Curetis AG prior to the Reorganisation and the Conversion and are ex-\n    pected to be well equipped to perform the duties as Supervisory Director. The intention is that Mr. Mueh-\n    lenbeck and Mr. Dekeyser will be appointed as Supervisory Directors for the term of one year. Mr.\n    Rhodes shall not be deemed independent within the meaning of best practice provision III.2.2 due to the\n    services agreement entered into between him and Curetis AG a few weeks prior to the date of this Pro-\n    spectus relating to his performance of consultancy services for Curetis AG as of 1 November 2015 in an-\n    ticipation of his expected appointment as Supervisory Director. It has been agreed that such services\n    agreement shall terminate automatically upon his appointment as Supervisory Director. Given his track\n    record in the diagnostics industry and previous executive top management roles with Becton Dickinson,\n    Mr. Rhodes is expected to be well equipped to perform the duties as Supervisory Director and Chairman\n    of the Supervisory Board;\n\uf0b7   Best practice provision III.5.1 provides that no more than one member of the Remuneration Committee\n    shall be not independent within the meaning of best practice provision III.2.2. As indicated above three\n    out of six Supervisory Directors are not deemed independent. However, given the wish of the Supervisory\n    Directors to be actively involved within the Supervisory Board and all of its Committees, the Remunera-\n    tion Committee shall be composed of more than one Supervisory Director which is not independent: all\n    three members of the Remuneration Committee (Mr. Rhodes, Mr. Muehlenbeck and Mr. Dekeyser) are\n    not independent. However, such persons are expected to be equipped best for the role as members of the\n    Remuneration Committee;\n\uf0b7   Best practice provision III.5.11 provides that the Remuneration Committee may not be chaired by the\n    chairman of the Supervisory Board or by a Supervisory Director who is a member of the management\n    board of another listed company. Mr. Rhodes however is a board member of other listed companies (as\n    indicated in his CV above) and shall be appointed both as chairman of the Supervisory Board and as\n    chairman of the Remuneration Committee since Mr. Rhodes is expected to be equipped best for the role\n    as chairman of the Remuneration Committee;\n\uf0b7   Principle III.3 provides the Supervisory Board shall aim for a diverse composition, including in terms of\n    gender and age. It is however expected that upon the Conversion the Supervisory Board will only have\n    members of the male gender. In the recruitment procedure for the appointment of the Supervisory Direc-\n    tors sincere efforts were made to find Supervisory Directors of the female gender. During that procedure\n    it appeared that suitable female candidates were not available. The Supervisory Board endorses the aim of\n    diversity and shall remain striving for appointment of female Supervisory Directors when vacancies have\n    to be filled;\n", "page_number": 183, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9230440359127833, "height": 0.5848653270628474, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-183-6", "text": "180\n", "page_number": 183, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-184-0", "text": "Principle II.2 and best practice provision III.7.2 provide that any Shares held by the Managing Directors\nor the Supervisory Directors shall be held as long-term investment. This is the case with the exception of\nthe Roll-Over Shares which will be held by the Managing Directors pursuant to the restructuring of the\nPSOP. See section \"\u2013 Share-based Compensation Plan\". After the expiry of the lock up period, the bene-\nficiaries under the Phantom Stock Option Plan, amongst which the Managing Directors, shall be allotted\nShares as a step of the settlement of the Phantom Stock Option Plan. As part of the settlement of the\nPhantom Stock Option Plan, one or several transactions are expected to be consummated in order to gen-\nerate the funds that will enable the beneficiaries to pay the German income taxes that will become due as\na result of the roll-up and settlement of the existing Phantom Stock Option Plan;\nBest practice provision IV.3.3 provides that the Company shall not pay fees to any party for the carrying\nout of research for analysts' reports or for the production or publication of analysts' reports on the Com-\npany (with the exception of payments to credit rating agencies). The Company reserves the right not to\nadhere to such best practice provision if and to the extent that such payments may be regarded as custom-\nary for listed companies in the biotech industry. Pursuant to the Management Board Rules, a resolution of\nthe Management Board to make such payments or to change the Companies policies in respect of making\nsuch payments, shall require the approval of the Supervisory Board. In any event, the amount and the\nterms and conditions of each of such payments shall be in conformity with market practice and be com-\npliant with the arm's length principle;\nBest practice provision IV.3.1 provides that the Company shall make provisions for all Shareholders to\nfollow meetings with analysts, presentations to analysts, presentations to investors and institutional inves-\ntors in real time, by means of webcasting, telephone or by any other means. However, the Company shall\ncomply with this rule for major investor conferences only. The Company believes that, considering its\nsize, enabling Shareholders to follow in real time all of the meetings with analysts, presentations to ana-\nlysts, and presentations to investors as referred to in this best practice provision would create an excessive\nburden on the Company's resources. The Company will make sure that all presentations shall be posted\non the website of the Company as soon practically possible.\n", "page_number": 184, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4566053869174861, "height": 0.3715262932877298, "width": 0.720677146311971}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-184-1", "text": "181\n", "page_number": 184, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-0", "text": "MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS\n", "page_number": 185, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8700120918984281, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.7448609431680775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-1", "text": "Corporate Reorganisation\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.12612227447627192, "lower_right_x": 0.3476420798065296, "lower_right_y": 0.14194100042753313, "height": 0.015818725951261214, "width": 0.22914147521160821}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-2", "text": "The Company was incorporated on 8 October 2015 as a private company with limited liability (besloten ven-\nnootschap met beperkte aansprakelijkheid) by LSP Curetis Pooling B.V. At the time of incorporation, one Share\nwas issued to LSP Curetis Pooling B.V. (the \"Incorporation Share\"). Immediately upon determination of the\nOffer Price a corporate reorganisation (the \"Reorganisation\") will be effected whereby the Incorporation Share\nwill be cancelled and new Shares will be issued to the current shareholders of Curetis AG which, as considera-\ntion, shall transfer all shares in the share capital of Curetis AG as a contribution in kind and the Company will be\nconverted into a public company with limited liability (naamloze vennootschap) named Curetis N.V. (see also\n\"Description of Share Capital \u2013 General\"). As a result of the Reorganisation, Curetis AG will become a wholly\nowned subsidiary of the Company and the shareholders of Curetis AG will become Shareholders, in aggregate\nholding 11,107,378 Shares.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.29157759726378796, "height": 0.13467293715262935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-3", "text": "As part of the Reorganisation, the current shareholders of Curetis AG will exchange their shares in Curetis AG,\nconsisting of common shares, class (A) voting preference shares and class (B) voting preference shares, for\nShares in accordance with individual exchange ratios (the \"Share Swap\"). All of the shares in Curetis AG will\nbe converted into Shares on a one-to-two ratio for the aggregate number of shares, so that 5,553,689 shares in\nCuretis AG will be converted into 11,107,378 Shares, it being understood that the individual exchange ratios will\nbe different, so that some shareholders will receive less than two Shares for one Curetis AG share, and some will\nreceive more. In detail, the respectively applicable individual exchange ratio will depend on (i) the Offer Price,\n(ii) the applicable liquidation preference factor and (iii) the individual contributions rendered by the respective\nshareholder to Curetis AG. Generally, under the applicable shareholders' agreements (which will be terminated\nwith effect as of the effectiveness of the Share Swap except for those of aeris CAPITAL and KfW who will\ncontinue to pool their voting rights), the shareholders holding class (A) voting preference shares and/or class (B)\nvoting preference shares of Curetis AG are entitled to receive more Shares for each class (A) voting preference\nshare and/or class (B) voting preference share held by them immediately prior to Reorganisation as those shares\nbenefit from liquidation preferences. The applicable shareholders' agreements provide for a fixed liquidation\npreference factor (as a factor of the individual contributions of the respective shareholder to Curetis AG). How-\never, the shareholders have resolved, prior to the Share Swap, to change such liquidation preference factor. Ac-\ncording to this resolution, the liquidation preference factor will be determined by a sliding scale which will de-\npend on the Offer Price (the factor will be decreasing straight proportionally to the Offer Price, beginning at 1.5x\nat an Offer Price of \u20ac8.10 and decreasing to 0 at an Offer Price of \u20ac16.20). The applicable liquidation preference,\nif any, will be fulfilled by applying different individual exchange ratios in the Share Swap.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.572894399315947, "height": 0.27233860624198375, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-4", "text": "As a consequence, the final number of Shares to be received by each Shareholder can only be determined imme-\ndiately upon determination of the Offer Price. The final number of Shares to be received by each Shareholder\nwho has a notifiable interest will be set out in such Shareholder's filings with the AFM.\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6203505771697306, "height": 0.03933304831124407, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-5", "text": "Holdings immediately prior to and after the Offering\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.5755743651753326, "lower_right_y": 0.6515604959384352, "height": 0.015818725951261214, "width": 0.46009673518742444}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-6", "text": "At the date of this Prospectus, only one Share is outstanding, which is held by LSP Curetis Pooling B.V. The\nfollowing table sets forth the Shareholders upon completion of the Reorganisation (see above) which to the\nCompany's knowledge, directly or indirectly, will have a notifiable interest in the Company's capital and voting\nrights within the meaning of the Dutch Financial Supervision Act following the Reorganisation and prior to the\nissuance of the Offer Shares and Settlement, immediately following the issuance of the Offer Shares and\nSettlement and assuming (i) an Offer Price at the mid-point of the Offer Price Range, (ii) that either a number of\nOffer Shares leading to gross proceeds corresponding to the Target Proceeds at the mid-point of the Offer Price\nRange or the maximum number of Offer Shares are subscribed for and (iii) either no exercise of the Over-\nallotment Option or full exercise of the Over-allotment Option:\n", "page_number": 185, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7896536981616076, "height": 0.12312954253954689, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-185-7", "text": "182\n", "page_number": 185, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-0", "text": "Shareholdings\n", "page_number": 186, "bounding_box": {"top_left_x": 0.5223700120918985, "top_left_y": 0.0837964942283027, "lower_right_x": 0.624546553808948, "lower_right_y": 0.10303548525010689, "height": 0.019238991021804194, "width": 0.10217654171704948}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-1", "text": "                      Following the          Following         the   Following the Set-       Following       the   Following the Set-\n                      Reorganisation and     Settlement (assum-      tlement (assuming        Settlement (assum-    tlement    (assuming\n                      prior to issuance of   ing the issuance of a   the issuance of a        ing issuance of the   issuance    of   the\n                      the Offer Shares       number of Offer         number of Offer          maximum number        maximum number of\n                                             Shares at the mid-      Shares at the mid-       of Offer Shares       Offer Shares with\n                                             point of the Offer      point of the Offer       without exercise of   full exercise of the\n                                             Price Range leading     Price Range leading      the Over-allotment    Over-allotment\n                                             to the Target Pro-      to the Target Pro-       Option)               Option)\n                                             ceeds        without    ceeds    with     full\n                                             exercise    of    the   exercise of the Over-\n                                             Over-allotment          allotment Option)\n                                             Option)\nName of               Shares         in %    Shares         in %     Shares         in %      Shares        in %    Shares        in %\nShareholder\naeris CAPITAL\nEquity Invest-\nments, L.P.1            2,439,165     22%      2,890,666     21%      2,890,666       20%      2,890,666    19%       2,890,666    18%\nLSP       Curetis\nPooling B.V. 2          2,208,528     20%      2,590,639     19%      2,590,639       18%      2,590,639    17%       2,590,639    16%\nForbion Capital\nFund II Co\u00f6per-\natief U.A.3             1,111,269     10%      1,297,212      9%      1,297,212        9%      1,297,212      8%      1,297,212      8%\nKfW                       935,162      8%       935,162       7%        935,162        7%        935,162      6%        935,162      6%\nHBM BioCapital\nII Invest S.a.r.l.4     1,047,268      9%      1,204,527      9%      1,204,527        8%      1,204,527      8%      1,204,527      8%\nBioMed Invest II\nLP5                       780,202      7%       863,922       6%        863,922        6%        863,922      6%        863,922      5%\nRoche        Finanz\nAG6                       777,887      7%       908,119       7%        908,119        6%        908,119    6%          908,119      6%\nCD-Venture\nGmbH                      435,182      4%       453,786       3%        453,786        3%        453,786      3%        453,786      3%\nQiagen N.V.               307,259      3%       307,259       2%        307,259        2%        307,259      2%        307,259      2%\n         7\nOthers                  1,065,456     10%      2,381,667     17%      2,790,504       20%      3,822,753    25%       4,447,753    28%\nTotal                  11,107,378     100    13,832,959       100    14,241,796        100    15,274,045     100     15,899,045     100\n", "page_number": 186, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.10987601539119282, "lower_right_x": 0.9177750906892382, "lower_right_y": 0.5750320649850363, "height": 0.4651560495938435, "width": 0.8004836759371221}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-2", "text": "1\n  With aeris CAPITAL Equity Investments Ltd. as its general partner.\n2\n  The voting rights are attributed to LSP HEF Holding C.V. (with LSP Health Economics Fund Management B.V. acting as general partner) and to Co\u00f6peratif\nLSP IV U.A. (with LSP IV Management B.V. acting as the director) .\n3\n  The voting rights are attributed to Forbion II Management B.V.\n4\n  The voting rights are attributed to HBM BioCapital II LP.\n5\n  The voting rights are attributed to BioMedInvest AG I.\n6\n  The voting rights are attributed to Roche Holding Ltd. Includes the shares that Roche Finance Ltd. has committed to subscribe in the Offering.\n7\n  Others refer to shareholdings with less than three percent in the Company.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.6566908935442497, "height": 0.07909362975630618, "width": 0.7503022974607013}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-3", "text": "With the completion of the Offering, the existing phantom stock option programme of Curetis AG will be cash-\nsettled for some beneficiaries at the level of Curetis AG and restructured and settled in Shares at the level of the\nCompany for others (see \"Management, Employees and Corporate Governance \u2013 Share-based Compensation\nPlan\"). To be able to settle such phantom stock options in Shares, the Company will, assuming an Offer Price at\nthe upper end of the Offer Price Range, issue 665,020 new Shares following expiry of the lock-up period for the\nexisting Shareholders of 365 days from the Settlement Date.\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7451902522445489, "height": 0.08208636169303118, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-4", "text": "Related Party Transactions\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.7759726378794357, "height": 0.017101325352714913, "width": 0.24244256348246673}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-5", "text": "In accordance with IAS 24, transactions with persons or companies which are, inter alia, members of the same\ngroup as the Company or which are in control of or controlled by the Company must be disclosed, unless they\nare already included as consolidated companies in the Company's audited consolidated financial statements.\nControl exists if a shareholder owns more than half of the voting rights in the Company or, by virtue of an\nagreement, has the power to control the financial and operating policies of the Company's management. The\ndisclosure requirements under IAS 24 also extend to transactions with associated companies (including joint\nventures) as well as transactions with persons who have significant influence on the Company's financial and\noperating policies, including close family members and intermediate entities. This includes Managing Directors\nand Supervisory Directors (or the members of the corresponding governing bodies of Curetis AG, respectively)\nand close members of their families, as well as those entities over which the members of the Management Board\n", "page_number": 186, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9264643009833262, "height": 0.13681060282171864, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-186-6", "text": "183\n", "page_number": 186, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-0", "text": "and Supervisory Board or their close family members are able to exercise a significant influence or in which they\nhold a significant share of voting rights.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-1", "text": "Set forth below is a summary of such transactions with related parties for the fiscal years ended 31 December\n2014, 31 December 2013 and 31 December 2012 as well as for the current fiscal year up to and including the\ndate of this prospectus. Further information, including quantitative amounts, of related party transactions are\ncontained in the notes to Curetis AG's audited financial statements under IFRS as of and for the years ended\n31 December 2014, 31 December 2013 and 31 December 2012 and in the notes to Curetis AG's unaudited inter-\nim financial statements under IFRS as of and for the six months ended 30 June 2015, which are all included in\nthe section \"Financial Information\" of this Prospectus.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.2129115006412997, "height": 0.09362975630611374, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"periods_of_audited_financial_statements": ["for the years ended31 December 2014, 31 December 2013 and 31 December 2012"], "audited_financial_statements": ["Curetis AG's audited financial statements under IFRS as of and for the years ended31 December 2014, 31 December 2013 and 31 December 2012"]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-2", "text": "the section \"Financial Information\" of this Prospectus.\nTransactions with related parties occur in the normal course of business. Related party transactions have been\nlisted below.\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21333903377511756, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.24625908507909364, "height": 0.03292005130397607, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-3", "text": "Compensation of key management\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.3573155985489722, "lower_right_y": 0.27704147071398033, "height": 0.014108593415989745, "width": 0.2418379685610641}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-4", "text": "Key management includes the Company's officers and directors. The compensation of key management for em-\nployee services is shown below(1):\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.31124412141941, "height": 0.02778965369816161, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-5", "text": "in \u20ac thousand                                     2014   2013   2012\nSalaries and other short-term employee benefits    490    586    585\nPost-employment benefits                            \u2013      \u2013       \u2013\nShare-based payments                               488    -66   1,012\nOther                                               14     3       7\nTotal                                              992    523   1,604\n", "page_number": 187, "bounding_box": {"top_left_x": 0.11185006045949214, "top_left_y": 0.31765711842667804, "lower_right_x": 0.9141475211608222, "lower_right_y": 0.4480547242411287, "height": 0.13039760581445065, "width": 0.80229746070133}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-6", "text": "(1) Including the increases for respective years in profit sharing bonuses (interest-effect) as described under \"Management, Employees and Corporate Govern-\nance \u2013 Profit Sharing Bonus\".\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47498931167165453, "height": 0.020521590423257796, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-7", "text": "Compensation of supervisory board\n", "page_number": 187, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.36698911729141476, "lower_right_y": 0.5027789653698161, "height": 0.014108593415989745, "width": 0.25151148730350664}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-8", "text": "The compensation of supervisory board is shown below:\n\nin \u20ac thousand                                           2014   2013   2012\nBoard member remuneration                                 36     10     10\nTotal                                                     36     10     10\n", "page_number": 187, "bounding_box": {"top_left_x": 0.11064087061668681, "top_left_y": 0.5096194955109021, "lower_right_x": 0.9141475211608222, "lower_right_y": 0.5942710560068405, "height": 0.08465156049593836, "width": 0.8035066505441354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-187-9", "text": "184\n", "page_number": 187, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-0", "text": "DESCRIPTION OF SHARE CAPITAL\n", "page_number": 188, "bounding_box": {"top_left_x": 0.29443772672309554, "top_left_y": 0.09191962377084224, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.4062877871825876}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-1", "text": "The following paragraphs summarise certain information concerning the Company's share capital and certain\nmaterial provisions of the Articles of Association and applicable laws of the Netherlands. This section\nsummarises the Articles of Association as amended pursuant to the Deed of Amendment (as defined below)\nimmediately after determination of the Offer Price.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17999144933732364, "height": 0.05386917486105172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-2", "text": "This summary does not purport to give a complete overview and should be read in conjunction with, and is qual-\nified in its entirety by reference to the relevant provisions of the laws of the Netherlands as in force on the date\nof this Prospectus, the Articles of Association, the Management Board Rules and the Supervisory Board Rules as\nin effect upon the Conversion. The Articles of Association in the governing Dutch language and in an unofficial\nEnglish translation thereof are available on the Company's website (www.curetis.com), the Management Board\nRules and the Supervisory Board Rules will be available immediately after the Conversion. See also \"Manage-\nment, Employees and Corporate Governance\" for a summary of certain material provisions of the Articles of\nAssociation, Management Board Rules, Supervisory Board Rules and the laws of the Netherlands relating to the\nManagement Board and the Supervisory Board.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.880894800483676, "lower_right_y": 0.3099615220179564, "height": 0.1222744762719111, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-3", "text": "General\n", "page_number": 188, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.324497648567764, "lower_right_x": 0.186819830713422, "lower_right_y": 0.3381787088499359, "height": 0.01368106028217192, "width": 0.07073760580411124}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-4", "text": "The Company was incorporated as a private limited liability company (besloten vennootschap met beperkte\naansprakelijkheid) under the laws of the Netherlands on 8 October 2015. The Company is domiciled in\nHolzgerlingen, Germany. The Company will be converted to a public company with limited liability (naamloze\nvennootschap) immediately after determination of the Offer Price by execution of a notarial deed of conversion\nand amendment of the articles of association of the Company (the \"Deed of Amendment\"). The legal and\ncommercial name of the Company will then become Curetis N.V. The statutory seat of the Company is in\nAmsterdam, The Netherlands, and its principal place of business is at Holzgerlingen, Germany. The Company is\nregistered in the Commercial Register of the Chamber of Commerce (Handelsregister van de Kamer van\nKoophandel) under number 64302679.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47798204360837965, "height": 0.12270200940572895, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-5", "text": "Corporate Purpose\n", "page_number": 188, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.4920906370243694, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.5087644292432664, "height": 0.016673792218896977, "width": 0.16565900846432888}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-6", "text": "Pursuant to article 3 of the Articles of Association, the corporate objectives of the Company are:\n(a)    to develop, to produce and to sell products and solutions for molecular diagnostics (MDx) combating\n       infectious diseases and other diseases;\n(b)    to participate in, to take an interest in any other way in and to conduct the management of other business\n       enterprises, of whatever nature;\n(c)    to finance other persons and to give security, to give guarantees and to bind itself in any other manner for\n       debts of other persons;\n(d)    to borrow, to lend and to raise funds, including the issue of bonds, debt instruments and other securities,\n       as well as to enter into agreements in connection therewith;\n(e)    to render advice and services to other persons;\n(f)    to acquire, manage, exploit and dispose of immovables and other registered properties;\n(g)    to develop, exploit and trade in patents, trademarks, licenses, know-how, copyrights, database rights and\n       other intellectual property rights;\n(h)    to perform all activities of an industrial, financial or commercial nature,\nas well as all activities which are incidental to or which may be conducive to any of the foregoing in the broadest\nsense.\nIn pursuing its objectives, the Company shall also take into account the interests of the legal entities and\ncompanies with which it forms a group.\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5228730226592561, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8405301410859342, "height": 0.3176571184266781, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-7", "text": "Share Capital\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.23941958887545345, "lower_right_y": 0.8704574604531852, "height": 0.015818725951261325, "width": 0.12394195888754535}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-8", "text": "Authorised and issued share capital of the Company\n", "page_number": 188, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8854211201368106, "lower_right_x": 0.47944377267230953, "lower_right_y": 0.8986746472851646, "height": 0.013253527148353927, "width": 0.3633615477629988}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-9", "text": "Prior to the execution of the Deed of Amendment, the issued share capital of the Company consists of\n11,107,378 Shares. After the execution of the Deed of Amendment, the authorised capital of the Company will\n", "page_number": 188, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8991021804189825, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9328772979905943, "height": 0.03377511757161178, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-188-10", "text": "185\n", "page_number": 188, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-0", "text": "amount to \u20ac550,000 and will consist of 55,000,000 Shares with a nominal value of \u20ac0.01 each and the issued\nshare capital will consist of 15,899,045 Shares (assuming the maximum number of Offer Shares are issued and\nfull exercise of the Over-allotment Option). As of the date of this Prospectus, no Shares are held by the\nCompany. The Incorporation Share is fully paid-up and is subject to, and is been created under, the laws of the\nNetherlands.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.06541256947413425, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-1", "text": "History of share capital\n", "page_number": 189, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1671654553227875, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.18127404873877725, "height": 0.014108593415989745, "width": 0.16928657799274488}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-2", "text": "Other than the Incorporation Share upon the Company's incorporation, the Company has not issued any shares\nprior to the date of this Prospectus.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.879081015719468, "lower_right_y": 0.21547669944420692, "height": 0.02778965369816161, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-3", "text": "Shareholders' register\n", "page_number": 189, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.22873022659256093, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.24283882000855067, "height": 0.014108593415989745, "width": 0.158403869407497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-4", "text": "The Shares are in registered form (op naam). No share certificates (aandeelbewijzen) are or may be issued. If\nrequested, the Management Board will provide a Shareholder, usufructuary or pledgee of such Shares with an\nextract from the register relating to his or her title to a Share free of charge. If the Shares are encumbered with a\nright of usufruct or a right of pledge, the extract will state to whom such rights will fall to. The shareholders'\nregister is kept by the Management Board.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.880894800483676, "lower_right_y": 0.3180846515604959, "height": 0.0688328345446772, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-5", "text": "The Company's shareholders register records the names and addresses of the Shareholders, the number of Shares\nheld, the amount paid on each Share and the date of registration in the shareholders' register. In addition, each\ntransfer or passing of ownership is registered in the shareholders' register. The shareholders register also includes\nthe names and addresses of persons and legal entities with a right of pledge (pandrecht) or a right of usufruct\n(vruchtgebruik) on those Shares.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39333048311244123, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-6", "text": "For shares as referred to in the Dutch Securities Giro Transfers Act (Wet giraal effectenverkeer), including the\nOffer Shares, which belong to (i) a collective depot as referred to in that Dutch Securities Giro Transfers Act, of\nwhich shares form part as being kept by an intermediary, as referred to in the Dutch Securities Giro Transfers\nAct or (ii) a giro depot as referred to in that Dutch Securities Giro Transfers Act of which shares form part, as\nbeing kept by a central institute as referred to in the Dutch Securities Giro Transfers Act, the name and address\nof the intermediary or the central institute shall be entered in the shareholders' register, stating the date on which\nthose shares became part of such collective depot or giro depot, the date of acknowledgement by or giving of\nnotice to, as well as the paid-up amount on each share.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.5096194955109021, "height": 0.10987601539119285, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-7", "text": "Issuance of Shares\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.5386917486105173, "height": 0.012398460880718165, "width": 0.13603385731559853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-8", "text": "Prior to the Conversion, the General Meeting shall resolve to issue the Offer Shares following the Conversion\nand to exclude the pre-emptive rights of Shareholders with respect to the issuance of the Offer Shares.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.572894399315947, "height": 0.02607952116289014, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-9", "text": "The General Meeting may, on a proposal of the Management Board, which is approved by the Supervisory\nBoard, resolve to issue Shares or grant rights to subscribe for Shares and to restrict and/or exclude statutory pre-\nemptive rights in relation to the issuance of Shares or the granting of rights to subscribe for Shares. The Articles\nof Association provide that the General Meeting may, upon a proposal of the Management Board which is ap-\nproved by the Supervisory Board, designate the Management Board as the body authorised, subject to approval\nof the Supervisory Board, to resolve to issue Shares and to grant rights to subscribe for Shares and to restrict or\nexclude statutory pre-emptive rights in relation to the issue of Shares or the granting of rights to subscribe for\nShares. Pursuant to the Articles of Association and Dutch law, the period of designation may not exceed five\nyears but the designation may be renewed by a resolution of the General Meeting for periods of up to five years.\nUnless provided otherwise in the designation, the designation cannot be cancelled. The resolution designating\nsuch authority to the Management Board must specify the number of Shares which may be issued and, if appli-\ncable, any conditions to the issuance.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7434801197092775, "height": 0.16246259085079096, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-10", "text": "No resolution of the General Meeting or, if designated, the Management Board is required for an issue of Shares\npursuant to the exercise of a previously granted right to subscribe for Shares. The Company may not subscribe\nfor its own Shares on issue.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7520307823856349, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7900812312954254, "height": 0.03805044890979048, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-11", "text": "The General Meeting shall designate the Management Board, for a period that ends 18 months following the\nConversion, as the corporate body authorised to, subject to approval of the Supervisory Board, issue Shares or\ngrant rights to subscribe for Shares and to restrict or exclude pre-emptive rights in respect thereof. Pursuant to\nthis designation, the Management Board may, subject to approval of the Supervisory Board, resolve to issue\nShares or grant rights to subscribe for Shares (i) up to a maximum of 10% of the total number of Shares issued\nand outstanding on the Settlement Date (as defined below) plus (ii) an additional 10% of the total number of\nShares issued and outstanding on the Settlement Date in connection with or on the occasion of mergers and ac-\nquisitions and strategic alliances. Such authorisation may from time to time be extended by a resolution of the\nGeneral Meeting subject to the limitations set out above.\n", "page_number": 189, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.9221889696451475, "height": 0.12227447627191113, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-189-12", "text": "186\n", "page_number": 189, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-0", "text": "Pre-emptive Rights\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.13603385731559853}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-1", "text": "Each Shareholder shall have a pre-emptive right in proportion to the aggregate nominal amount of his or her\nShares. Shareholders do not have pre-emptive rights in respect of Shares issued against contribution in kind,\nShares issued to employees of the Company and any of its group companies or Shares issued to persons\nexercising a previously granted right to subscribe for Shares.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16032492518170158, "height": 0.05472424112868747, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-2", "text": "Prior to the Conversion, the General Meeting shall resolve to issue the Offer Shares following the Conversion\nand to exclude the pre-emptive rights of Shareholders with respect to the issuance of the Offer Shares.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19452757588713127, "height": 0.027362120564343756, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-3", "text": "Pre-emptive rights may be restricted or excluded by a resolution of the General Meeting at the proposal of the\nManagement Board, which is subject to the approval of the Supervisory Board. Such resolution of the General\nMeeting requires a majority of at least two-thirds of the votes cast, if less than half of the issued and outstanding\nshare capital of the Company is present or represented at the General Meeting.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25651988029072254, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-4", "text": "The Management Board is authorised, subject to the approval of the Supervisory Board to resolve on the\nrestriction or exclusion of the pre-emptive right if and to the extent the Management Board has been designated\nby the General Meeting to do so. The designation will only be valid for a specific period and may from time to\ntime be extended by the General Meeting, in each case not exceeding five years. Unless provided otherwise in\nthe designation, the designation cannot be cancelled.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3317657118426678, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-5", "text": "The General Meeting shall designate the Management Board, for a period that ends 18 months following the\nConversion, as the corporate body authorised to, subject to approval of the Supervisory Board, issue Shares or\ngrant rights to subscribe for Shares and to restrict and/or exclude statutory pre-emptive rights in relation to the\nissuances of Shares or the granting of rights to subscribe for Shares. Such authorisation of the Management\nBoard is limited to (i) up to a maximum of 10% of the total number of Shares issued and outstanding on the\nSettlement Date plus (ii) an additional 10% of the total number of Shares issued and outstanding on the Settle-\nment Date in connection with or on the occasion of mergers and acquisitions and strategic alliances and such\nauthorisation may from time to time be extended by a resolution of the General Meeting, subject to the limita-\ntions set out above.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3381787088499359, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4583155194527576, "height": 0.12013681060282172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-6", "text": "Acquisition of Shares by the Company\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.3863361547762999, "lower_right_y": 0.4890979050876443, "height": 0.014108593415989745, "width": 0.2708585247883918}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-7", "text": "The Company may acquire fully paid-up Shares at any time for no consideration or, subject to the laws of the\nNetherlands and the Articles of Association if: (i) the distributable part of the Shareholders' equity is at least\nequal to the total purchase price of the repurchased Shares; (ii) the aggregate nominal value of the Shares which\nthe Company acquires, holds or holds as pledge or which are held by a subsidiary does not exceed 50% of the\nissued share capital; and (iii) the Management Board has been authorised by the General Meeting to repurchase\nShares, which authorisation can only be granted at the proposal of the Management Board, which proposal is\nsubject to the approval of the Supervisory Board. The General Meeting's authorisation is valid for a specific\nperiod not exceeding 18 months. As part of the authorisation, the General Meeting must specify the number of\nShares that may be acquired, the manner in which the Shares may be acquired and the price range within which\nthe Shares may be acquired.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.880894800483676, "lower_right_y": 0.6327490380504489, "height": 0.13723813595553658, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-8", "text": "No authorisation from the General Meeting is required for the acquisition of fully paid-up Shares for the purpose\nof transferring these Shares to Curetis' employees pursuant to any share option plan.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6669516887558786, "height": 0.027789653698161665, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-9", "text": "The Company may not cast votes on, and is not entitled to dividends paid on, Shares held by it nor will such\nShares be counted for the purpose of calculating a voting quorum. For the computation of the profit distribution,\nthe Shares held by the Company in its own capital shall not be included. The Management Board is authorised,\nsubject to approval of the Supervisory Board, to dispose of the Company's own Shares held by it.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6733646857631467, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.728516460025652, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-10", "text": "The General Meeting shall designate the Management Board, for a period that ends 18 months following the\nConversion, as the corporate body authorised to, subject to approval of the Supervisory Board, cause the\nCompany to acquire its own fully paid-up Shares (including Shares issued as stock dividend), subject to the\napproval of the Supervisory Board, up to a maximum of 10% of the total number of Shares issued immediately\nfollowing the Settlement Date plus any and all of the Roll-Over Shares, provided the Company will hold no\nmore Shares in stock than at maximum 50% of the issued share capital, either through purchase on a stock\nexchange or otherwise, at a price, excluding expenses, not lower than the nominal value of the Shares and not\nhigher than the opening price on Euronext in Amsterdam and Euronext in Brussels on the day of the repurchase\nplus 10%.\n", "page_number": 190, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.73492945703292, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8584865327062847, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-190-11", "text": "187\n", "page_number": 190, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-0", "text": "Transfer of Shares\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.08507909362975631, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.13301088270858524}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-1", "text": "A transfer of a Share or a restricted right thereto (beperkt recht) requires a deed of transfer and the\nacknowledgment by the Company of the transfer in writing. Such acknowledgement is not required if the\nCompany itself is a party to the transfer.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1466438648995297, "height": 0.041043180846515606, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-2", "text": "A Share becomes a deposit share by transfer or issuance to Euroclear Nederland or to an intermediary, recording\nin writing that it is a deposit share. The deposit share shall be recorded in the Company's shareholders register in\nthe name of Euroclear Nederland or the relevant intermediary, stating in writing that it is a deposit share. Deposit\nShareholders are not recorded in the Company's shareholders register. Deposit shares can only be delivered from\na collective depot or giro depot with due observance of the related provisions of the Dutch Securities Giro\nTransfers Act and with the approval of the Management Board. The transfer by a deposit shareholder of its book-\nentry rights representing deposit shares shall be effected in accordance with the provisions of the Dutch\nSecurities Giro Transfers Act. The same applies to the establishment of a right of pledge and the establishment or\ntransfer of a usufruct on these book-entry rights.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27661393758016245, "height": 0.1231295425395468, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-3", "text": "Capital Reduction\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.2460701330108827, "lower_right_y": 0.30440359127832406, "height": 0.014108593415989745, "width": 0.1305925030229746}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-4", "text": "Subject to the provisions of the laws of the Netherlands and the Articles of Association, the General Meeting\nmay resolve to reduce the issued share capital by (i) cancelling Shares or (ii) reducing the nominal value of\nShares through an amendment of the Articles of Association. A resolution to cancel Shares may only relate to\nShares held by the Company itself or of which it holds the depositary receipts. A reduction of the nominal value\nof Shares, with or without repayment must be made pro rata on all Shares concerned. This pro rata requirement\nmay be waived if all Shareholders concerned so agree.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.39333048311244123, "height": 0.08251389482684912, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-5", "text": "A resolution of the General Meeting upon a proposal of the Management Board, which is subject to the prior\napproval of the Supervisory Board, to reduce the share capital requires a majority of at least two-thirds of the\nvotes cast, if less than half of the issued and outstanding share capital is present or represented at the General\nMeeting.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.45446772124839674, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-6", "text": "In addition, the laws of the Netherlands contain detailed provisions regarding the reduction of capital. A\nresolution to reduce the issued share capital shall not take effect as long as creditors have legal recourse against\nthe resolution. Certain aspects of taxation of a reduction of share capital are described in the section \"Taxation\"\nof this Prospectus.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.516460025651988, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-7", "text": "Dividends and Other Distributions\n", "page_number": 191, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.533133817870885, "lower_right_x": 0.4183796856106409, "lower_right_y": 0.5455322787516033, "height": 0.012398460880718276, "width": 0.3022974607013301}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-8", "text": "General\n", "page_number": 191, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5604959384352287, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.5737494655835828, "height": 0.013253527148354038, "width": 0.06287787182587666}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-9", "text": "Distribution of profits only takes place following the adoption of the annual accounts from which it appears that\nthe distribution is allowed. The Company may only make distributions, whether a distribution of profits or of\nfreely distributable reserves, to its shareholders if its shareholders' equity exceeds the sum of the paid-up and\ncalled-up share capital plus the reserves required to be maintained by the laws of the Netherlands or by the\nArticles of Association. See the section \"Dividends and Dividend Policy\" for a more detailed description\nregarding dividends.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6635314236853356, "height": 0.08251389482684901, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-10", "text": "Right to reserve\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.6930312099187687, "height": 0.012825994014536102, "width": 0.11185006045949215}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-11", "text": "The Management Board, subject to the prior approval of the Supervisory Board, may resolve to reserve the\nprofits or a part of the profits.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7007268063274904, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.728516460025652, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-12", "text": "Dissolution and liquidation\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.741769987174006, "lower_right_x": 0.309552599758162, "lower_right_y": 0.7554510474561779, "height": 0.013681060282171864, "width": 0.1940749697702539}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-13", "text": "The Company may only be dissolved by a resolution of the General Meeting upon a proposal of the Management\nBoard, which is subject to the prior approval of the Supervisory Board. If the General Meeting has resolved to\ndissolve the Company, the Management Board must carry out the liquidation of the Company, unless otherwise\nresolved by the General Meeting. The Supervisory Board shall be charged with the supervision thereof. During\nliquidation, the provisions of the Articles of Association will remain in force to the extent possible.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7622915775972637, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8302693458743052, "height": 0.0679777682770415, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-14", "text": "The balance of the Company's assets remaining after all liabilities and the costs of liquidation have been\ndeducted shall be distributed among the Shareholders in proportion of their number of Shares.\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.837537409149209, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8653270628473707, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-15", "text": "Exchange Controls and other Provisions relating to non-Dutch Shareholders\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8790081231295426, "lower_right_x": 0.652962515114873, "lower_right_y": 0.8922616502778965, "height": 0.013253527148353927, "width": 0.5374848851269649}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-16", "text": "Under Dutch law, subject to the 1977 Sanction Act (Sanctiewet 1977) or otherwise by international sanctions,\nthere are no exchange control restrictions on investments in, or payments on, Shares (except as to cash amounts).\n", "page_number": 191, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8991021804189825, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-191-17", "text": "188\n", "page_number": 191, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-0", "text": "There are no special restrictions in the Articles of Association or the laws of the Netherlands that limit the right\nof Shareholders who are not citizens or residents of the Netherlands to hold or vote Shares.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.10944848225737494, "height": 0.02436938862761863, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-1", "text": "General Meetings and Voting Rights\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.14279606669516887, "height": 0.01667379221889695, "width": 0.31983071342200725}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-2", "text": "General Meetings\n", "page_number": 192, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.1569046601111586, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.17101325352714836, "height": 0.014108593415989745, "width": 0.12454655380894801}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-3", "text": "General Meetings shall be held in the Netherlands in Amsterdam, Haarlemmermeer, The Hague, Rotterdam,\nUtrecht or Arnhem. The annual General Meeting must be held at least once a year, no later than in June.\nExtraordinary General Meetings may be held, as often as the Management Board or the Supervisory Board deem\ndesirable. In addition, one or more Shareholders, who solely or jointly represent at least one-tenth of the issued\ncapital, may request that a General Meeting be convened, the request setting out in detail matters to be\nconsidered. If no General Meeting has been held within 42 days of the Shareholder(s) making such request,\nthat/those Shareholder(s) will be authorised to request in summary proceedings a Dutch District Court to\nconvene a General Meeting. In any event, a General Meeting will be held to discuss any requisite measures\nwithin three months of it becoming apparent to the Management Board that the shareholders' equity of the\nCompany has decreased to an amount equal to or lower than one-half of the issued and paid-up part of the\ncapital.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1774262505344164, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.32791791363830697, "height": 0.15049166310389056, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-4", "text": "The convocation of the General Meeting must be published through an announcement on the website of the\nCompany. The notice must state the time and place of the meeting, the record date, the manner in which persons\nentitled to attend the General Meeting may register and exercise their rights, the time on which registration for\nthe meeting must have occurred ultimately, as well as the place where the meeting documents may be obtained.\nThe notice must be given by at least such number of days prior to the day of the meeting as required by the laws\nof the Netherlands, which is currently 42 days.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41727233860624197, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-5", "text": "The agenda for the annual General Meeting must contain certain subjects, including, among other things, the\nadoption of the Company's annual accounts, the discussion of any substantial change in the Company's corporate\ngovernance structure and the allocation of the profit, insofar as this is at the disposal of the General Meeting. In\naddition, the agenda shall include such items as have been included therein by the Management Board, the\nSupervisory Board or Shareholders (with due observance of the laws of the Netherlands as described below). If\nthe agenda of the General Meeting contains the item of granting discharge to the Managing Directors and\nSupervisory Directors concerning the performance of their duties in the financial year in question, the matter of\nthe discharge shall be mentioned on the agenda as separate items for the Management Board and the Supervisory\nBoard respectively. The agenda shall also include such items as one or more Shareholders and others entitled to\nattend General Meetings, representing, pursuant to the Articles of Association, at least the percentage of the\nissued and outstanding share capital as required by law (which as of the date of this Prospectus is 3%), have\nrequested the Management Board by a motivated request to include in the agenda, at least 60 days before the day\nof the General Meeting. No resolutions may be adopted on items other than those which have been included in\nthe agenda, unless the resolution is adopted unanimously during a meeting where the entire issued capital of the\nCompany is present or represented.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.628901239846088, "height": 0.20521590423257796, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-6", "text": "Shareholders who individually or with other Shareholders, hold Shares that represent at least 1% of the issued\nand outstanding share capital or a market value of at least \u20ac250,000, may request the Company to disseminate\ninformation that is prepared by them in connection with an agenda item for a General Meeting. The Company\ncan only refuse disseminating such information, if received less than seven business days prior to the General\nMeeting, if the information gives or could give an incorrect of misleading signal or if, in light of the nature of the\ninformation, the Company cannot reasonably be required to disseminate it.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.718255664814023, "height": 0.08251389482684901, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-7", "text": "The General Meeting is chaired by the chairman of the Supervisory Board. Managing Directors and Supervisory\nDirectors may attend a General Meeting. In these General Meetings, they have an advisory vote. The chairman\nof the General Meeting may decide at his or her discretion to admit other persons to the General Meeting.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7246686618212912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7661393758016246, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-8", "text": "Each Shareholder may attend the General Meeting, address the General Meeting and exercise voting rights pro\nrata to his or her shareholding, either in person or by proxy. Shareholders may exercise these rights, if they are\nthe holders of Shares on the record date as required by the laws of the Netherlands, which is currently the 28 th\nday before the day of the General Meeting, and they or their proxy have notified the Company of their intention\nto attend the General Meeting in writing at the address and by the date specified in the notice of the meeting. The\nconvocation notice shall state the record date and the manner in which the persons entitled to attend the General\nMeeting may register and exercise their rights.\n", "page_number": 192, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8687473279179136, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-192-9", "text": "189\n", "page_number": 192, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-0", "text": "Voting rights\n", "page_number": 193, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.08507909362975631, "lower_right_x": 0.21100362756952842, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.09068923821039904}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-1", "text": "Each Share confers the right to cast one vote in the General Meeting. Subject to certain exceptions provided by\nDutch law or the Articles of Association, resolutions of the General Meeting are passed by an absolute majority\nof votes cast.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15049166310389056, "height": 0.03805044890979052, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-2", "text": "Pursuant to Dutch law, no votes may be cast at a General Meeting in respect of Shares which are held by the\nCompany.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19495510902094912, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-3", "text": "Amendment of the Articles of Association\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.22231722958529285, "height": 0.014108593415989718, "width": 0.29081015719467956}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-4", "text": "The General Meeting may resolve to amend the Articles of Association upon a proposal of the Management\nBoard which is subject to the prior approval of the Supervisory Board. A proposal to amend the Articles of\nAssociation must be included in the agenda. A copy of the proposal, containing the verbatim text of the proposed\namendment, must be lodged with the Company for the inspection of every Shareholder until the end of the\nGeneral Meeting.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2975630611372381, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-5", "text": "Dissolution and Liquidation\n", "page_number": 193, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3142368533561351, "lower_right_x": 0.36275695284159615, "lower_right_y": 0.32791791363830697, "height": 0.013681060282171864, "width": 0.2466747279322854}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-6", "text": "Under the Articles of Association, the Company may be dissolved by a resolution of the General Meeting,\nsubject to a proposal by the Management Board which has been approved by the Supervisory Board.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36938862761864044, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-7", "text": "In the event of dissolution, the Company's business will be liquidated in accordance with Dutch law and the\nArticles of Association and the liquidation shall be arranged by the Management Board under supervision of the\nSupervisory Board, unless the General Meeting has designated other liquidators. During liquidation, the\nprovisions of the Articles of Association will remain in force as far as possible.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43266353142368535, "height": 0.05344164172723387, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-8", "text": "The balance of the Company's remaining equity after payments of debts and liquidation costs will be distributed\nto holders of the Shares, in proportion to the aggregate nominal value of the Shares held by them.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4672937152629329, "height": 0.02650705429670802, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-9", "text": "Annual Accounts, Semi-Annual Accounts and Interim Management Statements\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8029020556227328, "lower_right_y": 0.496793501496366, "height": 0.014963659683625508, "width": 0.6874244256348246}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-10", "text": "Annually, within four months after the end of the financial year, the Management Board must prepare the annual\naccounts and make them available for inspection by the Shareholders at the Company's office. The annual ac-\ncounts must be accompanied by an independent auditors' report, an annual report and certain other information\nrequired under the laws of the Netherlands and a report of the Supervisory Board. The annual accounts must be\nsigned by the Managing Directors and the Supervisory Directors.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5805899957246686, "height": 0.06797776827704138, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-11", "text": "The annual accounts, the independent auditors' report, the annual report, the other information required under the\nlaws of the Netherlands and the report of the Supervisory Board must be made available to the Shareholders for\nreview as from the day of the notice convening the annual General Meeting. The annual accounts must be adopt-\ned by the General Meeting. The Management Board must send the adopted annual accounts to the AFM within\nfive business days after adoption.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6554082941427961, "height": 0.06755023514322367, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-12", "text": "The Company must prepare and make publicly available a semi-annual financial report as soon as possible, but\nat the latest two months after the end of the first six months of the financial year. It is expected that this period of\ntwo months will be extended to three months in November 2015. If the semi-annual financial report is audited or\nreviewed, the independent auditor's audit or review report, respectively, must be published together with the\nsemi-annual financial report.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7297990594271055, "height": 0.0666951688755878, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-13", "text": "During the period between ten weeks after the start and six weeks before the end of each half of the financial\nyear, the Company must prepare an interim management statement and make it publicly available. The interim\nmanagement statement must contain an explanation of the important events and transactions that took place\nduring the period between the start of the relevant period and publication of the interim management statement\nand the consequences for the Company's financial position. The interim management statement must also con-\ntain a general description of the Company's financial position and the performance during that period. It is ex-\npected that this requirement will be abolished in November 2015 and as such the Company will no longer be\npublishing interim management statements. To the extent required, the disclosure under \"Operating and Finan-\ncial Review \u2013 Recent Developments\" qualifies as the Company's interim management statements for the second\nhalf of 2015.\n", "page_number": 193, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.13381787088499353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-193-14", "text": "190\n", "page_number": 193, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-0", "text": "Dutch Financial Reporting Supervision Act\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.4207980652962515, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.3053204353083434}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-1", "text": "On the basis of the Dutch Financial Reporting Supervision Act (Wet toezicht financi\u00eble verslaggeving) (the\n\"FRSA\") the AFM supervises the application of financial reporting standards by, among others, companies\nwhose corporate seat is in the Netherlands and whose securities are listed on a regulated Dutch or foreign stock\nexchange, such as the Company.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.16032492518170158, "height": 0.05472424112868747, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-2", "text": "Pursuant to the FRSA, the AFM has an independent right to (i) request an explanation from the Company regard-\ning its application of the applicable financial reporting standards if, based on publicly known facts or circum-\nstances, it has reason to doubt that the Company's financial reporting meets such standards and (ii) recommend\nthe Company to make available further explanations. If the Company does not comply with such a request or\nrecommendation, the AFM may request that the enterprise chamber of the court of appeal in Amsterdam\n(Ondernemingskamer van het Gerechtshof te Amsterdam) (the \"Enterprise Chamber\") orders the Company to\n(i) provide an explanation of the way the Company has applied the applicable financial reporting standards to its\nfinancial reports or (ii) prepare its financial reports in accordance with the Enterprise Chamber's instructions.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.27661393758016245, "height": 0.10944848225737494, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-3", "text": "Rules Governing Obligations of Shareholders to Make a Public Takeover Bid\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.6577992744860943, "lower_right_y": 0.30440359127832406, "height": 0.014108593415989745, "width": 0.5423216444981862}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-4", "text": "Pursuant to the Dutch Financial Supervision Act and in accordance with European Directive 2004/25/EC, also\nknown as the takeover directive, the obligation to make a public takeover bid for all issued and outstanding\nshares or depositary receipts for shares in the share capital of a Dutch listed company arises when a party, by\nitself or together with parties with whom it is acting in concert, directly or indirectly acquires 'predominant con-\ntrol' in such listed company. 'Predominant control' is defined as being able to cast, alone or acting in concert, at\nleast 30% of the votes at the general meeting of such listed company.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39333048311244123, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-5", "text": "Under the Dutch Financial Supervision Act, \"persons with whom a party is acting in concert\" has been defined\nas natural persons, legal persons or companies collaborating under a contract with the aim to acquire predomi-\nnant control in a Dutch listed company or, if the target company is one of the collaborators, to frustrate the suc-\ncess of an announced public takeover bid for that company. The following categories of natural persons, legal\npersons or companies are deemed in any case to act in concert: (i) legal persons or companies which together\nform part of a group as referred to in Section 2:24b of the Dutch Civil Code; and (ii) natural persons, legal per-\nsons or companies and the undertakings controlled by these persons or companies.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.09619495510902093, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-6", "text": "No obligation to launch a public takeover bid exists if an exemption applies, including if a party has decreased\nits shareholding to below 30% within a period of 30 days, unless the loss of predominant control is the result of a\ntransfer of shares to a natural person, legal person or company that may invoke an exemption from the require-\nment to make a public takeover bid or if the controlling party has made use of its voting rights during that period.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-7", "text": "In addition, it is prohibited to launch a public takeover bid for shares of a listed company, such as the Offer\nShares, unless an offer document has been approved by the AFM. A public takeover bid may only be launched\nby way of publication of an approved offer document unless a company makes an offer for its shares. The public\ntakeover bid rules are intended to ensure that in the event of a public takeover bid, among others, sufficient in-\nformation will be made available to the holders of the shares, the holders of the shares will be treated equally,\nthat there will be no abuse of inside information and that there will be a proper and timely offer period.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5647712697734074, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6464300983326208, "height": 0.08165882855921336, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-8", "text": "Squeeze-out Proceedings\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6631038905515177, "lower_right_x": 0.29383313180169285, "lower_right_y": 0.675502351432236, "height": 0.012398460880718276, "width": 0.17835550181378473}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-9", "text": "Pursuant to Section 2:92a of the Dutch Civil Code, a shareholder who for his or her own account contributes at\nleast 95% of a Dutch company's issued share capital may institute proceedings against such company's minority\nshareholders jointly for the transfer of their shares to him or her. The proceedings are held before the Enterprise\nChamber and can be instituted by means of a writ of summons served upon each of the minority shareholders in\naccordance with the provisions of the Dutch Code of Civil Procedure (Wetboek van Burgerlijke Rechtsvorder-\ning). The Enterprise Chamber may grant the claim for squeeze-out in relation to all minority shareholders and\nwill determine the price to be paid for the shares, if necessary after appointment of one or three experts who will\noffer an opinion to the Enterprise Chamber on the value to be paid for the shares of the minority shareholders.\nOnce the order to transfer becomes final before the Enterprise Chamber, the person acquiring the shares shall\ngive written notice of the date and place of payment and the price to the holders of the shares to be acquired\nwhose addresses are known to him. Unless the addresses of all of them are known to him, he is required to pub-\nlish the same in a daily newspaper with nationwide circulation.\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8448054724241129, "height": 0.16117999144933737, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-10", "text": "The offeror under a public takeover bid is also entitled to start squeeze-out proceedings if, following the public\ntakeover bid, the offeror contributes at least 95% of the outstanding share capital and represents at least 95% of\nthe total voting rights. The claim of a takeover squeeze-out needs to be filed with the Enterprise Chamber within\nthree months following the expiry of the acceptance period of the offer. The Enterprise Chamber may grant the\nclaim for squeeze-out in relation to all minority shareholders and will determine the price to be paid for the\n", "page_number": 194, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8546387345019238, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.9200513039760582, "height": 0.06541256947413432, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-194-11", "text": "191\n", "page_number": 194, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-0", "text": "shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Cham-\nber on the value to be paid for the shares of the minority shareholders. In principle, the offer price is considered\nreasonable if the offer was a mandatory offer or if at least 90% of the shares to which the offer related were re-\nceived by way of voluntary offer.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1393758016246259, "height": 0.05429670799486959, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-1", "text": "The Dutch takeover provisions of the Dutch Financial Supervision Act also entitle those minority shareholders\nthat have not previously tendered their shares under an offer to transfer their shares to the offeror, provided that\nthe offeror has acquired at least 95% of the outstanding share capital and represents at least 95% of the total\nvoting rights. In regard to price, the same procedure as for takeover squeeze-out proceedings initiated by an\nofferor applies. The claim also needs to be filed with the Enterprise Chamber within three months following the\nexpiry of the acceptance period of the offer.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.22873022659256093, "height": 0.08208636169303121, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-2", "text": "Obligations to Disclose Holdings\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.3966142684401451, "lower_right_y": 0.25951261222744765, "height": 0.017101325352714858, "width": 0.28113663845223696}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-3", "text": "Holders of the Shares may be subject to notification obligations under the Dutch Financial Supervision Act.\nShareholders are advised to seek professional advice on these obligations.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2731936725096195, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.30055579307396324, "height": 0.027362120564343728, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-4", "text": "Shareholders\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3142368533561351, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.3266353142368534, "height": 0.012398460880718276, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-5", "text": "Pursuant to the Dutch Financial Supervision Act, any person who, directly or indirectly, acquires or disposes of\nan actual or potential interest in the capital or voting rights of the Company must immediately notify the AFM by\nmeans of a standard form, if, as a result of such acquisition or disposal, the percentage of capital interest or vot-\ning rights held by such person in the Company reaches, exceeds or falls below any of the following thresholds:\n3%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 75% and 95%.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4031637451902522, "height": 0.06840530141085932, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-6", "text": "A notification requirement also applies if a person's capital interest or voting rights reaches, exceeds or falls\nbelow the abovementioned thresholds as a result of a change in the Company's total outstanding share capital or\nvoting rights. Such notification has to be made no later than the fourth trading day after the AFM has published\nthe Company's notification of the change in its outstanding share capital.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46515604959384355, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-7", "text": "The Company is required to notify the AFM immediately of the changes to its total share capital or voting rights,\nif its issued share capital or voting rights changes by 1% or more since the Company's previous notification. The\nCompany must furthermore notify the AFM within eight days after each quarter, in the event its share capital or\nvoting rights changed by less than 1% in that relevant quarter since the Company's previous notification.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5267208208636169, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-8", "text": "In addition, every holder of 3% or more of the Company's share capital or voting rights whose interest at\n31 December at midnight has a different composition than in a previous notification to the AFM must notify the\nAFM within four weeks. It is expected that this obligation will be changed in November 2015 into the obligation\nthat every holder of 3% or more of the Company' share capital or voting rights who, in relation to its previous\nnotification, reaches, exceeds or falls below any of the abovementioned thresholds as a consequence of a differ-\nent composition by means of an exchange or conversion into shares or the exercise of rights pursuant to an\nagreement to acquire voting rights, shall notify the AFM at the latest within four trading days.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.629328772979906, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-9", "text": "Controlled entities, within the meaning of the Dutch Financial Supervision Act, do not have notification obliga-\ntions under the Dutch Financial Supervision Act, as their direct and indirect, interests are attributed to their (ul-\ntimate) parent. Any person may qualify as a parent for purposes of the Dutch Financial Supervision Act, includ-\ning an individual. A person who has a 3% or larger interest in the Company's share capital or voting rights and\nwho ceases to be a controlled entity for these purposes must immediately notify the AFM. As of that moment, all\nnotification obligations under the Dutch Financial Supervision Act will become applicable to the former con-\ntrolled entity.\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6365968362548098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.731936725096195, "height": 0.09533988884138522, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-10", "text": "For the purpose of calculating the percentage of capital interest or voting rights, the following interests must,\ninter alia, be taken into account: (i) shares and voting rights directly held (or acquired or disposed of) by any\nperson; (ii) shares and voting rights held (or acquired or disposed of) by such person's controlled entity or by a\nthird party for such person's account or by a third party with whom such person has concluded an oral or written\nvoting agreement; (iii) voting rights acquired pursuant to an agreement providing for a temporary transfer of\nvoting rights against a payment; (iv) shares which such person (directly or indirectly) or third party referred to\nabove, may acquire pursuant to any option or other right to acquire shares; (v) shares which determine the value\nof certain cash settled financial instruments such as contracts for difference and total return swaps; (vi) shares\nthat must be acquired upon exercise of a put option by a counterparty; and (vii) shares which are the subject of\nanother contract creating an economic position similar to a direct or indirect holding in those shares. Special\nattribution rules apply to shares and voting rights which are part of the property of a partnership or other com-\nmunity of property. A holder of a pledge or right of usufruct in respect of shares can also be subject to the report-\ning obligations, if such person has, or can acquire, the right to vote on the shares. The acquisition of (conditional)\n", "page_number": 195, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9166310389055152, "height": 0.17828131680205217, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-195-11", "text": "192\n", "page_number": 195, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-0", "text": "voting rights by a pledgee or beneficial owner may also trigger the reporting obligations as if the pledgee or\nbeneficial owner were the legal holder of the shares.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-1", "text": "For the purpose of the notification obligation, the following instruments qualify as \"shares\": (i) shares; (ii) de-\npositary receipts for shares (or negotiable instruments similar to such receipts); (iii) negotiable instruments for\nacquiring the instruments under (i) or (ii) (such as convertible bonds); and (iv) options for acquiring the instru-\nments under (i) or (ii).\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1735784523300556, "height": 0.05429670799486962, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-2", "text": "Gross short positions in shares must also be notified to the AFM. For these gross short positions the same\nthresholds apply as for notifying an actual or potential interest in the capital and/or voting rights of a Dutch listed\ncompany, as referred to above, and without any set-off against long positions.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.221889696451475, "height": 0.04104318084651562, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-3", "text": "In addition, pursuant to Regulation (EU) No 236/2012, each person holding a net short position attaining 0.2% of\nthe issued share capital of a Dutch listed company is required to notify such position to the AFM. Each subse-\nquent increase of this position by 0.1% above 0.2% must also be notified. Each net short position equal to 0.5%\nof the issued share capital of a Dutch listed company and any subsequent increase of that position by 0.1% will\nbe made public via the AFM short selling registers. To calculate whether a natural person or legal person has a\nnet short position, their short positions and long positions must be set-off. A short transaction in a Share can only\nbe contracted if a reasonable case can be made that the Shares sold can actually be delivered, which requires\nconfirmation of a third party that the Shares have been located.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3386062419837537, "height": 0.1098760153911928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-4", "text": "Management\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.3659683625480975, "height": 0.014108593415989745, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-5", "text": "Each Managing Director and Supervisory Director must notify the AFM: (a) immediately following the admis-\nsion to trading and listing of the Shares of the number of Shares he/she holds and the number of votes he/she is\nentitled to cast in respect of the Company's issued share capital, and (b) subsequently of each change in the num-\nber of Shares he/she holds and of each change in the number of votes he/she is entitled to cast in respect of the\nCompany's issued share capital, immediately after the relevant change.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.44121419410004276, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-6", "text": "Pursuant to the Dutch Financial Supervision Act, any Managing Director and Supervisory Director, as well as\nany other person who would have managerial or co-managerial responsibilities in respect of the Company or\nwho would have the authority to make decisions affecting the Company's future developments and business\nprospects regularly having access to inside information relating, directly or indirectly, to the Company, must\nnotify the AFM by means of a standard form of any transactions conducted for his or her own account relating to\nthe Shares or in financial instruments the value of which is also based on the value of the Shares.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4476271911073108, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5284309533988885, "height": 0.08080376229157765, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-7", "text": "In addition, in accordance with the Dutch Financial Supervision Act and the regulations promulgated thereunder\n(e.g., the Dutch Financial Supervision Act Decree on Market Abuse (Besluit Marktmisbruik Wft)), certain per-\nsons who are closely associated with Managing Directors, Supervisory Directors or any of the other persons as\ndescribed above, are required to notify the AFM of any transactions conducted for their own account relating to\nthe Shares or in financial instruments the value of which is also based on the value of the Shares. The Dutch\nFinancial Supervision Act and the regulations promulgated thereunder cover, inter alia, the following categories\nof persons: (i) the spouse or any partner considered by national law as equivalent to the spouse; (ii) dependent\nchildren; (iii) other relatives who have shared the same household for at least one year at the relevant transaction\ndate; and (iv) any legal person, trust or partnership whose, among other things, managerial responsibilities are\ndischarged by a person referred to under (i) to (iii) above or by the relevant Managing Director, the Supervisory\nDirector or other person with any authority in respect of the Company as described above.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5365540829414279, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6874732791791364, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-8", "text": "The AFM must be notified of transactions effected in either the Shares or financial instruments, the value of\nwhich is (in part) determined by the value of the Shares, no later than the fifth business day following the trans-\naction date by means of a standard form or by using the digital portal made available by the AFM. Notification\nmay be postponed until the date the value of the transactions carried out on that person's own account, together\nwith the transactions carried out by the persons associated with that person, reaches or exceeds the amount of\n\u20ac5,000 in the calendar year in question.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6938862761864044, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7764001710132535, "height": 0.08251389482684912, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-9", "text": "If a Managing Director or Supervisory Director has notified a transaction to the AFM under the Dutch Financial\nSupervision Act as described above under \"\u2013 Shareholders\", such notification is sufficient for purposes of the\nDutch Financial Supervision Act as described in this paragraph.\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8242838820008551, "height": 0.04147071398033353, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-10", "text": "Non-compliance\n", "page_number": 196, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.840957674219752, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.8533561351004703, "height": 0.012398460880718276, "width": 0.12031438935912937}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-11", "text": "Non-compliance with the notification obligations under the Dutch Financial Supervision Act could lead to crim-\ninal fines, administrative fines, imprisonment or other sanctions. In addition, non-compliance with some of the\nnotification obligations under the Dutch Financial Supervision Act may lead to civil sanctions, including suspen-\nsion of the voting rights relating to the Shares held by the offender for a period of not more than three years,\nvoiding of a resolution adopted by the General Meeting in certain circumstances and ordering the person violat-\n", "page_number": 196, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9286019666524156, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-196-12", "text": "193\n", "page_number": 196, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-0", "text": "ing the disclosure obligations to refrain, during a period of up to five years, from acquiring Shares and/or voting\nrights in Shares.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-1", "text": "Public registry\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.2218863361547763, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.10640870616686819}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-2", "text": "The AFM does not issue separate public announcements of these notifications. It does, however, keep a public\nregister of all notifications under the Dutch Financial Supervision Act on its website (www.afm.nl). Third parties\ncan request to be notified automatically by e-mail of changes to the public register in relation to a particular\ncompany's shares or a particular notifying party.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20179563916203505, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-3", "text": "Identity of Shareholders\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.21504916631038906, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.2291577597263788, "height": 0.014108593415989745, "width": 0.16626360338573154}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-4", "text": "The Company may in accordance with Chapter 3A of the Dutch Securities Giro Transfers Act request Euroclear\nNederland, admitted institutions, intermediaries, institutions abroad, and managers of investment institutions, to\nprovide certain information on the identity of the Shareholders. Such request may only be made during a period\nof 60 days up to the day on which the General Meeting will be held. No information will be given on Sharehold-\ners with an interest of less than 0.5% of the issued share capital. A Shareholder who, individually or together\nwith other Shareholders, holds an interest of at least 10% of the issued share capital may request the Company to\nestablish the identity of the Shareholders. This request may only be made during a period of 60 days until (and\nnot including) the 42nd day before the day on which the General Meeting will be held.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23557075673364686, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34544677212483965, "height": 0.1098760153911928, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-5", "text": "Market Abuse Regulation\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.343409915356711, "lower_right_y": 0.3758016246259085, "height": 0.013681060282171864, "width": 0.2279322853688029}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-6", "text": "The Dutch Financial Supervision Act provides for specific rules intended to prevent market abuse, such as insid-\ner trading, tipping and market manipulation. Pursuant to these rules, the Company is required to adopt rules\ngoverning the holding and carrying out of transactions in the Shares or in financial instruments the value of\nwhich is determined by the value of the Shares by Managing Directors and the Supervisory Directors as well as\nemployees. The Company has complied with these rules by drawing up an insider list and adopting its Policy on\nInsider Trading, which is available on the Company's website.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.38948268490808036, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4719965797349295, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-7", "text": "Transparency Directive\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.4886703719538264, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.5027789653698161, "height": 0.014108593415989745, "width": 0.20556227327690446}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-8", "text": "The Netherlands will be the Company's home member state for the purposes of Directive 2004/109/EC (as\namended by Directive 2013/50/EU) as a consequence of which the Company will be subject to the Dutch Finan-\ncial Supervision Act in respect of certain on-going transparency and disclosure obligations.\n", "page_number": 197, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5575032064985036, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-197-9", "text": "194\n", "page_number": 197, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-0", "text": "THE OFFERING\n", "page_number": 198, "bounding_box": {"top_left_x": 0.40870616686819833, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5900846432889963, "lower_right_y": 0.1085934159897392, "height": 0.016673792218896963, "width": 0.18137847642079802}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-1", "text": "Introduction\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.11608222490931076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-2", "text": "The Company is offering up to 4,791,667 Offer Shares. Assuming no exercise of the Over-allotment Option, the\nOffer Shares will constitute not more than approximately 37.5% of the Shares. Assuming the Over-allotment\nOption is fully exercised, the Offer Shares will constitute not more than approximately 43.1% of the Shares. The\nOffering consists of (i) a public offering to institutional and retail investors in Germany, and (ii) a private place-\nment to certain institutional investors and other eligible in various other jurisdictions. The Offer Shares are being\noffered: (a) within the United States, to QIBs as defined in Rule 144A under the US Securities Act, pursuant to\nRule 144A or another applicable exemption from, or in a transaction not subject to, the registration requirements\nof the US Securities Act and applicable state securities laws, and (b) outside the United States in offshore trans-\nactions as defined in, and in accordance with Regulation S. The Offer Shares including the Additional Shares (if\nany) have not been and will not be registered under the US Securities Act. The Offering is made only in those\njurisdictions in which, and only to those persons to whom, the Offering may be lawfully made.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.30611372381359553, "height": 0.14920906370243692, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"regulation_s_applies": ["Regulation S."]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-3", "text": "Over-allotment Option\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.3192261185006046, "lower_right_y": 0.33689610944848225, "height": 0.015818725951261214, "width": 0.2037484885126965}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-4", "text": "The Company expects to grant the Sole Global Coordinator, on behalf of the Underwriters, the Over-allotment\nOption, exercisable within 30 calendar days after the First Trading Date, pursuant to which the Sole Global Co-\nordinator, on behalf of the Underwriters, may require the Company to issue to the Underwriters at the Offer\nPrice up to 625,000 Additional Shares, comprising up to 15% of the total number of Offer Shares issued in the\nOffering, to cover over-allotments or short positions, if any, in connection with the Offering.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4194100042753313, "height": 0.06755023514322356, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-5", "text": "Timetable\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43394613082513894, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.4476271911073108, "height": 0.013681060282171864, "width": 0.09250302297460701}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-6", "text": "Subject to acceleration or extension of the timetable for, or withdrawal of, the Offering, the timetable below lists\ncertain expected key dates for the Offering:\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4916631038905515, "height": 0.026934587430525847, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-7", "text": "Event                                                Time (CET) and date\nStart of Offer Period                                09:00 on 28 October 2015\nEnd of Offer Period                                  16:00 on 10 November 2015\nPricing                                              10 November 2015\nFirst Trading Date (trading on an \"as-if-and-when-   11 November 2015\nissued\" basis)\nSettlement Date                                      13 November 2015\n", "page_number": 198, "bounding_box": {"top_left_x": 0.10701330108827085, "top_left_y": 0.5032064985036341, "lower_right_x": 0.8742442563482467, "lower_right_y": 0.6412997007268063, "height": 0.13809320222317223, "width": 0.7672309552599758}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-8", "text": "The Company, after consultation with the Sole Global Coordinator, may adjust the dates, times and periods giv-\nen in the timetable and throughout this Prospectus. Should such adjustment be decided on, then the Company\nwill make this public through a press release, which will also be posted on the Company's website. See also \"\u2013\nAcceleration or Extension\" below.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.7011543394613082, "height": 0.051731509191962344, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-9", "text": "Offer Period\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.731936725096195, "height": 0.0141085934159898, "width": 0.11185006045949215}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-10", "text": "Subject to acceleration or extension of the timetable for the Offering, prospective investors may subscribe for\nOffer Shares during the period commencing on 28 October 2015 at 09:00 CET and ending on 10 November\n2015 at 16:00 CET. The Company, after consultation with the Sole Global Coordinator, may accelerate or extend\nthe Offer Period. See \"\u2013 Acceleration or Extension\" below. In the event of an acceleration or extension of the\nOffer Period, pricing, Allocation, admission and first trading and payment (in euro) for and delivery of the Offer\nShares may be advanced or extended accordingly.\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8298418127404874, "height": 0.08123129542539553, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-11", "text": "Acceleration or Extension\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.34280532043530837, "lower_right_y": 0.8580589995724669, "height": 0.013681060282171864, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-12", "text": "Any extension of the timetable for the Offering will be published in a press release on the Company's website at\nleast three hours before the end of the original Offer Period, provided that any extension will be for a minimum\nof one full business day. Any acceleration of the timetable for the Offering will be published in a press release on\n", "page_number": 198, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.9157759726378795, "height": 0.04061564771269777, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-198-13", "text": "195\n", "page_number": 198, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-0", "text": "the Company's website at least three hours before the proposed end of the accelerated Offer Period. In any event,\nthe Offer Period will be at least six business days.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11115861479264642, "height": 0.026079521162890112, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-1", "text": "Offer Price and Number of Offer Shares\n", "page_number": 199, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.12612227447627192, "lower_right_x": 0.46916565900846435, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.3524788391777509}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-2", "text": "The Offer Price and the exact number of Offer Shares will be determined on the basis of a book-building pro-\ncess. The Offer Price may be set within, above or below the Offer Price Range. The Offer Price Range is be-\ntween \u20ac9.50 and \u20ac12 per Offer Share. The Offer Price Range is an indicative price range.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.19794784095767423, "height": 0.04104318084651562, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-3", "text": "The Offer Price and the exact number of Offer Shares offered in the Offering will be determined after the Offer\nPeriod has ended, including any acceleration or extension, by the Company, after consultation with the Sole\nGlobal Coordinator, on the basis of the book-building process and taking into account market conditions, a quali-\ntative assessment of demand for the Offer Shares and any other factors deemed appropriate.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20478837109876016, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2599401453612655, "height": 0.05515177426250531, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-4", "text": "The Offer Price and the exact number of Offer Shares to be issued and the maximum number of Additional\nShares will be set out in the Pricing Statement that will be filed with the AFM and published through a press\nrelease that will also be posted on the Company's website. The Offer Price Range, which is an indicative price\nrange, may be changed and/or the number of Offer Shares being offered may be increased or decreased. The\nCompany, after consultation with the Sole Global Coordinator, reserves the right to change the Offer Price\nRange and/or increase or decrease the number of Offer Shares being offered prior to Allocation. Any increase in\nthe top end of the Offer Price Range on the last day of the Offer Period or the determination of an Offer Price\nabove the Offer Price Range will result in the Offer Period being extended by at least two business days; any\nincrease in the top end of the Offer Price Range on the day prior to the last day of the Offer Period will result in\nthe Offer Period being extended by at least one business day. Any such change in the Offer Price Range and/or\nthe number of Offer Shares being offered will be published in a press release that will also be posted on the\nCompany's website.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2663531423685336, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.43095339888841383, "height": 0.16460025651988025, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-5", "text": "Retail offering\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.44420692603676787, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.46173578452330055, "height": 0.017528858486532684, "width": 0.13119709794437728}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-6", "text": "The Offer Shares will be offered to the public in Germany in accordance with applicable law and regulations.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8555018137847642, "lower_right_y": 0.4890979050876443, "height": 0.014108593415989745, "width": 0.7382103990326481}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-7", "text": "All investors must inform themselves regarding the investment restrictions of the Offering. Please see Section\n\"Selling and Transfer Restrictions\".\n", "page_number": 199, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.523300555793074, "height": 0.027789653698161665, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-8", "text": "The Company consents to the use of this Prospectus for a subsequent resale or final placement of Offer Shares\nby those financial intermediaries that are specifically engaged by the Retail Coordinator for purposes of the offer\nto retail investors in Germany. Germany is the only jurisdiction in which the relevant financial intermediaries\nmay use this Prospectus for a subsequent resale or a final placement of the Offer Shares and such use is limited\nto the Offer Period for the Offering, which is expected to commence on 28 October 2015 at 09:00 CET and to\nend on 10 November 2015 at 16:00 CET. When using this Prospectus, each such financial intermediary must\ncomply with all applicable laws and regulations and the selling restrictions set out in this Prospectus.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.529713552800342, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6259085079093629, "height": 0.09619495510902087, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-9", "text": "The Company accepts responsibility for the consent of this Prospectus with respect to a subsequent resale or\nfinal placement of the Offer Shares by the financial intermediaries referred to above. This Prospectus may only\nbe delivered by such financial intermediaries to potential eligible retail investors in Germany together with all\nsupplements published before such delivery. Any supplement to this Prospectus and the names and address of\nthe financial intermediaries engaged by ICF will be available for viewing in electronic form on the website of the\nCompany (www.curetis.com).\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.880894800483676, "lower_right_y": 0.7148353997434801, "height": 0.08251389482684901, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-10", "text": "In the event of an offer being made by financial intermediaries as referred to above, such financial inter-\nmediaries will provide information to the investors on the terms and conditions of the offer at the time the\noffer is made.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7627191107310817, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-11", "text": "The Company does not intend to give consent to anyone other than the financial intermediaries that are specifi-\ncally engaged by ICF to use this Prospectus in the future.\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7695596408721675, "lower_right_x": 0.8784764207980653, "lower_right_y": 0.7969217614365113, "height": 0.027362120564343728, "width": 0.7629987908101572}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-12", "text": "Subscription and Allocation\n", "page_number": 199, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8135955536554083, "lower_right_x": 0.36215235792019346, "lower_right_y": 0.827704147071398, "height": 0.0141085934159898, "width": 0.2460701330108827}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-13", "text": "Eligible retail investors in Germany are entitled to cancel or amend their application, at the financial intermedi-\nary where their original application was submitted, at any time prior to the end of the Offer Period (if applicable,\nas amended or extended). Eligible retail investors in Germany can submit their subscriptions through their own\nfinancial intermediary. The financial intermediary will be responsible for collecting subscriptions from eligible\nretail investors in Germany and for submitting their subscriptions to ICF as the retail coordinator (the \"Retail\nCoordinator\"). The Retail Coordinator will consolidate all subscriptions submitted by eligible retail investors in\n", "page_number": 199, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9234715690466011, "height": 0.07909362975630607, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-199-14", "text": "196\n", "page_number": 199, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-0", "text": "Germany to financial intermediaries and inform the Sole Global Coordinator and the Company. Eligible retail\ninvestors in Germany are not required to subscribe on a market order (billigst) basis and may therefore submit\norders providing for a price limit. All questions concerning the timelines, validity and form of instructions to a\nfinancial intermediary in relation to the purchase of Offer Shares will be determined by the financial intermediar-\nies in accordance with their usual procedures or as otherwise notified to the retail investors in Germany. Neither\nthe Company nor the Underwriters are liable for any action or failure to act by a financial intermediary in con-\nnection with any purchase, or purported purchase, of Offer Shares.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.18041898247114152, "height": 0.09533988884138521, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-1", "text": "Allocation is expected to take place on 10 November 2015, subject to acceleration or extension of the timetable\nof the Offering. Allocations to investors who applied to subscribe for Offer Shares will be determined by the\nCompany after consultation with the Joint Bookrunners and full discretion will be exercised as to whether or not\nand how to allocate the Offer Shares subscribed for. There is no maximum or minimum number of Offer Shares\nfor which prospective investors may subscribe and multiple (applications for) subscriptions are permitted. In the\nevent that the Offering is over-subscribed, investors may not be allocated all of the Offer Shares for which they\nsubscribe. The Company and the Joint Bookrunners may, at their own discretion and without stating the reasons,\nreject any subscriptions wholly or partly. Any monies received in respect of subscriptions which are not accepted\nin whole or in part will be returned to the investors without interest and at the investors' risk.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3103890551517743, "height": 0.12270200940572898, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-2", "text": "Investors participating in the Offering will be deemed to have checked and confirmed that they meet the selling\nand transfer restrictions described in \"Selling and Transfer Restrictions\". Each investor should consult his/her\nown advisers as to the legal, tax, business, financial and related aspects of a purchase of Offer Shares.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3587002992731937, "height": 0.04104318084651565, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-3", "text": "The Joint Bookrunners will communicate to institutional investors the number of Offer Shares allocated to them\non the date of Allocation.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3655408294142796, "lower_right_x": 0.879081015719468, "lower_right_y": 0.38991021804189824, "height": 0.024369388627618616, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-4", "text": "Payment\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4078666096622488, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.4236853356135101, "height": 0.01581872595126127, "width": 0.08282950423216444}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-5", "text": "Payment in euro for and delivery of the Offer Shares will take place on the Settlement Date. Taxes and expenses,\nif any, must be borne by the investor (for more information, see \"Taxation\"). Eligible retail investors in Germany\nmay be charged expenses by their financial intermediary. The Offer Price must be paid by eligible retail inves-\ntors in Germany by authorising their financial intermediary to debit their bank account with such amount on or\nabout the Settlement Date (or earlier in the case of an early closing of the Offer Period and consequent accelera-\ntion of pricing, Allocation, first trading and payment and delivery). The Offer Price must be paid in immediately\navailable funds in full in euro on or before the Settlement Date (or earlier in the case of an early closing of the\nOffer Period and consequent acceleration of pricing, Allocation, first trading and payment and delivery) and is\nexclusive of any taxes and expenses, if any, which must be borne by the investor.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43736639589568194, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5609234715690466, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-6", "text": "Delivery, Clearing and Settlement\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5741769987174006, "lower_right_x": 0.4105199516324063, "lower_right_y": 0.5917058572039333, "height": 0.01752885848653274, "width": 0.2950423216444982}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-7", "text": "The Offer Shares will be delivered in book-entry form through the facilities of Euroclear Nederland. Application\nhas been made for the Shares to be accepted for clearance through the book-entry facilities of Euroclear Neder-\nland. Euroclear Nederland is located at Herengracht 459-469, 1017 BS Amsterdam, the Netherlands.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6049593843522874, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6464300983326208, "height": 0.04147071398033342, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-8", "text": "Delivery of the Offer Shares is expected to take place on the Settlement Date through the book-entry facilities of\nEuroclear Nederland, in accordance with its normal settlement procedures applicable to equity securities and\nagainst payment (in euro) for the Offer Shares, including, if applicable, the Additional Shares, in immediately\navailable funds.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7045746045318512, "height": 0.051731509191962344, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-9", "text": "Prior to the Offering, there has been no public market for the Shares. Application has been made to list all of the\nShares on Euronext in Amsterdam and Euronext in Brussels under the symbol \"CURE\" with ISIN code\nNL0011509294. Subject to acceleration or extension of the timetable for the Offering, trading on an \"as-if-and-\nwhen-issued\" basis in the Offer Shares is expected to commence on or about 11 November 2015.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7695596408721675, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {"isin": ["NL0011509294"]}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-10", "text": "Settlement of the Offering may not take place on the Settlement Date or at all if certain conditions or events\nreferred to in the Underwriting Agreement are not satisfied or waived or occur on or prior to such date. See\n\"Plan of Distribution \u2013 Underwriting Arrangements\".\n", "page_number": 200, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8174433518597691, "height": 0.04147071398033342, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-11", "text": "If Settlement does not take place on the Settlement Date as planned or at all, the Offering may be withdrawn, in\nwhich case all subscriptions for Offer Shares will be disregarded, any allotments made will be deemed not to\nhave been made and any subscription payments made will be returned without interest or other compensation.\nAny dealings in Shares prior to Settlement are at the sole risk of the parties concerned. None of the Company,\nthe Underwriters, the Listing and Paying Agent, Euronext Amsterdam nor Euronext Brussels accepts any re-\nsponsibility or liability for any loss incurred by any person as a result of a withdrawal of the Offering or the\nrelated annulment of any transactions in Shares on Euronext in Amsterdam and Euronext in Brussels.\n", "page_number": 200, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8238563488670372, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-200-12", "text": "197\n", "page_number": 200, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-0", "text": "Dilution\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.07799274486094317}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-1", "text": "The voting interest of the existing Shareholders will be diluted as a result of the issuance of the Offer Shares.\nThe maximum dilution for the existing Shareholders not participating in the Offering pursuant to the issuance of\nthe Offer Shares would be 37.5%, assuming the issuance of the maximum number of Offer Shares and no exer-\ncise of the Over-allotment Option and 43.1% assuming the issuance of the maximum number of Offer Shares\nand full exercise of the Over-allotment Option.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.115861479264643, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.1838392475416845, "height": 0.06797776827704148, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-2", "text": "Voting Rights\n", "page_number": 201, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.19794784095767423, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.21462163317657118, "height": 0.01667379221889695, "width": 0.11910519951632406}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-3", "text": "Each Share confers the right to cast one vote in the General Meeting, see \"Description of Share Capital-General\nMeetings and Voting Rights-Voting rights\". All Shareholders have the same voting rights.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.25609234715690465, "height": 0.027362120564343728, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-4", "text": "Ranking and Dividends\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2697734074390765, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.2868747327917914, "height": 0.017101325352714858, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-5", "text": "The Offer Shares rank equally in all respects. The Offer Shares will carry dividend rights as of the date of issue.\nSee \"Dividends and Dividend Policy\".\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.30055579307396324, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.32834544677212485, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-6", "text": "Sole Global Coordinator\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.3557075673364686, "height": 0.014108593415989745, "width": 0.21825876662636035}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-7", "text": "RBC is acting as the Sole Global Coordinator for the Offering.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37280889268918344, "lower_right_x": 0.5374848851269649, "lower_right_y": 0.3864899529713553, "height": 0.013681060282171864, "width": 0.4220072551390568}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-8", "text": "Joint Bookrunners\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4031637451902522, "lower_right_x": 0.279322853688029, "lower_right_y": 0.4159897392047884, "height": 0.012825994014536157, "width": 0.1638452237001209}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-9", "text": "RBC and Degroof Petercam are together acting as Joint Bookrunners.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.430525865754596, "lower_right_x": 0.585247883917775, "lower_right_y": 0.4446344591705857, "height": 0.01410859341598969, "width": 0.4691656590084643}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-10", "text": "Joint Lead Manager\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46130825138948267, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.4754168448054724, "height": 0.014108593415989745, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-11", "text": "ICF is acting as Joint Lead Manager.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48952543822146216, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.5027789653698161, "height": 0.013253527148353983, "width": 0.2521160822249093}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-12", "text": "Underwriters\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5194527575887131, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.5318512184694314, "height": 0.012398460880718276, "width": 0.12091898428053204}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-13", "text": "RBC, Degroof Petercam and ICF are acting as the Underwriters.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5480974775545104, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.5609234715690466, "height": 0.012825994014536213, "width": 0.43591293833131806}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-14", "text": "Listing and Paying Agent\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.5917058572039333, "height": 0.0141085934159898, "width": 0.2230955259975816}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-15", "text": "ABN AMRO is acting as listing agent with respect to the listing of the Shares on Euronext in Amsterdam and\nEuronext in Brussels and is also acting as paying agent for the Shares in the Netherlands.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.635741769987174, "height": 0.027362120564343728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-16", "text": "Retail Coordinator\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.6635314236853356, "height": 0.01410859341598969, "width": 0.16928657799274482}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-17", "text": "ICF is the Retail Coordinator with respect to the Offering.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.5066505441354293, "lower_right_y": 0.6934587430525866, "height": 0.013253527148354038, "width": 0.3911729141475212}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-18", "text": "Stabilisation Manager\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.7238135955536554, "height": 0.01624625908507915, "width": 0.19347037484885127}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-19", "text": "RBC is the Stabilisation Manager with respect to the Shares on Euronext in Amsterdam and Euronext in Brus-\nsels.\n", "page_number": 201, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7627191107310817, "height": 0.024369388627618616, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-201-20", "text": "198\n", "page_number": 201, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-0", "text": "PLAN OF DISTRIBUTION\n", "page_number": 202, "bounding_box": {"top_left_x": 0.3573155985489722, "top_left_y": 0.09191962377084224, "lower_right_x": 0.6414752116082225, "lower_right_y": 0.10902094912355707, "height": 0.01710132535271483, "width": 0.2841596130592503}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-1", "text": "Commitment of Committing Shareholders\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.12612227447627192, "lower_right_x": 0.4836759371221282, "lower_right_y": 0.14194100042753313, "height": 0.015818725951261214, "width": 0.3651753325272068}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-2", "text": "Pursuant to the Commitment Letters, each of the Committing Shareholders, severally and not jointly, has\nirrevocably committed to subscribe for Offer Shares in the Offering in the maximum amount set forth to its\nrespective name in the table below. The number of Offer Shares each Committing Shareholder has agreed to\nsubscribe for will be determined by dividing the commitment amount of each Committing Shareholder by the\nOffer Price, rounded down to the nearest full number of Offer Shares. The Company has agreed to issue and allot\nthe Offer Shares to the Committing Shareholders in accordance with their commitments subject to the terms and\nconditions set out in this Prospectus.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.25181701581872595, "height": 0.09491235570756734, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-3", "text": "The aggregate commitments of all Committing Shareholders pursuant to the Commitment Letters amount to\napproximately \u20ac15,150,777.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25951261222744765, "lower_right_x": 0.879081015719468, "lower_right_y": 0.2860196665241556, "height": 0.026507054296707966, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-4", "text": "Committing Shareholder                                              Amount of Commitment\naeris CAPITAL Equity Investments, L.P.                              \u20ac4,853,643\nLSP Curetis Pooling B.V.                                            \u20ac4,107,701\nBioMed Invest II LP                                                 \u20ac900,000\nCD-Venture GmbH                                                     \u20ac200,000\nForbion Capital Fund II Co\u00f6peratief U.A. and/or Forbion CF II Co-   \u20ac1,998,893\nInvest I Co\u00f6peratief U.A.1\nRoche Finance Ltd.                                                  \u20ac1,400,000\nHBM BioCapital II Invest S.a r.l.                                   \u20ac1,690,539\nTotal                                                               \u20ac15,150,777\n", "page_number": 202, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.2902949978623343, "lower_right_x": 0.873639661426844, "lower_right_y": 0.5104745617785378, "height": 0.22017956391620347, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-5", "text": "1\n The two entities have committed to collectively subscribe for Offer Shares in the mentioned amount with the decision which entity will subscribe for which\nnumber of Offer Shares yet to be taken.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5262932877297991, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5472424112868748, "height": 0.020949123557075677, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-6", "text": "The commitments of the Committing Shareholders are unconditional and irrevocable and terminate only in the\nevent that (i) the Underwriting Agreement is terminated, (ii) the Settlement Date not having occurred before 31\nDecember 2015 or (iii) the Sole Global Coordinator on the one hand, or the Company on the other hand,\ninforming the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed\nwith the Offering.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.62248824283882, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-7", "text": "In addition to the Committing Shareholders and under the same terms and conditions listed above, STRATEC\nhas committed to subscribe for, and the Company has agreed to issue and allot to STRATEC, Offer Shares at the\nOffer Price in the Offering for the total amount of approximately \u20ac1 million. STRATEC has not agreed to a lock-\nup and does not fall under any lock-up arrangement described in this Prospectus.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6840530141085934, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-8", "text": "The Committing Shareholders and STRATEC will subscribe for the Offer Shares pursuant to, and as part of the\nOffering. The Offer Shares to be subscribed for by the Committing Shareholders and STRATEC will rank pari\npassu with the Offer Shares issued in the Offering. The Committing Shareholders shall not receive any fee or\nother compensation for their commitment. In addition, no special rights have been granted to any of the\nCommitting Shareholders as part of its commitment to subscribe for the Offer Shares pursuant to the\nCommitment Letters.\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7725523728088927, "height": 0.08208636169303118, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-9", "text": "Underwriting Arrangements\n", "page_number": 202, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.7896536981616076, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.8037622915775973, "height": 0.01410859341598969, "width": 0.24848851269649333}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-10", "text": "The Company and the Underwriters expect to enter into the Underwriting Agreement on or about 10 November\n2015 with respect to the issue of the Offer Shares in connection with the Offering. The material terms and\nconditions of the Underwriting Agreement are set out below.\nUnder the terms and subject to the conditions set forth in the Underwriting Agreement, the Company will agree\nto issue the Offer Shares subscribed for by investors at the Offer Price, and the Underwriters severally but not\njointly, will agree to procure subscribers for, or failing which, to subscribe for themselves at the Offer Price from\nthe Company, the Offer Shares subscribed for by investors. Subject to the satisfaction of these conditions\n", "page_number": 202, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.10303548525010686, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-202-11", "text": "199\n", "page_number": 202, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-0", "text": "precedent, the proportion of Offer Shares that each Underwriter may severally be required to subscribe for is\nindicated below.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.10944848225737494, "height": 0.02436938862761863, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-1", "text": "Underwriters                  Underwriting Commitment of Offer Shares\nRBC Europe Limited            42.5%\nBank Degroof Petercam nv/sa   35%\nICF BANK AG                   22.5%\nTotal                         100%\n", "page_number": 203, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.11671654553227875, "lower_right_x": 0.879081015719468, "lower_right_y": 0.22402736212056434, "height": 0.10731081658828559, "width": 0.7732769044740024}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-2", "text": "In the Underwriting Agreement, the Company makes certain representations and warranties. In addition, the\nCompany will indemnify the Underwriters against liabilities in connection with the Offering. The Underwriting\nAgreement will provide that the obligations of the Underwriters to procure subscribers for, or failing which, to\nsubscribe for themselves, the Offer Shares are subject to, among other things the following conditions: (i) the\napproval of this Prospectus by the AFM being in full force and effect, (ii) receipt at closing of opinions on\ncertain legal matters from counsel, (iii) receipt of customary officers' certificates, (iv) the absence of a material\nadverse change in respect of the business, financial position, results of operations or prospects of Curetis or in\nfinancial markets since the date of the Underwriting Agreement, (v) the admission of the Shares to listing on\nEuronext in Amsterdam and Euronext in Brussels occurring no later than 09:00 a.m. CET on the First Trading\nDate and (vi) certain other customary conditions, most notably in respect of the accuracy of certain\nrepresentations and warranties by the Company, required disclosure by the Company having been made and the\nCompany having complied with the terms of the Underwriting Agreement.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2321504916631039, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39675074818298417, "height": 0.16460025651988028, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-3", "text": "Upon the occurrence of certain specific events, such as the occurrence of (i) a material adverse change in respect\nof the business, financial position, results of operations or prospects of the Company and its subsidiaries taken as\na whole or in financial markets since the date of the Underwriting Agreement, (ii) a material breach of the\nUnderwriting Agreement or (iii) a statement in this Prospectus, the Pricing Statement or any amendment or\nsupplement to this Prospectus being untrue, inaccurate or misleading, the Underwriters may elect to terminate\nthe Underwriting Agreement until admission to listing on Euronext in Amsterdam and Euronext in Brussels (or\nin the case of the Additional Shares, the time for payment thereof).\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4031637451902522, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4993587002992732, "height": 0.09619495510902099, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-4", "text": "In consideration of the agreement by the Underwriters to procure subscribers for or, failing which, to subscribe\nfor themselves, the Offer Shares at the Offer Price and subject to the Offer Shares being issued as provided for in\nthe Underwriting Agreement, the Company will agree to pay the Underwriters an aggregate commission of 4.5%\nof the gross proceeds of the Offering (including, if applicable, any gross proceeds relating to the Over-allotment\nOption). This does not include an incentive commission of up to 1.25% of the gross proceeds of the Offering\n(including, if applicable, any gross proceeds relating to the Over-allotment Option), which may be paid to the\nUnderwriters at the discretion of the Company. The Company will also pay the Sole Global Coordinator an\nadditional fee of \u20ac150 thousand. The Company has also agreed to reimburse the Underwriters for certain\nexpenses incurred by them in connection with the Offering.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.880894800483676, "lower_right_y": 0.629328772979906, "height": 0.12355707567336471, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-5", "text": "The Offer Shares have not been and will not be registered under the US Securities Act or the applicable\nsecurities laws of any state or other jurisdiction of the US and may not be offered, sold, pledged or transferred\nwithin the US, except pursuant to an applicable exemption from, or in a transaction not subject to, the\nregistration requirements of the US Securities Act. The Offer Shares may be offered and sold: (i) in the US only\nto QIBs in reliance on Rule 144A; and (ii) outside the US in compliance with Regulation S. Any offer or sale of\nOffer Shares in reliance on Rule 144A will be made by broker dealers who are registered as such under the\nExchange Act. Terms used in this paragraph have the meanings given to them by Regulation S and Rule 144A.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.635741769987174, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.731936725096195, "height": 0.09619495510902099, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-6", "text": "Lock-up Arrangements\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7486105173150919, "lower_right_x": 0.32285368802902054, "lower_right_y": 0.7627191107310817, "height": 0.0141085934159898, "width": 0.20737605804111242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-7", "text": "The restrictions of the lock-up arrangements described below, including those on sales, issues or transfers of\nShares, may be waived by the Joint Bookrunners (acting on behalf of the Underwriters), in their sole discretion\nand at any time, provided that during the first 180 days the lock-up of the existing Shareholders may not be\nwaived and that the lock-up for management and employees may not be waived at all. If the consent of the Joint\nBookrunners (acting on behalf of the Underwriters) in respect of a waiver of the lock-up arrangements is\nrequested as described below, the Joint Bookrunners (acting on behalf of the Underwriters) shall not\nunreasonably withhold their consent and may give their consent conditionally.\n", "page_number": 203, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.880894800483676, "lower_right_y": 0.8738777255237281, "height": 0.09448482257374946, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-203-8", "text": "200\n", "page_number": 203, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-0", "text": "Company lock-up\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.08507909362975631, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.12273276904474004}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-1", "text": "Pursuant to the Underwriting Agreement, the Company is expected to agree with the Underwriters that, for a\nperiod from the date of the Underwriting Agreement until 365 days from the Settlement Date (the company lock-\nup period), it will not, except as set forth below, without the prior consent of the Joint Bookrunners (acting on\nbehalf of the Underwriters), (i) directly or indirectly, issue, offer, pledge, sell, contract to sell, sell or grant any\noption, right, warrant or contract to purchase, exercise any option to sell, purchase any option or contract to sell,\nor lend or otherwise transfer or dispose of any Shares or other shares of the Company or any securities converti-\nble into or exercisable or exchangeable for Shares or other shares of the Company or file any registration state-\nment under the US Securities Act or any similar document with any other securities regulator, stock exchange or\nlisting authority with respect to any of the foregoing; (ii) enter into any swap or any other agreement or any\ntransaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of\nany Shares or other shares of the Company, whether any such transaction is to be settled by delivery of Shares or\nsuch other securities, in cash or otherwise; (iii) publicly announce such an intention to effect any transaction\nreferred to in (i) or (ii) above; or (iv) submit to its Shareholders or any other body of the Company a proposal to\neffect any of the foregoing.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.29286019666524155, "height": 0.18725951261222745, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-2", "text": "effect any of the foregoing.\nThe foregoing shall not apply to: (a) the issue and offer by or on behalf of the Company of the Offer Shares, (b)\nthe issue of Shares upon exercise of the Over-allotment Option and (c) the granting of awards in options or\nShares by the Company or the issuance of Shares upon exercise of options granted by the Company pursuant to\nemployee incentive schemes disclosed in, and as such grant or issue is disclosed in, the Prospectus.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2932877297990594, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3587002992731937, "height": 0.06541256947413426, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-3", "text": "Existing Shareholders lock-up\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.3282950423216445, "lower_right_y": 0.3864899529713553, "height": 0.014108593415989745, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-4", "text": "On 26 October 2015, all existing Shareholders (except for the Managing Directors and all former and current\nemployees of Curetis holding Shares who have entered into a separate lock-up agreement) are expected to enter\ninto a lock-up agreement with the Sole Global Coordinator (acting on behalf of the Underwriters). Pursuant to\nsuch lock-up agreement and except as set forth below, all such existing Shareholders have agreed, that for a\nperiod from the date of the lock-up agreement until 180 days from the Settlement Date, they will not and will not\nthereafter for an additional period of 185 days without the prior consent of the Joint Bookrunners (acting on\nbehalf of the Underwriters), (i) directly or indirectly, offer, pledge, sell, contract to sell, sell or grant any option,\nright, warrant or contract to purchase, exercise any option to sell, purchase any option or contract to sell, or lend\nor otherwise transfer or dispose of, directly or indirectly, any Shares or other shares of the Company or any secu-\nrities convertible into or exercisable or exchangeable for, or substantially similar to, Shares or other shares of the\nCompany; (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part,\ndirectly or indirectly, any of the economic consequence of ownership of any Shares or other shares in the capital\nof the Company, whether any such transaction is to be settled by delivery of Shares or such other securities, in\ncash or otherwise; (iii) make any request or demand that the Company files any registration statement under the\nUS Securities Act, as amended, or any similar document with any other securities regulator, stock exchange or\nlisting authority with respect to any of the foregoing; or (iv) any announcement or other publication of the inten-\ntion to do any of the foregoing.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6259085079093629, "height": 0.23300555793073957, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-5", "text": "The foregoing restrictions shall not apply to (a) any Offer Shares subscribed for in the Offering or any Shares\nacquired on Euronext in Amsterdam, Euronext in Brussels or any other stock exchange after the First Trading\nDate, (b) the lending of Shares to the Sole Global Coordinator (acting on behalf of the Underwriters) pursuant to\nthe stock lending agreement, it being understood that the Shares that are delivered to the lenders pursuant to the\nstock lending agreement shall be subject to the lock-up undertakings set out in this lock-up agreement, (c) an\nacceptance of a general offer for the Shares in the capital of the Company made in accordance with the Dutch\nFinancial Supervision Act or the provision of an irrevocable undertaking to accept such an offer, (d) any disposal\nas a result of a legal merger or demerger of the Company, or (e) any disposal to personal representatives of an\nindividual who dies during the lock-up period, provided that such personal representative shall have entered into\na lock-up agreement similar to this lock-up agreement or adheres to the provisions of this lock-up agreement and\nassumes all rights and obligations.\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6323215049166311, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7832407011543394, "height": 0.15091919623770833, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-6", "text": "Management and employees lock-up\n", "page_number": 204, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7964942283026935, "lower_right_x": 0.3724304715840387, "lower_right_y": 0.8106028217186833, "height": 0.0141085934159898, "width": 0.2551390568319226}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-7", "text": "On 26 October 2015, the Managing Directors and all former and current employees of Curetis holding Shares\nhave entered into a lock-up agreement with the Sole Global Coordinator (acting on behalf of the Underwriters).\nPursuant to such lock-up agreement, each of the Managing Directors and all former and current employees of\nCuretis holding Shares for a period from the date of the lock-up agreement until 365 days from the Settlement\nDate will not, except as set forth below (i) directly or indirectly, offer, pledge, sell, contract to sell, sell or grant\nany option, right, warrant or contract to purchase, exercise any option to sell, purchase any option or contract to\nsell, or lend or otherwise transfer or dispose of, directly or indirectly, any Shares or other shares of the Company\nor any securities convertible into or exercisable or exchangeable for, or substantially similar to, Shares or other\n", "page_number": 204, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8170158187259513, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.926891834117144, "height": 0.10987601539119274, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-204-8", "text": "201\n", "page_number": 204, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-0", "text": "shares of the Company; (ii) enter into any swap or any other agreement or any transaction that transfers, in whole\nor in part, directly or indirectly, the economic consequence of ownership of any Shares or other shares of the\nCompany, whether any such transaction is to be settled by delivery of Shares or such other securities, in cash or\notherwise; (iii) vote in favour of or any submission to the General Meeting or any other body of the Company of\na proposal to effect any of the foregoing or to (directly or indirectly) effect an increase in the Company\u2019s share\ncapital or any request or demand that the Company files any registration statement under the US Securities Act,\nas amended, or any similar document with any other securities regulator, stock exchange or listing authority with\nrespect to any of the foregoing; or (iv) any announcement or other publication of the intention to do any of the\nforegoing.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.20863616930312098, "height": 0.12355707567336467, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-1", "text": "The foregoing restrictions shall not apply to (a) an acceptance of a general offer for the Shares made in accord-\nance with the Dutch Financial Supervision Act or the provision of an irrevocable undertaking to accept such an\noffer, (b) any disposal as a result of a legal merger or demerger of the Company and (c) any disposal to personal\nrepresentatives of an individual who dies during the lock-up period, provided that such personal representative\nshall have entered into a lock-up agreement similar to this lock-up agreement or adheres to the provisions of this\nlock-up agreement and assumes all rights and obligations.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2967079948696024, "height": 0.08165882855921336, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-2", "text": "Potential conflicts of interests\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3108165882855921, "lower_right_x": 0.37182587666263606, "lower_right_y": 0.32492518170158186, "height": 0.014108593415989745, "width": 0.25634824667472794}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-3", "text": "The Underwriters are acting exclusively for the Company and for no one else and will not regard any other\nperson (whether or not a recipient of this Prospectus) as their respective clients in relation to the Offering and\nwill not be responsible to anyone other than to the Company for giving advice in relation to the Offering and for\nthe listing and trading of the Shares and/or any other transaction or arrangement referred to in this Prospectus.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34159897392047883, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3963232150491663, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-4", "text": "Certain of the Underwriters and/or their respective affiliates have in the past been engaged, and may in the\nfuture, from time to time, engage in commercial banking, investment banking and financial advisory and\nancillary activities in the ordinary course of their business with the Company or any parties related to it, in\nrespect of which they have received, and may in the future receive, customary fees and commissions.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4031637451902522, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.4583155194527576, "height": 0.05515177426250539, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-5", "text": "In connection with the Offering, each of the Underwriters and any of their respective affiliates, acting as an\ninvestor for its own account, may take up Offer Shares in the Offering and in that capacity may retain, purchase\nor sell for its own account such securities and any Offer Shares or related investments and may offer or sell such\nOffer Shares or other investments otherwise than in connection with the Offering. Accordingly, references in this\nProspectus to Offer Shares being issued should be read as including any issuance of Offer Shares to any of the\nUnderwriters or any of their respective affiliates acting in such capacity. None of the Underwriters intends to\ndisclose the extent of any such investment or transactions otherwise than pursuant to any legal or regulatory\nobligation to do so. In addition, certain of the Underwriters or their affiliates may enter into financing\narrangements (including swaps) with investors in connection with which such Underwriters (or their affiliates)\nmay from time to time acquire, hold or dispose of Offer Shares.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6019666524155622, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-6", "text": "As a result of acting in the capacities described above, the Underwriters may have interests that may not be\naligned, or could potentially conflict, with the interests of investors and the Company.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.6361693031209918, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-7", "text": "Over-allotment and Stabilisation\n", "page_number": 205, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6494228302693459, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.6635314236853356, "height": 0.01410859341598969, "width": 0.284764207980653}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-8", "text": "In connection with the Offering, RBC as the Stabilisation Manager, or any of its agents, on behalf of the\nUnderwriters may (but will be under no obligation to), to the extent permitted by applicable law, over-allot\nShares or effect other transactions with a view to supporting the market price of the Shares at a higher level than\nthat which might otherwise prevail in the open market. The Stabilisation Manager will not be required to enter\ninto such transactions and such transactions may be effected on any securities market, over-the-counter market,\nstock exchange (including Euronext in Amsterdam and Euronext in Brussels) or otherwise and may be\nundertaken at any time during the period commencing on the First Trading Date and ending no later than 30\ncalendar days thereafter. The Stabilisation Manager or any of its agents will not be obligated to effect stabilising\ntransactions, and there will be no assurance that stabilising transactions will be undertaken. Such stabilising\ntransactions, if commenced, may be discontinued at any time without prior notice. Save as required by law or\nregulation, neither the Stabilisation Manager nor any of its agents intends to disclose the extent of any over-\nallotments made and/or stabilisation transactions under the Offering. The Underwriting Agreement will provide\nthat the Stabilisation Manager may, for purposes of stabilising transactions, over-allot Shares up to a maximum\nof 15% of the total number of Offer Shares issued in the Offering.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8721675929884566, "height": 0.19196237708422403, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-9", "text": "In connection with the Over-allotment Option, up to a maximum of 15% of the total number of Offer Shares will\nbe made available by aeris CAPITAL Equity Investments L.P. to the Stabilisation Manager through a securities\nloan to be entered into on or around the date of the Underwriting Agreement.\n", "page_number": 205, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8785805899957246, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-205-10", "text": "202\n", "page_number": 205, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-206-0", "text": "None of the Company or any of the Underwriters makes any representation or prediction as to the direction or\nthe magnitude of any effect that the transactions described above may have on the price of the Shares or any\nother securities of the Company. In addition, none of the Company or any of the Underwriters makes any repre-\nsentation that the Stabilisation Manager will engage in these transactions or that these transactions, once com-\nmenced, will not be discontinued without notice.\n", "page_number": 206, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.15220179563916203, "height": 0.06712270200940572, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-206-1", "text": "203\n", "page_number": 206, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-0", "text": "SELLING AND TRANSFER RESTRICTIONS\n", "page_number": 207, "bounding_box": {"top_left_x": 0.26118500604594924, "top_left_y": 0.09191962377084224, "lower_right_x": 0.7400241837968561, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.47883917775090684}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-1", "text": "General\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.1368106028217187, "height": 0.01068832834544678, "width": 0.06287787182587666}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-2", "text": "The offering of the Offer Shares to persons resident in, or who are citizens of, a particular jurisdiction may be\naffected by the laws of that jurisdiction. Investors should consult their professional adviser as to whether they\nrequire any governmental or any other consent or need to observe any other formalities to enable the investor to\naccept, sell or purchase Offer Shares.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20094057289439932, "height": 0.0542967079948696, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-3", "text": "No action has been or will be taken to permit a public offering of the Offer Shares in any jurisdiction outside the\nNetherlands and Germany. Receipt of this Prospectus will not constitute an offer in those jurisdictions in which\nit would be illegal to make an offer and, in those circumstances, this Prospectus will be sent for informational\npurposes only and should not be copied or redistributed.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2625053441641727, "height": 0.054296707994869575, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-4", "text": "If an investor receives a copy of this Prospectus in any territory other than the Netherlands and Germany, the\ninvestor may not treat this Prospectus as constituting an invitation or offer to the investor of the Offer Shares,\nunless, in the relevant jurisdiction, such an offer could lawfully be made to the investor, or the Offer Shares\ncould lawfully be dealt in without contravention of any unfulfilled registration or other legal requirements. Ac-\ncordingly, if the investor receives a copy of this Prospectus or any other offering materials or advertisements, the\ninvestor should not distribute the same to any person in or into any jurisdiction where to do so would or may\ncontravene local securities laws or regulations.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2697734074390765, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.36511329628046174, "height": 0.09533988884138522, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-5", "text": "If an investor forwards this Prospectus or any other offering materials or advertisements into any such territories\n(whether under a contractual or legal obligation or otherwise) the investor should draw the recipient's attention to\nthe contents of this \"Selling and Transfer Restrictions\" section.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.41342454040188115, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-6", "text": "Subject to the specific restrictions described below, if investors (including, without limitation, any investor's\nnominees and trustees) are outside the Netherlands or Germany and wish to accept, sell or purchase Offer\nShares, they must satisfy themselves as to full observance of the applicable laws of any relevant territory includ-\ning obtaining any requisite governmental or other consents, observing any other requisite formalities and paying\nany issue, transfer or other taxes due in such territories.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.413852073535699, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4886703719538264, "height": 0.07481829841812737, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-7", "text": "The information set out in this \"Selling and Transfer Restrictions\" section is intended as a general guideline\nonly. Investors that are in any doubt as to whether they are eligible to purchase Offer Shares should consult their\nprofessional adviser without delay.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5369816160752459, "height": 0.04147071398033353, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-8", "text": "Selling Restrictions\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5502351432235998, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.5677640017101325, "height": 0.01752885848653274, "width": 0.16989117291414751}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-9", "text": "United States\n", "page_number": 207, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5810175288584866, "lower_right_x": 0.21221281741233375, "lower_right_y": 0.5934159897392048, "height": 0.012398460880718276, "width": 0.09431680773881501}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-10", "text": "The Offer Shares have not been and will not be registered under the US Securities Act, or with any securities\nregulatory authority of any state or other jurisdiction in the United States, and may not be offered, sold, sub-\nscribed for, pledged or otherwise transferred within the United States, except pursuant to an applicable exemp-\ntion from, or in a transaction not subject to, the registration requirements of the US Securities Act. Accordingly,\nthe Offer Shares may be offered or sold: (i) within the United States to qualified institutional buyers (\"QIBs\") as\ndefined in Rule 144A under the US Securities Act (\"Rule 144A\") in reliance on Rule 144A or pursuant to anoth-\ner exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act, and\n(ii) outside the United States in offshore transactions in reliance on Regulation S under the US Securities Act.\nAny offer or sale of the Offer Shares in the United States will be made through US broker-dealer affiliates of the\nUnderwriters. Transfers of the Offer Shares will be restricted and each purchaser will be deemed to have made\nacknowledgements, representations and agreements, as described in the section \"\u2013 Transfer Restrictions\".\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7524583155194527, "height": 0.15091919623770844, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-11", "text": "In addition, until the end of the 40th calendar day after the commencement of the Offering, an offer or sale of the\nOffer Shares within the United States by a dealer (whether or not participating in the Offering) may violate the\nregistration requirements of the US Securities Act if such offer or sale is made otherwise than in accordance with\nRule 144A or another exemption from registration under the US Securities Act.\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8140230867892262, "height": 0.05515177426250539, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-12", "text": "European Economic Area\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.827704147071398, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.8413852073535699, "height": 0.013681060282171864, "width": 0.18440145102781136}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-13", "text": "In relation to each state other than the Netherlands and Germany which is a party to the agreement relating to the\nEuropean Economic Area (\"EEA\") and which has implemented the Prospectus Directive (a \"Relevant Member\nState\"), with effect from and including the date on which the Prospectus Directive is implemented in that Rele-\nvant Member State, an offer to the public of any Offer Shares which are the subject of the Offering contemplated\nby this Prospectus may not be made in that Relevant Member State, except that an offer to the public in that\n", "page_number": 207, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.847798204360838, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9166310389055152, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-207-14", "text": "204\n", "page_number": 207, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-0", "text": "Relevant Member State of any Offer Shares may be made at any time under the following exemptions from the\nProspectus Directive, if they have been implemented in that Relevant Member State:\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-1", "text": "(i)     to any legal entity which is a qualified investor as defined under the Prospectus Directive;\n(ii)    to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus\n        Directive), subject to obtaining the prior consent of the Sole Global Coordinator; or\n(iii)   in any other circumstances falling within Article 3(2) of the Prospectus Directive,\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881145788798632, "height": 0.06883283454467722, "width": 0.7611850060459493}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-2", "text": "provided that no such offer of Offer Shares shall require the Company or any Underwriter to publish a prospec-\ntus pursuant to Article 3 of the Prospectus Directive or any measure implementing the Prospectus Directive in a\nRelevant Member State or supplement to a prospectus pursuant to Article 16 of the Prospectus Directive.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23599828986746474, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-3", "text": "For the purposes of this provision, the expression an \"offer to the public\" in relation to any Offer Shares in any\nRelevant Member State means the communication in any form and by any means of sufficient information on the\nterms of the Offering and any Offer Shares to be offered so as to enable an investor to decide to purchase any\nOffer Shares, as the same may be varied in that Relevant Member State by any measure implementing the Pro-\nspectus Directive in that Relevant Member State and the expression \"Prospectus Directive\" means Directive\n2003/71/EC, as amended, including Directive 2010/73/EU and includes any relevant implementing measure in\neach Relevant Member State.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3351859769132108, "height": 0.09277469003847799, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-4", "text": "United Kingdom\n", "page_number": 208, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.35185976913210776, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.3659683625480975, "height": 0.014108593415989745, "width": 0.11487303506650544}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-5", "text": "This Prospectus and any other material in relation to the Offer Shares described herein is directed at and for\ndistribution in the United Kingdom only to persons in the United Kingdom that are qualified investors within the\nmeaning of Article 2(1)(e) of the Prospective Directive (\"qualified investors\") that are also (i) persons who have\nprofessional experience in matters relating to investments falling within Article 19(5) of the Financial Services\nand Markets Act 2000, as amended (the \"FSMA\") (Financial Promotion) Order 2005 (the \"Order\"), or (ii) high\nnet worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons being together referred to as\n\"relevant persons\"). The Offer Shares are only available to, and any invitation, offer or agreement to subscribe,\npurchase or otherwise acquire such Offer Shares will be engaged in only with, relevant persons. Any person in\nthe United Kingdom who is not a relevant person should not act or rely on this Prospectus or any of its contents.\nAny investment or investment activity to which this Prospectus relates is available only to relevant persons and\nwill be engaged in only with relevant persons. This Prospectus and its contents are confidential and should not be\ndistributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person in the\nUnited Kingdom.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5506626763574177, "height": 0.17828131680205217, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-6", "text": "Furthermore, the Underwriters have warranted that they (i) have only invited or will only invite participation in\ninvestment activities in connection with the offering or the sale of the Offer Shares within the meaning of Sec-\ntion 21 of the FSMA, and have only initiated or will only initiate such investment activities to the extent that\nSection 21(1) of the FSMA does not apply to the Company; and (ii) have complied and will comply with all\napplicable provisions of FSMA with respect to all activities already undertaken by each of them or will under-\ntake in the future in relation to the Offer Shares in, from, or otherwise involving the United Kingdom.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6395895681915349, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-7", "text": "Switzerland\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6562633604104318, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.6669516887558786, "height": 0.010688328345446862, "width": 0.08766626360338574}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-8", "text": "This document as well as any other material relating to the Offer Shares which are the subject of the offering\ncontemplated by this Prospectus does not constitute an issue prospectus pursuant to Articles 652a and/or 1156 of\nthe Swiss Code of Obligations. The Offer Shares will not be listed on the SIX Swiss Exchange and, therefore,\nthe documents relating to the Offer Shares including, but not limited to, this document, do not claim to comply\nwith the disclosure standards of the listing rules of the SIX Swiss Exchange and corresponding prospectus\nschemes annexed to the listing rules of the SIX Swiss Exchange.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7571611799914494, "height": 0.08037622915775977, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-9", "text": "The Offer Shares are being offered in Switzerland by way of a private placement, i.e., to a small number of se-\nlected investors only, without any public offer and only to investors who do not purchase the Offer Shares with\nthe intention to distribute them to the public. The investors will be individually approached by the Company\nfrom time to time.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.879081015719468, "lower_right_y": 0.8170158187259513, "height": 0.05130397605814452, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-10", "text": "This document as well as any other material relating to the Offer Shares is personal and confidential and does not\nconstitute an offer to any other person. This document may only be used by those investors to whom it has been\nhanded out in connection with the Offering described herein and may neither directly nor indirectly be distribut-\ned or made available to other persons without the express consent of the Company. It may not be used in connec-\ntion with any other offer and shall in particular not be copied and/or distributed to the public in (or from) Swit-\nzerland.\n", "page_number": 208, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8272766139375801, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9059427105600684, "height": 0.07866609662248825, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-208-11", "text": "205\n", "page_number": 208, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-0", "text": "Qatar\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.15840386940749698, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.04232164449818622}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-1", "text": "The Offer Shares have not been offered sold or delivered, and will not be offered, sold or delivered at any time\ndirectly or indirectly in the State of Qatar (including the Qatar Financial Centre) in a manner that will constitute\na public offering. No application has been made nor will be made for the Offer Shares to be listed or traded on\nthe Qatar Exchange or the QE Venture Market.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16032492518170158, "height": 0.05472424112868747, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-2", "text": "This Prospectus has not been, and will not be registered with, filed with, nor reviewed or approved by Qatar\nCentral Bank, Qatar Financial Markets Authority, Qatar Financial Centre Regulatory Authority nor any other\nauthority in Qatar and may not be publicly distributed. This Prospectus is intended only for the original recipient\nand must not be provided to any other person. It is not for general circulation in the State of Qatar and may not\nbe reproduced or used for any other purpose.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23557075673364686, "height": 0.06840530141085935, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-3", "text": "Transfer Restrictions\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.24925181701581872, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.26336041043180847, "height": 0.014108593415989745, "width": 0.18802902055622733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-4", "text": "The Offer Shares have not been and will not be registered under the US Securities Act or the applicable securi-\nties laws of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise\ntransferred within the United States, except pursuant to an applicable exemption from, or in a transaction not\nsubject to, the registration requirements of the US Securities Act and applicable state securities laws.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28003420265070544, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3351859769132108, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-5", "text": "Outside the United States\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.3612654980761009, "height": 0.012825994014536157, "width": 0.17956469165659006}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-6", "text": "Each investor of the Offer Shares outside the United States will, pursuant to Regulation S, be deemed to have\nrepresented and agreed that it has received a copy of this Prospectus and such other information as it deems\nnecessary to make an informed investment decision and that:\n(i)     the investor acknowledges that the Offer Shares have not been and will not be registered under the US\n        Securities Act, or with any securities regulatory authority of any state of the United States, and are sub-\n        ject to significant restrictions on transfer;\n(ii)    the investor and the person, if any, for whose account or benefit the investor is acquiring the Offer\n        Shares, were located outside the United States at the time the buy order for such Offer Shares was origi-\n        nated and continue to be located outside the United States and has not purchased the Offer Shares for\n        the benefit of any person in the United States or entered into any arrangement for the transfer of the Of-\n        fer Shares to any person in the United States;\n(iii)   the investor is aware of the restrictions on the offer and sale of the Offer Shares pursuant to Regulation\n        S as described in this Prospectus; and\n(iv)    the Offer Shares have not been offered to it by means of any \"directed selling efforts\" as defined in\n        Regulation S.\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6023941855493801, "height": 0.2334330910645575, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-7", "text": "Within the United States\n", "page_number": 209, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.6186404446344592, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.629328772979906, "height": 0.010688328345446751, "width": 0.16989117291414754}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-8", "text": "Each investor of Offer Shares in reliance on Rule 144A, by accepting delivery of this Prospectus, will be deemed\nto have represented, agreed and acknowledged as follows (terms used in the following paragraphs that are de-\nfined in Rule 144A have the respective meanings given to them in Rule 144A):\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6797776827704147, "height": 0.04061564771269777, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-9", "text": "the investor is (a) a QIB, (b) acquiring the Shares for its own account or for the account of one or more\nQIBs, (c) not formed for the purpose of investing in the Offer Shares or the Company, and (d) is aware,\nand each beneficial owner of such Offer Shares has been advised, that the sale of the Offer Shares to it\nis being made in reliance on Rule 144A or in reliance on another exemption from, or in a transaction not\nsubject to, the registration requirements of the US Securities Act;\nthe investor understands that (1) the Offer Shares have not been, and will not be, registered under the\nUnited States Securities Act or with the securities regulatory authority of any state or other jurisdiction\nof the United States, and may not be offered, sold, pledged or otherwise transferred except (a) in ac-\ncordance with Rule 144A to a person that it, and any person acting on its behalf, reasonably believes is\na QIB purchasing for its own account or for the account of one or more QIBs, (b) in an offshore transac-\ntion in accordance with Rule 903 or Rule 904 of regulation S under the US Securities Act, (c) pursuant\nto an exemption from registration under the US Securities Act provided by Rule 144 thereunder (if\navailable), (d) pursuant to an effective registration statement under the US Securities Act, or (e) to the\nCompany or any of their respective affiliates, in each case in accordance with any applicable securities\nlaws of any State of the United States, and (2) it will, and each subsequent holder of the Offer Shares is\nrequired to, notify any investor of the Offer Shares from it of the resale restrictions applicable to the Of-\nfer Shares;\n", "page_number": 209, "bounding_box": {"top_left_x": 0.1735187424425635, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9264643009833262, "height": 0.23941855493800768, "width": 0.7110036275695284}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-10", "text": "(i)\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6870457460453185, "lower_right_x": 0.13482466747279323, "lower_right_y": 0.7002992731936725, "height": 0.013253527148353927, "width": 0.018742442563482467}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-11", "text": "(ii)\n", "page_number": 209, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.7622915775972637, "lower_right_x": 0.14026602176541716, "lower_right_y": 0.7759726378794357, "height": 0.013681060282171975, "width": 0.021160822249093103}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-209-12", "text": "206\n", "page_number": 209, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-210-0", "text": "(iii)   the investor understands that the Offer Shares (to the extent they are in certificated form) will bear a\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.09833262077811031, "height": 0.013253527148353997, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-210-1", "text": "      legend to the following effect, unless we determine otherwise in accordance with applicable law:\nTHE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN, AND WILL NOT BE, REGISTERED\nUNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE \"US SECURITIES\nACT\") OR ANY SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION OF THE UNITED\nSTATES. THE HOLDER HEREOF, BY PURCHASING THE SECURITIES REPRESENTED HEREBY,\nAGREES THAT THE SECURITIES REPRESENTED HEREBY MAY BE REOFFERED, RESOLD,\nPLEDGED OR OTHERWISE TRANSFERRED ONLY IN COMPLIANCE WITH THE SECURITIES ACT\nAND OTHER APPLICABLE LAWS AND ONLY (1) PURSUANT TO RULE 144A UNDER THE\nSECURITIES ACT TO A PERSON THAT THE HOLDER REASONABLY BELIEVES IS A QUALIFIED\nINSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A PURCHASING FOR ITS OWN\nACCOUNT OR A PERSON PURCHASING FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL\nBUYER WHOM THE HOLDER HAS INFORMED, IN EACH CASE, THAT THE REOFFER, RESALE,\nPLEDGE OR OTHER TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, (2) IN AN\nOFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR 904 OF REGULATION S UNDER\nTHE SECURITIES ACT OR (3) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED\nBY RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE), IN EACH CASE IN ACCORDANCE\nWITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. NO\nREPRESENTATION CAN BE MADE AS TO THE AVAILABILITY OF THE EXEMPTION PROVIDED BY\nRULE 144 UNDER THE SECURITIES ACT FOR RESALES OF THIS SECURITY. NOTWITHSTANDING\nANYTHING TO THE CONTRARY OR FOREGOING, THE SECURITIES REPRESENTED HEREBY ARE\n\"RESTRICTED SECURITIES\" WITHIN THE MEANING OF 144(A) (3) UNDER THE SECURITIES ACT\nAND FOR SO LONG AS SUCH SECURITIES ARE \"RESTRICTED SECURITIES\" (AS SO DEFINED) THE\nSECURITIES MAY NOT BE DEPOSITED INTO ANY UNRESTRICTED DEPOSITORY RECEIPT\nFACILITY IN RESPECT OF THE SECURITIES ESTABLISHED OR MAINTAINED BY A DEPOSITORY\nBANK. EACH HOLDER, BY ITS ACCEPTANCE OF THIS SECURITY, REPRESENTS THAT IT\nUNDERSTANDS AND AGREES TO THE FOREGOING RESTRICTIONS.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09876015391192818, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47370671227020095, "height": 0.3749465583582728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-210-2", "text": "has", "page_number": 210, "bounding_box": {"top_left_x": 0.8258766626360339, "top_left_y": 0.46943138093202225, "lower_right_x": 0.8476420798065296, "lower_right_y": 0.47755451047456177, "height": 0.00812312954253952, "width": 0.021765417170495738}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-210-3", "text": "(iv)   if it is acquiring any Shares for the account of one or more QIBs, the investor represents that it has sole\n       investment discretion with respect to each such account and that it has full power to make the foregoing\n       acknowledgements, representations and agreements on behalf of each such account; and\n(v)    the investor understands that the Company, the Underwriters and their affiliates and others will rely\n       upon the truth and accuracy of the foregoing acknowledgements, representations and agreements.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.47413424540401883, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5433946130825139, "height": 0.06926036767849508, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-210-4", "text": "Prospective investors that are QIBs are hereby notified that sellers of the Offer Shares may be relying on the\nexemption from the provisions of Section 5 of the US Securities Act provided by Rule 144A.\n", "page_number": 210, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5502351432235998, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5775972637879435, "height": 0.027362120564343728, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-210-5", "text": "207\n", "page_number": 210, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-0", "text": "TAXATION\n", "page_number": 211, "bounding_box": {"top_left_x": 0.4347037484885127, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5640870616686819, "lower_right_y": 0.1085934159897392, "height": 0.016673792218896963, "width": 0.12938331318016927}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-1", "text": "Dutch Tax Considerations\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12612227447627192, "lower_right_x": 0.343409915356711, "lower_right_y": 0.1393758016246259, "height": 0.013253527148353983, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-2", "text": "The following summary of certain Dutch taxation matters is based on the laws and practice in force as of the\ndate of this Prospectus and is subject to any changes in law and the interpretation and application thereof,\nwhich changes could be made with retroactive effect. The following summary does not purport to be a compre-\nhensive description of all the tax considerations that may be relevant to a decision to acquire, hold or dispose of\na Share, and does not purport to deal with the tax consequences applicable to all categories of investors.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.22445489525438223, "height": 0.06755023514322361, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-3", "text": "Except for the section \"Withholding tax\" below, this summary does not describe the Dutch tax consequences for\nan individual or non-resident entity holding a Share which individual or non-resident entity has or will have a\nsubstantial interest or a deemed substantial interest in the Company.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2321504916631039, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.27233860624198375, "height": 0.04018811457887986, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-4", "text": "Generally speaking, an individual holding a Share has a substantial interest in the Company if (a) such individ-\nual, either alone or together with his partner, directly or indirectly has, or (b) certain relatives of such individual\nor his partner, directly or indirectly have, (i) the ownership of, a right to acquire the ownership of, or certain\nrights over, shares representing 5% or more of either the total issued and outstanding capital of the Company or\nthe issued and outstanding capital of any class of shares of the Company, or (ii) the ownership of, or certain\nrights over, profit participating certificates (winstbewijzen) that relate to 5% or more of either the annual profit\nor the liquidation proceeds of the Company. Also, an individual holding a Share has a substantial interest in the\nCompany if his partner has, or if certain relatives of the individual or his partner have, a deemed substantial\ninterest in the Company. Generally, an individual holding a Share, or his partner or relevant relative, has a\ndeemed substantial interest in the Company if either (a) such person or his predecessor has disposed of or is\ndeemed to have disposed of all or part of a substantial interest or (b) such person has transferred an enterprise\nin exchange for shares in the Company, on a non-recognition basis. In the event an individual holding a Share\nhas a substantial interest in the Company, all classes of shares and / or any profit participating certificates are\ndeemed to be part of this substantial interest.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27276613937580163, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.47071398033347583, "height": 0.1979478409576742, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-5", "text": "Generally speaking, a non-resident entity holding a Share has a substantial interest in the Company if such enti-\nty, directly or indirectly has (i) the ownership of, a right to acquire the ownership of, or certain rights over\nshares representing 5% or more of either the total issued and outstanding capital of the Company or the issued\nand outstanding capital of any class of shares of the Company, or (ii) the ownership of, or certain rights over,\nprofit participating certificates (winstbewijzen) that relate to 5% or more of either the annual profit or the liqui-\ndation proceeds of the Company. Generally, an entity holding a Share has a deemed substantial interest in the\nCompany if such entity has disposed of or is deemed to have disposed of all or part of a substantial interest on a\nnon-recognition basis. The above is applicable in the event the substantial interest is held with tax avoidance as\none of the main purposes and the substantial interest cannot be allocated to the business assets of an enterprise.\nIn this respect, it should be noted that it has been proposed to amend this legislation as per January 1 st 2016\nwhere the above is applicable in the event the substantial interest is held with tax avoidance as one of the main\npurposes and it is not put in place for valid commercial reasons which reflect economic reality.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.6417272338606242, "height": 0.16331765711842672, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-6", "text": "For the purpose of this summary, the term entity means a corporation as well as any other person that is taxable\nas a corporation for Dutch corporate income tax purposes as defined under the Dutch corporate income tax act\n(Wet op de vennootschapsbelasting 1969). Hence, this summary is not applicable for corporations which are\nexempt from Dutch corporate income tax or are subject to a special tax regime.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6494228302693459, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7032920051303976, "height": 0.053869174861051694, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-7", "text": "Where this summary refers to a holder of a Share, an individual holding a Share or an entity holding a Share,\nsuch reference is restricted to an individual or entity holding legal title to as well as an economic interest in such\nShare or otherwise being regarded as owning a Share for Dutch tax purposes. It is noted that for purposes of\nDutch income, corporate, gift and inheritance tax, assets legally owned by a third party such as a trustee, foun-\ndation or similar entity, may be treated as assets owned by the (deemed) settlor, grantor or similar originator or\nthe beneficiaries in proportion to their interest in such arrangement.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7109876015391193, "lower_right_x": 0.8814993954050786, "lower_right_y": 0.7892261650277896, "height": 0.07823856348867031, "width": 0.7660217654171705}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-8", "text": "the beneficiaries in proportion to their interest in such arrangement.\nWhere the summary refers to \"the Netherlands\" or \"Dutch\" it refers only to the European part of the Kingdom of\nthe Netherlands.\nInvestors are advised to consult their professional advisers as to the tax consequences of purchase, ownership\nand disposition of a Share.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8614792646430098, "height": 0.07182556648140226, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-9", "text": "Withholding tax\n", "page_number": 211, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.8751603249251817, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.8884138520735357, "height": 0.013253527148354038, "width": 0.11185006045949214}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-10", "text": "In general, the Company must withhold Dutch tax (dividend withholding tax) from dividends distributed on the\nShares at the rate of 15%.\n", "page_number": 211, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8956819153484396, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9209063702436939, "height": 0.025224454895254378, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-211-11", "text": "208\n", "page_number": 211, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-0", "text": "Dividends include, without limitation:\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.37726723095526, "lower_right_y": 0.09747755451047456, "height": 0.012398460880718248, "width": 0.2617896009673519}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-1", "text": "(i)     Distributions of profits (including paid-in capital not recognised for dividend withholding tax purposes) in\n        cash or in kind, including deemed and constructive dividends;\n(ii)    liquidation distributions and, generally, proceeds realised upon a repurchase of Shares by the Company or\n        upon the transfer of Shares to the Company's direct or indirect subsidiary, in excess of the average paid-in\n        capital recognised for dividend withholding tax purposes;\n(iii)   the nominal value of Shares issued or any increase in the nominal value of Shares, except where such\n        (increase in) the nominal value of Shares is funded out of the Company's paid-in capital recognised for\n        dividend withholding tax purposes;\n(iv)    repayments of paid-in capital recognised for dividend withholding tax purposes up to the amount of the\n        Company's profits (zuivere winst) unless the Company's General Meeting has resolved in advance that the\n        Company shall make such repayments and the nominal value of the Shares concerned has been reduced\n        by a corresponding amount through an amendment of the Articles of Association;\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.09790508764429243, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2907225309961522, "height": 0.19281744335185977, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-2", "text": "A holder of a Share which is, or is deemed to be, resident in the Netherlands for Dutch tax purposes is generally\nentitled to credit the dividend withholding tax withheld against such holder's liability to Dutch tax on income and\ncapital gains or, in certain cases, to apply for a full refund of the dividend withholding tax withheld or apply for a\ncomplete exemption of dividend withholding tax.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3522873022659256, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-3", "text": "A holder of a Share which is not, and is not deemed to be, resident in the Netherlands for Dutch tax purposes\nmay be eligible for a partial or complete exemption or refund of all or a portion of the dividend withholding tax\nunder an income tax convention in effect between the Netherlands and the holder's country of residence.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3993159469858914, "height": 0.04061564771269771, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-4", "text": "Under the terms of Dutch domestic anti-dividend stripping rules, a recipient of dividends distributed on a Share\nwill not be entitled to an exemption from, reduction, refund, or credit of dividend tax if the recipient is not the\nbeneficial owner of such dividends as meant in those rules.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4065840102607952, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4463445917058572, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-5", "text": "Legislation has been passed as a result of which, as of 1 January 2016, the revised version of the Convention\nbetween the Kingdom of the Netherlands and the Federal Republic of Germany for the avoidance of double\ntaxation and the prevention of fiscal evasion with respect to taxes on Income (the \"DTT-GER/NL\") should\ncome in force. Under the revised version of the DTT-GER/NL, a holder of Shares will not be subject to Nether-\nlands dividend withholding tax on dividends distributed by the Company, irrespective of the nature or form of\nsuch dividend and irrespective of such holder's place of residence (unless such holder is tax resident in the Neth-\nerlands), if and for as long as the Company is tax resident solely in Germany for the purpose of the revised ver-\nsion of the DTT-GER/NL. The Company intends to be tax resident solely in Germany for the purposes of the\nrevised version of the DTT-GER/NL.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5767421975203079, "height": 0.12227447627191113, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-6", "text": "Please note that until the revised version of the DTT-GER/NL will come into force, there is a significant risk of\ndouble taxation for a holder of Shares which is a resident of a third country, as the current version of the DTT-\nGER/NL does not offer protection for such a holder of Shares.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5844377939290295, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6259085079093629, "height": 0.04147071398033342, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-7", "text": "Taxes on income and capital gains\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6425823001282599, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.6549807610089782, "height": 0.012398460880718276, "width": 0.2418379685610641}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-8", "text": "Resident entities\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6631038905515177, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.6733646857631467, "height": 0.010260795211628926, "width": 0.11608222490931076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-9", "text": "An entity holding a Share which is, or is deemed to be, resident in the Netherlands for Dutch tax purposes and\nwhich is not tax exempt, will generally be subject to corporate income tax in the Netherlands in respect of in-\ncome or a capital gain derived from such Share at the prevailing statutory rates, unless the holder has the benefit\nof the participation exemption (deelnemingsvrijstelling) with respect to such Share. Generally speaking, the\nholder of a Share will have the benefit of the participation exemption (deelnemingsvrijstelling) if the holder\nowns at least 5% of the nominally paid-up share capital of the Company. In the event the participation exemption\n(deelnemingsvrijstelling) is applicable, a capital loss derived from such Share and costs related to the acquisition\nor disposal of such Share are not deductible for Dutch corporate income tax purposes.\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6836254809747755, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7935014963659683, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-10", "text": "Resident individuals\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7999144933732364, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.8106028217186833, "height": 0.010688328345446862, "width": 0.1402660217654172}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-11", "text": "An individual holding a Share who is, or is deemed to be, resident in the Netherlands for Dutch tax purposes will\nbe subject to income tax in the Netherlands in respect of income or a capital gain derived from such Share at\nrates up to 52% if:\n", "page_number": 212, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8204360837964942, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.861051731509192, "height": 0.04061564771269777, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-12", "text": "(i)    the holder has an enterprise or an interest in an enterprise to which the Share is attributable; or\n(ii)   the income or capital gain qualifies as income from miscellaneous activities (belastbaar resultaat uit\n       overige werkzaamheden) as defined in the Income Tax Act (Wet inkomstenbelasting 2001).\n", "page_number": 212, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9162035057716973, "height": 0.054724241128687456, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-212-13", "text": "209\n", "page_number": 212, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-0", "text": "If neither condition (i) nor condition (ii) applies, such individual will be subject to income tax on the basis of a\ndeemed return, regardless of any actual income or capital gain derived from a Share. The deemed return amounts\nto 4% of the value of the individual's net assets as per the beginning of the relevant fiscal year (including the\nShare). Subject to application of personal allowances, the deemed return shall be taxed at a rate of 30%.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.14023086789226166, "height": 0.05515177426250535, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-1", "text": "Non residents\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.1573321932449765, "height": 0.01068832834544678, "width": 0.09733978234582828}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-2", "text": "A holder of a Share which is not and is not deemed to be resident in the Netherlands for Dutch tax purposes will\nnot be subject to taxation in the Netherlands on income or a capital gain derived from a Share unless:\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1671654553227875, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19452757588713127, "height": 0.027362120564343756, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-3", "text": "(i)    such income or capital gain is attributable to an enterprise or part thereof which is either effectively man-\n       aged in the Netherlands or carried on through a permanent establishment (vaste inrichting) or permanent\n       representative (vaste vertegenwoordiger) taxable in the Netherlands; or\n(ii)   the holder is an individual and such income or capital gain qualifies as income from miscellaneous activi-\n       ties (belastbaar resultaat uit overige werkzaamheden) in the Netherlands as defined in the Income Tax\n       Act (Wet inkomstenbelasting 2001).\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19495510902094912, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2907225309961522, "height": 0.09576742197520308, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-4", "text": "Gift and inheritance tax\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3039760581445062, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.3180846515604959, "height": 0.014108593415989745, "width": 0.1686819830713422}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-5", "text": "Dutch gift or inheritance taxes will not be levied on the occasion of the transfer of a Share by way of gift by, or\non the death of, a holder, unless:\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.324497648567764, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.3522873022659256, "height": 0.02778965369816161, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-6", "text": "(i)    the holder is or is deemed to be resident in the Netherlands for the purpose of the relevant provisions; or\n(ii)   the transfer is construed as an inheritance or gift made by, or on behalf of, a person who, at the time of the\n       gift or death, is or is deemed to be resident in the Netherlands for the purpose of the relevant provisions.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4070115433946131, "height": 0.048311244121419405, "width": 0.7611850060459493}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-7", "text": "Value added tax\n", "page_number": 213, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.4236853356135101, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.4343736639589568, "height": 0.010688328345446751, "width": 0.11185006045949214}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-8", "text": "No value added tax will be due in the Netherlands in respect of payments in consideration for the issuance of a\nShare, payments on Share, or payments made upon a transfer of a Share.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.44420692603676787, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.47071398033347583, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-9", "text": "Other taxes and duties\n", "page_number": 213, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.48525010688328346, "lower_right_x": 0.2756952841596131, "lower_right_y": 0.4959384352287302, "height": 0.010688328345446751, "width": 0.158403869407497}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-10", "text": "There is no registration tax, capital tax, customs duty, transfer tax, stamp duty, or any other similar tax or duty\npayable in the Netherlands in respect of or in connection with the subscription, issue, placement, allotment, de-\nlivery or transfer of a Share.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5057716973065413, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5468148781530568, "height": 0.04104318084651559, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-11", "text": "Residence\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5604959384352287, "lower_right_x": 0.18863361547763, "lower_right_y": 0.5724668661821292, "height": 0.01197092774690045, "width": 0.0731559854897219}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-12", "text": "A holder of a Share will not be, or deemed to be, resident in the Netherlands or will not have, or deemed to have,\na permanent establishment (vaste inrichting) in the Netherlands for Dutch tax purposes, by reason only of acquir-\ning, holding or disposing of a Share.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.62248824283882, "height": 0.04147071398033342, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-13", "text": "Belgian Tax Considerations\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.6532706284737068, "height": 0.0141085934159898, "width": 0.24244256348246673}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-14", "text": "The paragraphs below are a summary of certain material Belgian federal income tax consequences of the owner-\nship and disposal of Shares by an investor that acquires such Shares in connection with this Offering. The sum-\nmary is based on our understanding of laws, treaties and regulatory interpretations in effect in Belgium on the\ndate of this Prospectus, all of which are subject to change, including changes that could have retroactive effect.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7216759298845661, "height": 0.05515177426250539, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-15", "text": "This summary does not purport to address all tax consequences of the investment in, ownership in and disposal\nof Shares, and does not take into account the specific circumstances of particular investors, some of which may\nbe subject to special rules, or the tax laws of any country other than Belgium. In particular, this summary deals\nonly with investors who hold the shares as capital assets and does not address the tax treatment of investors who\nare subject to special rules, such as financial institutions, insurance companies, collective investment undertak-\nings, dealers in securities or currencies or persons who hold the shares as a position in a straddle, share-\nrepurchase transactions, conversion transactions, a synthetic security or other integrated financial transaction.\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8242838820008551, "height": 0.09619495510902099, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-16", "text": "For purposes of this summary, a Belgian resident is an individual subject to Belgian personal income tax (i.e., an\nindividual who is domiciled in Belgium or has his seat of wealth in Belgium or a person assimilated to a resident\nfor purposes of Belgian tax law), a company subject to Belgian corporate income tax (i.e., a corporate entity that\nhas its statutory seat, its main establishment, its administrative seat or seat of management in Belgium), an Or-\nganisation for Financing Pensions subject to Belgian corporate income tax (i.e., a Belgian pension fund incorpo-\nrated under the form of an Organisation for Financing Pensions), or a legal entity subject to Belgian income tax\non legal entities (i.e., a legal entity other than a company subject to Belgian corporate income tax, that has its\n", "page_number": 213, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.926891834117144, "height": 0.09619495510902087, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-213-17", "text": "210\n", "page_number": 213, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-0", "text": "statutory seat, its main establishment, its administrative seat or seat of management in Belgium). A non-resident\nis any person that is not a Belgian resident.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-1", "text": "This summary does not address the tax regime applicable to Shares held by Belgian tax residents through a fixed\nbasis or a permanent establishment situated outside Belgium.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.1470713980333476, "height": 0.027789653698161623, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-2", "text": "Investors should consult their own advisers regarding the tax consequences of an investment in Shares in the\nlight of their particular circumstances, including the effect of any state, local or other national laws, treaties and\nregulatory interpretations thereof.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.15348439504061565, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19452757588713127, "height": 0.04104318084651562, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-3", "text": "Taxation of dividends on Shares\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.20820863616930313, "lower_right_x": 0.343409915356711, "lower_right_y": 0.22231722958529285, "height": 0.014108593415989718, "width": 0.22732769044740025}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-4", "text": "For Belgian income tax purposes, the gross amount of all benefits paid on or attributed to the Shares is generally\ntreated as a dividend distribution. By way of exception, the repayment of capital carried out in accordance with\nthe Belgian Companies Code is not treated as a dividend distribution to the extent that such repayment is imput-\ned to the fiscal capital. This fiscal capital includes, in principle, the actual paid-up statutory share capital and,\nsubject to certain conditions, the paid-up issuance premiums and the cash amounts subscribed to at the time of\nthe issue of profit sharing certificates.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.3108165882855921, "height": 0.08208636169303118, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-5", "text": "Belgian withholding tax of 25% is normally levied on dividends, subject to such relief as may be available under\napplicable domestic or tax treaty provisions.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.34544677212483965, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-6", "text": "Upon redemption of the Shares, the redemption distribution (after deduction of the portion of the fiscal capital\nrepresented by the redeemed Shares) will be treated as a dividend subject to a Belgian withholding tax of 25%,\nsubject to such relief as may be available under applicable domestic or tax treaty provisions. No withholding tax\nwill be triggered if this redemption is carried out on Euronext or a similar stock exchange and meets certain\nconditions.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4189824711415135, "height": 0.06712270200940573, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-7", "text": "In the event of liquidation of the Company, any amounts distributed in excess of the fiscal capital will in princi-\nple be subject to withholding tax at a rate of 25%, subject to such relief as may be available under applicable\ndomestic or tax treaty provisions.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4685763146643865, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-8", "text": "On 23 July 2015, the Belgian government has announced its plan to increase the percentage of withholding tax to\n27%. On the date of this Prospectus, no entry into force date has been determined.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5027789653698161, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-9", "text": "Belgian resident individuals\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5126122274476272, "lower_right_x": 0.309552599758162, "lower_right_y": 0.5250106883283454, "height": 0.012398460880718165, "width": 0.19347037484885127}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-10", "text": "For Belgian resident individuals who acquire and hold the Shares as a private investment, the Belgian dividend\nwithholding tax fully discharges their personal income tax liability. This means that they do not have to declare\nthe dividends in their personal income tax return and that the Belgian withholding tax constitutes a final tax.\nThese Belgian resident individuals may nevertheless elect to report the dividends in their personal income tax\nreturn. Where such individual opts to report them, dividends will normally be taxable at the lower of the general-\nly applicable 25% withholding tax rate on dividends or at the progressive personal income tax rates applicable to\nthe taxpayer's overall declared income. If the Belgian resident individual reports the dividends, the income tax\ndue on such dividends will not be increased by local surcharges. In addition, if the dividends are reported, the\ndividend withholding tax levied at source may, in both cases, be credited against the personal income tax due\nand is reimbursable to the extent that it exceeds the personal income tax due, provided that the dividend distribu-\ntion does not result in a reduction in value of or a capital loss on the Shares. This condition is not applicable if\nthe individual can demonstrate that he has held the Shares in full legal ownership for an uninterrupted period of\n12 months prior to the payment or attribution of the dividends.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.533133817870885, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7097050021376656, "height": 0.17657118426678065, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-11", "text": "For Belgian resident individuals who acquire and hold the Shares for professional purposes, the Belgian with-\nholding tax does not fully discharge their personal income tax liability. Dividends received must be reported by\nthe investor and will, in such case, be taxable at the investor's personal income tax rate (up to 50%) increased\nwith local surcharges. The Belgian withholding tax levied at source may be credited against the personal income\ntax due and is reimbursable to the extent that it exceeds the personal income tax due, subject to two conditions:\n(i) the taxpayer must own the Shares in full legal ownership at the time the dividends are paid or attributed and\n(ii) the dividend distribution may not result in a reduction in value of or a capital loss on the Shares. The latter\ncondition is not applicable if the investor can demonstrate that he has held the full legal ownership of Shares for\nan uninterrupted period of 12 months prior to the payment or attribution of the dividends.\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8396750748182984, "height": 0.12184694313809319, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-12", "text": "Belgian resident companies\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.847798204360838, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.8601966652415562, "height": 0.012398460880718276, "width": 0.18863361547763002}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-13", "text": "Corporate income tax\n", "page_number": 214, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8683197947840958, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.8811457887986319, "height": 0.012825994014536102, "width": 0.14993954050785974}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-14", "text": "For Belgian resident companies, the dividend withholding tax does not fully discharge the corporate income tax\nliability. For such companies, the gross dividend income (including the withholding tax) must be declared in the\n", "page_number": 214, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8815733219324497, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9153484395040615, "height": 0.03377511757161178, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-214-15", "text": "211\n", "page_number": 214, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-0", "text": "corporate income tax return and will be subject to a corporate income tax rate of 33.99%, unless the reduced\ncorporate income tax rates apply.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.879081015719468, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-1", "text": "Belgian resident companies can generally (although subject to certain limitations) deduct 95% of gross dividends\nreceived from their taxable income (\"dividend received deduction\"), provided that at the time of a dividend pay-\nment or attribution: (i) the Belgian resident company holds Shares representing at least 10% of the share capital\nof the Company or a participation in the Company with an acquisition value of at least \u20ac2,500,000; (ii) the\nShares have been held or will be held in full ownership for an uninterrupted period of at least one year; and (iii)\nthe conditions relating to the taxation of the underlying distributed income, as described in article 203 of the\nBelgian Income Tax Code (the \"Article 203 ITC Taxation Condition\") are met (together, the \"Conditions for the\napplication of the dividend received deduction regime\"). Under certain circumstances the conditions referred to\nunder (i) and (ii) do not need to be fulfilled in order for the dividend received deduction to apply.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2424112868747328, "height": 0.12312954253954682, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-2", "text": "The Conditions for the application of the dividend received deduction regime depend on a factual analysis, upon\neach distribution, and for this reason the availability of this regime should be verified upon each distribution.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.27661393758016245, "height": 0.027362120564343728, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-3", "text": "Any Belgian dividend withholding tax levied at source may be credited against the corporate income tax due and\nis reimbursable to the extent that it exceeds the corporate income tax due, subject to two conditions: (i) the tax-\npayer must own the Shares in full legal ownership at the time the dividends are paid or attributed and (ii) the\ndividend distribution may not result in a reduction in value of or a capital loss on the Shares. The latter condition\nis not applicable: (i) if the company can demonstrate that it has held the Shares in full legal ownership for an\nuninterrupted period of 12 months prior to the payment or attribution of the dividends or (ii) if, during that peri-\nod, the Shares never belonged to a taxpayer other than a resident company or a non-resident company which has,\nin an uninterrupted manner, invested the Shares in a permanent establishment (\"PE\") in Belgium.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.39290294997862335, "height": 0.10944848225737497, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-4", "text": "Withholding tax\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3997434801197093, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.413852073535699, "height": 0.014108593415989745, "width": 0.11608222490931076}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-5", "text": "Dividends distributed to a Belgian resident company will be exempt from Belgian withholding tax provided that\nthe Belgian resident company holds, upon payment or attribution of the dividends, at least 10% of the share\ncapital of the Company and such minimum participation is held or will be held during an uninterrupted period of\nat least one year.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.4754168448054724, "height": 0.05515177426250534, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-6", "text": "In order to benefit from this exemption, the Belgian resident company must provide the Company or its paying\nagent with a certificate confirming its qualifying status and the fact that it meets the two required conditions. If\nthe Belgian resident company holds the required minimum participation for less than one year, at the time the\ndividends are paid on or attributed to the Shares, the Company will levy the withholding tax but will not transfer\nit to the Belgian Treasury provided that the Belgian resident company certifies its qualifying status, the date from\nwhich it has held such minimum participation, and its commitment to hold the minimum participation for an\nuninterrupted period of at least one year. The Belgian resident company must also inform the Company or its\npaying agent if the one-year period has expired or if its shareholding will drop below 10% of the share capital of\nthe Company before the end of the one-year holding period. Upon satisfying the one-year shareholding require-\nment, the dividend withholding tax which was temporarily withheld, will be refunded to the Belgian resident\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.619067977768277, "height": 0.13723813595553658, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-7", "text": "company.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6220607097050022, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.6327490380504489, "height": 0.010688328345446751, "width": 0.06590084643288995}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-8", "text": "Belgian resident organisations for financing pensions\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.646002565198803, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.6601111586147926, "height": 0.01410859341598969, "width": 0.37605804111245467}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-9", "text": "For organisations for financing pensions (\"OFPs\"), i.e., Belgian pension funds incorporated under the form of an\nOFP (\"organismes de financement de pensions\") within the meaning of article 8 of the Belgian Act of 27 Octo-\nber 2006, the dividend income is generally tax exempt.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6665241556220607, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7079948696023942, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-10", "text": "Subject to certain limitations, any Belgian dividend withholding tax levied at source may be credited against the\ncorporate income tax due and is reimbursable to the extent that it exceeds the corporate income tax due.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7144078666096623, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7421975203078238, "height": 0.027789653698161554, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-11", "text": "Other Belgian resident legal entities subject to Belgian legal entities tax\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.7729799059427106, "height": 0.0141085934159898, "width": 0.4987908101571946}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-12", "text": "For taxpayers subject to the Belgian income tax on legal entities, the Belgian dividend withholding tax in princi-\nple fully discharges their income tax liability\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7793929029499786, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.8071825566481402, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-13", "text": "Non-resident individuals or non-resident companies\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8204360837964942, "lower_right_x": 0.4788391777509069, "lower_right_y": 0.8341171440786661, "height": 0.013681060282171864, "width": 0.36275695284159615}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-14", "text": "Non-resident income tax\n", "page_number": 215, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.840957674219752, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.8516460025651988, "height": 0.010688328345446862, "width": 0.16928657799274488}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-15", "text": "For non-resident individuals and companies, the dividend withholding tax will be the only tax on dividends in\nBelgium, unless the non-resident holds Shares in connection with a business conducted in Belgium through a\nfixed base in Belgium or a Belgian PE.\n", "page_number": 215, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8614792646430098, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9025224454895254, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-215-16", "text": "212\n", "page_number": 215, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-0", "text": "If Shares are acquired by a non-resident in connection with a business in Belgium, the investor must report any\ndividends received, which will be taxable at the applicable non-resident personal or corporate income tax rate, as\nappropriate. Belgian withholding tax levied at source may be credited against non-resident personal or corporate\nincome tax and is reimbursable to the extent that it exceeds the income tax due, subject to two conditions: (i) the\ntaxpayer must own Shares in full legal ownership at the time the dividends are paid or attributed and (ii) the\ndividend distribution may not result in a reduction in value of or a capital loss on Shares. The latter condition is\nnot applicable if (i) the non-resident individual or the non-resident company can demonstrate that Shares were\nheld in full legal ownership for an uninterrupted period of 12 months prior to the payment or attribution of the\ndividends or (ii) with regard to non-resident companies only, if, during the said period, Shares have not belonged\nto a taxpayer other than a resident company or a non-resident company which has, in an uninterrupted manner,\ninvested Shares in a Belgian PE.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23514322359982898, "height": 0.15006412997007268, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-1", "text": "Non-resident companies whose Shares are invested in a Belgian PE may deduct 95% of the gross dividends\nreceived from their taxable income if, at the date the dividends are paid or attributed, the\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2424112868747328, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.26934587430525864, "height": 0.026934587430525847, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-2", "text": "Conditions for the application of the dividend received deduction regime are met. Application of the dividend\nreceived deduction regime depends, however, on a factual analysis to be made upon each distribution and its\navailability should be verified upon each distribution.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31765711842667804, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-3", "text": "Belgian dividend withholding tax relief for non-residents\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.3386062419837537, "height": 0.014108593415989745, "width": 0.38754534461910517}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-4", "text": "Under Belgian tax law, withholding tax is not due on dividends paid to a foreign pension fund which satisfies the\nfollowing conditions: (i) to be a legal entity with fiscal residence outside of Belgium and without a PE in Bel-\ngium; (ii) whose corporate purpose consists solely in managing and investing funds collected in order to pay\nlegal or complementary pensions; (iii) whose activity is limited to the investment of funds collected in the exer-\ncise of its corporate purpose, without any profit making aim; (iv) which is exempt from income tax in its country\nof residence; and (v) provided that it is not contractually obligated to redistribute the dividends to any ultimate\nbeneficiary of such dividends for whom it would manage the Shares, nor obligated to pay a manufactured divi-\ndend with respect to the Shares under a securities borrowing transaction. The exemption will only apply if the\nforeign pension fund provides a certificate confirming that it is the full legal owner or usufruct holder of the\nShares and that the above conditions are satisfied. The organisation must then forward that certificate to the\nCompany or its paying agent.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3450192389910218, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.1509191962377084, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-5", "text": "Dividends distributed to non-resident qualifying parent companies established in a Member State of the EU or in\na country with which Belgium has concluded a double tax treaty that includes a qualifying exchange of infor-\nmation clause, will, under certain conditions, be exempt from Belgian withholding tax provided that Shares held\nby the non-resident company, upon payment or attribution of the dividends, amount to at least 10% of the share\ncapital of the Company and such minimum participation is held or will be held during an uninterrupted period of\nat least one year. A non-resident company qualifies as a parent company provided that (i) for companies estab-\nlished in a Member State of the EU, it has a legal form as listed in the annex to the EU Parent-Subsidiary Di-\nrective of 23 July 1990 (90/435/EC), as amended by Directive 2003/123/EC of 22 December 2003, or, for com-\npanies established in a country with which Belgium has concluded a qualifying double tax treaty it has a legal\nform similar to the ones listed in such annex; (ii) it is considered to be a tax resident according to the tax laws of\nthe country where it is established and the double tax treaties concluded between such country and third coun-\ntries; and (iii) it is subject to corporate income tax or a similar tax without benefiting from a tax regime that\nderogates from the ordinary tax regime.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.6802052159042326, "height": 0.17785378366823423, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-6", "text": "In order to benefit from this exemption, the non-resident-company must provide the Company or its paying agent\nwith a certificate confirming its qualifying status and the fact that it meets the required conditions.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7148353997434801, "height": 0.027789653698161554, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-7", "text": "If the non-resident company holds a minimum participation for less than one year at the time the dividends are\npaid on or attributed to Shares, the Company must levy the withholding tax but does not need to transfer it to the\nBelgian Treasury provided that the non-resident company provides the Company or its paying agent with a cer-\ntificate confirming, in addition to its qualifying status, the date as of which it has held the minimum participa-\ntion, and its commitment to hold the minimum participation for an uninterrupted period of at least one year. The\nnon-resident company must also inform the Company or its paying agent when the one-year period has expired\nor if its shareholding drops below 10% of the Company's share capital before the end of the one-year holding\nperiod. Upon satisfying the one-year holding requirement, the dividend withholding tax which was temporarily\nwithheld, will be refunded to the non-resident company.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7212483967507481, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8448054724241129, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-8", "text": "Belgian dividend withholding tax is subject to such relief as may be available under applicable tax treaty provi-\nsions. Belgium has concluded tax treaties with more than 90 countries, reducing the dividend withholding tax\nrate to 20%, 15%, 10%, 5% or 0% for residents of those countries, depending on conditions, among others, relat-\ned to the size of the shareholding and certain identification formalities.\n", "page_number": 216, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9063702436938863, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-216-9", "text": "213\n", "page_number": 216, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-0", "text": "Prospective holders should consult their own tax advisers to determine whether they qualify for a reduction in\nwithholding tax upon payment or attribution of dividends, and, if so, to understand the procedural requirements\nfor obtaining a reduced withholding tax upon the payment of dividends or for making claims for reimbursement.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.12654980761008977, "height": 0.04147071398033346, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-1", "text": "Belgian taxation of capital gains and losses on Shares\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13980333475844378, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.15391192817443353, "height": 0.014108593415989745, "width": 0.37726723095526}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-2", "text": "Belgian resident individuals\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.16032492518170158, "lower_right_x": 0.309552599758162, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.1940749697702539}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-3", "text": "In principle, Belgian resident individuals acquiring the Shares as a private investment should not be subject to\nBelgian capital gains tax on the disposal of the Shares and capital losses will not be tax deductible.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.20863616930312098, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-4", "text": "However, capital gains realised by a Belgian resident individual are taxable at 33% (plus local surcharges) if the\ncapital gain on the Shares is deemed to be speculative or realised outside the scope of the normal management of\nthe individual's private estate. Moreover, capital gains realised by Belgian resident individuals on the disposal of\nthe Shares, outside the exercise of a professional activity, to a non-resident company (or body constituted in a\nsimilar legal form), to a foreign State (or one of its political subdivisions or local authorities) or to a non-resident\nlegal entity, each time established outside the European Economic Area, are in principle taxable at a rate of\n16.5% (plus local surcharges) if, at any time during the five years preceding the sale, the Belgian resident indi-\nvidual has owned, directly or indirectly, alone or with his/her spouse or with certain relatives, a substantial\nshareholding in the Company (i.e., a shareholding of more than 25% in the Company). Capital losses are, how-\never, not tax deductible.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3514322359982899, "height": 0.13638306968790082, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-5", "text": "Belgian resident individuals who hold the Shares for professional purposes are taxable at the ordinary progres-\nsive personal income tax rates (which are currently in the range of 25% to 50%, plus local surcharges) on any\ncapital gains realised upon the disposal of the Shares, except for the Shares held for more than five years, which\nare taxable at a separate rate of 16.5% (plus local surcharges). Capital losses on the Shares incurred by Belgian\nresident individuals who hold the Shares for professional purposes are in principle tax deductible.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4275331338178709, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-6", "text": "Capital gains realised by Belgian resident individuals upon redemption of the Shares or upon liquidation of the\nCompany will generally be taxable as a dividend.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.43394613082513894, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.46173578452330055, "height": 0.02778965369816161, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-7", "text": "Belgian resident companies\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.4681487815305686, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.48225737494655835, "height": 0.014108593415989745, "width": 0.18802902055622733}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-8", "text": "Belgian resident companies (other than small companies within the meaning of article 15 of the Belgian Compa-\nnies Code (\"SMEs\")) are subject to Belgian capital gains taxation at a separate rate of 0.412% on gains realised\nupon the disposal of Shares provided that: (i) the Article 203 ITC Taxation Condition is met and (ii) the Shares\nhave been held in full legal ownership for an uninterrupted period of at least one year. The 0.412% separate\ncapital gains tax cannot be off-set against any tax assets (such as e.g. tax losses) and can moreover not be off-set\nagainst any tax credits.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4886703719538264, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5711842667806755, "height": 0.08251389482684907, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-9", "text": "Belgian resident companies qualifying as SMEs (within the meaning of Article 15 of the Belgian Companies\nCode) are normally not subject to Belgian capital gains taxation on gains realised upon the disposal of the Shares\nprovided that (i) the Article 203 ITC Taxation Condition is met and (ii) the Shares have been held in full legal\nownership for an uninterrupted period of at least one year.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6327490380504489, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-10", "text": "If the one-year minimum holding period condition is not met (but the Article 203 ITC Taxation Condition is\nmet),the capital gains realised upon the disposal of Shares by Belgian resident companies (both non-SMEs and\nSMEs) are taxable at a separate corporate income tax rate of 25.75%.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6823428815733219, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-11", "text": "If the one-year minimum holding period condition is not met and the article 203 ITC Taxation Condition would\nnot be met, any capital gain realised would be taxable at the standard corporate income tax rate of 33.99%, un-\nless the reduced corporate income tax rates apply.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6904660111158615, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.7302265925609235, "height": 0.039760581445062004, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-12", "text": "Capital losses on Shares incurred by Belgian resident companies (both non-SMEs and SMEs) are as a general\nrule not tax deductible.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7383497221034631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7627191107310817, "height": 0.024369388627618616, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-13", "text": "Shares held in the trading portfolios of Belgian qualifying credit institutions, investment enterprises and man-\nagement companies of collective investment undertakings are subject to a different regime. The capital gains on\nsuch Shares are taxable at the ordinary corporate income tax rate of 33.99% and the capital losses on such Shares\nare tax deductible. Internal transfers to and from the trading portfolio are assimilated to a realisation.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8251389482684908, "height": 0.052586575459598106, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-14", "text": "Capital gains realised by Belgian resident companies upon redemption of Shares or upon liquidation of the\nCompany will, in principle, be subject to the same taxation regime as dividends.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8255664814023087, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.861051731509192, "height": 0.035485250106883304, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-15", "text": "Belgian resident organisations for financing pensions\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8683197947840958, "lower_right_x": 0.48125755743651755, "lower_right_y": 0.8820008550662677, "height": 0.013681060282171864, "width": 0.36577992744860943}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-16", "text": "Capital gains on the Shares realised by OFPs within the meaning of article 8 of the Belgian Act of October 27,\n2006 are in principle exempt from corporate income tax and capital losses are not tax deductible.\n", "page_number": 217, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8888413852073536, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9162035057716973, "height": 0.027362120564343728, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-217-17", "text": "214\n", "page_number": 217, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-0", "text": "Other Belgian resident legal entities subject to Belgian legal entities tax\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.6045949214026602, "lower_right_y": 0.09747755451047456, "height": 0.012398460880718248, "width": 0.48911729141475213}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-1", "text": "Capital gains realised upon disposal of the Shares by Belgian resident legal entities are in principle not subject to\nBelgian income tax and capital losses are not tax deductible.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.13296280461735785, "height": 0.027362120564343742, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-2", "text": "Capital gains realised upon disposal of (part of) a substantial participation in a Belgian company (i.e., a partici-\npation representing more than 25% of the share capital of the Company at any time during the last five years\nprior to the disposal) may, however, under certain circumstances be subject to income tax in Belgium at a rate of\n16.5%.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.13980333475844378, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.19153484395040615, "height": 0.05173150919196237, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-3", "text": "Capital gains realised by Belgian resident legal entities upon redemption of the Shares or upon liquidation of the\nCompany will, in principle, be subject to the same taxation regime as dividends.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2013681060282172, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.2291577597263788, "height": 0.02778965369816161, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-4", "text": "Non-residents individuals or non-resident companies\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2291577597263788, "lower_right_x": 0.47702539298669894, "lower_right_y": 0.2496793501496366, "height": 0.020521590423257796, "width": 0.3615477629987908}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-5", "text": "Non-resident individuals or companies are, in principle, not subject to Belgian income tax on capital gains real-\nised upon disposal of the Shares, unless the Shares are held as part of a business conducted in Belgium through a\nfixed base in Belgium or a Belgian PE. In such a case, the same principles apply as described with regard to\nBelgian individuals (holding the Shares for professional purposes) or Belgian companies.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.25609234715690465, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31124412141941, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-6", "text": "Non-resident individuals who do not use the Shares for professional purposes and who have their fiscal residence\nin a country with which Belgium has not concluded a tax treaty or with which Belgium has concluded a tax trea-\nty that confers the authority to tax capital gains on the Shares to Belgium, might be subject to tax in Belgium if\nthe capital gains arise from transactions which are to be considered speculative or beyond the normal manage-\nment of one's private estate or in case of disposal of a substantial participation in a Belgian company as men-\ntioned in the tax treatment of the disposal of the Shares by Belgian individuals. Such non-resident individuals\nmight therefore be obliged to file a tax return and should consult their own tax adviser.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.413852073535699, "height": 0.09619495510902099, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-7", "text": "Capital gains realised by non-resident individuals or non-resident companies upon redemption of the Shares\nupon liquidation of the Company will, in principle, be subject to the same taxation regime as dividends.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4202650705429671, "lower_right_x": 0.8591293833131801, "lower_right_y": 0.4480547242411287, "height": 0.02778965369816161, "width": 0.7430471584038694}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-8", "text": "s or\n", "page_number": 218, "bounding_box": {"top_left_x": 0.8591293833131801, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.4330910645575032, "height": 0.009405728943993108, "width": 0.02055622732769047}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-9", "text": "Uncertain effect of article 228, \u00a73 ITC for non-residents\n", "page_number": 218, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.45446772124839674, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.4685763146643865, "height": 0.014108593415989745, "width": 0.3821039903264813}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-10", "text": "Under a strict reading of article 228, \u00a73 ITC, capital gains realised on the Shares by non-residents could be sub-\nject to Belgian taxation, levied in the form of a professional withholding tax, if the following three conditions are\ncumulatively met: (i) the capital gain would have been taxable if the non-resident were a Belgian tax resident;\n(ii) the income is \"borne by\" a Belgian resident or by a Belgian establishment of a foreign entity (which would,\nin such a context, mean that the capital gain is realised upon a transfer of the Shares to a Belgian resident or to a\nBelgian establishment of a foreign entity, together a Belgian Purchaser); and (iii) Belgium has the right to tax\nsuch capital gain pursuant to the applicable double tax treaty, or, if no such tax treaty applies, the non-resident\ndoes not demonstrate that the capital gain is effectively taxed in its state of residence.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.880894800483676, "lower_right_y": 0.5848653270628473, "height": 0.1098760153911928, "width": 0.7654171704957679}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-11", "text": "However, it is unclear whether a capital gain included in the purchase price of an asset can be considered to be\n\"borne by\" the purchaser of the asset within the meaning of the second condition mentioned above.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5912783240701154, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.619067977768277, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-12", "text": "Furthermore, applying this withholding tax would require that the Belgian Purchaser is aware of (i) the identity\nof the non-resident (to assess the third condition mentioned above); and (ii) the amount of the capital gain real-\nised by the non-resident (since such amount determines the amount of professional withholding tax to be levied\nby the Belgian Purchaser). Consequently, the application of this professional withholding tax on transactions\nwith respect to the Shares occurring on the central stock exchange of Euronext would give rise to practical diffi-\nculties as the seller and purchaser typically do not know each other.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.628901239846088, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7097050021376656, "height": 0.0808037622915776, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-13", "text": "In addition to the uncertainties referred to above, the parliamentary documents of the law that introduced article\n228, \u00a73 ITC support the view that the legislator did not intend for article 228, \u00a73 ITC to apply to a capital gain\nincluded in the purchase price of an asset.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7178281316802052, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7575887131252672, "height": 0.039760581445062004, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-14", "text": "On 23 July 2014, formal guidance on the interpretation of article 228, \u00a73 ITC has been issued by the Belgian tax\nauthorities (published in the Belgian Official Gazette of 23 July 2014). The Belgian tax\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7657118426678068, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7922188969645148, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-15", "text": "authorities state therein that article 228, \u00a73 ITC only covers payments for services, as a result of which no pro-\nfessional withholding tax should apply to capital gains realised by non-residents in the situations described\nabove. It should, however, be noted that a formal guidance issued by the tax authorities does not supersede and\ncannot amend the law if the latter is found to be sufficiently clear in itself. Accordingly, in case of dispute, it\ncannot be ruled out that the interpretation of article 228, \u00a73 ITC made by the tax authorities in their formal guid-\nance is not upheld by the competent courts.\n", "page_number": 218, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7999144933732364, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8811457887986319, "height": 0.08123129542539553, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-218-16", "text": "215\n", "page_number": 218, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-0", "text": "Tax on stock exchange transactions\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.08507909362975631, "lower_right_x": 0.3675937122128174, "lower_right_y": 0.09876015391192818, "height": 0.013681060282171864, "width": 0.249093107617896}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-1", "text": "The purchase and the sale and any other acquisition or transfer for consideration of the Shares (secondary mar-\nket) in Belgium through a professional intermediary is subject to the tax on stock exchange transactions (taxe sur\nles op\u00e9rations de bourse/ taks op de beursverrichtingen) of 0.27% of the purchase price, capped at \u20ac800 per\ntransaction and per party. A separate tax is due from each party to the transaction, both collected by the profes-\nsional intermediary. Upon the issue of the New Shares (primary market), no tax on stock exchange transactions\nis due.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10560068405301411, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.18469431380932022, "height": 0.07909362975630611, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-2", "text": "No tax on stock exchange transactions is due on transactions entered into by the following parties, provided they\nare acting for their own account: (i) professional intermediaries described in article 2,9\u00b0 and 10\u00b0 of the Belgian\nLaw of August 2, 2002; (ii) insurance companies described in article 2, \u00a71 of the Belgian Law of 9 July 1975;\n(iii) professional retirement institutions referred to in article 2,1\u00b0 of the Belgian Law of 27 October 2006 con-\ncerning the supervision on institutions for occupational pension; (iv) collective investment institutions; and (v)\nBelgian non-residents provided they deliver a certificate to their financial intermediary in Belgium confirming\ntheir non-resident status.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.28730226592560926, "height": 0.09277469003847799, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-3", "text": "The EU Commission adopted on 14 February 2013 the Draft Directive on an FTT. The Draft Directive currently\nstipulates that once the FTT enters into force, the Participating Member States shall not maintain or introduce\ntaxes on financial transactions other than the FTT (or VAT as provided in the Council Directive 2006/112/EC of\n28 November 2006 on the common system of value added tax).\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29713552800342025, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.35185976913210776, "height": 0.05472424112868751, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-4", "text": "For Belgium, the tax on stock exchange transactions should thus be abolished once the FTT enters into force.\nThe Draft Directive regarding the FTT is still subject to negotiation between the Participating Member States\nand therefore may be changed at any time.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.40017101325352716, "height": 0.04147071398033347, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-5", "text": "German Tax Considerations\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.41342454040188115, "lower_right_x": 0.36577992744860943, "lower_right_y": 0.4275331338178709, "height": 0.014108593415989745, "width": 0.24969770253929868}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-6", "text": "General\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.44420692603676787, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.45746045318512185, "height": 0.013253527148353983, "width": 0.061668681983071336}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-7", "text": "This section describes some key German taxation principles that may become relevant when acquiring, holding\nand transferring Offer Shares. It is not a comprehensive or exhaustive description of all aspects of German taxa-\ntion that may be relevant for Shareholders. The description is based on the German taxation acts and the relevant\nprovisions of double taxation treaties that Germany has entered into with other countries in force on the date of\nthis Prospectus. The acts, treaties and the opinion of the tax authorities are subject to change \u2013 including, in cer-\ntain cases, retrospectively.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5472424112868748, "height": 0.08251389482684912, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-8", "text": "Potential purchasers of Offer Shares are therefore advised to consult their tax advisor on the tax implications of\nacquiring, holding and transferring Offer Shares and on the procedure to be followed for any refund of German\nwithholding tax paid (Kapitalertragsteuer). Due consideration to a shareholder's specific tax-related circum-\nstances can only be given within the scope of an individual tax consultation.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6088071825566481, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-9", "text": "Taxation of the Company\n", "page_number": 219, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6254809747755451, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.6378794356562634, "height": 0.012398460880718276, "width": 0.17896009673518742}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-10", "text": "In Germany, corporations are generally subject to corporate income tax (K\u00f6rperschaftsteuer) at a rate of 15%\nplus a 5.5% solidarity surcharge (Solidarit\u00e4tszuschlag) thereon (in total 15.825%).\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6703719538264216, "height": 0.024369388627618616, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-11", "text": "Dividends and other shares in profits which corporations receive from domestic or foreign corporations are gen-\nerally exempt from corporate income tax in case they hold 10% or more of the distributing company's registered\nshare capital. However, 5% of such income qualifies as non-deductible business expenses and is therefore sub-\nject to corporate income tax at a rate of 15% (plus solidarity surcharge of 5.5% thereon). Capital gains from the\ndisposition of shares in domestic or foreign corporations are also tax exempt except for 5%. Capital losses are\nnot deductible for tax purposes. Currently, there are no specific rules for the taxation of capital gains arising\nfrom the disposal of portfolio participations (i.e. participations equalling less than 10% of a company's registered\nshare capital). However, according to a draft bill of the German Ministry of Finance, from 2018 onwards the\n10% threshold applicable to dividends received from such participations (see above) shall also be introduced\nwith regard to capital gains arising from the disposal of portfolio participations. If this bill was enacted, from\n2018 onwards capital gains from the disposal of portfolio participations (or parts thereof) would fully be subject\nto corporate income tax at 15.825% (including solidarity surcharge) and trade tax.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6802052159042326, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.8413852073535699, "height": 0.16117999144933737, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-12", "text": "In addition, corporations are subject to trade tax (Gewerbesteuer) on their business income, i.e., income that has\nbeen generated at their German places of business and is subject to certain adjustments for trade tax purposes.\nThe trade tax depends on the municipalities in which the corporations maintain permanent establishments. The\ntrade tax rate amounts from 7 % to 18.2 % of the trade taxable income (Gewerbeertrag) depending in each case\non the trade tax assessment rate (Hebesatz) of the relevant municipality.\n", "page_number": 219, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.917058572039333, "height": 0.06584010260795214, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-219-13", "text": "216\n", "page_number": 219, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-0", "text": "For trade tax purposes, dividends received from shares in domestic and foreign corporations and capital gains\nfrom the disposition of shares in other corporations are generally treated in the same manner as for corporate\nincome tax purposes. However, dividends are, in general, 95% tax-exempt only if the corporations have held at\nleast 15% of the distributing company's registered share capital (\"trade tax participation exemption privilege\") as\nof the beginning of the relevant assessment period (Erhebungszeitraum). Additional restrictions apply to divi-\ndends received from foreign corporations.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.16673792218896966, "height": 0.08165882855921335, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-1", "text": "With regard to the possibility of deducting net interest expenses, the interest barrier (Zinsschranke) applies. The\ninterest barrier restricts the deductibility of interest expenses exceeding the interest earnings of the relevant fi-\nnancial year (\"net interest expenses\") to 30% of the earnings before interest, taxes, depreciation and amortisation\n(\"Creditable EBITDA\") determined for corporate income tax and trade tax purposes. The non-deductible part\nof the interest expenses can be carried forward to future fiscal years (\"interest carried forward\") and might re-\nduce the taxable profit of the Company in the future if the interest expenses in such period are deductible under\nthe interest barrier. In addition, a five year EBITDA carried forward applies according to which a positive differ-\nence between the Creditable EBITDA and the net interest expenses may be carried forward for five financial\nyears so that future net interest expenses, within certain limits, can be offset against the EBITDA carried forward\nin future years. However, there is a risk that the interest carried forward might be forfeited in case of a change of\nownership on the basis of the same rules as applicable to losses carried forward (see below). The interest barrier\nwill not apply if the net interest expenses are less than \u20ac3 million in one tax assessment period or in the event the\nCompany complies with the \"escape clause\" or if the Company is not part of a group, provided there is no harm-\nful shareholder debt financing. The escape clause stipulates the complete deductibility of interest expenses in the\nevent that the Company's equity ratio is not lower than that of the group. For this purpose the equity ratios of the\nfinancial statements at the end of the preceding business year are relevant. Only in case that there is no harmful\nshareholder debt financing, the escape clause will be applicable. A harmful shareholder debt financing exists if\nthe shareholder (holding directly or indirectly more than 25% of the shares) or any related party hereto or any\nthird party who has a right of recourse against the shareholder or a related party hereto receives interest exceed-\ning 10% of the negative interest balance (difference between interest income and interest expenses) from the\nrespective corporation or from another affiliated company. For trade tax purposes 25% of the interest expenses\nhave to be added back to the trade earnings.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.17400598546387344, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4745617785378367, "height": 0.3005557930739633, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-2", "text": "Corporate income tax losses incurred by the Company in one year may be carried back to the immediately pre-\nceding assessment period up to an amount of \u20ac1 million. Trade tax losses cannot be carried back. Any remaining\nlosses regarding corporate income tax and trade tax may only be offset within certain restrictions against profits\nfrom future years (\"minimum taxation\"). Up to an amount of \u20ac1 million taxable profits may be offset against\nexisting tax losses carried forward without limitation. Taxable profits in excess of \u20ac1 million may be offset\nagainst existing tax losses carried forward for corporate income and trade tax purposes only by 60%. Unused tax\nlosses carried forward may, in principle, be carried forward indefinitely and are subject to the above described\nminimum taxation rules when determining future taxable profits. However, to the extent an acquirer, a person\naffiliated with such acquirer or a group of acquirers with similar interests acquires directly or indirectly more\nthan 25% of the Company's shares within five years, the tax losses carried forward and current losses existing at\nthe time the threshold is exceeded will be forfeited on a pro rata basis, unless there is an acquisition of more than\n50%, in which case the tax losses carried forward will be forfeited completely. As an exception, in case of an\nabove-described harmful transfer of shares, tax losses carried forward in an amount equal to certain built-in gains\nof the Company may still be upheld.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6733646857631467, "height": 0.1915348439504062, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-3", "text": "Taxation of Shareholders\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1185006045949214, "top_left_y": 0.6870457460453185, "lower_right_x": 0.29443772672309554, "lower_right_y": 0.7007268063274904, "height": 0.013681060282171864, "width": 0.17593712212817414}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-4", "text": "The Shareholders are generally subject to taxation in connection with the holding of Offer Shares (taxation of\ndividends), the disposal of Offer Shares (taxation of capital gains) and gratuitous transfers of Offer Shares (in-\nheritance and gift tax).\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8821039903264812, "lower_right_y": 0.7486105173150919, "height": 0.04104318084651559, "width": 0.7666263603385731}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-5", "text": "Taxation of Dividends\n", "page_number": 220, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7554510474561779, "lower_right_x": 0.2708585247883918, "lower_right_y": 0.7691321077383497, "height": 0.013681060282171864, "width": 0.15477629987908104}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-6", "text": "Withholding Tax\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7759726378794357, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.7900812312954254, "height": 0.01410859341598969, "width": 0.1215235792019347}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-7", "text": "In the case of dividends paid by a non-German corporation, German withholding tax is generally withheld re-\ngardless of whether and to what extent the dividend is exempt from tax at the level of a German tax resident\nshareholder if the shares are kept in custody with a German Disbursing Agent (as defined herein). The full\namount of a dividend distributed by the Company is, in general, subject to German withholding tax at a rate of\n25% plus solidarity surcharge of 5.5% on the withholding tax, resulting in an aggregate rate of 26.375% (plus\nchurch tax, if any). However, no German withholding tax should be imposed on such dividends that are paid to\nGerman tax resident corporations, non-German Shareholders or, subject to certain prerequisites, if the dividends\nare business income of a domestic business. The basis for the withholding tax is the dividend approved for dis-\ntribution by the Company's general shareholder meeting.\n", "page_number": 220, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7964942283026935, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9200513039760582, "height": 0.12355707567336471, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-220-8", "text": "217\n", "page_number": 220, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-0", "text": "If shares \u2013 as is the case with the Offer Shares \u2013 are held in collective safe custody (Sammelverwahrung) with a\ncentral securities depository (Wertpapiersammelbank) pursuant to \u00a7 5 German Act on Securities Accounts\n(Depotgesetz) and are entrusted to such central securities depository for collective safe custody in Germany,\nwhich is tax resident in Germany, the withholding tax is withheld and remitted for the account of the German tax\nresident Shareholders to the German tax authorities by the disbursing agent (auszahlende Stelle), i.e., the domes-\ntic credit or financial services institution (inl\u00e4ndisches Kredit- oder Finanzdienstleistungsinstitut), the domestic\nsecurities trading enterprise (inl\u00e4ndisches Wertpapierhandelsunternehmen) or the domestic securities trading\nbank (inl\u00e4ndische Wertpapierhandelsbank) (in each case including a German branch of a foreign enterprise, but\nexcluding a foreign branch of a German enterprise) that keeps and administers the shares in custody and disburs-\nes or credits the dividends (hereinafter referred to jointly or separately as \"German Disbursing Agent\"). The\nCompany assumes no responsibility for the withholding of German taxes at the source.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2304403591278324, "height": 0.1453612654980761, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-1", "text": "Company assumes no responsibility for the withholding of German taxes at the source.\nFor taxpayers who are subject to church tax, an automatic procedure for deducting church tax applies unless the\nshareholder has filed a blocking notice (Sperrvermerk) with the German Federal Central Tax Office (Bundeszen-\ntralamt f\u00fcr Steuern). The church tax payable will be withheld with the withholding tax and passed on by the\nGerman Disbursing Agent. The taxpayer may refuse (block) the automatic query to the Federal Central Tax\nOffice, which will then force an assessment by the taxpayer and the shareholder will be obliged to declare the\ndividends in his income tax return.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.23086789226165028, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3215049166310389, "height": 0.09063702436938864, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-2", "text": "If and to the extent funds from the tax contribution account (steuerliches Einlagekonto) are declared to be used\nfor the distribution, the dividend payment is generally not taxable and, therefore, not subject to withholding tax,\nhowever provided that the Company applies for a special assessment procedure with the German tax authorities\nand subject to further prerequisites. Such dividends from the tax contribution account accordingly reduce the\nacquisition costs of the Offer Shares, which may result in a greater amount of taxable capital gain upon the re-\nspective shareholder's sale of the Offer Shares. To the extent that dividends from the tax contribution account\nexceed the acquisition costs of the Offer Shares, a capital gain is recognised by the shareholder, which may be\nsubject to tax in accordance with the provisions outlined below.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.440359127832407, "height": 0.10902094912355703, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-3", "text": "Shareholders Tax Resident in Germany\n", "page_number": 221, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.4476271911073108, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.4608807182556648, "height": 0.013253527148353983, "width": 0.28960096735187424}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-4", "text": "Taxation of Dividend Income of Investors Tax Resident in Germany Holding their Shares as Private Assets\n(Privatverm\u00f6gen)\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4681487815305686, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.4959384352287302, "height": 0.02778965369816161, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-5", "text": "For individual Shareholders who are tax resident in Germany and who hold the Offer Shares as part of their\nprivate assets, dividends are subject to the final flat tax (Abgeltungsteuer) at a rate of 25% plus a 5.5% solidarity\nsurcharge thereon (aggregate tax burden: 26.375%) and church tax, if applicable. In principle, the tax liability\napplicable to dividends is generally satisfied by the withholding of such tax as described above. Except for an\nannual lump sum allowance (Sparerpauschbetrag) of \u20ac801 (\u20ac1,602 for married couples and registered partners\nwho are jointly assessed) on all private capital income (Eink\u00fcnfte aus Kapitalverm\u00f6gen), private investors will\nnot be entitled to deduct expenses incurred in connection with the capital investments from their dividend in-\ncome. In certain cases, however, upon election and filing of an annual income tax return, the dividend payments\nmay be taxed at the shareholder's individual tax rate if this results in a lower income tax burden. The withholding\ntax will then be credited against the income tax. In such cases, private investors are also not entitled to deduct\nexpenses incurred in connection with the capital investments from their income except of the annual lump sum\nallowance. However, the restriction of the deductibility of income related expenses in these cases is subject to a\npending court case at the federal fiscal court. This option may be exercised only for all capital income from capi-\ntal investments received in the relevant assessment period uniformly and jointly assessed married couples and\nregistered partners may only jointly exercise the option. Furthermore, dividend income can generally only be\noffset by losses from investment income, except for losses generated by the disposal of shares.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.7212483967507481, "height": 0.21889696451474983, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-6", "text": "Individual Shareholders who privately hold, directly or indirectly, an interest of at least 25% in the Company,\nand Shareholders who privately hold, directly or indirectly, at least 1% in the Company and work for the Com-\npany, may in principle request an exemption from the flat-rate withholding tax. In this case, 60% of the divi-\ndends paid to the shareholder are subject to income tax according to the applicable rate plus solidarity surcharge\nthereon. Expenses incurred in connection with dividend income are then generally 60% tax-deductible. The\nlevied withholding tax is offset against the income tax and any excess withholding tax is refunded. Dividend\npayments that are made using funds from the tax contribution account (steuerliches Einlagekonto) are generally,\nsubject to certain prerequisites, not taxable.\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7280889268918341, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.837964942283027, "height": 0.10987601539119285, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-7", "text": "Taxation of Dividend Income of Investors Tax Resident in Germany Holding their Shares as Business Assets\n(Betriebsverm\u00f6gen)\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8721675929884566, "height": 0.027789653698161554, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-8", "text": "If Offer Shares are held as business assets of a shareholder, the taxation depends on whether the shareholder is a\ncorporation, a sole proprietor, or a partnership (Mitunternehmerschaft). Withholding tax (including the solidarity\nsurcharge thereon) withheld and remitted to the German tax authorities is credited against the respective share-\n", "page_number": 221, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8785805899957246, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9200513039760582, "height": 0.04147071398033353, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-221-9", "text": "218\n", "page_number": 221, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-0", "text": "holder's individual or corporate income tax liability or if in excess thereof, is refundable to the shareholder. The\nflat tax regime does not apply to shares held as business assets.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-1", "text": "Corporations. Dividends paid to German tax resident corporations are generally subject to corporate income tax\n(and solidarity surcharge thereon) at a rate of 15.825%. However dividends received are effectively 95% exempt\nfrom corporate tax (and solidarity surcharge thereon), if the corporation holds a direct participation of at least\n10% in the share capital of the Company at the beginning of the calendar year in which the dividends are paid.\nAcquisitions of at least 10% during the year are deemed to take place at the start of the calendar year for the\npurpose of this rule. Participations in the share capital of the Company, which a corporate shareholder holds\nthrough a partnership, including co-entrepreneurships (Mitunternehmerschaften), are attributable to such corpo-\nrate shareholder only on a pro rata basis at the ratio of the interest share of the corporate shareholder in the assets\nof relevant partnership. Expenses incurred in connection with the dividend income from a tax perspective are\ngenerally tax-deductible. However, 5% of the tax-exempt dividend income is deemed to be a non-deductible\nbusiness expense for tax purposes and is therefore subject to corporate income tax (plus solidarity surcharge\nthereon).\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2821718683197948, "height": 0.16289012398460884, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-2", "text": "For trade tax purposes, dividends are fully subject to trade tax after deduction of related business expenses, un-\nless the corporation has held at least 15% of the Company's registered share capital at the beginning of the rele-\nvant assessment period. In the latter case, effectively 5% of the dividends will be subject to trade tax as described\nabove. Special rules for banks, financial services institutions, financial enterprises, life and health insurance\ncompanies, and pension funds, are described below.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2902949978623343, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3587002992731937, "height": 0.06840530141085938, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-3", "text": "No withholding tax should be imposed on dividends to corporations that are German tax residents by the German\nDisbursing Agent, subject to certain prerequisites. The same applies to the solidarity surcharge, which is levied\nin addition to the corporate income tax. Dividend payments that are made using funds from the tax contribution\naccount (steuerliches Einlagekonto) are generally, subject to certain prerequisites, not taxable.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3655408294142796, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4202650705429671, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-4", "text": "Sole Proprietors. If the shares are held by a sole proprietor who is tax resident in Germany as part of its busi-\nness assets, the \"partial income method\" (Teileink\u00fcnfteverfahren) applies. Accordingly, for income tax purposes,\ngenerally 60% of the dividend distributions are subject to income tax at the investor's individual tax rate plus\nsolidarity surcharge of 5.5% thereon, plus church tax, if applicable. Correspondingly, generally only 60% of the\nbusiness expenses related to the dividend income are deductible for tax purposes (subject to any other re-\nstrictions on deductibility). Subject to certain prerequisites, no withholding tax should be imposed on to sole\nproprietors that are German tax residents by the German Disbursing Agent. To the extent withholding tax is\nlevied, such withholding tax is offset against the personal income tax due and any excess amount is refunded.\nThe same applies to the solidarity surcharge and church tax, if any.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5502351432235998, "height": 0.12312954253954678, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-5", "text": "In addition, the dividends are subject to trade tax unless the shareholder holds at least 10% of the share capital of\nthe Company at the beginning of the relevant assessment period. The trade tax levied \u2013 depending on the munic-\nipal trade tax rate and the individual tax situation \u2013 is partly or entirely credited against the shareholder's person-\nal income tax liability by means of a lump-sum tax credit system.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6122274476271911, "height": 0.05515177426250528, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-6", "text": "Dividend payments that are made using funds from the tax contribution account (steuerliches Einlagekonto) are\ngenerally, subject to certain prerequisites, not taxable.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6464300983326208, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-7", "text": "Commercial Partnerships. If the shareholder is a commercial partnership, income tax or corporate income tax\n(in each case including solidarity surcharge and church tax, if any) is not levied at the level of the partnership\n(Mitunternehmerschaft) but rather the respective partner is subject to income or corporation tax plus solidarity\nsurcharge (and church tax, if any). If the partner is a corporation, the dividends contained in its profit share are\ntaxed in accordance with the principles applicable to corporations (see \"\u2013 Corporations\" above). If the partner is\nan individual and the shares are held as business assets of the partnership, dividends contained in their profit\nshare are taxed in accordance with the principles applicable to sole proprietors (see \"\u2013 Sole Proprietors\" above).\nSubject to certain conditions, an individual partner may request that its personal income tax may be lowered for\nearnings not withdrawn from the partnership.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6528430953398888, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7764001710132535, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-8", "text": "If the partnership is liable for trade tax, such trade tax is levied at the level of the partnership. The dividends are\nsubject to trade tax, unless the partnership held at least 15% of the Company's registered share capital at the\nbeginning of the relevant assessment period. If a partner is an individual, the trade tax paid by the partnership\nmay generally be credited, fully or partly, against his or her individual income tax.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7828131680205216, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.837964942283027, "height": 0.05515177426250539, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-9", "text": "Dividend payments that are made using funds from the tax contribution account (steuerliches Einlagekonto) are\ngenerally, subject to certain prerequisites, not taxable.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.844377939290295, "lower_right_x": 0.8706166868198307, "lower_right_y": 0.8721675929884566, "height": 0.027789653698161554, "width": 0.7551390568319226}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-10", "text": "Taxation of Dividend Income of Certain Investors in the Financial and Insurance Sector\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8785805899957246, "lower_right_x": 0.7110036275695284, "lower_right_y": 0.8909790508764429, "height": 0.012398460880718276, "width": 0.5955259975816203}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-11", "text": "The tax exemption applicable to dividends does not apply to dividends paid to certain companies in the financial\nand insurance sector.\n", "page_number": 222, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8991021804189825, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9256092347156905, "height": 0.026507054296707966, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-222-12", "text": "219\n", "page_number": 222, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.009405728943993164, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-0", "text": "Dividends from shares that are part of the trading books of banks and financial services institutions in the mean-\ning of the German Banking Act (Kreditwesengesetz), as well as dividends from shares that are acquired by cer-\ntain financial enterprises with the aim of generating a short-term proprietary trading profit, are fully liable for\ncorporate income tax (plus solidarity surcharge). If the stake held at the beginning of the relevant assessment\nperiod is 15% or higher, subject to certain conditions, the dividends can effectively be 95% exempted from trade\ntax. Dividends from shares that are classified as investments in the case of life insurers, health insurers and pen-\nsion funds are fully subject to corporate income tax and trade tax.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.18041898247114152, "height": 0.09533988884138521, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-1", "text": "Shareholders not Tax Resident in Germany\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1876870457460453, "lower_right_x": 0.4111245465538089, "lower_right_y": 0.2013681060282172, "height": 0.013681060282171892, "width": 0.2950423216444982}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-2", "text": "Dividends paid to foreign Shareholders who are not German tax residents and who do not hold their Offer Shares\nas part of business assets in Germany (that is, via a permanent establishment or fixed base in Germany, or as part\nof business assets for which a permanent representative has been appointed in Germany) should, in principle not\nbe subject to German taxation. However, Shareholders who hold their Offer Shares as part of business assets in\nGermany are principally subject to the same rules described above for Shareholders resident in Germany. The\ntax withheld and remitted (including solidarity surcharge thereon) is credited against the shareholder's income\ntax or corporate income tax liability or, if in excess thereof, will be refunded to the shareholder.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.20820863616930313, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3039760581445062, "height": 0.09576742197520305, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-3", "text": "Taxation of Capital Gains\n", "page_number": 223, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.31765711842667804, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.3317657118426678, "height": 0.014108593415989745, "width": 0.18379685610640872}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-4", "text": "", "page_number": 223, "bounding_box": {"top_left_x": 0.1626360338573156, "top_left_y": 0.3381787088499359, "lower_right_x": 0.33192261185006044, "lower_right_y": 0.3381787088499359, "height": 0.0, "width": 0.16928657799274485}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-5", "text": "Shareholders Tax Resident in Germany\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3386062419837537, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.3522873022659256, "height": 0.013681060282171864, "width": 0.2714631197097944}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-6", "text": "Taxation of Capital Gains of Investors Tax Resident in Germany Holding their Shares as Private Assets (Privat-\nverm\u00f6gen)\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3587002992731937, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.3864899529713553, "height": 0.02778965369816161, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-7", "text": "Capital gains are classified as income from capital investments and are subject to income tax (plus solidarity\nsurcharge and church tax, if any) irrespective of how long the shares have been held.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.39290294997862335, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.42069260367678496, "height": 0.02778965369816161, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-8", "text": "If the Offer Shares are held in custody or administered by a German Disbursing Agent, any gains from the sale\nor redemption of the shares will be subject to a final flat tax (Abgeltungsteuer) of 25% plus solidarity surcharge\nof 5.5% thereon resulting in an aggregate tax burden of 26.375% and church tax if applicable. The taxable capi-\ntal gain is calculated by deducting the acquisition costs of the Offer Shares and the expenses directly related to\nthe disposal from the proceeds of the disposal.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.427105600684053, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4959384352287302, "height": 0.0688328345446772, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-9", "text": "Except for an annual lump sum allowance (Sparerpauschbetrag) of \u20ac801 (\u20ac1,602 for married couples and regis-\ntered partners who are jointly assessed) on all private capital income (Eink\u00fcnfte aus Kapitalverm\u00f6gen), private\ninvestors will not be entitled to deduct expenses incurred in connection with the capital investments for the pur-\nposes of calculating a capital gain or loss from the disposal of the Offer Shares. In principle, the tax liability\napplicable to dividends is generally satisfied by the withholding of such tax as described above. In certain cases,\nhowever, upon election and filing of an annual income tax return, the capital gains may be taxed at the share-\nholder's individual tax rate if this results in a lower income tax burden. The tax withheld at source is then credit-\ned against the individual income tax liability assessed or, in excess of such liability, refunded. The option may\nonly be exercised for all capital income from capital investments received in the relevant assessment period\nuniformly and jointly assessed married couples and registered partners may only exercise the option jointly.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5023514322359983, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6395895681915349, "height": 0.13723813595553658, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-10", "text": "Capital gains generated by the disposal of shares can be offset against any type of losses from capital investment\nincome. Losses from the disposal of Offer Shares may only be offset against other capital gains resulting from\nthe disposal of shares. Such losses may be carried forward in future years and offset against capital gains deriv-\ning from the sale of shares.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.05515177426250528, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-11", "text": "Individual Shareholders may be liable for church tax, which is generally deducted by way of withholding by the\nGerman Disbursing Agent, unless the shareholder has filed a blocking notice (Sperrvermerk) with the Federal\nCentral Tax Office. Where church tax is not levied by way of withholding, it is determined by means of an in-\ncome tax assessment.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7614365113296281, "height": 0.053869174861051805, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-12", "text": "The general flat tax will not apply if the seller of the shares \u2013 or, in the event of a sale of shares acquired without\nconsideration, its legal predecessor \u2013 has held, directly or indirectly, at least 1% of the share capital of the Com-\npany at any time during the five years prior to the disposal. In such cases, 60% of the capital gains are taxable at\nthe individual income tax rate of the shareholder (plus 5.5% solidarity surcharge thereon and church tax, if any).\nCorrespondingly, 60% of any capital loss is recognised for income tax purposes. The withholding tax and soli-\ndarity and church tax, if any, surcharge withheld are credited towards the Shareholders' tax liability or refunded\nin the amount of any excess paid on their tax assessment.\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7725523728088927, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.8674647285164601, "height": 0.0949123557075674, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-13", "text": "Taxation of Capital Gains of Investors Tax Resident in Germany Holding their Shares as Business Assets (Be-\ntriebsverm\u00f6gen)\n", "page_number": 223, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8751603249251817, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.8999572466866183, "height": 0.024796921761436552, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-223-14", "text": "220\n", "page_number": 223, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-0", "text": "If shares are held as business assets of a shareholder, the taxation of capital gains realised upon disposal depends\non whether the shareholder is a corporation, a sole proprietor, or a partnership:\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-1", "text": "Corporations. Capital gains realised by a corporate shareholder upon disposal of shares are generally not sub-\nject to withholding tax and are in principle exempt from corporate income tax and trade tax. Capital gains for\nthis purpose is the amount by which the selling price or the equivalent value after deduction of selling costs\nexceeds the tax base at the time of disposal. However, 5% of the capital gain is deemed to be a non-deductible\nbusiness expense and is therefore subject to corporate income tax (plus solidarity surcharge and church tax, if\napplicable) and trade tax. As a rule, losses or other profit reductions relating to the sold shares are not tax deduct-\nible.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.21205643437366395, "height": 0.09277469003847798, "width": 0.7696493349455864}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-2", "text": "Currently, there are no specific rules for the taxation of capital gains arising from the disposal of portfolio partic-\nipations (i.e. participations equalling less than 10% of a company's registered share capital). However, according\nto a draft bill of the German Ministry of Finance, from 2018 onwards the 10% threshold applicable to dividends\nreceived from such participations (see above) shall also be introduced with regard to capital gains arising from\nthe disposal of portfolio participations. If this bill was enacted, from 2018 onwards capital gains from the dispos-\nal of portfolio participations (or parts thereof) would fully be subject to corporate income tax at 15.825% (in-\ncluding solidarity surcharge) and trade tax.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.221889696451475, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.31765711842667804, "height": 0.09576742197520305, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-3", "text": "Sole Proprietors. If the shares are held by sole proprietors, pursuant to the partial income method (Teilein-\nk\u00fcnfteverfahren), 60% of the capital gains realised upon disposal are subject to income tax and solidarity sur-\ncharge. Correspondingly, 60% of the business expenses related to such capital gains and 60% of any losses in-\ncurred upon disposal of shares are tax deductible. In addition, 60% of the capital gains are subject to trade tax if\nthe sole proprietor is subject to trade tax. However, trade tax is partly or entirely credited against the sharehold-\ner's personal income tax liability depending on the applicable municipal trade tax rate and individual circum-\nstances. Gains from the disposal of shares held by individuals are not subject to withholding tax if the disposal\nproceeds are part of the business income of a business based in Germany and the shareholder declares this fact to\nthe German Disbursing Agent on the designated official form. If withholding tax including solidarity surcharge\nwas levied, this does not satisfy the tax liability. Instead, the amounts withheld are credited towards the seller's\nincome tax (plus solidarity surcharge) liability or refunded in the amount of any excess paid. If the shareholder is\nsubject to church tax, such tax may become due as well.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.324497648567764, "lower_right_x": 0.8839177750906893, "lower_right_y": 0.4886703719538264, "height": 0.16417272338606242, "width": 0.7684401451027811}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-4", "text": "Commercial Partnerships. If the shareholder is a commercial partnership (Mitunternehmerschaft), income tax\nor corporate income tax is not levied at the level of the partnership but at the level of the respective partner. Tax-\nation is determined as if the partner held a direct interest in the Company according to the rules outlined above,\ndepending on whether the partner is a corporation (see \"\u2013 Corporations.\" above) or an individual (see \"\u2013 Sole\nProprietors.\" above). Trade tax, however, is assessed and levied at the level of the partnership considering the\ntrade tax rules applicable to the partners holding the interest in the relevant partnership. However, the trade tax\npaid at the level of a partnership may partly or entirely be credited \u2013 depending on the applicable municipal trade\ntax rate and individual circumstances \u2013 against the personal income tax liability of the partners who are individu-\nals.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.49551090209491233, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6152201795639162, "height": 0.11970927746900384, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-5", "text": "Taxation of Capital Gains of Certain Investors in the Financial and Insurance Sector\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6254809747755451, "lower_right_x": 0.686819830713422, "lower_right_y": 0.6395895681915349, "height": 0.0141085934159898, "width": 0.5713422007255139}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-6", "text": "Capital gains realised by certain companies in the financial and insurance sector are, as an exception to the\naforementioned rules, fully taxable. This applies to gains from the disposal of shares in the trading books of\nbanks and financial services companies in the meaning of the German Banking Act (Kreditwesengesetz), to gains\nfrom the disposal of shares that were acquired by financial enterprises with the aim of generating a short-term\nproprietary trading profit, as well as to gains from the disposal of shares held as investments by life insurers,\nhealth insurers and pension funds. In turn, capital losses are generally fully tax deductible.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.646002565198803, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.728516460025652, "height": 0.08251389482684901, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-7", "text": "Shareholders not Tax Resident in Germany\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.73492945703292, "lower_right_x": 0.4105199516324063, "lower_right_y": 0.7490380504489098, "height": 0.0141085934159898, "width": 0.29443772672309554}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-8", "text": "Capital gains realised upon disposal of Offer Shares by a shareholder that is not tax resident in Germany should\ngenerally not be subject to German taxation.\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7554510474561779, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7832407011543394, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-9", "text": "gains from the disposal of Offer Shares held as part of German business assets (that is, in a permanent establish-\nment or through a fixed base in Germany, or held as assets for which a permanent representative has been ap-\npointed in Germany) by non-resident Shareholders are taxed in Germany principally according to the same pro-\nvisions that apply to the taxation of Shareholders that are German tax residents holding the shares as business\nassets (see \"\u2013 Taxation of Capital Gains\" above).\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7896536981616076, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8584865327062847, "height": 0.06883283454467715, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-10", "text": "Inheritance and Gift Tax\n", "page_number": 224, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8648995297135528, "lower_right_x": 0.28476420798065294, "lower_right_y": 0.8790081231295426, "height": 0.0141085934159898, "width": 0.1680773881499395}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-11", "text": "The transfer of shares by way of gift or succession is, in principle, subject to German inheritance and gift tax in\nparticular if one of the following criteria is met:\n", "page_number": 224, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8854211201368106, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9132107738349722, "height": 0.027789653698161554, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-224-12", "text": "221\n", "page_number": 224, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-0", "text": "(i)    the testator, donor, heir, donee, or any other beneficiary has his or her residence or habitual abode, regis-\n       tered domicile or place of management in Germany at the time of the transfer or is a German citizen who\n       has not stayed abroad for more than five years without having a place of residence in Germany (this term\n       is extended to ten years for German expatriates with US residence); or\n(ii)   irrespective of these personal circumstances, the testator's or donor's shares were held as business assets\n       for which a permanent establishment was maintained or a permanent representative was appointed in\n       Germany.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.1881145788798632, "height": 0.10303548525010688, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-1", "text": "The few double taxation treaties on inheritance and gift tax which Germany has entered into generally provide\nthat German inheritance or gift tax is levied only in cases under (i) and, subject to certain restrictions, in cases\nunder (ii). Special provisions apply to certain German expatriates and former German citizens.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.19452757588713127, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.23557075673364686, "height": 0.04104318084651559, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-2", "text": "Other Taxes\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.23557075673364686, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.25309961522017954, "height": 0.017528858486532684, "width": 0.08585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-3", "text": "In general, no German capital transfer tax, value-added tax, stamp duty, or similar tax is levied on the acquisi-\ntion, sale, or other forms of transferring shares. However, an entrepreneur may opt for value-added tax being\nlevied on a transaction that is normally tax-exempt if the transaction is executed for the enterprise of another\nentrepreneur. Net wealth tax (Verm\u00f6gensteuer) is currently not levied in Germany.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3180846515604959, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-4", "text": "US Federal Income Tax Considerations\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33133817870884996, "lower_right_x": 0.45949214026602175, "lower_right_y": 0.34544677212483965, "height": 0.01410859341598969, "width": 0.34401451027811364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-5", "text": "The following is a description of certain US federal income tax consequences that may be relevant with respect\nto the acquisition, ownership, and disposition of the Shares by a US Holder (as defined below). This summary\ndeals only with initial purchasers of Shares in the Offering who are US Holders (as defined below), use the US\nDollar as their functional currency, and will hold the Offered Shares as capital assets.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.36212056434373663, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.41727233860624197, "height": 0.05515177426250534, "width": 0.7672309552599758}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-6", "text": "This description does not purport to address all material US tax consequences of the acquisition, ownership, and\ndisposition of the Shares and does not address aspects of US federal income taxation that may be applicable to\ninvestors that are subject to special tax rules, including without limitation:\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4236853356135101, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.46515604959384355, "height": 0.04147071398033347, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-7", "text": "\uf0b7   certain financial institutions;\n\uf0b7   dealers or certain traders in securities;\n\uf0b7   persons holding Shares as part of a straddle, wash sale, conversion transaction or integrated transaction\n    or persons entering into a constructive sale with respect to the Shares;\n\uf0b7   persons whose functional currency for US federal income tax purposes is not the US Dollar;\n\uf0b7   persons who receive Shares as compensation for the performance of services;\n\uf0b7   persons who are resident in or have a permanent establishment in the Netherlands;\n\uf0b7   certain US expatriates;\n\uf0b7   \"dual resident\" corporations;\n\uf0b7   persons that own or are deemed to own 10%. or more of the Company's voting stock;\n\uf0b7   S corporations;\n\uf0b7   regulated investment companies;\n\uf0b7   insurance companies;\n\uf0b7   tax-exempt investors (including an individual retirement account or \"Roth IRA\" as defined in Section 408\n    or 408A of the Code); or\n\uf0b7   persons holding Shares in connection with a trade or business outside the United States.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7969217614365113, "height": 0.32193244976485674, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-8", "text": "Further, this description does not address state, local, foreign, or other tax laws, nor does it address the 3.8%.\nUS federal Medicare tax on net investment income, the alternative minimum tax, or the US federal gift and estate\ntax consequences of the acquisition, ownership, and disposition of the Shares.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8033347584437794, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8448054724241129, "height": 0.04147071398033342, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-9", "text": "This summary is based on the Internal Revenue Code of 1986, as amended (the \"Internal Revenue Code\"), the\nTreasury Regulations promulgated under the Internal Revenue Code and administrative and judicial interpreta-\ntions. These income tax laws, regulations and interpretations, however, may change at any time, possibly with\nretroactive effect.\n", "page_number": 225, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8512184694313809, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9059427105600684, "height": 0.054724241128687456, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-225-10", "text": "222\n", "page_number": 225, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-0", "text": "The Company has not requested, and does not intend to request, a ruling from the US Internal Revenue Service\n(the \"IRS\") with respect to matters addressed herein.\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-1", "text": "US Holders\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.12612227447627192, "lower_right_x": 0.20133010882708585, "lower_right_y": 0.1368106028217187, "height": 0.01068832834544678, "width": 0.08403869407496976}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-2", "text": "You are a \"US Holder\" for purposes of this discussion if for US federal income tax purposes you are a beneficial\nowner of the Company's Shares and are:\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.17101325352714836, "height": 0.024369388627618643, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-3", "text": "of the Company's Shares and are:\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1686819830713422, "top_left_y": 0.17101325352714836, "lower_right_x": 0.46735187424425634, "lower_right_y": 0.1838392475416845, "height": 0.01282599401453613, "width": 0.29866989117291415}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-4", "text": "\uf0b7   a citizen or individual resident of the United States;\n\uf0b7   a corporation created or organised in or under the laws of the United States, any state therein or the\n    District of Columbia;\n\uf0b7   an estate, the income of which is subject to US federal income taxation regardless of its source; or\n\uf0b7   a trust if (i) a court within the United States is able to exercise primary supervision over its administra-\n    tion and one or more US persons have the authority to control all of the substantial decisions of such\n    trust, or (ii) such trust has a valid election in effect to be treated as a US person for US federal income\n    tax purposes.\n", "page_number": 226, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.18426678067550234, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.314664386489953, "height": 0.13039760581445065, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-5", "text": "If a partnership (or any other entity treated as a partnership for US federal income tax purposes) holds Shares,\nthe tax treatment of the partnership and a partner in such partnership will generally depend on the status of the\npartner and the activities of the partnership. Such a partner or partnership should consult its tax adviser as to\nthe US federal income tax consequences of acquiring, holding, or disposing of the Shares.\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3762291577597264, "height": 0.05515177426250534, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-6", "text": "The summary of US federal income tax consequences set out below is for general information only. All prospec-\ntive purchasers should consult their tax advisers as to the particular tax consequences to them of owning the\nShares, including the applicability and effect of state, local, foreign and other tax laws and possible changes in\ntax law.\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4365113296280462, "height": 0.05386917486105175, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-7", "text": "Taxation of distributions\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45446772124839674, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.4672937152629329, "height": 0.012825994014536157, "width": 0.17472793228536881}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-8", "text": "Subject to the PFIC rules discussed below, distributions paid on the Shares (including the amount of any Dutch\ntaxes withheld) will be treated as dividends to the extent paid out of the Company's current or accumulated earn-\nings and profits, as determined under US federal income tax principles. Distributions in excess of current and\naccumulated earnings and profits will be treated as a non-taxable return of capital to the extent of a US Holder's\nbasis in its Shares and thereafter as capital gain. Because the Company does not maintain calculations of its\nearnings and profits under US federal income tax principles, it is expected that distributions generally will be\nreported to you as dividends. For US federal income tax purposes, US Holders will be treated as having received\nthe amount of Dutch taxes withheld by the Company, and as then having paid over the withheld taxes to the\nDutch taxing authorities. As a result of this rule, the amount of dividend income included in gross income for US\nfederal income tax purposes by a US Holder with respect to a payment of dividends may be greater than the\namount of cash actually received (or receivable) by the US Holder from the Company with respect to the pay-\nment.\nSubject to applicable limitations, if you are a non-corporate US Holder, dividends paid to you may be eligible for\ntaxation as \"qualified dividend income\" and therefore may be taxable at favourable rates. Dividends will be\ntreated as qualified dividends if (a) certain holding period requirements are satisfied, (b) the Company is eligible\nfor the benefits of the income tax treaty between the United States and the Netherlands (the \"Treaty\"), which the\nCompany expects will be the case provided that its Shares are regularly traded on the regulated market of Euron-\next Amsterdam, and (c) the Company was not, in the year prior to the year in which the dividend was paid, and is\nnot, in the year in which the dividend is paid, a PFIC. The Company does not believe it has been or will become\na PFIC in the future. However, its status in the current year and future years will depend upon its income and\nassets (which for this purpose depends in part on the market value of the Shares) in those years. See the discus-\nsion below under \"\u2013 Passive foreign investment company rules\". You should consult your tax adviser regarding\nthe availability of the reduced tax rate on qualified dividends.\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47498931167165453, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7935014963659683, "height": 0.3185121846943138, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-9", "text": "the availability of the reduced tax rate on qualified dividends.\nDividends will generally be included in your income on the date of receipt. Dividends will not be eligible for the\ndividends-received deduction generally available to US corporations under the Code. The amount of any divi-\ndend income paid in euro will be the US Dollar amount calculated by reference to the spot rate in effect on the\ndate of receipt, regardless of whether the payment is in fact converted into US dollars. If the dividend is convert-\ned into US dollars on the date of receipt, you should not be required to recognise foreign currency gain or loss in\nrespect of the amount received. You may have foreign currency gain or loss if the dividend is converted into US\ndollars after the date of receipt, and any such gain or loss will be US-source ordinary income or loss.\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7939290294997863, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8961094484822574, "height": 0.1021804189824711, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-10", "text": "dollars after the date of receipt, and any such gain or loss will be US-source ordinary income or loss.\nDividends paid by the Company generally will constitute income from sources outside the United States for US\nforeign tax credit limitation purposes and will be categorised as \"passive income\" for US foreign tax credit pur-\n", "page_number": 226, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8965369816160752, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.9324497648567764, "height": 0.03591278324070124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-226-11", "text": "223\n", "page_number": 226, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-0", "text": "poses. Subject to applicable limitations, some of which vary depending upon your circumstances, Dutch income\ntaxes withheld from dividend payments on Shares at a rate not exceeding the applicable Treaty rate will be cred-\nitable against your US federal income tax liability. Dutch income taxes withheld in excess of the applicable\nTreaty rate will not be eligible for credit against your US federal income tax liability. Additionally, if a US\nHolder receives a dividend from the Company that qualifies for the favourable rate applicable to qualified divi-\ndend income described above, the amount of the dividend taken into account in calculating the foreign tax credit\nlimitation generally will be limited to the gross amount of the dividend, multiplied by the favourable rate divided\nby the highest rate of tax normally applicable to dividends. The rules governing foreign tax credits are complex,\nand you should consult your tax adviser regarding the creditability of foreign taxes in your particular circum-\nstances. In lieu of claiming a foreign tax credit, you may elect to deduct foreign taxes, including any Dutch taxes,\nin computing your taxable income, subject to applicable limitations. An election to deduct foreign taxes instead\nof claiming foreign tax credits applies to all foreign taxes paid or accrued in the relevant taxable year.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2496793501496366, "height": 0.1646002565198803, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-1", "text": "Sale or other taxable disposition of Shares\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2629328772979906, "lower_right_x": 0.4111245465538089, "lower_right_y": 0.27704147071398033, "height": 0.014108593415989745, "width": 0.2956469165659008}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-2", "text": "Subject to the PFIC rules discussed below, you generally will recognise taxable gain or loss on a sale or other\ntaxable disposition of the Shares equal to the difference between the amount realised on the sale or disposition\nand your adjusted tax basis in the Shares, each as determined in US dollars. This gain or loss will generally be\ncapital gain or loss, and will be long-term capital gain or loss if at the time of sale or disposition the Shares have\nbeen held for more than one year. Any gain or loss will generally be US-source for foreign tax credit purposes.\nThe deductibility of capital losses is subject to limitations.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2834544677212484, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3655408294142796, "height": 0.08208636169303124, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-3", "text": "A US Holder's adjusted tax basis in a Share generally will be its US dollar cost. The US dollar cost of a Share\npurchased with euro (or other currency other than US dollars) will generally be the US dollar value of the pur-\nchase price on the date of purchase, or, in the case of Shares traded on an \"established securities market\" that are\npurchased by a cash basis taxpayer (or an accrual basis taxpayer, if it so elects), the settlement date for the pur-\nchase. Such an election by an accrual basis US Holder must be applied consistently from year to year and cannot\nbe revoked without the consent of the IRS. If you receive euro (or other currency other than US dollars) upon a\nsale, exchange or other disposition of the Shares, the amount realised generally will be the US dollar value of the\npayment received determined on (a) the date of receipt of payment in the case of a cash basis US Holder and (b)\nthe date of disposition in the case of an accrual basis US Holder. If the Shares are traded on an \"established secu-\nrities market\", a cash basis taxpayer or, if it so elects, an accrual basis taxpayer, will determine the US dollar\nvalue of the amount realised by translating the amount received at the spot rate of exchange on the settlement\ndate of the sale. A US Holder will have a tax basis in the foreign currency received equal to the US dollar\namount realised. Any currency exchange gain or loss realised on a subsequent conversion of the foreign currency\ninto US dollars for a different amount generally will be treated as ordinary income or loss from sources within\nthe United States. However, if such foreign currency is converted into US dollars on the date received by the US\nHolder, a cash basis or electing accrual basis US Holder should not recognise any gain or loss on such conver-\nsion.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.37238135955536555, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6019666524155622, "height": 0.2295852928601967, "width": 0.7690447400241838}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-4", "text": "Passive foreign investment company rules\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6186404446344592, "lower_right_x": 0.40870616686819833, "lower_right_y": 0.6327490380504489, "height": 0.01410859341598969, "width": 0.2932285368802902}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-5", "text": "A non-US corporation will be classified as a \"passive foreign investment company\", or a PFIC, for US federal\nincome tax purposes in any taxable year in which, after applying certain look through rules, either:\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.639162035057717, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.6669516887558786, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-6", "text": "\uf0b7   at least 75% of its gross income is \"passive income\"; or\n\uf0b7   at least 50% of the quarterly average value of its gross assets is attributable to assets that produce \"passive\n    income\" or are held for the production of passive income.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.725096194955109, "height": 0.048311244121419405, "width": 0.76360338573156}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-7", "text": "Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and\ngains from commodities and securities transactions and from the sale or exchange of property that gives rise to\npassive income. In determining whether a non-US corporation is a PFIC, a proportionate share of the income and\nassets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into\naccount.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7315091919623771, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7969217614365113, "height": 0.06541256947413421, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-8", "text": "The Company does not believe that it was a PFIC for US federal income tax purposes for its most recent taxable\nyear and does not expect that it will be a PFIC for its current taxable year or in the foreseeable future. However,\nthe determination of PFIC status is a factual determination that must be made annually at the close of each taxa-\nble year and, therefore; there can be no certainty as to its status in this regard until the close of the current or any\nfuture taxable year. The Company's status could change depending, among other things, upon a decrease in the\ntrading price of the Shares, changes in the composition and relative values of its assets, and the sources of its\nincome.\n", "page_number": 227, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8067550235143224, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8995297135528003, "height": 0.09277469003847794, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-227-9", "text": "224\n", "page_number": 227, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-0", "text": "If the Company were a PFIC in any year during a US Holder's holding period for the Shares, the Company\nwould ordinarily continue to be treated as a PFIC for each subsequent year during which the US Holder owned\nthe Shares. If the Company were a PFIC for a taxable year during a US Holder's holding period for the Shares,\nUS Holders generally would be subject to additional taxes (including taxation at ordinary income rates and an\ninterest charge) on any \"excess distributions\" received from the Company and on any gain realised from a sale or\nother disposition of the Shares. A US Holder would have an excess distribution to the extent that distributions on\nthe Shares during a taxable year exceed 125% of the average amount received during the three preceding taxable\nyears (or, if shorter, the US Holder's holding period). To compute the tax on excess distributions or any gain, (i)\nthe excess distribution or gain would be allocated rateably over the US Holder's holding period, (ii) amounts\nallocated to the current taxable year and any year before the Company became a PFIC would be taxed as ordi-\nnary income in the current year and (iii) amounts allocated to other taxable years would be taxed at the highest\napplicable marginal rate in effect for each such year (i.e., at ordinary income tax rates) and (iv) an interest charge\nwould be imposed to recover the deemed benefit from the deferred payment of the tax attributable to each year\ndescribed in (iii). Gain on the disposition of the Shares will be subject to taxation in the same manner as an ex-\ncess distribution, described immediately above.\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.2864471996579735, "height": 0.2013681060282172, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-1", "text": "cess distribution, described immediately above.\nIf the Company were a PFIC in any year during which you hold the Shares, you would not be able to avoid the\ntax consequences described above by electing to treat the Company as a qualified electing fund (\"QEF\"), be-\ncause the Company does not intend to provide US Holders with the information that would be necessary to make\na QEF election with respect to the Shares. However, in the event the Company were a PFIC, a US Holder may\nbe able to avoid some of the adverse effects of the PFIC rules described above with respect to Shares by electing\nto mark the Shares to market annually. The election is available only if the Shares are regularly traded in more\nthan de minimis quantities on Euronext Amsterdam. Any gain from marking the Shares to market or from dis-\nposing of them would be ordinary income. Any loss from marking the Shares to market would be recognised\nonly to the extent of un-reversed gains previously included in income. Loss from marking the Shares to market\nwould be ordinary, but loss on disposing of them would be capital loss except to the extent of mark to market\ngains previously included in income. Each US Holder should ask its own tax adviser whether a mark to market\nelection is available or desirable. A valid mark to market election cannot be revoked without the consent of the\nIRS unless the Shares cease to be marketable.\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2868747327917914, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.4719965797349295, "height": 0.1851218469431381, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-2", "text": "If you own the Company's Shares during any year in which the Company is a PFIC, you must file IRS Form\n8621 with respect to the Company, generally with your federal income tax return for that year.\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.48182984181274047, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5087644292432664, "height": 0.026934587430525903, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-3", "text": "You should consult your tax adviser regarding whether the Company is a PFIC and the potential application of\nthe PFIC rules to your ownership of Shares for any taxable year.\n", "page_number": 228, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5160324925181702, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.5438221462163317, "height": 0.027789653698161554, "width": 0.7642079806529626}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-4", "text": "Backup withholding and information reporting\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5570756733646858, "lower_right_x": 0.4443772672309553, "lower_right_y": 0.5711842667806755, "height": 0.01410859341598969, "width": 0.32889963724304716}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-5", "text": "Payments of dividends and sales proceeds that are made within the United States or through US or certain US-\nrelated intermediaries will generally be subject to information reporting and backup withholding, unless (i) you\nare an exempt recipient or (ii) in the case of backup withholding, you provide a correct taxpayer identification\nnumber and certify that you are not subject to backup withholding. Any amounts withheld under the backup\nwithholding rules will be allowed as a refund or a credit against your US federal income tax liability, provided\nthat the required information is timely furnished to the IRS. You may be required to report information relating\nto non-US accounts through which the Shares are held (or information regarding the Shares if the Shares are not\nheld through any financial institution). You should consult your tax adviser regarding your reporting obligations\nwith respect to the Shares.\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5775972637879435, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7011543394613082, "height": 0.12355707567336471, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-6", "text": "Certain Non-corporate US Holders are required to report information relating to an interest in the Shares, subject\nto certain exceptions (including an exception for Shares held in accounts maintained at US financial institutions)\nby filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return.\nUS Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with\nrespect to their ownership and disposition of the Shares.\n", "page_number": 228, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7075673364685763, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.7764001710132535, "height": 0.06883283454467726, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-228-7", "text": "225\n", "page_number": 228, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-0", "text": "GENERAL INFORMATION\n", "page_number": 229, "bounding_box": {"top_left_x": 0.35066505441354295, "top_left_y": 0.09191962377084224, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.1085934159897392, "height": 0.016673792218896963, "width": 0.29746070133010877}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-1", "text": "Independent Auditors\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.12612227447627192, "lower_right_x": 0.309552599758162, "lower_right_y": 0.14194100042753313, "height": 0.015818725951261214, "width": 0.1940749697702539}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-2", "text": "The financial statements of Curetis AG, prepared in accordance with IFRS as of and for the fiscal years ended\nDecember 31, 2014, 2013 and 2012, included in this Prospectus, have been audited by PricewaterhouseCoopers\nAktiengesellschaft Wirtschaftspr\u00fcfungsgesellschaft (\"PwC\"), Bernhard-Wicki-Stra\u00dfe 8, 80636 Munich,\nGermany, as stated in the unqualified auditor's report appearing herein.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.1569046601111586, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.21077383497221033, "height": 0.05386917486105172, "width": 0.7678355501813785}, "blob_type": "paragraph", "predictions": {}, "annotations": {"external_auditor": ["PricewaterhouseCoopersAktiengesellschaftWirtschaftspr\u00fcfungsgesellschaft(\"PwC\"),"]}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-3", "text": "PwC is a member of the German Chamber of Public Accountants (Wirtschaftspr\u00fcferkammer), Rauchstra\u00dfe 26,\n10787 Berlin, Germany.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.21846943138093203, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.24497648567764002, "height": 0.026507054296707994, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-4", "text": "PwC was appointed as the auditor of Curetis AG in the general shareholders' meeting in 2014. The German\nGAAP (HGB) annual financial statements as of and for the years ended 31 December 2012 and 2013 were\naudited by B\u00f6hret Sehmsdorf GmbH Wirtschaftspr\u00fcfungsgesellschaft, Maxstra\u00dfe 8, 01067 Dresden, Germany,\nalso a member of the German Chamber of Public Accountants (Wirtschaftspr\u00fcferkammer).\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.2526720820863617, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3069687900812313, "height": 0.054296707994869575, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-5", "text": "Significant Change in the Company's Financial or Trading Position\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.32107738349722104, "lower_right_x": 0.7007255139056832, "lower_right_y": 0.337751175716118, "height": 0.016673792218896977, "width": 0.585247883917775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-6", "text": "No significant change in the financial or trading position of Curetis has occurred since 30 June 2015.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35185976913210776, "lower_right_x": 0.7980652962515115, "lower_right_y": 0.3655408294142796, "height": 0.013681060282171864, "width": 0.6825876662636033}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-7", "text": "Expenses of the Offering\n", "page_number": 229, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3792218896964515, "lower_right_x": 0.33373639661426846, "lower_right_y": 0.3963232150491663, "height": 0.017101325352714802, "width": 0.2176541717049577}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-8", "text": "The expenses related to the Offering are estimated at approximately \u20ac4.3 (assuming that the Target Proceeds are\nraised) and include, among other things, the fees due to the AFM and Euronext, the commission for the\nUnderwriters and legal and administrative expenses, as well as publication costs and applicable taxes, if any. See\nalso \"Reasons for the Offering and Use of Proceeds\".\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.46472851646002566, "height": 0.05472424112868751, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-9", "text": "Documents on Display\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.47840957674219753, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.49551090209491233, "height": 0.017101325352714802, "width": 0.1989117291414752}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-10", "text": "The following documents (or copies thereof) will be available for inspection free of charge on the website of the\nCompany (www.curetis.com) for as long as this Prospectus is valid:\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5091919623770842, "lower_right_x": 0.8796856106408706, "lower_right_y": 0.5369816160752459, "height": 0.027789653698161665, "width": 0.7642079806529625}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-11", "text": "\uf0b7   this Prospectus;\n\uf0b7   the Articles of Association;\n\uf0b7   the Pricing Statement;\n\uf0b7   the Management Board Rules;\n\uf0b7   the Supervisory Board Rules;\n\uf0b7   the rules for the Audit Committee;\n\uf0b7   the rules for the Nomination and Appointment Committee;\n\uf0b7   the rules for the Remuneration Committee;\n\uf0b7   the audited financial statements of Curetis AG under IFRS as of and for the years ended 31 December\n    2014, 2013 and 2012; and\n\uf0b7   the unaudited interim condensed financial statements of Curetis AG under IFRS as of 30 June 2015 and\n    for the six months ended 30 June 2015 and 2014.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5468148781530568, "lower_right_x": 0.8833131801692866, "lower_right_y": 0.7798204360837965, "height": 0.23300555793073963, "width": 0.7678355501813785}, "blob_type": "table", "predictions": {}, "annotations": {"periods_of_audited_financial_statements": ["for the years ended 31 December2014, 2013 and 2012;"], "audited_financial_statements": ["the audited financial statements of Curetis AG under IFRS as of and for the years ended 31 December2014, 2013 and 2012;"]}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-12", "text": "This Prospectus will also be available free of charge from the Company's registered address at Max-Eyth-Stra\u00dfe\n42, 71088 Holzgerlingen, Germany.\n", "page_number": 229, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7862334330910645, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.8140230867892262, "height": 0.027789653698161665, "width": 0.7648125755743652}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-229-13", "text": "226\n", "page_number": 229, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-0", "text": "GLOSSARY\n", "page_number": 230, "bounding_box": {"top_left_x": 0.43530834340991537, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5652962515114873, "lower_right_y": 0.10816588285592134, "height": 0.016246259085079096, "width": 0.12998790810157196}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-1", "text": "\"AACC\"\n\"ABN AMRO \"\n\"ACA\"\n\"AIA\"\n\"Additional Shares\"\n\n\"AFM\"\n\n\"Annual Financial Statements\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.13296280461735785, "lower_right_x": 0.3403869407496977, "lower_right_y": 0.2975630611372381, "height": 0.16460025651988028, "width": 0.22430471584038697}, "blob_type": "image", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-2", "text": "American Association for Clinical Chemistry\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.13296280461735785, "lower_right_x": 0.6717049576783555, "lower_right_y": 0.1466438648995297, "height": 0.013681060282171864, "width": 0.3089480048367593}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-3", "text": "ABN AMRO Bank N.V.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.15348439504061565, "lower_right_x": 0.532043530834341, "lower_right_y": 0.16417272338606242, "height": 0.01068832834544678, "width": 0.16928657799274482}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-4", "text": "Affordable Care Act\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.17400598546387344, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.18469431380932022, "height": 0.01068832834544678, "width": 0.14026602176541714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-5", "text": "Leahy-Smith America Invents Act\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.19452757588713127, "lower_right_x": 0.599758162031439, "lower_right_y": 0.20863616930312098, "height": 0.014108593415989718, "width": 0.2376058041112455}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-6", "text": "the additional Shares that may be available pursuant to the Over-\nallotment Option\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.21504916631038906, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.2424112868747328, "height": 0.027362120564343728, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-7", "text": "the Dutch Authority for the Financial Markets (Stichting Autoriteit Fi-\nnanci\u00eble Markten)\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.24925181701581872, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.27704147071398033, "height": 0.02778965369816161, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-8", "text": "the audited financial statements of Curetis AG as of and for the years\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.28388200085506626, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.29713552800342025, "height": 0.013253527148353983, "width": 0.5030229746070134}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-9", "text": "ended 31 December 2014, 2013 and 2012, prepared in accordance with\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.2975630611372381, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.31124412141941, "height": 0.013681060282171864, "width": 0.5030229746070134}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-10", "text": "IFRS\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.31124412141941, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.3232150491663104, "height": 0.011970927746900395, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-11", "text": "\"Allocation\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.33219324497648567, "lower_right_x": 0.20556227327690446, "lower_right_y": 0.34416417272338606, "height": 0.011970927746900395, "width": 0.0894800483675937}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-12", "text": "the allocation of Offer Shares\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.33219324497648567, "lower_right_x": 0.56590084643289, "lower_right_y": 0.34416417272338606, "height": 0.011970927746900395, "width": 0.2031438935912938}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-13", "text": "\"Articles of Association\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.35271483539974346, "lower_right_x": 0.29443772672309554, "lower_right_y": 0.36468576314664386, "height": 0.011970927746900395, "width": 0.1783555018137848}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-14", "text": "the Company's articles of association (statuten) as they read immediately\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.35271483539974346, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.3659683625480975, "height": 0.013253527148354038, "width": 0.5030229746070133}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-15", "text": "after Conversion\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.36639589568191533, "lower_right_x": 0.4782345828295042, "lower_right_y": 0.3783668234288157, "height": 0.011970927746900395, "width": 0.11608222490931075}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-16", "text": "\"ASEAN\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.387345019238991, "lower_right_x": 0.18742442563482467, "lower_right_y": 0.3997434801197093, "height": 0.012398460880718276, "width": 0.07013301088270858}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-17", "text": "Association of Southeast Asian Nations\n", "page_number": 230, "bounding_box": {"top_left_x": 0.3639661426844015, "top_left_y": 0.387345019238991, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.3993159469858914, "height": 0.011970927746900395, "width": 0.26964933494558646}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-18", "text": "\"BaFin\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.41000427533133815, "lower_right_x": 0.17472793228536881, "lower_right_y": 0.4202650705429671, "height": 0.010260795211628926, "width": 0.05804111245465539}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-19", "text": "the German Federal Financial Supervisory Authority (Bundesanstalt f\u00fcr\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.41000427533133815, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.4228302693458743, "height": 0.012825994014536157, "width": 0.5030229746070134}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-20", "text": "Finanzdienstleistungsaufsicht)\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4236853356135101, "lower_right_x": 0.5701330108827086, "lower_right_y": 0.4356562633604104, "height": 0.01197092774690034, "width": 0.20798065296251517}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-21", "text": "\"Cash-settled PSOP Beneficiar-\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.44420692603676787, "lower_right_x": 0.34522370012091896, "lower_right_y": 0.45446772124839674, "height": 0.01026079521162887, "width": 0.22853688029020552}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-22", "text": "payment claims of the 38 PSOP Beneficiaries who are each entitled to\n", "page_number": 230, "bounding_box": {"top_left_x": 0.3651753325272068, "top_left_y": 0.44420692603676787, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.4557503206498504, "height": 0.011543394613082514, "width": 0.5}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-23", "text": "1,000 phantom stock options or less\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4561778537836682, "lower_right_x": 0.6076178960096735, "lower_right_y": 0.47071398033347583, "height": 0.014536126549807626, "width": 0.24546553808948007}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-24", "text": "ies\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45788798631893973, "lower_right_x": 0.14510278113663846, "lower_right_y": 0.4681487815305686, "height": 0.01026079521162887, "width": 0.029625151148730364}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-25", "text": "Chief Commercial Officer\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.47840957674219753, "lower_right_x": 0.5411124546553809, "lower_right_y": 0.4886703719538264, "height": 0.01026079521162887, "width": 0.1783555018137848}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-26", "text": "\"CCO\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.47840957674219753, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.4890979050876443, "height": 0.010688328345446751, "width": 0.04957678355501813}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-27", "text": "Central European Time\nChief Executive Officer\nChina Food and Drug Administration\nClinical Laboratory Fee Schedule\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4989311671654553, "lower_right_x": 0.6185006045949214, "lower_right_y": 0.5746045318512185, "height": 0.07567336468576319, "width": 0.25634824667472794}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-28", "text": "\"CEST\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4989311671654553, "lower_right_x": 0.1759371221281741, "lower_right_y": 0.5096194955109021, "height": 0.010688328345446807, "width": 0.05622732769044739}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-29", "text": "\"CEO\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5194527575887131, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.5301410859341599, "height": 0.010688328345446751, "width": 0.0513905683192261}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-30", "text": "\"CFDA\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.539974348011971, "lower_right_x": 0.17896009673518742, "lower_right_y": 0.5506626763574177, "height": 0.010688328345446751, "width": 0.06287787182587666}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-31", "text": "\"CLFS\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5604959384352287, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.5711842667806755, "height": 0.010688328345446751, "width": 0.057436517533252726}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-32", "text": "aeris CAPITAL Equity Investments, L.P., LSP Curetis Pooling B.V.,\nBioMed Invest II LP, CD-Venture GmbH, Forbion Capital Fund II\nCo\u00f6peratief U.A. and/or Forbion CF II Co-Invest I Co\u00f6peratief U.A.,\nRoche Finance Ltd. and HBM BioCapital II Invest S.a r.l.\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5810175288584866, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.6348867037195383, "height": 0.053869174861051694, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-33", "text": "\"Commiting Shareholders\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5810175288584866, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.5951261222744763, "height": 0.01410859341598969, "width": 0.19830713422007257}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-34", "text": "\"Commitment Letters\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6425823001282599, "lower_right_x": 0.282950423216445, "lower_right_y": 0.6532706284737068, "height": 0.010688328345446862, "width": 0.16686819830713423}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-35", "text": "the commitment letters have been entered into on 26 October 2015, be-\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6425823001282599, "lower_right_x": 0.8645707376058042, "lower_right_y": 0.6558358272766139, "height": 0.013253527148354038, "width": 0.5024183796856108}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-36", "text": "the commitment letters have been entered into on 2\ntween the Company and the commiting shareholders\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6562633604104318, "lower_right_x": 0.7194679564691656, "lower_right_y": 0.6703719538264216, "height": 0.0141085934159898, "width": 0.35731559854897216}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-37", "text": "the rules on each Supervisory Board committee's role, responsibilities and\nfunctioning, which rules will be in effect upon Conversion\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6767849508336896, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.7045746045318512, "height": 0.027789653698161554, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-38", "text": "\"Committee Rules\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6772124839675074, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.6874732791791364, "height": 0.010260795211628926, "width": 0.13784764207980651}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-39", "text": "Curetis N.V. (at the date of this Prospectus still a private limited liability\ncompany (besloten vennootschap met beperkte aansprakelijkheid) named\nCuretis B.V., will be converted into a public company with limited liabil-\nity (naamloze vennootschap) immediately after determination of the Of-\nfer Price pursuant to the Deed of Amendment\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.718683197947841, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.7866609662248825, "height": 0.0679777682770415, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-40", "text": "\"Company\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.718683197947841, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.731936725096195, "height": 0.013253527148354038, "width": 0.08706166868198308}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-41", "text": "\"Competent Authorities\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7939290294997863, "lower_right_x": 0.29866989117291415, "lower_right_y": 0.8071825566481402, "height": 0.013253527148353927, "width": 0.1825876662636034}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-42", "text": "regulatory agencies and other national or supra-national regulatory au-\n", "page_number": 230, "bounding_box": {"top_left_x": 0.3633615477629988, "top_left_y": 0.7939290294997863, "lower_right_x": 0.8627569528415961, "lower_right_y": 0.8071825566481402, "height": 0.013253527148353927, "width": 0.49939540507859737}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-43", "text": "thorities that lay down regulatory regulations\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.8076100897819581, "lower_right_x": 0.6674727932285369, "lower_right_y": 0.8208636169303121, "height": 0.013253527148353927, "width": 0.3047158403869408}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-44", "text": "\"Conversion\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8285592133390338, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.840957674219752, "height": 0.012398460880718165, "width": 0.1003627569528416}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-45", "text": "the conversion of the Company into a\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.8285592133390338, "lower_right_x": 0.6154776299879081, "lower_right_y": 0.8418127404873877, "height": 0.013253527148353927, "width": 0.25332527206771466}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-46", "text": "a public company with limited liabil-\n", "page_number": 230, "bounding_box": {"top_left_x": 0.6160822249093107, "top_left_y": 0.8285592133390338, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.8413852073535699, "height": 0.012825994014536102, "width": 0.24969770253929868}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-47", "text": "ity (naamloze vennootschap)\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.8422402736212057, "lower_right_x": 0.5610640870616687, "lower_right_y": 0.8550662676357418, "height": 0.012825994014536102, "width": 0.1983071342200725}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-48", "text": "Chief Operating Officer\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.8623343309106456, "lower_right_x": 0.5272067714631197, "lower_right_y": 0.8755878580589995, "height": 0.013253527148353927, "width": 0.16444981862152352}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-49", "text": "\"COO\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8627618640444634, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.8751603249251817, "height": 0.012398460880718276, "width": 0.051995163240628764}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-50", "text": "\"CTO\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8854211201368106, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.8956819153484396, "height": 0.010260795211628926, "width": 0.052599758162031426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-51", "text": "Chief Technology Officer\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.8854211201368106, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.8982471141513467, "height": 0.012825994014536102, "width": 0.17956469165659011}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-52", "text": "Curetis AG and for time periods after incorporation of the Company on 8\nOctober 2015, to Curetis AG and the Company\n", "page_number": 230, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.8986746472851646, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.9324497648567764, "height": 0.03377511757161189, "width": 0.5012091898428053}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 53, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-53", "text": "\"Curetis\"\n", "page_number": 230, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.9059427105600684, "lower_right_x": 0.1837968561064087, "lower_right_y": 0.9166310389055152, "height": 0.010688328345446862, "width": 0.06408706166868197}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 54, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-230-54", "text": "227\n", "page_number": 230, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-0", "text": "Germany, Austria and Switzerland\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.09191962377084224, "lower_right_x": 0.599758162031439, "lower_right_y": 0.10560068405301411, "height": 0.013681060282171864, "width": 0.2376058041112455}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-1", "text": "\"DACH\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09191962377084224, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.10260795211628901, "height": 0.010688328345446765, "width": 0.06711003627569527}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-2", "text": "the notarial deed of conversion and amendment of the articles of associa-\ntion of the Company, which deed will be executed immediately after\ndetermination of the Offer Price\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8645707376058042, "lower_right_y": 0.15049166310389056, "height": 0.03805044890979052, "width": 0.5024183796856108}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-3", "text": "\"Deed of Amendment\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.11244121419410004, "lower_right_x": 0.2799274486094317, "lower_right_y": 0.12312954253954682, "height": 0.01068832834544678, "width": 0.16384522370012095}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-4", "text": "\"Degroof Petercam\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.16032492518170158, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.1444981862152358}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-5", "text": "Bank Degroof Petercam nv/sa\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.16032492518170158, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.2085852478839178}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-6", "text": "\"DGHM\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18127404873877725, "lower_right_x": 0.18802902055622733, "lower_right_y": 0.19153484395040615, "height": 0.010260795211628898, "width": 0.0701330108827086}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-7", "text": "Deutsche Gesellschaft f\u00fcr Hygiene und Mikrobiologie\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.18127404873877725, "lower_right_x": 0.7297460701330108, "lower_right_y": 0.19495510902094912, "height": 0.013681060282171864, "width": 0.3675937122128174}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-8", "text": "lawful currency of the United States, like US$ or US dollars\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.2013681060282172, "lower_right_x": 0.7690447400241838, "lower_right_y": 0.21547669944420692, "height": 0.014108593415989718, "width": 0.4068923821039903}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-9", "text": "\"dollars\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.20179563916203505, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.21248396750748183, "height": 0.01068832834544678, "width": 0.0652962515114873}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-10", "text": "the proposal that the EU Commission adopted on 14 February 2013 for a\nCouncil Directive on a common financial transaction tax\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.221889696451475, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.248396750748183, "height": 0.026507054296707994, "width": 0.5012091898428053}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-11", "text": "\"Draft Directive\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.22274476271911073, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.23471569046601112, "height": 0.011970927746900395, "width": 0.12575574365175335}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-12", "text": "Diagnosis Related Group\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.25609234715690465, "lower_right_x": 0.5362756952841596, "lower_right_y": 0.2702009405728944, "height": 0.014108593415989745, "width": 0.17412333736396618}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-13", "text": "\"DRG\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2573749465583583, "lower_right_x": 0.16807738814993953, "lower_right_y": 0.2697734074390765, "height": 0.01239846088071822, "width": 0.05078597339782344}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-14", "text": "the Dutch corporate governance code issued on 9 December 2003 and as\namended as of 1 January 2009\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.30440359127832406, "height": 0.02778965369816161, "width": 0.5012091898428053}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-15", "text": "\"Dutch Corporate Governance\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2778965369816161, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.2911500641299701, "height": 0.013253527148353983, "width": 0.23095525997581623}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-16", "text": "Code\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.29157759726378796, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.3039760581445062, "height": 0.01239846088071822, "width": 0.04836759371221282}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-17", "text": "the Dutch Civil Code (Burgerlijk Wetboek)\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.3142368533561351, "lower_right_x": 0.652962515114873, "lower_right_y": 0.3266353142368534, "height": 0.012398460880718276, "width": 0.29081015719467956}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-18", "text": "\"Dutch Civil Code\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3142368533561351, "lower_right_x": 0.2551390568319226, "lower_right_y": 0.32492518170158186, "height": 0.010688328345446751, "width": 0.13845223700120918}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-19", "text": "\"Dutch Code of\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3347584437793929, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.34544677212483965, "height": 0.010688328345446751, "width": 0.12998790810157196}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-20", "text": "Civil\n", "page_number": 231, "bounding_box": {"top_left_x": 0.250906892382104, "top_left_y": 0.3347584437793929, "lower_right_x": 0.29020556227327693, "lower_right_y": 0.34544677212483965, "height": 0.010688328345446751, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-21", "text": "Proce-\n", "page_number": 231, "bounding_box": {"top_left_x": 0.2992744860943168, "top_left_y": 0.3347584437793929, "lower_right_x": 0.34522370012091896, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.04594921402660218}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-22", "text": "the\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.3347584437793929, "lower_right_x": 0.38694074969770254, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.024788391777509078}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-23", "text": "Dutch\n", "page_number": 231, "bounding_box": {"top_left_x": 0.39600967351874244, "top_left_y": 0.3347584437793929, "lower_right_x": 0.44014510278113667, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.04413542926239422}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-24", "text": "Code\n", "page_number": 231, "bounding_box": {"top_left_x": 0.4540507859733978, "top_left_y": 0.3347584437793929, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.34544677212483965, "height": 0.010688328345446751, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-25", "text": "of\n", "page_number": 231, "bounding_box": {"top_left_x": 0.5042321644498187, "top_left_y": 0.3347584437793929, "lower_right_x": 0.5223700120918985, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.01813784764207982}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-26", "text": "Civil\n", "page_number": 231, "bounding_box": {"top_left_x": 0.5362756952841596, "top_left_y": 0.3347584437793929, "lower_right_x": 0.5707376058041113, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.03446191051995162}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-27", "text": "Procedure\n", "page_number": 231, "bounding_box": {"top_left_x": 0.585247883917775, "top_left_y": 0.3347584437793929, "lower_right_x": 0.652962515114873, "lower_right_y": 0.3450192389910218, "height": 0.010260795211628926, "width": 0.06771463119709797}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-28", "text": "(Wetboek\n", "page_number": 231, "bounding_box": {"top_left_x": 0.6668681983071342, "top_left_y": 0.3347584437793929, "lower_right_x": 0.7345828295042321, "lower_right_y": 0.34544677212483965, "height": 0.010688328345446751, "width": 0.06771463119709797}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-29", "text": "Burgerlijke\n", "page_number": 231, "bounding_box": {"top_left_x": 0.7835550181378477, "top_left_y": 0.3347584437793929, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.347584437793929, "height": 0.012825994014536102, "width": 0.08162031438935913}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-30", "text": "van\n", "page_number": 231, "bounding_box": {"top_left_x": 0.7442563482466747, "top_left_y": 0.3360410431808465, "lower_right_x": 0.7732769044740024, "lower_right_y": 0.3450192389910218, "height": 0.008978195810175338, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-31", "text": "dure\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34843950406156476, "lower_right_x": 0.15719467956469166, "lower_right_y": 0.3587002992731937, "height": 0.010260795211628926, "width": 0.04171704957678356}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-32", "text": "Rechtsvordering)\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.34843950406156476, "lower_right_x": 0.4830713422007255, "lower_right_y": 0.3595553655408294, "height": 0.011115861479264633, "width": 0.12091898428053205}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-33", "text": "\"Dutch\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.36896109448482256, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.37964942283026937, "height": 0.010688328345446807, "width": 0.048972188633615465}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-34", "text": "Financial\n", "page_number": 231, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.36896109448482256, "lower_right_x": 0.250906892382104, "lower_right_y": 0.37964942283026937, "height": 0.010688328345446807, "width": 0.07255139056831925}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-35", "text": "Supervision\n", "page_number": 231, "bounding_box": {"top_left_x": 0.26118500604594924, "top_left_y": 0.36896109448482256, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.3817870884993587, "height": 0.012825994014536157, "width": 0.08706166868198306}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-36", "text": "the Dutch Financial Supervision Act (Wet op het financieel toezicht)\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.36896109448482256, "lower_right_x": 0.8270858524788391, "lower_right_y": 0.3822146216331766, "height": 0.013253527148354038, "width": 0.4649334945586457}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-37", "text": "Act\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3826421547669944, "lower_right_x": 0.14933494558645707, "lower_right_y": 0.39333048311244123, "height": 0.010688328345446807, "width": 0.03385731559854897}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-38", "text": "\"Dutch\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4031637451902522, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.413852073535699, "height": 0.010688328345446807, "width": 0.048972188633615465}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-39", "text": "Financial\n", "page_number": 231, "bounding_box": {"top_left_x": 0.17835550181378476, "top_left_y": 0.4031637451902522, "lower_right_x": 0.250906892382104, "lower_right_y": 0.413852073535699, "height": 0.010688328345446807, "width": 0.07255139056831925}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-40", "text": "Supervision\n", "page_number": 231, "bounding_box": {"top_left_x": 0.26118500604594924, "top_left_y": 0.4031637451902522, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.4151346729371526, "height": 0.011970927746900395, "width": 0.08706166868198306}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-41", "text": "the Dutch Financial Supervision Act Decree on Market Abuse (Besluit\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4031637451902522, "lower_right_x": 0.8645707376058042, "lower_right_y": 0.41641727233860626, "height": 0.013253527148354038, "width": 0.5024183796856108}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-42", "text": "\"Dutch Financial Supervisio\nAct Decree on Market Abuse\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4155622060709705, "lower_right_x": 0.33192261185006044, "lower_right_y": 0.4275331338178709, "height": 0.011970927746900395, "width": 0.21644498186215233}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-43", "text": "Marktmisbruik Wft)\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.41684480547242414, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.4300983326207781, "height": 0.013253527148353983, "width": 0.13603385731559858}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-44", "text": "\"Dutch Securities Giro Trans-   the Dutch Securities Giro Transfers Act (Wet giraal effectenverkeer)\nfers Act\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.430525865754596, "lower_right_x": 0.8270858524788391, "lower_right_y": 0.46173578452330055, "height": 0.031209918768704548, "width": 0.711608222490931}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-45", "text": "\"ECCMID\"\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4715690466011116, "lower_right_x": 0.20737605804111245, "lower_right_y": 0.48225737494655835, "height": 0.010688328345446751, "width": 0.09129383313180169}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-46", "text": "European Congress of Clinical Microbiology and Infectious Diseases\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4715690466011116, "lower_right_x": 0.8319226118500604, "lower_right_y": 0.48567764001710134, "height": 0.014108593415989745, "width": 0.469770253929867}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-47", "text": "\"EEA\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4920906370243694, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.5027789653698161, "height": 0.010688328345446751, "width": 0.05320435308343409}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-48", "text": "European Economic Area\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4920906370243694, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.5057716973065413, "height": 0.013681060282171864, "width": 0.17956469165659011}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-49", "text": "\"EMS\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5126122274476272, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.5228730226592561, "height": 0.010260795211628815, "width": 0.05320435308343409}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-50", "text": "Electronic Manufacturing Services\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5126122274476272, "lower_right_x": 0.599758162031439, "lower_right_y": 0.5267208208636169, "height": 0.01410859341598969, "width": 0.2376058041112455}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-51", "text": "the enterprise chamber of the Amsterdam court of appeal (Onderneming-\nskamer van het Gerechtshof te Amsterdam)\n", "page_number": 231, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.533133817870885, "lower_right_x": 0.8609431680773881, "lower_right_y": 0.5609234715690466, "height": 0.027789653698161665, "width": 0.4987908101571947}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-52", "text": "\"Enterprise Chamber\"\n", "page_number": 231, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.533133817870885, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.5472424112868748, "height": 0.0141085934159898, "width": 0.16444981862152358}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 53, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-53", "text": "\"EU\"                            European Union\n\"euro\"                          lawful currency of the European Union, like \u20ac\n\"Euroclear Nederland\"           Nederlands Centraal Instituut voor Giraal Effectenverkeer B.V\n\"Euronext Amsterdam\"            Euronext Amsterdam N.V.\n\"Euronext Brussels\"             Euronext Brussels NV/SA\n\"Euronext\"                      Euronext Amsterdam and Euronext Brussels\n\"FDA\"                           US Food and Drug Administration\n\"Financial Promotion Order\"     the Financial Services and Markets Act 2000 (Financial Promotion) Or-\n                                der 2005, as amended\n\"Financial Reporting Supervi-   the Dutch Financial Reporting Supervision Act (Wet toezicht financi\u00eble\nsion Reporting Act\"             verslaggeving)\n\"Financial Transaction Tax\"     the common financial transaction tax as proposed by the Draft Directive\n\"First Trading Date\"            the date on which trading on an \"as-if-and-when-issued\" basis in the\n                                Shares on Euronext in Amsterdam and Euronext in Brussels commences,\n                                which is expected to be 11 November 2015\n\"FRSA\"                          Dutch Financial Reporting Supervision Act (Wet toezicht financi\u00eble\n                                verslaggeving)\n\"FSMA 2000\"                     the Financial Services and Markets Act 2000\n\"FSMA\"                          the Belgian Financial Services and Markets Authority (Autorit\u00e9 des ser-\n", "page_number": 231, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5673364685763147, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.9200513039760582, "height": 0.35271483539974346, "width": 0.7503022974607013}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 54, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-231-54", "text": "228\n", "page_number": 231, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-0", "text": "vices et march\u00e9s financiers)\nfull time equivalent\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5544135429262395, "lower_right_y": 0.11928174433518597, "height": 0.03420265070542966, "width": 0.192261185006046}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-1", "text": "\"FTE\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.10560068405301411, "lower_right_x": 0.16324062877871826, "lower_right_y": 0.11628901239846089, "height": 0.01068832834544678, "width": 0.04715840386940749}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-2", "text": "any general meeting (algemene vergadering), being the corporate body\nor, where the context so requires, the physical meeting of Shareholders\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.15391192817443353, "height": 0.02778965369816161, "width": 0.503627569528416}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-3", "text": "\"General Meeting\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12612227447627192, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.1354292623941959}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-4", "text": "Federal Republic of Germany (Bundesrepublik Deutschland)\nChina, Taiwan and Hong Kong\nInterscience Conference on Antimicrobial Agents and Chemotherapy\nICF BANK AG\nInternational financial reporting standards as adopted by the European\nUnion.\ninvestigational device exemption\nthe unaudited interim condensed financial statements of Curetis AG as of\n30 June 2015 and for the six months ended 30 June 2015 and 2014 pre-\npared in accordance with IAS 34\nIndependent Payment Advisory Board\nInternational Organisation for Standardisation\nspecifies requirements for a quality management system where an organi-\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.16032492518170158, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.40145361265498075, "height": 0.24112868747327917, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-5", "text": "\"Germany\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.16032492518170158, "lower_right_x": 0.2007255139056832, "lower_right_y": 0.17400598546387344, "height": 0.013681060282171864, "width": 0.08464328899637243}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-6", "text": "\"Greater China\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18127404873877725, "lower_right_x": 0.23639661426844014, "lower_right_y": 0.19153484395040615, "height": 0.010260795211628898, "width": 0.1185006045949214}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-7", "text": "\"ICAAC\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.20179563916203505, "lower_right_x": 0.18621523579201935, "lower_right_y": 0.21205643437366395, "height": 0.010260795211628898, "width": 0.06831922611850061}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-8", "text": "\"ICF\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.22274476271911073, "lower_right_x": 0.16324062877871826, "lower_right_y": 0.23514322359982898, "height": 0.012398460880718248, "width": 0.04715840386940749}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-9", "text": "\"IFRS\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2436938862761864, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.25609234715690465, "height": 0.012398460880718248, "width": 0.051995163240628764}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-10", "text": "\"IDE\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.2778965369816161, "lower_right_x": 0.1626360338573156, "lower_right_y": 0.28986746472851643, "height": 0.01197092774690034, "width": 0.045344619105199505}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-11", "text": "\"Interim Financial Statements\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.30055579307396324, "lower_right_x": 0.343409915356711, "lower_right_y": 0.31124412141941, "height": 0.010688328345446751, "width": 0.22672309552599756}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-12", "text": "\"IPAB\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.34843950406156476, "lower_right_x": 0.17110036275695284, "lower_right_y": 0.3587002992731937, "height": 0.010260795211628926, "width": 0.054413542926239414}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-13", "text": "\"ISO\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.36896109448482256, "lower_right_x": 0.1596130592503023, "lower_right_y": 0.37964942283026937, "height": 0.010688328345446807, "width": 0.039903264812575584}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-14", "text": "\"ISO 13485\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.38948268490808036, "lower_right_x": 0.20737605804111245, "lower_right_y": 0.40017101325352716, "height": 0.010688328345446807, "width": 0.09008464328899636}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-15", "text": "sation needs to demonstrate its ability to provide medical devices and\nrelated services\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.40188114578879863, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.4275331338178709, "height": 0.02565198802907226, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-16", "text": "\"ITI\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.43736639589568194, "lower_right_x": 0.154776299879081, "lower_right_y": 0.4480547242411287, "height": 0.010688328345446751, "width": 0.03748488512696492}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-17", "text": "implant and tissue infection\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.43736639589568194, "lower_right_x": 0.5495767835550182, "lower_right_y": 0.4510474561778538, "height": 0.013681060282171864, "width": 0.1874244256348247}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-18", "text": "\"IVD\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.45788798631893973, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.4685763146643865, "height": 0.010688328345446751, "width": 0.04836759371221282}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-19", "text": "In Vitro Diagnostics\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.45788798631893973, "lower_right_x": 0.5030229746070133, "lower_right_y": 0.4719965797349295, "height": 0.014108593415989745, "width": 0.14087061668681983}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-20", "text": "\"IVD Directive\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.47840957674219753, "lower_right_x": 0.2309552599758162, "lower_right_y": 0.4890979050876443, "height": 0.010688328345446751, "width": 0.11487303506650544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-21", "text": "European Directive 98/79/EC on in vitro diagnostic medical devices\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.47840957674219753, "lower_right_x": 0.8216444981862152, "lower_right_y": 0.4925181701581873, "height": 0.014108593415989745, "width": 0.45949214026602175}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-22", "text": "\"Joint Bookrunners\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4989311671654553, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.5121846943138093, "height": 0.013253527148353983, "width": 0.1493349455864571}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-23", "text": "RBC and Degroof Petercam\n", "page_number": 232, "bounding_box": {"top_left_x": 0.3639661426844015, "top_left_y": 0.4989311671654553, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.5130397605814451, "height": 0.014108593415989745, "width": 0.1922611850060459}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-24", "text": "\"Joint Lead Manager\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5194527575887131, "lower_right_x": 0.28053204353083433, "lower_right_y": 0.5335613510047028, "height": 0.01410859341598969, "width": 0.16444981862152358}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-25", "text": "ICF\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5194527575887131, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.5301410859341599, "height": 0.010688328345446751, "width": 0.029625151148730378}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-26", "text": "\"KOLs\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5404018811457888, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.5519452757588713, "height": 0.011543394613082514, "width": 0.060459492140266025}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-27", "text": "key opinion leaders\n", "page_number": 232, "bounding_box": {"top_left_x": 0.3639661426844015, "top_left_y": 0.5404018811457888, "lower_right_x": 0.49818621523579204, "lower_right_y": 0.5540829414279607, "height": 0.013681060282171864, "width": 0.13422007255139057}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-28", "text": "\"LDTs\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5613510047028645, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.5733219324497648, "height": 0.01197092774690034, "width": 0.05804111245465539}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-29", "text": "laboratory developed tests\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5613510047028645, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.5746045318512185, "height": 0.013253527148354038, "width": 0.17956469165659011}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-30", "text": "\"Listing and Paying Agent\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5818725951261223, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.5951261222744763, "height": 0.013253527148353927, "width": 0.19770253929866988}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-31", "text": "ABN AMRO\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5818725951261223, "lower_right_x": 0.4546553808948005, "lower_right_y": 0.5938435228730227, "height": 0.01197092774690034, "width": 0.09250302297460705}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-32", "text": "the lock-up agreements entered into on 26 October 2015, between all\nexisting shareholders, all former and current employees of Curetis hold-\ning Shares and the Managing Directors, as the case may be, and the Sole\nGlobal Coordinator (acting on behalf of the Underwriters)\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6015391192817443, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.6566908935442497, "height": 0.05515177426250539, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-33", "text": "\"Lock-up Agreements\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6028217186831979, "lower_right_x": 0.28536880290205563, "lower_right_y": 0.6156477126977341, "height": 0.012825994014536213, "width": 0.16807738814993956}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-34", "text": "\"LRT\"\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6643864899529713, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.6763574176998718, "height": 0.01197092774690045, "width": 0.051995163240628764}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-35", "text": "lower respiratory tract\n", "page_number": 232, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.6665241556220607, "lower_right_x": 0.5145102781136639, "lower_right_y": 0.6772124839675074, "height": 0.010688328345446751, "width": 0.15175332527206775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-36", "text": "\"Management Board\"         the Company's management board (bestuur)\n\"Management Board Rules\"   rules regarding the Management Board's functioning and internal organi-\n                           sation\n\"Managing Director(s)\"     member of the Management Board\n\"MDx\"                      molecular diagnostics\n\"MAB\"                      the Company's medical advisory board\n\"NSE\"                      not substantially equivalent\n\"OEM\"                      Original Equipment Manufacturer\n\"\u00d6GHMP\"                    \u00d6sterreichische Gesellschaft f\u00fcr Hygiene, Mikrobiologie und Pr\u00e4ventiv-\n                           medizin\n\"Offer Period\"             the period during which the Offering will take place, commencing on\n                           09:00 CET on 28 October 2015 and ending on 10 November 2015 at\n                           16:00 CET for prospective investors, subject to acceleration or extension\n", "page_number": 232, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6870457460453185, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.9200513039760582, "height": 0.23300555793073963, "width": 0.7496977025392987}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-232-37", "text": "229\n", "page_number": 232, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8506650544135429, "lower_right_y": 0.9568191534843951, "height": 0.0098332620778111, "width": 0.024183796856106388}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-0", "text": "of the timetable for the Offering\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.08507909362975631, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.09918768704574604, "height": 0.014108593415989731, "width": 0.2182587666263604}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-1", "text": "\"Offer Price \"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.10560068405301411, "lower_right_x": 0.2140266021765417, "lower_right_y": 0.11628901239846089, "height": 0.01068832834544678, "width": 0.09794437726723094}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-2", "text": "\"", "page_number": 233, "bounding_box": {"top_left_x": 0.2140266021765417, "top_left_y": 0.10560068405301411, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.11201368106028217, "height": 0.006412997007268065, "width": 0.003627569528415975}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-3", "text": "the offer price per Offer Share\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.10560068405301411, "lower_right_x": 0.5695284159613059, "lower_right_y": 0.11928174433518597, "height": 0.013681060282171864, "width": 0.20737605804111242}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-4", "text": "\"Offer Price Range\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.12612227447627192, "lower_right_x": 0.26481257557436516, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.1487303506650544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-5", "text": "the expected price range of \u20ac9.50 to \u20ac12 (inclusive) per Offer Share\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.12612227447627192, "lower_right_x": 0.8222490931076178, "lower_right_y": 0.14023086789226166, "height": 0.014108593415989745, "width": 0.4600967351874244}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-6", "text": "the Shares to be issued by the Company in the Offering, which includes\nthe Additional Shares, unless the context indicates otherwise\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.1466438648995297, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.17400598546387344, "height": 0.027362120564343728, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-7", "text": "\"Offer Shares\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1466438648995297, "lower_right_x": 0.22611850060459493, "lower_right_y": 0.1569046601111586, "height": 0.010260795211628898, "width": 0.11003627569528417}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-8", "text": "the public offering to retail and institutional investors in Germany and a\nprivate placement to certain institutional and other eligible investors in\nvarious other jurisdictions\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.18084651560495937, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.2214621633176571, "height": 0.04061564771269774, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-9", "text": "\"Offering\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18127404873877725, "lower_right_x": 0.19226118500604594, "lower_right_y": 0.19495510902094912, "height": 0.013681060282171864, "width": 0.0743651753325272}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-10", "text": "the option to be granted to the Sole Global Coordinator (on behalf of the\nUnderwriters), exercisable within 30 calendar days after the Settlement\nDate, pursuant to which the Sole Global Coordinator, on behalf of the\nUnderwriters, may require the Company to issue the Additional Shares at\nthe Offer Price\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.22873022659256093, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.294570329200513, "height": 0.06584010260795209, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-11", "text": "\"Over-allotment Option\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.22873022659256093, "lower_right_x": 0.2968561064087062, "lower_right_y": 0.2424112868747328, "height": 0.013681060282171864, "width": 0.17896009673518745}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-12", "text": "the Member States of the European Union (Austria, Belgium, Estonia,\nFrance, Germany, Greece, Italy, Portugal, Spain, Slovakia and Slovenia)\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.3039760581445062, "lower_right_x": 0.8609431680773881, "lower_right_y": 0.3394613082513895, "height": 0.035485250106883304, "width": 0.498186215235792}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-13", "text": "\"Participating Member States\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3039760581445062, "lower_right_x": 0.33796856106408707, "lower_right_y": 0.3180846515604959, "height": 0.014108593415989745, "width": 0.22188633615477632}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-14", "text": "that intend to implement the Financial Transaction Tax\nentitling the PSOP Beneficiaries to a payment by Curetis AG in the event\nof a trade sale, merger, stock exchange listing or comparable transaction\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.33988884138520736, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.37964942283026937, "height": 0.039760581445062004, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-15", "text": "\"Payment Claims\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.35271483539974346, "lower_right_x": 0.24969770253929868, "lower_right_y": 0.3659683625480975, "height": 0.013253527148354038, "width": 0.13361547762998793}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-16", "text": "\"PCT\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.387345019238991, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.3997434801197093, "height": 0.012398460880718276, "width": 0.04715840386940749}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-17", "text": "Patent Cooperation Treaty\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.38820008550662677, "lower_right_x": 0.5411124546553809, "lower_right_y": 0.40017101325352716, "height": 0.011970927746900395, "width": 0.17896009673518748}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-18", "text": "\"PFIC\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.4078666096622488, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.4202650705429671, "height": 0.012398460880718276, "width": 0.056831922611850064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-19", "text": "passive foreign investment company\n", "page_number": 233, "bounding_box": {"top_left_x": 0.3651753325272068, "top_left_y": 0.4078666096622488, "lower_right_x": 0.6136638452237001, "lower_right_y": 0.42069260367678496, "height": 0.012825994014536157, "width": 0.2484885126964933}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-20", "text": "pre-market approval\n", "page_number": 233, "bounding_box": {"top_left_x": 0.3651753325272068, "top_left_y": 0.430525865754596, "lower_right_x": 0.5006045949214026, "lower_right_y": 0.44249679350149634, "height": 0.01197092774690034, "width": 0.13542926239419584}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-21", "text": "\"PMA\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.430525865754596, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.4407866609662249, "height": 0.01026079521162887, "width": 0.052599758162031426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-22", "text": "\"Pricing Statement\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4510474561778538, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.4643009833262078, "height": 0.013253527148353983, "width": 0.14147521160822252}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-23", "text": "the statement setting out the Offer Price and the exact number of Offer\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4510474561778538, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.4643009833262078, "height": 0.013253527148353983, "width": 0.5012091898428053}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-24", "text": "Shares, which will be deposited with the AFM and published through a\npress release\nDirective 2003/71/EC and amendments thereto, including Directive\n2010/73/EU\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.46472851646002566, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.523300555793074, "height": 0.05857203933304833, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-25", "text": "\"Prospectus Directive\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.4989311671654553, "lower_right_x": 0.27871825876662637, "lower_right_y": 0.5121846943138093, "height": 0.013253527148353983, "width": 0.15900846432889965}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-26", "text": "\"Prospectus\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.533133817870885, "lower_right_x": 0.21039903264812576, "lower_right_y": 0.546387345019239, "height": 0.013253527148354038, "width": 0.09310761789600967}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-27", "text": "this prospectus dated 27 October 2015\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.533133817870885, "lower_right_x": 0.6257557436517533, "lower_right_y": 0.5468148781530568, "height": 0.013681060282171864, "width": 0.2636033857315599}, "blob_type": "undefined", "predictions": {}, "annotations": {"filing_date": ["27 October 2015"]}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-28", "text": "\"PSOP\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5536554082941428, "lower_right_x": 0.17412333736396615, "lower_right_y": 0.5643437366395896, "height": 0.010688328345446751, "width": 0.056831922611850064}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-29", "text": "Curetis' existing phantom stock options program\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5536554082941428, "lower_right_x": 0.6910519951632407, "lower_right_y": 0.5673364685763147, "height": 0.013681060282171864, "width": 0.3288996372430472}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-30", "text": "\"PSOP Beneficiaries\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5741769987174006, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.5848653270628473, "height": 0.010688328345446751, "width": 0.15417170495767835}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-31", "text": "PSOs awarded to officers, employees, freelancers and advisors of Curetis\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5741769987174006, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.5882855921333904, "height": 0.0141085934159898, "width": 0.5030229746070134}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-32", "text": "AG\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.5882855921333904, "lower_right_x": 0.39177750906892383, "lower_right_y": 0.5985463873450192, "height": 0.010260795211628815, "width": 0.029020556227327687}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-33", "text": "\"PwC\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6083796494228303, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.619067977768277, "height": 0.010688328345446751, "width": 0.05320435308343409}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-34", "text": "PricewaterhouseCoopers\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6083796494228303, "lower_right_x": 0.532043530834341, "lower_right_y": 0.6207781103035486, "height": 0.012398460880718276, "width": 0.16989117291414751}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-35", "text": "Aktiengesellschaft\n", "page_number": 233, "bounding_box": {"top_left_x": 0.5411124546553809, "top_left_y": 0.6083796494228303, "lower_right_x": 0.6723095525997581, "lower_right_y": 0.62248824283882, "height": 0.01410859341598969, "width": 0.13119709794437717}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-36", "text": "Wirtschaftspr\u00fcfungsgesell-\n", "page_number": 233, "bounding_box": {"top_left_x": 0.6765417170495768, "top_left_y": 0.6083796494228303, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.62248824283882, "height": 0.01410859341598969, "width": 0.18742442563482464}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-37", "text": "schaft\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6220607097050022, "lower_right_x": 0.4062877871825877, "lower_right_y": 0.6327490380504489, "height": 0.010688328345446751, "width": 0.04413542926239422}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-38", "text": "\"QEF\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6425823001282599, "lower_right_x": 0.16686819830713423, "lower_right_y": 0.6562633604104318, "height": 0.013681060282171864, "width": 0.05078597339782347}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-39", "text": "qualified electing fund\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6425823001282599, "lower_right_x": 0.5175332527206772, "lower_right_y": 0.6566908935442497, "height": 0.0141085934159898, "width": 0.15538089480048373}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-40", "text": "\"QIBs\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6635314236853356, "lower_right_x": 0.1686819830713422, "lower_right_y": 0.6772124839675074, "height": 0.013681060282171864, "width": 0.05078597339782345}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-41", "text": "qualified institutional buyers within the meaning of, and pursuant to Rule\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6635314236853356, "lower_right_x": 0.8633615477629988, "lower_right_y": 0.6772124839675074, "height": 0.013681060282171864, "width": 0.5012091898428053}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-42", "text": "144A under the US Securities Act\n", "page_number": 233, "bounding_box": {"top_left_x": 0.3633615477629988, "top_left_y": 0.6772124839675074, "lower_right_x": 0.5949214026602176, "lower_right_y": 0.6874732791791364, "height": 0.010260795211628926, "width": 0.23155985489721886}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-43", "text": "Quality System Regulation for FDA regulated products\nRBC Europe Limited\nResearch and Development\nRegulation S under the US Securities Act\neach member state of the EEA that has implemented the Prospectus Di-\nrective\nthe corporate reorganisation that will be effected immediately upon de-\ntermination of the Offer Price\nICF\nRest of the World\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6973065412569475, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.8824283882000855, "height": 0.18512184694313805, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-44", "text": "\"QSR\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.6977340743907653, "lower_right_x": 0.1674727932285369, "lower_right_y": 0.7114151346729372, "height": 0.013681060282171864, "width": 0.049576783555018156}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-45", "text": "\"RBC\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.718683197947841, "lower_right_x": 0.1674727932285369, "lower_right_y": 0.7310816588285592, "height": 0.012398460880718276, "width": 0.05139056831922613}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-46", "text": "\"R&D\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7392047883710987, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.7511757161179992, "height": 0.01197092774690045, "width": 0.05320435308343409}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-47", "text": "\"Regulation S\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.7601539119281744, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.7729799059427106, "height": 0.012825994014536213, "width": 0.11003627569528417}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-48", "text": "\"Relevant Member State\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.7828131680205216, "lower_right_x": 0.3004836759371221, "lower_right_y": 0.7935014963659683, "height": 0.010688328345446751, "width": 0.18379685610640867}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-49", "text": "\"Reorganisation\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8170158187259513, "lower_right_x": 0.2418379685610641, "lower_right_y": 0.8281316802052159, "height": 0.011115861479264577, "width": 0.12515114873035066}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-50", "text": "\"Retail Coordinator\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.8512184694313809, "lower_right_x": 0.26964933494558646, "lower_right_y": 0.8619067977768277, "height": 0.010688328345446751, "width": 0.14993954050785974}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-51", "text": "\"RoW\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.8717400598546388, "lower_right_x": 0.16928657799274485, "lower_right_y": 0.8824283882000855, "height": 0.010688328345446751, "width": 0.04957678355501813}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-52", "text": "\"Rule 144A\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.8922616502778965, "lower_right_x": 0.20737605804111245, "lower_right_y": 0.9029499786233434, "height": 0.010688328345446862, "width": 0.09008464328899636}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 53, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-53", "text": "Rule 144A under the US Securities Act\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.8922616502778965, "lower_right_x": 0.6318016928657799, "lower_right_y": 0.9029499786233434, "height": 0.010688328345446862, "width": 0.26964933494558646}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 54, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-54", "text": "\"Securities Giro Act\"\n", "page_number": 233, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.9127832407011544, "lower_right_x": 0.26904474002418377, "lower_right_y": 0.9234715690466011, "height": 0.010688328345446751, "width": 0.1517533252720677}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 55, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-55", "text": "the Dutch securities giro Act (Wet giraal effecten verkeer)\n", "page_number": 233, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.9127832407011544, "lower_right_x": 0.75453446191052, "lower_right_y": 0.9264643009833262, "height": 0.013681060282171864, "width": 0.3923821039903265}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 56, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-233-56", "text": "230\n", "page_number": 233, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9474134245404019, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.008978195810175227, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-0", "text": "\"Settlement\"\n\"Settlement Date\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.09191962377084224, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.12270200940572894, "height": 0.030782385634886694, "width": 0.1305925030229746}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-1", "text": "delivery of, the Offer Shares\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5550181378476421, "lower_right_y": 0.10560068405301411, "height": 0.013681060282171864, "width": 0.19286577992744863}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-2", "text": "the date on which Settlement occurs which is expected to be on or about\n13 November 2015, subject to acceleration or extension of the timetable\nof the Offering\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.11244121419410004, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.15391192817443353, "height": 0.04147071398033349, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-3", "text": "\"SGM\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.16032492518170158, "lower_right_x": 0.17049576783555018, "lower_right_y": 0.17058572039333048, "height": 0.010260795211628898, "width": 0.054413542926239414}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-4", "text": "Schweizer Gesellschaft f\u00fcr Mikrobiologie\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.16032492518170158, "lower_right_x": 0.6481257557436517, "lower_right_y": 0.17443351859769132, "height": 0.014108593415989745, "width": 0.2853688029020556}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-5", "text": "\"Shareholder\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.18127404873877725, "lower_right_x": 0.2218863361547763, "lower_right_y": 0.1936725096194955, "height": 0.012398460880718248, "width": 0.10399032648125756}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-6", "text": "a holder of Shares\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.18127404873877725, "lower_right_x": 0.48851269649334944, "lower_right_y": 0.19153484395040615, "height": 0.010260795211628898, "width": 0.12636033857315598}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-7", "text": "\"Shares\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.20179563916203505, "lower_right_x": 0.18319226118500603, "lower_right_y": 0.21419410004275333, "height": 0.012398460880718276, "width": 0.0652962515114873}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-8", "text": "the ordinary shares in the issued share capital of the Company, with\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.20179563916203505, "lower_right_x": 0.8518742442563483, "lower_right_y": 0.21547669944420692, "height": 0.013681060282171864, "width": 0.4897218863361548}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-9", "text": "a\n", "page_number": 234, "bounding_box": {"top_left_x": 0.8524788391777509, "top_left_y": 0.20521590423257802, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.21205643437366395, "height": 0.006840530141085932, "width": 0.011487303506650504}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-10", "text": "nominal value of \u20ac0.01 each\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.21547669944420692, "lower_right_x": 0.5562273276904474, "lower_right_y": 0.22573749465583584, "height": 0.010260795211628926, "width": 0.1940749697702539}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-11", "text": "\"Share Swap\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2364258230012826, "lower_right_x": 0.21704957678355502, "lower_right_y": 0.2496793501496366, "height": 0.01325352714835401, "width": 0.10096735187424426}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-12", "text": "The exchange of shares in Curetis AG for Shares in accordance with\n", "page_number": 234, "bounding_box": {"top_left_x": 0.3639661426844015, "top_left_y": 0.2364258230012826, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.2496793501496366, "height": 0.01325352714835401, "width": 0.49999999999999994}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-13", "text": "individual exchange ratios\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.2501068832834545, "lower_right_x": 0.5417170495767836, "lower_right_y": 0.26336041043180847, "height": 0.013253527148353983, "width": 0.17956469165659011}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-14", "text": "\"Sole Global Coordinator\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.27105600684053016, "lower_right_x": 0.3089480048367594, "lower_right_y": 0.2834544677212484, "height": 0.01239846088071822, "width": 0.1916565900846433}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-15", "text": "RBC\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.27276613937580163, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.2830269345874305, "height": 0.01026079521162887, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-16", "text": "\"Stabilisation Manager\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.29157759726378796, "lower_right_x": 0.28960096735187424, "lower_right_y": 0.30440359127832406, "height": 0.012825994014536102, "width": 0.17230955259975816}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-17", "text": "RBC\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.2932877297990594, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.30354852501068835, "height": 0.010260795211628926, "width": 0.03929866989117292}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-18", "text": "\"STRATEC\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3142368533561351, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.32492518170158186, "height": 0.010688328345446751, "width": 0.09613059250302296}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-19", "text": "STRATEC Biomedical AG\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.3142368533561351, "lower_right_x": 0.5513905683192262, "lower_right_y": 0.324497648567764, "height": 0.01026079521162887, "width": 0.1892382103990327}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-20", "text": "\"Supervisory Board\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.3347584437793929, "lower_right_x": 0.2666263603385732, "lower_right_y": 0.347584437793929, "height": 0.012825994014536102, "width": 0.14993954050785974}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-21", "text": "the Company's supervisory board (raad van commissarissen)\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.3347584437793929, "lower_right_x": 0.7744860943168077, "lower_right_y": 0.347584437793929, "height": 0.012825994014536102, "width": 0.41233373639661425}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-22", "text": "\"Supervisory Board Rules\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11970979443772672, "top_left_y": 0.3552800342026507, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.3685335613510047, "height": 0.013253527148353983, "width": 0.1940749697702539}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-23", "text": "the rules regarding the Supervisory Board's functioning and internal or-\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.3552800342026507, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.3685335613510047, "height": 0.013253527148353983, "width": 0.503627569528416}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-24", "text": "ganisation\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.36938862761864044, "lower_right_x": 0.43530834340991537, "lower_right_y": 0.3822146216331766, "height": 0.012825994014536157, "width": 0.07315598548972191}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-25", "text": "\"Supervisory Director\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.38948268490808036, "lower_right_x": 0.28355501813784767, "lower_right_y": 0.4031637451902522, "height": 0.013681060282171864, "width": 0.1662636033857316}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-26", "text": "each member of the Supervisory Board\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.38948268490808036, "lower_right_x": 0.628174123337364, "lower_right_y": 0.4031637451902522, "height": 0.013681060282171864, "width": 0.26541717049576785}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-27", "text": "lawful currency of the United States, like dollars or US dollars\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.41000427533133815, "lower_right_x": 0.786577992744861, "lower_right_y": 0.4236853356135101, "height": 0.01368106028217192, "width": 0.4244256348246675}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-28", "text": "\"US$\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.41043180846515603, "lower_right_x": 0.16142684401451027, "lower_right_y": 0.42069260367678496, "height": 0.010260795211628926, "width": 0.04413542926239418}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-29", "text": "\"US dollars\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.430525865754596, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.44121419410004276, "height": 0.010688328345446751, "width": 0.09189842805320435}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-30", "text": "lawful currency of the United States, like dollars or US$\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.430525865754596, "lower_right_x": 0.7448609431680774, "lower_right_y": 0.4446344591705857, "height": 0.01410859341598969, "width": 0.3827085852478839}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-31", "text": "\"US Exchange Act\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4510474561778538, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.46515604959384355, "height": 0.014108593415989745, "width": 0.1396614268440145}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-32", "text": "the US Securities Exchange Act of 1934, as amended\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4510474561778538, "lower_right_x": 0.7255139056831923, "lower_right_y": 0.46515604959384355, "height": 0.014108593415989745, "width": 0.36336154776299884}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-33", "text": "\"US PTO\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4715690466011116, "lower_right_x": 0.1928657799274486, "lower_right_y": 0.48225737494655835, "height": 0.010688328345446751, "width": 0.07678355501813784}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-34", "text": "the US Patent and Trademark Office\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4715690466011116, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.48225737494655835, "height": 0.010688328345446751, "width": 0.2472793228536881}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-35", "text": "\"US Securities Act\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.4925181701581873, "lower_right_x": 0.25574365175332525, "lower_right_y": 0.5049166310389055, "height": 0.01239846088071822, "width": 0.13784764207980651}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-36", "text": "the US Securities Act of 1933, as amended\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4925181701581873, "lower_right_x": 0.652962515114873, "lower_right_y": 0.5061992304403591, "height": 0.013681060282171809, "width": 0.29081015719467956}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-37", "text": "the underwriting agreement expected to be entered into on or about 10\nNovember 2015 between the Company and the Underwriters\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5126122274476272, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.5404018811457888, "height": 0.027789653698161554, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-38", "text": "\"Underwriting Agreement\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11789600967351874, "top_left_y": 0.5130397605814451, "lower_right_x": 0.3137847642079806, "lower_right_y": 0.5262932877297991, "height": 0.013253527148354038, "width": 0.1958887545344619}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-39", "text": "each of the Joint Bookrunners and Joint Lead Manager\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5468148781530568, "lower_right_x": 0.7345828295042321, "lower_right_y": 0.5609234715690466, "height": 0.0141085934159898, "width": 0.3724304715840387}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-40", "text": "\"Underwriters\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5476699444206926, "lower_right_x": 0.23155985489721886, "lower_right_y": 0.5600684053014109, "height": 0.012398460880718276, "width": 0.1154776299879081}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-41", "text": "\"United Kingdom\" or \"UK\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5681915348439504, "lower_right_x": 0.3143893591293833, "lower_right_y": 0.5814450619923044, "height": 0.013253527148354038, "width": 0.19830713422007257}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-42", "text": "the United Kingdom of Great Britain and Northern Ireland\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.5681915348439504, "lower_right_x": 0.7593712212817413, "lower_right_y": 0.5814450619923044, "height": 0.013253527148354038, "width": 0.39661426844014513}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-43", "text": "the United States of America, its territories and possessions, any state of\nthe United States of America and the District of Columbia\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5878580589995724, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.6156477126977341, "height": 0.027789653698161665, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-44", "text": "\"United States\" or \"US\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.589140658401026, "lower_right_x": 0.2841596130592503, "lower_right_y": 0.6015391192817443, "height": 0.012398460880718276, "width": 0.16686819830713423}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-45", "text": "\"VAP\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.6254809747755451, "lower_right_x": 0.16505441354292624, "lower_right_y": 0.6361693031209918, "height": 0.010688328345446751, "width": 0.04836759371221282}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-46", "text": "Ventilator-Associated Pneumonia\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6254809747755451, "lower_right_x": 0.594316807738815, "lower_right_y": 0.635741769987174, "height": 0.010260795211628926, "width": 0.23216444981862155}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-47", "text": "securities (including any new Shares issuable upon exercise of any op-\ntions and/or warrants) convertible into or exercisable or exchangeable for\nShares or other shares of the Company or shares of Curetis N.V.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.646002565198803, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.685763146643865, "height": 0.039760581445062004, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-48", "text": "\"Warrants\"\n", "page_number": 234, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.646002565198803, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.6566908935442497, "height": 0.010688328345446751, "width": 0.08645707376058041}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-49", "text": "The following explanations are not intended to be exhaustive definitions, but to assist understanding of certain\nterms used in this Prospectus.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7144078666096623, "lower_right_x": 0.879081015719468, "lower_right_y": 0.7409149209063702, "height": 0.026507054296707966, "width": 0.7636033857315598}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-50", "text": "In the field of diagnostics, an assay is a process or method aimed at de-\ntermining the presence or amount (quantitative assay) of a certain sub-\nstance in a sample.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.7759726378794357, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.8170158187259513, "height": 0.04104318084651559, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-51", "text": "Assay\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7764001710132535, "lower_right_x": 0.16384522370012092, "lower_right_y": 0.7900812312954254, "height": 0.013681060282171864, "width": 0.04836759371221282}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-52", "text": "A Biomarker is any molecular characteristic, feature or parameter that\ncan be objectively measured through an assay and evaluated as an indica-\ntor of: (i) normal biologic processes; (ii) abnormal biologic processes;\n(iii) pathogenic processes; or (iv) pharmacologic responses to a therapeu-\ntic intervention or other action/intervention.\n", "page_number": 234, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.8306968790081232, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.8961094484822574, "height": 0.06541256947413421, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 53, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-53", "text": "Biomarker (or Marker)\n", "page_number": 234, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8306968790081232, "lower_right_x": 0.2871825876662636, "lower_right_y": 0.844377939290295, "height": 0.013681060282171864, "width": 0.17170495767835547}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 54, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-234-54", "text": "231\n", "page_number": 234, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.9478409576742197, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.008550662676357401, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-0", "text": "CDx is a bio-analytical method designed to assess: (i) whether or not a\npatient will respond favourably to a specific medical treatment; (ii) what\nthe optimal dose is for a patient; and (iii) whether the patient can expect\ncertain side effects from a medical treatment. Any prescription of a drug\nwith a CDx is based on the outcome of the CDx. CDx tests are also used\nin the drug development process\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.09191962377084224, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.17443351859769132, "height": 0.08251389482684908, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-1", "text": "Companion Diagnostics (CDx)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.09191962377084224, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.22128174123337363}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-2", "text": "The CE-IVD-mark is a mandatory conformance mark on many products\nplaced on the market in the European Union. With the CE-IVD-marking\non a product, the manufacturer ensures that the product is in conformity\nwith the essential requirements of the applicable European Union direc-\ntives. The letters \"CE\" stand for \"Conformit\u00e9 Europ\u00e9enne\" (\"European\nConformity\").\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.1876870457460453, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.2702009405728944, "height": 0.0825138948268491, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-3", "text": "CE-IVD-mark\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.1881145788798632, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.20051303976058144, "height": 0.012398460880718248, "width": 0.11124546553808949}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-4", "text": "DNA is a nucleic acid molecule that contains the genetic instructions\nused in the development and functioning of living organisms.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.27661393758016245, "lower_right_x": 0.8627569528415961, "lower_right_y": 0.30440359127832406, "height": 0.02778965369816161, "width": 0.5006045949214026}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-5", "text": "Deoxyribonucleic acid (DNA)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.27661393758016245, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.2907225309961522, "height": 0.014108593415989745, "width": 0.21342200725513905}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-6", "text": "The FDA is a federal agency of the United States Department of Health\nand Human Services responsible for protecting and promoting public\nhealth through the regulation and supervision of, among other things,\nmedical devices.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.31765711842667804, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.3710987601539119, "height": 0.05344164172723387, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-7", "text": "US Food and Drug Administra-\ntion (FDA)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.31765711842667804, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.34544677212483965, "height": 0.02778965369816161, "width": 0.2327690447400242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-8", "text": "Investigational Device Exemp-\ntion (IDE)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3792218896964515, "lower_right_x": 0.34582829504232165, "lower_right_y": 0.4070115433946131, "height": 0.02778965369816161, "width": 0.23035066505441354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-9", "text": "IDE is an FDA exemption that allows an investigational device to be used\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.3800769559640872, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.3937580162462591, "height": 0.01368106028217192, "width": 0.5018137847642079}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-10", "text": "a clinical study in order to collect the safety and effectiveness data\n", "page_number": 235, "bounding_box": {"top_left_x": 0.3966142684401451, "top_left_y": 0.3937580162462591, "lower_right_x": 0.8639661426844014, "lower_right_y": 0.4070115433946131, "height": 0.013253527148353983, "width": 0.46735187424425634}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-11", "text": "in\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.39418554938007694, "lower_right_x": 0.3814993954050786, "lower_right_y": 0.40572894399315945, "height": 0.011543394613082514, "width": 0.019347037484885143}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-12", "text": "a\n", "page_number": 235, "bounding_box": {"top_left_x": 0.38210399032648124, "top_left_y": 0.3963232150491663, "lower_right_x": 0.39117291414752114, "lower_right_y": 0.404018811457888, "height": 0.007695596408721694, "width": 0.00906892382103991}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-13", "text": "required to support\n", "page_number": 235, "bounding_box": {"top_left_x": 0.3633615477629988, "top_left_y": 0.407439076528431, "lower_right_x": 0.4969770253929867, "lower_right_y": 0.42069260367678496, "height": 0.013253527148353983, "width": 0.13361547762998793}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-14", "text": "a PMA application or premarket notification to the\n", "page_number": 235, "bounding_box": {"top_left_x": 0.5102781136638452, "top_left_y": 0.407439076528431, "lower_right_x": 0.8645707376058042, "lower_right_y": 0.42069260367678496, "height": 0.013253527148353983, "width": 0.35429262394195893}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-15", "text": "ta\n", "page_number": 235, "bounding_box": {"top_left_x": 0.5024183796856106, "top_left_y": 0.41000427533133815, "lower_right_x": 0.5096735187424426, "lower_right_y": 0.41769987174005985, "height": 0.007695596408721694, "width": 0.00725513905683195}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-16", "text": "FDA.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.3645707376058041, "top_left_y": 0.42154766994442067, "lower_right_x": 0.40084643288996374, "lower_right_y": 0.4330910645575032, "height": 0.011543394613082514, "width": 0.03627569528415964}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-17", "text": "IVD is a diagnostic test outside of a living body in contrast to \"in vivo\",\nin which tests are conducted in a living body (for example an X-ray or\nCT-scan).\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4407866609662249, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.48225737494655835, "height": 0.04147071398033347, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-18", "text": "In vitro diagnostics or In vitro\ndiagnosis (IVD)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4407866609662249, "lower_right_x": 0.3482466747279323, "lower_right_y": 0.4685763146643865, "height": 0.02778965369816161, "width": 0.2327690447400242}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-19", "text": "LIS are a class of software that process, store and manage data from all\nstages of medical laboratory processes and tests. LIS systems often inter-\nface with other information systems such as HIS.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.4989311671654553, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.5369816160752459, "height": 0.038050448909790535, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-20", "text": "Laboratory\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4989311671654553, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.5096194955109021, "height": 0.010688328345446807, "width": 0.08766626360338574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-21", "text": "information\n", "page_number": 235, "bounding_box": {"top_left_x": 0.21704957678355502, "top_left_y": 0.4989311671654553, "lower_right_x": 0.3047158403869408, "lower_right_y": 0.5096194955109021, "height": 0.010688328345446807, "width": 0.08766626360338575}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-22", "text": "sys-\n", "page_number": 235, "bounding_box": {"top_left_x": 0.3192261185006046, "top_left_y": 0.4997862334330911, "lower_right_x": 0.34522370012091896, "lower_right_y": 0.5096194955109021, "height": 0.009833262077811045, "width": 0.025997581620314347}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-23", "text": "tems (LIS)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5126122274476272, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.523300555793074, "height": 0.010688328345446751, "width": 0.07799274486094317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-24", "text": "MDx is a form of diagnostic testing used to detect specific sequences in\nDNA or RNA that may or may not be associated with disease. Clinical\napplications of MDx include infectious disease testing, oncology, phar-\nmacogenomics and genetic disease screening.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.5536554082941428, "lower_right_x": 0.8651753325272068, "lower_right_y": 0.6075245831551945, "height": 0.053869174861051694, "width": 0.5030229746070134}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-25", "text": "Molecular diagnostics (MDx)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5536554082941428, "lower_right_x": 0.32889963724304716, "lower_right_y": 0.5677640017101325, "height": 0.01410859341598969, "width": 0.2128174123337364}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-26", "text": "The simultaneous detection of more than one analyte or biomarker from a\nsingle sample.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6152201795639162, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.6417272338606242, "height": 0.026507054296708077, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-27", "text": "Multiplexing\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6152201795639162, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.628901239846088, "height": 0.013681060282171864, "width": 0.09673518742442562}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-28", "text": "PMA is the most stringent type of device regulatory clearance required by\nthe FDA before a medical device can be marketed in the United States.\nPMA is the FDA process of scientific and regulatory review to evaluate\nand review the safety and effectiveness of Class III medical devices.\nClass III medical devices are those that support or sustain human life, are\nof substantial importance in preventing impairment of human health, or\nwhich present a potential, unreasonable risk of illness or injury.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.6562633604104318, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.7520307823856349, "height": 0.09576742197520316, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-29", "text": "Pre-market approval (PMA)\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6562633604104318, "lower_right_x": 0.32406287787182586, "lower_right_y": 0.6703719538264216, "height": 0.0141085934159898, "width": 0.20858524788391775}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-30", "text": "Polypeptide chain built from the 20 natural amino acids. Proteins are\nsynthesised from a messenger RNA copy of a gene and can have many\nfunctions in the cytoskeleton of the cell, enzymatic, messenger functions\nin cells and blood such as immune cytokines, DNA binding proteins that\nregulate expression, etc.\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.7588713125267208, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.8272766139375801, "height": 0.06840530141085932, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-31", "text": "Protein\n", "page_number": 235, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7588713125267208, "lower_right_x": 0.1735187424425635, "lower_right_y": 0.7695596408721675, "height": 0.010688328345446751, "width": 0.05804111245465539}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-32", "text": "Sample preparation refers to the ways in which a sample is treated prior\nto its analysis. Sample preparation is a very important step in most analyt-\nical techniques, because the techniques are often not responsive to the\nanalytes in its original matrix, or the results are distorted by the presence\nof interfering substances. Sample preparation may involve dissolution of\nmatrix components, reaction with certain chemicals, pulverizing the sam-\nple, treatment with a chelating agent (e.g. EDTA), masking or neutralisa-\n", "page_number": 235, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.8341171440786661, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.9298845660538692, "height": 0.09576742197520305, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-33", "text": "Sample preparation\n", "page_number": 235, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.8341171440786661, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.8482257374946558, "height": 0.01410859341598969, "width": 0.1487303506650544}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-235-34", "text": "232\n", "page_number": 235, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-236-0", "text": "tion of interfering substances, filtering, dilution or concentration of the\nanalytes, sub-sampling or many other techniques.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.08507909362975631, "lower_right_x": 0.8609431680773881, "lower_right_y": 0.11201368106028217, "height": 0.02693458743052586, "width": 0.4987908101571947}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-236-1", "text": "Sensitivity and specificity are statistical measures of the performance of a\nbinary classification test, also known in statistics as classification func-\ntion. Sensitivity (also called recall rate in some fields) measures the pro-\nportion of actual positives that are correctly identified as such (e.g. the\npercentage of sick people who are correctly identified as having the con-\ndition). Specificity measures the proportion of negatives that are correctly\nidentified (e.g. the percentage of healthy people who are correctly identi-\nfied as not having the condition). These two measures are closely related\nto the concepts of type I and type II errors. A theoretical, optimal predic-\ntion aims to achieve 100% sensitivity (i.e., predict all people from the\nsick group as sick) and 100% specificity (i.e., not predict anyone from the\nhealthy group as sick), however theoretically any predictor will possess a\nminimum error bound known as the Bayes error rate.\nFDA Statistical Guidance on Reporting Results from Studies Evaluating\nDiagnostic Tests \u2013 When a new test is evaluated by comparison to a non-\nreference standard, you cannot directly calculate unbiased estimates of\nsensitivity and specificity. Therefore, the terms sensitivity and specificity\nare not appropriate to describe the comparative results. Instead, the same\nnumerical calculations are made, but the estimates are called positive\npercent agreement and negative percent agreement, rather than sensitivity\nand specificity. This reflects that the estimates are not of accuracy but of\nagreement of the new test with the non-reference standard.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.11928174433518597, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.427105600684053, "height": 0.30782385634886705, "width": 0.503627569528416}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-236-2", "text": "Sensitivity and specificity\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.11928174433518597, "lower_right_x": 0.2992744860943168, "lower_right_y": 0.1333903377511757, "height": 0.014108593415989731, "width": 0.18258766626360334}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-236-3", "text": "Severe overall inflammatory response of the body to an infection.\n", "page_number": 236, "bounding_box": {"top_left_x": 0.36275695284159615, "top_left_y": 0.45446772124839674, "lower_right_x": 0.8053204353083434, "lower_right_y": 0.4685763146643865, "height": 0.014108593415989745, "width": 0.44256348246674726}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-236-4", "text": "Sepsis\n", "page_number": 236, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.45446772124839674, "lower_right_x": 0.16444981862152358, "lower_right_y": 0.4672937152629329, "height": 0.012825994014536157, "width": 0.047762998790810154}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-236-5", "text": "233\n", "page_number": 236, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-0", "text": "ANNEX I\n", "page_number": 237, "bounding_box": {"top_left_x": 0.36215235792019346, "top_left_y": 0.10004275331338179, "lower_right_x": 0.46432889963724305, "lower_right_y": 0.115861479264643, "height": 0.015818725951261214, "width": 0.1021765417170496}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-1", "text": "I \u2013 FOOTNOTES\n", "page_number": 237, "bounding_box": {"top_left_x": 0.46856106408706166, "top_left_y": 0.10004275331338179, "lower_right_x": 0.6336154776299879, "lower_right_y": 0.115861479264643, "height": 0.015818725951261214, "width": 0.16505441354292627}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-2", "text": "", "page_number": 237, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.16417272338606242, "lower_right_x": 0.36094316807738813, "lower_right_y": 0.1671654553227875, "height": 0.002992731936725085, "width": 0.24183796856106407}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-3", "text": "1\n    ECDC (2008); Chalmers, J.D. et al. (2014); CDC (2010).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.17144078666096624, "lower_right_x": 0.39903264812575573, "lower_right_y": 0.18170158187259514, "height": 0.010260795211628898, "width": 0.2823458282950423}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-4", "text": "    E\n2\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.18170158187259514, "lower_right_x": 0.12333736396614269, "lower_right_y": 0.1876870457460453, "height": 0.00598546387345017, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-5", "text": "    ECDC (2008); Chalmers, J.D. et al. (2014); CDC (2010).\n2\n    Margolis et al. (2011); American Diabetes Association (2014); Diabetes Deutschland (2012); Richard et al. (2011); Livesley and Chow (2002); Dorner et al.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12091898428053205, "top_left_y": 0.182129115006413, "lower_right_x": 0.8645707376058042, "lower_right_y": 0.1911073108165883, "height": 0.00897819581017531, "width": 0.7436517533252721}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-6", "text": "  Margolis et al. (2011); American Diabetes Association (2014); Diabetes Deutschland (2012); Richard et al. (2011); Livesley and Chow (2002); Dorner et al.\n(2009); Deutsche Gesellschaft f\u00fcr Verbrennungsmedizin (2014); Mayhall (2003); Klevens et al. (2007) in Jhung (2009); Geffers (2011); Brun-Buisson (2001);\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.19153484395040615, "lower_right_x": 0.8657799274486094, "lower_right_y": 0.20179563916203505, "height": 0.010260795211628898, "width": 0.7496977025392987}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-7", "text": "(2009); Deutsche Gesellschaft f\u00fcr Verbrenn\nMichelotti et al. (2012); Sunderlin (2006)..\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.20179563916203505, "lower_right_x": 0.3186215235792019, "lower_right_y": 0.2116289012398461, "height": 0.009833262077811045, "width": 0.20253929866989118}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-8", "text": "3\n    WHO (2015a).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11668681983071343, "top_left_y": 0.2116289012398461, "lower_right_x": 0.20253929866989118, "lower_right_y": 0.21975203078238564, "height": 0.008123129542539548, "width": 0.08585247883917775}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-9", "text": "    W\n4\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.21975203078238564, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.22530996152201796, "height": 0.005557930739632316, "width": 0.00785973397823457}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-10", "text": "    WHO (2015a).\n4\n    Arias et al. (2009).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12333736396614269, "top_left_y": 0.2201795639162035, "lower_right_x": 0.21765417170495768, "lower_right_y": 0.22958529286019666, "height": 0.009405728943993164, "width": 0.094316807738815}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-11", "text": "    A\n5\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.22873022659256093, "lower_right_x": 0.12454655380894801, "lower_right_y": 0.23471569046601112, "height": 0.0059854638734501975, "width": 0.008464328899637247}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-12", "text": "    Arias et al. (20\n5\n    Laroy (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.23001282599401454, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.2381359555365541, "height": 0.008123129542539548, "width": 0.07315598548972188}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-13", "text": "    Laroy (2015).\n6\n    MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.23856348867037194, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.248396750748183, "height": 0.009833262077811045, "width": 0.13905683192261187}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-14", "text": "    MarketsandMarkets (2014).\n7\n    MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.24882428388200087, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.25951261222744765, "height": 0.01068832834544678, "width": 0.13724304715840388}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-15", "text": "7\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.24925181701581872, "lower_right_x": 0.1185006045949214, "lower_right_y": 0.2552372808892689, "height": 0.00598546387345017, "width": 0.002418379685610636}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-16", "text": "    MarketsandMarkets (2014)\n8\n    Cantor Fitzgerald (2012).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.2586575459598119, "lower_right_x": 0.2503022974607013, "lower_right_y": 0.26763574176998717, "height": 0.008978195810175282, "width": 0.13422007255139057}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-17", "text": "9\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.26763574176998717, "lower_right_x": 0.1185006045949214, "lower_right_y": 0.27276613937580163, "height": 0.005130397605814463, "width": 0.002418379685610636}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-18", "text": "    Cantor Fitzgerald (2012).\n9\n    MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11910519951632406, "top_left_y": 0.26806327490380505, "lower_right_x": 0.25634824667472794, "lower_right_y": 0.27618640444634457, "height": 0.00812312954253952, "width": 0.13724304715840388}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-19", "text": " MarketsandMarkets (2014).\n10\n MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.27661393758016245, "lower_right_x": 0.2599758162031439, "lower_right_y": 0.28730226592560926, "height": 0.010688328345446807, "width": 0.14389359129383317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 20, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-20", "text": "     MarketsandMa\n11\n     IDSA (2011).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.28730226592560926, "lower_right_x": 0.1989117291414752, "lower_right_y": 0.29628046173578454, "height": 0.008978195810175282, "width": 0.0834340991535671}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 21, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-21", "text": "     IDSA (201\n12\n     Morens &\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.29628046173578454, "lower_right_x": 0.17835550181378476, "lower_right_y": 0.30440359127832406, "height": 0.00812312954253952, "width": 0.06287787182587666}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 22, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-22", "text": "011).\n& Fauci (2015); Saker et al. (2004).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.17472793228536881, "top_left_y": 0.2967079948696024, "lower_right_x": 0.3385731559854897, "lower_right_y": 0.30739632321504917, "height": 0.010688328345446751, "width": 0.1638452237001209}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 23, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-23", "text": "     Morens & Fauci (2015); Sake\n13\n     Tavernise and Shear (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.30483112441214194, "lower_right_x": 0.26360338573155984, "lower_right_y": 0.31680205215904234, "height": 0.011970927746900395, "width": 0.14631197097944376}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 24, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-24", "text": "     Tavernise and Shear (2015\n14\n     Hacker & Kumm (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.31680205215904234, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.32364258230012827, "height": 0.006840530141085932, "width": 0.13422007255139057}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 25, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-25", "text": "14\n     Hacker & Kumm (2015).\n15\n     Magiorakos et al. (2012).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.32407011543394615, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.3334758443779393, "height": 0.009405728943993164, "width": 0.1354292623941959}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 26, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-26", "text": "     Magiorakos et al. (2012).\n16\n     Hacker & Kumm (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.33390337751175714, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.34544677212483965, "height": 0.011543394613082514, "width": 0.13603385731559853}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 27, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-27", "text": "     Hacker & Kumm (20\n17\n     N-TV online (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.34544677212483965, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.3522873022659256, "height": 0.006840530141085932, "width": 0.11185006045949215}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 28, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-28", "text": "17\n     N-TV online (2015).\n18\n     N-TV online (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.35271483539974346, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.36212056434373663, "height": 0.009405728943993164, "width": 0.11185006045949215}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 29, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-29", "text": "     N-TV online (2015).\n19\n     Hacker & Kumm (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3625480974775545, "lower_right_x": 0.25151148730350664, "lower_right_y": 0.37280889268918344, "height": 0.010260795211628926, "width": 0.13603385731559853}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 30, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-30", "text": "     Hacker & Kumm (201\n20\n     N-TV online (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.37280889268918344, "lower_right_x": 0.23216444981862153, "lower_right_y": 0.3830696879008123, "height": 0.01026079521162887, "width": 0.11608222490931076}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 31, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-31", "text": "     N-TV online (2\n21\n     IDSA (2004).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.3830696879008123, "lower_right_x": 0.19709794437726724, "lower_right_y": 0.390765284309534, "height": 0.007695596408721694, "width": 0.08162031438935914}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 32, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-32", "text": "     IDSA (2004).\n22\n     The White House (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.3911928174433519, "lower_right_x": 0.2503022974607013, "lower_right_y": 0.4031637451902522, "height": 0.01197092774690034, "width": 0.13422007255139057}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 33, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-33", "text": "     The White Hous\n23\n     WHO (2015b).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4031637451902522, "lower_right_x": 0.20193470374848851, "lower_right_y": 0.4125694741342454, "height": 0.009405728943993164, "width": 0.08585247883917775}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 34, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-34", "text": "     WHO (2015\n24\n     G7 (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4125694741342454, "lower_right_x": 0.18198307134220074, "lower_right_y": 0.4194100042753313, "height": 0.006840530141085932, "width": 0.06650544135429264}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 35, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-35", "text": "     G7 (2015).\n25\n     \u00c4rzteblatt (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4198375374091492, "lower_right_x": 0.21281741233373638, "lower_right_y": 0.43095339888841383, "height": 0.011115861479264633, "width": 0.09673518742442562}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 36, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-36", "text": "     \u00c4rzteblatt (2015\n26\n     WHO (2015b).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.43095339888841383, "lower_right_x": 0.20435308343409916, "lower_right_y": 0.43822146216331764, "height": 0.007268063274903813, "width": 0.08887545344619106}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 37, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-37", "text": "     WHO (2015b).\n27\n     Schulte (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4386489952971355, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.4493373236425823, "height": 0.010688328345446751, "width": 0.08766626360338574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 38, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-38", "text": "28\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4493373236425823, "lower_right_x": 0.12515114873035066, "lower_right_y": 0.4548952543822146, "height": 0.005557930739632344, "width": 0.009068923821039895}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 39, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-39", "text": "     Schulte (2014).\n28\n     Jamal et al. (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12515114873035066, "top_left_y": 0.44976485677640016, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.45746045318512185, "height": 0.007695596408721694, "width": 0.0973397823458283}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 40, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-40", "text": "     Jamal et al. (2014).\n29\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.45788798631893973, "lower_right_x": 0.2581620314389359, "lower_right_y": 0.466866182129115, "height": 0.008978195810175282, "width": 0.1426844014510278}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 41, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-41", "text": "     MarketsandMarkets (2014).\n30\n     European Commission (2013).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4672937152629329, "lower_right_x": 0.2750906892382104, "lower_right_y": 0.47669944420692606, "height": 0.009405728943993164, "width": 0.15900846432889965}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 42, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-42", "text": "     European Commission (2013).\n31\n     Baron (1996); Mayo Foundation for Medical Education and Research (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4771269773407439, "lower_right_x": 0.49334945586457074, "lower_right_y": 0.4890979050876443, "height": 0.011970927746900395, "width": 0.3778718258766626}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 43, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-43", "text": "     Baron (1996); Mayo Foundat\n32\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.4890979050876443, "lower_right_x": 0.2623941958887545, "lower_right_y": 0.4959384352287302, "height": 0.006840530141085932, "width": 0.14631197097944376}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 44, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-44", "text": "32\n     MarketsandMarkets (2014).\n33\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.4963659683625481, "lower_right_x": 0.2593712212817412, "lower_right_y": 0.5053441641727234, "height": 0.008978195810175338, "width": 0.1438935912938331}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 45, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-45", "text": "33\n     MarketsandMarkets (2014).\n34\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5057716973065413, "lower_right_x": 0.2581620314389359, "lower_right_y": 0.5147498931167166, "height": 0.008978195810175338, "width": 0.14087061668681983}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 46, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-46", "text": "34\n     MarketsandMarkets (2014).\n35\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5151774262505344, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.5245831551945276, "height": 0.009405728943993164, "width": 0.1451027811366385}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 47, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-47", "text": "     MarketsandMarkets (2014).\n36\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5250106883283454, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.5339888841385207, "height": 0.008978195810175338, "width": 0.14570737605804113}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 48, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-48", "text": "36\n     MarketsandMarkets (2014).\n37\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5344164172723386, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.5433946130825139, "height": 0.008978195810175338, "width": 0.1444981862152358}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 49, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-49", "text": "37\n     MarketsandMarkets (2014).\n38\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5438221462163317, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.5532278751603249, "height": 0.009405728943993164, "width": 0.14570737605804113}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 50, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-50", "text": "     MarketsandMarkets (2014).\n39\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5536554082941428, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.563061137238136, "height": 0.009405728943993164, "width": 0.14510278113663844}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 51, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-51", "text": "     MarketsandMarkets (2014).\n40\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.5634886703719538, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.5746045318512185, "height": 0.011115861479264688, "width": 0.14510278113663844}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 52, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-52", "text": "     MarketsandM\n41\n     CDC (2013).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5746045318512185, "lower_right_x": 0.18923821039903266, "lower_right_y": 0.5818725951261223, "height": 0.007268063274903813, "width": 0.0731559854897219}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 53, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-53", "text": "     CDC (2013).\n42\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.5823001282599402, "lower_right_x": 0.26058041112454655, "lower_right_y": 0.5912783240701154, "height": 0.008978195810175227, "width": 0.1444981862152358}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 54, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-54", "text": "     MarketsandMarkets (2014).\n43\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.5917058572039333, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.6023941855493801, "height": 0.010688328345446751, "width": 0.14389359129383317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 55, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-55", "text": "44\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6019666524155622, "lower_right_x": 0.12333736396614269, "lower_right_y": 0.6088071825566481, "height": 0.0068405301410858765, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 56, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-56", "text": "     MarketsandMarkets (2014).\n44\n     Ettel (2015); The Economist (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12394195888754535, "top_left_y": 0.6028217186831979, "lower_right_x": 0.2998790810157195, "lower_right_y": 0.6122274476271911, "height": 0.009405728943993164, "width": 0.17593712212817414}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 57, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-57", "text": "     Ettel (2015); The Eco\n45\n     N-TV online (2015).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6122274476271911, "lower_right_x": 0.22551390568319227, "lower_right_y": 0.6203505771697306, "height": 0.008123129542539576, "width": 0.11003627569528417}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 58, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-58", "text": "     N-TV online (2015).\n46\n     Kalorama Information (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6207781103035486, "lower_right_x": 0.2702539298669891, "lower_right_y": 0.6301838392475417, "height": 0.009405728943993164, "width": 0.15417170495767835}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 59, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-59", "text": "     Kalorama Information (2014)\n47\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6301838392475417, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.639162035057717, "height": 0.008978195810175227, "width": 0.14993954050785974}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 60, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-60", "text": "     MarketsandMarkets (2014).\n48\n     ECDC (2008); Chalmers, J.D. et al. (2014); CDC (2010).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6395895681915349, "lower_right_x": 0.4014510278113664, "lower_right_y": 0.6498503634031637, "height": 0.010260795211628815, "width": 0.2841596130592503}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 61, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-61", "text": "     ECDC (2008); C\n49\n     See Footnote 2.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.6498503634031637, "lower_right_x": 0.20556227327690446, "lower_right_y": 0.6584010260795211, "height": 0.008550662676357401, "width": 0.08827085852478837}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 62, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-62", "text": "     See Footnote 2.\n50\n     See Footnote 1, 2\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.658828559213339, "lower_right_x": 0.2037484885126965, "lower_right_y": 0.6678067550235143, "height": 0.008978195810175227, "width": 0.08766626360338574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 63, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-63", "text": "2.\n1, 2\n", "page_number": 237, "bounding_box": {"top_left_x": 0.2037484885126965, "top_left_y": 0.6601111586147926, "lower_right_x": 0.20737605804111245, "lower_right_y": 0.6678067550235143, "height": 0.007695596408721639, "width": 0.003627569528415947}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 64, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-64", "text": "2 and CDC (2010), Martin (2012), Dellinger, R.P. (2012), HCUP (2013a), CDC (2007), Statista (2015a), Statista (2015b).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.2079806529625151, "top_left_y": 0.6601111586147926, "lower_right_x": 0.782950423216445, "lower_right_y": 0.6703719538264216, "height": 0.010260795211628926, "width": 0.5749697702539299}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 65, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-65", "text": "     See Footnote 1, 2 and CDC (2\n51\n     MarketsandMarkets (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6682342881573322, "lower_right_x": 0.26541717049576785, "lower_right_y": 0.6802052159042326, "height": 0.01197092774690034, "width": 0.14993954050785974}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 66, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-66", "text": "     MarketsandMarkets\n52\n     Kollef et al. (2005).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6802052159042326, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.6870457460453185, "height": 0.0068405301410859876, "width": 0.10640870616686819}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 67, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-67", "text": "     Kollef et al. (2005).\n53\n     Kollef et al. (2005).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.6874732791791364, "lower_right_x": 0.2218863361547763, "lower_right_y": 0.6964514749893117, "height": 0.008978195810175338, "width": 0.10640870616686819}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 68, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-68", "text": "53\n     Kollef et al. (2005).\n54\n     Spoorenberg (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.6968790081231295, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.7058572039333049, "height": 0.008978195810175338, "width": 0.11124546553808949}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 69, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-69", "text": "54\n     Spoorenberg (2014).\n55\n     American Thoracic Society (2005).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7062847370671227, "lower_right_x": 0.2950423216444982, "lower_right_y": 0.718255664814023, "height": 0.01197092774690034, "width": 0.17956469165659006}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 70, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-70", "text": "     American Thoracic S\n56\n     Kollef et al. (1999).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.718255664814023, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.7268063274903805, "height": 0.008550662676357512, "width": 0.10640870616686819}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 71, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-71", "text": "     Kollef et al. (1\n57\n     Rello (2011).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7268063274903805, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.73492945703292, "height": 0.008123129542539465, "width": 0.0773881499395405}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 72, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-72", "text": "     Rello (2011).\n58\n     Rello (2011).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.735356990166738, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.7456177853783669, "height": 0.010260795211628926, "width": 0.07799274486094317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 73, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-73", "text": "     Rello (201\n59\n     Borgatta &\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7456177853783669, "lower_right_x": 0.17533252720677148, "lower_right_y": 0.7537409149209063, "height": 0.008123129542539465, "width": 0.059250302297460714}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 74, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-74", "text": "2011).\n a & Rello (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.17049576783555018, "top_left_y": 0.7460453185121847, "lower_right_x": 0.24667472793228537, "lower_right_y": 0.7558785805899957, "height": 0.00983326207781099, "width": 0.0761789600967352}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 75, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-75", "text": "     Borgatta & Rello (20\n60\n     Kollef et al. (2005).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7541684480547243, "lower_right_x": 0.2279322853688029, "lower_right_y": 0.7661393758016246, "height": 0.01197092774690034, "width": 0.11245465538089479}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 76, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-76", "text": "61\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7661393758016246, "lower_right_x": 0.12333736396614269, "lower_right_y": 0.7716973065412569, "height": 0.0055579307396322886, "width": 0.007255139056831922}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 77, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-77", "text": "61\n     Schulte et al. (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12394195888754535, "top_left_y": 0.7661393758016246, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.7729799059427106, "height": 0.0068405301410859876, "width": 0.10338573155985491}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 78, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-78", "text": "     Schulte et al. (2014).\n62\n     Kollef et al. (1999).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.7734074390765284, "lower_right_x": 0.22732769044740025, "lower_right_y": 0.7823856348867038, "height": 0.008978195810175338, "width": 0.11185006045949215}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 79, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-79", "text": "     Kollef et al. (1999).\n63\n     Kollef et al. (1999).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.7828131680205216, "lower_right_x": 0.2218863361547763, "lower_right_y": 0.7947840957674219, "height": 0.01197092774690034, "width": 0.10580411124546553}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 80, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-80", "text": "     Kollef et al. (19\n64\n     ECDC (2008).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1215235792019347, "top_left_y": 0.7947840957674219, "lower_right_x": 0.19830713422007254, "lower_right_y": 0.8029072253099615, "height": 0.008123129542539576, "width": 0.07678355501813784}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 81, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-81", "text": "     ECDC (2008).\n65\n     Chalmers, J.D. et al. (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12333736396614269, "top_left_y": 0.8033347584437794, "lower_right_x": 0.2660217654171705, "lower_right_y": 0.8140230867892262, "height": 0.010688328345446751, "width": 0.1426844014510278}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 82, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-82", "text": "65\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8037622915775973, "lower_right_x": 0.12273276904474002, "lower_right_y": 0.8097477554510475, "height": 0.005985463873450225, "width": 0.006650544135429259}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 83, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-83", "text": "     Chalmers, J.D\n66\n     CDC (2010).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8135955536554083, "lower_right_x": 0.19347037484885127, "lower_right_y": 0.8208636169303121, "height": 0.007268063274903813, "width": 0.07799274486094317}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 84, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-84", "text": "     CDC (2010).\n67\n     See Footnote 2.\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.82129115006413, "lower_right_x": 0.20314389359129384, "lower_right_y": 0.8315519452757588, "height": 0.010260795211628815, "width": 0.08766626360338574}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 85, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-85", "text": "68\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8315519452757588, "lower_right_x": 0.12696493349455865, "lower_right_y": 0.837964942283027, "height": 0.006412997007268162, "width": 0.010882708585247883}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 86, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-86", "text": "     See Footnote 2.\n68\n     Curetis (2015a).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12333736396614269, "top_left_y": 0.8319794784095768, "lower_right_x": 0.2079806529625151, "lower_right_y": 0.840957674219752, "height": 0.008978195810175227, "width": 0.08464328899637243}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 87, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-87", "text": "     Curetis (2015a).\n69\n     Schulte (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11729141475211609, "top_left_y": 0.840957674219752, "lower_right_x": 0.2067714631197098, "lower_right_y": 0.8495083368961095, "height": 0.008550662676357512, "width": 0.0894800483675937}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 88, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-88", "text": "     Schulte (2014).\n70\n     Kurtz et al. (2012).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.8499358700299273, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.8601966652415562, "height": 0.010260795211628926, "width": 0.10701330108827085}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 89, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-89", "text": "     Kurtz et al. (2012).\n71\n     Trampuz & Widmer (2006).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.8606241983753741, "lower_right_x": 0.26118500604594924, "lower_right_y": 0.8687473279179136, "height": 0.008123129542539576, "width": 0.13845223700120923}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 90, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-90", "text": "71\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8614792646430098, "lower_right_x": 0.12212817412333736, "lower_right_y": 0.8653270628473707, "height": 0.003847798204360875, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 91, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-91", "text": "     Trampuz & Widmer (2006).\n72\n     Trampuz & Widmer (2006).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8691748610517315, "lower_right_x": 0.26360338573155984, "lower_right_y": 0.8815733219324497, "height": 0.012398460880718276, "width": 0.1475211608222491}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 92, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-92", "text": "73\n     Kurtz et al. (2007).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12333736396614269, "top_left_y": 0.8815733219324497, "lower_right_x": 0.22249093107617895, "lower_right_y": 0.8879863189397178, "height": 0.006412997007268051, "width": 0.09915356711003627}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 93, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-93", "text": "     Kurtz et al. (2007).\n74\n     Trampuz & Widmer (2006).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8884138520735357, "lower_right_x": 0.26360338573155984, "lower_right_y": 0.8995297135528003, "height": 0.011115861479264577, "width": 0.1475211608222491}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 94, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-94", "text": "75\n", "page_number": 237, "bounding_box": {"top_left_x": 0.11608222490931076, "top_left_y": 0.8995297135528003, "lower_right_x": 0.12212817412333736, "lower_right_y": 0.9055151774262505, "height": 0.005985463873450225, "width": 0.006045949214026597}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 95, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-95", "text": "     Trampuz & Widmer (20\n75\n     Assmann et al. (2014).\n", "page_number": 237, "bounding_box": {"top_left_x": 0.12273276904474002, "top_left_y": 0.8995297135528003, "lower_right_x": 0.2370012091898428, "lower_right_y": 0.9097905087644292, "height": 0.010260795211628926, "width": 0.11426844014510278}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 96, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-237-96", "text": "234\n", "page_number": 237, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-238-0", "text": "76\n   NHS (2008).\n77\n   ECDC (2008).\n78\n   Geffers (2011).\n79\n   Kirkland et al. (1999).\n80\n   Klevens et al. (2007) in Jhung (2009).\n81\n   Mittermayer (2006).\n82\n   Infekt-Liga (2010).\n83\n   Lipsky et al. (2012).\n84\n   Sharp (1978).\n85\n   Tennvall & Apelqvist (2004).\n86\n   Abad et al. (2011).\n87\n   Geffers (2010).\n88\n   Fletcher, S. (2005).\n89\n   Geffers (2010).\n90\n   See Footnote 2.\n91\n   Curetis (2015b).\n92\n   Bone et al. (1992).\n93\n   Levy et al. (2003).\n94\n   Levy et al. (2003).\n95\n   Jawad et al. (2012).\n96\n   HCUP (2011).\n97\n   HCUP (2011).\n98\n   Bataar et al. (2010).\n99\n   Global Sepsis Alliance (2013).\n100\n    Jawad et al. (2012).\n101\n    Deutschman et al. (2014).\n102\n    HCUP (2011).\n103\n    Dellinger et al. (2013).\n104\n    Afshari et al. (2012).\n105\n    Kumar et al. (2006).\n106\n    MarketsandMarkets (2015).\n107\n    MarketsandMarkets (2015).\n108\n    Peralta et al. (2006).\n109\n    Afshari et al. (2012).\n110\n    CDC (2010).\n111\n    Martin (2012).\n112\n    Afshari et al. (2012).\n113\n    HCUP (2013a).\n114\n    HCUP (2013a).\n115\n    Buss et al. (2015).\n116\n    Vogelmann & Ebert (2014).\n117\n    Vogelmann & Ebert (2014).\n118\n    Solomonkin et al. (2010).\n119\n    Sartelli et al. (2012).\n120\n    Solomonkin et al. (2010).\n121\n    Sartelli et al. (2012).\n122\n    Daley, B. et al. (2015).\n123\n    HCUP (2013b).\n124\n    Tenner et al. (2013).\n125\n    Vogelmann & Ebert (2014).\n126\n    HCUP (2013a).\n127\n    CDC (2007).\n128\n    Statista (2015b).\n129\n    CDC (2014).\n130\n    Martin (2012); Statista (2015a); ECDC (2008).\n131\n    Bundesministerium f\u00fcr Gesundheit (2014); Data information intelligence GmbH (2015)\n132\n    Data information intelligence GmbH (2015)\n133\n    Universit\u00e4tsklinikum M\u00fcnster (2015).\n134\n    Kollef et al. (1999).\n135\n    Piskin et al. (2012).\n136\n    Rello et al. (2011).\n137\n    Kollef et al. (1999).\n138\n    Ost et al. (2003).\n139\n    Results from Curetis Unyvero BaseCase App.\n140\n    Results from Curetis Unyvero BaseCase App.\n141\n    Results from Curetis Unyvero BaseCase App.\n142\n    Results from Curetis Unyvero BaseCase App.\n", "page_number": 238, "bounding_box": {"top_left_x": 0.1154776299879081, "top_left_y": 0.10260795211628901, "lower_right_x": 0.5465538089480049, "lower_right_y": 0.7456177853783669, "height": 0.6430098332620778, "width": 0.43107617896009676}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-238-1", "text": "235\n", "page_number": 238, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-239-0", "text": "ANNEX II \u2013 LIST OF REFERENCES\n", "page_number": 239, "bounding_box": {"top_left_x": 0.3041112454655381, "top_left_y": 0.09191962377084224, "lower_right_x": 0.6910519951632407, "lower_right_y": 0.10944848225737494, "height": 0.017528858486532697, "width": 0.3869407496977026}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-239-1", "text": "Author                     Title                               Source /Name                                   Date of\n                                                                                                              origin /\n                                                                                                              Access date\n\nAbad et al. (2011)         Catheter related bloodstream        Infectious disease special edition 2011, pp.   Accessed:\n                           infections.                         84-98                                          25 August\n(\"Abad et al. (2011)\")                                                                                        2015\n\nAfshari et al. (2012)      Bench-to-bedside review: rapid      Critical Care, Vol. 16, No. 3, Article 222,    Accessed:\n                           molecular diagnostics for blood-    2012, p. 1                                     24 August\n(\"Afshari et al.           stream infection-a new frontier?    http://www.ncbi.nlm.nih.gov/pmc/articles/P     2015\n(2012)\")                                                       MC3580598/\n\nAmerican Diabetes          Statistics about Diabetes           www.diabetes.org/diabetes-basics/statistics/   Accessed:\nAssociation (2014)                                                                                            13 August\n                                                                                                              2015\n(\"American Diabetes\nAssociation (2014)\")\n\nAmerican Thoracic          Guidelines for the Management       American Journal of Respiratory and Criti-     Accessed:\nSociety (2005)             of Adults with Hospital-acquired,   cal Care Medicine 171: pp. 338-416             17 August\n                           Ventilator-associated, and                                                         2015\n(\"American Thoracic        Healthcare-associated Pneumonia\nSociety (2005)\")\n\nArias et al. (2009)        Antibiotic-resistant bugs in the    The New England Journal of Medicine            Accessed 28\n                           21st Century \u2013 a clinical super-    360(5): pp. 439-443                            August\n(\"Arias et al. (2009)\")    challenge                                                                          2015\n\n\u00c4rzteblatt (2015)          Obama stellt Plan gegen Antibio-    27 March 2015,                                 Accessed:\n                           tika-Resistenz vor                  http://www.aerzteblatt.de/nachrichten/6232     29 May\n(\"\u00c4rzteblatt (2015)\")                                          0/Obama-stellt-Plan-gegen-Antibiotika-         2015\n                                                               Resistenz-vor <\n\nAsia Pacific Observato-    Public Hospital Governance in       http://www.wpro.who.int/asia_pacific_obse      Accessed:\nry on Health Systems       Asia and the Pacific                rvato-                                         01 Septem-\nand Policies (2015)                                            ry/country_comparative_studies/ccs_public      ber 2015\n                                                               _hospital_goverance.pdf?ua=1\n(\"Asia Pacific Obser-\nvatory on Health\nSystems and Policies\n(2015)\")\n\nAssmann et al. (2014)      Comparison of health care costs     The Journal of arthroplasty, 10/2014;          Accessed:\n                           between aseptic and two stage       29(10): pp.1925-1931.                          24 August\n(\"Assmann et al.           septic hip revision                 http://www.researchgate.net/publication/26     2015\n(2014)\")                                                       2227413_Comparison_of_Health_Care_Co\n                                                               sts_Between_Aseptic_and_Two_Stage_Sep\n                                                               tic_Hip_Revision\n\n\n\nBaron (1996)               Medical Microbiology                Chapter 93 Infections of the Respiratory       Accessed 11\n                                                               System by Dasaraju, P.V. and Liu, C.,          August\n(\"Baron (1996)\")                                               Gavelston (TX): University of Texas Medi-      2015\n                                                               cal Branch at Gavelston, Available at:\n                                                               http://www.ncbi.nlm.nih.gov/books/NBK81\n                                                               42/\n\nBataar et al. (2010)       Bulletin of the World Health        http://www.who.int/bulletin/volumes/88/11/     Accessed:\n                           Organisation: Nationwide survey     10-077073/en/                                  24 August\n(\"Bataar et al. (2010)\")   on resource availability for im-                                                   2015\n                           plementing current sepsis guide-\n                           lines in Mongolia\n", "page_number": 239, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.12270200940572894, "lower_right_x": 0.8827085852478839, "lower_right_y": 0.9238991021804189, "height": 0.80119709277469, "width": 0.7769044740024184}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-239-2", "text": "236\n", "page_number": 239, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-240-0", "text": "Author                    Title                                 Source /Name                                  Date of\n                                                                                                              origin /\n                                                                                                              Access date\n\nBone et al. (1992)        Definitions for sepsis and organ      Chest Journal, 1992 Jun; Vol 101 No. 6:       Accessed:\n                          failure and guidelines for the use    1644-55.                                      17 August\n(\"Bone et al. (1992)\")    innovative therapies in sepsis.                                                     2015\n                          The ACCP/SCCM Consensus\n                          Conference Committee. American\n                          College of Chest Physi-\n                          cians/Society of Critical Care\n                          Medicine.\n\nBorgatta & Rello          How to approach and treat VAP         BMC Infectious Diseases 14:211                Accessed:\n(2014)                    in ICU patients                                                                     27 August\n                                                                                                              2015\n(\"Borgatta & Rello\n(2014)\")\n\nBrun-Buisson (2001)       New Technologies and Infection        American Journal of Respiratory and Criti-    Accessed:\n                          control practices to prevent intra-   cal Care Medicine 164(9):pp. 1557-1558,       13 August\n(\"Brun-Buisson            vascular catheter-related infec-      http://www.atsjournals.org/doi/pdf/10.1164/   2015\n(2001)\")                  tions                                 ajrccm.164.9.2109051\n\nBundesministerium f\u00fcr     Ge\u00f6ffnete Krankenanstalten mit        www.kaz.bmg.gv.at/fileadmin/user_upload/      Accessed:\nGesundheit (2014)         ausgew\u00e4hlten Merkmalen 2013           Krankenanstalten/5_T_KH.pdf                   24 August\n                                                                                                              2015\n(\"Bundesministerium\nf\u00fcr Gesundheit\n(2014)\")\n\nBuss et al. (2015)        Multicentre Evaluation of the         Journal of Clinical Microbiology 53(3): pp.   Accessed:\n                          BioFire FilmArray Gastrointesti-      915-925.                                      10 August\n(\"Buss et al. (2015)\")    nal Panel for Etiologic Diagnosis                                                   2015\n                          of Infectious Gastroenteritis\n\nCantor Fitzgerald         II. MDx Industry Overview             presentation                                  Accessed:\n(2012)                                                                                                        28 August\n                                                                                                              2015\n(\"Cantor Fitzgerald\n(2012)\")\n\nCDC (2007)                National Hospital Discharge           CDC Vital and health statistics, December     Accessed:\n                          Survey: 2005 Annual Summary           2007 13 (165)                                 26 August\n(\"CDC (2007)\")            with detailed diagnosis and pro-                                                    2015\n                          cedure data\n\nCDC (2010)                Number and rate of discharges         http://www.cdc.gov/nchs/data/nhds/2averag     Accessed:\n                          from short-stay hospitals and of      e/2010ave2_firstlist.pdf                      20 August\n(\"CDC (2010)\")            days of care, with average length                                                   2015\n                          of stay and standard error, by\n                          selected first-listed diagnostic\n                          categories\n\nCDC (2013)                Antibiotic use in nursing homes                                                     Accessed:\n                                                                                                              19 August\n(\"CDC (2013)\")                                                                                                2015\n\nCDC (2014)                Sepsis Questions and Answers          http://www.cdc.gov/sepsis/basic/qa.html       Accessed:\n                                                                                                              27 August\n(\"CDC (2014)\")                                                                                                2015\n\nChalmers, J.D. et al.     European Respiratory Mono-            http://www.ers-                               Accessed:\n(2014)                    graph: Community-Acquired             education.org/publications/ers-               27 August\n                          Pneumonia                             monograph/archive/community-acquired-         2015\n(\"Chalmers, J.D. et al.                                         pneumonia.aspx\n(2014)\")\n\n\n                                                                                                                  237\n", "page_number": 240, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9576742197520308, "height": 0.8755878580589996, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-241-0", "text": "Author                    Title                                Source /Name                                    Date of\n                                                                                                               origin /\n                                                                                                               Access date\n\nCuretis (2015a)           Unyvero P55 Pneumonia applica-                                                       Accessed:\n                          tion guide, p.62                                                                     17 August\n(\"Curetis (2015a)\")                                                                                            2015\n\nCuretis (2015b)           Unyvero i60 implant & tissue                                                         Accessed:\n                          infection application guide, p. 64                                                   17 August\n(\"Curetis (2015b)\")                                                                                            2015\n\nDaley, B. et al. (2015)   Peritonitis and abdominal Sepsis:    http://emedicine.medscape.com/article/180       Accessed:\n                          Background, Anatomy, Patho-          234-overview#showall                            20 August\n(\"Daley, B. et al.        physiology                                                                           2015\n(2015)\")\n\nData information intel-                                                                                        Accessed:\nligence GmbH (2015)                                                                                            28 July\n                                                                                                               2015\n(\"Data information\nintelligence GmbH\n(2015)\")\n\nDellinger et al. (2013)   Surviving sepsis campaign: inter-    Intensive Care Medicine, vol. 39, no. 2, pp.    Accessed:\n                          national guidelines for manage-      165-228, 2013.                                  25 August\n(\"Dellinger et al.        ment of severe sepsis and septic                                                     2015\n(2013)\")                  shock, 2012\n\nDeutsche Gesellschaft     Verbrennungsstatistik 2013'          www.verbrennungsmedizin.de/pdf/verbren          Accessed:\nf\u00fcr Verbrennungsmedi-                                          nungsstatistik-2013.pdf                         13 August\nzin (2014)                                                                                                     2015\n(\"Deutsche Gesell-\nschaft f\u00fcr Verbren-\nnungsmedizin (2014)\")\n\nDeutschman et al.         Sepsis: current dogma and new        Immunity, 2014 Apr 17;40(4):463-75              Accessed:\n(2014)                    perspectives                                                                         17 August\n                                                                                                               2015\n(\"Deutschman et al.\n(2014)\")\n\nDiabetes Deutschland      Diabetes: Themen und Fakten          www.diabetes-                                   Accessed:\n(2012)                                                         deutschland.de/aktuellesituation.html           13 August\n                                                                                                               2015\n(\"Diabetes Deutsch-\nland (2012)\")\n\nDorner et al. (2009)      The role of nutrition in pressure    www.npuap.org/wp-                               Accessed:\n                          ulcer prevention and treatment:      content/uploads/2012/03/Nutrition-White-        13 August\n(\"Dorner et al.           national pressure ulcer advisory     Paper-Website-Version.pdf                       2015\n(2009)\")                  panel white paper\n\nECDC (2008)               Annual Epidemiological report on     http://ec.europa.eu/health/ph_threats/com/d     Accessed:\n                          communicable diseases in Europe      ocs/hcai_ecdc_en.pdf                            20 August\n(\"ECDC (2008)\")           2008                                                                                 2015\n\nEttel (2015)              Antibiotika-Resistenz \u2013 die Su-      >http://www.welt.de/wirtschaft/article1421      Accessed:\n                          perseuche der Zukunft                10146/Antibiotika-Resistenz-die-                05 June\n(\"Ettel (2015)\")                                               Superseuche-der-Zukunft.html<                   2015\n\nEuropean Commission       Staff Working Documents 436          http://ec.europa.eu/health/files/latest_news/   Accessed:\n(2013)                    final of 25.10.2013 on use of \u2018-     2013-10_personalised_medicine_en.pdf            24 July\n                          omics' technologies in the devel-                                                    2014\n(\"European Commis-        opment of personalised medicine\nsion (2013)\")\n\n\n                                                                                                                   238\n", "page_number": 241, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9576742197520308, "height": 0.8755878580589996, "width": 0.7787182587666264}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-242-0", "text": "Author                    Title                                 Source /Name                                  Date of\n                                                                                                              origin /\n                                                                                                              Access date\n\nExim Bank Malaysia        Industry brief: healthcare sector     http://www.exim.com.my/sites/default/files/   Accessed:\n(2014)                    in Indonesia                          industry_brief_-_indonesia_healthcare.pdf     01 Septem-\n                                                                                                              ber 2015\n(\"Exim Bank Malay-\nsia (2014)\")\n\nFletcher, S. (2005)       Catheter-related bloodstream          Continuing Education in Anaesthesia,          Accessed:\n                          infection                             Critical Care & Pain, Vol. 5 No. 2 (2005):    24 August\n(\"Fletcher, S. (2005)\")                                         49-51.                                        2015\n\nG7 (2015)                 Leader's Declaration G7 Summit        >https://www.g7germany.de/Content/DE/_        Accessed:\n                                                                Anlagen/G8_G20/2015-06-08-g7-                 26 June\n(\"G7 (2015)\")                                                   abschluss-                                    2015\n                                                                eng.pdf?__blob=publicationFile&v=6<\n\nGeffers (2010)            Pathogenese der Gef\u00e4\u00dfkatheter-        http://www.bvmed.de/stepone/data/downlo       Accessed:\n                          assoziierten Infektionen              ads/9c/d1/00/GeffersEinftextGefaess10021      26 August\n(\"Geffers (2010)\")                                              6.pdf                                         2015\n\nGeffers (2011)            Postoperative Wundinfektionen                                                       Accessed:\n                                                                                                              20 August\n(\"Geffers (2011)\")                                                                                            2015\n\nGlobal Sepsis Alliance    Fact Sheet Sepsis                                                                   Accessed:\n(2013)                                                                                                        20 August\n                                                                                                              2015\n(\"Global Sepsis Alli-\nance (2013)\")\n\nHacker & Kumm             Antibiotika und Antibiotikaresis-     Deutsches \u00c4rzteblatt 112 (23): A 1046 \u2013 A     Accessed:\n(2015)                    tenzen \u2013 Vorkommen und Per-           1049, 5 June 2015,                            05 June\n                          spektiven                             >http://www.aerzteblatt.de/archiv/170838/     2015\n(\"Hacker & Kumm                                                 Antibiotika-und-Antibiotikaresistenzen-\n(2015)\")                                                        Vorkommen-und-Perspektiven?src=search<\n\nHCUP (2011)               Statistical brief #122 \u2013 Septice-                                                   Accessed:\n                          mia in U.S. Hospitals 2009                                                          27 August\n(\"HCUP (2011)\")                                                                                               2015\n\nHCUP (2013a)              Statistical brief #150 \u2013 Infectious   http://www.hcup-                              Accessed:\n                          Enteritis and Foodborne Illness in    us.ahrq.gov/reports/statbriefs/sb150.jsp      07 August\n(\"HCUP (2013a)\")          the United States, 2010                                                             2015\n\nHCUP (2013b)              Statistical brief #159 \u2013 Trends in                                                  Accessed:\n                          rates of perforated appendix,                                                       27 August\n(\"HCUP (2013b)\")          2001-2010                                                                           2015\n\nIDSA (2004)               Bad bugs, no drugs: as antibiotics    http://www.idsociety.org/uploadedFiles/ID     Accessed:\n                          discovery stagnates, a public         SA/Policy_and_Advocacy/Current_Topics_        14 August\n(\"IDSA (2004)\")           health crisis brews                   and_Issues/Advancing_Product_Research_        2015\n                                                                and_Development/Bad_Bugs_No_Drugs/St\n                                                                ate-\n                                                                ments/As%20Antibiotic%20Discovery%20\n                                                                Stag-\n                                                                nates%20A%20Public%20Health%20Crisis\n                                                                %20Brews.pdf\n\nIDSA (2011)               An unmet medical need: rapid          Supplement article IDSA public policy         Accessed:\n                          molecular diagnostics tests for       Clinical Infectious Diseases 52 (Suppl 4):    14 August\n(\"IDSA (2011)\")           respiratory tract infections          S384-S395                                     2015\n\n\n\n\n                                                                                                                  239\n", "page_number": 242, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9563916203505771, "height": 0.8743052586575459, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-243-0", "text": "Author                     Title                                  Source /Name                                  Date of\n                                                                                                                origin /\n                                                                                                                Access date\n\nInfekt-Liga (2010)         Diabetisches Fu\u00dfsyndrom                http://www.infektliga.de/empfehlungen/hau     Accessed:\n                                                                  t-weichgewebeinfektionen/diabetisches-        25 August\n(\"Infekt-Liga (2010)\")                                            fusssyndrom/                                  2015\n\nJamal et al. (2014)        Evaluation of Curetis Unyvero, a       Journal of Clinical Microbiology, July        Accessed:\n                           multiplex PCR-based testing            2014, 52(7): pp. 2487-2492                    28 August\n(\"Jamal et al. (2014)\")    system, for rapid detection of                                                       2015\n                           bacteria and antibiotic resistance\n                           and impact of the assay on Man-\n                           agement of severe nosocomial\n                           pneumonia\n\nJawad et al. (2012)        Assessing available information        Journal of global health, 2(1):pp. 1-9.       Accessed:\n                           on the burden of sepsis: global                                                      24 August\n(\"Jawad et al. (2012)\")    estimates of incidence, prevalence                                                   2015\n                           and mortality\n\nKalorama Information       The Market and Potential for           www.kaloramainformation.com                   Accessed:\n(2014)                     Molecular Point of Care Diagnos-                                                     29 July\n                           tics                                                                                 2015\n(\"Kalorama Infor-\nmation (2014)\")\n\nKirkland et al. (1999)     The impact of Surgical-site Infec-     Infection control and hospital epidemiology   Accessed:\n                           tions in the 1990s: Attributable       20(11): pp. 725-730.                          26 August\n(\"Kirkland et al.          mortality, excess length of hospi-                                                   2015\n(1999)\")                   talization and extra costs, infec-\n                           tion control and hospital epidemi-\n                           ology\n\nKlevens et al. (2007) in   Introduction to Surgical Site          www.fda.gov/downloads/AdvisoryCommitt         Accessed:\nJhung (2009)               Infections' CDC presentation           ees/CommitteesMeetingMaterials/Drugs/A        13 August\n                                                                  dvisoryCommitteeforPharmaceuticalScien-       2015\n(\"Klevens et al. (2007)                                           ceandClinicalPharmacolo-\nin Jhung (2009)\")                                                 gy/UCM179000.pdf\n\nKollef (2000)              Inadequate antimicrobial treat-        Clinical Infectious Diseases                  Accessed:\n                           ment: an important determinant of      31(Suppl4):S131-138                           28 August\n(\"Kollef (2000)\")          outcome for hospitalised patients                                                    2015\n\nKollef et al. (1999)       Inadequate antimicrobial treat-        American College of chest physicians          Accessed:\n                           ment of infections: a risk factor      115(2): pp. 462-474                           26 August\n(\"Kollef et al. (1999)\")   for hospital mortality among                                                         2015\n                           critically III patients\n\nKollef et al. (2005)       Epidemiology and outcomes of           Chest 2005, 128: pp. 3854-3862                Accessed:\n                           health-care-associated pneumonia                                                     27 August\n(\"Kollef et al. (2005)\")                                                                                        2015\n\nKumar et al. (2006)        Duration of hypotension before         Critical Care Medicine 34(6): pp.1589-        Accessed:\n                           initiation of effective antimicrobi-   1596.                                         21 August\n(\"Kumar et al.             al therapy is the critical determi-                                                  2015\n(2006)\")                   nant of survival in human septic\n                           shock\n\nKurtz et al. (2007)        Projections of primary and revi-       J Bone Joint Surg Am                          Accessed:\n                           sion hip and knee arthroplasty in                                                    27 August\n(\"Kurtz et al. (2007)\")    the United States from 2005 to                                                       2015\n                           2030\n\nKurtz et al. (2012)        Economic burden of periprosthet-       The Journal of arthroplasty 27(8) Suppl.1:    Accessed:\n                           ic joint infection in the United                                                     28 August\n\n                                                                                                                    240\n", "page_number": 243, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9576742197520308, "height": 0.8755878580589996, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-244-0", "text": "Author                     Title                                  Source /Name                                   Date of\n                                                                                                                 origin /\n                                                                                                                 Access date\n(\"Kurtz et al. (2012)\")    States                                 pp. 61-65                                      2015\n\nLaroy (2015)               Next in line: Personalized             http://www.phar-in.eu/wp-                      Accessed:\n                           Healthcare                             con-                                           12 Septem-\n(\"Laroy (2015)\")                                                  tent/uploads/2015/07/EIPG25_complete.pdf       ber 2015\n\nLevy et al. (2003)         2001                                   Intensive Care Medicine 29: pp. 530-538        Accessed:\n                           SCCM/ESICM/ACCP/ATS/SIS                                                               17 August\n(\"Levy et al. (2003)\")     International Sepsis Definition                                                       2015\n                           Conference\n\nLipsky et al. (2012)       2012 Infectious Diseases Society       Clinical Infectious Diseases 54(12): pp.132-   Accessed:\n                           of America Clinical Practice           173                                            26 August\n(\"Lipsky et al. (2012)\")   Guideline for the Diagnosis and                                                       2015\n                           Treatment of Diabetic Foot Infec-\n                           tions\n\nLivesley and Chow          'Infected pressure ulcers in elderly   Aging and infectious diseases 35: pp.1390-     Accessed:\n(2002)                     individuals                            1396,                                          13 August\n                                                                  http://cid.oxfordjournals.org/content/35/11/   2015\n(\"Livesley and Chow                                               1390.full.pdf+html\n(2002)\")\n\nMagiorakos et al.          Multidrug-resistant, extensively       European Society of Clinical Microbiology      Accessed:\n(2012)                     drug-resistant     and     pandrug-    and Infectious Diseases 18: pp. 268-281        28 August\n                           resistant bacteria: an international                                                  2015\n(\"Magiorakos et al.        expert proposal for interim stand-\n(2012)\")                   ard definitions for acquired re-\n                           sistance\n\nMargolis et al. (2011)     Incidence of diabetic foot ulcer       http://www.ncbi.nlm.nih.gov/books/NBK65        Accessed:\n                           and lower extremity amputation         149/                                           13 August\n(\"Margolis et al.          among Medicare beneficiaries,                                                         2015\n(2011)\")                   2006 to 2008\n\nMarketsandMarkets          Molecular diagnostics market \u2013                                                        Accessed:\n(2014)                     global forecasts to 2018                                                              06 August\n                                                                                                                 2015\n(\"MarketsandMarkets\n(2014)\")\n\nMarketsandMarkets          Blood Culture Tests Market             http://www.marketsandmarkets.com/PressR        Accessed:\n(2015)                     worth $3,893.5 Million by 2019         eleases/blood-culture-test.asp                 27 August\n                                                                                                                 2015\n(\"MarketsandMarkets\n(2015)\")\n\nMartin (2012)              Sepsis, severe sepsis and septic       Expert Review of Anti Infective Therapy        Accessed:\n                           shock: changes in incidence,           10(6): pp. 701-706.                            25 August\n(\"Martin (2012)\")          pathogens and outcomes                                                                2015\n\nMayhall (2003)              The epidemiology of burn wound        37: pp.543-50, Available at                    Accessed:\n                           infections: then and now'              http://cid.oxfordjournals.org/content/37/4/5   13 August\n(\"Mayhall (2003)\")         Healthcare Epidemiology                43.full.pdf+html                               2015\n\nMayo Foundation for        Disease and conditions: Pneumo-        http://www.mayoclinic.org/diseases-            Accessed:\nMedical Education and      nia                                    conditions/pneumonia/basics/causes/CON-        11 August\nResearch (2015)                                                   20020032                                       2015\n(\"Mayo Foundation\nfor Medical Education\nand Research (2015)\")\n", "page_number": 244, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.9166310389055152, "height": 0.834544677212484, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-244-1", "text": "241\n", "page_number": 244, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8500604594921403, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.023579201934703753}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-245-0", "text": "Author                     Title                                   Source /Name                                     Date of\n                                                                                                                    origin /\n                                                                                                                    Access date\n\nMichelotti et al. (2012)   Cardiovascular implantable elec-        http://www.escardio.org/Guidelines-&-            Accessed:\n                           tronic device infection: diagnosis      Education/Journals-and-publications/ESC-         20 August\n(\"Michelotti et al.        and treatment                           journals-family/E-journal-of-Cardiology-         2015\n(2012)\")                                                           Practice/Volume-11/Cardiovascular-\n                                                                   implantable-electronic-device-infection-\n                                                                   diagnosis-and-treatment#.UfYu1mTwDIU\n\nMinistry of Health         Healthcare Institution Statistics:      https://www.moh.gov.sg/content/moh_web/          Accessed:\nSingapore (2014)           Introduction to Healthcare Institu-     home/statistics/healthcare_institutionstatisti   12 Septem-\n                           tion Statistics                         cs.html                                          ber 2015\n(\"Ministry of Health\nSingapore (2014)\")\n\nMittermayer (2006)         Infektion beim diabetischen Fu\u00df \u2013       Antibiotika Monitor, Vol. XXII, 4/5/2006         Accessed:\n                           Mikrobiologie                                                                            26 August\n(\"Mittermayer                                                                                                       2015\n(2006)\")\n\nMorens & Fauci (2015)      Emerging       Infectious        dis-   PLOS Pathogens 9 (7): 1-3,                       Accessed:\n                           ease/pathogens                          http://www.ncbi.nlm.nih.gov/pmc/articles/P       30 July\n(\"Morens & Fauci                                                   MC3701702/<                                      2015\n(2015)\")\n\nNHS (2008)                 Surgical site infection: Prevention     NICE clinical guideline 74                       Accessed:\n                           and treatment of surgical site                                                           10 August\n(\"NHS (2008)\")             infection                                                                                2015\n\nNovumed (2013a)            Market access strategies for Cu-                                                         Accessed:\n                           retis Unyvero System \u2013 Final                                                             16 Septem-\n(\"Novumed (2013a)\")        presentation                                                                             ber 2015\n\n\n\nNovumed (2013b)            Country analysis and market                                                              Accessed:\n                           access strategies for Curetis'                                                           16 Septem-\n(\"Novumed (2013b)\")        Unyvero System                                                                           ber 2015\n\n\n\nN-TV online (2015)         Studie: Millionen werden sterben        http://www.n-tv.de/wissen/Multiresistente-       Accessed:\n                           \u2013 Multiresistente Keime schlim-         Keime-schlimmer-als-Krebs-                       03 June\n(\"N-TV online              mer als Krebs                           article15219316.html<                            2015\n(2015)\")\n\n\n\nOst et al. (2003)          Decision Analysis of Antibiotic         American Journal of Respiratory and Criti-       Accessed:\n                           and Diagnostic Strategies in            cal Care Medicine Vol. 168 2003                  02 Septem-\n(\"Ost et al. (2003)\")      Ventilator-associated Pneumonia                                                          ber 2015\n\nPeralta et al. (2006)      Time to positivity in blood cul-        BMC Infectious Diseases, vol. 6, article 79,     Accessed:\n                           tures of adults with Streptococcus      2006.                                            25 August\n(\"Peralta et al.           pneumonia bacteraemia                   http://www.ncbi.nlm.nih.gov/pmc/articles/P       2015\n(2006)\")                                                           MC1475865/pdf/1471-2334-6-79.pdf\n\nPiskin et al. (2012)       Inadequate treatment of ventila-        http://www.biomedcentral.com/1471-               Accessed:\n                           tor-associated and hospital-            2334/12/268                                      01 Septem-\n(\"Piskin et al. (2012)\")   acquired pneumonia: Risk factors                                                         ber 2015\n                           and impact on outcomes\n\nREFSA (2015)               Private healthcare in Malaysia          http://www.refsa.org/relevant-                   Accessed:\n                           gains strength against public           number/private-healthcare-in-malaysia-           01 Septem-\n(\"REFSA (2015)\")           healthcare                              gains-strength-against-public-healthcare/        ber 2015\n", "page_number": 245, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8851269649334945, "lower_right_y": 0.926891834117144, "height": 0.8448054724241129, "width": 0.779322853688029}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-245-1", "text": "242\n", "page_number": 245, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-246-0", "text": "Author                    Title                               Source /Name                                      Date of\n                                                                                                                origin /\n                                                                                                                Access date\n\nRello (2011)              Determinants of prescription and    European Respiratory Journal 37: 1332-            Accessed:\n                          choice of empirical therapy for     1339                                              27 August\n(\"Rello (2011)\")          hospital-acquired and ventilator-                                                     2015\n                          associated pneumonia\n\nRichard et al. (2011)     New insights in diabetic foot       World Journal of Diabetes 2(2):pp.24-32;          Accessed:\n                          infection                           http://www.ncbi.nlm.nih.gov/pmc/articles/P        13 August\n(\"Richard et al.                                              MC3083903/                                        2015\n(2011)\")\n\nSaker et al. (2004)       Globalisation and infectious        WHO Special topics NO. 3,                         Accessed:\n                          diseases: A review of linkages      http://www.who.int/tdr/publications/docum         28 July\n(\"Saker et al. (2004)\")                                       ents/seb_topic3.pdf<                              2015\n\nSartelli et al. (2012)    Complicated intra-abdominal         World Journal of Emergency Surgery                Accessed:\n                          infections in Europe: a compres-    7(36): pp. 1-9.                                   26 August\n(\"Sartelli et al.         sive review of the CIAO study                                                         2015\n(2012)\")\n\nSchulte et al. (2014)     Detection of pneumonia associat-    PLOS ONE November 2014 9(11): 1-7                 Accessed:\n                          ed pathogens using a prototype      e110566                                           27 August\n(\"Schulte et al.          multiplexed pneumonia test in                                                         2015\n(2014)\")                  hospitalized patients with severe\n                          pneumonia\n\nSharp et al. (1978)       Microbiology of deep tissue in      Diabetes Care. 1978 Sep-Oct;1(5):289-92,          Accessed:\n                          diabetic gangrene.                  http://www.ncbi.nlm.nih.gov/pubmed/7201           02 October\n(\"Sharp et al. (1978)\")                                       82                                                2015\n\nSolomonkin et al.         Diagnosis and management of          Clinical Infectious Diseases 50: pp. 133-        Accessed:\n(2010)                    complicated intra-abdominal         164                                               26 August\n                          infection in adults and children:                                                     2015\n(\"Solomonkin et al.       guidelines by the surgical infec-\n(2010)\")                  tion society and the Infectious\n                          Diseases Society of America\n\nSpoorenberg et al.        Microbial aetiology, outcomes       BMC Infectious Diseases 14: 335                   Accessed:\n(2014)                    and costs of hospitalisation for                                                      27 August\n                          community-acquired pneumonia;                                                         2015\n(\"Spoorenberg et al.      an observational analysis\n(2014)\")\n\nStatista (2015a)          Total population in the United      http://www.statista.com/statistics/263762/to      Accessed:\n                          States from 2010 to 2020 (in        tal-population-of-the-united-states/              27 August\n(\"Statista (2015a)\")      millions)                                                                             2015\n\nStatista (2015b)          Europ\u00e4ische Union & Euro-Zone:      http://de.statista.com/statistik/daten/studie/1   Accessed:\n                          Gesamtbev\u00f6lkerung von 2005 bis      4035/umfrage/europaeische-union-                  27 August\n(\"Statista (2015b)\")      2015 (in Millionen Einwohner)       bevoelkerung-einwohner/                           2015\n\nSunderlin (2006)          Keeping pace with cardiac devic-    http://www.modernmedicine.com/modern-             Accessed:\n                          es                                  medicine/content/keeping-pace-cardiac-            13 August\n(\"Sunderlin (2006)\")                                          devices                                           2015\n\nTennvall & Apelqvist      Health-economic consequences of     Clinical Infectious Diseases 39: 132-9            Accessed:\n(2004)                    diabetic foot lesions                                                                 21 July\n                                                                                                                2015\n(\"Tennvall & Apel-\nqvist (2004)\")\n\nTavernise and Shear       Obama Seeks to Double Funding       New York Times, 28 March 2015,                    Accessed:\n(2015)                    to Fight Antibiotic Resistance      >http://www.nytimes.com/2015/03/28/us/p           28 May\n                                                              olitics/obama-seeks-to-double-funding-to-\n", "page_number": 246, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.9303120991876871, "height": 0.8482257374946559, "width": 0.7787182587666264}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-246-1", "text": "243\n", "page_number": 246, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-247-0", "text": "Author                  Title                                Source /Name                                 Date of\n                                                                                                          origin /\n                                                                                                          Access date\n(\"Tavernise and Shear                                        fight-antibiotic-resistance.html?_r=0<       2015\n(2015)\")\n\nTenner et al. (2013)    American College of Gastroen-        The American Journal of Gastroenter-         Accessed:\n                        terology Guideline: Management       ology, pp. 1-16, available at:               25 August\n(\"Tenner et al.         of Acute Pancreatitis                                                             2015\n(2013)\")                                                     http://gi.org/guideline/acute-\n                                                             pancreatitis/\n\nThe Economist (2014)    The cost of resistance               http://www.eiu.com/industry/article/173257   Accessed:\n                                                             5957/the-cost-of-resistance/2014-12-16       20 August\n(\"The Economist                                                                                           2015\n(2014)\")\n\nThe White House         Obama Administration Takes           <https://www.whitehouse.gov/the-press-       Accessed:\n(2014)                  Actions to Combat Antibiotic-        office/2014/09/18/fact-sheet-obama-          07 August\n                        Resistant Bacteria                   administration-takes-actions-combat-         2015\n(\"The White House                                            antibiotic-resistan>\n(2014)\")\n\nTrampuz & Widmer        \u2018infections associated with ortho-   http://www.ff.ul.pt/FCT/EXPL/CTM-            Accessed:\n(2006)                  paedic implants                      BIO/1141/2012/Ref%202.pdf                    05 August\n                                                                                                          2015\n(\"Trampuz & Widmer\n(2006)\")\n\nUniversit\u00e4tsklinikum    DRG Research Group                   http://drg.uni-                              Accessed:\nM\u00fcnster (2015)          Medizinisches Management \u2013           muen-                                        27 August\n                        Webgrouper                           ster.de/index.php?option=com_webgrouper      2015\n(\"Universit\u00e4tsklin-                                          &view=webgrouper&Itemid=26\nikum M\u00fcnster\n(2015)\")\n\nVogelmann & Ebert       Multiresistente Erreger in der       Gastroenterologe 2014,                       Accessed:\n(2014)                  Gastroenterologie                    DOI10.1007/s11377-014-947-7                  26 August\n                                                                                                          2015\n(\"Vogelmann & Ebert\n(2014)\")\n\nWHO (2015a)             The top 10 causes of death \u2013 The     http://www.who.int/mediacentre/factsh        Accessed 28\n                        10 leading causes of death by        eets/fs310/en/index1.html                    August\n(\"WHO (2015a)\")         country income group (2012)                                                       2015\n\nWHO (2015b)             Antimicrobial resistance \u2013 Draft     >http://apps.who.int/gb/ebwha/pdf_files/W    Accessed:\n                        Global Action Plan on Antimi-        HA68/A68_20-en.pdf?ua=1<                     26 June\n(\"WHO (2015b)\")         crobial Resistance                                                                2015\n", "page_number": 247, "bounding_box": {"top_left_x": 0.10580411124546554, "top_left_y": 0.08208636169303121, "lower_right_x": 0.8845223700120919, "lower_right_y": 0.6977340743907653, "height": 0.6156477126977341, "width": 0.7787182587666264}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-247-1", "text": "244\n", "page_number": 247, "bounding_box": {"top_left_x": 0.8264812575574365, "top_left_y": 0.946985891406584, "lower_right_x": 0.8512696493349455, "lower_right_y": 0.9563916203505771, "height": 0.009405728943993164, "width": 0.024788391777509022}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-248-0", "text": "FINANCIAL SECTION\n", "page_number": 248, "bounding_box": {"top_left_x": 0.3776470588235294, "top_left_y": 0.10636363636363637, "lower_right_x": 0.6211764705882353, "lower_right_y": 0.12318181818181818, "height": 0.016818181818181815, "width": 0.24352941176470594}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-248-1", "text": "Contents\n", "page_number": 248, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.14863636363636365, "lower_right_x": 0.20705882352941177, "lower_right_y": 0.16, "height": 0.011363636363636354, "width": 0.061764705882352944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-248-2", "text": "Annual Financial Statements of Curetis AG for the Financial Years\n                                                                                   F\nfrom January 1, 2012 through December 31, 2014\n   Statement of profit or loss and other comprehensive income                      F\n   for the years ended 31 December\n   Statement of financial position for the years ended 31 December                 F\n   Statement of cash flows for the years ended 31 December                         F\n   Statement of changes in equity                                                  F\n   Notes to the financial statements                                               F\n   Independent auditor's report                                                    F\n\nInterim Financial Statements of Curetis AG for the six months period ended\n                                                                                   F\n30 June 2015\n   Statement of profit or loss and other comprehensive income as of 30 June 2015   F\n   Statement of financial position as of 30 June 2015                              F\n   Statement of cash flows as of 30 June 2015                                      F\n   Statement of changes in equity as of 30 June 2015                               F\n   Notes to the financial statements                                               F\n", "page_number": 248, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.17045454545454544, "lower_right_x": 0.88, "lower_right_y": 0.5227272727272727, "height": 0.3522727272727273, "width": 0.7676470588235295}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-248-3", "text": "", "page_number": 248, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02117647058823524}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-249-0", "text": "Annual Financial Statements for the Financial Years\nfrom January 1, 2012 through December 31, 2014", "page_number": 249, "bounding_box": {"top_left_x": 0.27705882352941175, "top_left_y": 0.545, "lower_right_x": 0.7194117647058823, "lower_right_y": 0.5786363636363636, "height": 0.033636363636363575, "width": 0.44235294117647056}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-249-1", "text": "", "page_number": 249, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.022941176470588243}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-250-0", "text": "CURETIS AG\nSTATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOM\nFor the years ended 31 December\n", "page_number": 250, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.7105882352941176, "lower_right_y": 0.1340909090909091, "height": 0.04363636363636364, "width": 0.5982352941176471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-250-1", "text": "in Euro                                                                   2014                 2013                 201\n\nRevenue [4]                                                           274,552              671,255              145,75\nCost of sales [5]                                                     642,519              219,248              428,91\nGross profit                                                          -367,967             452,007             -283,16\n\nDistribution costs [7]                                              1,939,334            1,575,923            1,863,56\nAdministrative expenses [8]                                         1,637,406            1,256,411            1,436,80\nResearch and development expenses [10]                              6,297,554            5,894,522            5,357,95\nOther income                                                          110,600               48,896               22,24\nOperating profit                                                  -10,131,661           -8,225,953           -8,919,23\n\nFinance income                                                          5,754               29,934               71,41\nFinance costs                                                          22,363               28,298               42,59\nFinance costs fair value measurement                                2,285,652            2,496,979           32,098,21\nFinance income/costs - net [11]                                    -2,302,261           -2,495,343          -32,069,40\n\n\nProfit before income tax                                          -12,433,922          -10,721,296          -40,988,63\nTax income [29]                                                             -                    -              -76,98\nProfit for the year                                               -12,433,922          -10,721,296          -40,911,65\nOther comprehensive income for the year, net of tax                         -                    -\nTotal comprehensive income for the year                           -12,433,922          -10,721,296          -40,911,65\n\nEarnings/loss per share [12]                                              2014                 2013                 201\nBasic                                                                   -18.97               -16.35               -62.4\nDiluted                                                                 -18.97               -16.35               -62.4\n\n\n[..] Bracketed numbers refer to the related notes to the financial statements, which form an integral part of these fin\n", "page_number": 250, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.145, "lower_right_x": 0.8611764705882353, "lower_right_y": 0.6336363636363637, "height": 0.48863636363636365, "width": 0.7488235294117648}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-250-2", "text": "[..] Bracketed numbers refer to the related notes to the financial statements, which form an integral part of these financial\nstatements.", "page_number": 250, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.665, "lower_right_x": 0.8794117647058823, "lower_right_y": 0.6909090909090909, "height": 0.02590909090909088, "width": 0.7664705882352941}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-250-3", "text": "F-3", "page_number": 250, "bounding_box": {"top_left_x": 0.8629411764705882, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9513636363636364, "height": 0.010000000000000009, "width": 0.02176470588235302}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-251-0", "text": "CURETIS AG\nSTATEMENT OF FINANCIAL POSITION\nFor the years ended 31 December\n", "page_number": 251, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.4264705882352941, "lower_right_y": 0.13772727272727273, "height": 0.04727272727272727, "width": 0.3141176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-251-1", "text": "Assets\n\nin Euro\n                                          31.12.2014   31.12.2013   31.12.2012   01.01.201\nCurrent assets                             6,485,882    8,798,456   11,129,221   12,204,47\nCash and cash equivalents [13]             2,993,883    5,381,963    9,777,456   11,856,93\nTrade receivables [14]                        42,235      139,879       55,635\nInventories [16]                           3,153,137    2,785,994    1,005,299      86,59\nOther current assets [17]                    296,627      490,620      290,831     260,93\n\n\nNon-current assets                         7,307,395    7,308,403    6,988,977    5,425,62\nIntangible assets [18]                       286,355      330,856      336,412      176,68\nProperty, plant and equipment [19]         6,591,674    6,457,050    5,986,285    5,198,71\nOther non-current assets                         390        6,571       16,054\nOther non-current financial assets [20]      428,976      513,926      650,226      50,22\nDeferred tax assets [29]                           -            -            -\n\nTOTAL ASSETS                              13,793,277   16,106,859   18,118,198   17,630,09\n", "page_number": 251, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1740909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4868181818181818, "height": 0.31272727272727274, "width": 0.7723529411764707}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-251-2", "text": "[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financial\nstatements.", "page_number": 251, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5159090909090909, "lower_right_x": 0.8752941176470588, "lower_right_y": 0.5418181818181819, "height": 0.025909090909090993, "width": 0.7629411764705882}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-251-3", "text": "", "page_number": 251, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02352941176470591}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-252-0", "text": "CURETIS AG\nSTATEMENT OF FINANCIAL POSITION\nFor the years ended 31 December\n", "page_number": 252, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.4264705882352941, "lower_right_y": 0.13772727272727273, "height": 0.04727272727272727, "width": 0.3141176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-252-1", "text": "Equity and Liabilities\n", "page_number": 252, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.17045454545454544, "lower_right_x": 0.2776470588235294, "lower_right_y": 0.18772727272727271, "height": 0.017272727272727273, "width": 0.1652941176470588}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-252-2", "text": "in Euro                                       31.12.2014            31.12.2013            31.12.2012            01.01.20\nCurrent liabilities                            1,304,748             1,089,513             1,258,963             1,330,4\nTrade and other payables [21]                    579,862               615,968               633,503               947,2\n\nProvisions current [22]                            34,800                 5,599                   651\nOther current liabilities [23]                   316,817               300,977               445,928               383,1\nOther current financial liabilities\n[24]                                             373,269               166,969               178,881\n\n\nNon-current liabilities                      131,024,233           121,119,128          112,239,721             70,768,5\nProvisions non-current [22]                      816,065               777,210               770,281               741,5\nProvision PSO [25]                             3,913,841             2,957,022             3,089,847             1,086,6\nOther non-current financial liabili-\nties [26]                                        258,168               391,918               519,440\nFinancial liability for preferred and\ncommon shares [28]                           126,036,159           116,992,978          107,860,153             68,863,3\n\nDeferred tax liabilities [29]                            -                     -                     -              76,9\n\nTOTAL LIABILITIES                            132,328,981           122,208,641          113,498,684             72,098,9\n\n\nEQUITY                                      -118,535,704          -106,101,782           -95,380,486           -54,468,8\nSubscribed equity [30]                             50,000                50,000               50,000                50,0\n\nAdditional paid-in capital                               -                     -                     -\nRetained earnings                           -118,585,704          -106,151,782           -95,430,486           -54,518,8\n\n TOTAL EQUITY AND\n LIABILITIES                                  13,793,277              16,106,859         18,118,198             17,630,0\n[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financi\nstatements.\n", "page_number": 252, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19590909090909092, "lower_right_x": 0.8811764705882353, "lower_right_y": 0.6845454545454546, "height": 0.48863636363636365, "width": 0.7688235294117648}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-252-3", "text": "statements.\n", "page_number": 252, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.685, "lower_right_x": 0.8811764705882353, "lower_right_y": 0.7268181818181818, "height": 0.041818181818181754, "width": 0.7688235294117648}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-252-4", "text": "", "page_number": 252, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02352941176470591}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-253-0", "text": "CURETIS AG\nSTATEMENT OF CASH FLOWS\nFor the years ended 31 December\n", "page_number": 253, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.34823529411764703, "lower_right_y": 0.13772727272727273, "height": 0.04727272727272727, "width": 0.23588235294117643}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-253-1", "text": "in Euro                                                                        2014             2013            201\n\nProfit before income tax                                               -12,433,922      -10,721,296      -40,988,63\nAdjustments for:\n- Net finance cost                                                        2,302,261       2,495,343       32,069,40\n- Depreciation, amortization and impairments                              1,448,455       1,271,931          956,42\n- Changes in provisions (excluding deferred taxes)                        1,023,028        -120,948        2,032,63\n\nChanges in working capital relating to:\n- Inventories                                                              -367,143      -1,780,695         -918,70\n- Trade receivables and other receivables                                   382,767        -138,250         -701,58\n- Trade payables and other payables                                         179,807        -180,335          496,31\n\nIncome taxes received (+) / paid (-)                                              -                -\nInterest received (+) / paid (-)                                            -16,609            1,636          28,81\nNet cash flow provided by operating activities                           -7,481,356      -9,172,614       -7,025,34\n\nInvestments in intangible assets                                            -66,878         -89,223         -210,21\nInvestments in property, plant and equipment                             -1,512,013      -1,648,814       -2,383,50\n\nReceipts from sale of assets                                                  4,000                 -        690,00\n\nProceeds from disposal of fixed assets                                       38,161              897\nNet cash flow used in investing activities                               -1,536,730      -1,737,140       -1,903,71\n\nPayments of finance lease liabilities                                      -127,523        -121,585          -48,97\nCash received from issuance of preferred shares                           6,757,529       6,635,846        6,898,55\nNet cash flow provided by / used in financing activities                  6,630,006       6,514,261        6,849,57\n\nNet change in cash and cash equivalents                                  -2,388,080      -4,395,493       -2,079,48\n\nCash and cash equivalents at the beginning of the year                    5,381,963       9,777,456       11,856,93\nChange in cash and cash equivalents                                      -2,388,080      -4,395,493       -2,079,48\nCash and cash equivalents at the end of the year                            2,993,883      5,381,963       9,777,45\n[..]      Bracketed numbers refer to the related notes to the financial statements which form an integral part of the\n   financial statements.\n", "page_number": 253, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.14954545454545454, "lower_right_x": 0.8464705882352941, "lower_right_y": 0.7768181818181819, "height": 0.6272727272727273, "width": 0.7341176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-253-2", "text": "[.] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these\nfinancial statements.", "page_number": 253, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.7768181818181819, "lower_right_x": 0.8452941176470589, "lower_right_y": 0.8036363636363636, "height": 0.02681818181818174, "width": 0.731764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-253-3", "text": "F-6", "page_number": 253, "bounding_box": {"top_left_x": 0.8629411764705882, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9509090909090909, "height": 0.009545454545454524, "width": 0.02176470588235302}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-254-0", "text": "CURETIS AG\nSTATEMENT OF CHANGES IN EQUITY\n", "page_number": 254, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.1159090909090909, "lower_right_x": 0.40941176470588236, "lower_right_y": 0.14772727272727273, "height": 0.03181818181818183, "width": 0.29647058823529415}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-254-1", "text": "                                                 Subscribed                                   Retained\nin Euro                                              capital     Capital reserve              earnings         Total equi\nBalance as of 1 January 2012\n(German GAAP)                                      3,888,786           25,910,552          -15,606,817           14,192,5\nIFRS 1 Opening Adjustments                        -3,838,786          -25,910,552          -38,912,013          -68,661,3\n\nBalance as of 1 January 2012 (IFRS)                   50,000                      -        -54,518,830          -54,468,8\n\n\nProfit of the year 2012                                      -                    -        -40,911,656          -40,911,6\nTotal comprehensive income for the\nyear 2012                                                    -                    -        -40,911,656          -40,911,6\n\nBalance as of 31 December 2012\n(IFRS)                                                50,000                      -        -95,430,486          -95,380,4\n\n\nProfit of the year 2013                                      -                    -        -10,721,296          -10,721,2\nTotal comprehensive income for the\nyear 2013                                                    -                    -        -10,721,296          -10,721,2\n\nBalance as of 31 December 2013\n(IFRS)                                                50,000                      -       -106,151,782         -106,101,7\n\n\nProfit of the year 2014                                      -                    -        -12,433,922          -12,433,9\nTotal comprehensive income for the\nyear 2014                                                    -                    -        -12,433,922          -12,433,9\n\n Balance as of 31 December 2014\n (IFRS)                                                 50,000                     -     -118,585,704           -118,535,7\n [..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financia\nstatements.\n", "page_number": 254, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.15954545454545455, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.68, "height": 0.5204545454545455, "width": 0.7694117647058824}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-254-2", "text": "", "page_number": 254, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02352941176470591}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-0", "text": "NOTES TO THE FINANCIAL STATEMENTS\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.44176470588235295, "lower_right_y": 0.10181818181818182, "height": 0.011363636363636367, "width": 0.32941176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-1", "text": "General Information\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.2917647058823529, "lower_right_y": 0.14, "height": 0.013181818181818183, "width": 0.17941176470588233}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-2", "text": "Curetis AG (Curetis or the Company) was incorporated in 2007 and is domiciled in Holzgerlingen, Germany. T\naddress of its registered office is Max-Eyth-Str. 42, 71088 Holzgerlingen.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.1559090909090909, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.18545454545454546, "height": 0.02954545454545454, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-3", "text": "Curetis is a molecular diagnostics company specialized in the development of solutions for diagnosing severe inf\ntious diseases in hospitalized patients. The solutions enable physicians to detect pathogens and antibiotic resista\nmarkers early.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.24363636363636362, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-4", "text": "2. Accounting and valuation methods", "page_number": 255, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.26136363636363635, "lower_right_x": 0.3905882352941176, "lower_right_y": 0.2731818181818182, "height": 0.011818181818181839, "width": 0.27705882352941175}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-5", "text": "plied consistently to all years presented, unless otherwise stated.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29045454545454547, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.31863636363636366, "height": 0.028181818181818197, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-6", "text": "2.1. Basis of preparation", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3340909090909091, "lower_right_x": 0.2823529411764706, "lower_right_y": 0.3481818181818182, "height": 0.014090909090909098, "width": 0.16999999999999998}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-7", "text": "accordance with the International Financial Reporting Standards (IFRS) and the Interpretations (IFRIC) as endor\nby the European Union (EU) and were approved for issuance by the Board of Management on 22 October 2015.\n\nThe financial statements have been prepared under the historical cost convention except for the financial liabilit\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11411764705882353, "top_left_y": 0.36318181818181816, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4072727272727273, "height": 0.044090909090909125, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-8", "text": "connected with preferred and common shares that are measured at fair value as required by IFRS. The statement\nprofit or loss is prepared based on the cost-of-sales method.\n\nThe financial statements have been prepared on a going concern basis. However, in the event Curetis would not\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4213636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.46545454545454545, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-9", "text": "by risks. The business plan prepared in case of a withdrawn IPO includes significant reductions to operating expe\nes through elimination of anticipated costs of \u201cbeing public\u201d and suspension of clinical trials. Personnel cost red\ntions are to be achieved through reductions in planned head count and cancellation of salary increases. Additiona\nin order to improve working capital, reductions will be made to capital expenditure for new projects. Managemen\nof the opinion that the combination of these measures enables Curetis to continue as a going concern for at least\nmonths as of the date of the financial statements. In order to ensure going concern beyond these 12 months the co\npany may rely on further significant operating expenditure and capital expenditure reductions or may also seek ad\ntional financing from current or future shareholders privately, whether in the form of bridge loans and/or equity\nferings.\n\nConsidering the above stated countermeasures, even in case of a withdrawn IPO, Curetis would be able to contin\nas a going concern for at least 12 months as of the date of the financial statements.\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.47954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.64, "height": 0.16045454545454546, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-10", "text": "These financial statements cover the business year from 1 January 2014 to 31 December 2014 (comparative ann\nperiod: 1 January 2013 to 31 December 2013 as well as 1 January 2012 to 31 December 2012) and represent Cure\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6540909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6836363636363636, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-11", "text": "first financial statements prepared in accordance with IFRS, following the guidance of IFRS 1.\n\nThe functional currency of the Company is Euro. The primary financial statements are presented in Euro and\nnotes to the financial statements are presented in thousands of Euros (kEUR) in accordance with commercial rou\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6977272727272728, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7418181818181818, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-12", "text": "The following explanatory notes are an integral part of the financial statements which further comprise the statem\nof profit or loss and other comprehensive income, the statement of financial position, the statement of cash flows a\n", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7595454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8018181818181818, "height": 0.04227272727272724, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-13", "text": "The following explanatory notes are an integral part of the financial statements which further comprise the statement\nof profit or loss and other comprehensive income, the statement of financial position, the statement of cash flows and\nthe statement of changes in equity.", "page_number": 255, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8177272727272727, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.8604545454545455, "height": 0.042727272727272725, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-255-14", "text": "", "page_number": 255, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02352941176470591}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-0", "text": "2.2. Standards, interpretations, and amendments issued, but not yet to be applie\n", "page_number": 256, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.6588235294117647, "lower_right_y": 0.10545454545454545, "height": 0.015, "width": 0.5464705882352942}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-1", "text": "The International Accounting Standards Board (IASB) continues to issue new standards, interpretations and ame\nments to existing standards. Curetis applies these new standards when their mandatory application is required by\nEU. Curetis has not opted for early adoption for any of these standards.\n", "page_number": 256, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.16363636363636364, "height": 0.04409090909090908, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-2", "text": "New standards, amendments and interpretations revised but not yet effecti\n", "page_number": 256, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.17045454545454544, "lower_right_x": 0.6164705882352941, "lower_right_y": 0.18545454545454546, "height": 0.015000000000000013, "width": 0.5041176470588236}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-3", "text": "The following new standards and interpretations and amendments to existing standards will become effective on\nafter 1 January 2015.\n", "page_number": 256, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.20681818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.23636363636363636, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-4", "text": "                                                                             Adopted              Applicatio\nStandard/Interpretation             Content                                  by the EU         mandatory fro\nIFRS 9: Financial Instruments       Classification and Measurement re-       No                            -\n                                    quirements, Hedge Accounting and\n                                    amendments to IFRS 9, IFRS 7 and\n                                    IAS 39\nIFRS 14: Regulatory deferral ac-    Accounting for regulatory deferral       No                             -\ncounts                              accounts\nIFRS 15: Revenue from contracts     Accounting for revenue recognition       No                             -\nwith customers\nAmendments to IAS 1                 Disclosure Initiative                    No                             -\n\nAmendments to IFRS 10 and IAS       Sale or contribution of assets between   No                             -\n28                                  an investor and an associate or joint\n                                    venture\nAmendments to IFRS 10, IFRS 12      Investment Entities: Applying the        Yes                     01.02.201\nand IAS 28                          Consolidation Exception\nAmendments to IFRS 11               Acquisition of an interest in a joint    No                             -\n                                    operation\nAmendments to IAS 16 and IAS        Acceptable methods of depreciation       No                             -\n38                                  and amortization\nAmendments to IAS 16 and IAS        Agriculture: Bearer Plants               No                             -\n41\nAmendments to IAS 19                Defined Benefit Plans: Employee          Yes                     01.02.201\n                                    Contribution\nAmendments to IAS 27                Equity method in separate financial      No                             -\n                                    statements\nIFRIC 21: Levies                    Account for liabilities to pay levies    Yes                     17.06.201\n                                    imposed by governments\nAmendments to IFRSs                 Annual Improvements to IFRSs 2010- Yes                           01.02.201\n                                    2012 Cycle\nAmendments to IFRSs                 Annual Improvements to IFRSs 2011- Yes                           01.01.201\n                                    2013 Cycle\nAmendments to IFRSs                 Annual Improvements to IFRSs 2012- No                                   -\n                                    2014 Cycle\n\nCuretis is yet to analyze the impact of these new standards and amendments to standards and interpretations on\nfinancial statements and does not expect major impacts.\n", "page_number": 256, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.2431818181818182, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.8245454545454546, "height": 0.5813636363636364, "width": 0.7741176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-5", "text": "IFRS 9 \u2018Financial Instruments\u2019 contains rules for the classification and measurement of financial assets and liab\nties. The new standard defines two instead of four measurement categories for financial assets, with classification\n", "page_number": 256, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.8468181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8763636363636363, "height": 0.02954545454545454, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-6", "text": "IFRS 9 \u2018Financial Instruments\u2019 contains rules for the classification and measurement of financial assets and liabili-\nties. The new standard defines two instead of four measurement categories for financial assets, with classification to", "page_number": 256, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8904545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.92, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-256-7", "text": "", "page_number": 256, "bounding_box": {"top_left_x": 0.8611764705882353, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02352941176470591}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-0", "text": "be based partly on the Company\u2019s business model and partly on the characteristics of the contractual cash flows fr\nthe respective financial asset. In the case of equity investments that are not held for trading, an entity may irrevo\nbly opt at initial recognition to recognize future changes in their fair value outside profit or loss in the statement\ncomprehensive income. In November 2013, the IASB issued further amendments under the title \u2018Hedge Account\nand amendments to IFRS 9, IFRS 7 and IAS 39\u2019. The focus of the amendments is on a thorough revision of hed\naccounting rules with the aim of more appropriately reflecting risk management activities in the financial statemen\nThis involves additional disclosures in the notes. In July 2014, the IASB published the new rules for the disclosure\nfinancial instrument impairments. This new impairment model is based on the principle of accounting for expec\nlosses.\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.21818181818181817, "height": 0.12772727272727272, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-1", "text": "count, with some limited changes, for \u2018regulatory deferral accounts balances\u2019 in accordance with its previous GAA\nboth on initial adoption of IFRS and in subsequent financial statements. Regulatory deferral account balances, a\nmovements in them, are presented separately in the statement of financial position and statement of profit or loss a\nother comprehensive income, and specific disclosures are required.\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2359090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.30863636363636365, "height": 0.07272727272727275, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-2", "text": "reporting useful information to users of financial statements about the nature, amount, timing and uncertainty\nrevenue and cash flows arising from an entity\u2019s contracts with customers. Revenue is recognized when a custom\nobtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the good\nservice. The standard replaces IAS 18 \u2018Revenue\u2019 and IAS 11 \u2018Construction contracts\u2019 and related interpretatio\nThe standard is effective for annual periods beginning on or after 1 January 2017 and earlier application is permitte\nThe IASB voted to publish an Exposure Draft proposing a one-year deferral of the effective date of the standard to\nJanuary 2018. Curetis is currently evaluating the impact the changes will have on the presentation of its financ\nposition.\n\nThe amendment to IAS 1 \u2018Presentation of Financial Statements\u2019 clarify, rather than significantly change, existi\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3231818181818182, "lower_right_x": 0.8876470588235295, "lower_right_y": 0.45454545454545453, "height": 0.13136363636363635, "width": 0.7752941176470589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-3", "text": "The amendment to IFRS 10 and IAS 28 address an acknowledgement inconsistency between the requirements\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.46863636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.49727272727272726, "height": 0.028636363636363626, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-4", "text": "associate or joint venture. The main consequence of the amendments is that a full gain or loss is recognized whe\ntransaction involves a business (whether it is housed in a subsidiary or not). A partial gain or loss is recognized wh\na transaction involves assets that do not constitute a business, even if these assets in a subsidiary.\n\nThe amendment to IFRS 10, IFRS 12 and IAS 28 \u201cInvestment Entities: Applying the Consolidation Exception\u201d\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5122727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5854545454545454, "height": 0.07318181818181813, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-5", "text": "The amendment to IFRS 11 adds new guidance on how to account for the acquisition of an interest in a joint ope\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5995454545454545, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.6290909090909091, "height": 0.029545454545454652, "width": 0.77}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-6", "text": "The amendment to IAS 16 and IAS 38 prohibit entities from using a revenue-based depreciation method for items\nproperty, plant and equipment. The amendments introduce a rebuttable presumption that revenue is not an approp\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6468181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6745454545454546, "height": 0.02772727272727271, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-7", "text": "The amendment to IAS 16 and IAS 41 define a bearer plant and require biological assets that meet the definition o\nbearer plant to be accounted for as property, plant and equipment in accordance with IAS 16. Curetis is not engag\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6904545454545454, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.7331818181818182, "height": 0.042727272727272725, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-8", "text": "The objective of the amendment to IAS 19 is to simplify the accounting for contributions from employees or th\nparties to a defined benefit plan. The simplified accounting permits such contributions to be recognized as a red\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7486363636363637, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7918181818181819, "height": 0.04318181818181821, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-9", "text": "is independent of the number of years of service.\n\nThe amendment to IAS 27 will help some jurisdictions move to IFRS for separate financial statements, reduc\ncompliance costs without reducing the information available to investors.\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8068181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.865, "height": 0.05818181818181822, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-10", "text": "F\n", "page_number": 257, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8795454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9090909090909091, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-257-11", "text": "F-10", "page_number": 257, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.026470588235294135}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-0", "text": "The interpretation IFRIC 21 sets out criteria for the recognition of a liability, one of which is the requirement for\nentity to have a present obligation as a result of a past event (known as an obligating event). The interpretation cla\nfies that the obligating event that gives rise to a liability to pay a levy is the activity described in the relevant legis\ntion that triggers the payment of the levy.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.14863636363636365, "height": 0.058181818181818196, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-1", "text": "The IASB issued Annual Improvements to IFRSs 2010-2012 Cycle, Annual Improvements to IFRSs 2011-20\nCycle and Annual Improvements to IFRSs 2012-2014 Cycle which amended various standards in detail. The i\nprovements primarily aim to provide clarifications. The date of initial application varies from standard to standard.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.16318181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.20727272727272728, "height": 0.0440909090909091, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-2", "text": "2.3. Revenue Recognition\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.22136363636363637, "lower_right_x": 0.29, "lower_right_y": 0.23636363636363636, "height": 0.014999999999999986, "width": 0.17705882352941174}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-3", "text": "Curetis recognizes revenue at the time that the relevant risks and opportunities associated with the ownership of\nsold goods and products are transferred to the customer and when it is probable that future economic benefits w\nflow to the entity. Revenues are presented net of value-added tax, rebates and discounts.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.25045454545454543, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3090909090909091, "height": 0.05863636363636365, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-4", "text": "2.4. Cost of sales", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.325, "lower_right_x": 0.23058823529411765, "lower_right_y": 0.34, "height": 0.015000000000000013, "width": 0.11823529411764706}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-5", "text": "Manufacturing costs for products manufactured in-house include the directly allocable individual material and p\nduction costs, the allocable parts of the overhead costs for production including depreciation of production equ\nment and reduction in inventories.\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3559090909090909, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.41, "height": 0.05409090909090908, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-6", "text": "Research expenses are defined as costs i\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.42863636363636365, "lower_right_x": 0.3905882352941176, "lower_right_y": 0.44272727272727275, "height": 0.014090909090909098, "width": 0.278235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-7", "text": "cation of research findings or other knowledge to a plan or design for the production of new or substantially i\nproved materials, devices, products, processes, systems or services before the start of commercial production or us\n\nResearch and development costs are expensed as incurred unless the recognition criteria outlined in IAS 38 are m\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4577272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5159090909090909, "height": 0.05818181818181817, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-8", "text": "and only if, there is reasonable certainty of receiving future cash flows that will cover an asset\u2019s carrying amou\nSince Curetis\u2019 development projects are often subject to regulatory approval procedures and other uncertainties, t\nconditions for the recognition of costs incurred before receipt of approvals are not satisfied in the ordinary course\nbusiness of Curetis.\n\n2.6. Leases\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5304545454545454, "lower_right_x": 0.8894117647058823, "lower_right_y": 0.6145454545454545, "height": 0.0840909090909091, "width": 0.7770588235294118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-9", "text": "Leasing tran\nhas entered\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.6322727272727273, "lower_right_x": 0.19294117647058823, "lower_right_y": 0.6459090909090909, "height": 0.013636363636363558, "width": 0.07999999999999999}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-10", "text": "certain arrangements are analyzed with regard to embedded leases (IFRIC 4). If specific criteria are met, cert\narrangements should be accounted as leases that do not take the legal form of a lease.\n\n2.6.1 As the lessee\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6613636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.72, "height": 0.0586363636363636, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-11", "text": "either as finance le\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7340909090909091, "lower_right_x": 0.23941176470588235, "lower_right_y": 0.7490909090909091, "height": 0.015000000000000013, "width": 0.12705882352941178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-12", "text": "lease\u2019s commencement at the lower of the fair value of the leased property and the present value of the minim\nlease payments. Accordingly, Curetis recognizes the asset and the associated liability in equal amounts. The lea\nproperty is depreciated over its useful economic life or, if it is shorter, the term of the lease. The liability is measu\nby using the effective interest method.\n\nEach lease payment is allocated between the liability and finance charges. The corresponding rental obligations,\nof finance charges, are included in other current financial liabilities and other non-current financial liabilities. T\ninterest element of the finance cost is charged to the income statement over the lease period so as to produce a c\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7668181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8672727272727273, "height": 0.10045454545454546, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-13", "text": "F\n", "page_number": 258, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8831818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9259090909090909, "height": 0.042727272727272725, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-258-14", "text": "F-11", "page_number": 258, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.0252941176470588}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-0", "text": "stant periodic rate of interest on the remaining balance of the liability for each period. The property, plant a\nequipment acquired under finance leases are depreciated over the shorter of the useful life of the asset and lease te\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.11954545454545455, "height": 0.029090909090909098, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-1", "text": "All other transactions not classified as a finance lease in which Curetis is the lessee are classified as operating leas\nPayments made under operating leases (net of any incentives received from the lessor) are charged to the inco\nstatement on a straight-line basis over the period of the lease.\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1340909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.1781818181818182, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-2", "text": "2.6.2 As the lessor\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19227272727272726, "lower_right_x": 0.2388235294117647, "lower_right_y": 0.20363636363636364, "height": 0.011363636363636381, "width": 0.1264705882352941}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-3", "text": "In case Curetis acts as the lessor and substantially all the risks and rewards incident to ownership of the leased pr\nerty are transferred to the lessee, the leasing transactions are classified as finance leases.\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.22136363636363637, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.2509090909090909, "height": 0.02954545454545454, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-4", "text": "value of the minimum lease payments as well as the unguaranteed residual value accruing to Curetis, in sum the\ninvestment in the lease, is recognized as a receivable. The difference between the net investment in the lease and\ngross investment in the lease (that is the nominal values of the minimum lease payments as well as the unguarant\nresidual value accruing to Curetis) is recognized as interest over the lease term using the effective interest method.\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2686363636363636, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3381818181818182, "height": 0.06954545454545458, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-5", "text": "balance sheet as an asset, and the lease payments are generally recorded on a straight-line basis as income over\nterm of the lease.\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3559090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.39590909090909093, "height": 0.040000000000000036, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-6", "text": "Interest income and expenses are recog\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.41409090909090907, "lower_right_x": 0.3764705882352941, "lower_right_y": 0.42818181818181816, "height": 0.014090909090909098, "width": 0.2641176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-7", "text": "2.8. Earnings per share\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4431818181818182, "lower_right_x": 0.6429411764705882, "lower_right_y": 0.4577272727272727, "height": 0.014545454545454528, "width": 0.5305882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-8", "text": "Basic earnings per shar\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4722727272727273, "lower_right_x": 0.2735294117647059, "lower_right_y": 0.48727272727272725, "height": 0.014999999999999958, "width": 0.1611764705882353}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-9", "text": "calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. T\nnumber of shares included with respect to options, warrants and similar instruments is computed using the treas\nstock method. Curetis\u2019 potentially dilutive shares comprise two classes of preferred shares. Potential ordinary sha\nare antidilutive when their conversion to ordinary shares increases earnings per share or decreases loss per share.\n\n2.9. Cash and cash equivalents\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5013636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5886363636363636, "height": 0.08727272727272728, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-10", "text": "Cash and cash equivalents com\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6031818181818182, "lower_right_x": 0.3247058823529412, "lower_right_y": 0.6181818181818182, "height": 0.015000000000000013, "width": 0.21235294117647058}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-11", "text": "2.10.   Trade receivables\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6322727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6618181818181819, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-12", "text": "of business. Receivables q\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.6795454545454546, "lower_right_x": 0.2917647058823529, "lower_right_y": 0.6909090909090909, "height": 0.011363636363636354, "width": 0.1788235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-13", "text": "provisions for impairment. A provision for impairment of trade receivables is established when there is object\nevidence that Curetis will not be able to collect all amounts due, according to the original terms of the receivables\ncollection is expected in one year or less, they are classified as current assets. If not, they are presented as n\ncurrent assets.\n\n2.11.    Inventories\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7086363636363636, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8072727272727273, "height": 0.09863636363636363, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-14", "text": "and\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.825, "lower_right_x": 0.14647058823529413, "lower_right_y": 0.8363636363636363, "height": 0.011363636363636354, "width": 0.034117647058823544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-15", "text": "perating mater\n", "page_number": 259, "bounding_box": {"top_left_x": 0.1688235294117647, "top_left_y": 0.825, "lower_right_x": 0.24941176470588236, "lower_right_y": 0.8363636363636363, "height": 0.011363636363636354, "width": 0.08058823529411765}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-16", "text": "estimated selling price in the ordinary course of business less the estimated costs of completion and the estima\ncosts necessary to make the sale.\n\n                                                                                                              F\n", "page_number": 259, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8540909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9272727272727272, "height": 0.07318181818181813, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-259-17", "text": "F-12", "page_number": 259, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-0", "text": "If the net realizable value of a finished good is lower than costs, the difference is recognized as impairment imme\nately.\n\n2.12.   Intangible Assets\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.14909090909090908, "height": 0.058636363636363625, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-1", "text": "Intangible assets that are acquired against payment are recognized at acquisition cost. They are amortized system\ncally in accordance with their respective useful life (between three and five years). Intangible assets are amortiz\naccording to the straight-line method. There are no intangible assets with an indefinite useful life. Intangible ass\nare reviewed for impairment whenever events or changes in circumstances indicate that the book value may no lo\ner be recoverable. An impairment loss is recognized for the amount by which the asset\u2019s book value exceeds its\ncoverable amount. Impairments are reversed if and to the extent that the reasons for impairment no longer exist. T\nrecoverable amount is defined as the higher of an asset\u2019s fair value less cost to sell and its value in use.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.16318181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.26545454545454544, "height": 0.10227272727272727, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-2", "text": "2.13. Property, plant and equipment", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.27954545454545454, "lower_right_x": 0.3811764705882353, "lower_right_y": 0.29454545454545455, "height": 0.015000000000000013, "width": 0.2688235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-3", "text": "costs (e.g. materials, direct labor and work contracted out) and directly attributable overhead costs.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.30863636363636365, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3381818181818182, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-4", "text": "ciation over the asset\u2019s estimated useful life or as impairment charges. The estimated useful lives of the princ\nproperty, plant and equipment categories are as follows:\n\nAsset class                                                        Depreciation term\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3559090909090909, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.3981818181818182, "height": 0.042272727272727295, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-5", "text": "Building on third-parties\u2019 land                                    Max. 10 years\nTechnical equipment                                                3-13 years\nOffice equipment                                                   2-14 years\nUnyvero-Platforms                                                  3-5 years\n\nProperty, plant and equipment is depreciated using the straight-line method, based on estimated useful life, t\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4036363636363636, "lower_right_x": 0.8670588235294118, "lower_right_y": 0.5022727272727273, "height": 0.09863636363636369, "width": 0.7547058823529412}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-6", "text": "circumstances indicate that the book value of the assets concerned may not be recoverable. An impairment loss\nrecognized for the amount by which the asset\u2019s book value exceeds its recoverable amount. The recoverable amo\nis defined as the higher of an asset\u2019s fair value less cost to sell and its value in use. Impairments are reversed if and\nthe extent that the reasons for impairment no longer exist.\n\nThe assets\u2019 residual values and useful lives are reviewed at least annually and adjusted if appropriate.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5122727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6, "height": 0.08772727272727265, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-7", "text": "2.14.   Original financial instruments\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.615909090909091, "lower_right_x": 0.7811764705882352, "lower_right_y": 0.6309090909090909, "height": 0.014999999999999902, "width": 0.668235294117647}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-8", "text": "Financial instruments are contracts tha\ninstrument at another.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6468181818181818, "lower_right_x": 0.3811764705882353, "lower_right_y": 0.6609090909090909, "height": 0.014090909090909043, "width": 0.2688235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-9", "text": "Financial assets and liabilities are disclosed on the balance sheet when Curetis becomes a contractual party to a\nnancial instrument. Financial assets are recognized at their fair value in the initial disclosure. Subsequent valuat\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6759090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7018181818181818, "height": 0.02590909090909088, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-10", "text": "IAS 39 classifies financial assets into the following categories:\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7195454545454546, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7636363636363637, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-11", "text": "IAS 39 classifies financial assets into the following categories:", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7777272727272727, "lower_right_x": 0.5270588235294118, "lower_right_y": 0.7927272727272727, "height": 0.015000000000000013, "width": 0.4147058823529412}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-12", "text": "\uf0b7   loans and receivables, and\n\n\uf0b7   available-for-sale financial assets.\n", "page_number": 260, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8104545454545454, "lower_right_x": 0.4894117647058824, "lower_right_y": 0.9127272727272727, "height": 0.10227272727272729, "width": 0.3770588235294118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-260-13", "text": "F-13", "page_number": 260, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-0", "text": "Financial instruments of the \u2018Loans and receivables\u2019 category are recognized upon delivery or settlement of the s\nvice, e.g. at the time the claim to payment arises (settlement date). Derivatives are recorded on the day of the trans\ntion, and all other financial assets are recorded on the settlement date. The transaction day is the day on which C\nretis enters into the obligation to purchase or sell an asset. The settlement date is the day on which an asset is del\nered to or by the Company.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.16318181818181818, "height": 0.07272727272727272, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-1", "text": "Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted\nan active market. After initial measurement, loans and receivables are carried at amortized cost using the effect\ninterest rate, less an allowance for uncollectibility. Amortized cost is calculated by taking into account any discou\nor premiums on acquisition and transactions costs. Effects from subsequent measurement using the effective inter\nrate are recognized in the statement of profit or loss under finance income. Loans and receivables are included\ncurrent assets, except for maturities greater than 12 months after the end of the reporting period which are classif\nas non-current assets. Curetis\u2019 loans and receivables comprise \u2018trade receivables\u2019 and \u2018other non-current financ\nassets\u2019, \u2018cash and cash equivalents\u2019 in the balance sheet which are measured at amortized cost using the effect\ninterest rate, less any impairment.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.17772727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.30863636363636365, "height": 0.13090909090909092, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-2", "text": "Derecognition also takes place when a receivable has become irrecoverable. Any effects arising from derecognit\nare recognized through profit or loss.\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.3231818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.36727272727272725, "height": 0.04409090909090907, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-3", "text": "instrument could include:\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.38136363636363635, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4081818181818182, "height": 0.026818181818181852, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-4", "text": "\uf0b7     breach of contract by the debtor, e.g. defaulting on interest or debt repayments,\n\n\uf0b7     concessions made to a debtor that would not have been made under normal circumstances,\n\n\uf0b7     a high probability of insolvency proceedings or other financial restructuring by the debtor,\n\n\uf0b7     observable information from which a reduction in the expected future cash flows can be deduced (e.g. adve\n      changes in the conduct of debtor payments, national or local commercial circumstances), as well as\n\n\uf0b7     a lasting or significant reduction in the fair value of equity instruments under acquisition costs.\n\nThe impairment is determined by taking into account collateral held, or other credit enhancements, with recourse\nthe objective indications. The carrying amount of the asset is reduced by using an adjustment account and recogn\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.42863636363636365, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.610909090909091, "height": 0.1822727272727273, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-5", "text": "ing the impairment loss with an effect on profit or loss. Interest earnings, based on the original effective interest r\nof the asset, continue to be reported on the reduced carrying amount. Receivables, together with the relevant amo\nzation, are derecognized when they are classified as irrecoverable and when all collateral has been accessed a\nutilized. If the amount of an estimated amortization expense increases or decreases in a later reporting period due\nan event occurring after the amortization expense was reported, then the previously reported amortization expense\nincreased or decreased with an effect on profit or loss by adjusting the amortization account. If a derecognized\nceivable is again classified as recoverable due to an event occurring after derecognition, then the relevant amoun\nimmediately reported as recoverable with an effect on profit or loss. The cash value of the expected future cash fl\nis reduced by the original effective interest rate of the financial asset.\n\nCuretis\u2019 financial liabilities include liabilities from preferred and common shares, finance lease agreements as w\nas payables related to the operating activities (trade and other payables).\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.625, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7840909090909091, "height": 0.15909090909090906, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-6", "text": "They are to be recognized when the Company becomes a contractual party to the provisions of a financial inst\nment. Liabilities incurred due to an obligation to purchase goods or services are recognized on the settlement date\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.7995454545454546, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8281818181818181, "height": 0.02863636363636357, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-7", "text": "tlement date, i.e. the value date. Derivatives are recognized on the day of the transaction. Financial liabilities\nderecognized when they have been settled, i.e. when the obligations stated in the contract have been met, lifted\n\n\n                                                                                                                F\n", "page_number": 261, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8431818181818181, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9159090909090909, "height": 0.07272727272727275, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-261-8", "text": "F-14", "page_number": 261, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-0", "text": "expired. Initial disclosure is made at fair value. Where there is a financial liability that is valued at fair value with\nan effect on profit or loss, valuation occurs after deducting transaction costs from the consideration received. T\nsubsequent valuation is dependent on the categorization.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.13454545454545455, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-1", "text": "IAS 39 classifies financial liabilities into the following categories:\n\n\uf0b7      financial liabilities measured at fair value through profit or loss, an\n\n\uf0b7      other liabilities.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.14863636363636365, "lower_right_x": 0.6064705882352941, "lower_right_y": 0.22181818181818183, "height": 0.07318181818181818, "width": 0.4935294117647059}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-2", "text": "they are recognized at the redemption or settlement amount. Non-current liabilities and financial debts are accoun\nfor using the effective interest method.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.23954545454545453, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.28363636363636363, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-3", "text": "tion at every reporting date, except \u2018Financial liabilities measured at fair value through profit or loss\u2019.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29772727272727273, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.32727272727272727, "height": 0.02954545454545454, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-4", "text": "ties into the category \u2018Financial liabilities measured at amortized cost\u2019 (referred to in IAS 39 as \"other liabilitie\nand its liabilities relating to preferred and common shares into the category \u2018Financial liabilities measured at\nvalue through profit or loss\u2019.\n\nFinancial liabilities are classified as current liabilities unless Curetis has an unconditional right to defer settlemen\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.34136363636363637, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4, "height": 0.05863636363636365, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-5", "text": "the liability for at least 12 months after the reporting date.\n\nFinancial assets and liabilities are offset and reported on a net basis on Curetis\u2019 statement of financial position o\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.41409090909090907, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.44363636363636366, "height": 0.029545454545454597, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-6", "text": "when there currently is a legally enforceable right to offset the recognized amounts and there is an intention eithe\nsettle on a net basis or to realize the asset and settle the liability simultaneously.\n\n2.15.    Trade payables\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.45954545454545453, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5036363636363637, "height": 0.044090909090909125, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-7", "text": "Trade payables are oblig\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5195454545454545, "lower_right_x": 0.2776470588235294, "lower_right_y": 0.5336363636363637, "height": 0.014090909090909154, "width": 0.1652941176470588}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-8", "text": "accordance with IAS 39 (see above). Trade payables are initially recognized at fair value, net of directly attributa\ntransaction costs. After initial recognition, they are subsequently carried at amortized cost; any difference betw\nthe proceeds (net of transaction costs) and the redemption value is recognized in the statement of profit or loss u\nmaturity of the liability using the effective interest method. Amortized cost is calculated by taking into account a\ndiscounts or premiums on acquisition or issuance and transaction costs. The effective interest rate amortization\nrecognized in the statement of profit or loss under finance costs.\n\nAccounts payable are classified as current liabilities if payment is due within one year or less (or in the normal op\nating cycle of the business if longer). If not, they are presented as non-current liabilities.\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5486363636363636, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6645454545454546, "height": 0.11590909090909096, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-9", "text": "2.16.   Provisions for other liabilities and charges\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6795454545454546, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.7086363636363636, "height": 0.029090909090909056, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-10", "text": "is more likely than not that an outflow of resource\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.7231818181818181, "lower_right_x": 0.46058823529411763, "lower_right_y": 0.7381818181818182, "height": 0.015000000000000013, "width": 0.3476470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-11", "text": "present value of their expected settlement amounts if the interest rate effect resulting from discounting is material.\n\n2.17.    Current and deferred tax income\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7531818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8109090909090909, "height": 0.05772727272727274, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-12", "text": "extent that it relates to items recog\n", "page_number": 262, "bounding_box": {"top_left_x": 0.17411764705882352, "top_left_y": 0.8259090909090909, "lower_right_x": 0.3952941176470588, "lower_right_y": 0.84, "height": 0.014090909090909043, "width": 0.22117647058823528}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-13", "text": "to the\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8263636363636364, "lower_right_x": 0.15058823529411763, "lower_right_y": 0.8390909090909091, "height": 0.012727272727272698, "width": 0.03823529411764705}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-14", "text": "F\n", "page_number": 262, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8577272727272728, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9, "height": 0.04227272727272724, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-262-15", "text": "F-15", "page_number": 262, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-0", "text": "The current income tax charge is calculated on the basis of the tax law enacted or substantively enacted at the b\nance sheet date where the Company operates and generates taxable income. Management periodically evalua\npositions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretati\nIt establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.14863636363636365, "height": 0.058181818181818196, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-1", "text": "Deferred income tax is recognized on temporary differences arising between the tax bases of assets and liabilities a\ntheir carrying amounts in the financial statements, as well as for tax loss carryforward. However, deferred tax liab\nties are not recognized if they arise from the initial recognition of goodwill. In addition, deferred income tax is\naccounted for if it arises from initial recognition of an asset or liability in a transaction other than a business com\nnation that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred income tax\ndetermined applying tax rates (and laws) that have been enacted or substantively enacted by the balance sheet d\nand are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability\nsettled.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.16318181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.27636363636363637, "height": 0.11318181818181819, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-2", "text": "able against which the temporary differences can be utilized.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29409090909090907, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.3236363636363636, "height": 0.02954545454545454, "width": 0.77}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-3", "text": "assets against current tax liabilities and when the deferred income taxes assets and liabilities relate to income ta\nlevied by the same taxation authority on either the same taxable entity or different taxable entities where there is\nintention to settle the balances on a net basis.\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3377272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3936363636363636, "height": 0.05590909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-4", "text": "non-current assets/ liabilities in the balance sheet.\n\n2.18.    Equity\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.41045454545454546, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.43863636363636366, "height": 0.028181818181818197, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-5", "text": "Share capital is\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4577272727272727, "lower_right_x": 0.22, "lower_right_y": 0.4709090909090909, "height": 0.013181818181818183, "width": 0.10764705882352942}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-6", "text": "equity.\n\n2.19.     Share-based payments\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4868181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5309090909090909, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-7", "text": "Cure\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.545, "lower_right_x": 0.14647058823529413, "lower_right_y": 0.5563636363636364, "height": 0.011363636363636354, "width": 0.034117647058823544}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-8", "text": "s operates a cash-settled\n", "page_number": 263, "bounding_box": {"top_left_x": 0.16941176470588235, "top_left_y": 0.545, "lower_right_x": 0.3235294117647059, "lower_right_y": 0.56, "height": 0.015000000000000013, "width": 0.15411764705882355}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-9", "text": "Curetis is accounted for in accordance with IFRS 2, \u2018Share-Based Payment\u2019. The plan involves share-based paym\ntransactions that are settled in cash and measured at fair value. The fair value of a PSO is determined using an opt\npricing model after assessing the fair value through a discounted cash flow model. Expenses occurred in the vest\nperiod are recognized as a provision. The vesting period starts at the grant date up to the time the claims are vest\nThe grant date is defined as the date on which both parties agree to the plan. This is usually the date of signing\ncontract. In case of a listing, the beneficiaries receive cash in the amount of the opening quotation less the str\nprice. The acquired services and the incurred debt are recognized at the fair value of the debt. Services received, a\na liability to pay for those services are recognized, as the employees render service. Until the debt has been settl\nthe fair value of the debt is re-measured at every balance sheet date and all changes to the fair value are recogni\nas profit or loss.\n\n2.20.    Currency translation\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5740909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7486363636363637, "height": 0.17454545454545456, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-10", "text": "the transaction. Gains and los\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7631818181818182, "lower_right_x": 0.31529411764705884, "lower_right_y": 0.7781818181818182, "height": 0.015000000000000013, "width": 0.20294117647058824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-11", "text": "2.21.   Use of assumptions and estimates\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7922727272727272, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8336363636363636, "height": 0.04136363636363638, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-12", "text": "sumptions that affect the reported amount\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8504545454545455, "lower_right_x": 0.4, "lower_right_y": 0.8654545454545455, "height": 0.015000000000000013, "width": 0.2876470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-13", "text": "F\n", "page_number": 263, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8831818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9109090909090909, "height": 0.02772727272727271, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-263-14", "text": "F-16", "page_number": 263, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-0", "text": "at the date of the financial statements and the reported amount of revenue and expenses during the period. Act\nresults could differ from those estimates.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.11636363636363636, "height": 0.02590909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-1", "text": "Significant areas requiring the use of management estimates relate to determination of the useful lives of prope\nplant and equipment, inventories, valuation of phantom stock options, provisions, valuation of preferred shares, d\ncounted cash flows for impairment testing, recognition of deferred tax assets and the determination of the fair va\nof certain financial instruments.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1340909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.1890909090909091, "height": 0.05499999999999999, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-2", "text": "The uniform determination of the useful economic life for intangible assets and property, plant and equipment\nCuretis is subject to the estimations made by the management.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.20681818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.23636363636363636, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-3", "text": "realizable value is determined by subtracting the costs incurred up to completion from the expected sales price of\nend product. If assumptions regarding future share prices or end product market potentials are not appropriate, t\nmay lead to a further need for depreciating inventories.\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.25045454545454543, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3090909090909091, "height": 0.05863636363636365, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-4", "text": "options is based on an option pricing model. Estimating the fair value for share-based payment transactions requi\ndetermination of the most appropriate valuation model, which depends on the terms and conditions of the opt\nplan. The estimate also requires determination of the most appropriate inputs to the valuation model including\nexpected life of the phantom stock option, volatility, likely exit scenarios and their respective probabilities and d\ndend yield and making assumptions about them.\n\nWhen accounting for provisions, management must make assumptions regarding the probability of certain busin\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3231818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4109090909090909, "height": 0.08772727272727271, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-5", "text": "transactions resulting in an impending loss of commercial benefit for Curetis. Estimates regarding the amount a\ntiming of possible economic outflows form the basis for the measurement of provisions. If the actual amount and\ntiming differ from estimates made, then this may affect the results of Curetis.\n\nPreferred and common shares are measured at their fair value. For the determination of the fair value managem\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.42863636363636365, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.48545454545454547, "height": 0.05681818181818182, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-6", "text": "beta factors).\n\nTo test for impairment, the value in use is determined by means of the discounted cash flow method. Assumptio\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5013636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5431818181818182, "height": 0.041818181818181865, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-7", "text": "changes in these input factors, the recognition of an impairment may be necessary.\n\nThe calculation of deferred tax assets requires assumptions to be made with regard to the level of future taxable\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5595454545454546, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6027272727272728, "height": 0.04318181818181821, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-8", "text": "and the impact on earnings of the reversal of taxable temporary differences. Since future business developme\ncannot be predicted with certainty and to some extent cannot be influenced by Curetis, the measurement of defer\ntax assets is subject to uncertainty.\n\n    First Time adoption of IFRS\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6177272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6904545454545454, "height": 0.07272727272727275, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-9", "text": "transition to IFRS as of 1 Januar\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.705, "lower_right_x": 0.34294117647058825, "lower_right_y": 0.72, "height": 0.015000000000000013, "width": 0.23058823529411765}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-10", "text": "quires that all IFRS standards and interpretations that are effective for the first IFRS financial statements as of\nDecember 2014 shall be applied consistently and retrospectively for all periods presented.\n\nThe following reconciliations describe the effect of the differences between German GAAP and IFRS on equity as\n31 December 2014, 31 December 2013, 31 December 2012 and 1 January 2012 as well as on net income for\n", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7340909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8072727272727273, "height": 0.07318181818181813, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-11", "text": "The following reconciliations describe the effect of the differences between German GAAP and IFRS on equity as of\n31 December 2014, 31 December 2013, 31 December 2012 and 1 January 2012 as well as on net income for the\nannual periods 2012, 2013 and 2014.", "page_number": 264, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8213636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8654545454545455, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-264-12", "text": "F-17", "page_number": 264, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-0", "text": "(a) Property, plant and equipment \u2013 Useful Lif\n", "page_number": 265, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.09045454545454545, "lower_right_x": 0.46588235294117647, "lower_right_y": 0.105, "height": 0.014545454545454542, "width": 0.3205882352941176}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-1", "text": "The Company reassessed the useful life of its property, plant and equipment. Under German GAAP, the useful life\nproperty, plant and equipment is shorter than under IFRS.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12318181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.15272727272727274, "height": 0.029545454545454555, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-2", "text": "(b) Asset retirement obligation\n", "page_number": 265, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.16318181818181818, "lower_right_x": 0.35294117647058826, "lower_right_y": 0.17636363636363636, "height": 0.013181818181818183, "width": 0.20764705882352943}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-3", "text": "Curetis has contractual obligations to remove its clean rooms which have been constructed in one of Curetis\u2019 s\nleased from third parties. According to IFRS, provisions for such asset retirement obligations shall be recognized\ntheir present value as part of the cost of the related property, plant and equipment and accordingly as a provisi\nSubsequently, the provision is increased by the accrued interest and the item of property, plant and equipmen\ndepreciated applying the increased depreciation charge. Contrary to IFRS, under German GAAP dismantling,\nmoval and restoration costs cannot be recognized as part of property, plant and equipment and are recorded rata\nover time.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19590909090909092, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.29454545454545455, "height": 0.09863636363636363, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-4", "text": "(c) Profit sharing provision", "page_number": 265, "bounding_box": {"top_left_x": 0.14588235294117646, "top_left_y": 0.305, "lower_right_x": 0.32941176470588235, "lower_right_y": 0.32, "height": 0.015000000000000013, "width": 0.18352941176470589}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-5", "text": "purposes it is required that the amount of a provision must be the present value of the expected expenditures if\neffect of the time value of money is material. The main difference between IFRS and German GAAP is the under\ning discount rate. In accordance with German GAAP, the liability is discounted using a 7-years average discount r\npreset by the German Federal Bank. Under IFRS, a high quality corporate bond interest rate is used.\n    (d) Preferred and common shares\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.34136363636363637, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4127272727272727, "height": 0.07136363636363635, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-6", "text": "(d) Preferred and common shares", "page_number": 265, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.4213636363636364, "lower_right_x": 0.37058823529411766, "lower_right_y": 0.43454545454545457, "height": 0.013181818181818183, "width": 0.22529411764705884}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-7", "text": "the preferred shares of the Company need to be classified as financial liabilities. At initial recognition, the financ\nliability was measured at its fair value. Any changes in the fair value are recorded in the income statement.\n    (e) Phantom Stock Options\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4540909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.49818181818181817, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-8", "text": "accordance with German GA\n", "page_number": 265, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.505, "lower_right_x": 0.32941176470588235, "lower_right_y": 0.52, "height": 0.015000000000000013, "width": 0.18411764705882352}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-9", "text": "date. Under IFRS, the Phantom Stock Option Plan is classified as a cash-settled, share-based payment transact\nand a provision is recognized over the vesting period and also assessed to its fair value at each reporting date. T\nmain differences between German GAAP and IFRS are the underlying valuation model and the discount rate.\n    (f) Deferred taxes\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6136363636363636, "height": 0.07227272727272727, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-10", "text": "der German GAAP\n", "page_number": 265, "bounding_box": {"top_left_x": 0.14588235294117646, "top_left_y": 0.6213636363636363, "lower_right_x": 0.26823529411764707, "lower_right_y": 0.635, "height": 0.013636363636363669, "width": 0.12235294117647061}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-11", "text": "ferred tax liabilities in respect of all taxable temporary differences with a few exceptions not applicable for the Co\npany. Furthermore, under IFRS, deferred tax assets are recognized in respect of all deductible temporary differen\nto the extent that it is probable that taxable profit will be available against which the deductible temporary differe\nwill be utilized. Curetis does not recognize deferred taxes for German GAAP purposes. Adjustments regarding\nferred tax assets and deferred tax liabilities refer to additional differences between the carrying amount of assets a\nliabilities under IFRS and the corresponding tax basis. Deferred tax assets and liabilities were recognized on tem\nrary differences.\n    (g) Fixed purchase model\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6577272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7886363636363637, "height": 0.13090909090909097, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-12", "text": " der German GAAP, a fina\nnce leases was classified a\n", "page_number": 265, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.7959090909090909, "lower_right_x": 0.32, "lower_right_y": 0.8109090909090909, "height": 0.015000000000000013, "width": 0.17470588235294118}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-13", "text": "curred.\n", "page_number": 265, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8322727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8872727272727273, "height": 0.05500000000000005, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-265-14", "text": "F-18", "page_number": 265, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-266-0", "text": "(h) Lease contract classification\n", "page_number": 266, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.09045454545454545, "lower_right_x": 0.3623529411764706, "lower_right_y": 0.1040909090909091, "height": 0.013636363636363641, "width": 0.21705882352941178}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-266-1", "text": "Under German GAAP, the lease accounting classification generally follows certain tax-based regulations. Un\nIFRS, the classifications of leased property are based on the allocation of risk and rewards incidental to ownersh\nLease contracts in which Curetis is the lessee were classified as operating leases under German GAAP and classif\nas finance leases under IFRS. According to IFRS, as a lessee, Curetis recognizes finance lease assets and liabilities\ntheir statement of financial position. Different classification of leasing contracts, led to a reversal of German GA\nlease expenses and a breakdown of minimum lease payments between finance charges and reductions of outstand\nliabilities.\n", "page_number": 266, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.22545454545454546, "height": 0.09863636363636363, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-266-2", "text": "F-19", "page_number": 266, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-267-0", "text": "(i) Inventories\n", "page_number": 267, "bounding_box": {"top_left_x": 0.14529411764705882, "top_left_y": 0.09045454545454545, "lower_right_x": 0.24941176470588236, "lower_right_y": 0.10454545454545454, "height": 0.014090909090909085, "width": 0.10411764705882354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-267-1", "text": "In accordance with German GAAP\u2019s underlying principle of prudence, write-downs on inventories are higher\ncomparison to write-downs in accordance with IFRS.\n", "page_number": 267, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.1559090909090909, "height": 0.029090909090909084, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-267-2", "text": "Reconciliation of shareholders' equity\n\n                                                  31 December      31 December       31 December       1 Janua\nin kEuro                                                 2014             2013              2012            201\nEquity under previous (German) GAAP as\npublished                                                9,876           12,646               14,137     14,19\nCorrection of an error                                       -                -                    -\nEquity under previous (German) GAAP ad-\njusted                                                    9,876           12,646            14,137       14,19\n(a) Property, plant and equipment - Useful Life             697              409                121\n(b) Assets retirement obligation                               1                1                  2\n(c) Profit sharing provision                                - 40               -8               - 12         -1\n(d) Preferred and common shares                      - 126,036         - 116,993         - 107,860      - 68,86\n(e) Phantom Stock Options                               - 3,101           -2,121            - 1,757          28\n(f) Deferred taxes                                             -                -                  -         -7\n(g) Fixed purchase model                                       -                -                  -\n(h) Lease contract classification                           - 53             - 35               - 12\n(i) Inventories                                             120                 -                  -\n\nTotal Impact of Change to IFRS                       - 128,412         - 118,748         - 109,517      - 68,66\nEquity under IFRS                                    - 118,536         - 106,102           - 95,380     - 54,46\n\nin kEuro                                                        2014                  2013                 201\nIncome/loss under previous (German) GAAP                      -9,527                 -8,127              -6,95\nCorrection of an error                                             -                      -\nIncome/loss under previous (German) GAAP\nadjusted                                                      -9,527                 -8,127              -6,95\n(a) Property, plant and equipment - Useful Life                  288                    288                 11\n(b) Assets retirement obligation                                   -                     -1\n(c) Profit sharing provision                                     -32                      4\n(d) Preferred and common shares                               -2,286                 -2,497             -32,09\n(e) Phantom Stock Options                                       -980                   -365              -2,03\n(f) Deferred taxes                                                 -                      -                  7\n(g) Fixed purchase model                                           -                      -\n(h) Lease contract classification                                -17                    -23                 -1\n(i) Inventories                                                  120                      -\nTotal impact of change to IFRS                                -2,907                 -2,594             -33,95\n\nProfit under IFRS                                            -12,434                -10,721             -40,91\n\nOther comprehensive income                                         -                      -\nComprehensive income                                         -12,434                -10,721             -40,91\n\n\n                                                                                                         F-20\n", "page_number": 267, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.15954545454545455, "lower_right_x": 0.908235294117647, "lower_right_y": 0.9127272727272727, "height": 0.7531818181818182, "width": 0.7958823529411765}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-267-3", "text": "F-20", "page_number": 267, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.026470588235294135}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-268-0", "text": "Differences between German GAAP and IFRS in the statement of cash flows arise from the allocation of cash o\nflows to operating and financing activities for some leases with the Company as lessee that are classified as fina\nleases under IFRS which were treated as operating leases under German GAAP (see (h) above). This has a posit\nimpact on net cash flow used in operating activities and a negative impact on cash flow provided by financing acti\nties. Under German GAAP, the cash inflow from interests is classified as cash flow used in investing activities. U\nder IFRS, these cash inflows are classified under cash flow used in operating activities. Further differences in\nstatement of cash flow arise from the definition of cash and cash equivalents under IFRS. For IFRS purposes c\nequivalents are short-term, highly liquid investments that are readably convertible to known amounts of cash. The\nfore, an assigned account was reclassified as other non-current financial asset.\n", "page_number": 268, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.22090909090909092, "height": 0.13045454545454546, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-268-1", "text": "in kEuro\n", "page_number": 268, "bounding_box": {"top_left_x": 0.11411764705882353, "top_left_y": 0.23272727272727273, "lower_right_x": 0.18588235294117647, "lower_right_y": 0.24181818181818182, "height": 0.009090909090909094, "width": 0.07176470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-268-2", "text": "                                                           Cash flows un-\n                                                            der previous\n                                                               (German)     Cash flows un-   Total impact\nReconciliation of cash flows 2014                                  GAAP          der IFRS    change to IFR\nNet cash flow provided by operating activities                     -7,680           -7,481               19\nNet cash flow provided by investing activities                     -1,532           -1,537\nNet cash flow provided by / used in financing activities            6,739            6,630             -10\n\nNet change in cash and cash equivalents                            -2,473           -2,388               8\nCash and cash equivalents at the beginning of the year              5,832            5,382             -45\nCash and cash equivalents at the end of the year                    3,359            2,994             -36\n", "page_number": 268, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.24227272727272728, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.45590909090909093, "height": 0.21363636363636365, "width": 0.7811764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-268-3", "text": "F-21", "page_number": 268, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.0252941176470588}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-0", "text": "NOTES TO THE STATEMENT OF PROFIT OR LOS\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.5129411764705882, "lower_right_y": 0.10181818181818182, "height": 0.011363636363636367, "width": 0.40058823529411763}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-1", "text": "Revenues\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11411764705882353, "top_left_y": 0.11227272727272727, "lower_right_x": 0.21058823529411766, "lower_right_y": 0.12636363636363637, "height": 0.014090909090909098, "width": 0.09647058823529413}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-2", "text": "in kEuro                  2014   2013   201\nSale of Unyvero-Systems    33    250    13\nSales of cartridges       154     33     1\nSales of services          46    388\nSale of spare parts        42       -\nTotal revenues            275    671    14\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.14863636363636365, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.26590909090909093, "height": 0.11727272727272728, "width": 0.771764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-3", "text": "on the destination of the customer are as follows:\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29409090909090907, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.32, "height": 0.025909090909090937, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-4", "text": "in kEuro                                                                 2014               2013             201\nGermany, Austria, Switzerland                                             157                 388\nWestern Europe                                                               -                   -\nRest of the world                                                         118                 283            14\nTotal revenues                                                            275                 671            14\nAll revenues are derived from 12 external customers, including hospitals as well as distribution partners.\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.3559090909090909, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.455, "height": 0.09909090909090912, "width": 0.7711764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-5", "text": "Cost of sales\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.465, "lower_right_x": 0.8, "lower_right_y": 0.48, "height": 0.014999999999999958, "width": 0.6876470588235295}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-6", "text": "Cost of sales incl\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4940909090909091, "lower_right_x": 0.23058823529411765, "lower_right_y": 0.5081818181818182, "height": 0.014090909090909098, "width": 0.11823529411764706}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-7", "text": "Expenses by nature\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5231818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5527272727272727, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-8", "text": "                                             2014    2013    201\nEmployee benefit expenses                    4,734   3,567   5,19\nDepreciation, amortization and impairment\ncharges                                      1,448   1,272    95\nChanges in inventories of finished goods\nand work in progress                            71    -111     -7\nRaw material and consumables used              393     318     44\nOther expenses                               3,871   3,900   2,56\nTotal Cost of Sales, distribution costs,\nadministrative expenses and research &\ndevelopment expenses                        10,517   8,946   9,08\n\n\n\n   Distribution costs\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5704545454545454, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.7890909090909091, "height": 0.21863636363636363, "width": 0.771764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-9", "text": "marketing, materials a\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.825, "lower_right_x": 0.26823529411764707, "lower_right_y": 0.8390909090909091, "height": 0.014090909090909154, "width": 0.15588235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-10", "text": "F\n", "page_number": 269, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8540909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8981818181818182, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-269-11", "text": "F-22", "page_number": 269, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-0", "text": "Administrative expense\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09045454545454545, "lower_right_x": 0.31470588235294117, "lower_right_y": 0.105, "height": 0.014545454545454542, "width": 0.20176470588235293}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-1", "text": "Administrative expenses include personnel, depreciation and other costs of the central administrative areas, wh\nare not related to production, sales or research and development. In 2014, administrative expenses amounting\nkEUR 1,637 (2013: kEUR 1,256, 2012: kEUR 1,437).\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.16318181818181818, "height": 0.043636363636363626, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-2", "text": "Employee benefit expenses\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.17772727272727273, "lower_right_x": 0.3341176470588235, "lower_right_y": 0.19272727272727272, "height": 0.014999999999999986, "width": 0.22117647058823528}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-3", "text": "in kEuro\n                                                             2014                2013               20\nWages and salaries                                           3,334              3,221               2,9\nSocial security costs                                          506                470                 4\n\nPSOPs granted to management and employees                     894                -124               1,8\nTotal employee benefits                                      4,734              3,567               5,1\nThe employer's contribution paid to the statutory pension scheme (Deutsche Rentenversicherung) in Germa\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19954545454545455, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.3195454545454545, "height": 0.11999999999999997, "width": 0.7794117647058824}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-4", "text": "amounted to kEUR 233 in 2014 (2013: kEUR 225, 2012: kEUR 186).\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.32681818181818184, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.3563636363636364, "height": 0.02954545454545454, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-5", "text": "10. Research and development expenses", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3709090909090909, "lower_right_x": 0.4, "lower_right_y": 0.38545454545454544, "height": 0.014545454545454528, "width": 0.2876470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-6", "text": "2,881), depreciation and amortization amounting to kEUR 1,142 (2013: kEUR 1,133, 2012: kEUR 871) as well\nmaterial costs amounting to kEUR 740 (2013: kEUR 576, 2012: kEUR 0) and other costs amounting to kEUR 1,6\n(2013: kEUR 1,971, 2012: kEUR 1,606).\n\n    Finance income/costs \u2013 net\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4031818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4581818181818182, "height": 0.05499999999999999, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-7", "text": "Finance costs - net amounting t\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4759090909090909, "lower_right_x": 0.3341176470588235, "lower_right_y": 0.48727272727272725, "height": 0.011363636363636354, "width": 0.22176470588235292}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-8", "text": "primarily to updated fair value calculations.\n", "page_number": 270, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.505, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5481818181818182, "height": 0.04318181818181821, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-270-9", "text": "F-23", "page_number": 270, "bounding_box": {"top_left_x": 0.8576470588235294, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9504545454545454, "height": 0.009090909090909038, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-271-0", "text": "Earnings/loss per share\n", "page_number": 271, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.31, "lower_right_y": 0.11272727272727273, "height": 0.015, "width": 0.1976470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-271-1", "text": "Basic earnings/loss per share is calculated by dividing the profit attributable to holders of common shares of\nCompany by the weighted average number of ordinary shares in issue during the year.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.15636363636363637, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-271-2", "text": "Diluted earnings/loss per share is calculated by adjusting the weighted average number of ordinary shares outsta\ning to assume conversion of all dilutive potential ordinary shares. The Company has preferred shares as poten\ndilutive ordinary shares.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.17045454545454544, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.21454545454545454, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-271-3", "text": "                                                                 2014        2013        20\nTotal profit in kEUR                                           -12,434     -10,721     -40,9\nWeighted average number of ordinary shares in issue            655,556     655,556     655,5\nAdjustment for conversion of preferred shares                4,094,169   3,773,357   3,233,2\nWeighted average number of ordinary shares for diluted EPS   4,749,725   4,428,913   3,888,7\nBasic earnings/loss per share in EUR                            -18.97      -16.35      -62.\nDiluted earnings/loss per share in EUR                          -18.97      -16.35      -62.\n", "page_number": 271, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.22136363636363637, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.36727272727272725, "height": 0.14590909090909088, "width": 0.7794117647058824}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-271-4", "text": "F-24", "page_number": 271, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-0", "text": "NOTES TO THE STATEMENT OF FINANCIAL POSITION\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.5552941176470588, "lower_right_y": 0.10181818181818182, "height": 0.011363636363636367, "width": 0.4429411764705882}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-1", "text": "Cash and cash equivalent\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.32823529411764707, "lower_right_y": 0.14181818181818182, "height": 0.014999999999999986, "width": 0.21588235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-2", "text": "At 31 December 2014, cash and cash equivalents amounted to kEUR 2,994 (31 December 2013: kEUR 5,382,\nDecember 2012: kEUR 9,777, 1 January 2012: kEUR 11,857). These consist of bank balances and cash on hand.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1559090909090909, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.18545454545454546, "height": 0.02954545454545454, "width": 0.7694117647058824}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-3", "text": "Trade receivable\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19954545454545455, "lower_right_x": 0.26823529411764707, "lower_right_y": 0.21409090909090908, "height": 0.014545454545454528, "width": 0.15588235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-4", "text": "interest bearing.\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.23227272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.26, "height": 0.02772727272727274, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-5", "text": "in kEUR\n                              31 December 2014 31 December 2013 31 December 2012   1 January 20\n\n\nTrade receivables, gross                   43              141               56\nless provision for doubtful\nreceivables                                -1               -1                 -\nTrade receivables, net                     42              140               56\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.26045454545454544, "lower_right_x": 0.8929411764705882, "lower_right_y": 0.3922727272727273, "height": 0.13181818181818183, "width": 0.7805882352941177}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-6", "text": "in kEUR\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11529411764705882, "top_left_y": 0.4177272727272727, "lower_right_x": 0.6247058823529412, "lower_right_y": 0.43227272727272725, "height": 0.014545454545454528, "width": 0.5094117647058825}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-7", "text": "                          31 December 2014          31 December 2013         31 December 2012                    1 January 201\n                         gross        provision   gross         provision   gross        provision       gross         provisio\n\n\nAmounts undue                    43          -1           89            -           56               -             -\nPast due 0-30 days                -           -            1            -            -               -             -\nPast due 31-60 days               -           -           51           -1            -               -             -\nPast due 61-90 days               -           -            -            -            -               -             -\nPast due 91-180 days              -           -            -            -            -               -             -\nPast due 181-270 days             -           -            -            -            -               -             -\nPast due 271-360 days             -           -            -            -            -               -             -\nMore than one year                -           -            -            -            -               -             -\nTotal                            43          -1           141          -1           56           -                 -\nTrade receivables, net                       42                       140                       56\n", "page_number": 272, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.4359090909090909, "lower_right_x": 0.8923529411764706, "lower_right_y": 0.6954545454545454, "height": 0.2595454545454545, "width": 0.7847058823529411}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-8", "text": "31 December 2014   31 December 2013   31 December 2012   1 January 201\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7340909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7645454545454545, "height": 0.0304545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-9", "text": "Up to 3 months   -   52   -\n3 to 6 months    -    -   -\nTotal            -   52   -\n", "page_number": 272, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.765, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.8622727272727273, "height": 0.09727272727272729, "width": 0.771764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-272-10", "text": "F-25", "page_number": 272, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-273-0", "text": "Movements in the Company's provision for impairment of trade receivables are as follows:\nin kEUR                             2014                      2013                         2012\nBalance as of 1 January             1                         -                            -\nNet additions (+) / reversals (-)   -1                        1                            -\nUse                                 -                         -                            -\nBalance as of 31 December           -                         1                            -\n", "page_number": 273, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1159090909090909, "lower_right_x": 0.8605882352941177, "lower_right_y": 0.23272727272727273, "height": 0.11681818181818182, "width": 0.7482352941176471}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-273-1", "text": "", "page_number": 273, "bounding_box": {"top_left_x": 0.8747058823529412, "top_left_y": 0.13090909090909092, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.23272727272727273, "height": 0.10181818181818181, "width": 0.010000000000000009}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-273-2", "text": "an impairment of finance lease receivables amounting to kEUR 2 (2013: kEUR 0, 2012: kEUR 0) was conducted.\n", "page_number": 273, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.25772727272727275, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2859090909090909, "height": 0.02818181818181814, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-273-3", "text": "F-26", "page_number": 273, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-274-0", "text": "in kEUR                            31 December 2014   31 December 2013   31 December 2012   1 January 201\nNon-current receivables\nFinance leases - gross receiva-\nbles                                              -                 3                   -\nUnearned finance income                           -                -1                   -\nTotal                                             -                 2\nCurrent receivables\nFinance leases - gross receiva-\nbles                                              -                40                   -\nUnearned finance income                           -                -4                   -\nTotal                                             -                36\nGross receivables from finance\nleases                                            -                                     -\n- No later than 1 year                            -                40                   -\n- Later that 1 year and no later\nthan 5 years                                      -                 3                   -\n- Later than 5 years                              -                  -                  -\nTotal                                             -                43\nUnearned future finance in-\ncome on finance leases                            -                -5                   -\nNet investment in finance\nleases                                            -                38                   -\n\n\nThe net investment in finance\nleases may be analyzed as\nfollows:\nNo later than 1 year                              -                36                   -\nLater than 1 year and no later\nthan 5 years                                      -                 2                   -\nLater than 5 years                                -                  -                  -\nTotal                                             -                38                   -\n", "page_number": 274, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1159090909090909, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.6836363636363636, "height": 0.5677272727272726, "width": 0.771764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-274-1", "text": "F-27", "page_number": 274, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-275-0", "text": "Financial instruments by category\n", "page_number": 275, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.38588235294117645, "lower_right_y": 0.11272727272727273, "height": 0.015, "width": 0.27352941176470585}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-275-1", "text": "The following table displays the carrying amounts of Curetis\u2019 financial assets and liabilities:\n\n                                                              31 December 2014\n\nAssets as per balance sheet date                                    Loans and receivables                  Tot\nTrade receivables [14]                                                                   42                  4\nOther non-current financial assets [20]                                                 429                 42\nCash and cash equivalents [13]                                                        2,994                2,99\nTotal                                                                                 3,465                3,46\n\n                                                      Liabilities at fair Other financial liabil-\nLiabilities as per balance sheet date              value through profit       ities at amortized           Tot\n                                                               and loss                      cost\nFinance lease liabilities [24] [27]                                     -                    391            39\nOther financial liabilities [24]                                        -                    240            24\nTrade payables [21]                                                     -                    580            58\nFinancial liabilities for preferred and common\n                                                                126,036                              -   126,03\nshares [28]\nTotal                                                           126,036                       1,211      127,24\n\n                                                               31 December 2013\n\nAssets as per balance sheet date                                     Loans and receivables                 Tot\nTrade receivables                                                                       140                 14\nOther non-current financial assets                                                      514                 51\nCash and cash equivalents                                                             5,382                5,38\nTotal                                                                                 6,036                6,03\n\n                                                      Liabilities at fair    Other financial lia-\nLiabilities as per balance sheet date              value through profit     bilities at amortized          Tot\n                                                               and loss                      cost\nFinance lease liabilities                                               -                     520           52\nOther financial liabilities                                             -                      39            3\nTrade payables                                                          -                     616           61\nFinancial liabilities for preferred and common\n                                                                116,993                          -       116,99\nshares\nTotal                                                           116,993                    1,175         118,16\n", "page_number": 275, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.11954545454545455, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.7631818181818182, "height": 0.6436363636363637, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-275-2", "text": "F-28", "page_number": 275, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-276-0", "text": "                                                            31 December 2012\n\nAssets as per balance sheet date\n                                                                  Loans and receivables                  Tot\nTrade receivables                                                                   56                     5\nOther non-current financial assets                                                 650                    65\nCash and cash equivalents                                                           9,777                9,77\nTotal                                                                             10,483                10,48\n\n                                                     Liabilities at fair\nLiabilities as per balance sheet date             value through profit Other financial liabil-\n                                                              and loss ities at amortized cost           Tot\nFinance lease liabilities                                              -                  641             64\nOther financial liabilities                                            -                   57              5\nTrade payables                                                         -                  634             63\nFinancial liabilities for preferred and common\nshares                                                        107,860                              -   107,86\nTotal                                                         107,860                       1,332      109,19\n\n\n                                                             1 January 2012\n\nAssets as per balance sheet date\n                                                                   Loans and receivables                 Tot\nTrade receivables                                                                      -\nOther non-current financial assets                                                   50                    5\nCash and cash equivalents                                                          11,857               11,85\nTotal                                                                              11,907               11,90\n\n                                                    Liabilities at fair    Other financial lia-\nLiabilities as per balance sheet date            value through profit     bilities at amortized\n                                                             and loss                      cost          Tot\nFinance lease liabilities                                             -                       -\nOther financial liabilities                                           -                       -\nTrade payables                                                        -                     947           94\nFinancial liabilities for preferred and common\nshares                                                         68,863                          -        68,86\nTotal                                                          68,863                       947         69,81\n\n\nPlease refer to the corresponding notes (bracketed numbers) for further information.\n", "page_number": 276, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.1159090909090909, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.7509090909090909, "height": 0.635, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-276-1", "text": "Please refer to the corresponding notes (bracketed numbers) for further information.", "page_number": 276, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7813636363636364, "lower_right_x": 0.6658823529411765, "lower_right_y": 0.7954545454545454, "height": 0.014090909090909043, "width": 0.5535294117647059}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-276-2", "text": "F-29", "page_number": 276, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-277-0", "text": "   Inventories\nin kEUR                    31 December   31 December   31 December\n                                  2014          2013          2012   1 January 20\nRaw materials                      623          647           390\nSemi-finished goods                 56          117            46\nTrade goods                      2,734         1,959          544\nFinished goods                      56           65            25\nTotal inventories, gross         3,469         2,788         1,005\n\n\nValuation allowance              - 316           -2              -\nTotal inventories, net           3,153         2,786         1,005\n", "page_number": 277, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.8929411764705882, "lower_right_y": 0.3090909090909091, "height": 0.21136363636363636, "width": 0.7805882352941177}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-277-1", "text": "355 (2013: kEUR 2, 2012: kEUR 0).\n", "page_number": 277, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.345, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.37454545454545457, "height": 0.029545454545454597, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-277-2", "text": "17, Other current assets", "page_number": 277, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3922727272727273, "lower_right_x": 0.28705882352941176, "lower_right_y": 0.4036363636363636, "height": 0.011363636363636354, "width": 0.17470588235294116}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-277-3", "text": "cember 2013: kEUR 267, 31 December 2012: kEUR 118, 1 January 2012: kEUR 116). Furthermore, other curr\nassets include deferred expenses.\n", "page_number": 277, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4213636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.46454545454545454, "height": 0.043181818181818155, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-277-4", "text": "F-30", "page_number": 277, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.026470588235294135}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-278-0", "text": "    Intangible assets\n\nin kEUR                                                  Software    Advance payments                    Tot\nBalance as of 1 January 2012                                  177                                          1\n\n\nAdditions                                                     198                     12                   2\nDisposals                                                        -                     -\nDepreciation                                                  - 51                     -                   -\nReclassifications                                                -                     -\nBalance as of 31 December 2012                                324                     12                   3\nCost                                                          378                     12                   3\nAccumulated depreciation / impairments                        - 54                     -                   -\nBalance as of 31 December 2012                                324                     12                   3\n\n\nAdditions                                                      84                      5\nDisposals                                                        -                     -\nDepreciation                                                  - 94                     -                   -\nReclassifications                                              17                   - 17\nBalance as of 31 December 2013                                331                      -                   3\nCost                                                          479                      -                   4\nAccumulated depreciation / impairments                       - 148                     -                 -1\nBalance as of 31 December 2013                                331                      -                   3\n\n\nAdditions                                                      67                      -\nDisposals                                                        -                     -\nDepreciation                                                 - 112                     -                 -1\nReclassifications\nBalance as of 31 December 2014                                286                      -                   2\nCost                                                          546                      -                   5\nAccumulated depreciation / impairments                       - 260                     -                 -2\nBalance as of 31 December 2014                                286                      -                   2\nAmortization of kEUR 1 (2013: kEUR 1, 2012: kEUR 0) is included in 'Cost of sales', in distribution costs kEU\n(2013: kEUR 5, 2012: kEUR 0), in R&D costs kEUR 8 (2013: kEUR 3, 2012: kEUR 0) and kEUR 94 (2013: kE\n", "page_number": 278, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.6868181818181818, "height": 0.589090909090909, "width": 0.7694117647058824}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-278-1", "text": "Amortization of KEUR 1 (2013: KEUR 1, 2012: KEUR 0) is included in \u2018Cost of sales', in distribution costs KEUR 9\n(2013: KEUR 5, 2012: KEUR 0), in R&D costs KEUR 8 (2013: KEUR 3, 2012: KEUR 0) and KEUR 94 (2013: KEUR\n86, 2012: KEUR 49) in administrative expenses.", "page_number": 278, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6977272727272728, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7390909090909091, "height": 0.04136363636363638, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-278-2", "text": "F-31", "page_number": 278, "bounding_box": {"top_left_x": 0.8576470588235294, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9509090909090909, "height": 0.009545454545454524, "width": 0.024705882352941133}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-279-0", "text": "Property, plant and equipmen\n", "page_number": 279, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.3623529411764706, "lower_right_y": 0.14181818181818182, "height": 0.014999999999999986, "width": 0.25}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-279-1", "text": "                                                         Property,                   Assets un-\nin kEUR                                   Land and       plant and    Other tan-            der\n                                          buildings     equipment     gible assets construction          Tot\nBalance as of 1 January 2012                      58         2,654            647         1,840          5,1\n\nAdditions                                          -         1,649            410           323          2,3\nDisposals                                          -          -690              -             -           -6\nDepreciation                                      -7          -476           -422             -           -9\nReclassifications                                  -         1,970              -        -1,970\nBalance as of 31 December 2012                    51         5,107            635           193          5,9\n\nCost                                              63         5,653          1,141           193          7,0\nAccumulated depreciation / impair-\nments                                            -12          -546           -506              -        -1,0\nBalance as of 31 December 2012                    51         5,107            635           193          5,9\n\nAdditions                                          -           320            646           683          1,6\nDisposals                                          -            -1              -             -\nDepreciation                                      -7          -823           -347             -         -1,1\nReclassifications                                  -           115              -          -115\nBalance as of 31 December 2013                    44         4,718            934           761          6,4\n\nCost                                              63         6,087          1,787           761          8,6\nAccumulated depreciation / impair-\nments                                            -19        -1,369           -853              -        -2,2\nBalance as of 31 December 2013                    44         4,718            934           761          6,4\n\nAdditions                                          2           154            702           657          1,5\nDisposals                                          -            -4            -39             -            -\nDepreciation                                      -7          -957           -373             -         -1,3\nReclassifications                                  -         1,183              -        -1,183\nBalance as of 31 December 2014                    39         5,094          1,224           235          6,5\n\nCost                                              65         7,420          2,450           235         10,1\nDisposals (Cost)                                   -             -           -453             -           -4\nAccumulated depreciation / impair-\nments                                            -26        -2,326         -1,226              -        -3,5\nDisposals (Accumulated Depreciation)               -             -            453              -           4\nBalance as of 31 December 2014                    39         5,094          1,224           235          6,5\nThe net book value of property, plant and equipment of which Curetis as the lessee is the beneficial owner un\nfinance lease programs amounted to kEUR 339 as of 31 December 2014 (31 December 2013: kEUR 484, 31 Dec\nber 2012: kEUR 629, 1 January 2012: kEUR 0). For further details please refer to note 27.\n", "page_number": 279, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.145, "lower_right_x": 0.8811764705882353, "lower_right_y": 0.8490909090909091, "height": 0.7040909090909091, "width": 0.7688235294117648}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-279-2", "text": "F\n", "page_number": 279, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8577272727272728, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9, "height": 0.04227272727272724, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-279-3", "text": "F-32", "page_number": 279, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-0", "text": "Lease rentals amounting to kEUR 71 (2013: kEUR 83, 2012: kEUR 0) relating to the lease of machinery are incl\ned in the income statement.\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.11636363636363636, "height": 0.02590909090909091, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-1", "text": "Curetis leases a laser-welding-machine under a non-cancellable finance lease arrangement. The lease term is 5 ye\nand the ownership of the machine lies within the Company.\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11470588235294117, "top_left_y": 0.1340909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.16363636363636364, "height": 0.02954545454545454, "width": 0.77}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-2", "text": "Other non-current financial asset\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.17772727272727273, "lower_right_x": 0.38588235294117645, "lower_right_y": 0.19136363636363637, "height": 0.013636363636363641, "width": 0.27294117647058824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-3", "text": "Other non-current financial assets solely include assigned accounts for rent and bank deposits as follow\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.20681818181818182, "lower_right_x": 0.8047058823529412, "lower_right_y": 0.22181818181818183, "height": 0.015000000000000013, "width": 0.691764705882353}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-4", "text": "in kEUR        31 December 2014 31 December 2013 31 December 2012   1 January 201\nRent deposit                64               64               50               5\nBank deposit               365              450              600\nTotal                      429              514              650               5\n", "page_number": 280, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.2290909090909091, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.30636363636363634, "height": 0.07727272727272724, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-5", "text": "in kEUR\n                           31 December 2014 31 December 2013 31 December 2012   1 January 201\nTrade and other payables               580              616              634              94\nTotal                                  580              616              634              94\n", "page_number": 280, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.345, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.4340909090909091, "height": 0.08909090909090911, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-6", "text": "The following t\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.4722727272727273, "lower_right_x": 0.22058823529411764, "lower_right_y": 0.48545454545454547, "height": 0.013181818181818183, "width": 0.1076470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-7", "text": "in kEUR\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4940909090909091, "lower_right_x": 0.8329411764705882, "lower_right_y": 0.509090909090909, "height": 0.014999999999999958, "width": 0.7205882352941176}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-8", "text": "Asset retirement obliga-\ntions                         34        32       33\nProfit sharing               779       743      735     7\nPSOP provision             3,914     2,957    3,090   1,0\nOther provisions              38         8        3\nBalance                    4,765    3,740    3,861    1,82\n- of which: current            35        6        1\n- of which: non-current     4,730    3,734    3,860   1,8\n", "page_number": 280, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5195454545454545, "lower_right_x": 0.9058823529411765, "lower_right_y": 0.6968181818181818, "height": 0.17727272727272725, "width": 0.7935294117647059}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-280-9", "text": "F-33", "page_number": 280, "bounding_box": {"top_left_x": 0.8576470588235294, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9504545454545454, "height": 0.009090909090909038, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-281-0", "text": "The movements in the provisions are as follow\n", "page_number": 281, "bounding_box": {"top_left_x": 0.11529411764705882, "top_left_y": 0.09045454545454545, "lower_right_x": 0.43117647058823527, "lower_right_y": 0.10363636363636364, "height": 0.013181818181818183, "width": 0.31588235294117645}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-281-1", "text": "                          Asset retirement\nin kEUR                        obligations   Profit sharing   PSOP provision   Other provision\nBalance as of 1 January\n2012                                   23              717             1,087\nAdditions                              10               18             2,003                -\nDisposals                               -                -                 -\nChange in estimates                     -                -                 -\nInterest                                -                -                 -\nBalance as of\n31 December 2012                       33              735             3,090\nAdditions                               -                8             - 133\nDisposals                               -                -                 -\nChange in estimates                    -1                -                 -\nInterest                                -                -                 -\nBalance as of\n31 December 2013                       32              743             2,957\nAdditions                               2               36               957                3\nDisposals                               -                -                 -\nChange in estimates                     -                -                 -\nInterest                                -                -                 -\nBalance as of\n31 December 2014                       34              779             3,914                3\n", "page_number": 281, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1159090909090909, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.5004545454545455, "height": 0.3845454545454546, "width": 0.771764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-281-2", "text": "Furthermore, Curetis has a contractual obligation to pay members of the management board and certain employee\n", "page_number": 281, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5377272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5663636363636364, "height": 0.028636363636363682, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-281-3", "text": "the event of a positive operating profit or a trade sale, merger or IPO.\n\nOther provisions relate to various risks and commitments for warranty costs and expenses in relation with the pre\nration of annual financial statements.\n", "page_number": 281, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5813636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.625, "height": 0.043636363636363584, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-281-4", "text": "Other provisions relate to various risks and commitments for warranty costs and expenses in relation with the prepa-\nration of annual financial statements.", "page_number": 281, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6395454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6654545454545454, "height": 0.02590909090909088, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-281-5", "text": "F-34", "page_number": 281, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-0", "text": "Other current liabilitie\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09772727272727273, "lower_right_x": 0.31058823529411766, "lower_right_y": 0.11090909090909092, "height": 0.013181818181818183, "width": 0.19764705882352943}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-1", "text": "                        31 December   31 December   31 December\nin kEUR                        2014          2013          2012   1 January 201\nAccruals for vacation           105          124           113               6\nOther tax liabilities            66           68            60               4\nOther liabilities               146          109           273              27\nTotal                           317          301           446              38\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11136363636363636, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.22545454545454546, "height": 0.1140909090909091, "width": 0.771764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-2", "text": "December 2014 (31 December 2013: kEUR 59, 31 December 2012: kEUR 210, 1 January 2012: kEUR 99).\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2431818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2727272727272727, "height": 0.029545454545454514, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-3", "text": "24, Other current financial liabilities", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2831818181818182, "lower_right_x": 0.37529411764705883, "lower_right_y": 0.2968181818181818, "height": 0.013636363636363613, "width": 0.26294117647058823}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-4", "text": "31 December   31 December   31 Decem\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.31227272727272726, "lower_right_x": 0.7276470588235294, "lower_right_y": 0.32727272727272727, "height": 0.015000000000000013, "width": 0.6147058823529412}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-5", "text": "in kEUR                           2014   2013   2012   1 January 201\nLiabilities for outstanding in-\nvoices                            240     39     57\nLease liabilities                 133    128    122\nTotal                             373    167    179\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3340909090909091, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.4309090909090909, "height": 0.0968181818181818, "width": 0.7711764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-6", "text": "In September 2010, Cureti\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.46863636363636363, "lower_right_x": 0.2958823529411765, "lower_right_y": 0.48363636363636364, "height": 0.015000000000000013, "width": 0.18352941176470589}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-7", "text": "beneficiaries to a cash settlement in case of a trade sale, merger or initial public offering.\n\nIn the event of a stock exchange listing, the beneficiaries are entitled to sell all of their PSOs which have beco\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5013636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5436363636363636, "height": 0.04227272727272724, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-8", "text": "price per PSO will be assessed at the value per share that will be established as first stock quotation of the price\nCuretis\u2019 shares in the course of the listing, reduced by the Strike Price (nominal amount of the Common share pr\n1\u20ac).\n\nIn an exit-event corresponding to trade sale, merger, dissolution, liquidation, share swap or contribution, the bene\nciaries are entitled to swap the vested PSOs. One PSO entitles to all payments connected with one Common Sh\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5595454545454546, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6304545454545455, "height": 0.07090909090909092, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-9", "text": "reduced by the Strike Price (nominal amount of the Common share price 1\u20ac).\n\nThe PSOs have a lifetime of 10 years after the grant date. The plan shall terminate at the end of the lifetime of\nPSOs granted under this plan if the period is not extended. In case of an exit-event, all options immediately beco\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6468181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6909090909090909, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-10", "text": "As of 31 December 2014, there are 52 beneficiaries entitled to 311,342 options and the grant dates reach from\nSeptember 2010 to 1 April 2014. The options have a vesting period of 4 years. After this period - or upon accelera\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.705, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7486363636363637, "height": 0.043636363636363695, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-11", "text": "The basis for calculating the individual allotment of PSOs was the average price of the Curetis share at the respect\nbalance sheet date. The scheme is recognized in accordance with IFRS 2 under the regulations for share-based co\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7631818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8072727272727273, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-12", "text": "applying an option pricing valuation model. The total calculated value is recorded as personnel expenses over\nperiod in which the beneficiary provides services to the Company. The value of the phantom stock option multipl\nwith the number of phantom stock options fully vested results in the maximum liability from the phantom sto\noption plan as the date of valuation.\n\n                                                                                                             F\n", "page_number": 282, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8213636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9236363636363636, "height": 0.10227272727272718, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-282-13", "text": "F-35", "page_number": 282, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-0", "text": "As at 31 December 2014 a total of kEUR 957 was recognized as expenses (2013: kEUR -133, 2012: kEUR 2,0\nand as of 31 December 2014 kEUR 3,914 as liabilities (31 December 2013: kEUR 2,957, 31 December 2012: kE\n3,090, 1 January 2012: kEUR 1,087) for the above mentioned remuneration scheme in accordance with IFRS 2.\n", "page_number": 283, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.1340909090909091, "height": 0.04363636363636364, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-1", "text": "Out of the 311,342 outstanding options (2013: 301,342, 2012: 294,842) no options were exercisab\n", "page_number": 283, "bounding_box": {"top_left_x": 0.11411764705882353, "top_left_y": 0.14863636363636365, "lower_right_x": 0.7747058823529411, "lower_right_y": 0.16363636363636364, "height": 0.014999999999999986, "width": 0.6605882352941176}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-2", "text": "Share options outstanding at the end of period of the year have the following expiry date and exercise price:\n\n                  Expiry date - exercise price in\nGrant vested      1 January       EUR per PSO                      2014                 2013                      20\n2010              2020                             1            145,969              145,969                    145,9\n2011              2021                             1             91,356                91,356                    91,3\n2012              2022                             1             57,017                57,017                    57,0\n2013              2023                             1              7,000                 7,000\n2014              2024                             1             10,000                      -\n                                                                311,342              301,342                    294,3\nAn option pricing method is used to determine the fair value of a PSO after assessing the fair value through a di\n", "page_number": 283, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1781818181818182, "lower_right_x": 0.8935294117647059, "lower_right_y": 0.3886363636363636, "height": 0.21045454545454542, "width": 0.7811764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-3", "text": "counted cash flow model. The significant inputs into the model were exit assumptions regarding time, probabil\nvolatility and marketability.\n\n    Other non-current financial liabilites\n", "page_number": 283, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.39954545454545454, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.44363636363636366, "height": 0.044090909090909125, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-4", "text": "Other non-current financial liabilities only\n", "page_number": 283, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.4577272727272727, "lower_right_x": 0.4041176470588235, "lower_right_y": 0.4713636363636364, "height": 0.013636363636363669, "width": 0.29117647058823526}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-5", "text": "Other non-current financial liabilities only refer to the non-current liabilities from finance leases.", "page_number": 283, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.4868181818181818, "lower_right_x": 0.7482352941176471, "lower_right_y": 0.5018181818181818, "height": 0.015000000000000013, "width": 0.6352941176470589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-283-6", "text": "F-36", "page_number": 283, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-0", "text": "Finance Lease\n", "page_number": 284, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09772727272727273, "lower_right_x": 0.24411764705882352, "lower_right_y": 0.11090909090909092, "height": 0.013181818181818183, "width": 0.13117647058823528}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-1", "text": "The Company\u2019s finance lease liabilities are split into non-current and current amounts as follows and relate to\nlease of machinery as described below:\n", "page_number": 284, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.155, "height": 0.02818181818181817, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-2", "text": "                                           31 December                31 December   31 December   1 Janua\nIn kEUR                                              2014                   2013          2012        201\nFinance lease liabilities                              391                   520           641\n \u2013 of which: current                                   133                   128           122\n \u2013 of which: non-current1                              258                   392           519\n1 The non-current minimum lease payments are all due within 1 - 5 years\n", "page_number": 284, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.15954545454545455, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.27454545454545454, "height": 0.11499999999999999, "width": 0.7741176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-3", "text": "+ + +\n1 The non-current minimum lease payments are all due within | - 5 years", "page_number": 284, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.27454545454545454, "lower_right_x": 0.5047058823529412, "lower_right_y": 0.28954545454545455, "height": 0.015000000000000013, "width": 0.3970588235294118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-4", "text": "Curetis leases machinery under finance lease agreements. The lease term is 5 years.", "page_number": 284, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.3231818181818182, "lower_right_x": 0.66, "lower_right_y": 0.3381818181818182, "height": 0.015000000000000013, "width": 0.5470588235294118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-5", "text": "reporting period and their present value:\n                                   31 December\n", "page_number": 284, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3522727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.38181818181818183, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-6", "text": "In kEUR                                    2014 31 December 2013 31 December 2012                   1 January 201\nGross finance lease liabili-\nties \u2013 minimum lease\npayments:\nLess than 1 year                            133                  128                  122\n1- 5 years                                  258                  392                  519\nMore than 5 years                             -                    -                    -\nTotal                                       391                  520                  641\nFuture finance charges on\nfinance lease liabilities                    27                   49                    77\nPresent value of finance\nlease liabilities                           419                  569                  718\n\nProperty, plant and equipment includes the following amounts related to the lease of a laser welding machine.\n", "page_number": 284, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.3886363636363636, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.5890909090909091, "height": 0.2004545454545455, "width": 0.7764705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-7", "text": "                            31 December   31 December    31 December   1 Januar\nIn kEUR                            2014          2013           2012        201\nCost-capitalized  finance\nlease                               690           690            690\nAccumulated depreciation           -351          -206            -61\nTotal                               339           484            629\n\n\n                            31 December   31 December   31 December    1 Januar\nIn kEUR                            2014          2013          2012         201\nLess than 1 year                    145           145           145\n1- 5 years                          194           339           484\nMore than 5 years                     -             -             -\nTotal                               339           484           629\n", "page_number": 284, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.6031818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.850909090909091, "height": 0.2477272727272728, "width": 0.7770588235294118}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-284-8", "text": "F-37", "page_number": 284, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-0", "text": "Financial liability for preferred and common share\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09772727272727273, "lower_right_x": 0.5064705882352941, "lower_right_y": 0.11272727272727273, "height": 0.015, "width": 0.3935294117647059}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-1", "text": "After completion of the series B financing round of the Company, Curetis' share capital under German GA\namounted to kEUR 4,660 (2013: kEUR 4,660, 2012: kEUR 3,889) and was divided into 655,556 common shar\n3,233,230 class A voting preferred shares and 771,610 class B voting preferred shares. Among the shareholders\nalso managers of the Company.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.18545454545454546, "height": 0.058636363636363625, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-2", "text": "Under IFRS, preferred (A & B shares) and common shares amounting to kEUR 126,036 as of 31 December 2014\nDecember 2013: kEUR 116,993, 31 December 2012: kEUR 107,860, 1 January 2012: kEUR 68,863) are recogni\nat fair value.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.24227272727272728, "height": 0.042727272727272725, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-3", "text": "yond control of the Company and given that these events may occur at any time, the Company determined it is\npropriate to apply the measurement guidance for financial liabilities for preferred and common shares with a dema\nfeature in IFRS 13.47 by analogy. The agreements governing preferred shares include a right and in certain event\ncontingent obligation to trigger a preference payment or to convert into common shares. As these events may oc\nat any time, the Company elected to designate the common as well as preferred shares as a financial liability throu\nprofit or loss. Upon successful completion of the IPO preferred shares are to be converted into common shares.\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.25772727272727275, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.36, "height": 0.10227272727272724, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-4", "text": "cash flow model using weighted average cost of capital at each valuation date.\n\n    Taxation\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.37772727272727274, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.40545454545454546, "height": 0.02772727272727271, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-5", "text": "In Germany, i\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4213636363636364, "lower_right_x": 0.21176470588235294, "lower_right_y": 0.43272727272727274, "height": 0.011363636363636354, "width": 0.09941176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-6", "text": "effective tax rate of 15.825% (2013-2011: 15.825%). Municipalities impose a trade tax. Each municipality set\nindividual local multiplier rate, so that no uniform trade tax rate exists in Germany. In 2014, Curetis has a trade\nrate of 12.05% (2013: 12.05%, 2012-2011: 11.76%).\n\nIn 2014, the income statement effect resulting from current and deferred taxes is kEUR 0 (2013: kEUR 0, 20\n", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.45045454545454544, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5218181818181818, "height": 0.0713636363636364, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-7", "text": "In 2014, the income statement effect resulting from current and deferred taxes is KEUR 0 (2013: KEUR 0, 2012:\nkEUR 77).", "page_number": 285, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5377272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5672727272727273, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-285-8", "text": "F-38", "page_number": 285, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-286-0", "text": "The reconciliation from the statutory tax to the effective tax rate is explained in the table belo\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09772727272727273, "lower_right_x": 0.7435294117647059, "lower_right_y": 0.11272727272727273, "height": 0.015, "width": 0.6305882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-286-1", "text": "in kEUR\n                                                           2014                   2013                   201\nLoss before income tax                                  -12,434                -10,721                -40,98\nExpected income tax at a tax rate 2014:\n27.880 % (2013: 27.880%, 2012:\n27.590%)                                                  3,467                  2,989                 11,30\nNon-taxable income and non-deductible\nexpenses                                                      -4                    -11\n\nChanges in recognition and measurement\nof deferred tax assets                                    -2,594                 -2,202                 -1,88\nTax effect from local taxes                                  -55                    -52                    -3\nPermanent differences                                       -811                   -724                 -9,46\nOther effects                                                 -3                      -\nIncome tax as stated in P&L                                    -                      -                   -7\n\nEffective tax rate                                          0%                      0%                    0\nPermanent differences refer to the fair value valuation of preferred and common shares. For IFRS purposes equ\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1340909090909091, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.42272727272727273, "height": 0.28863636363636364, "width": 0.7705882352941177}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-286-2", "text": "was classified as financial liabilities and expenses were recognized. No tax effect will arise from this reclassificati\n\nDeferred tax assets and liabilities\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.43227272727272725, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4618181818181818, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-286-3", "text": "The breakdown of deferred taxes b\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4759090909090909, "lower_right_x": 0.34823529411764703, "lower_right_y": 0.48954545454545456, "height": 0.013636363636363669, "width": 0.23588235294117643}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-286-4", "text": "                  31 December 2014   31 December 2013     31 December 2012            1 January 20\n                           thereof              thereof             thereof\nin kEUR           total                 total               total             total    thereof curre\n                           current              current             current\n\n\nDTA                329         39        256        40      215         34        -\ncurrent inco-\nme tax recei-        -           -          -         -         -         -       -\nvables\nDTL                329         34        256          -     215           -     77\ncurrent inco-\nme tax liabili-      -          -           -         -         -         -       -\ntes\n", "page_number": 286, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5086363636363637, "lower_right_x": 0.8935294117647059, "lower_right_y": 0.7363636363636363, "height": 0.22772727272727267, "width": 0.7811764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-286-5", "text": "F-39", "page_number": 286, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-287-0", "text": "Deferred taxes relate to the following balance sheet item\n", "page_number": 287, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11954545454545455, "lower_right_x": 0.4958823529411765, "lower_right_y": 0.1340909090909091, "height": 0.014545454545454542, "width": 0.3835294117647059}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-287-1", "text": "in kEUR\n                             Deferred tax assets                                      Deferred tax liabilities\n                              31 De-    31 De-                                                                         1 Ja-\n                   31 Decem- cember     cember         1 Janua-       31 Decem-        31 Decem-       31 Decem-       nuary\n                   ber 2014   2013      2012           ry 2012        ber 2014         ber 2013        ber 2012        2012\nAssets\nTrade and other\nreceivables                 1         1            -              -           -                    -               -\nInventories                 -         3            -              -          32                    -               -\nProperty, plant\nand equipement               -        -            -              -         295                256               215\nLiabilities\nOther current\nliabilities                  -        -            -              -               -                -               -\nOther current\nfinancial liabi-\nlities                     38        36        34                             1                    -               -\nProvisions\ncurrent                      -        0            -              -           1                    -               -\nProvision\nPSOP                      251       173       164                 -               -                -               -\nOther non-\ncurrent finani-\ncal liabilities            21        33            6              -               -                -               -\nProvisons non-\ncurrent                    18        10        11                 -               -                -               -\nDeferred\nTaxes (gross)             329       256       215                 -         329                256               215\nOffsetting                329       256       215                 -         329                256               215\nDeferred\nTaxes (net)                  -        -            -              -               -                -               -\n", "page_number": 287, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.145, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6286363636363637, "height": 0.48363636363636364, "width": 0.7723529411764707}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-287-2", "text": "cient future taxable profits or offsetting deferred tax liabilities are available.\n\nAs of 31 December 2014, Curetis had tax loss carryforwards that were not utilizable and for which no deferred ta\nwere recognized. These tax loss carryforwards amount to kEUR 38,000 for corporate tax purposes and kEUR 37,9\n", "page_number": 287, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.665, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7077272727272728, "height": 0.042727272727272725, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-287-3", "text": "tax purposes). Those are available unlimited for offsetting against future taxable profits of Curetis. Deferred\nassets have not been recognized in respect of these losses as no sufficient certainty is given whether such tax l\ncarryforwards will enable Curetis to offset its future taxable profits.\n", "page_number": 287, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7231818181818181, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.81, "height": 0.0868181818181819, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-287-4", "text": "F-40", "page_number": 287, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.026470588235294135}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-288-0", "text": "Equity\n", "page_number": 288, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.1923529411764706, "lower_right_y": 0.11272727272727273, "height": 0.015, "width": 0.08}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-288-1", "text": "At 31 December 2014 the share capital of kEUR 50 is divided into 50,000 ordinary shares with a par value of 1 Eu\n", "page_number": 288, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.14181818181818182, "height": 0.014999999999999986, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-288-2", "text": "As of 31 December 2014, 5,553,689 shares are issued with a par value of 1\u20ac. All shares are fully paid. Besides\nminimum amount of share capital, required under German law, there are no distribution restrictions applicable. T\nentity itself does not hold any shares.\n", "page_number": 288, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1559090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-288-3", "text": "F-41", "page_number": 288, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.0252941176470588}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-0", "text": "ADDITIONAL DISCLOSURES ON FINANCIAL INSTRUMENT\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09045454545454545, "lower_right_x": 0.5923529411764706, "lower_right_y": 0.10181818181818182, "height": 0.011363636363636367, "width": 0.4794117647058824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-1", "text": "Financial risk managemen\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.3388235294117647, "lower_right_y": 0.14181818181818182, "height": 0.014999999999999986, "width": 0.2264705882352941}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-2", "text": "31.1. Financial risk factors\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1559090909090909, "lower_right_x": 0.30058823529411766, "lower_right_y": 0.1709090909090909, "height": 0.014999999999999986, "width": 0.18823529411764706}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-3", "text": "Curetis' activities expose the Company to a variety of financial risks such as currency risks, fair value interest ris\ncash flow risks, interest rate risks and price risks. Curetis' finance department has created controlling instruments a\nkey metrics to identify and evaluate such risks in close co-operation with the operating units.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.185, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2290909090909091, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-4", "text": "Market risk\n", "page_number": 289, "bounding_box": {"top_left_x": 0.1688235294117647, "top_left_y": 0.2359090909090909, "lower_right_x": 0.25176470588235295, "lower_right_y": 0.24954545454545454, "height": 0.013636363636363641, "width": 0.08294117647058824}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-5", "text": "", "page_number": 289, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.23954545454545453, "lower_right_x": 0.13117647058823528, "lower_right_y": 0.2509090909090909, "height": 0.011363636363636381, "width": 0.018235294117647044}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-6", "text": "changes in market prices. Curetis has a strong international business focus and therefore the Company is influen\nby foreign currency exchange rates and interest rates. However, Curetis currently does not hold any securities ava\nble for sale and Curetis keeps all its liquidity in immediately available money market funds.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.26136363636363635, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.31636363636363635, "height": 0.05499999999999999, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-7", "text": "Curetis is exposed to foreign\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.34136363636363637, "lower_right_x": 0.3241176470588235, "lower_right_y": 0.35454545454545455, "height": 0.013181818181818183, "width": 0.21117647058823527}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-8", "text": "currency risk in US Dollar, because certain purchase transactions are undertaken in US Dollar (\u201cUSD\"). Curetis\nnot yet entered into any currency hedging arrangements in order to cover its exposure. Curetis is managing its f\neign currency risks by identifying its mid-term-USD-demands within its rolling forecast and take opportunistic\nbounds on the currently historical low FX rates to cover these demands.\n\nIn summary it can be said that the foreign exchange risk in 2012-2013-2014 was very limited at Curetis AG, due\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.36318181818181816, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.43454545454545457, "height": 0.0713636363636364, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-9", "text": "rency risk except for the USD expenses for the US FDA trial. Revenues are mainly generated in Euro.\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.45045454545454544, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.49318181818181817, "height": 0.042727272727272725, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-10", "text": "is not exposed to\n", "page_number": 289, "bounding_box": {"top_left_x": 0.17352941176470588, "top_left_y": 0.5159090909090909, "lower_right_x": 0.2911764705882353, "lower_right_y": 0.5272727272727272, "height": 0.011363636363636354, "width": 0.11764705882352944}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-11", "text": "Cu\nme\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5172727272727272, "lower_right_x": 0.13117647058823528, "lower_right_y": 0.5295454545454545, "height": 0.012272727272727324, "width": 0.018823529411764697}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-12", "text": "d)   Credit risk\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5377272727272727, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.5636363636363636, "height": 0.02590909090909088, "width": 0.77}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-13", "text": "rel\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.5886363636363636, "lower_right_x": 0.13117647058823528, "lower_right_y": 0.6031818181818182, "height": 0.014545454545454528, "width": 0.017647058823529405}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-14", "text": "to account\n", "page_number": 289, "bounding_box": {"top_left_x": 0.17352941176470588, "top_left_y": 0.5886363636363636, "lower_right_x": 0.24352941176470588, "lower_right_y": 0.6, "height": 0.011363636363636354, "width": 0.07}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-15", "text": "and delivery terms and conditions are offered. Curetis has also implemented a well-organized dunning system and\n2014, Curetis had had write-downs on trade receivables of kEUR 2 in (2013: kEUR 0, 2012: kEUR 0). The cre\nrisk on the accounts receivables is limited because Curetis primarily sells to big laboratories, pharma-companies a\npublic hospitals in Curetis' home markets in Central and Western Europe, all of these partners have very good cre\nratings. Outside of Europe Curetis works together with large and experienced distributors. If Curetis expands\nbusiness to other more credit-risky countries Curetis will consider implementing a commercial credit insurance\ncover the risks.\n\nCash and cash equivalents as well as short-term deposits are invested in \u20ac denominated money market funds w\nhighly reputable banks. Curetis follows a strong no-risk-policy what means that Curetis just has sight deposits\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6104545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7381818181818182, "height": 0.1277272727272727, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-16", "text": "e) Liquidity risk\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7559090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8, "height": 0.04409090909090918, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-17", "text": "obtained throug\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.8213636363636364, "lower_right_x": 0.2211764705882353, "lower_right_y": 0.8363636363636363, "height": 0.014999999999999902, "width": 0.10764705882352943}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-18", "text": "financial reports. Curetis has not yet established any credit line with financial institutions. The ability of Curetis\n\n\n\n                                                                                                                    F\n", "page_number": 289, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8431818181818181, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9018181818181819, "height": 0.05863636363636371, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-289-19", "text": "F-42", "page_number": 289, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-290-0", "text": "maintain adequate cash reserves to sustain the Company's activities in the medium to long term is highly depend\non our ability to increase cash inflows from product sales, as well as the sale of new shares.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.11954545454545455, "height": 0.029090909090909098, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-290-1", "text": "In the event Curetis would not be able to attract any additional funds from the IPO, the company\u00b4s ability to contin\nas a going concern is threatened by risks. The business plan prepared in case of a withdrawn IPO includes signific\nreductions to operating expenses through elimination of anticipated costs of \u201cbeing public\u201d and suspension of clini\ntrials. Personnel cost reductions are to be achieved through reductions in planned head count and cancellation\nsalary increases. Management is of the opinion that the combination of these measures enables Curetis to continue\na going concern for at least 12 months as of the date of the financial statements. In order to ensure going conc\nbeyond these 12 months the company may rely on further significant cost reductions and reduced operating expen\ntures, more delayed capital expenditures or may also seek additional financing from current or future sharehold\nprivately, whether in the form of bridge loans and/or equity offerings.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1340909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.265, "height": 0.13090909090909092, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-290-2", "text": "a going concern for at least 12 months as of the date of the financial statements.\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.27954545454545454, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.3090909090909091, "height": 0.02954545454545454, "width": 0.7711764705882354}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-290-3", "text": "on the remaining date on the balance sheet date. The amounts disclosed are the contractual undiscounted cash flow\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3231818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3527272727272727, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-290-4", "text": "Balance as at 1 January\n2012                          Up to 1 year   1-3 years   3-5 years   More than 5 yea\nTrade and other payables              947            -           -\nFinance lease liabilities                -           -           -\nFinancial liabilities for\npreferred and common\nshares                                   -           -           -             68,86\nOther financial liabilities              -           -           -\n\nBalance as at 31 Decem-\nber 2012                      Up to 1 year   1-3 years   3-5 years   More than 5 yea\nTrade and other payables               634          -           -\nFinance lease liabilities              122        261         258\nFinancial liabilities for\npreferred and common\nshares                                   -           -           -            107,86\nOther financial liabilities             57           -           -\n\n\nBalance as at 31 Decem-\nber 2013                      Up to 1 year   1-3 years   3-5 years   More than 5 yea\nTrade and other payables              616            -           -\nFinance lease liabilities             128         274         118\nFinancial liabilities for\npreferred and common\nshares                                   -           -           -            116,99\nOther financial liabilities            39            -           -\n", "page_number": 290, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3740909090909091, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.8459090909090909, "height": 0.47181818181818186, "width": 0.781764705882353}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-290-5", "text": "F-43", "page_number": 290, "bounding_box": {"top_left_x": 0.8576470588235294, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9504545454545454, "height": 0.009090909090909038, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-0", "text": "Balance as at 31 Decem-\nber 2014                      Up to 1 year   1-3 years   3-5 years   More than 5 yea\nTrade and other payables              580            -           -\nFinance lease liabilities             133         258            -\nFinancial liabilities for\npreferred and common\nshares                                   -           -           -            126,0\nOther financial liabilities           240            -           -\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.08681818181818182, "lower_right_x": 0.8923529411764706, "lower_right_y": 0.24227272727272728, "height": 0.15545454545454546, "width": 0.78}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-1", "text": "31.2. Capital management", "page_number": 291, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2831818181818182, "lower_right_x": 0.2958823529411765, "lower_right_y": 0.2968181818181818, "height": 0.013636363636363613, "width": 0.18352941176470589}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-2", "text": "strong base in terms of equity capital (including preference shares) and sufficient cash balance in order to maint\ninvestor and creditor confidence and to sustain the future development of the business. Our primary goals wh\nmanaging capital are to ensure sufficient liquidity to meet our working capital requirements, fund capital investme\nand purchase and to safeguard our ability to continue operating as going concern.\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.31227272727272726, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3845454545454545, "height": 0.07227272727272727, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-3", "text": "status frequently within the management meetings and also within its supervisory board meetings.\n31.3. Fair value estimation\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.39954545454545454, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.42863636363636365, "height": 0.02909090909090911, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-4", "text": "The table below analyses f\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.4395454545454546, "lower_right_x": 0.2964705882352941, "lower_right_y": 0.4509090909090909, "height": 0.011363636363636354, "width": 0.18294117647058822}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-5", "text": "been defined as follows:\n\n\uf0b7     Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1).\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.46136363636363636, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4909090909090909, "height": 0.02954545454545454, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-6", "text": "\uf0b7   Inputs other than quoted prices included within level 1 that are observable for the asset or liability, eit\n    directly (that is, as prices) or indirectly (that is, derived from prices) (Level 2).\n\n\uf0b7   Inputs for the asset or liability that are not based on observable market data (that is, unobservable inpu\n    (Level 3).\n\n\n                                                   31 December        31 December        1 January\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.5086363636363637, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.610909090909091, "height": 0.10227272727272729, "width": 0.7711764705882354}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-7", "text": "                                                                                                              Fair val\nin kEUR                              Fair value            Fair value          Fair value      Fair value          lev\nFinancial liabilities\nMeasured at fair value\nthrough profit or loss\nFinancial liabilities for\npreferred and common\nshares                                  126,036              116,993             107,860           68,863\n\n\n\nThere were no transfers between the different levels of the fair value hierarchy in any of the periods presented.\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6359090909090909, "lower_right_x": 0.8935294117647059, "lower_right_y": 0.7963636363636364, "height": 0.16045454545454552, "width": 0.7811764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-8", "text": "with IAS 39. Given the input parameters and the valuation method used, their fair value measurement is categori\nwithin Level 3 of the fair value hierarchy.\n\n\n                                                                                                              F\n", "page_number": 291, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8322727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9068181818181819, "height": 0.07454545454545458, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-291-9", "text": "F-44", "page_number": 291, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-0", "text": "The fair value of the financial liability was determined using a discounted cash flow model. The model uses the\nlowing input parameters to the valuation as of the respective dates:\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.11954545454545455, "height": 0.029090909090909098, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-1", "text": "                   Projection Period   Long-term growth     Discount rate   Level allocation\n                             (years)              rate %               %      input paramete\n31 December 2014                  10                  2.0           15.5\n31 December 2013                  10                  2.0           17.0\n31 December 2012                  10                  2.0           19.5\n1 January 2012                    10                  2.0           20.0\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.12318181818181818, "lower_right_x": 0.8888235294117647, "lower_right_y": 0.2318181818181818, "height": 0.10863636363636363, "width": 0.7758823529411765}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-2", "text": "shares liability included in non-current financial liabilities.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.25772727272727275, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2863636363636364, "height": 0.028636363636363626, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-3", "text": "In kEUR                                 2014      2013      20\nBalance as of 1 January               116,993   107,860    68,8\nAdditional paid-in Series B shares      6,758     6,636     6,8\nLosses recognized in profit or loss     2,285     2,497    32,0\nBalance as of 31 December             126,036   116,993   107,8\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29045454545454547, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.3968181818181818, "height": 0.10636363636363633, "width": 0.7694117647058824}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-4", "text": "affect the fair value of these liabilities. The following table provides an overview of the effects on the equity value\nMio. EUR of Curetis of changes in those input factors:\n\n                                          31 December           31 December          31 December\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.42863636363636365, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4718181818181818, "height": 0.043181818181818155, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-5", "text": "Change in                                          2014                 2013                 2012   1 January 20\nDiscount factor\n  +0.25%                                            127                  116                 110\n  -0.25%                                            132                  120                 113\nLong-term growth rate\n  +0.5%                                             132                  120                 112\n  -0.5%                                             127                  116                 110\nCash flows in projection period\n  +10%                                              141                  128                 121\n  -10%                                              118                  107                 101\n\nFinancial Instruments at fair value through profit and loss include changes of fair value.\n", "page_number": 292, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.48318181818181816, "lower_right_x": 0.8817647058823529, "lower_right_y": 0.6681818181818182, "height": 0.18500000000000005, "width": 0.7694117647058824}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-6", "text": "Financial Instruments at fair value through profit and loss include changes of fair value.", "page_number": 292, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6904545454545454, "lower_right_x": 0.6876470588235294, "lower_right_y": 0.7045454545454546, "height": 0.014090909090909154, "width": 0.5752941176470588}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-292-7", "text": "F-45", "page_number": 292, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-0", "text": "Commitments\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.2447058823529412, "lower_right_y": 0.14045454545454544, "height": 0.013636363636363613, "width": 0.13235294117647062}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-1", "text": "Operating lease commitment\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1409090909090909, "lower_right_x": 0.3241176470588235, "lower_right_y": 0.16363636363636364, "height": 0.022727272727272735, "width": 0.2117647058823529}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-2", "text": "Curetis leases its offices and production facility under non-cancellable operating leases agreements. The lease term\n5 years and the agreements are renewable at the end of the lease term at market rate.\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.17045454545454544, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2, "height": 0.02954545454545457, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-3", "text": "Curetis also leases machinery and vehicles under non-cancellable operating leases agreements. The lease term i\nyears and the agreements are not renewable at the end of the lease term. The future aggregate minimum lease p\nments under non-cancellable operating leases and existing purchase commitments are as follows:\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.21409090909090908, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.2581818181818182, "height": 0.0440909090909091, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-4", "text": "in kEUR                                       2014    2013    20\nNo later than 1 year                          2,528   4,515   1,7\nLater than 1 year and no later than 5 years   1,323     143    2\nLater than 5 years                               34       -\nTotal                                         3,885   4,658   2,0\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.265, "lower_right_x": 0.8935294117647059, "lower_right_y": 0.36727272727272725, "height": 0.10227272727272724, "width": 0.7811764705882354}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-5", "text": "33. Related parties", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3886363636363636, "lower_right_x": 0.2535294117647059, "lower_right_y": 0.4036363636363636, "height": 0.015000000000000013, "width": 0.1411764705882353}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-6", "text": "below.\n\nCompensation of key management\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4213636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.44636363636363635, "height": 0.024999999999999967, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-7", "text": "Key management includes the Com\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.465, "lower_right_x": 0.35764705882352943, "lower_right_y": 0.47863636363636364, "height": 0.013636363636363613, "width": 0.2447058823529412}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-8", "text": "Key management includes the Company\u2019s officers and directors. The compensation of key management for employ-\nee services is shown below:", "page_number": 293, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4940909090909091, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.52, "height": 0.025909090909090937, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-9", "text": "Salaries and other short-term employee benefits   490   586    58\nPost-employment benefits                            -     -\nShare-based payments                              488   -66   1,01\nOther                                              14     3\nTotal                                             992   523   1,60\n\n\nCompensation of Supervisory Board\n", "page_number": 293, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.5413636363636364, "lower_right_x": 0.8876470588235295, "lower_right_y": 0.665, "height": 0.12363636363636366, "width": 0.78}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-10", "text": "in kEUR\n", "page_number": 293, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.6940909090909091, "lower_right_x": 0.4888235294117647, "lower_right_y": 0.730909090909091, "height": 0.03681818181818186, "width": 0.37588235294117645}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-11", "text": "Total   36   10   1\n", "page_number": 293, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.7486363636363637, "lower_right_x": 0.8894117647058823, "lower_right_y": 0.81, "height": 0.0613636363636364, "width": 0.7817647058823529}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-293-12", "text": "F-46", "page_number": 293, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-0", "text": "Events after the reporting dat\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.3623529411764706, "lower_right_y": 0.11272727272727273, "height": 0.015, "width": 0.25}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-1", "text": "The formal kick-off meeting for the project aimed at preparing Curetis for an IPO not before Q4-2015 was held\n29th July 2015. Subsequently during the months of August and September there have been significant efforts a\ncosts incurred on the part of legal counsels to issuer and underwriter, auditors with regards to prospectus review a\nfuture comfort letter preparation, corporate communications advisors, road show related expenses. With the f\nsubmission of a confidential prospectus draft to the AFM on 31st August 2015 certain discounts in case of a brok\nIPO deal no longer apply.\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.21454545454545454, "height": 0.08772727272727271, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-2", "text": "On 25 September 2015, Curetis and Beijing CLEAR Biotech Co., Ltd (\"Beijing CLEAR Biotech\") entered into\nexclusive international distributor agreement under which Curetis appointed Beijing CLEAR Biotech as the exc\nsive distributor of the Unyvero Platform in China, Taiwan and Hong Kong. During the registration period, Beij\nCLEAR Biotech will conduct and fully fund the prospective multi-centre clinical trials and approval procedure\nquired for the approval of the Unyvero System and the P55 and i60 ITI Application Cartridges for distribution\nChina. If and once granted, Curetis shall be the owner of the respective license and is obligated to reward Beij\nCLEAR Biotech for certain achievements in starting the clinical trial and pursuing the CFDA clinical trial and reg\ntration process through milestone payments. Marketing in Taiwan will start earlier, as no specific trial is required\nproduct registration. For the commercialisation of the Unyvero i60 ITI Application Cartridge, Beijing CLEAR B\ntech will partner with LandMover Medical Technologies Co. Ltd. (Beijing, China), the exclusive Chinese distribu\nof HM.\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.22863636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.38545454545454544, "height": 0.1568181818181818, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-3", "text": "co-operation with regard to the development and marketing of a sepsis host response test and the distribution of\nUnyvero System and the Application Cartridges in the ASEAN markets, starting with Singapore, Malaysia, Indo\nsia and Thailand. Acumen granted Curetis the non-exclusive worldwide rights to develop and market a sepsis h\nresponse test as an Application Cartridge for the Unyvero System on the basis of Acumen\u2019s proprietary sepsis h\nresponse biomarker panel. During the R&D phase, Curetis will be responsible for adapting its technology to run\nAcumen sepsis host response biomarker panel with the Unyvero Platform, e.g.; transferring the current pre-analyti\nworkflow. It is Acumen's responsibility to further evaluate and optimise the biomarker panel for its intended use a\nto do health economic analyses and studies. Both parties will collaborate in the performance evaluation studies\nAsia and Europe required for commercialisation of the product. Curetis intends to first launch the Application C\ntridge as CE-IVD Application Cartridge in Europe and other regions accepting CE-IVD markings.\n\nQ1-2015 saw the full payment of the first tranche of the November 2014 Series B extension financing and sub\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4031818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5636363636363636, "height": 0.1604545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-4", "text": "the payment of the remaining financing tranche into the agio of kEUR 6,789 during Q3-2015. The key element\nsaid milestone has been the start of the prospective enrolment of Curetis\u2019 FDA trial for Unyvero LRT55 in the US\n\nIn October 2015, Curetis identified and recruited the Company's future Supervisory Directors, including the\nnowned industry experts Bill Rhodes (future chairman of the board) and Mario Crovetto (future chairman auf\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5777272727272728, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6363636363636364, "height": 0.0586363636363636, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-5", "text": "audit committee).\n\nIn the third quarter of 2015, Curetis received \u20ac 5,989 thousand of the second and final tranche of its Series B Fina\ning Round, while the remaining kEUR 800 will be paid into the newly incorporated Company.\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6504545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6945454545454546, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-6", "text": "In the event Curetis would not be able to attract any additional funds from the IPO, the company\u00b4s ability to conti\nas a going concern is threatened by risks. The business plan prepared in case of a withdrawn IPO includes cost red\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7122727272727273, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.7413636363636363, "height": 0.029090909090909056, "width": 0.77}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-7", "text": "continue as a going concern for at least 12 months as of the date of the financial statements. In order to ensure go\nconcern beyond these 12 months the company may rely on further significant cost reductions and reduced operat\nexpenditures, more delayed capital expenditures or may also seek additional financing from current or future sha\nholders privately, whether in the form of bridge loans and/or equity offerings.\n\nConsidering the above stated countermeasures, even in case of a withdrawn IPO Curetis would be able to continue\na going concern for at least 12 months as of the date of the financial statements. If however the company fails\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7559090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8568181818181818, "height": 0.10090909090909095, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-8", "text": "F\n", "page_number": 294, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8722727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9013636363636364, "height": 0.029090909090909056, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-294-9", "text": "F-47", "page_number": 294, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-0", "text": "implement the above stated countermeasures in case of a withdrawn IPO, it may be unable to continue as a go\nconcern and may ultimately have to file for insolvency.\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.11954545454545455, "height": 0.029090909090909098, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-1", "text": "Holzgerlingen, 22 October 2015\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.16318181818181818, "lower_right_x": 0.3288235294117647, "lower_right_y": 0.1781818181818182, "height": 0.015000000000000013, "width": 0.21647058823529408}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-2", "text": "Curetis AG\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19363636363636363, "lower_right_x": 0.1923529411764706, "lower_right_y": 0.20636363636363636, "height": 0.012727272727272726, "width": 0.08}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-3", "text": "Chief Executive Off\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11588235294117646, "top_left_y": 0.24681818181818183, "lower_right_x": 0.24941176470588236, "lower_right_y": 0.2581818181818182, "height": 0.011363636363636354, "width": 0.1335294117647059}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-4", "text": "Chief Executive Officer (CEO)", "page_number": 295, "bounding_box": {"top_left_x": 0.11588235294117646, "top_left_y": 0.26136363636363635, "lower_right_x": 0.32, "lower_right_y": 0.27636363636363637, "height": 0.015000000000000013, "width": 0.20411764705882354}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-5", "text": "Chief Technol\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2909090909090909, "lower_right_x": 0.21058823529411766, "lower_right_y": 0.30227272727272725, "height": 0.011363636363636354, "width": 0.09823529411764707}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-6", "text": "Chief Technology Officer (CTO)", "page_number": 295, "bounding_box": {"top_left_x": 0.11470588235294117, "top_left_y": 0.30863636363636365, "lower_right_x": 0.3341176470588235, "lower_right_y": 0.32272727272727275, "height": 0.014090909090909098, "width": 0.21941176470588236}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-7", "text": "Chief Commerci\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3377272727272727, "lower_right_x": 0.2252941176470588, "lower_right_y": 0.3490909090909091, "height": 0.011363636363636409, "width": 0.11294117647058823}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-8", "text": "Chief Commercial Officer (CCO)", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.35363636363636364, "lower_right_x": 0.3388235294117647, "lower_right_y": 0.36727272727272725, "height": 0.013636363636363613, "width": 0.2264705882352941}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-9", "text": "Chief Operating Officer (COO\n", "page_number": 295, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.38136363636363635, "lower_right_x": 0.32294117647058823, "lower_right_y": 0.41454545454545455, "height": 0.0331818181818182, "width": 0.21058823529411763}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-295-10", "text": "F-48", "page_number": 295, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-0", "text": "Independent Auditor's repor\nTo Curetis AG, Holzgerlingen\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.34352941176470586, "lower_right_y": 0.13363636363636364, "height": 0.04318181818181818, "width": 0.23117647058823526}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-1", "text": "We have audited the accompanying financial statements of Curetis AG, Holzgerlingen, which comprise the sta\nment of financial position as at December 31, 2014, December 31, 2013, and December 31, 2012, and the stateme\nof profit or loss and other comprehensive income, changes in equity and cash flows for the periods then ended, a\nthe notes to the financial statements.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.14136363636363636, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.19636363636363635, "height": 0.05499999999999999, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-2", "text": "Management\u2019s responsibility for the financial statement\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.20681818181818182, "lower_right_x": 0.4894117647058824, "lower_right_y": 0.22136363636363637, "height": 0.014545454545454556, "width": 0.3770588235294118}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-3", "text": "with International Financial Reporting Standards (IFRS) as adopted by the European Union, and for such inter\ncontrol as management determines is necessary to enable the preparation of financial statements that are free fr\nmaterial misstatement, whether due to fraud or error.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.22863636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.28545454545454546, "height": 0.05681818181818182, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-4", "text": "Our responsibility is to\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29409090909090907, "lower_right_x": 0.27294117647058824, "lower_right_y": 0.30863636363636365, "height": 0.014545454545454584, "width": 0.16058823529411764}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-5", "text": "in accordance with International Standards on Auditing. Those standards require that we comply with ethical\nquirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements\nfree from material misstatement.\nAn audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financ\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3159090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3709090909090909, "height": 0.05499999999999999, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-6", "text": "statements. The procedures selected depend on the auditor\u2019s judgment, including the assessment of the risks of ma\nrial misstatement of the financial statements, whether due to fraud or error. In making those risk assessments,\nauditor considers internal control relevant to the entity\u2019s preparation of financial statements that give a true and\nview in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expre\ning an opinion on the effectiveness of the entity\u2019s internal control. An audit also includes evaluating the appropria\nness of accounting policies used and the reasonableness of accounting estimates made by management, as well\nevaluating the overall presentation of the financial statements.\nWe believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our au\nopinion.\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.38136363636363635, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.49818181818181817, "height": 0.11681818181818182, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-7", "text": "Opinion\nIn our opinion the financial statements give a true and fair view of the financial position of Curetis AG as at Dece\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.505, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5418181818181819, "height": 0.03681818181818186, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-8", "text": "In our o\nber 31,\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.5422727272727272, "lower_right_x": 0.16823529411764707, "lower_right_y": 0.5563636363636364, "height": 0.014090909090909154, "width": 0.05529411764705883}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-9", "text": "years then ended in accordance with International Financial Reporting Standards (IFRS) as adopted by the Europ\nUnion.\nEmphasis of matter\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5631818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6218181818181818, "height": 0.0586363636363636, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-10", "text": "which describe tha\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6295454545454545, "lower_right_x": 0.24411764705882352, "lower_right_y": 0.6436363636363637, "height": 0.014090909090909154, "width": 0.13176470588235295}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-11", "text": "closed that the company\u2019s ability to continue as a going concern depends on either attracting additional funds fr\nthe IPO, or in case of a withdrawn IPO relying on countermeasures including significant personnel cost and ope\ning expenditure reductions, delayed capital expenditures or seeking additional financing from current or fut\nshareholders. If the company fails to implement these measures in case of a withdrawn IPO, it may be unable\ncontinue as a going concern and may ultimately have to file for insolvency.\n\n\nMunich, October 22, 2015\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6509090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7527272727272727, "height": 0.10181818181818181, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-12", "text": "Wirtschaftspr\u00fcfungsgesel\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7886363636363637, "lower_right_x": 0.28941176470588237, "lower_right_y": 0.8, "height": 0.011363636363636354, "width": 0.17705882352941177}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-13", "text": "Stefano Mulas\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8177272727272727, "lower_right_x": 0.4041176470588235, "lower_right_y": 0.8309090909090909, "height": 0.013181818181818183, "width": 0.2917647058823529}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-14", "text": "Wirtschaftspr\u00fcfer\n", "page_number": 296, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8313636363636364, "lower_right_x": 0.32941176470588235, "lower_right_y": 0.8468181818181818, "height": 0.015454545454545388, "width": 0.21705882352941175}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 15, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-15", "text": "Stefano Mulas", "page_number": 296, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.8613636363636363, "lower_right_x": 0.21176470588235294, "lower_right_y": 0.8727272727272727, "height": 0.011363636363636354, "width": 0.0988235294117647}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 16, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-16", "text": "Dietmar Eglauer", "page_number": 296, "bounding_box": {"top_left_x": 0.5029411764705882, "top_left_y": 0.8613636363636363, "lower_right_x": 0.6164705882352941, "lower_right_y": 0.875, "height": 0.013636363636363669, "width": 0.11352941176470588}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 17, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-17", "text": "Wirtschaftspriifer", "page_number": 296, "bounding_box": {"top_left_x": 0.5035294117647059, "top_left_y": 0.8754545454545455, "lower_right_x": 0.6247058823529412, "lower_right_y": 0.8904545454545455, "height": 0.015000000000000013, "width": 0.12117647058823533}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 18, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-18", "text": "Wirtschaftspriifer", "page_number": 296, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.8759090909090909, "lower_right_x": 0.23529411764705882, "lower_right_y": 0.8909090909090909, "height": 0.015000000000000013, "width": 0.12176470588235294}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 19, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-296-19", "text": "F-49", "page_number": 296, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-297-0", "text": "Interim Financial Statements of Curetis AG for the six months period ended\n30 June 2015", "page_number": 297, "bounding_box": {"top_left_x": 0.17823529411764705, "top_left_y": 0.5631818181818182, "lower_right_x": 0.8176470588235294, "lower_right_y": 0.5954545454545455, "height": 0.03227272727272723, "width": 0.6394117647058823}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-297-1", "text": "F-50", "page_number": 297, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.026470588235294135}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-298-0", "text": "CURETIS AG\nSTATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOM\nAs of 30 June, 2015\n", "page_number": 298, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.7105882352941176, "lower_right_y": 0.13363636363636364, "height": 0.04318181818181818, "width": 0.5982352941176471}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-298-1", "text": "                                                                                Six months ended Six months ende\nin Euro                                                                             30 June 2015     30 June 201\n\nRevenue [3]                                                                                742,035              253,68\nCost of sales [4]                                                                          665,151              359,00\nGross profit                                                                                76,884             -105,32\n\nDistribution costs [5]                                                                    1,396,725           1,107,18\nAdministrative expenses [5]                                                               1,365,739             867,23\nResearch and development expenses [5]                                                     2,943,167           3,305,20\nOther income                                                                                 41,235              23,22\nOperating profit                                                                         -5,587,512          -5,361,72\n\nFinance income                                                                                5,493               4,86\nFinance costs                                                                                 8,866              11,94\nFinance costs fair value measurement                                                      6,782,819           1,340,14\nFinance income/costs - net [6]                                                           -6,786,192          -1,347,21\n\nProfit/loss before income tax                                                          -12,373,704           -6,708,94\nTax income                                                                                       -\nProfit/loss for the year                                                               -12,373,704           -6,708,94\nOther comprehensive income for the year, net of tax                                              -\nTotal comprehensive income for the year                                                -12,373,704           -6,708,94\n\n                                                                                 Six months ended Six months ende\nEarnings/loss per share                                                               30 June 2015         30 June 201\nBasic                                                                                         -18.88              -10.2\nDiluted                                                                                       -18.88              -10.2\nShares Used in Computing Basic Net Result per Share                                        655,556               655,55\nShares Used in Computing Diluted Net Result per Share                                      655,556               655,55\n[..] Bracketed numbers refer to the related notes to the financial statements, which form an integral part of these\nfinancial statements.\n", "page_number": 298, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.15954545454545455, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.7186363636363636, "height": 0.5590909090909091, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-298-2", "text": "financial statements.", "page_number": 298, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.7195454545454546, "lower_right_x": 0.2488235294117647, "lower_right_y": 0.7304545454545455, "height": 0.010909090909090868, "width": 0.13588235294117645}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-298-3", "text": "F-51", "page_number": 298, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.0252941176470588}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-299-0", "text": "CURETIS AG\nSTATEMENT OF FINANCIAL POSITION\n", "page_number": 299, "bounding_box": {"top_left_x": 0.11470588235294117, "top_left_y": 0.09045454545454545, "lower_right_x": 0.4264705882352941, "lower_right_y": 0.12, "height": 0.02954545454545454, "width": 0.31176470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-299-1", "text": "As of 30 June, 2015\n", "page_number": 299, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.13772727272727273, "lower_right_x": 0.25058823529411767, "lower_right_y": 0.14909090909090908, "height": 0.011363636363636354, "width": 0.13823529411764707}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-299-2", "text": "Assets\n\nin Euro                                                                           30 June 2015      31 December 201\nCurrent assets                                                                        9,835,013               6,485,88\nCash and cash equivalents [7]                                                         5,940,328               2,993,88\nTrade receivables [8]                                                                   486,377                  42,23\nInventories [9]                                                                       3,198,665               3,153,13\nOther current assets [10]                                                               209,643                 296,62\n                                                                          -\nNon-current assets                                                                    6,718,626               7,307,39\nIntangible assets                                                                       225,178                 286,35\nProperty, plant and equipment                                                         6,069,981               6,591,67\nOther non-current assets                                                                 11,491                     39\nOther non-current financial assets [11]                                                 411,976                 428,97\nDeferred tax assets                                                                           -\n\n\nTOTAL ASSETS                                                                         16,553,639               13,793,27\n[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these fi-\nnancial statements.\n", "page_number": 299, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.1668181818181818, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.4818181818181818, "height": 0.315, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-299-3", "text": "[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these fi-\nnancial statements.", "page_number": 299, "bounding_box": {"top_left_x": 0.10823529411764705, "top_left_y": 0.4818181818181818, "lower_right_x": 0.86, "lower_right_y": 0.509090909090909, "height": 0.027272727272727226, "width": 0.7517647058823529}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-299-4", "text": "F-52", "page_number": 299, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-300-0", "text": "CURETIS AG\nSTATEMENT OF FINANCIAL POSITION\n", "page_number": 300, "bounding_box": {"top_left_x": 0.11470588235294117, "top_left_y": 0.09045454545454545, "lower_right_x": 0.4264705882352941, "lower_right_y": 0.12, "height": 0.02954545454545454, "width": 0.31176470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-300-1", "text": "As of 30 June, 2015\n", "page_number": 300, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.13772727272727273, "lower_right_x": 0.25058823529411767, "lower_right_y": 0.14909090909090908, "height": 0.011363636363636354, "width": 0.13823529411764707}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-300-2", "text": "Equity and Liabilities\n", "page_number": 300, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1668181818181818, "lower_right_x": 0.3, "lower_right_y": 0.18181818181818182, "height": 0.015000000000000013, "width": 0.1876470588235294}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-300-3", "text": "in Euro                                                                           30 June 2015      31 December 201\nCurrent liabilities                                                                   1,504,705               1,304,74\nTrade and other payables [12]                                                           830,782                 579,86\nProvisions current [13]                                                                  49,800                  34,80\nOther current liabilities [14]                                                          370,606                 316,81\nOther current financial liabilities [15] [18]                                           253,517                 373,26\n\n\nNon-current liabilities                                                            145,958,342             131,024,23\nProvisions non-current [13]                                                            819,478                 816,06\nProvision PSOP [13] [17]                                                             5,341,995               3,913,84\nOther non-current financial liabilities [16] [18]                                      188,864                 258,16\nFinancial liability for preferred and common shares [19]                           139,608,005             126,036,15\nDeferred tax liabilities                                                                     -\n\n\nTOTAL LIABILITIES                                                                  147,463,047             132,328,98\n\nEQUITY                                                                            -130,909,408            -118,535,70\nSubscribed equity [20]                                                                  50,000                  50,00\nAdditional paid-in capital                                                                   -\nRetained earnings                                                                 -130,959,408            -118,585,70\n\n\nTOTAL EQUITY AND LIABILITIES                                                         16,553,639               13,793,27\n[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these fi-\nnancial statements.\n", "page_number": 300, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.19590909090909092, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.6140909090909091, "height": 0.4181818181818182, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-300-4", "text": "[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these fi-\nnancial statements.", "page_number": 300, "bounding_box": {"top_left_x": 0.10823529411764705, "top_left_y": 0.6140909090909091, "lower_right_x": 0.8605882352941177, "lower_right_y": 0.6404545454545455, "height": 0.026363636363636367, "width": 0.7523529411764706}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-300-5", "text": "F-53", "page_number": 300, "bounding_box": {"top_left_x": 0.8576470588235294, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9504545454545454, "height": 0.009090909090909038, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-301-0", "text": "CURETIS AG\nSTATEMENT OF CASH FLOWS\n", "page_number": 301, "bounding_box": {"top_left_x": 0.11470588235294117, "top_left_y": 0.09045454545454545, "lower_right_x": 0.34823529411764703, "lower_right_y": 0.12, "height": 0.02954545454545454, "width": 0.23352941176470587}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-301-1", "text": "For the period ended 30 June, 2015\n\n                                                                                                       Six months              Six month\n                                                                                                            ended                   ende\nin Euro                                                                                              30 June 2015            30 June 201\n\n\nProfit before income tax                                                                                -12,373,704             -6,708,94\nAdjustments for:\n - Net finance cost                                                                                       6,786,192              1,347,21\n - Depreciation, amortization and impairments                                                               836,514                 682,63\n - Changes in provisions (excluding deferred taxes)                                                       1,444,870                 858,32\n\n\nChanges in working capital relating to:\n - Inventories                                                                                               -45,528               -453,67\n - Trade receivables and other receivables                                                                 -351,258                 399,71\n - Trade payables and other payables                                                                        181,732                -109,87\n\n\nIncome taxes received (+) / paid (-)                                                                                 -\nInterest received (+) / paid (-)                                                                              -3,373                  -7,07\nNet cash flow used in operating activities                                                               -3,524,556             -3,991,67\n\n\nInvestments in intangible assets                                                                              -2,230                -43,54\nInvestments in property, plant and equipment                                                               -251,606                -430,81\nReceipts from sale of assets                                                                                         -                    4,00\nProceeds from disposal of fixed assets                                                                         1,889\nNet cash flow used in investing activities                                                                 -251,947                -470,36\n\n\nPayments of finance lease liabilities                                                                        -66,078                -63,00\nCash received from issuance of preferred shares                                                           6,789,027              5,864,23\nNet cash flow provided by financing activities                                                            6,722,949              5,801,23\n\n\nNet change in cash and cash equivalents                                                                   2,946,445              1,339,19\n\n\nCash and cash equivalents at the beginning of the year                                                    2,993,883              5,381,96\nChange in cash and cash equivalents                                                                       2,946,445              1,339,19\nCash and cash equivalents at the end of the period                                                        5,940,328              6,721,15\n[..]Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financial statements.\n", "page_number": 301, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.13772727272727273, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.8009090909090909, "height": 0.6631818181818182, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-301-2", "text": "Cash and cash equivalents at the end of the period 5,940,328 6,721,156\n\n \n\n[..]Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financial statements.", "page_number": 301, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.8013636363636364, "lower_right_x": 0.8911764705882353, "lower_right_y": 0.8313636363636364, "height": 0.030000000000000027, "width": 0.7835294117647059}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-301-3", "text": "F-54", "page_number": 301, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-302-0", "text": "CURETIS AG\n\nSTATEMENT OF CHANGES IN EQUITY\n\nAs of 30 June, 2015\n", "page_number": 302, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.40941176470588236, "lower_right_y": 0.15818181818181817, "height": 0.06772727272727272, "width": 0.29705882352941176}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-302-1", "text": "                                                           Subscribed         Capital re-       Retained earni-\nin Euro                                                        capital             serve                   ngs               Total equi\nBalance as of 01 January 2014                                  50,000                   -         -106,151,781               -106,101,78\n\nProfit of H1-2014                                                       -                  -           -6,708,941               -6,708,94\nTotal comprehensive income for H1-2014                                  -                  -           -6,708,941               -6,708,94\n\nBalance as of 30 June 2014                                       50,000                    -        -112,860,722             -112,810,72\n\nBalance as of 01 January 2015                                    50,000                    -        -118,585,704             -118,535,70\n\nProfit of H1-2015                                                       -                  -          -12,373,704             -12,373,70\nTotal comprehensive income for H1-2015                                  -                  -          -12,373,704             -12,373,70\n\n\nBalance as of 30 June 2015                                       50,000                    -        -130,959,408             -130,909,40\n[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financial statements.\n", "page_number": 302, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.19954545454545455, "lower_right_x": 0.8923529411764706, "lower_right_y": 0.47954545454545455, "height": 0.28, "width": 0.7847058823529411}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-302-2", "text": "[..] Bracketed numbers refer to the related notes to the financial statements which form an integral part of these financial statements.", "page_number": 302, "bounding_box": {"top_left_x": 0.11176470588235295, "top_left_y": 0.47954545454545455, "lower_right_x": 0.8611764705882353, "lower_right_y": 0.4940909090909091, "height": 0.014545454545454528, "width": 0.7494117647058823}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-302-3", "text": "F-55", "page_number": 302, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9522727272727273, "height": 0.010909090909090868, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-0", "text": "NOTES TO THE FINANCIAL STATEMENTS\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.44176470588235295, "lower_right_y": 0.10181818181818182, "height": 0.011363636363636367, "width": 0.32941176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-1", "text": "General Information\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.2917647058823529, "lower_right_y": 0.14, "height": 0.013181818181818183, "width": 0.17941176470588233}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-2", "text": "Curetis AG (Curetis or the Company) was incorporated in 2007 and is domiciled in Holzgerlingen, Germany. T\naddress of its registered office is Max-Eyth-Str. 42, 71088 Holzgerlingen.\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.1559090909090909, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.18545454545454546, "height": 0.02954545454545454, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-3", "text": "Curetis is a molecular diagnostics company specialized in the development of solutions for diagnosing severe inf\ntious diseases in hospitalized patients. The solutions enable physicians to detect pathogens and antibiotic resista\nmarkers early.\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.24363636363636362, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-4", "text": "2. Accounting and valuation methods", "page_number": 303, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.26136363636363635, "lower_right_x": 0.3905882352941176, "lower_right_y": 0.2731818181818182, "height": 0.011818181818181839, "width": 0.27705882352941175}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-5", "text": "plied consistently to all years presented, unless otherwise stated.\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.29045454545454547, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3195454545454545, "height": 0.029090909090909056, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-6", "text": "2.1. Basis of preparation", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3340909090909091, "lower_right_x": 0.28647058823529414, "lower_right_y": 0.3481818181818182, "height": 0.014090909090909098, "width": 0.17411764705882354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-7", "text": "nancial Reporting Standards (IFRS) and the Interpretations (IFRIC) as endorsed by the European Union (EU). Th\ninterim financial statements comply with IAS 34 \u201cInterim Financial Reporting\u201d and is approved for issuance by\nBoard of Management on 22 October 2015. The same accounting policies and methods of computation are follow\nin the interim financial report as compared with the most recent annual financial statements prepared as of Decem\n31, 2014.\n\nThese financial statements have been prepared under the historical cost convention except for the financial liabili\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.36318181818181816, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4509090909090909, "height": 0.08772727272727276, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-8", "text": "profit or loss is prepared based on the cost-of-sales method.\n\nThe financial statements have been prepared on a going concern basis. However, in the event Curetis would not\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.465, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.509090909090909, "height": 0.044090909090909014, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-9", "text": "by risks. The business plan prepared in case of a withdrawn IPO includes significant reductions to operating expe\nes through elimination of anticipated costs of \u201cbeing public\u201d and suspension of clinical trials. Personnel cost red\ntions are to be achieved through reductions in planned head count and cancellation of salary increases. Additiona\nin order to improve working capital, reductions will be made to capital expenditure for new projects. Managemen\nof the opinion that the combination of these measures enables Curetis to continue as a going concern for at least\nmonths as of the date of the financial statements. In order to ensure going concern beyond these 12 months the co\npany may rely on further significant operating expenditure and capital expenditure reductions or may also seek ad\ntional financing from current or future shareholders privately, whether in the form of bridge loans and/or equity\nferings.\n\nConsidering the above stated countermeasures, even in case of a withdrawn IPO, Curetis would be able to contin\nas a going concern for at least 12 months as of the date of the financial statements.\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5231818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6831818181818182, "height": 0.16000000000000003, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-10", "text": "The functional currency of the Company is Euro. The notes to the financial statements are presented in thousands\nEuros (kEUR) in accordance with commercial rounding practices unless stated otherwise. The reporting period\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6977272727272728, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7272727272727273, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-11", "text": "retis AG as of December 31, 2014, which should be referred to for further information.\n\nThe following explanatory notes are an integral part of the financial statements which further comprise the statem\nof profit or loss and other comprehensive income, the statement of financial position, the statement of cash flows a\n", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7413636363636363, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.8, "height": 0.05863636363636371, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-12", "text": "The following explanatory notes are an integral part of the financial statements which further comprise the statement\nof profit or loss and other comprehensive income, the statement of financial position, the statement of cash flows and\nthe statement of changes in equity.", "page_number": 303, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8177272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.86, "height": 0.04227272727272724, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-303-13", "text": "F-56", "page_number": 303, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-304-0", "text": "2.2. Standards, interpretations, and amendments issued, but not yet to be applie\n", "page_number": 304, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.6588235294117647, "lower_right_y": 0.10545454545454545, "height": 0.015, "width": 0.5464705882352942}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-304-1", "text": "The following new and revised standards and interpretations that were not yet mandatory for the financial year\nwere not yet adopted by the European Union, have not been applied in advance. Standards with the remark \u201cyes\u201d\nlikely to have an impact on the financial statements. Their impact is currently being assessed by the Compa\nStandards with the remark \u201cnone\u201d are not likely to have a material impact on the financial statements.\n", "page_number": 304, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.1781818181818182, "height": 0.05863636363636364, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-304-2", "text": "Standard / Inter-                           Mandatory applica-   Adopted by the   Possible impact o\npretation                                   tion for financial   European Union   Curetis\n                                            years starting on\nIAS 1 (A)           Disclosure Initiative   01/01/2016           No               Yes\n\nIAS 19 (A)          Employee Contribu-      01/02/2015           No               None\n                    tions to Defined\n                    Benefit Plans\nIFRIC 21            Levies                  17/06/2014           Yes              None\n                    Improvements      to    01/02/2015           No               None\n                    International Finan-\n                    cial       Reporting\n                    Standards, 2010 \u2013\n                    2012 cycle\n                    Improvements      to    01/02/2015           No               None\n                    International Finan-\n                    cial       Reporting\n                    Standards, 2011 \u2013\n                    2013 cycle\n(A) Amended\n", "page_number": 304, "bounding_box": {"top_left_x": 0.10294117647058823, "top_left_y": 0.18863636363636363, "lower_right_x": 0.8911764705882353, "lower_right_y": 0.5263636363636364, "height": 0.33772727272727276, "width": 0.7882352941176471}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-304-3", "text": "F-57", "page_number": 304, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-0", "text": "NOTES TO THE STATEMENT OF PROFIT OR LOS\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.49411764705882355, "lower_right_y": 0.10909090909090909, "height": 0.011363636363636354, "width": 0.38176470588235295}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-1", "text": "Revenues\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.21058823529411766, "lower_right_y": 0.14045454545454544, "height": 0.013636363636363613, "width": 0.09823529411764707}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-2", "text": "                                                                      Six months ended         Six months ende\nin kEuro\n                                                                          30 June 2015              30 June 201\nSales of Unyvero-Systems                                                             474                     10\n\nSales of cartridges                                                                  268                      5\n\nSales of services                                                                      -                      4\n\nSales of spare parts                                                                   -                      4\nTotal revenues                                                                       742                     25\nIn accordance with IFRS 8, Curetis is a single-segment entity. Revenues from external customers by country, base\n", "page_number": 305, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.14863636363636365, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.32727272727272727, "height": 0.17863636363636362, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-3", "text": "on the destination of the customer, are only disclosed in the company\u2019s annual financial statements.\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3377272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3668181818181818, "height": 0.02909090909090911, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-4", "text": "bution partners.\n\n    Cost of sales\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.38136363636363635, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4109090909090909, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-5", "text": "Cost of sales inclu\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.425, "lower_right_x": 0.23470588235294118, "lower_right_y": 0.4390909090909091, "height": 0.014090909090909098, "width": 0.1223529411764706}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-6", "text": "sold. Cost of sales for the six month period ended 30 June 2015 amounting to kEUR 665 (2014: kEUR 359).\n\n    Expenses by nature\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.4540909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.48363636363636364, "height": 0.02954545454545454, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-7", "text": "5. Expenses by nature", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5013636363636363, "lower_right_x": 0.2823529411764706, "lower_right_y": 0.515, "height": 0.013636363636363669, "width": 0.16999999999999998}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-8", "text": "in kEuro\n                                                                        30 June 2015            30 June 201\nEmployee benefit expenses                                                      3,317                   2,69\n\nDepreciation, amortization and impairment charges                                837                     68\n\nChanges in inventories of finished goods and work in progress                     -65                    -2\n\nRaw material and consumables used                                                567                     31\nOther expenses                                                                 1,714                   1,95\nTotal Cost of Sales, distribution costs, administrative expenses\nand research & development expenses                                            6,370                   5,63\n    Finance income/costs \u2013 net\n\nFor the six month period ended 30 June Finance costs - net amounting to kEUR 6,786 in 2015 (2014: kEUR 1,347\n", "page_number": 305, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.5195454545454545, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.7418181818181818, "height": 0.2222727272727273, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-9", "text": "arising primarily from the fair v\n", "page_number": 305, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.7486363636363637, "lower_right_x": 0.33294117647058824, "lower_right_y": 0.76, "height": 0.011363636363636354, "width": 0.22}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-10", "text": "For the six month period ended 30 June Finance costs - net amounting to KEUR 6,786 in 2015 (2014: KEUR 1,347)\narising primarily from the fair value measurement of Curetis\u2019 preferred and common shares. The changes in the fair\nvalue were due primarily to updated fair value calculations.", "page_number": 305, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7777272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8204545454545454, "height": 0.042727272727272725, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-305-11", "text": "F-58", "page_number": 305, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-0", "text": "NOTES TO THE STATEMENT OF FINANCIAL POSITION\n", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.5364705882352941, "lower_right_y": 0.10909090909090909, "height": 0.011363636363636354, "width": 0.42411764705882354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-1", "text": "Cash and cash equivalent\n", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.12681818181818183, "lower_right_x": 0.32823529411764707, "lower_right_y": 0.14181818181818182, "height": 0.014999999999999986, "width": 0.21588235294117647}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-2", "text": "At 30 June 2015, cash and cash equivalents amounted to kEUR 5,940 (31 December 2014: kEUR 2,994). Th\nconsist of bank balances and cash on hand.\n", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.1559090909090909, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.18545454545454546, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-3", "text": "The carrying amounts of the trade receivables approximate to their fair values. Current trade receivables are no\ninterest bearing.\n\n\nin kEUR                                                                      30 June 2015       31 December 201\nTrade receivables, gross                                                               490                      4\n\nless provision for doubtful receivables                                                  -4\nTrade receivables, net                                                                 486                      4\n    Inventories\n\nin kEUR                                                                      30 June 2015       31 December 201\nRaw materials                                                                          571                     62\nWork in progress                                                                        26                      5\nTrade goods                                                                          2,790                   2,73\nFinished goods                                                                         168                      5\nTotal inventories, gross                                                             3,555                   3,46\n\n\nValuation allowance                                                                   -356                    -31\nTotal inventories, net                                                               3,199                   3,15\nThe valuation allowance of inventories recognized as an expense for the six month period until 30 June and include\nin \u2018Cost of sales\u2019 amounted to kEUR 42 (2014: kEUR 155).\n", "page_number": 306, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.20318181818181819, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.6140909090909091, "height": 0.41090909090909095, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-4", "text": "Other current assets\n", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6213636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6509090909090909, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-5", "text": "As of 30 June 2015, othe\n2014: kEUR 170). Furthe\n", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.665, "lower_right_x": 0.28647058823529414, "lower_right_y": 0.68, "height": 0.015000000000000013, "width": 0.17411764705882354}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-6", "text": "Other non-current financial assets\n", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6940909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7236363636363636, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-7", "text": "11. Other non-current financial assets", "page_number": 306, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7377272727272727, "lower_right_x": 0.38588235294117645, "lower_right_y": 0.7527272727272727, "height": 0.015000000000000013, "width": 0.27352941176470585}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-8", "text": "Rent deposit   64    6\nBank deposit   348   36\nTotal          412   42\n", "page_number": 306, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.7681818181818182, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.8818181818181818, "height": 0.11363636363636365, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-306-9", "text": "F-59", "page_number": 306, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-0", "text": "Trade and other payable\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11954545454545455, "lower_right_x": 0.3235294117647059, "lower_right_y": 0.13454545454545455, "height": 0.015, "width": 0.2111764705882353}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-1", "text": "in kEUR                    30 June 2015   31 December 201\nTrade and other payables           831                58\nTotal                              831                58\n    Provisions\n", "page_number": 307, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.13772727272727273, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.2318181818181818, "height": 0.09409090909090909, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-2", "text": "in kEUR                                                                      30 June 2015        31 December 201\n\nAsset retirement obligations                                                             36                      3\nProfit sharing                                                                         780                      77\nPSOP provision                                                                        5,342                   3,91\nOther provisions                                                                         53                      3\nBalance                                                                               6,211                   4,76\n - of which: current                                                                     50                      3\n - of which: non-current                                                              6,161                   4,73\nCuretis has a contractual obligation to dismantle the cleanrooms, in which they produce their cartridges, and to r\n", "page_number": 307, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.24681818181818183, "lower_right_x": 0.8911764705882353, "lower_right_y": 0.46, "height": 0.2131818181818182, "width": 0.7835294117647059}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-3", "text": "Furthermore, Curetis has a contractual obligation to pay certain employees a profit sharing bonus (as compensat\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.46863636363636363, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.49818181818181817, "height": 0.02954545454545454, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-4", "text": "Other provisions relate to various risks and commitments for warranty costs and expenses in relation with the pre\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5122727272727273, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.5418181818181819, "height": 0.02954545454545454, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-5", "text": "Other current liabilities\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.5559090909090909, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.5854545454545454, "height": 0.02954545454545454, "width": 0.7694117647058824}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-6", "text": "in kEUR\n", "page_number": 307, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6031818181818182, "lower_right_x": 0.31058823529411766, "lower_right_y": 0.6145454545454545, "height": 0.011363636363636354, "width": 0.19823529411764707}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-7", "text": "Accruals for vacation                                                                   173                     10\nOther tax liabilities                                                                    71                      6\nOther liabilities                                                                       127                     14\nTotal                                                                                   371                     31\nOther liabilities mainly comprise liabilities for bonuses and other personnel expenses amounting to kEUR 52 as of 3\nJune 2015 (31 December 2014: kEUR 77).\n", "page_number": 307, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.6213636363636363, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.7381818181818182, "height": 0.11681818181818182, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-8", "text": "Other liabilities mainly comprise liabilities for bonuses and other personnel expenses amounting to KEUR 52 as of 30\nJune 2015 (31 December 2014: KEUR 77).", "page_number": 307, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.745, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.774090909090909, "height": 0.029090909090909056, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-307-9", "text": "F-60", "page_number": 307, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.026470588235294135}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-0", "text": "Other current financial liabilitie\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09772727272727273, "lower_right_x": 0.37529411764705883, "lower_right_y": 0.11136363636363636, "height": 0.013636363636363627, "width": 0.26294117647058823}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-1", "text": "Other current financial liabilities include liabilities for outstanding invoices and finance lea\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11411764705882353, "top_left_y": 0.12681818181818183, "lower_right_x": 0.7276470588235294, "lower_right_y": 0.14181818181818182, "height": 0.014999999999999986, "width": 0.6135294117647059}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-2", "text": "in kEUR                                       30 June 2015   31 December 201\n\nLiabilities for outstanding invoices                  117                24\nLease liabilities                                     137                13\nTotal                                                 254                37\n    Other non-current financial liabilities\n", "page_number": 308, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.145, "lower_right_x": 0.8941176470588236, "lower_right_y": 0.2581818181818182, "height": 0.11318181818181819, "width": 0.7864705882352941}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-3", "text": "16. Other non-current financial liabilities", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2586363636363636, "lower_right_x": 0.40941176470588236, "lower_right_y": 0.2727272727272727, "height": 0.014090909090909098, "width": 0.29705882352941176}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-4", "text": "Other non-current financial liabilities only refer to the non-current liabilities from finance leases.", "page_number": 308, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.2868181818181818, "lower_right_x": 0.7482352941176471, "lower_right_y": 0.3018181818181818, "height": 0.015000000000000013, "width": 0.6352941176470589}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-5", "text": "17. Share-based payment", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3195454545454545, "lower_right_x": 0.2964705882352941, "lower_right_y": 0.3331818181818182, "height": 0.013636363636363669, "width": 0.1841176470588235}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-6", "text": "as well as freelancers. Participants received an individual number of phantom stock options (PSOs), which entitle\nbeneficiaries to a cash settlement in case of a trade sale, merger or initial public offering.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.34863636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.39136363636363636, "height": 0.042727272727272725, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-7", "text": "vested back to Curetis after the expiry of the holding period defined for the then existing shareholders. The purch\nprice per PSO will be assessed at the value per share that will be established as first stock quotation of the price\nCuretis\u2019 shares in the course of the listing, reduced by the Strike Price (nominal amount of the Common share pr\n1\u20ac).\n\nIn an exit-event corresponding to trade sale, merger, dissolution, liquidation, share swap or contribution, the ben\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4068181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.47863636363636364, "height": 0.07181818181818184, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-8", "text": "reduced by the Strike Price (nominal amount of the Common share price 1\u20ac).\n\nThe PSOs have a lifetime of 10 years after the grant date. The plan shall terminate at the end of the lifetime of\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4940909090909091, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5377272727272727, "height": 0.04363636363636364, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-9", "text": "fully vested and can be exercised.\n\nAs of 30 June 2015, there are 58 beneficiaries entitled to 367,373 PSOs and the grant dates reach from 1 Septem\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.5522727272727272, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5963636363636363, "height": 0.04409090909090907, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-10", "text": "the case of a trade sale, merger or IPO -the PSOs are fully vested and non-forfeitable as well as exercisable up\nexpiry of the agreed upon lock-up period in the case of an IPO.\n\nThe basis for calculating the individual allotment of PSOs was the average price of the Curetis share at the respect\nbalance sheet date. The scheme is recognized in accordance with IFRS 2 under the regulations for share-based co\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6104545454545455, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.6690909090909091, "height": 0.0586363636363636, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-11", "text": "pensation transactions by cash settlement. Accordingly, the total value of the phantom stock options is determined\napplying an option pricing valuation model. The total calculated value is recorded as personnel expenses over\nperiod in which the beneficiary provides services to the Company. The value of the phantom stock option multipl\nwith the number of phantom stock options fully vested results in the maximum liability from the phantom sto\noption plan as the date of valuation.\n\nAs at 30 June 2015 a total of kEUR 1,428 was recognized as expenses (2014: kEUR 796) and as of 30 June 20\nkEUR 5,342 as liabilities (31 December 2014: kEUR 3,914) for the above mentioned remuneration scheme in\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6831818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7854545454545454, "height": 0.10227272727272718, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-12", "text": "Out of the 367,373 outstanding options (2014: 311,342) no options were exercisable.\n", "page_number": 308, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8031818181818182, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.8422727272727273, "height": 0.039090909090909065, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 13, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-13", "text": "Out of the 367,373 outstanding options (2014: 311,342) no options were exercisable.", "page_number": 308, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.8613636363636363, "lower_right_x": 0.6729411764705883, "lower_right_y": 0.875, "height": 0.013636363636363669, "width": 0.56}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 14, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-308-14", "text": "F-61", "page_number": 308, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8823529411764706, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.0252941176470588}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-0", "text": "Share options outstanding at the end of the period have the following expiry date and exercise pric\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.09772727272727273, "lower_right_x": 0.7717647058823529, "lower_right_y": 0.11227272727272727, "height": 0.014545454545454542, "width": 0.6588235294117647}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-1", "text": "                           Expiry date -   exercise price in EUR\nGrant vested                  1 January                  per PSO            30 June 2015         31 December 201\n2010                               2020                        1                 145,969                   145,96\n2011                               2021                        1                  91,356                     91,35\n2012                               2022                        1                  55,110                     57,01\n2013                               2023                        1                   6,688                      7,00\n2014                               2024                        1                  12,500                     10,00\n2015                               2025                        1                  55,750\n                                                                                 367,373                   311,34\nThe change of share options outstanding in prior periods is due to the fact that shares have been granted retrospe\n", "page_number": 309, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.1159090909090909, "lower_right_x": 0.8911764705882353, "lower_right_y": 0.31545454545454543, "height": 0.19954545454545453, "width": 0.7835294117647059}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-2", "text": "tively as well as forfeited during the first half of 2015.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3231818181818182, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.3527272727272727, "height": 0.02954545454545454, "width": 0.771764705882353}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-3", "text": "counted cash flow model. The significant inputs into the model were exit assumptions regarding time, probabil\nvolatility and marketability.\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3668181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4109090909090909, "height": 0.04409090909090907, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-4", "text": "The Company\u2019s fin\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.42863636363636365, "lower_right_x": 0.2447058823529412, "lower_right_y": 0.44, "height": 0.011363636363636354, "width": 0.13235294117647062}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-5", "text": "in kEUR   30 June 2015   31 December 20\n", "page_number": 309, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4577272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.48409090909090907, "height": 0.026363636363636367, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-6", "text": "Finance lease liabilities                                                               326                     39\n - of which: current                                                                    137                     13\n - of which: non-current                                                                189                     25\n1 The non-current minimum lease payments are all due within 1 - 5 years\n\nCuretis leases machinery under finance lease agreements. The lease term is 5 years.\n\nProperty, plant and equipment includes the following amounts related to the lease of a laser welding machine.\n\nin kEUR                                                                       30 June 2015       31 December 201\nCost-capitalized finance                                                                690                     69\nAccumulated depreciation                                                               -424                     -35\nTotal                                                                                   266                     33\nThe following table represents the remaining depreciation period.\n\nin kEUR                                                                       30 June 2015        31 December201\nless than 1 year                                                                        145                     14\n1-5 years                                                                               121                     19\nMore than 5 years                                                                          -\nTotal                                                                                   266                     33\n\n\n                                                                                                                F-\n", "page_number": 309, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.4904545454545455, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.9090909090909091, "height": 0.4186363636363636, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-309-7", "text": "F-62", "page_number": 309, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8841176470588236, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.027058823529411802}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-0", "text": "Financial liability for preferred and common share\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.508235294117647, "lower_right_y": 0.105, "height": 0.014545454545454542, "width": 0.3958823529411764}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-1", "text": "After completion of the Series B Expansion financing round of the Company, Curetis\u2019 share capital under Germ\nGAAP amounted to kEUR 5,554 as of 30 June 2015 (31 December 2014: kEUR 4,660) and was divided i\n605,556 common shares, 3,233,230 class A voting preferred shares and 1,664,903 class B voting preferred shar\nAmong the shareholders are also managers of the Company.\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.11954545454545455, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.17772727272727273, "height": 0.05818181818181818, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-2", "text": "Under IFRS, preferred (A & B shares) and common shares amounting to kEUR 139,608 as of 30 June 20\n(31 December 2014: kEUR 126,036) are recognized at fair value. kEUR 6,783 of the change in preferred (A &\nshares) and common shares has been recognized through P&L. The remaining portion of the total change (kEU\n6,789) refers to a capital increase, changing capital reserves in accordance with German GAAP, and is theref\nreflected in the total amount of the liability for preferred shares on the balance sheet.\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19227272727272726, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.26545454545454544, "height": 0.07318181818181818, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-3", "text": "yond control of the Company and given that these events may occur at any time, the Company determined it is\npropriate to apply the measurement guidance for financial liabilities for preferred and common shares with a dema\nfeature in IFRS 13.47 by analogy. The agreements governing preferred shares include a right and in certain even\ncontingent obligation to trigger a preference payment or to convert into common shares. As these events may oc\nat any time, the Company elected to designate the common as well as preferred shares as a financial liability throu\nprofit or loss. Upon successful completion of the IPO preferred shares are to be converted into common shares.\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.27954545454545454, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.38181818181818183, "height": 0.10227272727272729, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-4", "text": "cash flow model using weighted average cost of capital at each valuation date.\n\n    Equity\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.39590909090909093, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.4254545454545455, "height": 0.02954545454545454, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-5", "text": "At 30 June\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4431818181818182, "lower_right_x": 0.19294117647058823, "lower_right_y": 0.45681818181818185, "height": 0.013636363636363669, "width": 0.08058823529411764}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-6", "text": "As of 30 June 2015, 5,553,689 shares are issued with a par value of 1\u20ac. All shares are fully paid. Besides\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4722727272727273, "lower_right_x": 0.8464705882352941, "lower_right_y": 0.4859090909090909, "height": 0.013636363636363613, "width": 0.7341176470588235}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-7", "text": "itself does not hold any shares.\n\n    Fair value estimation\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5013636363636363, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.5445454545454546, "height": 0.04318181818181821, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-8", "text": "The table below analyses f\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.5595454545454546, "lower_right_x": 0.2958823529411765, "lower_right_y": 0.5731818181818182, "height": 0.013636363636363669, "width": 0.18294117647058825}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-9", "text": "\uf0b7   Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1).\n", "page_number": 310, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.5886363636363636, "lower_right_x": 0.8835294117647059, "lower_right_y": 0.6145454545454545, "height": 0.02590909090909088, "width": 0.7711764705882354}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-10", "text": "\uf0b7      Inputs other than quoted prices included within level 1 that are observable for the asset or liability, eith\n       directly (that is, as prices) or indirectly (that is, derived from prices) (Level 2).\n\n\uf0b7      Inputs for the asset or liability that are not based on observable market data (that is, unobservable input\n       (Level 3).\n\n                                                                       30 June 2015                 31 December 201\nin kEUR                                                                   Fair value                         Fair valu\nFinancial liabilities\n\nMeasured at fair value through profit or loss\n\nFinancial liabilities for preferred and common\nshares                                                                       139,608                           126,03\nThere were no transfers between the different levels of the fair value hierarchy in any of the periods presented.\n\n                                                                                                                    F-6\n", "page_number": 310, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.6359090909090909, "lower_right_x": 0.8935294117647059, "lower_right_y": 0.8986363636363637, "height": 0.2627272727272728, "width": 0.7858823529411765}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-11", "text": "There were no transfers between the different levels of the fair value hierarchy in any of the periods presented.", "page_number": 310, "bounding_box": {"top_left_x": 0.11529411764705882, "top_left_y": 0.905, "lower_right_x": 0.8376470588235294, "lower_right_y": 0.92, "height": 0.015000000000000013, "width": 0.7223529411764706}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-310-12", "text": "F-63", "page_number": 310, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-0", "text": "Preferred and common shares are designated as financial liabilities at fair value through profit and loss in accorda\nwith IAS 39. Given the input parameters and the valuation method used, their fair value measurement is categori\nwithin Level 3 of the fair value hierarchy.\n", "page_number": 311, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.13363636363636364, "height": 0.04318181818181818, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-1", "text": "The fair value of the financial liability was determined using a discounted cash flow model. The model uses the f\nlowing input parameters to the valuation as of the respective dates:\n", "page_number": 311, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.14863636363636365, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.17772727272727273, "height": 0.029090909090909084, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-2", "text": "                                                        Discount rate\n                   Projection Period Long-term growth                   Level allocation\n                              (years)          rate %             %      input paramete\n\n30 June 2015                    10                2.0            14.0\n\n31 December 2014                10                2.0            15.5\n", "page_number": 311, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.18136363636363637, "lower_right_x": 0.8894117647058823, "lower_right_y": 0.2868181818181818, "height": 0.10545454545454544, "width": 0.7770588235294118}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-3", "text": "shares liability included in non-current financial liabilities.\n", "page_number": 311, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3013636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.3290909090909091, "height": 0.02772727272727271, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-4", "text": "In kEUR                                                                                                            201\nBalance as of 1 January                                                                                         126,03\nAdditional paid-in Series B shares                                                                                 6,78\nLosses recognized in profit or loss                                                                                6,78\nBalance as of 30 June                                                                                           139,60\n\n\n\nIn kEUR                                                                                                            201\nBalance as of 1 January                                                                                         116,99\nAdditional paid-in Series B shares                                                                                 6,75\nLosses recognized in profit or loss                                                                                2,28\nBalance as of 31 December                                                                                       126,03\nReasonable changes to the main input factors of the valuation of the preferred and common shares may significant\naffect the fair value of these liabilities. The following table provides an overview of the effects on the equity value\n", "page_number": 311, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.33454545454545453, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.6, "height": 0.26545454545454544, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-5", "text": "Mio. EUR of Curetis of changes in those input factors:\n\nChange in                                                30 June 2015   31 December 20\n", "page_number": 311, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6068181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.65, "height": 0.04318181818181821, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-6", "text": "Discount factor\n+0.25%                                                                                       142   12\n-0.25%                                                                                       149   13\nLong-term growth rate\n+0.5%                                                                                        149   13\n-0.5%                                                                                        141   12\nCash flows in projection period\n+10%                                                                                         158   14\n-10%                                                                                         132   11\nFinancial Instruments at fair value through profit and loss include changes of fair value.\n", "page_number": 311, "bounding_box": {"top_left_x": 0.10764705882352942, "top_left_y": 0.6563636363636364, "lower_right_x": 0.8917647058823529, "lower_right_y": 0.8872727272727273, "height": 0.23090909090909095, "width": 0.7841176470588235}, "blob_type": "table", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-7", "text": "Financial Instruments at fair value through profit and loss include changes of fair value.", "page_number": 311, "bounding_box": {"top_left_x": 0.11, "top_left_y": 0.8872727272727273, "lower_right_x": 0.6882352941176471, "lower_right_y": 0.9077272727272727, "height": 0.020454545454545392, "width": 0.5782352941176471}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-311-8", "text": "F-64", "page_number": 311, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-0", "text": "Related parties\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.2541176470588235, "lower_right_y": 0.105, "height": 0.014545454545454542, "width": 0.1417647058823529}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-1", "text": "There have not been any other material changes in related party transactions since December 31, 201\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11294117647058824, "top_left_y": 0.11954545454545455, "lower_right_x": 0.79, "lower_right_y": 0.13454545454545455, "height": 0.015, "width": 0.6770588235294118}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-2", "text": "Events after the reporting date\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11352941176470588, "top_left_y": 0.14863636363636365, "lower_right_x": 0.3623529411764706, "lower_right_y": 0.16363636363636364, "height": 0.014999999999999986, "width": 0.24882352941176472}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-3", "text": "The formal kick-off meeting for the project aimed at preparing Curetis for an IPO not before Q4-2015 was held\n29th July 2015. Subsequently during the months of August and September there have been significant efforts a\ncosts incurred on the part of legal counsels to issuer and underwriter, auditors with regards to prospectus review a\nfuture comfort letter preparation, corporate communications advisors, road show related expenses. With the f\nsubmission of a confidential prospectus draft to the AFM on 31st August 2015 certain discounts in case of a brok\nIPO deal no longer apply.\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.17772727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.26545454545454544, "height": 0.08772727272727271, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-4", "text": "exclusive international distributor agreement under which Curetis appointed Beijing CLEAR Biotech as the exc\nsive distributor of the Unyvero Platform in China, Taiwan and Hong Kong. During the registration period, Beij\nCLEAR Biotech will conduct and fully fund the prospective multi-centre clinical trials and approval procedure\nquired for the approval of the Unyvero System and the P55 and i60 ITI Application Cartridges for distribution\nChina. If and once granted, Curetis shall be the owner of the respective license and is obligated to reward Beij\nCLEAR Biotech for certain achievements in starting the clinical trial and pursuing the CFDA clinical trial and reg\ntration process through milestone payments. Marketing in Taiwan will start earlier, as no specific trial is required\nproduct registration. For the commercialisation of the Unyvero i60 ITI Application Cartridge, Beijing CLEAR B\ntech will partner with LandMover Medical Technologies Co. Ltd. (Beijing, China), the exclusive Chinese distribu\nof HM.\n\nOn 5 October 2015, Curetis and Singapore-based Acumen Research Laboratories Pte Ltd. (\"Acumen\") agreed o\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.27954545454545454, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.44, "height": 0.16045454545454546, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-5", "text": "Unyvero System and the Application Cartridges in the ASEAN markets, starting with Singapore, Malaysia, Indo\nsia and Thailand. Acumen granted Curetis the non-exclusive worldwide rights to develop and market a sepsis h\nresponse test as an Application Cartridge for the Unyvero System on the basis of Acumen\u2019s proprietary sepsis h\nresponse biomarker panel. During the R&D phase, Curetis will be responsible for adapting its technology to run\nAcumen sepsis host response biomarker panel with the Unyvero Platform, e.g.; transferring the current pre-analyti\nworkflow. It is Acumen's responsibility to further evaluate and optimise the biomarker panel for its intended use a\nto do health economic analyses and studies. Both parties will collaborate in the performance evaluation studies\nAsia and Europe required for commercialisation of the product. Curetis intends to first launch the Application C\ntridge as CE-IVD Application Cartridge in Europe and other regions accepting CE-IVD markings.\n\nQ1-2015 saw the full payment of the first tranche of the November 2014 Series B extension financing and sub\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.4577272727272727, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6145454545454545, "height": 0.1568181818181818, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-6", "text": "the payment of the remaining financing tranche into the agio of kEUR 6,789 during Q3-2015. The key element\nsaid milestone has been the start of the prospective enrolment of Curetis\u2019 FDA trial for Unyvero LRT55 in the US\n\nIn October 2015, Curetis identified and recruited the Company's future Supervisory Directors, including the\nnowned industry experts Bill Rhodes (future chairman of the board) and Mario Crovetto (future chairman auf\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.6322727272727273, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.6877272727272727, "height": 0.05545454545454542, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-7", "text": "In the third quarter of 2015, Curetis received \u20ac 5,989 thousand of the second and final tranche of its Series B Fina\ning Round, while the remaining kEUR 800 will be paid into the newly incorporated Company.\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.705, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.7472727272727273, "height": 0.04227272727272735, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-8", "text": "In the event Curetis would not be able to attract any additional funds from the IPO, the company\u00b4s ability to conti\nas a going concern is threatened by risks. The business plan prepared in case of a withdrawn IPO includes cost red\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.7631818181818182, "lower_right_x": 0.8829411764705882, "lower_right_y": 0.7927272727272727, "height": 0.02954545454545454, "width": 0.7705882352941177}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-9", "text": "continue as a going concern for at least 12 months as of the date of the financial statements. In order to ensure go\nconcern beyond these 12 months the company may rely on further significant cost reductions and reduced operat\nexpenditures, more delayed capital expenditures or may also seek additional financing from current or future sha\nholders privately, whether in the form of bridge loans and/or equity offerings.\n\n\n                                                                                                                  F\n", "page_number": 312, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.8068181818181818, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9090909090909091, "height": 0.10227272727272729, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-312-10", "text": "F-65", "page_number": 312, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-0", "text": "Considering the above stated countermeasures, even in case of a withdrawn IPO Curetis would be able to continue\na going concern for at least 12 months as of the date of the financial statements. If however the company fails\nimplement the above stated countermeasures in case of a withdrawn IPO, it may be unable to continue as a go\nconcern and may ultimately have to file for insolvency.\n", "page_number": 313, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.09045454545454545, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.1481818181818182, "height": 0.05772727272727274, "width": 0.7723529411764707}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-1", "text": "Holzgerlingen, 22 October 2015\n", "page_number": 313, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.19272727272727272, "lower_right_x": 0.3288235294117647, "lower_right_y": 0.20727272727272728, "height": 0.014545454545454556, "width": 0.21647058823529408}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-2", "text": "Curetis AG", "page_number": 313, "bounding_box": {"top_left_x": 0.11470588235294117, "top_left_y": 0.22227272727272726, "lower_right_x": 0.19294117647058823, "lower_right_y": 0.235, "height": 0.012727272727272726, "width": 0.07823529411764706}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-3", "text": "Chief Operating Officer (CO\n", "page_number": 313, "bounding_box": {"top_left_x": 0.5782352941176471, "top_left_y": 0.2540909090909091, "lower_right_x": 0.7852941176470588, "lower_right_y": 0.28, "height": 0.025909090909090937, "width": 0.20705882352941174}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-4", "text": "Chief Executive Officer (CEO\n", "page_number": 313, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.2540909090909091, "lower_right_x": 0.31941176470588234, "lower_right_y": 0.28, "height": 0.025909090909090937, "width": 0.20705882352941174}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-5", "text": "Chief Commercial Officer (CC\n", "page_number": 313, "bounding_box": {"top_left_x": 0.5782352941176471, "top_left_y": 0.3559090909090909, "lower_right_x": 0.8, "lower_right_y": 0.3845454545454545, "height": 0.028636363636363626, "width": 0.22176470588235297}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-6", "text": "Chief Technology Officer (CTO\n", "page_number": 313, "bounding_box": {"top_left_x": 0.11235294117647059, "top_left_y": 0.3559090909090909, "lower_right_x": 0.3341176470588235, "lower_right_y": 0.385, "height": 0.02909090909090911, "width": 0.22176470588235292}, "blob_type": "paragraph", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-313-7", "text": "F-66", "page_number": 313, "bounding_box": {"top_left_x": 0.8570588235294118, "top_left_y": 0.9413636363636364, "lower_right_x": 0.8847058823529412, "lower_right_y": 0.9527272727272728, "height": 0.011363636363636354, "width": 0.02764705882352947}, "blob_type": "header/footer", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 0, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-0", "text": "THE ISSUER\n", "page_number": 314, "bounding_box": {"top_left_x": 0.4347037484885127, "top_left_y": 0.09191962377084224, "lower_right_x": 0.5610640870616687, "lower_right_y": 0.10602821718683197, "height": 0.014108593415989731, "width": 0.12636033857315598}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 1, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-1", "text": "  Curetis N.V.\nMax-Eyth-Stra\u00dfe 42\n71088 Holzgerlingen\n     Germany\n", "page_number": 314, "bounding_box": {"top_left_x": 0.41777509068923824, "top_left_y": 0.10902094912355707, "lower_right_x": 0.5749697702539298, "lower_right_y": 0.17101325352714836, "height": 0.06199230440359128, "width": 0.15719467956469158}, "blob_type": "paragraph", "predictions": {}, "annotations": {"issuer_name": ["Curetis N.V."]}}, {"blob_number_in_page": 2, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-2", "text": "   SOLE GLOBAL\n   COORDINATOR\n  RBC Europe Limited\nRiverbank House, 2 Swan Lane\n     London EC4R 3BF\n       United Kingdom\n", "page_number": 314, "bounding_box": {"top_left_x": 0.37726723095526, "top_left_y": 0.18426678067550234, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.27704147071398033, "height": 0.09277469003847799, "width": 0.23700120918984274}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 3, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-3", "text": "JOINT BOOKRUNNERS\n", "page_number": 314, "bounding_box": {"top_left_x": 0.38210399032648124, "top_left_y": 0.2937152629328773, "lower_right_x": 0.6094316807738815, "lower_right_y": 0.30739632321504917, "height": 0.013681060282171864, "width": 0.2273276904474003}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 4, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-4", "text": " Bank Degroof Petercam nv/sa\nNijverheidsstraat | Rue de l\u2019Industrie 44\n            1040 Brussels\n               Belgium\n", "page_number": 314, "bounding_box": {"top_left_x": 0.6088270858524788, "top_left_y": 0.324497648567764, "lower_right_x": 0.8802902055622733, "lower_right_y": 0.3830696879008123, "height": 0.05857203933304833, "width": 0.27146311970979453}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 5, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-5", "text": "  RBC Europe Limited\nRiverbank House, 2 Swan Lane\n     London EC4R 3BF\n       United Kingdom\n", "page_number": 314, "bounding_box": {"top_left_x": 0.12031438935912939, "top_left_y": 0.324497648567764, "lower_right_x": 0.35792019347037485, "lower_right_y": 0.3830696879008123, "height": 0.05857203933304833, "width": 0.23760580411124546}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 6, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-6", "text": "JOINT LEAD MANAGER\n     ICF BANK AG\n      Kaiserstra\u00dfe 1\n 60311 Frankfurt am Main\n        Germany\n", "page_number": 314, "bounding_box": {"top_left_x": 0.37726723095526, "top_left_y": 0.4236853356135101, "lower_right_x": 0.6142684401451027, "lower_right_y": 0.5027789653698161, "height": 0.07909362975630607, "width": 0.23700120918984274}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 7, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-7", "text": "                   LEGAL ADVISERS TO THE UNDERWRITERS\n\n     As to Dutch law            As to German law            As to US law\n     Linklaters LLP              Linklaters LLP            Linklaters LLP\nWTC Amsterdam Tower H, 22/F    Mainzer Landstra\u00dfe 16     Mainzer Landstra\u00dfe 16\n      Zuidplein 180           60325 Frankfurt am Main   60325 Frankfurt am Main\n   1077 XV Amsterdam                 Germany                   Germany\n     The Netherlands\n", "page_number": 314, "bounding_box": {"top_left_x": 0.12575574365175332, "top_left_y": 0.5194527575887131, "lower_right_x": 0.8561064087061668, "lower_right_y": 0.6395895681915349, "height": 0.12013681060282178, "width": 0.7303506650544135}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 8, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-8", "text": "             INDEPENDENT AUDITOR OF CURETIS AG\nPricewaterhouseCoopers Aktiengesellschaft Wirtschaftspr\u00fcfungsgesellschaft\n                          Bernhard-Wicki-Stra\u00dfe 8\n                              80636 Munich\n                                 Germany\n", "page_number": 314, "bounding_box": {"top_left_x": 0.16384522370012092, "top_left_y": 0.6596836254809748, "lower_right_x": 0.8361547762998791, "lower_right_y": 0.735356990166738, "height": 0.07567336468576313, "width": 0.6723095525997582}, "blob_type": "headline", "predictions": {}, "annotations": {"external_auditor": ["PricewaterhouseCoopers Aktiengesellschaft Wirtschaftspr\u00fcfungsgesellschaft"]}}, {"blob_number_in_page": 9, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-9", "text": "LISTING AND PAYING AGENT\n    ABN AMRO Bank N.V.\n", "page_number": 314, "bounding_box": {"top_left_x": 0.35368802902055624, "top_left_y": 0.7486105173150919, "lower_right_x": 0.6475211608222491, "lower_right_y": 0.7798204360837965, "height": 0.031209918768704603, "width": 0.29383313180169285}, "blob_type": "headline", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 10, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-10", "text": "Gustav Mahlerlaan 10\n", "page_number": 314, "bounding_box": {"top_left_x": 0.41717049576783555, "top_left_y": 0.7828131680205216, "lower_right_x": 0.585247883917775, "lower_right_y": 0.7935014963659683, "height": 0.010688328345446751, "width": 0.1680773881499395}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 11, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-11", "text": "1082 PP Amsterdam\n", "page_number": 314, "bounding_box": {"top_left_x": 0.42503022974607013, "top_left_y": 0.7973492945703292, "lower_right_x": 0.5804111245465539, "lower_right_y": 0.8106028217186833, "height": 0.013253527148354038, "width": 0.15538089480048373}, "blob_type": "undefined", "predictions": {}, "annotations": {}}, {"blob_number_in_page": 12, "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "blob_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a-314-12", "text": "The Netherlands\n", "page_number": 314, "bounding_box": {"top_left_x": 0.439540507859734, "top_left_y": 0.8135955536554083, "lower_right_x": 0.5640870616686819, "lower_right_y": 0.8242838820008551, "height": 0.010688328345446862, "width": 0.12454655380894797}, "blob_type": "undefined", "predictions": {}, "annotations": {}}], "document_id": "c4876eb6617dbb7fd1ca249684f13867fb810562d55b841f6e8002d21da6f25a", "pages_in_documents": 315}